PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Karjalainen, J; Kujala, UM; Kaprio, J; Sarna, S; Viitasalo, M				Karjalainen, J; Kujala, UM; Kaprio, J; Sarna, S; Viitasalo, M			Lone atrial fibrillation in vigorously exercising middle aged men: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; PREVALENCE		Cent Mil Hosp, Helsinki 00301, Finland; Univ Helsinki, Inst Biomed, Unit Sports & Exercise Med, Helsinki 00250, Finland; Univ Helsinki, Dept Publ Hlth, FIN-00290 Helsinki, Finland; Helsinki Univ Hosp, Dept Med 1, Helsinki 00290, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Karjalainen, J (corresponding author), Cent Mil Hosp, Box 50, Helsinki 00301, Finland.	jouko.kajalainen@pp.inet.fi	Kujala, Urho/AAP-2547-2020; Kaprio, Jaakko/A-1820-2008	Kaprio, Jaakko/0000-0002-3716-2455; Kujala, Urho/0000-0002-9262-1992; Sarna, Seppo/0000-0003-3458-1627				COUMEL P, 1994, EUR HEART J, V15, P9, DOI 10.1093/eurheartj/15.suppl_A.9; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; KRAHN AD, 1995, AM J MED, V98, P476, DOI 10.1016/S0002-9343(99)80348-9; KUJALA UM, 1994, METABOLISM, V43, P1255, DOI 10.1016/0026-0495(94)90219-4; MORRIS JN, 1980, LANCET, V2, P1207	5	220	224	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	1998	316	7147					1784	+		10.1136/bmj.316.7147.1784	http://dx.doi.org/10.1136/bmj.316.7147.1784			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624065	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000074286300025
J	Abbate, E; Albianelli, A; Azzaroli, A; Benvenuti, M; Tesfamariam, B; Bruni, P; Cipriani, N; Clarke, RJ; Ficcarelli, G; Macchiarelli, R; Napoleone, G; Papini, M; Rook, L; Sagri, M; Tecle, TM; Torre, D; Villa, I				Abbate, E; Albianelli, A; Azzaroli, A; Benvenuti, M; Tesfamariam, B; Bruni, P; Cipriani, N; Clarke, RJ; Ficcarelli, G; Macchiarelli, R; Napoleone, G; Papini, M; Rook, L; Sagri, M; Tecle, TM; Torre, D; Villa, I			A one-million-year-old Homo cranium from the Danakil (Afar) Depression of Eritrea	NATURE			English	Article							MIDDLE-AWASH VALLEY; ETHIOPIA	One of the most contentious topics in the study of human evolution is that of the time, place and mode of origin of Homo sapiens(1-3). The discovery in the Northern Danakil (Afar) Depression, Eritrea, of a well-preserved Homo cranium with a mixture of characters typical of H. erectus and H. sapiens contributes significantly to this debate. The cranium was found in a succession of fluvio-deltaic and lacustrine deposits and is associated with a rich mammalian fauna of early to early-middle Pleistocene age. A magnetostratigraphic survey indicates two reversed and two normal magnetozones. The layer in which the cranium was found is near the top of the lower normal magnetozone, which is identified as the Jaramillo subchron. Consequently, the human remains can be dated at similar to 1 million years before present.	Univ Florence, Dipartimento Sci Terra, I-50121 Florence, Italy; Univ Florence, Sez Geol & Paleontol, Museo Storia Nat, I-50121 Florence, Italy; Eritrea Natl Museum, Asmara, Eritrea; Univ Witwatersrand, Sch Med, Dept Anat Sci, Palaeoanthropol Res Unit, ZA-2193 Johannesburg, South Africa; Museo Nazl Preistor Etnog L Pigorini, Sez Antropol, I-00144 Rome, Italy; Minist Energy Water & Mineral Resources, Dept Mines, Asmara, Eritrea; Univ Bern, Inst Mineral, Abt Isotopengeol, CH-3012 Bern, Switzerland	University of Florence; University of Florence; University of Witwatersrand; University of Bern	Abbate, E (corresponding author), Univ Florence, Dipartimento Sci Terra, I-50121 Florence, Italy.	abbate@cesitl.unifi.it	Benvenuti, Marco/G-9229-2011; Rook, Lorenzo/AAA-5014-2019; Rook, Lorenzo/D-9675-2011	Rook, Lorenzo/0000-0001-8923-5428; Rook, Lorenzo/0000-0001-8923-5428; Tecle, Tesfaldet/0000-0002-3558-5673				BANNERT D, 1970, GEOL RUNDSCH, V59, P409; BARBERI F, 1977, GEOL SOC AM BULL, V88, P1251, DOI 10.1130/0016-7606(1977)88<1251:VOASPT>2.0.CO;2; Berggren WA, 1995, GEOCHRONOLOGY TIME S, V54, P129, DOI DOI 10.2110/PEC.95.04.0129; Brauer G, 1997, NATURE, V386, P337, DOI 10.1038/386337a0; Brinckmann J., 1970, GEOLOGICAL SKETCHMAP; CLARK JD, 1994, SCIENCE, V264, P1907, DOI 10.1126/science.8009220; deCastro JMB, 1997, SCIENCE, V276, P1392; GARLAND CR, 1980, GEOLOGICAL SURVEY ET, V1; KALB JE, 1982, NATURE, V298, P17, DOI 10.1038/298017a0; Merla G., 1979, GEOLOGICAL MAP ETHIO; TOBIAS PVOLDUVATI, 1991, WOLP, V4, pCH5; Ward R, 1997, NATURE, V388, P225, DOI 10.1038/40746; WOLPOFF MH, HUMAN EVOLUTION, P97; Wood B., 1991, HOMINID CRANIAL REMA, V4	14	107	109	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					458	460		10.1038/30954	http://dx.doi.org/10.1038/30954			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9623999				2022-12-24	WOS:000074020000041
J	de Jong, R; Altare, F; Haagen, IA; Elferink, DG; de Boer, T; Vriesman, PJCV; Kabel, PJ; Draaisma, JMT; van Dissel, JT; Kroon, FP; Casanova, JL; Ottenhoff, THM				de Jong, R; Altare, F; Haagen, IA; Elferink, DG; de Boer, T; Vriesman, PJCV; Kabel, PJ; Draaisma, JMT; van Dissel, JT; Kroon, FP; Casanova, JL; Ottenhoff, THM			Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients	SCIENCE			English	Article							IFN-GAMMA PRODUCTION; INTERFERON-GAMMA; CYTOKINE; RESISTANCE; COMPLEX; CELLS	Interleukin-12 (IL-12) is a cytokine that promotes cell-mediated immunity to intracellular pathogens by inducing type 1 helper T cell (T(H)1) responses and interferon-gamma (IFN-gamma) production. IL-12 binds to high-affinity beta 1/beta 2 heterodimeric IL-12 receptor (IL-12R) complexes on T cell and natural killer cells. Three unrelated individuals with severe, idiopathic mycobacterial and Salmonella infections were found to lack IL-12R beta 1 chain expression. Their cells were deficient in IL-12R signaling and IFN-gamma production, and their remaining T cell responses were independent of endogenous IL-12. IL-12R beta 1 sequence analysis revealed genetic mutations that resulted in premature stop codons in the extracellular domain. The lack of IL-12R beta 1 expression results in a human immunodeficiency and shows the essential role of IL-12 in resistance to infections due to intracellular bacteria.	Leiden Univ, Med Ctr, Dept Immunohematol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Blood Bank, NL-2300 RC Leiden, Netherlands; Hop Necker Enfants Malad, INSERM, U429, F-75743 Paris, France; Univ Hosp Maastricht, Dept Immunol, NL-6202 AZ Maastricht, Netherlands; St Elizabeth Hosp, Dept Med Microbiol & Immunol, NL-5000 AS Tilburg, Netherlands; St Elizabeth Hosp, Dept Pediat, NL-5000 AS Tilburg, Netherlands; Leiden Univ, Med Ctr, Dept Infect Dis, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Maastricht University; Maastricht University Medical Centre (MUMC); Elisabeth-TweeSteden Ziekenhuis (ETZ); Elisabeth-TweeSteden Ziekenhuis (ETZ); Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Ottenhoff, THM (corresponding author), Leiden Univ, Med Ctr, Dept Immunohematol, POB 9600, NL-2300 RC Leiden, Netherlands.	ihbsecr@euronet.nl	Draaisma, J.M.T./L-4283-2015; altare, frederic/K-8664-2015; Casanova, Jean-Laurent/I-3418-2017	altare, frederic/0000-0002-5077-4616; Casanova, Jean-Laurent/0000-0002-7782-4169				Altare F, 1998, AM J HUM GENET, V62, P723, DOI 10.1086/301750; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; Casanova JL, 1996, PEDIATRICS, V98, P774; CHIZZONITE R, 1992, J IMMUNOL, V148, P3117; Cooper AM, 1997, J EXP MED, V186, P39, DOI 10.1084/jem.186.1.39; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; deJong R, 1997, J IMMUNOL, V159, P786; DEJONG R, UNPUB; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; Frucht DM, 1996, J IMMUNOL, V157, P411; Gollob JA, 1996, J IMMUNOL, V157, P1886; HENDRZAK JA, 1995, LAB INVEST, V72, P619; Hilkens CMU, 1996, J IMMUNOL, V157, P4316; HOLLAND SM, 1994, NEW ENGL J MED, V330, P1348, DOI 10.1056/NEJM199405123301904; Jouanguy E, 1997, J CLIN INVEST, V100, P2658, DOI 10.1172/JCI119810; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; Kohno K, 1997, J IMMUNOL, V158, P1541; LEVIN M, 1995, LANCET, V345, P79, DOI 10.1016/S0140-6736(95)90059-4; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Modlin RL, 1995, RES IMMUNOL, V146, P526, DOI 10.1016/0923-2494(96)83027-6; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; PierreAudigier C, 1997, CLIN INFECT DIS, V24, P982, DOI 10.1093/clinids/24.5.982; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; Presky DH, 1995, RES IMMUNOL, V146, P439, DOI 10.1016/0923-2494(96)83013-6; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; VANLIER RAW, 1988, EUR J IMMUNOL, V18, P167; Wu CY, 1997, J IMMUNOL, V159, P1658	30	668	680	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 29	1998	280	5368					1435	1438						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9603733				2022-12-24	WOS:000073883400056
J	Nagar, B; Jones, RG; Diefenbach, RJ; Isenman, DE; Rini, JM				Nagar, B; Jones, RG; Diefenbach, RJ; Isenman, DE; Rini, JM			X-ray crystal structure of C3d: A C3 fragment and ligand for complement receptor 2	SCIENCE			English	Article							B-CELL RESPONSE; SEQUENCE ALIGNMENTS; ACQUIRED-IMMUNITY; PROTEIN-STRUCTURE; 3RD COMPONENT; BINDING-SITE; PROGRAM; LYMPHOCYTES; THIOESTER; MODULES	Activation and covalent attachment of complement component C3 to pathogens is the key step in complement-mediated host defense. Additionally, the antigen-bound C3d fragment interacts with complement receptor 2 (CR2; also known as CD21) on B cells and thereby contributes to the initiation of an acquired humoral response. The x-ray crystal structure of human C3d solved at 2.0 angstroms resolution reveals an a-a barrel with the residues responsible for thioester formation and covalent attach ment at one end and an acidic pocket at the other. The structure supports a model whereby the transition of native C3 to its functionally active stale involves the disruption of a complementary domain interface and provides insight into the basis for the interaction between C3d and CR2.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Rini, JM (corresponding author), Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada.		Nagar, Bhushan/C-1297-2010; Jones, Russell/AAC-2861-2022; Jones, Russell Graham/ABD-5261-2021; Diefenbach, Russell J./E-9602-2015	Jones, Russell Graham/0000-0003-2250-4675; Diefenbach, Russell J./0000-0002-8433-4336				Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; ALESHIN A, 1992, J BIOL CHEM, V267, P19291; Alzari PM, 1996, STRUCTURE, V4, P265, DOI 10.1016/S0969-2126(96)00031-7; BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger A. T, 1992, XPLOR 3 1 SYSTEM XRA; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; DIEFENBACH RJ, 1995, J IMMUNOL, V154, P2303; Dodds AW, 1996, NATURE, V379, P177, DOI 10.1038/379177a0; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; Fischer MB, 1996, J IMMUNOL, V157, P549; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GADJEVA M, IN PRESS J IMMNOL; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; ISAAC L, 1992, J BIOL CHEM, V267, P10062; Isaac L, 1998, BIOCHEM J, V329, P705, DOI 10.1042/bj3290705; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIS JD, 1985, P NATL ACAD SCI USA, V82, P4235, DOI 10.1073/pnas.82.12.4235; LAW SK, 1977, P NATL ACAD SCI USA, V74, P2701, DOI 10.1073/pnas.74.7.2701; LAW SKA, 1983, BIOCHEM J, V211, P381, DOI 10.1042/bj2110381; Law SKA, 1997, PROTEIN SCI, V6, P263; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; MOLINA H, 1995, J IMMUNOL, V154, P5426; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; RICHARDS FM, 1993, Q REV BIOPHYS, V26, P423, DOI 10.1017/S0033583500002845; TACK BF, 1980, P NATL ACAD SCI-BIOL, V77, P5764, DOI 10.1073/pnas.77.10.5764; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1	40	158	181	3	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 22	1998	280	5367					1277	1281		10.1126/science.280.5367.1277	http://dx.doi.org/10.1126/science.280.5367.1277			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596584				2022-12-24	WOS:000073852500053
J	Cavalli, G; Paro, R				Cavalli, G; Paro, R			The Drosophila Fab-7 chromosomal element conveys epigenetic inheritance during mitosis and meiosis	CELL			English	Article							POSITION-EFFECT VARIEGATION; BITHORAX COMPLEX; REGULATORY SEQUENCES; RESPONSE ELEMENT; GENE ENCODES; GAGA FACTOR; WHITE GENE; POLYCOMB; MELANOGASTER; CHROMATIN	Polycomb group (PcG) and trithorax group (trxG) gene products are responsible for the maintenance of repressed and active expression patterns of many developmentally important regulatory genes including the homeotic genes. In Drosophila embryos, Polycomb protein and the trxG protein GAGA factor colocalize at the Fab-7 DNA element of the bithorax complex. In transgenic lines, the Fab-7 element induces extensive silencing on a flanking GAL4-driven lacZ reporter and mini-white genes. However, a short single pulse of GAL4 during embryogenesis is sufficient to release PcG-dependent silencing from the transgene. Such an activated state of Fab-7 is mitotically inheritable through development and can be transmitted in a GAL4-independent manner to the subsequent generations through female meiosis. Thus, Fab-7 is a switchable chromosomal element, which can convey memory of epigenetically determined active and repressed chromatin states.	Univ Heidelberg, ZMBH, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Paro, R (corresponding author), Univ Heidelberg, ZMBH, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.		Cavalli, Giacomo/A-7958-2008; cavalli, giacomo/Z-2754-2019	Cavalli, Giacomo/0000-0003-3709-3469; cavalli, giacomo/0000-0003-3709-3469				Ahmad K, 1996, GENETICS, V144, P657; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BAKER WK, 1963, AM ZOOL, V3, P57; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CAMPBELL SD, 1991, GENETICS, V127, P367; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; CHANG YL, 1995, MOL CELL BIOL, V15, P6601; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; DORN R, 1993, GENETICS, V133, P279; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FAUVARQUE MO, 1993, GENE DEV, V7, P1508, DOI 10.1101/gad.7.8.1508; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GINDHART JG, 1995, GENETICS, V139, P797; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; GRANOK H, 1995, CURR BIOL, V5, P238, DOI 10.1016/S0960-9822(95)00048-0; Grewal SIS, 1996, CELL, V86, P95, DOI 10.1016/S0092-8674(00)80080-X; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; Hagstrom K, 1997, GENETICS, V146, P1365; Hollick JB, 1997, TRENDS GENET, V13, P302, DOI 10.1016/S0168-9525(97)01184-0; KARCH F, 1994, NUCLEIC ACIDS RES, V22, P3138, DOI 10.1093/nar/22.15.3138; KASSIS JA, 1994, GENETICS, V136, P1025; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KUZIORA MA, 1988, EMBO J, V7, P3233, DOI 10.1002/j.1460-2075.1988.tb03190.x; LEVIS R, 1985, EMBO J, V4, P3489, DOI 10.1002/j.1460-2075.1985.tb04108.x; Lyko F, 1997, NAT GENET, V16, P171, DOI 10.1038/ng0697-171; MARTIN CH, 1995, P NATL ACAD SCI USA, V92, P8398, DOI 10.1073/pnas.92.18.8398; Mihaly J, 1997, DEVELOPMENT, V124, P1809; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Paro R., 1996, EPIGENETIC MECH GENE, P507; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; PIRROTTA V, 1995, GENETICS, V141, P1429; Poux S, 1996, EMBO J, V15, P4713, DOI 10.1002/j.1460-2075.1996.tb00848.x; REIJNEN MJ, 1995, MECH DEVELOP, V53, P35, DOI 10.1016/0925-4773(95)00422-X; REUTER G, 1981, MOL GEN GENET, V182, P516, DOI 10.1007/BF00293947; REUTER G, 1985, CHROMOSOMA, V93, P132, DOI 10.1007/BF00293160; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; SIMON J, 1993, DEV BIOL, V158, P131, DOI 10.1006/dbio.1993.1174; STELLER H, 1985, EMBO J, V4, P3765, DOI 10.1002/j.1460-2075.1985.tb04146.x; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; Strutt H, 1997, MOL CELL BIOL, V17, P6773, DOI 10.1128/MCB.17.12.6773; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; Zhou JM, 1996, GENE DEV, V10, P3195, DOI 10.1101/gad.10.24.3195; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x; ZINK D, 1994, THESIS U HEIDELBERG	51	299	311	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					505	518		10.1016/S0092-8674(00)81181-2	http://dx.doi.org/10.1016/S0092-8674(00)81181-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604927	Bronze			2022-12-24	WOS:000073722200005
J	Roberts, DL; Weix, DJ; Dahms, NM; Kim, JJP				Roberts, DL; Weix, DJ; Dahms, NM; Kim, JJP			Molecular basis of lysosomal enzyme recognition: Three-dimensional structure of the cation-dependent mannose 6-phosphate receptor	CELL			English	Article							GROWTH FACTOR-II; HUMAN BETA-GLUCURONIDASE; LIGAND-BINDING; ARGININE RESIDUES; BOVINE LIVER; CLONING; EXPRESSION; SITES; GLYCOSYLATION; PURIFICATION	Targeting of newly synthesized lysosomal hydrolases to the lysosome is mediated by the cation-dependent mannose 6-phosphate receptor (CD-MPR) and the insulin-like growth factor II/cation-independent mannose 6-phosphate receptor (IGF-II/CI-MPR). The two receptors, which share sequence similarities, constitute the P-type family of animal lectins. We now report the three-dimensional structure of a glycosylation-deficient, yet fully functional form of the extracytoplasmic domain of the bovine CD-MPR (residues 3-154) complexed with mannose 6-phosphate at 1.8 Angstrom resolution. The extracytoplasmic domain of the CD-MPR crystallizes as a dimer, and each monomer folds into a nine-stranded flattened beta barrel, which bears a striking resemblance to avidin. The distance of 40 Angstrom between the two ligand-binding sites of the dimer provides a structural basis for the observed differences in binding affinity exhibited by the CD-MPR toward various lysosomal enzymes.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Dahms, NM (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.			Weix, Daniel/0000-0002-9552-3378	NIDDK NIH HHS [DK-42667] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042667, R29DK042667, R56DK042667] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARTER C, 1979, J BIOL CHEM, V246, P12219; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DAHMS NM, 1995, ARCH BIOCHEM BIOPHYS, V317, P497, DOI 10.1006/abbi.1995.1193; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DISTLER JJ, 1991, J BIOL CHEM, V266, P21687; DRICKAMER K, 1995, NAT STRUCT BIOL, V2, P437, DOI 10.1038/nsb0695-437; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; FUREY W, 1997, MACROMOLECULAR CRYST; HOFLACK B, 1987, J BIOL CHEM, V262, P123; HOFLACK B, 1985, P NATL ACAD SCI USA, V82, P4428, DOI 10.1073/pnas.82.13.4428; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOSTER A, 1991, BIOL CHEM H-S, V372, P297, DOI 10.1515/bchm3.1991.372.1.297; LI M, 1990, ARCH BIOCHEM BIOPHYS, V283, P150, DOI 10.1016/0003-9861(90)90625-9; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MA ZM, 1992, J BIOL CHEM, V267, P19017; MA ZM, 1991, J BIOL CHEM, V266, P10589; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McPherson A, 1982, PREPARATION ANAL PRO; MunierLehmann H, 1996, J BIOL CHEM, V271, P15166, DOI 10.1074/jbc.271.25.15166; MunierLehmann H, 1996, BIOCHEM SOC T, V24, P133, DOI 10.1042/bst0240133; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; OTOWINSKI Z, 1996, METHOD ENZYMOL, V276, P307; Punnonen EL, 1996, EUR J BIOCHEM, V237, P809, DOI 10.1111/j.1432-1033.1996.0809p.x; READ RA, 1986, ACTA CRYSTALLOGR D, V5, P760; ROUSSEL A, 1994, TURBOFRODO MANUAL VE; SHIPLEY JM, 1993, J BIOL CHEM, V268, P12193; Sleat DE, 1997, J BIOL CHEM, V272, P731, DOI 10.1074/jbc.272.2.731; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; TERWILLIGER T, 1994, HEAVY VERSION 3 0 MA; TONG PY, 1988, J BIOL CHEM, V263, P2585; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1988, BIOCHEM BIOPH RES CO, V152, P1248, DOI 10.1016/S0006-291X(88)80419-4; WAHEED A, 1990, BIOCHEMISTRY-US, V29, P2449, DOI 10.1021/bi00462a003; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WENDLAND M, 1989, BIOCHEM J, V260, P201, DOI 10.1042/bj2600201; WENDLAND M, 1991, J BIOL CHEM, V266, P7132; WENDLAND M, 1991, J BIOL CHEM, V266, P2917; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; ZHANG Y, 1993, BIOCHEM J, V295, P841, DOI 10.1042/bj2950841	50	92	97	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					639	648		10.1016/S0092-8674(00)81192-7	http://dx.doi.org/10.1016/S0092-8674(00)81192-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604938	Bronze			2022-12-24	WOS:000073722200016
J	Lieberman, DE				Lieberman, DE			Sphenoid shortening and the evolution of modern human cranial shape	NATURE			English	Article							HOMINID FACE; MORPHOLOGY; ONTOGENY; SKULLS; HOMO	Crania of 'anatomically modern' Homo sapiens from the Holocene and Upper Pleistocene epochs differ from those of other Homo taxa, including Neanderthals, by only a few features. These include a globular braincase, a vertical forehead, a dimunitive browridge, a canine fossa and a pronounced chin(1-4). Humans are also unique among mammals in lacking facial projection: the face of the adult H. sapiens Lies almost entirely beneath the anterior cranial fossa, whereas the face in all other adult mammals, including Neanderthals, projects to some extent in front of the braincase. Here I use radiographs and computed tomography to show that many of these unique human features stem partly from a single, ontogenetically early reduction in the length of the sphenoid, the central bone of the cranial base from which the re face grows forward. Sphenoid reduction, through its effects on facial projection and cranial shape, may account for the apparently rapid evolution of modern human cranial form, and suggests that Neanderthals and other archaic Homo should be excluded from H. sapiens.	Rutgers State Univ, Dept Anthropol, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick	Lieberman, DE (corresponding author), Rutgers State Univ, Dept Anthropol, New Brunswick, NJ 08903 USA.							Aiello L, 1990, INTRO HUMAN EVOLUTIO; ARENSBURG B, 1990, AM J PHYS ANTHROPOL, V83, P137, DOI 10.1002/ajpa.1330830202; BILSBOROUGH A, 1988, AM J PHYS ANTHROPOL, V76, P61, DOI 10.1002/ajpa.1330760107; BROMAGE TG, 1992, J HUM EVOL, V23, P235, DOI 10.1016/S0047-2484(05)80002-8; BROMAGE TG, 1989, J HUM EVOL, V18, P751, DOI 10.1016/0047-2484(89)90088-2; CORRUCCINI RS, 1992, AM J PHYS ANTHROPOL, V87, P433, DOI 10.1002/ajpa.1330870405; DUTERLOO HS, 1970, AM J ANAT, V127, P357, DOI 10.1002/aja.1001270403; Enlow D. H., 1990, FACIAL GROWTH; ENLOW DH, 1975, MORPHOGENESIS MALFOR, P217; Fant G., 1960, ACOUSTIC THEORY SPEE; Howells W. W., 1989, PEABODY MUSEUM PAPER, V79; KRNGS M, 1997, CELL, V90, P19; Lahr M. M, 1996, EVOLUTION MODERN HUM; Lieberman DE, 1996, AM J PHYS ANTHROPOL, V101, P217, DOI 10.1002/(SICI)1096-8644(199610)101:2<217::AID-AJPA7>3.0.CO;2-Z; LIEBERMAN DE, 1995, CURR ANTHROPOL, V36, P159, DOI 10.1086/204348; Lieberman P., 1984, BIOL EVOLUTION LANGU; Lumley M. A, 1982, HOMO ERECTUS PLACE H, P814; MACCAMMON R, 1970, HUMAN GROWTH DEV; RAVOSA MJ, 1991, AM J PHYS ANTHROPOL, V85, P95, DOI 10.1002/ajpa.1330850111; Ruff CB, 1997, NATURE, V387, P173, DOI 10.1038/387173a0; Schwartz JH, 1996, P NATL ACAD SCI USA, V93, P10852, DOI 10.1073/pnas.93.20.10852; SHEA BT, 1985, AM J PHYS ANTHROPOL, V68, P329, DOI 10.1002/ajpa.1330680304; Smith F. H., 1992, CONTINUITY REPLACEME, P157; SPENCER MA, 1995, AM J PHYS ANTHROPOL, V91, P1; Stevens K.N., 1972, HUMAN COMMUNICATION, P51; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; TRINKAUS E, 1987, J HUM EVOL, V16, P429, DOI 10.1016/0047-2484(87)90071-6; WEIDENREICH FRANZ, 1941, TRANS AMER PHIL SOC, V31, P321; White T.D., 1991, HUMAN OSTEOLOGY	29	112	115	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1998	393	6681					158	162		10.1038/30227	http://dx.doi.org/10.1038/30227			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZN200	9603517				2022-12-24	WOS:000073619900045
J	Billuart, P; Bienvenu, T; Ronce, N; Des Portes, V; Vinet, MC; Zemni, R; Roest Crollius, H; Carrie, A; Fauchereau, F; Cherry, M; Briault, S; Hamel, B; Fryns, JP; Beldjord, C; Kahn, A; Moraine, C; Chelly, J				Billuart, P; Bienvenu, T; Ronce, N; Des Portes, V; Vinet, MC; Zemni, R; Roest Crollius, H; Carrie, A; Fauchereau, F; Cherry, M; Briault, S; Hamel, B; Fryns, JP; Beldjord, C; Kahn, A; Moraine, C; Chelly, J			Oligophrenin-1 encodes a rhoGAP protein involved in X-linked mental retardation	NATURE			English	Article							GRADIENT GEL-ELECTROPHORESIS; MUTATIONS; GTPASES; GENES; RAS	Primary or nonspecific X-linked mental retardation (MRX) is a heterogeneous condition in which affected patients do not have any distinctive clinical or biochemical features in common apart from cognitive impairment(1). Although it is present in approximately 0.15-0.3% of males(2), most of the genetic defects associated with MRX, which may involve more than ten different genes, remain unknown(3). Here we report the characterization of a new gene on the long arm of the X-chromosome (position Xq12) and the identification in unrelated individuals of different mutations that are predicted to cause a loss of function. This gene is highly expressed in fetal brain and encodes a protein of relative molecular mass 91K, named oligophrenin-1, which contains a domain typical of a Rho-GTPase-activating protein (rhoGAP)(4,5). By enhancing their GTPase activity, GAP proteins inactivate small Rho and Pas proteins, so inactivation of rhoGAP proteins might cause constitutive activation of their GTPase targets. Such activation is known to affect cell migration and outgrowth of axons and dendrites in vivo(6-8). Our results demonstrate an association between cognitive impairment and a defect in a signalling pathway that depends on a Ras-like GTPase.	Fac Med Cochin, ICGM, INSERM, U129, F-75014 Paris, France; CHU Tours, Hop Bretonneau, Serv Genet, F-37044 Tours, France; Max Planck Inst Mol Genet, Berlin, Germany; CHU Nancy, Genet Lab, F-54511 Vandoeuvre Les Nancy, France; Univ Nijmegen Hosp, Dept Human Genet 417, NL-6500 HB Nijmegen, Netherlands; Univ Hosp Gasthuisberg, Ctr Human Genet, Clin Genet Unit, B-3000 Louvain, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; CHU Tours; Max Planck Society; CHU de Nancy; Radboud University Nijmegen; KU Leuven; University Hospital Leuven	Chelly, J (corresponding author), Fac Med Cochin, ICGM, INSERM, U129, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	chelly@cochin.inserm.fr	Chelly, Jamel/J-7528-2015; Billuart, Pierre/K-3832-2017	Chelly, Jamel/0000-0002-0939-8719; Billuart, Pierre/0000-0003-1913-1687; ROEST CROLLIUS, Hugues/0000-0002-8209-173X				[Anonymous], 1982, MOL CLONING LAB MANU; Bienvenu T, 1997, EUR J HUM GENET, V5, P105, DOI 10.1159/000484743; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Davies HR, 1997, J MED GENET, V34, P158, DOI 10.1136/jmg.34.2.158; FERNANDEZ E, 1993, PCR METH APPL, V3, P122; Gedeon AK, 1996, AM J MED GENET, V64, P158, DOI 10.1002/(SICI)1096-8628(19960712)64:1<158::AID-AJMG26>3.3.CO;2-V; HERBST DS, 1980, AM J MED GENET, V7, P461, DOI 10.1002/ajmg.1320070407; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; KEL AE, 1993, COMPUT APPL BIOSCI, V9, P617; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; Lubs HA, 1996, AM J MED GENET, V64, P147, DOI 10.1002/(SICI)1096-8628(19960712)64:1<147::AID-AJMG25>3.0.CO;2-M; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	20	356	364	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 30	1998	392	6679					923	926		10.1038/31940	http://dx.doi.org/10.1038/31940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582072				2022-12-24	WOS:000073359900049
J	Puri, KD; Chen, SQ; Springer, TA				Puri, KD; Chen, SQ; Springer, TA			Modifying the mechanical property and shear threshold of L-selectin adhesion independently of equilibrium properties	NATURE			English	Article							HYDRODYNAMIC SHEAR; ROLLING ADHESIONS; SIALOMUCIN CD34; P-SELECTIN; LIGAND; FLOW; BOND	Interactions between adhesion molecules on two different cells differ from interactions between receptors and soluble ligands in that the adhesion molecule interaction (bond) is often subjected to force. It is widely assumed by cell biologists that the 'strength' of a bond is a simple function of the affinity of one adhesion molecule for the other, whereas biophysicists suggest that bonds have 'mechanical properties' that affect their strength. Mechanical properties are a function of the shape of the energy landscape related to bond formation and dissociation, whereas affinity is related only to the net energy change(1-5). Mechanical properties determine the amount by which the kinetics and affinity of bonds are altered by applied force. To date there has been no experimental manipulation of an adhesion molecule that has been shown to affect mechanical properties. L-selectin is an adhesion molecule that mediates lymphocyte binding to, and rolling on, high endothelial venules; these are prerequisites for the emigration of lymphocytes from the bloodstream into lymph nodes. Here we report a selective and reversible chemical modification of a mucin-like ligand that alters the mechanical properties of its bond with L-selectin. The effect of force on the rate of bond dissociation, that is, on a mechanical property, is altered, whereas there is little or no effect of the modification on the rate of bond dissociation in the absence of force. Moreover, the puzzling requirement for hydrodynamic shear flow above a threshold level for L-selectin interactions(6-9) is dramatically altered.	Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School	Springer, TA (corresponding author), Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.							Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Bruinsma R, 1997, P NATL ACAD SCI USA, V94, P375, DOI 10.1073/pnas.94.2.375; Chen SQ, 1997, P NATL ACAD SCI USA, V94, P3172, DOI 10.1073/pnas.94.7.3172; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; DEMBO M, 1994, LECT MATH LIFE SCI, V25, P1; Evans E, 1997, BIOPHYS J, V72, P1541, DOI 10.1016/S0006-3495(97)78802-7; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kyte J., 1995, STRUCTURE PROTEIN CH; LASKY LA, 1992, INFLAMMATION BASIC P, V2, P407; Lawrence MB, 1997, J CELL BIOL, V136, P717, DOI 10.1083/jcb.136.3.717; LECKBAND D, 1995, BIOPHYS J, V69, P1162, DOI 10.1016/S0006-3495(95)79990-8; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; NORGARD KE, 1993, P NATL ACAD SCI USA, V90, P1068, DOI 10.1073/pnas.90.3.1068; Pierres A, 1996, J PHYS III, V6, P807, DOI 10.1051/jp3:1996156; Puri KD, 1996, J BIOL CHEM, V271, P5404, DOI 10.1074/jbc.271.10.5404; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; Puri KD, 1997, J IMMUNOL, V158, P405; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Taylor AD, 1996, BIOPHYS J, V71, P3488, DOI 10.1016/S0006-3495(96)79544-9	24	63	68	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					930	933		10.1038/31954	http://dx.doi.org/10.1038/31954			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582074				2022-12-24	WOS:000073359900051
J	Zou, L; Stillman, B				Zou, L; Stillman, B			Formation of a preinitiation complex by S-phase cyclin CDK-dependent loading of Cdc45p onto chromatin	SCIENCE			English	Article							DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; CDC6 PROTEIN; YEAST; ORIGINS; TRANSITION; KINASES	Cdc45p, a protein essential for initiation of DNA replication, associates with chromatin after "start" in late G(1) and during the S phase of the cell cycle. Binding of Cdc45p to chromatin depends on Clb-Cdc28 kinase activity as well as functional Cdc6p and Mcm2p, which suggests that Cdc45p associates with the prereplication complex after activation of S-phase cyclin-dependent kinases (CDKs). As indicated by the timing and the CDK dependence, binding of Cdc45p to chromatin is crucial for commitment to initiation of DNA replication, During S phase, Cdc45p physically interacts with minichromosome maintenance (MCM) proteins on chromatin; however, dissociation of Cdc45p from chromatin is slower than that of MCMs, which indicates that the proteins are released by different mechanisms.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Grad Program Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Stillman, B (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	stillman@cshl.org		Stillman, Bruce/0000-0002-9453-4091	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045436] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45436] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Dalton S, 1997, MOL CELL BIOL, V17, P5867, DOI 10.1128/MCB.17.10.5867; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Elsasser S, 1996, MOL BIOL CELL, V7, P1723, DOI 10.1091/mbc.7.11.1723; Hardy CFJ, 1997, GENE, V187, P239, DOI 10.1016/S0378-1119(96)00761-5; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; Hopwood B, 1996, P NATL ACAD SCI USA, V93, P12309, DOI 10.1073/pnas.93.22.12309; Hoyt MA, 1997, CELL, V91, P149, DOI 10.1016/S0092-8674(00)80396-7; Jallepalli PV, 1996, GENE DEV, V10, P541, DOI 10.1101/gad.10.5.541; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LIANG C, GENES DEV, V11, P3375; Lopez-Girona A, 1998, MOL BIOL CELL, V9, P63, DOI 10.1091/mbc.9.1.63; LUCCHINI G, 1990, GENE, V90, P99, DOI 10.1016/0378-1119(90)90444-V; NASMYTH K, 1996, DNA REPLICATION EUKA, P311; Owens JC, 1997, P NATL ACAD SCI USA, V94, P12521, DOI 10.1073/pnas.94.23.12521; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; WEINREICH M, UNPUB; Young MR, 1997, MOL BIOL CELL, V8, P1587, DOI 10.1091/mbc.8.8.1587; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553; ZOU L, UNPUB	32	272	272	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1998	280	5363					593	596		10.1126/science.280.5363.593	http://dx.doi.org/10.1126/science.280.5363.593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554851				2022-12-24	WOS:000073242100048
J	Pantev, C; Oostenveld, R; Engelien, A; Ross, B; Roberts, LE; Hoke, M				Pantev, C; Oostenveld, R; Engelien, A; Ross, B; Roberts, LE; Hoke, M			Increased auditory cortical representation in musicians	NATURE			English	Article							ABSOLUTE PITCH; TONOTOPIC ORGANIZATION; CORTEX; FIELDS; ADULT	Acoustic stimuli are processed throughout the auditory projection pathway including the neocortex, by neurons that are aggregated into 'tonotopic' maps according to their specific frequency tunings(1-3). Research on animals has shown that tonotopic representations are not statically fixed in the adult organism but can reorganize after damage to the cochlea(4) or after training the intact subject to discriminate between auditory stimuli(5). Here we used functional magnetic source imaging (single dipole model) to measure cortical representations int highly skilled musicians. Dipole moments for piano tones, but not for pure tones of similar fundamental frequency (matched in loudness), were found to be enlarged by about 25% in musicians compared with control subjects who had never played an instrument. Enlargement was correlated with the age at which musicians began to practise and did not differ between musicians with absolute or relative pitch. These results, when interpreted with evidence for modified somatosensory representations of the fingering digits in skilled violinists(6), suggest that use-dependent functional reorganization extends across the sensory cortices to reflect the pattern of sensory input processed by the subject during development of musical skill.	Univ Munster, Inst Expt Audiol, Biomagnetism Ctr, D-48129 Munster, Germany; Univ Munster, Dept Neurol, D-48129 Munster, Germany; McMaster Univ, Dept Psychol, Hamilton, ON L8S 4K1, Canada	University of Munster; University of Munster; McMaster University	Pantev, C (corresponding author), Univ Munster, Inst Expt Audiol, Biomagnetism Ctr, D-48129 Munster, Germany.	pantev@uni-muenster.de	Oostenveld, Robert/D-3259-2009	Oostenveld, Robert/0000-0002-1974-1293; Ross, Bernhard/0000-0001-7290-631X				BARNEA A, 1994, INT J PSYCHOPHYSIOL, V16, P29, DOI 10.1016/0167-8760(94)90039-6; BENGUEREL AP, 1991, MUSIC PERCEPT, V9, P105; ELBERT T, 1995, SCIENCE, V270, P305, DOI 10.1126/science.270.5234.305; Irvine D. R. F., 1995, ADV HEARING RES, P3; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; MERZENICH MM, 1976, J COMP NEUROL, V166, P387, DOI 10.1002/cne.901660402; MERZENICH MM, 1973, BRAIN RES, V63, P343, DOI 10.1016/0006-8993(73)90101-7; PANTEV C, 1988, ELECTROEN CLIN NEURO, V69, P160, DOI 10.1016/0013-4694(88)90211-8; RAUSCHECKER JP, 1995, SCIENCE, V268, P111, DOI 10.1126/science.7701330; RECANZONE GH, 1993, J NEUROSCI, V13, P87; SCHLAUG G, 1995, SCIENCE, V267, P699, DOI 10.1126/science.7839149; TAKEUCHI AH, 1993, PSYCHOL BULL, V113, P345, DOI 10.1037/0033-2909.113.2.345; WILLIAMSON SJ, 1990, AUDITORY EVOKED MAGN, P1; Yakovlev PL, 1967, REGIONAL DEV BRAIN E, P3	14	576	589	4	83	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1998	392	6678					811	814		10.1038/33918	http://dx.doi.org/10.1038/33918			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZJ679	9572139				2022-12-24	WOS:000073241200052
J	Zhang, PJ; Toyoshima, C; Yonekura, K; Green, NM; Stokes, DL				Zhang, PJ; Toyoshima, C; Yonekura, K; Green, NM; Stokes, DL			Structure of the calcium pump from sarcoplasmic reticulum at 8-angstrom resolution	NATURE			English	Article							AMINO-ACIDS; NA,K PUMP; CA-2+-ATPASE; MEMBRANE; ATPASE; CA2+-ATPASE; THAPSIGARGIN; MUTAGENESIS; LOCATION; MUTATION	The calcium pump from sarcoplasmic reticulum (Ca2+-ATPase) is typical of the large family of P-type cation pumps. These couple ATP hydrolysis with cation transport, generating cation gradients across membranes. Ca2+-ATPase specifically maintains the low cytoplasmic calcium concentration of resting muscle by pumping calcium into the sarcoplasmic reticulum; subsequent release is used to initiate contraction. No high-resolution structure of a P-type pump has yet been determined, although a 14-Angstrom structure of Ca2+-ATPase, obtained by electron microscopy of frozen-hydrated, tubular crystals(1), showed a large cytoplasmic head connected to the transmembrane domain by a narrow stalk. We have now improved the resolution to 8 Angstrom and can discern ten transmembrane ol-helices, four of which continue into the stalk. On the basis of constraints from transmembrane topology, site-directed mutagenesis and disulphide crosslinking, we have made tentative assignments for these alpha-helices within the amino-acid sequence. A distinct cavity leads to the putative calcium-binding site, providing a plausible path for calcium release to the lumen of the sarcoplasmic reticulum.	NYU, Med Ctr, Skirball Inst Biomol Med, New York, NY 10016 USA; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 113, Japan; Natl Inst Med Res, London NW7 1AA, England	New York University; University of Tokyo; MRC National Institute for Medical Research	Stokes, DL (corresponding author), NYU, Med Ctr, Skirball Inst Biomol Med, 540 1st Ave, New York, NY 10016 USA.		YONEKURA, Koji/N-5060-2015; Toyoshima, Chikashi/R-4153-2019	Toyoshima, Chikashi/0000-0001-9640-0778; Yonekura, Koji/0000-0001-5520-4391				Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BEORUKHIM R, 1997, ULTRAMICROSCOPY, V70, P57; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DUX L, 1983, J BIOL CHEM, V258, P2599; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; GREEN NM, 1994, SODIUM PUMP, P110; GREEN NM, 1989, BIOCHEM SOC T, V17, P970; Guerini D, 1996, BIOCHEMISTRY-US, V35, P3290, DOI 10.1021/bi952572f; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; HUA SM, 1995, BIOCHEMISTRY-US, V34, P5137, DOI 10.1021/bi00015a026; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; STOKES DL, 1994, J BIOL CHEM, V269, P11606; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; TANI K, 1997, ULTRAMICROSCOPY, V65, P31; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; TOYOSHIMA C, 1993, ULTRAMICROSCOPY, V48, P165, DOI 10.1016/0304-3991(93)90179-2	26	271	275	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1998	392	6678					835	839		10.1038/33959	http://dx.doi.org/10.1038/33959			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572145				2022-12-24	WOS:000073241200059
J	Dell'Angelica, EC; Klumperman, J; Stoorvogel, W; Bonifacino, JS				Dell'Angelica, EC; Klumperman, J; Stoorvogel, W; Bonifacino, JS			Association of the AP-3 adaptor complex with clathrin	SCIENCE			English	Article							PROTEIN; VESICLES; MEMBRANE; SUBUNITS; BINDING; GOLGI	A heterotetrameric complex termed AP-3 is involved in signal-mediated protein sorting to endosomal-lysosomal organelles. AP-3 has been proposed to be a component of a nonclathrin coat. In vitro binding assays showed that mammalian AP-3 did associate with clathrin by interaction of the appendage domain of its beta 3 subunit with the amino-terminal domain of the clathrin heavy chain. The beta 3 appendage domain contained a conserved consensus motif for clathrin binding. AP-3 colocalized with clathrin in cells as observed by immunofluorescence and immunoelectron microscopy. Thus, AP-3 function in protein sorting may depend on clathrin.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Univ Utrecht, Sch Med, Dept Cell Biol, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Utrecht University	Bonifacino, JS (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.	juan@helix.nih.gov		Bonifacino, Juan S./0000-0002-5673-6370				BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; Brodsky FM, 1997, TRENDS CELL BIOL, V7, P175, DOI 10.1016/S0962-8924(97)01038-6; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; DELLANGELICA EC, UNPUB; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; Ooi CE, 1997, EMBO J, V16, P4508; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; Ramjaun A. R., 1997, Molecular Biology of the Cell, V8, p93A; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; Seymour A. B., 1997, Molecular Biology of the Cell, V8, p227A; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x	27	298	303	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1998	280	5362					431	434		10.1126/science.280.5362.431	http://dx.doi.org/10.1126/science.280.5362.431			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545220				2022-12-24	WOS:000073159600046
J	O'Brien, KL; Selanikio, JD; Hecdivert, C; Placide, MF; Louis, M; Barr, DB; Barr, JR; Hospedales, CJ; Lewis, MJ; Schwartz, B; Philen, RM; St Victor, S; Espindola, J; Needham, LL; Denerville, K				O'Brien, KL; Selanikio, JD; Hecdivert, C; Placide, MF; Louis, M; Barr, DB; Barr, JR; Hospedales, CJ; Lewis, MJ; Schwartz, B; Philen, RM; St Victor, S; Espindola, J; Needham, LL; Denerville, K		Acute Renal Failure Invest Team	Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG	Context.-Contaminated pharmaceutical products can result in substantial morbidity and mortality and should be included in the differential diagnosis of deaths of unknown origin. Objective.-To investigate an outbreak of deaths among children from acute renal failure in Haiti to determine the etiology and institute control measures. Design.-Case-control study, cohort study, and laboratory toxicologic evaluation. Setting.-Pediatric population of Haiti. Participants.-Cases were defined as Haitian residents younger than 18 years with idiopathic anuria or severe oliguria for 24 hours or longer, Febrile hospitalized children without renal failure were enrolled as control subjects. Main Outcome Measure.-The odds of exposure to suspected etiologic agents among cases and controls. Results.-We identified 109 cases of acute renal failure among children. The clinical syndrome included renal failure, hepatitis, pancreatitis, central nervous system impairment, coma, and death, Of 87 patients with follow-up information who remained in Haiti for treatment, 85 (98%) died; 3 (27%) of 11 patients transported to the United States for intensive care unit management died before hospital discharge. A locally manufactured acetaminophen syrup was highly associated with disease (odds ratio, 52.7; 95% confidence interval, 15.2-197.2), Diethylene glycol (DEG) was found in patients' bottles in a median concentration of 14.4%, The median estimated toxic dose of DEG was 1.34 mL/kg (range, 0.22-4.42 mL/kg). Glycerin, a raw material imported to Haiti and used in the acetaminophen formulation, was contaminated with 24% DEG. Conclusions.-An epidemic of severe systemic toxicity and deaths from DEG-contaminated acetaminophen syrup occurred in Haiti. Good manufacturing practice regulations should be used by all pharmaceutical manufacturers to prevent such tragedies.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Resp Dis Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Epidem Intelligence Serv, Atlanta, GA 30333 USA; Minist Publ & Populat, Port au Prince, Haiti; Univ Etat Haiti, Inst Haiten Enfance, Port au Prince, Haiti; Pan Amer Hlth Org, Port au Prince, Haiti; Pan Amer Hlth Org, Caribbean Epidemiol Ctr, Port of Spain, Trinidad Tobago	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Pan American Health Organization; Pan American Health Organization	O'Brien, KL (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Resp Dis Branch, 1600 Clifton Rd,Mailstop C-23, Atlanta, GA 30333 USA.		Barr, Dana B/E-2276-2013; Needham, Larry/E-4930-2011; Barr, Dana B/E-6369-2011	O'Brien, Katherine/0000-0002-0164-4030				CALVERY H. 0., 1939, SOUTHERN MED JOUR, V32, P1105; CANTARELL MC, 1987, ANN INTERN MED, V106, P478, DOI 10.7326/0003-4819-106-3-478_2; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P649; CLAESON M, 1990, PEDIATR INFECT DIS J, V9, P345, DOI 10.1097/00006454-199005000-00008; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; Douglas R M, 1991, Semin Respir Infect, V6, P217; DRUT R, 1994, MEDICINA-BUENOS AIRE, V54, P1; Geiling EMK., 1938, J AM MED ASS, V111, P919, DOI [10.1001/jama.1938.72790360005007, DOI 10.1001/JAMA.1938.72790360005007]; GRANT JP, 1988, STATE WORLDS CHILDRE; HANIF M, 1995, BRIT MED J, V311, P88, DOI 10.1136/bmj.311.6997.88; KENYON TA, 1994, B WORLD HEALTH ORGAN, V72, P615; OKUONGHAE HO, 1992, ANN TROP PAEDIATR, V12, P235, DOI 10.1080/02724936.1992.11747577; PANDYA SK, 1988, BRIT MED J, V297, P117, DOI 10.1136/bmj.297.6641.117; *POISINDEX ED STAF, 1998, POISINDEX SYST, V95; WAX PM, 1995, ANN INTERN MED, V122, P456, DOI 10.7326/0003-4819-122-6-199503150-00009	15	123	129	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1998	279	15					1175	1180		10.1001/jama.279.15.1175	http://dx.doi.org/10.1001/jama.279.15.1175			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG133	9555756	Bronze			2022-12-24	WOS:000072969400030
J	Duggan, AE; Tolley, K; Hawkey, CJ; Logan, RFA				Duggan, AE; Tolley, K; Hawkey, CJ; Logan, RFA			Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model	BRITISH MEDICAL JOURNAL			English	Article							DUODENAL-ULCER; THERAPY	Objective: To determine how small differences in the efficacy and cost of two antibiotic regimens to eradicate Helicobacter pylori can affect the overall cost effectiveness of H pylori eradication in duodenal ulcer disease. Design: A decision analysis to examine the cost effectiveness of eight H pylori eradication strategies for duodenal ulcer disease with and without C-13-urea breath testing to confirm eradication. Main outcome measures: Cumulative direct treatment costs per 100 patients with duodenal ulcer disease who were positive for H pylori. Results: In model 1 the strategy of omeprazole, clarithromycin, and metronidazole alone was the most cost effective of the four strategies assessed. The addition of the C-13-urea breath test and a second course of omeprazole, clarithromycin, and metronidazole achieved the highest eradication rate (97%) but was the most expensive (pound 62.63 per patient). The cost of each additional effective eradication was pound 589.00 (incremental cost per case) when compared with the cost of treating once only with omeprazole, clarithromycin, and metronidazole; equivalent to the cost of a patient receiving ranitidine for duodenal ulcer relapse for more than 15 years. Eradication strategies of omeprazole, amoxycillin, and metronidazole were less cost effective than omeprazole, clarithromycin, and metronidazole alone. in model 2 the addition of the C-13-urea breath test after treatment, and maintenance treatment, increased die cost of all the strategies and reduced the cost advantage of omeprazole, clarithromycin, and metronidazole alone. Conclusion: Small differences in efficacy can influence the comparative cost effectiveness of strategies for eradicating H pylori Of the strategies tested the most cost effective (omeprazole, clarithromycin, and metronidazole alone) was neither the least expensive (omeprazole, amoxycillin, and metronidazole alone) nor the most effective (omeprazole, clarithromycin, and metronidazole with further treatment for patients found positive for H pylori on C-13-urea breath testing). Cost effectiveness should be an important part of choosing an eradication strategy for H pylori.	Univ Nottingham, Dept Publ Hlth & Epidemiol, Nottingham NG7 2UH, England; Univ Nottingham, Div Gastroenterol, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Duggan, AE (corresponding author), Univ Nottingham, Dept Publ Hlth & Epidemiol, Nottingham NG7 2UH, England.			hobbs, richard/0000-0001-7976-7172				BELL GD, 1993, BR J MED EC, V6, P45; Carrere MO, 1997, PHARMACOECONOMICS, V11, P216, DOI 10.2165/00019053-199711030-00003; Johnston BJ, 1997, GUT, V41, pA166; Karlsson G, 1996, PHARMACOECONOMICS, V9, P113, DOI 10.2165/00019053-199609020-00003; LAMOULIATTE H, 1996, GASTROENTEROLOGY, V110, pA170; LOGAN RPH, 1996, CLIN CHALLENGES GAST, P42; MOAYYEDI P, 1995, EUR J GASTROEN HEPAT, V7, P835; PENSTON JG, 1993, ALIMENT PHARM THERAP, V7, P259; POUNDER RE, 1981, LANCET, V1, P29; PYM B, 1990, GASTROENTEROLOGY, V99, P27, DOI 10.1016/0016-5085(90)91225-U; SONNENBERG A, 1989, GASTROENTEROLOGY, V96, P1445, DOI 10.1016/0016-5085(89)90511-8; SONNENBERG A, 1996, GUT, V39, pA37; Sugden R., 1978, PRINCIPLES PRACTICAL; van der Hulst R W, 1996, Helicobacter, V1, P6	14	25	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1998	316	7145					1648	1654		10.1136/bmj.316.7145.1648	http://dx.doi.org/10.1136/bmj.316.7145.1648			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR867	9603748	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000074022700025
J	Smith, GD; Hart, C; Blane, D; Hole, D				Smith, GD; Hart, C; Blane, D; Hole, D			Adverse socioeconomic conditions in childhood and cause specific adult mortality: prospective observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; HELICOBACTER-PYLORI; CARDIOVASCULAR-DISEASE; LIVING-CONDITIONS; STOMACH-CANCER; SOCIAL-CLASS; RISK-FACTORS; EARLY-LIFE; MEN; ENGLAND	Objective: To investigate the association between social circumstances in childhood and mortality from various causes of death in adulthood. Design: Prospective observational study. Setting: 27 workplaces in the west of Scotland. Subjects: 5645 men aged 35-64 years at the time of examination. Main outcome measures: Death from various causes. Results: Men whose fathers had manual occupations when they were children were more likely as adults to have manual jobs and be living in deprived areas. Gradients in mortality fi-om coronary heart disease, stroke, lung cancer, stomach cancer, and respiratory disease were seen tall P < 0.05), generally increasing from men whose fathers had professional and managerial occupations (social class I and II) to those whose fathers had semiskilled and unskilled manual occupations (social class IV and V). Relative rates of mortality adjusted for age for men with fathers in manual versus non-manual occupations were 1.52 (95% confidence interval 1.24 to 1.87) for coronary heart disease, 1.83 (1.13 to 2.94) for stroke, 1.65 (1.12 to 2.43) for lung cancer, 2.06 (0.93 to 4.57) for stomach cancer, and 2.01 (1.17 to 3.48) for respiratory disease. Mortality from other cancers and accidental and violent death showed no association with fathers' social class. Adjustment for adult socioeconomic circumstances and risk factors did not alter results for mortality from stroke and stomach cancer, attenuated the increased risk of coronary heart disease and respiratory disease, and essentially eliminated the association with lung cancer. Conclusions: Adverse socioeconomic circumstances in childhood have a specific influence on mortality from stroke and stomach cancer in adulthood, which is not due to the continuity of social disadvantage throughout life. Deprivation in childhood influences risk of mortality from coronary heart disease and respiratory disease in adulthood, although an additive influence of adulthood circumstances is seen in these cases. Mortality from lung cancer, other cancer, and accidents and violence is predominantly influenced by risk factors that are related to social circumstances in adulthood.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland; Univ London Imperial Coll Sci Technol & Med, Div Neurosci, London W6 8RP, England; Ruchill Hosp, W Scotland Canc Surveillance Unit, Glasgow G20 9NB, Lanark, Scotland	University of Bristol; University of Glasgow; Imperial College London; University of Glasgow	Smith, GD (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall, Bristol BS8 2PR, Avon, England.	zetkin@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				BANATVALA N, 1993, J INFECT DIS, V168, P219, DOI 10.1093/infdis/168.1.219; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1990, BRIT J CANCER, V61, P575, DOI 10.1038/bjc.1990.129; BARKER DJP, 1990, ANN HUM BIOL, V17, P1, DOI 10.1080/03014469000000732; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; Blane D, 1996, BMJ-BRIT MED J, V313, P1434, DOI 10.1136/bmj.313.7070.1434; BURR ML, 1980, J EPIDEMIOL COMMUN H, V34, P93, DOI 10.1136/jech.34.2.93; COGGON D, 1990, BRIT J CANCER, V61, P573, DOI 10.1038/bjc.1990.128; ELO IT, 1992, POPUL INDEX, V58, P186, DOI 10.2307/3644718; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; FORSDAHL A, 1977, BRIT J PREV SOC MED, V31, P91; HASTE H, 1990, BRIT MED J, V300, P289; KRIEGER N, IN PRESS AM J EPIDEM; KUH D, 1993, SOC HIST MED, V6, P101; LEON DA, 1995, J EPIDEMIOL COMMUN H, V49, P5, DOI 10.1136/jech.49.1.5; MANN SL, 1992, J EPIDEMIOL COMMUNIT, V46, P256; Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MURRAY M, 1962, ANN ASSOC AM GEOGR, V52, P130, DOI 10.1111/j.1467-8306.1962.tb00401.x; NOTKOLA V, 1985, SOC SCI MED, V21, P517, DOI 10.1016/0277-9536(85)90035-8; PAYNE G, 1987, EMPLOYMENT OPPORTUNI; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P486, DOI 10.2105/AJPH.86.4.486; Smith GD, 1997, BMJ-BRIT MED J, V314, P547, DOI 10.1136/bmj.314.7080.547; Smith GD, 1994, EUROPEAN J PUBLIC HL, V4, P131, DOI DOI 10.1093/EURPUB/4.2.131; VAGERO D, 1994, LANCET, V343, P1224, DOI 10.1016/S0140-6736(94)92432-5; Wannamethee SG, 1996, LANCET, V348, P1259, DOI 10.1016/S0140-6736(96)02465-8; WATT GCM, 1995, SCOT MED J, V40, P108, DOI 10.1177/003693309504000403; WU JM, 1991, P 4 INT C COMB EFF E	29	433	439	1	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 30	1998	316	7145					1631	1635		10.1136/bmj.316.7145.1631	http://dx.doi.org/10.1136/bmj.316.7145.1631			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZR867	9603744	Green Accepted, Green Published, Green Submitted, Bronze			2022-12-24	WOS:000074022700019
J	Borg-Graham, LJ; Monier, C; Fregnac, Y				Borg-Graham, LJ; Monier, C; Fregnac, Y			Visual input evokes transient and strong shunting inhibition in visual cortical neurons	NATURE			English	Article							ORIENTATION SELECTIVITY; PYRAMIDAL CELLS; STRIATE CORTEX; CAT; MECHANISMS; EXCITATION; POTENTIALS; RESPONSES; SUMMATION; RAT	The function and nature of inhibition of neurons in the visual cortex have been the focus of both experimental and theoretical investigations(1-7), There are two ways in which inhibition can suppress synaptic excitation(2,8). In hyperpolarizing inhibition, negative and positive currents sum linearly to produce a net change in membrane potential. In contrast, shunting inhibition acts nonlinearly by causing an increase in membrane conductance; this divides the amplitude of the excitatory response. Visually evoked changes in membrane conductance have been reported to be nonsignificant or weak, supporting the hyperpolarization mode of inhibition(3,9-12). Here we present a new approach to studying inhibition that is based on in vivo whole-cell voltage clamping. This technique allows the continuous measurement of conductance dynamics during visual activation. We show, in neurons of cat primary visual cortex, that the response to optimally orientated flashed bars can increase the somatic input conductance to more than three times that of the resting state. The short latency of the visually evoked peak of conductance, and its apparent reversal potential suggest a dominant contribution from gamma-aminobutyric acid ((GABA)(A)) receptor-mediated synapses. We propose that nonlinear shunting inhibition may act during the initial stage of visual cortical processing, setting the balance between opponent 'On' and 'Off' responses in different locations of the visual receptive field.	CNRS, Inst Alfred Fessard, Equipe Cognisci, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Fregnac, Y (corresponding author), CNRS, Inst Alfred Fessard, Equipe Cognisci, Ave Terrasse, F-91198 Gif Sur Yvette, France.	fregnac@iaf.cnrs-gif.fr						ANDERSON JC, 1994, J COMP NEUROL, V341, P25, DOI 10.1002/cne.903410104; BARKER JL, 1988, J PHYSIOL-LONDON, V403, P41, DOI 10.1113/jphysiol.1988.sp017237; BERMAN NJ, 1991, J PHYSIOL-LONDON, V440, P697, DOI 10.1113/jphysiol.1991.sp018731; BERMAN NJ, 1989, J PHYSIOL-LONDON, V418, pP107; Bringuier V, 1997, J PHYSIOL-LONDON, V500, P751, DOI 10.1113/jphysiol.1997.sp022056; BUSH PC, 1994, J NEUROPHYSIOL, V71, P2183, DOI 10.1152/jn.1994.71.6.2183; Carandini M, 1997, SCIENCE, V276, P949, DOI 10.1126/science.276.5314.949; CARANDINI M, 1994, SCIENCE, V264, P1333, DOI 10.1126/science.8191289; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; DEBANNE D, 1998, J PHYSL, V500, P523; DOUGLAS RJ, 1988, NATURE, V332, P642, DOI 10.1038/332642a0; DREIFUSS JJ, 1969, EXP BRAIN RES, V9, P137, DOI 10.1007/BF00238327; Eccles, 2013, PHYSL SYNAPSES; FERSTER D, 1988, J NEUROSCI, V8, P1172; FERSTER D, 1992, J NEUROSCI, V12, P1262; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JAGADEESH B, 1993, SCIENCE, V262, P1901, DOI 10.1126/science.8266083; KOCH C, 1990, J NEUROSCI, V10, P1728; KOCH C, 1985, MODELS VISUAL CORTEX, P408; NEHER E, 1992, METHOD ENZYMOL, V207, P123; NELSON S, 1994, SCIENCE, V265, P774, DOI 10.1126/science.8047882; Orban GA, 1984, STUDIES BRAIN FUNCTI; PALMER LA, 1981, J NEUROPHYSIOL, V46, P260, DOI 10.1152/jn.1981.46.2.260; Rall W, 1964, NEURAL THEORY MODELI, P73; SHULZ D, 1993, SOC NEUR ABSTR, V19, P638; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P305, DOI 10.1113/jphysiol.1975.sp011056; SPRUSTON N, 1993, J NEUROPHYSIOL, V70, P781, DOI 10.1152/jn.1993.70.2.781; VOLGUSHEV M, 1993, VISUAL NEUROSCI, V10, P1151, DOI 10.1017/S0952523800010257; XING P, 1991, NEUROREPORT, V2, P485	29	506	515	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 28	1998	393	6683					369	373		10.1038/30735	http://dx.doi.org/10.1038/30735			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620800				2022-12-24	WOS:000073883600055
J	McLatchie, LM; Fraser, NJ; Main, MJ; Wise, A; Brown, J; Thompson, N; Solari, R; Lee, MG; Foord, SM				McLatchie, LM; Fraser, NJ; Main, MJ; Wise, A; Brown, J; Thompson, N; Solari, R; Lee, MG; Foord, SM			RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor	NATURE			English	Article							GENE-RELATED-PEPTIDE; XENOPUS-OOCYTES; ADRENOMEDULLIN; IDENTIFICATION; CLONING; CELLS; EXPRESSION; BRAIN	Calcitonin-gene-related peptide (CORP) and adrenomedullin are related peptides with distinct pharmacological profiles. Here we show that a receptor with seven transmembrane domains, the calcitonin-receptor-like receptor (CRLR), can function as either a CORP receptor or an adrenomedullin receptor, depending on which members of a new family of single-transmembrane-domain proteins, which we have called receptor-activity-modifying proteins or RAMPs, are expressed. RAMPs are required to transport CRLR to the plasma membrane. RAMP1 presents the receptor at the cell surface as a mature glycoprotein and a CORP receptor. RAMP2-transported receptors are core-glycosylated and are adrenomedullin receptors.	Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Receptor Syst Unit, Stevenage SG1 2NY, Herts, England; Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Cell Biol Unit, Stevenage SG1 2NY, Herts, England	GlaxoSmithKline; GlaxoSmithKline	Foord, SM (corresponding author), Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Receptor Syst Unit, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.							Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; Chen WJ, 1997, MOL PHARMACOL, V52, P1164, DOI 10.1124/mol.52.6.1164; FLUHMANN B, 1995, BIOCHEM BIOPH RES CO, V206, P341, DOI 10.1006/bbrc.1995.1047; FOORD SM, 1987, EUR J BIOCHEM, V170, P373, DOI 10.1111/j.1432-1033.1987.tb13710.x; GUILLEMARE E, 1994, PFLUG ARCH EUR J PHY, V428, P604, DOI 10.1007/BF00374584; Han ZQ, 1997, J MOL ENDOCRINOL, V18, P267, DOI 10.1677/jme.0.0180267; Kapas S, 1995, BIOCHEM BIOPH RES CO, V217, P832, DOI 10.1006/bbrc.1995.2847; KAPAS S, 1995, J BIOL CHEM, V270, P25344, DOI 10.1074/jbc.270.43.25344; KATO J, 1995, EUR J PHARM-MOLEC PH, V289, P383, DOI 10.1016/0922-4106(95)90117-5; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; Luebke AE, 1996, P NATL ACAD SCI USA, V93, P3455, DOI 10.1073/pnas.93.8.3455; MUFF R, 1995, EUR J ENDOCRINOL, V133, P17, DOI 10.1530/eje.0.1330017; NJUKI F, 1993, CLIN SCI, V85, P385, DOI 10.1042/cs0850385; Osajima A, 1996, EUR J PHARMACOL, V315, P319, DOI 10.1016/S0014-2999(96)00557-2; Owji AA, 1996, J NEUROCHEM, V67, P2172; Perry KJ, 1997, ENDOCRINOLOGY, V138, P3486, DOI 10.1210/en.138.8.3486; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POYNER DR, 1992, PHARMACOL THERAPEUT, V56, P23, DOI 10.1016/0163-7258(92)90036-Y; SIMMONS D, 1988, J IMMUNOL, V141, P2797; STANGL D, 1991, BIOCHEMISTRY-US, V30, P8605, DOI 10.1021/bi00099a016; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; UEZONO Y, 1993, RECEPTOR CHANNEL, V1, P233; WANG XK, 1995, P NATL ACAD SCI USA, V92, P11480, DOI 10.1073/pnas.92.25.11480; ZIMMERMANN U, 1995, PEPTIDES, V16, P421, DOI 10.1016/0196-9781(94)00195-C; Zimmermann U, 1996, BRAIN RES, V724, P238, DOI 10.1016/0006-8993(96)00337-X; ZIMMERMANN U, 1990, NEUROSCI LETT, V119, P195	27	1770	1863	0	68	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1998	393	6683					333	339		10.1038/30666	http://dx.doi.org/10.1038/30666			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620797				2022-12-24	WOS:000073883600044
J	Delacretaz, E; Michalopoulos, PG; Ruiz, J; Saner, H; Meier, B				Delacretaz, E; Michalopoulos, PG; Ruiz, J; Saner, H; Meier, B			Management of hyperlipidaemia after coronary revascularisation: follow up study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; CHOLESTEROL; PREVENTION		Univ Hosp Bern, CH-3010 Bern, Switzerland; Univ Lausanne Hosp, Div Endocrinol, CH-1011 Lausanne, Switzerland	University of Bern; University Hospital of Bern; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Delacretaz, E (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	edelacreta@bics.bwh.harvard.edu						BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Luepker Russell V., 1997, American Journal of Medicine, V102, P37, DOI 10.1016/S0002-9343(97)00466-X; PEDERSEN TR, 1994, LANCET, V344, P1383; PYORALA K, 1994, EUR HEART J, V15, P1300	5	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 16	1998	316	7143					1499	1499		10.1136/bmj.316.7143.1499	http://dx.doi.org/10.1136/bmj.316.7143.1499			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP020	9582137	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000073707700027
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Zeptomolar damage	SCIENCE			English	Editorial Material																		Le XC, 1998, SCIENCE, V280, P1066, DOI 10.1126/science.280.5366.1066	1	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1101	1102						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9616083				2022-12-24	WOS:000073663600054
J	Francis, ST; Duncan, KR; Moore, RJ; Baker, PN; Johnson, IR; Gowland, PA				Francis, ST; Duncan, KR; Moore, RJ; Baker, PN; Johnson, IR; Gowland, PA			Non-invasive mapping of placental perfusion	LANCET			English	Article							PLANAR MAGNETIC-RESONANCE; FETAL GROWTH-RETARDATION; PREGNANCY; WEIGHT	Background. We aim to develop a clinical technique for the non-invasive measurement of placental perfusion, to enable early detection of intrauterine growth restriction (IUGR). Pregnancies with this complication are characterised by low placental perfusion. Methods. We measured placental perfusion by means of perfusion-sensitive echoplanar imaging (EPI); a rapid method of making magnetic resonance images. Perfusion measurements were done on six healthy volunteers with normal pregnancies and nine with pregnancies complicated by IUGR. Perfusion maps were created to assess the relation between placental perfusion and fetal size at birth. Findings. Pregnancies complicated by IUGR differed significantly from normal pregnancies in patterns of perfusion within the placenta (p < 0.0001, ANOVA). Subsequent analysis showed that the proportion of placentas with low perfusion rates was higher in the IUGR group than in the normal group. A significant correlation between areas of reduced placental perfusion and fetal size was demonstrated (p = 0.041, Spearman's rank correlation). Interpretation. Non-invasive imaging of placental perfusion by means of EPI has potential as a clinical tool in assessing the dynamics of placental perfusion.	Univ Nottingham, Dept Phys, Magnet Resonance Ctr, Nottingham NG7 2RD, England; City Hosp, Dept Obstet & Gynaecol, Nottingham NG5 1PB, England	University of Nottingham; University of Nottingham	Gowland, PA (corresponding author), Univ Nottingham, Dept Phys, Magnet Resonance Ctr, Nottingham NG7 2RD, England.		Gowland, Penny A./I-9016-2012	Gowland, Penny A./0000-0002-4900-4817; Baker, Philip/0000-0002-4592-6427				BAKER PN, 1994, LANCET, V343, P644, DOI 10.1016/S0140-6736(94)92638-7; BAKER PN, 1994, AM J OBSTET GYNECOL, V170, P32; BODIS J, 1985, EUR J NUCL MED, V10, P286, DOI 10.1007/BF00254477; DOBSON PC, 1981, AUST NZ J OBSTET GYN, V21, P69, DOI 10.1111/j.1479-828X.1981.tb00781.x; Duncan K, 1996, BRIT MED J, V312, P1421; GOWLAND PA, IN PRESS MAGN RESON; HOWSEMAN AM, 1988, BRIT J RADIOL, V61, P822, DOI 10.1259/0007-1285-61-729-822; KWONG KK, 1995, MAGNET RESON MED, V34, P878, DOI 10.1002/mrm.1910340613; MANSFIELD P, 1990, BRIT J RADIOL, V63, P833, DOI 10.1259/0007-1285-63-755-833; NICOLAIDES KH, 1988, BRIT MED J, V297, P1026, DOI 10.1136/bmj.297.6655.1026; SHEPPARD BL, 1981, BRIT J OBSTET GYNAEC, V88, P695, DOI 10.1111/j.1471-0528.1981.tb01268.x; WILCOX MA, 1993, BRIT J OBSTET GYNAEC, V100, P342, DOI 10.1111/j.1471-0528.1993.tb12977.x	12	74	78	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 9	1998	351	9113					1397	1399		10.1016/S0140-6736(97)07089-X	http://dx.doi.org/10.1016/S0140-6736(97)07089-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM665	9593410				2022-12-24	WOS:000073563400010
J	Petukhova, G; Stratton, S; Sung, P				Petukhova, G; Stratton, S; Sung, P			Catalysis of homologous DNA pairing by yeast Rad51 and Rad54 proteins	NATURE			English	Article							STRAND EXCHANGE; RECOMBINATION; GENE	The Saccharomyces cerevisiae RAD51 and RAD54 genes are both required for the occurrence of homologous recombination and for the repair of double-stranded DNA breaks(1). Previous studies have indicated that Rad51 protein, together with the single-stranded DNA-binding factor replication protein A (RPA), can promote the formation of heteroduplex DNA(2-4), which is a key intermediate in homologous recombination(1), Here we report the purification of the Rad54 protein to near homogeneity and the biochemical testing of its molecular function. We find that Rad54 protein possesses a double-stranded DNA-dependent ATPase activity, and GRAPHICS that it interacts with the Rad51 protein. Addition of Rad54 protein to reactions containing Rad51 strongly stimulates the rate of pairing between homologous single-stranded and double-stranded DNA molecules. We conclude that Rad54 acts to overcome kinetic impediments that would limit homologous DNA pairing between recombining chromosomes in vivo.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Sung, P (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA.	sung@uthscsa.edu						Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RANDERATH K, 1964, J CHROMATOGR, V16, P111, DOI 10.1016/S0021-9673(01)82445-6; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4	17	342	353	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1998	393	6680					91	94		10.1038/30037	http://dx.doi.org/10.1038/30037			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590697				2022-12-24	WOS:000073497500055
J	Vu, TH; Shipley, JM; Bergers, G; Berger, JE; Helms, JA; Hanahan, D; Shapiro, SD; Senior, RM; Werb, Z				Vu, TH; Shipley, JM; Bergers, G; Berger, JE; Helms, JA; Hanahan, D; Shapiro, SD; Senior, RM; Werb, Z			MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes	CELL			English	Article							MATRIX METALLOPROTEINASES; IN-VITRO; INTERSTITIAL COLLAGENASE; MOUSE DEVELOPMENT; INDIAN HEDGEHOG; BONE-GROWTH; EXPRESSION; GENE; DEGRADATION; CARTILAGE	Homozygous mice with a null mutation in the MMP-9/gelatinase B gene exhibit an abnormal pattern of skeletal growth plate vascularization and ossification. Although hypertrophic chondrocytes develop normally, apoptosis, vascularization, and ossification are delayed, resulting in progressive lengthening of the growth plate to about eight times normal. After 3 weeks postnatal, aberrant apoptosis, vascularization, and ossification compensate to remodel the enlarged growth plate and ultimately produce an axial skeleton of normal appearance. Transplantation of wild-type bone marrow cells rescues vascularization and ossification in gelatinase B-null growth plates, indicating that these processes are mediated by gelatinase B-expressing cells of bone marrow origin, designated chondroclasts. Growth plates from gelatinase B-null mice in culture show a delayed release of an angiogenic activator, establishing a role for this proteinase in controlling angiogenesis.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Dept Orthoped Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Hormone Res Inst, San Francisco, CA 94143 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Internal Med,Div Pulm & Crit Care Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	Vu, TH (corresponding author), Univ Calif San Francisco, Dept Anat, Box 0452, San Francisco, CA 94143 USA.		Bergers, Gabriele/AAJ-5535-2020	Helms, Jill/0000-0002-0463-396X; Bergers, Gabriele/0000-0003-3545-5171	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD026732] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA037395, R37CA037395] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007185, R01HL047328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010306] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA037395, R01 CA037395, R01 CA037395-19] Funding Source: Medline; NHLBI NIH HHS [T32 HL007185-26, T32 HL007185, HL47328, R01 HL047328-08, R01 HL047328] Funding Source: Medline; NICHD NIH HHS [P01 HD026732-070003, HD26732] Funding Source: Medline; NIDCR NIH HHS [P50 DE010306-05S10005, DE10306] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AHARINEJAD S, 1995, ANAT REC, V242, P111, DOI 10.1002/ar.1092420115; Albrecht U, 1997, MOL CELLULAR METHODS, P23; Alexander CM, 1996, DEVELOPMENT, V122, P1723; Alini M, 1996, DEV BIOL, V176, P124, DOI 10.1006/dbio.1996.9989; Amizuka N, 1996, ENDOCRINOLOGY, V137, P5055, DOI 10.1210/en.137.11.5055; ANDERSON CE, 1966, J BONE JOINT SURG AM, VA 48, P899, DOI 10.2106/00004623-196648050-00008; BEHRENDTSEN O, 1992, DEVELOPMENT, V114, P447; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BROWN CC, 1989, J BONE JOINT SURG AM, V71A, P580, DOI 10.2106/00004623-198971040-00014; CANCEDDA FD, 1995, EUR J CELL BIOL, V66, P60; CAPLAN AI, 1988, CIBA F SYMP, V136, P3; Carlevaro MF, 1997, J CELL BIOL, V136, P1375, DOI 10.1083/jcb.136.6.1375; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; ELIMA K, 1993, BIOCHEM J, V289, P247, DOI 10.1042/bj2890247; FARNUM CE, 1989, J ORTHOPAED RES, V7, P654, DOI 10.1002/jor.1100070505; FISHER C, 1994, DEV BIOL, V162, P499, DOI 10.1006/dbio.1994.1104; Fisher S. J., 1995, EXTRACELLULAR MATRIX, P261; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HATORI M, 1995, J BONE MINER RES, V10, P1960, DOI 10.1002/jbmr.5650101216; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Iwasaki M, 1997, MECH DEVELOP, V69, P197, DOI 10.1016/S0925-4773(97)00145-7; JINGUSHI S, 1995, J ORTHOPAED RES, V13, P761, DOI 10.1002/jor.1100130516; KARELINA TV, 1995, J INVEST DERMATOL, V105, P411, DOI 10.1111/1523-1747.ep12321097; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kuettner K.E., 1983, SEFER RABIAH, V1, P281; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEWINSON D, 1992, ANAT REC, V233, P504, DOI 10.1002/ar.1092330403; MOSES MA, 1991, J CELL BIOCHEM, V47, P230, DOI 10.1002/jcb.240470308; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; OHSAWA Y, 1993, J HISTOCHEM CYTOCHEM, V41, P1075, DOI 10.1177/41.7.8515049; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; POOLE AR, 1991, CARTILAGE MOL ASPECT, P179; Rantakokko J, 1996, FEBS LETT, V393, P307, DOI 10.1016/0014-5793(96)00907-6; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; SCHENK RK, 1968, ACTA ANAT, V69, P1; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; SIRES UI, 1995, J CLIN INVEST, V95, P2089, DOI 10.1172/JCI117896; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	46	1438	1490	0	71	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1998	93	3					411	422		10.1016/S0092-8674(00)81169-1	http://dx.doi.org/10.1016/S0092-8674(00)81169-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590175	Green Accepted, Bronze			2022-12-24	WOS:000073471500016
J	Kemp, M				Kemp, M			Hesse-Honegger's hand-work	NATURE			English	Editorial Material								Cornelia Hesse-Honegger is fascinated by the beauty of bugs. After the Chernobyl disaster she set out with her paintbox on the trail of mutated insects, convinced that they were the result of radiation poisoning.	Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.								0	1	1	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					555	555		10.1038/33298	http://dx.doi.org/10.1038/33298			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560149	Bronze			2022-12-24	WOS:000072987200035
J	Grazzini, E; Guillon, G; Mouillac, B; Zingg, HH				Grazzini, E; Guillon, G; Mouillac, B; Zingg, HH			Inhibition of oxytocin receptor function by direct binding of progesterone	NATURE			English	Article							RAT GLOMERULOSA CELLS; RECIPROCAL MODULATION; VASOPRESSIN RECEPTOR; ANTAGONIST BINDING; PREGNANCY; AGONIST; SPECIFICITY; EXPRESSION; UTERUS; LIGAND	The steroid hormone progesterone (P-4) is essential for establishing and maintaining pregnancy in mammals(1-3). One of its functions includes maintenance of uterine quiescence by decreasing uterine sensitivity to the uterotonic peptide hormone oxytocin(3-5). Although it is generally held that steroid hormones such as P-4 act at a genomic level by binding to nuclear receptors and modulating the expression of specific target genes(6), we show here that the effect of P-4 on uterine sensitivity to oxytocin involves direct, nongenomic action of P-4 on the uterine oxytocin receptor (OTR), a member of the G-protein-coupled receptor family. P-4 inhibits oxytocin binding to OTR-containing membranes in virro, binds with high affinity to recombinant rat OTR expressed in CHO cells, and suppresses oxytocin-induced inositol phosphate production and calcium mobilization. These effects are highly steroid-and receptor-specific, because binding and signalling functions of the closely related human OTR are not affected by P-4 itself but by the P-4 metabolite 5 beta-dihydroprogesterone. Our findings provide the first evidence for a direct Interaction between a steroid hormone and a G-protein-coupled receptor and define a new level of crosstalk between the peptide-and steroid-hormone signalling pathways.	McGill Univ, Royal Victoria Hosp, Mol Endocrinol Lab, Res Inst, Montreal, PQ H3A 1A1, Canada; CNRS, INSERM, Ctr Pharmacol Endocrinol, U469, F-34094 Montpellier, France	McGill University; Royal Victoria Hospital; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Zingg, HH (corresponding author), McGill Univ, Royal Victoria Hosp, Mol Endocrinol Lab, Res Inst, Montreal, PQ H3A 1A1, Canada.	zingg@rvhri.lan.mcgill.ca	Zingg, Hans/GPS-9984-2022; MOUILLAC, Bernard/M-3896-2014	MOUILLAC, Bernard/0000-0002-3906-8673				Blackmore PF, 1996, MOL PHARMACOL, V49, P727; BURGISSER E, 1982, P NATL ACAD SCI-BIOL, V79, P1732, DOI 10.1073/pnas.79.6.1732; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; CSAPO AI, 1981, PROSTAGLANDINS, V22, P131, DOI 10.1016/0090-6980(81)90060-5; ELANDS J, 1988, EUR J PHARMACOL, V147, P197, DOI 10.1016/0014-2999(88)90778-9; FUCHS AR, 1983, ENDOCRINOLOGY, V113, P742, DOI 10.1210/endo-113-2-742; GARFIELD RE, 1982, AM J OBSTET GYNECOL, V142, P21; Grazzini E, 1996, MOL PHARMACOL, V50, P1273; Grazzini E, 1996, CELL CALCIUM, V19, P29, DOI 10.1016/S0143-4160(96)90011-1; GREEN RD, 1984, J NEUROSCI, V4, P2472; GUILLON G, 1995, ENDOCRINOLOGY, V136, P1285, DOI 10.1210/en.136.3.1285; Jeng YJ, 1996, NEUROPEPTIDES, V30, P557, DOI 10.1016/S0143-4179(96)90039-6; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; LARCHER A, 1995, ENDOCRINOLOGY, V136, P5350, DOI 10.1210/en.136.12.5350; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; PEPE GJ, 1995, ENDOCR REV, V16, P608, DOI 10.1210/er.16.5.608; PEPE GJ, 1974, ENDOCRINOLOGY, V95, P275, DOI 10.1210/endo-95-1-275; SCHMIDT A, 1991, FEBS LETT, V282, P77, DOI 10.1016/0014-5793(91)80448-C; SCHUMACHER M, 1989, P NATL ACAD SCI USA, V86, P6798, DOI 10.1073/pnas.86.17.6798; SOLOFF MS, 1983, CAN J BIOCHEM CELL B, V61, P625, DOI 10.1139/o83-078; SUNDARAM H, 1993, BIOCHEM PHARMACOL, V45, P1003, DOI 10.1016/0006-2952(93)90243-P; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VALERA S, 1992, P NATL ACAD SCI USA, V89, P9949, DOI 10.1073/pnas.89.20.9949; WASSERMAN WJ, 1980, P NATL ACAD SCI-BIOL, V77, P1534, DOI 10.1073/pnas.77.3.1534; WESTPHAL RS, 1994, MOL PHARMACOL, V46, P937; WONG M, 1994, J NEUROENDOCRINOL, V6, P347, DOI 10.1111/j.1365-2826.1994.tb00592.x; Zingg HH, 1996, BAILLIERE CLIN ENDOC, V10, P75, DOI 10.1016/S0950-351X(96)80314-4	27	371	384	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					509	512		10.1038/33176	http://dx.doi.org/10.1038/33176			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548257				2022-12-24	WOS:000072875200062
J	Deckert, G; Warren, PV; Gaasterland, T; Young, WG; Lenox, AL; Graham, DE; Overbeek, R; Snead, MA; Keller, M; Aujay, M; Huber, R; Feldman, RA; Short, JM; Olsen, GJ; Swanson, RV				Deckert, G; Warren, PV; Gaasterland, T; Young, WG; Lenox, AL; Graham, DE; Overbeek, R; Snead, MA; Keller, M; Aujay, M; Huber, R; Feldman, RA; Short, JM; Olsen, GJ; Swanson, RV			The complete genome of the hyperthermophilic bacterium Aquifex aeolicus	NATURE			English	Article							HYDROGEN-OXIDIZING BACTERIA; FACTOR-BASED VECTOR; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; HUMAN DNA; SP-NOV; GENE; PYROPHILUS; EXPRESSION; PROTEINS	Aquifex aeolicus was one of the earliest diverging, and is one of the most thermophilic, bacteria known. It can grow on hydrogen, oxygen, carbon dioxide, and mineral salts. The complex metabolic machinery needed for A. aeolicus to function as a chemolithoautotroph (an organism which uses an inorganic carbon source for biosynthesis and an inorganic chemical energy source) is encoded within a genome that is only one-third the size of the E, coli genome, Metabolic flexibility seems Po be reduced as a result of the limited genome size, The use of oxygen (albeit at very low concentrations) as an electron acceptor is allowed by the presence of a complex respiratory apparatus. Although this organism grows at 95 degrees C, the extreme thermal limit of the Bacteria, only a few specific indications of thermophily are apparent from the genome. Here we describe the complete genome sequence of 1,551,335 base pairs of this evolutionarily and physiologically interesting organism.	Diversa Corp, San Diego, CA 92121 USA; Argonne Natl Lab, Div Math & Comp Sci, Argonne, IL 60439 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; Univ Regensburg, Lehrstuhl Mikrobiol, D-8400 Regensburg, Germany	United States Department of Energy (DOE); Argonne National Laboratory; University of Illinois System; University of Illinois Urbana-Champaign; University of Regensburg	Swanson, RV (corresponding author), Diversa Corp, 10665 Sorrento Valley Rd, San Diego, CA 92121 USA.	Robert.huber@biologie.uni-regensburg.de; rswanson@diversa.com	Graham, David E/F-8578-2010; Keller, Martin/C-4416-2012	Graham, David E/0000-0001-8968-7344; Swanson, Ronald/0000-0002-6486-2676				ALTINGMEES MA, 1989, NUCLEIC ACIDS RES, V17, P9494, DOI 10.1093/nar/17.22.9494; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baldauf SL, 1996, P NATL ACAD SCI USA, V93, P7749, DOI 10.1073/pnas.93.15.7749; BEH M, 1993, ARCH MICROBIOL, V160, P306, DOI 10.1007/BF00292082; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bocchetta M, 1995, J MOL EVOL, V41, P803; BOHM G, 1994, INT J PEPT PROT RES, V43, P97; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BROCK TD, 1995, ANNU REV MICROBIOL, V49, P1; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURGGRAF S, 1992, SYST APPL MICROBIOL, V15, P352, DOI 10.1016/S0723-2020(11)80207-9; Choi IG, 1997, EXTREMOPHILES, V1, P125, DOI 10.1007/s007920050025; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FUCHS G, 1987, AUTOTROPHIC BACTERIA, P365; Gaasterland T, 1996, BIOCHIMIE, V78, P302, DOI 10.1016/0300-9084(96)84761-4; Gaasterland T, 1996, TRENDS GENET, V12, P76, DOI 10.1016/0168-9525(96)81406-5; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HUBER R, 1992, SYST APPL MICROBIOL, V15, P340, DOI 10.1016/S0723-2020(11)80206-7; Jarrell KF, 1996, J BACTERIOL, V178, P5057, DOI 10.1128/jb.178.17.5057-5064.1996; Kaneko T, 1996, DNA Res, V3, P109; KAWASUMI T, 1984, INT J SYST BACTERIOL, V34, P5, DOI 10.1099/00207713-34-1-5; KIM UJ, 1992, NUCLEIC ACIDS RES, V20, P1083, DOI 10.1093/nar/20.5.1083; KLENK HP, 1994, MOL BIOL ARCHAEA, P139; KRISTJANSSON JK, 1985, ARCH MICROBIOL, V140, P321, DOI 10.1007/BF00446971; KRYUKOV VR, 1983, MICROBIOLOGY+, V52, P611; LANDER E S, 1988, Genomics, V2, P231; Lim JH, 1997, FEBS LETT, V406, P142, DOI 10.1016/S0014-5793(97)00262-7; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Mai XH, 1996, J BACTERIOL, V178, P5890, DOI 10.1128/jb.178.20.5890-5896.1996; MOTOSHIMA H, 1990, AGR BIOL CHEM TOKYO, V54, P2385, DOI 10.1080/00021369.1990.10870335; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PITULLE C, 1994, INT J SYST BACTERIOL, V44, P620, DOI 10.1099/00207713-44-4-620; REYSENBACH AL, 1994, APPL ENVIRON MICROB, V60, P2113, DOI 10.1128/AEM.60.6.2113-2119.1994; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; RUDOLPH J, 1995, EMBO J, V14, P4249, DOI 10.1002/j.1460-2075.1995.tb00099.x; Setchell W A, 1903, Science, V17, P934, DOI 10.1126/science.17.441.934; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; WEISBURG WG, 1989, SYST APPL MICROBIOL, V11, P128, DOI 10.1016/S0723-2020(89)80051-7; WELCH M, 1994, BIOCHEMISTRY-US, V33, P10470, DOI 10.1021/bi00200a031; WETMUR JG, 1994, J BIOL CHEM, V269, P25928	49	941	1793	1	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 26	1998	392	6674					353	358		10.1038/32831	http://dx.doi.org/10.1038/32831			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537320	Bronze			2022-12-24	WOS:000072713600041
J	Mitchell, R; McCulloch, D; Lutz, E; Johnson, M; MacKenzie, C; Fennell, M; Fink, G; Zhou, W; Sealfon, SC				Mitchell, R; McCulloch, D; Lutz, E; Johnson, M; MacKenzie, C; Fennell, M; Fink, G; Zhou, W; Sealfon, SC			Rhodopsin-family receptors associate with small G proteins to activate phospholipase D	NATURE			English	Article							ADP-RIBOSYLATION-FACTOR; GUANINE-NUCLEOTIDE; HL-60 CELLS; GTP; ARF; RHO; EXCHANGE; FRACTIONS; FLUORIDE; CONTAINS	G-protein-coupled receptors of the rhodopsin family transduce many important neural and endocrine signals, These receptors activate heterotrimeric G proteins and in many cases also cause activation of phospholipase D, an enzyme that can be controlled by the small G proteins ARF and RhoA(1-3). Here we show that the activation of phospholipase D that is induced by many, but not all, Ca2+-mobilizing G-protein-coupled receptors is sensitive to inhibitors of ARF and of RhoA. Receptors of this type were coimmunoprecipitated with ARF or RhoA on exposure to agonists, and the effects of GTP analogues on ligand binding to the receptor changed to a profile that is characteristic of small G proteins, These receptors contain the amino-acid sequence Asn-ProXXTyr in their seventh transmembrane domain, whereas receptors capable of activating phospholipase D without involving ARF contain the sequence AspProXXTyr. Mutation of this latter sequence to AsnProXXTyr in the gonadotropin-releasing hormone receptor conferred sensitivity to an inhibitor of ARF, and the reciprocal mutation in the 5-HT2A receptor for 5-hydroxy-tryptamine reduced its sensitivity to the inhibitor, Receptors carrying the AsnProXXTyr motif thus seem to form functional complexes with ARF and RhoA.	MRC, Brain Metab Unit, Edinburgh EH8 9JZ, Midlothian, Scotland; Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; Mt Sinai Sch Med, Fishberg Ctr Neurobiol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Mitchell, R (corresponding author), MRC, Brain Metab Unit, 1 George Sq, Edinburgh EH8 9JZ, Midlothian, Scotland.			SEALFON, Stuart/0000-0001-5791-1217; Fink, George/0000-0002-0713-527X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAVANAGH MM, 1996, J BIOL CHEM, V271, P21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FENG DM, 1995, J MED CHEM, V38, P4125, DOI 10.1021/jm00020a029; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GILL DM, 1987, BIOCHEMISTRY-US, V26, P6364, DOI 10.1021/bi00394a009; Hoffenberg S, 1996, MOL PHARMACOL, V49, P156; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; Martin A, 1996, J BIOL CHEM, V271, P17397, DOI 10.1074/jbc.271.29.17397; MITCHELL R, 1995, BIOCHEM SOC T, V23, pS208, DOI 10.1042/bst023208s; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; NIETO M, 1994, MOL PHARMACOL, V46, P406; OGIER SA, 1987, J ENDOCRINOL, V115, P151, DOI 10.1677/joe.0.1150151; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; STUTCHFIELD J, 1993, BIOCHEM J, V293, P649, DOI 10.1042/bj2930649; WALL SJ, 1991, MOL PHARMACOL, V40, P783; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG LX, 1994, ENDOCRINOLOGY, V134, P1446, DOI 10.1210/en.134.3.1446; ZHOU W, 1994, MOL PHARMACOL, V45, P165	30	183	185	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					411	414		10.1038/32937	http://dx.doi.org/10.1038/32937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537328				2022-12-24	WOS:000072713600058
J	Walker, BR; McConnachie, A; Noon, JP; Webb, DJ; Watt, GCM				Walker, BR; McConnachie, A; Noon, JP; Webb, DJ; Watt, GCM			Contribution of parental blood pressures to association between low birth weight and adult high blood pressure: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR RISK; FETAL GROWTH; HYPERTENSION; CHILDREN; PREGNANCY; WOMEN	Objective: To examine the possibility that low birth weight is a feature of the inherited predisposition to high blood pressure. Design: Cross sectional study. Setting: Primary care medical centre in Edinburgh. Subjects: One offspring of 12 families (231 men and 221 women aged 16-26 years) in whom blood pressure, weight, and height were measured in 1986 and whose parents had blood pressure measured in 1979. Birth weights were obtained from case records (270 offspring) or by questionnaires sent to the mothers (182 offspring). Main outcome measures: Birth weight and adult systolic blood pressure in offspring in relation to parental blood pressure. Results: If parental blood pressures were not considered, a 1 kg decrease in birth weight was associated with a 2.24 mm Hg increase in systolic blood pressure of offspring (P = 0.06) after correction for current weight and sex. However, parental blood pressures correlated positively with blood pressure of offspring, and higher maternal blood pressure was associated with lower birth weight (-3.03 g/mm Hg, P < 0.01). After correction for parental blood pressures, a 1 kg decrease in birth weight was associated with only a 1.71 mm Hg increase in the systolic blood pressure of the offspring (P = 0.15). Conclusions: Low birth weight is a feature of the inherited predisposition to hypertension, perhaps because it is associated with higher maternal blood pressure during pregnancy. Parental blood pressure may be an important confounding factor in the relation between low birth weight and subsequent hypertension.	Univ Edinburgh, Western Gen Hosp, Dept Med, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Glasgow, Woodside Hlth Ctr, Dept Gen Practice, Glasgow G20 7LR, Lanark, Scotland	University of Edinburgh; University of Glasgow	Walker, BR (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Med, Edinburgh EH4 2XU, Midlothian, Scotland.							BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CHESLEY LC, 1980, CLIN EXP HYPERTENS, V2, P777, DOI 10.3109/10641968009037142; Churchill D, 1997, LANCET, V349, P7, DOI 10.1016/S0140-6736(96)06297-6; Curhan GC, 1996, CIRCULATION, V94, P1310, DOI 10.1161/01.CIR.94.6.1310; Curhan GC, 1996, CIRCULATION, V94, P3246, DOI 10.1161/01.CIR.94.12.3246; DGANI J, 1992, J PERINAT MED, V20, P365, DOI 10.1515/jpme.1992.20.5.365; Godfrey K, 1996, BRIT MED J, V312, P410, DOI 10.1136/bmj.312.7028.410; Harrap SB, 1997, CIRCULATION, V96, P556; HIMMELMANN A, 1994, J INTERN MED, V235, P347, DOI 10.1111/j.1365-2796.1994.tb01085.x; Lalande M, 1996, ANNU REV GENET, V30, P173, DOI 10.1146/annurev.genet.30.1.173; LangleyEvans SC, 1996, CLIN SCI, V91, P607, DOI 10.1042/cs0910607; Law CM, 1996, J HYPERTENS, V14, P935; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LUMEY LH, 1995, EUR J OBSTET GYN R B, V61, P23, DOI 10.1016/0028-2243(95)02149-M; LUMEY LH, 1994, INT J EPIDEMIOL, V23, P1006, DOI 10.1093/ije/23.5.1006; McCowan LME, 1996, BRIT J OBSTET GYNAEC, V103, P123, DOI 10.1111/j.1471-0528.1996.tb09662.x; MORTON NE, 1955, ANN HUM GENET, V20, P125; Noon JP, 1997, J CLIN INVEST, V99, P1873, DOI 10.1172/JCI119354; SEIDMAN DS, 1991, BRIT J OBSTET GYNAEC, V98, P1009, DOI 10.1111/j.1471-0528.1991.tb15339.x; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; Taittonen L, 1996, PEDIATR RES, V40, P627, DOI 10.1203/00006450-199610000-00019; Troy LM, 1996, INT J EPIDEMIOL, V25, P122, DOI 10.1093/ije/25.1.122; WATT GCM, 1991, J HYPERTENS, V9, P55; WHINCUP P, 1994, J HUM HYPERTENS, V8, P337	26	77	79	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					834	837		10.1136/bmj.316.7134.834	http://dx.doi.org/10.1136/bmj.316.7134.834			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549456	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000072584300034
J	Gekakis, N; Staknis, D; Nguyen, HB; Davis, FC; Wilsbacher, LD; King, DP; Takahashi, JS; Weitz, CJ				Gekakis, N; Staknis, D; Nguyen, HB; Davis, FC; Wilsbacher, LD; King, DP; Takahashi, JS; Weitz, CJ			Role of the CLOCK protein in the mammalian circadian mechanism	SCIENCE			English	Article							DNA-BINDING; SACCHAROMYCES-CEREVISIAE; EXPRESSION; CLONING; RETINA; SYSTEM	The mouse Clock gene encodes a bHLH-PAS protein that regulates circadian rhythms and is related to transcription factors that act as heterodimers. Potential partners of CLOCK were isolated in a two-hybrid screen, and one, BMAL1, was coexpressed with CLOCK and PER1 at known circadian clock sites in brain and retina. CLOCK-BMAL1 heterodimers activated transcription from E-box elements, a type of transcription factor-binding site, found adjacent to the mouse per1 gene and from an identical E-box known to be important for per gene expression in Drosophila. Mutant CLOCK from the dominant-negative Clock allele and BMAL1 formed heterodimers that bound DNA but failed to activate transcription, Thus, CLOCK-BMAL1 heterodimers appear to drive the positive component of per transcriptional oscillations, which are thought to underlie circadian rhythmicity.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Northeastern Univ, Dept Biol, Boston, MA 02115 USA; Northwestern Univ, Dept Neurobiol & Physiol, Howard Hughes Med Inst, Evanston, IL 60208 USA; Northwestern Univ, Natl Sci Fdn, Ctr Biol Timing, Evanston, IL 60208 USA	Harvard University; Harvard Medical School; Northeastern University; Howard Hughes Medical Institute; Northwestern University; National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University	Weitz, CJ (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.		Jansen, Heiko T./A-5770-2008; Takahashi, Joseph S/E-8482-2012; Takahashi, Joseph S./Y-2781-2019	Jansen, Heiko T./0000-0003-0178-396X; Takahashi, Joseph S/0000-0003-0384-8878; Takahashi, Joseph S./0000-0003-0384-8878				Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BESHARSE JC, 1983, NATURE, V305, P133, DOI 10.1038/305133a0; Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1117; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Edmunds LN, 1988, CELLULAR MOL BASES B; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GEKAKIS N, UNPUB; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; Hirose K, 1996, MOL CELL BIOL, V16, P1706; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Inouye S, 1997, BIOCHEM BIOPH RES CO, V233, P349, DOI 10.1006/bbrc.1997.6452; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; King DP, 1997, GENETICS, V146, P1049; Klein D.C., 1991, SUPRACHIASMATIC NUCL; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Moffett P, 1997, MOL CELL BIOL, V17, P4933, DOI 10.1128/MCB.17.9.4933; Morris ME, 1998, SCIENCE, V279, P1544, DOI 10.1126/science.279.5356.1544; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P291, DOI 10.1007/BF01417859; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLOVYEV V, 1997, ISMB, V5, P294; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; Stanewsky R, 1997, EMBO J, V16, P5006, DOI 10.1093/emboj/16.16.5006; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VITATERNA MH, UNPUB; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; ZELAER E, 1997, GENE DEV, V11, P2079; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZYLKA MJ, IN PRESS NEURON	43	1488	1548	9	183	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	1998	280	5369					1564	1569		10.1126/science.280.5369.1564	http://dx.doi.org/10.1126/science.280.5369.1564			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616112				2022-12-24	WOS:000074061200030
J	Teglund, S; McKay, C; Schuetz, E; van Deursen, JM; Stravopodis, D; Wang, DM; Brown, M; Bodner, S; Grosveld, G; Ihle, JN				Teglund, S; McKay, C; Schuetz, E; van Deursen, JM; Stravopodis, D; Wang, DM; Brown, M; Bodner, S; Grosveld, G; Ihle, JN			Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses	CELL			English	Article							COLONY-STIMULATING FACTOR; DNA-BINDING ACTIVITY; GROWTH FACTOR-I; MICE LACKING; ERYTHROPOIETIN RECEPTOR; TRANSCRIPTIONAL ACTIVATION; TYROSINE PHOSPHORYLATION; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION	A variety of cytokines mediate the activation of Janus protein tyrosine kinases (Jaks). The Jaks then phosphorylate cellular substrates, including members of the signal transducers and activators of transcription (Stat) family of transcription factors. Among the Stats, the two highly related proteins, Stat5a and Stat5b, are activated by a variety of cytokines. To assess the role of the Stat5 proteins, mutant mice were derived that have the genes deleted individually or together. The phenotypes of the mice demonstrate an essential, and often redundant, role for the two Stat5 proteins in a spectrum of physiological responses associated with growth hormone and prolactin. Conversely, the responses to a variety of cytokines that activate the Stat5 proteins, including erythropoietin, are largely unaffected.	St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Tennessee, Sch Med, Dept Biochem, Memphis, TN 38105 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Ihle, JN (corresponding author), St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA.		Schuetz, Erin/N-8087-2018; Wang, Demin/AAX-4449-2020; Brown, Michael/C-2081-2014	Wang, Demin/0000-0001-5549-3795; Brown, Michael/0000-0002-5796-1932; Stravopodis, Dimitrios/0000-0002-9535-2134	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angerer L.M., 1992, IN SITU HYBRIDIZATIO, P15; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DONAHUE LR, 1993, J ENDOCRINOL, V136, P91, DOI 10.1677/joe.0.1360091; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Hogan B, 1994, MANIPULATING MOUSE E; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nishinakamura R, 1996, BLOOD, V88, P2458, DOI 10.1182/blood.V88.7.2458.bloodjournal8872458; NORSTEDT G, 1984, CELL, V36, P805, DOI 10.1016/0092-8674(84)90030-8; Ogawa S, 1996, ONCOGENE, V13, P183; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; PARMER TG, 1991, ENDOCRINOLOGY, V129, P2924, DOI 10.1210/endo-129-6-2924; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shuai K, 1996, ONCOGENE, V13, P247; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SQUIRES EJ, 1988, J BIOL CHEM, V263, P4166; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; TIAN SS, 1994, BLOOD, V84, P1760; TWEARDY DJ, 1995, BLOOD, V86, P4409, DOI 10.1182/blood.V86.12.4409.bloodjournal86124409; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VANDEURSEN J, 1991, NUCLEIC ACIDS RES, V19, P2637, DOI 10.1093/nar/19.10.2637; Wakao H, 1997, BIOCHEM BIOPH RES CO, V234, P198, DOI 10.1006/bbrc.1997.6486; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Woldman I, 1997, J IMMUNOL, V159, P877; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; Zhong L, 1997, BIOCHEM BIOPH RES CO, V235, P587, DOI 10.1006/bbrc.1997.6833; ZHOU Y, 1994, P NATL ACAD SCI USA, V94, P13215	62	1041	1061	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1998	93	5					841	850		10.1016/S0092-8674(00)81444-0	http://dx.doi.org/10.1016/S0092-8674(00)81444-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630227	Bronze			2022-12-24	WOS:000073956700019
J	Duthie, RA; Bruce, MF; Hutchison, JD				Duthie, RA; Bruce, MF; Hutchison, JD			Changing proximal femoral geometry in northeast Scotland: an osteometric study	BRITISH MEDICAL JOURNAL			English	Article							HIP FRACTURE; INCREASE; FEMUR; WOMEN; 1950S; 1990S		Univ Aberdeen, Sch Med, Dept Orthopaed, Aberdeen AB9 2ZD, Scotland; Marischal Coll, Dept Biomed Sci, Aberdeen AB10 1YS, Scotland	University of Aberdeen; University of Aberdeen	Duthie, RA (corresponding author), Univ Aberdeen, Sch Med, Dept Orthopaed, Aberdeen AB9 2ZD, Scotland.							FAULKNER KG, 1993, J BONE MINER RES, V8, P1211, DOI 10.1002/jbmr.5650081008; ONeill TW, 1996, OSTEOPOROSIS INT, V6, P136, DOI 10.1007/BF01623937; REID IR, 1994, BRIT MED J, V309, P508, DOI 10.1136/bmj.309.6953.508; Vega E, 1991, Osteoporos Int, V1, P81, DOI 10.1007/BF01880448; WALLACE WA, 1983, LANCET, V1, P1413	5	13	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1998	316	7143					1498	1498		10.1136/bmj.316.7143.1498	http://dx.doi.org/10.1136/bmj.316.7143.1498			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP020	9582136	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000073707700026
J	Neubauer, H; Cumano, A; Muller, M; Wu, H; Huffstadt, U; Pfeffer, K				Neubauer, H; Cumano, A; Muller, M; Wu, H; Huffstadt, U; Pfeffer, K			Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis	CELL			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION PATHWAY; COLONY-STIMULATING FACTOR; MICE LACKING JAK3; STEM-CELL FACTOR; C-KIT; ERYTHROPOIETIN RECEPTOR; LYMPHOCYTE MATURATION; DEVELOPING MOUSE; YOLK-SAC	Janus kinases (Jaks) play an important role in signal transduction via cytokine and growth factor receptors. A targeted inactivation of Jak2 was performed. Jak2(-/-) embryos are anemic and die around day 12.5 postcoitum. Primitive erythrocytes are found, but definitive erythropoiesis is absent. Compared to erythropoietin receptor-deficient mice, the phenotype of Jak2 deficiency is more severe. Fetal liver BFU-E and CFU-E colonies are completely absent. However, multilineage hematopoietic stem cells (CD34(low), c-kit(pos)) can be found, and B lymphopoiesis appears intact. In contrast to IFN alpha stimulation, Jak2(-/-) cells do not respond to IFN gamma. Jak2(-/-) embryonic stem cells are competent for LIF signaling. The data provided demonstrate that Jak2 has pivotal functions for signal transduction of a set of cytokine receptors required in definitive erythropoiesis.	Tech Univ Munich, Inst Med Microbiol & Hyg, D-81675 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Dept Mammalian Genet, D-85758 Neuherberg, Germany; Inst Pasteur, Unite Biol Mol Gene, F-75024 Paris, France; Univ Vet Med, Dept Vet Biotechnol & Mol Genet, Inst Genet & Anim Breeding, A-1210 Vienna, Austria; Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Veterinary Medicine Vienna; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Pfeffer, K (corresponding author), Tech Univ Munich, Inst Med Microbiol & Hyg, Trogerstr 9, D-81675 Munich, Germany.		Neubauer, Hans/C-4467-2016	Neubauer, Hans/0000-0002-3467-4105; Cumano, Ana/0000-0002-4578-959X; Muller, Mathias/0000-0002-7879-3552; Pfeffer, Klaus/0000-0002-5652-6330				Aguila HL, 1997, IMMUNOL REV, V157, P13, DOI 10.1111/j.1600-065X.1997.tb00971.x; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Bach EA, 1996, MOL CELL BIOL, V16, P3214; Briscoe J, 1996, TRENDS CELL BIOL, V6, P336, DOI 10.1016/0962-8924(96)10028-3; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; Chen JZ, 1996, ADV IMMUNOL, V62, P31, DOI 10.1016/S0065-2776(08)60427-7; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CUMANO A, 1993, P NATL ACAD SCI USA, V90, P6429, DOI 10.1073/pnas.90.14.6429; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; EMERSON SG, 1985, J CLIN INVEST, V76, P1286, DOI 10.1172/JCI112087; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; GREGORY CJ, 1978, BLOOD, V51, P527; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; Kobayashi M, 1996, BLOOD, V88, P429, DOI 10.1182/blood.V88.2.429.bloodjournal882429; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; KRAUSE DS, 1994, BLOOD, V84, P691; Ku H, 1996, BLOOD, V87, P4544, DOI 10.1182/blood.V87.11.4544.bloodjournal87114544; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NISHINAKAMURA R, 1995, IMMUNITY, V2, P211, DOI 10.1016/1074-7613(95)90046-2; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PAZDRAK K, 1995, J IMMUNOL, V155, P397; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Sanchez MJ, 1996, IMMUNITY, V5, P513, DOI 10.1016/S1074-7613(00)80267-8; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIMODA K, 1994, BIOCHEM BIOPH RES CO, V203, P922, DOI 10.1006/bbrc.1994.2270; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; Watowich SS, 1996, ANNU REV CELL DEV BI, V12, P91, DOI 10.1146/annurev.cellbio.12.1.91; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; WURST W, 1993, GENE TARGETING PRACT; Yoder MC, 1997, IMMUNITY, V7, P335, DOI 10.1016/S1074-7613(00)80355-6; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Yoshida M, 1997, BRIT J HAEMATOL, V98, P254, DOI 10.1046/j.1365-2141.1997.2283045.x	69	626	712	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 1	1998	93	3					397	409		10.1016/S0092-8674(00)81168-X	http://dx.doi.org/10.1016/S0092-8674(00)81168-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590174	Bronze			2022-12-24	WOS:000073471500015
J	Dolmetsch, RE; Xu, KL; Lewis, RS				Dolmetsch, RE; Xu, KL; Lewis, RS			Calcium oscillations increase the efficiency and specificity of gene expression	NATURE			English	Article							INTRACELLULAR CA2+ STORES; NF-KAPPA-B; T-LYMPHOCYTES; ANTIGEN RECEPTOR; CYCLOSPORINE-A; CALCINEURIN; ACTIVATION; CHANNELS; CELLS; DEPLETION	Cytosolic calcium ([Ca2+](i)) oscillations are a nearly universal mode of signalling in excitable and non-excitable cells(1-4). Although Ca2+ is known to mediate a diverse array of cell functions, it is not known whether oscillations contribute to the efficiency or specificity of signalling or are merely an inevitable consequence of the feedback control of [Ca2+](i). We have developed a Ca2+ clamp technique to investigate the roles of oscillation amplitude and frequency in regulating gene expression driven by the proinflammatory transcription factors NF-AT, Oct/GAP and NF-kappa B. Here we report that oscillations reduce the effective Ca2+ threshold for activating transcription factors, thereby increasing signal detection at low levels of stimulation. In addition, specificity is encoded by the oscillation frequency: rapid oscillations stimulate all three transcription factors, whereas infrequent oscillations activate only NF-kappa B. The genes encoding the cytokines interleukin (IL)-2 and IL-8 are also frequency-sensitive in a way that reflects their degree of dependence on NF-AT versus NF-kappa B. Our results provide direct evidence that [Ca2+]i oscillations increase both the efficacy and the information content of Ca2+ signals that lead to gene expression and cell differentiation.	Stanford Univ, Sch Med, Beckman Ctr Mol & Genet Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Stanford University	Lewis, RS (corresponding author), Stanford Univ, Sch Med, Beckman Ctr Mol & Genet Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA.			Lewis, Richard/0000-0002-6010-7403	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045374] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM045374] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DOLMETSCH RE, IN PRESS IMAGING LIV; DONNADIEU E, 1992, J IMMUNOL, V148, P2643; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; DURAND DB, 1987, J EXP MED, V165, P3955; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.ph.55.030193.002235; Fields RD, 1997, J NEUROSCI, V17, P7252; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WECHSLER AS, 1994, J IMMUNOL, V153, P2515; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	30	1594	1636	1	102	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					933	936		10.1038/31960	http://dx.doi.org/10.1038/31960			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582075				2022-12-24	WOS:000073359900052
J	DeLong, E				DeLong, E			Microbiology - Archaeal means and extremes	SCIENCE			English	Editorial Material							RIBOSOMAL-RNA SEQUENCES; PHYLOGENETIC ANALYSIS; ARCHAEBACTERIA; EUKARYOTES; EVOLUTION; DIVERSITY		Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA	Monterey Bay Aquarium Research Institute	DeLong, E (corresponding author), Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA.							Barns SM, 1996, P NATL ACAD SCI USA, V93, P9188, DOI 10.1073/pnas.93.17.9188; Bintrim SB, 1997, P NATL ACAD SCI USA, V94, P277, DOI 10.1073/pnas.94.1.277; Blochl E, 1997, EXTREMOPHILES, V1, P14; Borneman J, 1997, APPL ENVIRON MICROB, V63, P2647, DOI 10.1128/AEM.63.7.2647-2653.1997; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; DELONG EF, 1992, P NATL ACAD SCI USA, V89, P5685, DOI 10.1073/pnas.89.12.5685; DeLong EF, 1998, APPL ENVIRON MICROB, V64, P1133; DELONG EF, 1994, NATURE, V371, P695, DOI 10.1038/371695a0; Fuhrman JA, 1997, MAR ECOL PROG SER, V150, P275, DOI 10.3354/meps150275; FUHRMAN JA, 1992, NATURE, V356, P148, DOI 10.1038/356148a0; Godon JJ, 1997, APPL ENVIRON MICROB, V63, P2802, DOI 10.1128/AEM.63.7.2802-2813.1997; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; Hershberger KL, 1996, NATURE, V384, P420, DOI 10.1038/384420a0; Holden JF, 1998, FEMS MICROBIOL ECOL, V25, P33, DOI 10.1111/j.1574-6941.1998.tb00458.x; HUBER R, 1990, NATURE, V345, P179, DOI 10.1038/345179a0; Hugenholtz P, 1998, J BACTERIOL, V180, P366, DOI 10.1128/JB.180.2.366-376.1998; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; Jurgens G, 1997, APPL ENVIRON MICROB, V63, P803, DOI 10.1128/AEM.63.2.803-805.1997; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kudo Y, 1997, BIOSCI BIOTECH BIOCH, V61, P917, DOI 10.1271/bbb.61.917; MASSANA R, 1997, NATURE, V63, P50; MCGREGOR BJ, 1997, APPL ENVIRON MICROB, V63, P1178; MCINERNEY JO, 1995, APPL ENVIRON MICROB, V61, P1646, DOI 10.1128/AEM.61.4.1646-1648.1995; Munson MA, 1997, APPL ENVIRON MICROB, V63, P4729, DOI 10.1128/AEM.63.12.4729-4733.1997; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Preston CM, 1996, P NATL ACAD SCI USA, V93, P6241, DOI 10.1073/pnas.93.13.6241; Schleper C, 1997, J BACTERIOL, V179, P7803, DOI 10.1128/jb.179.24.7803-7811.1997; Schleper C, 1997, APPL ENVIRON MICROB, V63, P321, DOI 10.1128/AEM.63.1.321-323.1997; Stein JL, 1996, J BACTERIOL, V178, P591, DOI 10.1128/jb.178.3.591-599.1996; UEDA T, 1995, EUR J SOIL SCI, V46, P415, DOI 10.1111/j.1365-2389.1995.tb01337.x; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1978, J MOL EVOL, V11, P245, DOI 10.1007/BF01734485; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	33	70	72	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					542	543		10.1126/science.280.5363.542	http://dx.doi.org/10.1126/science.280.5363.542			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9575100				2022-12-24	WOS:000073242100032
J	Mulle, C; Sailer, A; Perez-Otano, I; Dickinson-Anson, H; Castillo, PE; Bureau, I; Maron, C; Gage, FH; Mann, JR; Bettler, B; Heinemann, SF				Mulle, C; Sailer, A; Perez-Otano, I; Dickinson-Anson, H; Castillo, PE; Bureau, I; Maron, C; Gage, FH; Mann, JR; Bettler, B; Heinemann, SF			Altered synaptic physiology and reduced susceptibility to kainate-induced seizures in GluR6-deficient mice	NATURE			English	Article							KAINIC ACID; PYRAMIDAL CELLS; RECEPTORS; EXPRESSION; DEATH; HIPPOCAMPUS; PLASTICITY; SYNAPSES; CLONING; AMPA	L-glutamate, the neurotransmitter of the majority of excitatory synapses in the brain, acts on three classes of ionotropic receptors: NMDA (N-methyl-D-aspartate), AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) and kainate receptors. Little is known about the physiological role of kainate receptors because in many experimental situations it is not possible to distinguish them from AMPA receptors(1,2). Mice with disrupted kainate receptor genes enable the study of the specific role of kainate receptors in synaptic transmission as well as in the neurotoxic effects of kainate. We have now generated mutant mice lacking the kainate-receptor subunit GluR6. The hippocampal neurons in the CA3 region of these mutant mice are much less sensitive to kainate. In addition, a postsynaptic kainate current evoked in CA3 neurons by a train of stimulation of the mossy fibre system is absent in the mutant(3,4). We find that GluR6-deficient mice are less susceptible to systemic administration of kainate, as judged by onset of seizures and by the activation of immediate early genes in the hippocampus. Our results indicate that kainate receptors containing the GluR6 subunit are important in synaptic transmission as well as in the epileptogenic effects of kainate.	Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Fac Med, Dept Fisiol, Montevideo, Uruguay; City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA; Univ Bordeaux 2, CNRS, UMR 5541, F-33076 Bordeaux, France	Salk Institute; Salk Institute; Universidad de la Republica, Uruguay; City of Hope; Beckman Research Institute of City of Hope; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Heinemann, SF (corresponding author), Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA.		Perez-Otano, Isabel/S-9613-2017; bettler, bernhard/AAO-8018-2020; Sailer, Andreas/M-9913-2016; Bureau, Ingrid/O-3941-2016	Perez-Otano, Isabel/0000-0002-7222-8202; Sailer, Andreas/0000-0002-9015-7946; Mulle, Christophe/0000-0003-2709-6615; Bettler, Bernhard/0000-0003-0842-8207; Castillo, Pablo/0000-0002-9834-1801; Bureau, Ingrid/0000-0001-9166-2250				BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; Bischoff S, 1997, J COMP NEUROL, V379, P541, DOI 10.1002/(SICI)1096-9861(19970324)379:4<541::AID-CNE6>3.0.CO;2-2; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; Chittajallu R, 1996, NATURE, V379, P78, DOI 10.1038/379078a0; Clarke VRJ, 1997, NATURE, V389, P599, DOI 10.1038/39315; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; Kamiya H, 1996, J PHYSIOL-LONDON, V493, P447, DOI 10.1113/jphysiol.1996.sp021395; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; LASALLE GL, 1988, NEUROSCI LETT, V88, P127, DOI 10.1016/0304-3940(88)90112-7; Lerma J, 1997, TRENDS NEUROSCI, V20, P9, DOI 10.1016/S0166-2236(96)20055-4; MONAGHAN DT, 1982, BRAIN RES, V252, P91, DOI 10.1016/0006-8993(82)90981-7; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROBINSON JH, 1981, BRAIN RES, V221, P117, DOI 10.1016/0006-8993(81)91067-2; RodriguezMoreno A, 1997, NEURON, V19, P893, DOI 10.1016/S0896-6273(00)80970-8; Salin PA, 1996, P NATL ACAD SCI USA, V93, P13304, DOI 10.1073/pnas.93.23.13304; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; SMEYNE RJ, 1993, NATURE, V365, P279, DOI 10.1038/365279b0; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; Vignes M, 1997, NATURE, V388, P179, DOI 10.1038/40639; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	26	391	402	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					601	605		10.1038/33408	http://dx.doi.org/10.1038/33408			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9580260				2022-12-24	WOS:000072987200059
J	York, RD; Yao, H; Dillon, T; Ellig, CL; Eckert, SP; McCleskey, EW; Stork, PJS				York, RD; Yao, H; Dillon, T; Ellig, CL; Eckert, SP; McCleskey, EW; Stork, PJS			Rap1 mediates sustained MAP kinase activation induced by nerve growth factor	NATURE			English	Article							PC12 CELLS; NEURONAL DIFFERENTIATION; SIGNALING PATHWAYS; CRK PROTEIN; SH3 DOMAIN; FACTOR C3G; RECEPTOR; RAS; SPECIFICITY; SUFFICIENT	Activation of mitogen-activated protein (MAP) kinase (also known as extracellular-signal-regulated kinase, or ERK)(1) by growth factors can trigger either cell growth or differentiation. The intracellular signals that couple growth factors to MAP kinase may determine the different effects of growth factors: for example, transient activation of MAP kinase by epidermal growth factor stimulates proliferation of PC12 cells(1), whereas they differentiate in response to nerve growth factor, which acts partly by inducing a sustained activation of MAP kinase(1). Here we show that activation of MAP kinase by nerve growth factor involves two distinct pathways: the initial activation of MAP kinase requires the small G protein Ras, but its activation is sustained by the small G protein Rap1. Rap1 is activated by CRK adaptor proteins and the guanine-nucleotide-exchange factor C3G, and forms a stable complex with B-Raf, an activator of MAP kinase. Rap1 is required for at least two indices of neuronal differentiation by nerve growth factor: electrical excitability and the induction of neuron-specific genes. We propose that the activation of Rap1 by C3G represents a common mechanism to induce sustained activation of the MAP kinase cascade in cells that express B-Raf.	Oregon Hlth Sci Univ, Vollum Inst Adv Biomed Res, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Pathol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Stork, PJS (corresponding author), Oregon Hlth Sci Univ, Vollum Inst Adv Biomed Res, Portland, OR 97201 USA.	stork@ohsu.edu						Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DESOUZA S, 1995, J BIOL CHEM, V270, P9106, DOI 10.1074/jbc.270.16.9106; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; FANGER GR, 1993, J NEUROCHEM, V61, P1977, DOI 10.1111/j.1471-4159.1993.tb09844.x; FELLER SM, 1995, ONCOGENE, V10, P1465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; PAN MG, 1995, ONCOGENE, V11, P2005; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; TANAKA M, 1995, MOL CELL BIOL, V15, P689; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAO H, 1995, J BIOL CHEM, V270, P20748, DOI 10.1074/jbc.270.35.20748	30	757	771	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					622	626		10.1038/33451	http://dx.doi.org/10.1038/33451			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560161				2022-12-24	WOS:000072987200065
J	Parry, SM; Salmon, RL; Willshaw, GA; Cheasty, T				Parry, SM; Salmon, RL; Willshaw, GA; Cheasty, T			Risk factors for and prevention of sporadic infections with vero cytotoxin (shiga toxin) producing Escherichia coli O157	LANCET			English	Article							HEMORRHAGIC COLITIS	Background Recent outbreaks of vero cytotoxin (shiga toxin) producing Escherichia coli O157 (VTEC O157) infection have stimulated debate on food safety. However, 90% of cases in England and Wales are sporadic. We report a case-control study of sporadic VTEC O157 infection. Methods We compared 85 sporadic cases of VTEC O157 infection, identified through population surveillance, with 142 controls, randomly selected from general practitioners' lists. We matched cases and controls for age, sex, and family doctor's practice. Exposures to foods, water, animals, farms, and environmental factors were recorded. We visited the premises concerned when cases had eaten beefburgers or cooked sliced meats from caterers or had had contact with a farm. Findings Consumption of a beefburger from a catering premises other than from a fast-food chain A (a national chain) and consumption of cold cooked sliced meat leg, in a salad or sandwich) from caterers, but not butchers, was associated with VTEC O157 infection (odds ratios 4.63 [95% CI 1.33-30.14] and 3.36 [1.04-12.74), respectively). Policies for ensuring thorough cooking of burgers by one national fast-food chain differed from the other catering premises we visited. There was evidence of person-to-person spread and transmission of VTEC O157 infection from animals. Interpretation Local inspection of catering establishments that serve cooked meats together with public education to prevent spread on farms and in houses would reduce the burden of VTEC O157 infection by about 10% for each risk factor.	Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Cardiff CF4 3QX, S Glam, Wales; Welsh Combined Ctr Publ Hlth, Cardiff, S Glam, Wales; Cent Publ Hlth Lab, Lab Enter Pathogens, London NW9 5HT, England	Public Health England	Salmon, RL (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Abton House, Cardiff CF4 3QX, S Glam, Wales.							*ADV COMM MICR SAF, 1995, REP VER PROD ESCH CO; Allaby M A, 1995, Commun Dis Rep CDR Rev, V5, pR4; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; BRYANT HE, 1989, J INFECT DIS, V160, P858, DOI 10.1093/infdis/160.5.858; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P85; CHAPMAN PA, 1993, VET REC, V133, P171, DOI 10.1136/vr.133.7.171; COIA JE, 1994, RECENT ADV VEROCYTOT; Cowden J M, 1995, Commun Dis Rep CDR Rev, V5, pR109; DEV VJ, 1991, LANCET, V337, P1412, DOI 10.1016/0140-6736(91)93092-N; GREENLAND S, 1988, AM J EPIDEMIOL, V128, P1185, DOI 10.1093/oxfordjournals.aje.a115073; *INF AG SURV CTR, 1996, INFECT AGENTS SURVEI, V17, P180; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; LESAUX N, 1993, J INFECT DIS, V167, P500, DOI 10.1093/infdis/167.2.500; MARCH SB, 1986, J CLIN MICROBIOL, V23, P869, DOI 10.1128/JCM.23.5.869-872.1986; Mead PS, 1997, ARCH INTERN MED, V157, P204, DOI 10.1001/archinte.157.2.204; PARRY SM, 1995, LANCET, V346, P572, DOI 10.1016/S0140-6736(95)91407-2; Pennington Group, 1997, REP CIRC LEAD 1996 O; SALMON RL, 1994, RECENT ADV VEROCYTOX; *SCOTT CTR INF ENV, 1997, SCIEH WKLY REP, V31, P41; Shukla R, 1995, Commun Dis Rep CDR Rev, V5, pR86; Stevenson J, 1996, Commun Dis Rep CDR Rev, V6, pR116; Thomas A, 1996, EPIDEMIOL INFECT, V117, P1, DOI 10.1017/S0950268800001060; *WHO DIV FOOD NUTR, 1993, TRAIN CONS APPL HAZ	23	68	70	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1019	1022		10.1016/S0140-6736(97)08376-1	http://dx.doi.org/10.1016/S0140-6736(97)08376-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546508				2022-12-24	WOS:000072927200012
J	Kitazawa, S; Kimura, T; Yin, PB				Kitazawa, S; Kimura, T; Yin, PB			Cerebellar complex spikes encode both destinations and errors in arm movements	NATURE			English	Article							PURKINJE-CELL COMPLEX; MONKEY; DISCHARGE; NEURONS	Purkinje cells of the cerebellum discharge complex spikes, named after the complexity of their waveforms(1), with a frequency of similar to 1 Hz during arm movements(1-13). Despite the low frequency of firing, complex spikes have been proposed to contribute to the initiation of arm movements(2,7-10) or to the gradual improvement of motor skills(2,4-6,14-6). Here we recorded the activity of Purkinje cells from the hemisphere of cerebellar lobules IV-VI while trained monkeys made short-lasting reaching movements (of similar to 200 milliseconds in duration) to touch a visual target that appeared at a random location on a tangent screen, We examined the relationship between complex-spike discharges and the absolute touch position, and between complex-spike discharges and relative errors in touching the screen. We used information theory to show that the complex spikes occurring at the beginning of the reach movement encode the absolute destination of the reach, and the complex spikes occurring at the end of the short-lasting movements encode the relative errors, Thus, complex spikes convey multiple types of information, consistent with the idea that they contribute both to the generation of movements and to the gradual, long-term improvement of these movements.	Electrotech Lab, Informat Sci Div, Tsukuba, Ibaraki 3058568, Japan; Japan Sci & Technol Corp, PRESTO, Tsukuba, Ibaraki 3058568, Japan; Japan Sci & Technol Corp, CREST, Tsukuba, Ibaraki 3058568, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Kitazawa, S (corresponding author), Electrotech Lab, Informat Sci Div, 1-1-4 Umezono, Tsukuba, Ibaraki 3058568, Japan.							ABELES M, 1977, P IEEE, V65, P762, DOI 10.1109/PROC.1977.10559; ARBIB A, 1996, BEHAV BRAIN SCI, V19, P434; BAUSWEIN E, 1983, J PHYSIOL-LONDON, V339, P379, DOI 10.1113/jphysiol.1983.sp014722; FU QG, 1997, NEUROREPORT, V8, P253; GILBERT PFC, 1977, BRAIN RES, V128, P309, DOI 10.1016/0006-8993(77)90997-0; Houk JC, 1996, BEHAV BRAIN SCI, V19, P368, DOI 10.1017/S0140525X00081474; Ito M, 1984, CEREBELLUM NEURAL CO; KAWATO M, 1992, BIOL CYBERN, V68, P95, DOI 10.1007/BF00201431; KEATING JG, 1995, J NEUROPHYSIOL, V73, P1329, DOI 10.1152/jn.1995.73.4.1329; KITAZAWA S, 1995, J NEUROSCI, V15, P7644; MANO N, 1989, EXP BRAIN RES, V17, P265; MANO NI, 1986, J NEUROPHYSIOL, V56, P137, DOI 10.1152/jn.1986.56.1.137; OJAKANGAS CL, 1992, J NEUROPHYSIOL, V68, P2222, DOI 10.1152/jn.1992.68.6.2222; OJAKANGAS CL, 1994, J NEUROPHYSIOL, V72, P2617, DOI 10.1152/jn.1994.72.6.2617; Simpson JI, 1996, BEHAV BRAIN SCI, V19, P384, DOI 10.1017/S0140525X00081486; Thach W. T., 1996, Behavioral and Brain Sciences, V19, P411; THACH WT, 1968, J NEUROPHYSIOL, V31, P785, DOI 10.1152/jn.1968.31.5.785; THACH WT, 1970, J NEUROPHYSIOL, V33, P537, DOI 10.1152/jn.1970.33.4.537; WANG JJ, 1987, BRAIN RES, V410, P323, DOI 10.1016/0006-8993(87)90331-3	19	274	276	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					494	497		10.1038/33141	http://dx.doi.org/10.1038/33141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548253				2022-12-24	WOS:000072875200058
J	Wu, YC; Horvitz, HR				Wu, YC; Horvitz, HR			C-elegans phagocytosis and cell-migration protein CED-5 is similar to human DOCK180	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; GENE-EXPRESSION; DEATH; RECOGNITION; APOPTOSIS; MUTATIONS; ENCODES; MUSCLE	During programmed cell death, cell corpses are rapidly engulfed(1). This engulfment process involves the recognition and subsequent phagocytosis of cell corpses by engulfing cells(1-4). How cell corpses are engulfed is largely unknown, Here we report that ced-5, a gene that is required for cell-corpse engulfment in the nematode Caenorhabditis elegan(5), encodes a protein that is similar to the human protein DOCK180 and the Drosophila melanogaster protein Myoblast City (MBC), both of which have been implicated in the extension of cell surfaces(6). ced-5 mutants are defective not only in the engulfment of cell corpses but also in the migrations of two specific gonadal cells, the distal tip cells. The expression of human DOCK180 in C. elegans rescued the cell-migration defect of a ced-5 mutant. We present evidence that ced-5 functions in engulfing cells during the engulfment of cell corpses. We suggest that ced-5 acts in the extension of the surface of an engulfing cell around a dying cell during programmed cell death, We name this new family of proteins that function in the extension of cell surfaces the CDM (for CED-5, DOCK180 and MBC) family.	MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Horvitz, HR (corresponding author), MIT, Dept Biol, Howard Hughes Med Inst, 68-425,77 Massachusetts Ave, Cambridge, MA 02139 USA.	horvitz@mit.edu	Wu, Yi-Chun/F-7934-2012	Wu, Yi-Chun/0000-0002-8621-4098				BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; ELLIS RE, 1991, GENETICS, V129, P79; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Hart SP, 1996, EXPERIENTIA, V52, P950, DOI 10.1007/BF01920103; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HESEGAWA H, 1996, MOL CELL BIOL, V16, P1770; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; ROBERTSON AMG, 1982, J EMBRYOL EXP MORPH, V67, P89; RUSHTON E, 1995, DEVELOPMENT, V121, P1979; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	29	317	327	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					501	504		10.1038/33163	http://dx.doi.org/10.1038/33163			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548255				2022-12-24	WOS:000072875200060
J	Newman, B; Mu, H; Butler, LM; Millikan, RC; Moorman, PG; King, MC				Newman, B; Mu, H; Butler, LM; Millikan, RC; Moorman, PG; King, MC			Frequency of breast cancer attributable to BRCA1 in a population-based series of American women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OVARIAN-CANCER; FAMILIAL BREAST; GENETIC-HETEROGENEITY; SCREENING MAMMOGRAPHY; MUTATIONS; LINKAGE; JEWISH	Context.-Previous studies of BRCA1 mutation prevalence have been based on high-risk groups, yielding estimates that do not reflect the experience of the general population of US patients with breast cancer. Objective.-To determine prevalence of known disease-related mutations and other variants in BRCA1 and how it differs by race, age at diagnosis, and family history status in a population-based sample of white and black patients with breast cancer unselected for family history, Design.-Case-control study. Setting.-A 24-county area of central and eastern North Carolina. Participants.-Cases were women aged 20 to 74 years diagnosed as having a first invasive breast cancer between May 1993 and June 1996. Controls were frequency matched to cases by 5-year age range and race. The first 211 cases and 188 controls regardless of race and the subsequent 99 cases and 108 controls of African American ancestry are included in this report. Main Outcome Measure.-Germline variants at any site in the coding sequence, splice junctions, 5' untranslated region, or 3' untranslated region of the BRCA1 gene were analyzed in cases, and selected variants were analyzed in controls. Screening was performed using multiplex single-strand conformation analysis, with all potential variants confirmed using genomic sequencing. Results.-Three of 211 patients with breast cancer had disease-related variants at BRCA1, all of which were protein-truncating mutations. After adjustment for sampling probabilities, the proportion of patients with breast cancer with disease-related variants was 3.3% (95% confidence interval, 0%-7.2%) in white women and 0% in black women. Young age at diagnosis alone did not predict BRCA1 carrier status in this population, In white women, prevalence of inherited mutation was 23% for cases with family history of ovarian cancer, 13% for cases from families with at least 4 cases of breast cancer with or without ovarian cancer, and 33% for cases from families with both breast and ovarian cancer and at least 4 affected relatives. Because these results are based on few families at the highest levels of risk, confidence intervals around these estimates are wide. An additional 5 patients had rare missense mutations or a single amino acid deletion, the biological significance of which is unknown, In black women, a variant in the 3' untranslated region was statistically significantly more common in cases than in controls. Conclusions.-These data suggest that in the general US population, widespread screening of BRCA1 is not warranted. In contrast, BRCA1 mutations are sufficiently frequent in families with both breast and ovarian cancer, or at least 4 cases of breast cancer (at any age), that genotyping might be considered. The emerging picture of BRCA1 population genetics involves complex interactions of family history, age, and genetic ancestry, all of which should be taken into account when considering testing or interpreting results.	Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Div Med Genet, Dept Med, Seattle, WA 98195 USA; Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Yale University	Newman, B (corresponding author), Univ N Carolina, Dept Epidemiol, CB 7400 McGavran-Greenberg Hall, Chapel Hill, NC 27599 USA.	beth_newman@unc.edu		King, Mary-Claire/0000-0001-9426-1743	NATIONAL CANCER INSTITUTE [P50CA058223, R01CA027632] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA27632, P50-CA58223] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDRICH TE, 1995, BREAST CANCER RES TR, V35, P61, DOI 10.1007/BF00694746; *AM SOC HUM GEN AD, 1994, AM J HUM GENET, V55, P2; ARENA J, 1996, AM J HUM GENET, V59, P34; Bradley Martin B., 1992, CHURCHES CHURCH MEMB; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; COLLINS FS, 1994, JAMA-J AM MED ASSOC, V271, P785, DOI 10.1001/jama.1994.03510340075038; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; Durocher F, 1996, HUM MOL GENET, V5, P835, DOI 10.1093/hmg/5.6.835; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; Fletcher SW, 1997, NEW ENGL J MED, V336, P1180, DOI 10.1056/NEJM199704173361612; FORD D, 1995, AM J HUM GENET, V57, P1457; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Ford LG, 1997, PROG CLIN BIOL RES, V396, P271; FRIEDMAN LS, 1995, AM J HUM GENET, V57, P1284; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Gao Q, 1997, AM J HUM GENET, V60, P1233; HALL J, 1900, SCIENCE, V250, P1684; Hartmann L., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P168; Healy B, 1997, NEW ENGL J MED, V336, P1448, DOI 10.1056/NEJM199705153362009; Hubbard R, 1996, NEW ENGL J MED, V334, P1192, DOI 10.1056/NEJM199605023341812; Hubbard R., 1993, EXPLODING GENE MYTH; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P33, DOI 10.1001/jama.276.1.33; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Langston AA, 1996, AM J HUM GENET, V58, P881; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; MARGARITTE P, 1992, AM J HUM GENET, V50, P1231; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD S, 1995, AM J HUM GENET, V57, P957; NAROD SA, 1991, LANCET, V338, P82; Neuhausen SL, 1996, AM J HUM GENET, V58, P271; NEWMAN B, 1995, BREAST CANCER RES TR, V35, P51, DOI 10.1007/BF00694745; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Peelen T, 1997, AM J HUM GENET, V60, P1041; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Puget N, 1997, CANCER RES, V57, P828; Rebbeck TR, 1996, AM J HUM GENET, V59, P547; *RES TRIANGL I, 1996, SUDAAN SOFTW STAT AN; Rothenberg K, 1997, SCIENCE, V275, P1755, DOI 10.1126/science.275.5307.1755; Rothenberg KH, 1995, J LAW MED ETHICS, V23, P312, DOI 10.1111/j.1748-720X.1995.tb01373.x; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAS, 1996, SAS STAT SOFTW CHANG; *SAS I INC, 1993, SAS STAT SOFTW GENMO; Schubert EK, 1997, AM J HUM GENET, V60, P1031; Serova OM, 1997, AM J HUM GENET, V60, P486; ShattuckEidens D, 1997, JAMA-J AM MED ASSOC, V278, P1242, DOI 10.1001/jama.278.15.1242; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; WEINBERG CR, 1991, AM J EPIDEMIOL, V134, P421, DOI 10.1093/oxfordjournals.aje.a116104; WEINBERG CR, 1990, BIOMETRICS, V46, P963, DOI 10.2307/2532441; Whittemore AS, 1997, AM J HUM GENET, V60, P496	53	288	293	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1998	279	12					915	921		10.1001/jama.279.12.915	http://dx.doi.org/10.1001/jama.279.12.915			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC304	9544765	Bronze			2022-12-24	WOS:000072563600031
J	Nielsen, H; Pappot, H; Christensen, IJ; Brunner, N; Thorlacius-Ussing, O; Moesgaard, F; Dano, K; Grondahl-Hansen, J				Nielsen, H; Pappot, H; Christensen, IJ; Brunner, N; Thorlacius-Ussing, O; Moesgaard, F; Dano, K; Grondahl-Hansen, J			Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer	BRITISH MEDICAL JOURNAL			English	Article							PAI-1		Hvidovre Hosp, Dept Surg Gastroenterol, DK-2650 Hvidovre, Denmark; Rigshosp, Finsen Lab, DK-2100 Copenhagen, Denmark; Aalborg Hosp, Dept Surg Gastroenterol, DK-9000 Aalborg, Denmark	University of Copenhagen; Rigshospitalet; University of Copenhagen; Aalborg University; Aalborg University Hospital	Nielsen, H (corresponding author), Hvidovre Hosp, Dept Surg Gastroenterol, DK-2650 Hvidovre, Denmark.		Pappot, Helle/ADY-3530-2022	Nielsen, Hans Jorgen/0000-0003-2619-4379; Thorlacius-Ussing, Ole/0000-0003-4963-1551				ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; CASSLEN B, 1994, EUR J CANCER, V30A, P1302, DOI 10.1016/0959-8049(94)90178-3; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; MEIJER P, 1994, CLIN CHEM, V40, P110	5	75	77	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					829	830		10.1136/bmj.316.7134.829	http://dx.doi.org/10.1136/bmj.316.7134.829			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549453	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000072584300029
J	Tamura, M; Gu, JG; Matsumoto, K; Aota, S; Parsons, R; Yamada, KM				Tamura, M; Gu, JG; Matsumoto, K; Aota, S; Parsons, R; Yamada, KM			Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN	SCIENCE			English	Article							INTEGRINS; KINASE	The tumor suppressor PTEN is a phosphatase with sequence similarity to the cytoskeletal protein tensin. Here the cellular roles of PTEN were investigated. Overexpression of PTEN inhibited cell migration, whereas antisense PTEN enhanced migration. Integrin-mediated cell spreading and the formation of focal adhesions were down-regulated by wild-type PTEN but not by PTEN with an inactive phosphatase domain. PTEN interacted with the focal adhesion kinase FAK and reduced its tyrosine phosphorylation. Overexpression of FAK partially antagonized the effects of PTEN. Thus, PTEN phosphatase may function as a tumor suppressor by negatively regulating cell interactions with the extracellular matrix.	NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Columbia University; Columbia University	Tamura, M (corresponding author), NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bldg 30,Room 421,30 Convent Dr MSC 4370, Bethesda, MD 20892 USA.	mtamura@yoda.nidr.nih.gov; kyamada@yoda.nidr.nih.gov	Gu, Jianguo/ABC-9257-2020	Parsons, Ramon/0000-0002-6656-3514; Yamada, Kenneth/0000-0003-1512-6805				AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Arregui Carlos O., 1997, Molecular Biology of the Cell, V8, p290A; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Guldberg P, 1997, CANCER RES, V57, P3660; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Lin Shin, 1993, P240; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Okami K, 1998, CANCER RES, V58, P509; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TAMURA M, UNPUB; Teng DHF, 1997, CANCER RES, V57, P5221; Wang SI, 1997, CANCER RES, V57, P4183; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X	25	1019	1142	5	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	1998	280	5369					1614	1617		10.1126/science.280.5369.1614	http://dx.doi.org/10.1126/science.280.5369.1614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616126				2022-12-24	WOS:000074061200044
J	Gonzalez, CH; Marques-Dias, MJ; Kim, CA; Sugayama, SMM; Da Paz, JA; Huson, SM; Holmes, LB				Gonzalez, CH; Marques-Dias, MJ; Kim, CA; Sugayama, SMM; Da Paz, JA; Huson, SM; Holmes, LB			Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy	LANCET			English	Article							PARAPLEGIA; ABORTION; SEQUENCE	Background Misoprostol is commonly used to induce abortion in Brazil, and in other countries in South and Central America where abortions are illegal. However, misoprostol is not very effective in inducing abortions, and exposure to the drug in utero can cause abnormalities in the fetus. We aimed to define the common phenotypical effects of exposure to the drug. Methods We studied 42 infants from Sao Paulo, Brazil, who were exposed to misoprostol during the first 3 months of gestation, and then born with congenital abnormalities. We interviewed each of the infants' mothers to find out about misoprostol exposure and dosage. Each infant was physically examined by a geneticist or a neuropaediatrician. Findings 17 of the infants had equinovarus with cranial-nerve defects. Ten children had equinovarus as part of more extensive arthrogryposis. The most distinctive phenotypes were arthrogryposis confined to the legs (five cases) and terminal transverse-limb defects (nine cases) with or without Mobius sequence. The most common dose of misoprostol taken was 800 mu g (range 200-16 000 mu g). Interpretation Deformities attributed to vascular disruption were found in these children. We suggest that the uterine contractions induced by misoprostol cause vascular disruption in the fetus, including brain-stem ischaemia. Information on the effects of taking misoprostol during pregnancy should be made more widely available, to dissuade women from misusing the drug.	Massachusetts Gen Hosp, Genet & Teratol Univ, Boston, MA 02115 USA; Univ Sao Paulo, Fac Med, Inst Crianca, Sao Paulo, Brazil; Oxford Radcliffe Hosp, Dept Clin Genet, Oxford, England	Harvard University; Massachusetts General Hospital; Universidade de Sao Paulo; University of Oxford	Holmes, LB (corresponding author), Massachusetts Gen Hosp, Genet & Teratol Univ, Warren 801,55 Fruit St, Boston, MA 02115 USA.			Kim, Chong/0000-0002-1754-1300	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033222] Funding Source: NIH RePORTER; NICHD NIH HHS [R0I HD 33222] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOUWESBAVINCK JN, 1986, AM J MED GENET, V23, P903, DOI 10.1002/ajmg.1320230405; Bugalho A, 1996, CONTRACEPTION, V53, P243, DOI 10.1016/0010-7824(96)00044-3; CLEMENS GR, 1997, TOXICOLOGIST, V36, P260; COELHO HLL, 1991, LANCET, V338, P247, DOI 10.1016/0140-6736(91)90379-4; COSTA SH, 1993, LANCET, V341, P1258, DOI 10.1016/0140-6736(93)91156-G; DOWNIE WW, 1991, LANCET, V338, P247; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; FONSECA W, 1991, LANCET, V338, P56, DOI 10.1016/0140-6736(91)90046-R; GONZALEZ CH, 1993, AM J MED GENET, V47, P59, DOI 10.1002/ajmg.1320470113; GOVAERT P, 1989, PEDIATRICS, V84, P570; Hall JG, 1996, AM J MED GENET, V63, P293, DOI 10.1002/(SICI)1096-8628(19960503)63:1<293::AID-AJMG48>3.0.CO;2-G; HOLMES LB, 1995, J PEDIATR-US, V126, P131, DOI 10.1016/S0022-3476(95)70516-3; KOTSONIS FN, 1985, DIGEST DIS SCI, V30, pS142, DOI 10.1007/BF01309401; LIPSON AH, 1989, TERATOLOGY, V40, P339, DOI 10.1002/tera.1420400406; ORNOY A, 1982, ISRAEL J MED SCI, V18, P235; Pastuszak A. L., 1997, Teratology, V55, P36; PERSAUD TVN, 1979, ADV STUDY BIRTH DEFE, P161; RINGEL RE, 1983, J PEDIATR-US, V103, P251, DOI 10.1016/S0022-3476(83)80358-8; Schonhofar P S, 1991, Lancet, V337, P1534, DOI 10.1016/0140-6736(91)93212-R; Schuler L., 1997, Teratology, V55, P36; SHEPARD TH, 1995, LANCET, V346, P780, DOI 10.1016/S0140-6736(95)91540-0; SODRE H, 1990, J PEDIATR ORTHOPED, V10, P101; VERLOES A, 1990, J MED GENET, V27, P213, DOI 10.1136/jmg.27.3.213-b; WEYERTS LK, 1992, AM J MED GENET, V43, P751, DOI 10.1002/ajmg.1320430420	24	161	173	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1624	1627		10.1016/S0140-6736(97)12363-7	http://dx.doi.org/10.1016/S0140-6736(97)12363-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620717				2022-12-24	WOS:000074026600010
J	deCharms, RC; Blake, DT; Merzenich, MM				deCharms, RC; Blake, DT; Merzenich, MM			Optimizing sound features for cortical neurons	SCIENCE			English	Article							PRIMARY AUDITORY-CORTEX; CAT STRIATE CORTEX; SPECTRO-TEMPORAL CHARACTERISTICS; SPECIES-SPECIFIC VOCALIZATIONS; COMBINATION-SENSITIVE NEURONS; SIMPLE RECEPTIVE-FIELDS; SPATIOTEMPORAL ORGANIZATION; FUNCTIONAL-ORGANIZATION; MULTIFREQUENCY SOUNDS; POPULATION RESPONSES	The brain's cerebral cortex decomposes visual images into information about oriented edges, direction and velocity information, and color. How does the cortex decompose perceived sounds? A reverse correlation technique demonstrates that neurons in the primary auditory cortex of the awake primate have complex patterns of sound-feature selectivity that indicate sensitivity to stimulus edges in frequency or in time, stimulus transitions in frequency or intensity, and feature conjunctions. This allows the creation of classes of stimuli matched to the processing characteristics of auditory cortical neurons. Stimuli designed for a particular neuron's preferred feature pattern can drive that neuron with higher sustained firing rates than have typically been recorded with simple stimuli. These data suggest that the cortex decomposes an auditory scene into component parts using a feature-processing system reminiscent of that used for the cortical decomposition of visual images.	Univ Calif San Francisco, Keck Ctr Integrat Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Merzenich, MM (corresponding author), Univ Calif San Francisco, Keck Ctr Integrat Neurosci, San Francisco, CA 94143 USA.	merz@keck.ucsf.edu						ADELSON EH, 1985, J OPT SOC AM A, V2, P284, DOI 10.1364/JOSAA.2.000284; BAKER CL, 1990, VISUAL NEUROSCI, V4, P101, DOI 10.1017/S0952523800002273; Bieser A, 1996, EXP BRAIN RES, V108, P273; Brosch M, 1997, J NEUROPHYSIOL, V77, P923, DOI 10.1152/jn.1997.77.2.923; BRUGGE JF, 1973, J NEUROPHYSIOL, V36, P1138, DOI 10.1152/jn.1973.36.6.1138; BRUGGE JF, 1969, J NEUROPHYSIOL, V32, P1005, DOI 10.1152/jn.1969.32.6.1005; CALFORD MB, 1995, J NEUROPHYSIOL, V73, P1876, DOI 10.1152/jn.1995.73.5.1876; Chew SJ, 1996, SCIENCE, V274, P1909, DOI 10.1126/science.274.5294.1909; DEANGELIS GC, 1993, J NEUROPHYSIOL, V69, P1118, DOI 10.1152/jn.1993.69.4.1118; DEANGELIS GC, 1993, J NEUROPHYSIOL, V69, P1091, DOI 10.1152/jn.1993.69.4.1091; DEANGELIS GC, 1995, TRENDS NEUROSCI, V18, P451, DOI 10.1016/0166-2236(95)94496-R; DEAR SP, 1993, J NEUROPHYSIOL, V70, P1988, DOI 10.1152/jn.1993.70.5.1988; DEBOER E, 1968, IEEE T BIO-MED ENG, VBM15, P169, DOI 10.1109/TBME.1968.4502561; DEBOER E, 1978, J ACOUST SOC AM, V63, P115, DOI 10.1121/1.381704; deCharms RC, 1996, NATURE, V381, P610, DOI 10.1038/381610a0; Doupe AJ, 1997, J NEUROSCI, V17, P1147; EGGERMONT JJ, 1991, HEARING RES, V56, P153, DOI 10.1016/0378-5955(91)90165-6; EGGERMONT JJ, 1983, HEARING RES, V10, P167, DOI 10.1016/0378-5955(83)90052-7; EGGERMONT JJ, 1983, Q REV BIOPHYS, V16, P341, DOI 10.1017/S0033583500005126; EGGERMONT JJ, 1994, HEARING RES, V74, P51, DOI 10.1016/0378-5955(94)90175-9; FITZPATRICK DC, 1993, J NEUROSCI, V13, P931; GLASS I, 1979, EXP BRAIN RES, V34, P489; Heil P, 1997, J NEUROPHYSIOL, V77, P2616, DOI 10.1152/jn.1997.77.5.2616; Heil P, 1997, J NEUROPHYSIOL, V77, P2642, DOI 10.1152/jn.1997.77.5.2642; HERMES DJ, 1981, HEARING RES, V5, P147, DOI 10.1016/0378-5955(81)90043-5; HERMES DJ, 1982, HEARING RES, V6, P103, DOI 10.1016/0378-5955(82)90009-0; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JONES JP, 1987, J NEUROPHYSIOL, V58, P1187, DOI 10.1152/jn.1987.58.6.1187; JONES JP, 1987, J NEUROPHYSIOL, V58, P1233, DOI 10.1152/jn.1987.58.6.1233; Kao MC, 1997, BIOSYSTEMS, V40, P103, DOI 10.1016/0303-2647(96)01635-8; KAWASAKI M, 1988, J NEUROPHYSIOL, V59, P623, DOI 10.1152/jn.1988.59.2.623; KNUDSEN EI, 1987, ANNU REV NEUROSCI, V10, P41, DOI 10.1146/annurev.ne.10.030187.000353; KNUDSEN EI, 1995, ANNU REV NEUROSCI, V18, P19, DOI 10.1146/annurev.ne.18.030195.000315; KONISHI M, 1994, BRAIN BEHAV EVOLUT, V44, P279, DOI 10.1159/000113582; Kowalski N, 1996, J NEUROPHYSIOL, V76, P3524, DOI 10.1152/jn.1996.76.5.3524; Kowalski N, 1996, J NEUROPHYSIOL, V76, P3503, DOI 10.1152/jn.1996.76.5.3503; LEWICKI MS, 1995, P NATL ACAD SCI USA, V92, P5582, DOI 10.1073/pnas.92.12.5582; MARGOLIASH D, 1983, J NEUROSCI, V3, P1039; MENDELSON JR, 1985, BRAIN RES, V327, P331, DOI 10.1016/0006-8993(85)91530-6; MENDELSON JR, 1993, EXP BRAIN RES, V94, P65; MERZENICH MM, 1973, BRAIN RES, V63, P343, DOI 10.1016/0006-8993(73)90101-7; Merzenich MM., 1985, DYNAMIC ASPECTS NEOC, P397; MIDDLEBROOKS JC, 1994, SCIENCE, V264, P842, DOI 10.1126/science.8171339; MILLER JM, 1974, BRAIN RES, V69, P101, DOI 10.1016/0006-8993(74)90374-6; Nelken I, 1997, J NEUROPHYSIOL, V78, P800, DOI 10.1152/jn.1997.78.2.800; NELKEN I, 1994, HEARING RES, V72, P237, DOI 10.1016/0378-5955(94)90222-4; NELKEN I, 1994, HEARING RES, V72, P223, DOI 10.1016/0378-5955(94)90221-6; NELKEN I, 1994, HEARING RES, V72, P206, DOI 10.1016/0378-5955(94)90220-8; PHILLIPS DP, 1985, HEARING RES, V18, P87, DOI 10.1016/0378-5955(85)90112-1; PHILLIPS DP, 1987, EXP BRAIN RES, V67, P479; PHILLIPS DP, 1994, EXP BRAIN RES, V102, P210; RAUSCHECKER JP, 1995, SCIENCE, V268, P111, DOI 10.1126/science.7701330; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; REID RC, 1991, J NEUROPHYSIOL, V66, P505, DOI 10.1152/jn.1991.66.2.505; Rieke F., 1997, SPIKES EXPLORING NEU; Ringach DL, 1997, NATURE, V387, P281, DOI 10.1038/387281a0; RIQUIMAROUX H, 1991, SCIENCE, V251, P565, DOI 10.1126/science.1990432; Schreiner C E, 1992, Curr Opin Neurobiol, V2, P516, DOI 10.1016/0959-4388(92)90190-V; SCHREINER CE, 1988, HEARING RES, V32, P49, DOI 10.1016/0378-5955(88)90146-3; SCHREINER CE, 1990, J NEUROPHYSIOL, V64, P1442, DOI 10.1152/jn.1990.64.5.1442; SCHREINER CE, 1988, CODING TEMPORAL PATT; SCHREINER CE, COMMUNICATION; SEMPLE MN, 1993, J NEUROPHYSIOL, V69, P462, DOI 10.1152/jn.1993.69.2.462; SEMPLE MN, 1993, J NEUROPHYSIOL, V69, P449, DOI 10.1152/jn.1993.69.2.449; SHAMMA SA, 1985, HEARING RES, V19, P1, DOI 10.1016/0378-5955(85)90094-2; SHAMMA SA, 1997, SOC NEUR ABSTR, V23, P805; SIMMONS JA, 1993, J COMP PHYSIOL A, V172, P533, DOI 10.1007/BF00213677; SUGA N, 1987, J NEUROPHYSIOL, V58, P643, DOI 10.1152/jn.1987.58.4.643; SUGA N, 1992, PHILOS T ROY SOC B, V336, P423, DOI 10.1098/rstb.1992.0078; SUGA N, 1989, J EXP BIOL, V146, P277; SUGA N, 1965, J PHYSIOL-LONDON, V179, P26, DOI 10.1113/jphysiol.1965.sp007648; SUTTER ML, 1995, J NEUROPHYSIOL, V73, P190, DOI 10.1152/jn.1995.73.1.190; Wang XQ, 1995, J NEUROPHYSIOL, V74, P2685, DOI 10.1152/jn.1995.74.6.2685; WHITFIEL.IC, 1965, J NEUROPHYSIOL, V28, P655, DOI 10.1152/jn.1965.28.4.655; WOLLBERG Z, 1972, SCIENCE, V175, P212, DOI 10.1126/science.175.4018.212	75	335	337	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 29	1998	280	5368					1439	1443		10.1126/science.280.5368.1439	http://dx.doi.org/10.1126/science.280.5368.1439			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9603734				2022-12-24	WOS:000073883400057
J	Storey, A; Thomas, M; Kalita, A; Harwood, C; Gardiol, D; Mantovani, F; Breuer, J; Leigh, IM; Matlashewski, G; Banks, L				Storey, A; Thomas, M; Kalita, A; Harwood, C; Gardiol, D; Mantovani, F; Breuer, J; Leigh, IM; Matlashewski, G; Banks, L			Role of a p53 polymorphism in the development of human papillomavirus-associated cancer	NATURE			English	Article							CARCINOMA CELL-LINES; RENAL-TRANSPLANT RECIPIENTS; LUNG-CANCER; BROAD-SPECTRUM; GENE-PRODUCT; E6; DEGRADATION; PROTEIN; TYPE-16; BINDING	The E6 oncoprotein derived from tumour-associated human papillomaviruses (HPVs) binds to and induces the degradation of the cellular tumour-suppressor protein p53. A common polymorphism that occurs in the p53 amino-acid sequence results In the presence of either a proline or an arginine at position 72, The effect of this polymorphism on the susceptibility of p53 to EG-mediated degradation has been Investigated and the arginine form of p53 was found to be significantly more susceptible than the proline form. Moreover, allelic analysis of patients with HPV-associated tumours revealed a striking overrepresentation of homozygous arginine-72 p53 compared with the normal population, which indicated that individuals homozygous for arginine 72 are about seven times more susceptible to HPV-associated tumorigenesis than heterozygotes. The arginine-encoding allele therefore represents a significant risk factor in the development of HPV-associated cancers.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Imperial Canc Res Fund, Skin Tumour Lab, London E1 2AT, England; McGill Univ, Inst Parasitol, St Anne De Bellevue, PQ H9X 3V9, Canada; McGill Univ, McGill Canc Ctr, St Anne De Bellevue, PQ H9X 3V9, Canada; St Bartholomews & Royal London Hosp, Sch Med & Dent, Queen Mary & Westfield Coll, Dept Med Microbiol, London E1 1BB, England	International Center for Genetic Engineering & Biotechnology (ICGEB); Cancer Research UK; McGill University; McGill University; Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.			Storey, Alan/0000-0003-2001-9772; Harwood, Catherine/0000-0002-1375-0965; Breuer, Judith/0000-0001-8246-0534				ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228; BENTON EC, 1989, IMMUNODEFICIENCY SKI, P168; BERKHOUT RJM, 1995, J CLIN MICROBIOL, V33, P690, DOI 10.1128/JCM.33.3.690-695.1995; BIRGANDER R, 1995, CARCINOGENESIS, V16, P2233, DOI 10.1093/carcin/16.9.2233; BLESSING K, 1989, HISTOPATHOLOGY, V14, P129, DOI 10.1111/j.1365-2559.1989.tb02123.x; BOYLE J, 1993, CANCER RES, V53, P5328; BUTZ K, 1995, ONCOGENE, V10, P927; CHAN SY, 1995, J VIROL, V69, P3074, DOI 10.1128/JVI.69.5.3074-3083.1995; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; CROOK T, 1991, ONCOGENE, V6, P873; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Glover Mary T., 1993, Cancer Bulletin (Houston), V45, P220; GOLDBERG A, 1992, EUR J BIOCHEM, V203, P285; HERSHKO D, 1992, ANNU REV BIOCHEM, V61, P761; JIN XM, 1995, CARCINOGENESIS, V16, P2205, DOI 10.1093/carcin/16.9.2205; KAWAJIRI K, 1993, CARCINOGENESIS, V14, P1085, DOI 10.1093/carcin/14.6.1085; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; MANOS MM, 1989, CANCER CEL, V7, P209; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOREAU F, 1992, BIOCHEM CELL BIOL, V70, P1014, DOI 10.1139/o92-145; Murata M, 1996, CARCINOGENESIS, V17, P261, DOI 10.1093/carcin/17.2.261; PURDIE KJ, 1993, CANCER RES, V53, P5328; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shamanin V, 1996, JNCI-J NATL CANCER I, V88, P802, DOI 10.1093/jnci/88.12.802; SHAMANIN V, 1994, J GEN VIROL, V75, P1149, DOI 10.1099/0022-1317-75-5-1149; SHAMANIN V, 1994, CANCER RES, V54, P4610; SNIJDERS PJF, 1990, J GEN VIROL, V71, P173, DOI 10.1099/0022-1317-71-1-173; Sun XF, 1996, ONCOGENE, V13, P407; THOMAS M, 1995, ONCOGENE, V10, P261; VOGAN K, 1993, CANCER RES, V53, P5269; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WESTON A, 1994, CARCINOGENESIS, V15, P583, DOI 10.1093/carcin/15.4.583; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG W, 1992, GENE, V117, P271, DOI 10.1016/0378-1119(92)90738-B; ZURHAUSEN H, 1987, PAPOVAVIRIDAE PAPILL, P245	48	810	854	3	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					229	234		10.1038/30400	http://dx.doi.org/10.1038/30400			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607760				2022-12-24	WOS:000073761000041
J	Kheradmand, F; Werner, E; Tremble, P; Symons, M; Werb, Z				Kheradmand, F; Werner, E; Tremble, P; Symons, M; Werb, Z			Role of Rac1 and oxygen radicals in collagenase-1 expression induced by cell shape change	SCIENCE			English	Article							NF-KAPPA-B; GENE-EXPRESSION; RAS TRANSFORMATION; NADPH OXIDASE; FIBROBLASTS; FIBRONECTIN; ACTIVATION; TRANSLOCATION; RECEPTOR; PROTEINS	Integrin-mediated reorganization of cell shape leads to an altered cellular phenotype. Disruption of the actin cytoskeleton, initiated by binding of soluble antibody to alpha 5 beta 1 integrin, led to increased expression of the collagenase-1 gene in rabbit synovial fibroblasts. Activation of the guanosine triphosphate-binding protein Rac1, which was downstream of the integrin, was necessary for this process, and expression of activated Rac1 was sufficient to increase expression of collagenase-1. Rac1 activation generated reactive oxygen species that were essential for nuclear factor kappa B-dependent transcriptional regulation of interleukin-1 alpha, which, in an autocrine manner, induced collagenase-1 gene expression. Remodeling of the extracellular matrix and consequent alterations of integrin-mediated adhesion and cytoarchitecture are central to development, wound healing, inflammation, and malignant disease, The resulting activation of Rac1 may lead to altered gene regulation and alterations in cellular morphogenesis, migration, and invasion.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Werb, Z (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	zena@itsa.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010306] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03732] Funding Source: Medline; NIAMS NIH HHS [AR20684] Funding Source: Medline; NIDCR NIH HHS [DE10306] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; AGGELER J, 1984, J CELL BIOL, V98, P1662, DOI 10.1083/jcb.98.5.1662; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; DASH D, 1995, J BIOL CHEM, V270, P17321, DOI 10.1074/jbc.270.29.17321; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FORSAYETH JR, 1994, BIOTECHNIQUES, V17, P354; HARRIS ED, 1975, NATURE, V257, P243, DOI 10.1038/257243a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHERADMAND F, UNPUB; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; MICHIELS F, 1995, NATURE, V375, P388; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Roskelley CD, 1995, BIOCHEM CELL BIOL, V73, P391, DOI 10.1139/o95-046; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; RUCH W, 1983, J IMMUNOL METHODS, V63, P347, DOI 10.1016/S0022-1759(83)80008-8; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; TREMBLE P, 1994, MOL BIOL CELL, V5, P439, DOI 10.1091/mbc.5.4.439; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WESTMAYS JA, 1995, P NATL ACAD SCI USA, V92, P6768, DOI 10.1073/pnas.92.15.6768; XU XM, 1994, J BIOL CHEM, V269, P23569; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X	43	313	319	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1998	280	5365					898	902		10.1126/science.280.5365.898	http://dx.doi.org/10.1126/science.280.5365.898			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572733				2022-12-24	WOS:000073532900040
J	Maguire, EA; Burgess, N; Donnett, JG; Frackowiak, RSJ; Frith, CD; O'Keefe, J				Maguire, EA; Burgess, N; Donnett, JG; Frackowiak, RSJ; Frith, CD; O'Keefe, J			Knowing where and getting there: A human navigation network	SCIENCE			English	Article							CEREBRAL-CORTEX; BASAL GANGLIA; RAT; HIPPOCAMPUS; PROJECTION; LESIONS	The neural basis of navigation by humans was investigated with functional neuroimaging of brain activity during navigation ina familiar, yet complex virtual reality town. Activation of the right hippocampus was strongly associated with knowing accurately where places were located and navigating accurately between them. Getting to those places quickly was strongly associated with activation of the right caudate nucleus. These two right-side brain structures function in the context of associated activity in right inferior parietal and bilateral medial parietal regions that support egocentric movement through the virtual town, and activity in other left-side regions (hippocampus, frontal cortex) probably involved in nonspatial aspects of navigation. These findings outline a network of brain areas that support navigation in humans and link the functions of these regions to physiological observations in other mammals.	UCL, Neurol Inst, Wellcome Dept Cognit Neurol, London WC1N 3BG, England; UCL, Dept Anat & Dev Biol, London WC1E 6BT, England; UCL, Inst Cognit Neurosci, London WC1E 6BT, England	University of London; University College London; University of London; University College London; University of London; University College London	Maguire, EA (corresponding author), UCL, Neurol Inst, Wellcome Dept Cognit Neurol, 12 Queen Sq, London WC1N 3BG, England.	e.maguire@fil.ion.ucl.ac.uk	Frith, Chris D/A-2171-2009; Frackowiak, Richard S/I-1809-2013; Burgess, Neil/B-2420-2009; Frackowiak, Richard/H-4383-2011	Frith, Chris D/0000-0002-8665-0690; Burgess, Neil/0000-0003-0646-6584; Frackowiak, Richard/0000-0002-3151-822X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aguirre GK, 1997, J NEUROSCI, V17, P2512; Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; Andersen RA, 1997, PHILOS T ROY SOC B, V352, P1421, DOI 10.1098/rstb.1997.0128; [Anonymous], 1983, CANADIAN PSYCHOL; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; Buchel C, 1996, NEUROIMAGE, V4, P60, DOI 10.1006/nimg.1996.0029; Burgess N, 1997, PHILOS T ROY SOC B, V352, P1397, DOI 10.1098/rstb.1997.0125; Burgess N, 1996, HIPPOCAMPUS, V6, P749; DEJONG BM, 1994, BRAIN, V117, P1039; Devan BD, 1996, NEUROBIOL LEARN MEM, V66, P305, DOI 10.1006/nlme.1996.0072; Elliott R, 1997, NEUROPSYCHOLOGIA, V35, P1395, DOI 10.1016/S0028-3932(97)00055-9; Evans AC, 1993, P IEEE NUCL SCI S ME; Friston K.J., 1994, HUMAN BRAIN MAPPING, V2, P211, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Ghaem O, 1997, NEUROREPORT, V8, P739, DOI 10.1097/00001756-199702100-00032; HOUK JC, 1995, CEREB CORTEX, V5, P95, DOI 10.1093/cercor/5.2.95; Karnath HO, 1997, PHILOS T ROY SOC B, V352, P1411, DOI 10.1098/rstb.1997.0127; KELLEY AE, 1982, NEUROSCIENCE, V7, P615, DOI 10.1016/0306-4522(82)90067-7; Luria A.R., 1966, HIGHER CORTICAL FUNC, P3; Maguire EA, 1996, P ROY SOC B-BIOL SCI, V263, P1745, DOI 10.1098/rspb.1996.0255; Maguire EA, 1998, J COGNITIVE NEUROSCI, V10, P61, DOI 10.1162/089892998563789; Maguire EA, 1996, NEUROPSYCHOLOGIA, V34, P993, DOI 10.1016/0028-3932(96)00022-X; Maguire EA, 1997, J NEUROSCI, V17, P7103; MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0; Milner B, 1972, Clin Neurosurg, V19, P421; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKeefe J, 1991, BRAIN SPACE, P273, DOI DOI 10.1016/j.neuron.2015.06.011; OKEEFE J, IN PRESS PHILOS T B; Passingham R., 1995, FRONTAL LOBES VOLUNT; PASSINGHAM RE, 1987, NEURAL BEHAV APPROAC; POTEGAL M, 1908, SPATIAL ABILITIES DE; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; SWANSON LW, 1986, J NEUROSCI, V6, P3010; Talairach I., 1988, COPLANAR STEREOTACTI; TAUBE JS, 1990, J NEUROSCI, V10, P420; Vallar G, 1997, PHILOS T ROY SOC B, V352, P1401, DOI 10.1098/rstb.1997.0126; VarghaKhadem F, 1997, SCIENCE, V277, P376, DOI 10.1126/science.277.5324.376; WIENER SI, 1993, J NEUROSCI, V13, P3802; Wood F., 1975, SHORT TERM MEMORY, P257	42	1023	1041	3	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1998	280	5365					921	924		10.1126/science.280.5365.921	http://dx.doi.org/10.1126/science.280.5365.921			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572740				2022-12-24	WOS:000073532900047
J	Fischer, MB; Goerg, S; Shen, LM; Prodeus, AP; Goodnow, CC; Kelsoe, G; Carroll, MC				Fischer, MB; Goerg, S; Shen, LM; Prodeus, AP; Goodnow, CC; Kelsoe, G; Carroll, MC			Dependence of germinal center B cells on expression of CD21/CD35 for survival	SCIENCE			English	Article							FOLLICULAR DENDRITIC CELL; LYMPHOCYTES-B; COMPLEMENT RECEPTOR-1; IMMUNE-RESPONSE; ANTIGEN; MICE; CR-2; MEMORY; CD19; C3D	Affinity-driven selection of B lymphocytes within germinal centers is critical for the development of high-affinity memory cells and host protection. To investigate the role of the CD21/CD35 coreceptor in B cell competition for follicular retention and survival within the germinal center, either Cr2(+) or Cr2(null) lysozyme-specific transgenic B cells were adoptively transferred into normal mice immunized with duck (DEL) or turkey (TEL) lysozyme, which bind with different affinities. In mice injected with high-affinity turkey lysozyme, Cr2(null) B cells responded by follicular retention; however, they could not survive within germinal centers. This suggests that CD21 provides a signal independent of antigen that is required for survival of B cells in the germinal center.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Australian Natl Univ, John Curtin Sch Med Res, Med Genome Ctr, Canberra, ACT 2601, Australia; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	Harvard University; Harvard Medical School; Australian National University; John Curtin School of Medical Research; University System of Maryland; University of Maryland Baltimore	Carroll, MC (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.		Fischer, Michael/AAU-5579-2020; Goodnow, Christopher C/V-8108-2018	Fischer, Michael/0000-0002-5876-0243; Goodnow, Christopher C/0000-0001-5296-6155				Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; Cook MC, 1997, J EXP MED, V186, P631, DOI 10.1084/jem.186.5.631; Croix DA, 1996, J EXP MED, V183, P1857, DOI 10.1084/jem.183.4.1857; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Diacovo TG, 1996, SCIENCE, V273, P252, DOI 10.1126/science.273.5272.252; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FEARON DT, 1983, ANNU REV IMMUNOL, V1, P243, DOI 10.1146/annurev.iy.01.040183.001331; Fischer M., UNPUB; Fischer MB, 1996, J IMMUNOL, V157, P549; FISCHER MB, IN PRESS J IMMUNOL; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; KLAUS GGB, 1980, IMMUNOL REV, V53, P3, DOI 10.1111/j.1600-065X.1980.tb01038.x; LAVOIE TB, 1992, J IMMUNOL, V148, P503; LAW SK, 1980, P NATL ACAD SCI-BIOL, V77, P7194, DOI 10.1073/pnas.77.12.7194; MOLINA H, 1990, J IMMUNOL, V145, P2974; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; PRAGER EM, 1971, J BIOL CHEM, V246, P5978; QIN DL, UNPUB; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; Tooze RM, 1997, IMMUNITY, V7, P59, DOI 10.1016/S1074-7613(00)80510-5; VANNOESEL CJM, 1993, IMMUNOL TODAY, V9, P8; WEIS JJ, 1984, P NATL ACAD SCI-BIOL, V81, P881, DOI 10.1073/pnas.81.3.881; Wu JH, 1996, J IMMUNOL, V157, P3404; ZHENG B, 1996, J EXP MED, V184, P1	27	211	216	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					582	585		10.1126/science.280.5363.582	http://dx.doi.org/10.1126/science.280.5363.582			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554848				2022-12-24	WOS:000073242100045
J	Mazel, D; Dychinco, B; Webb, VA; Davies, J				Mazel, D; Dychinco, B; Webb, VA; Davies, J			A distinctive class of integron in the Vibrio cholerae genome	SCIENCE			English	Article							SITE-SPECIFIC INTEGRATION; GENES; EVOLUTION; ELEMENTS; BACTERIA; FAMILY	The ability of bacteria to acquire and disseminate heterologous genes has been a major factor in the development of multiple drug resistance. A gene, intl4, was identified that encodes a previously unknown integrase that is associated with a "gene-VCR" organization (VCRs are Vibrio cholerae repeated sequences), similar to that of the well-characterized antibiotic resistance integrons, The similarity was confirmed by Intl1-mediated recombination of a gene-VCR cassette into a class 1 integron. VCR cassettes are found in a number of Vibrio species including a strain of V. metschnikovii isolated in 1888, suggesting that this mechanism of heterologous gene acquisition predated the antibiotic era.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Davies, J (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.		Mazel, Didier/F-9200-2013	Mazel, Didier/0000-0001-6482-6002				Barker A, 1997, MICROBIOL-SGM, V143, P1805, DOI 10.1099/00221287-143-6-1805; BARKER A, 1994, J BACTERIOL, V176, P5450, DOI 10.1128/JB.176.17.5450-5458.1994; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BUNNY KL, 1995, ANTIMICROB AGENTS CH, V39, P686, DOI 10.1128/AAC.39.3.686; *GENB, U14749 GENB; HALL RM, 1993, GENETICA, V90, P115, DOI 10.1007/BF01435034; KITATSUKAMOTO K, 1993, INT J SYST BACTERIOL, V43, P8, DOI 10.1099/00207713-43-1-8; Kovach ME, 1996, MICROBIOL-SGM, V142, P2165, DOI 10.1099/13500872-142-8-2165; Lee CA, 1996, INFECT AGENT DIS, V5, P1; MARTINEZ E, 1988, MOL GEN GENET, V211, P320, DOI 10.1007/BF00330610; MARTINEZ E, 1990, EMBO J, V9, P1275, DOI 10.1002/j.1460-2075.1990.tb08236.x; MAZEL D, UNPUB; OCHMAN H, 1987, J MOL EVOL, V26, P74, DOI 10.1007/BF02111283; OGAWA A, 1993, MICROBIOL IMMUNOL, V37, P607, DOI 10.1111/j.1348-0421.1993.tb01683.x; Recchia GD, 1997, TRENDS MICROBIOL, V5, P389, DOI 10.1016/S0966-842X(97)01123-2; Recchia GD, 1995, MICROBIOL-UK, V141, P3015, DOI 10.1099/13500872-141-12-3015; van Dongen WMAM, 1987, MOL GEN LIFE SCI ADV, V6, P85; Vicente ACP, 1997, J MED MICROBIOL, V46, P398, DOI 10.1099/00222615-46-5-398; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910	19	284	320	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					605	608		10.1126/science.280.5363.605	http://dx.doi.org/10.1126/science.280.5363.605			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554855				2022-12-24	WOS:000073242100052
J	Kolk, MH; van der Graaf, M; Wijmenga, SS; Pleij, CWA; Heus, HA; Hilbers, CW				Kolk, MH; van der Graaf, M; Wijmenga, SS; Pleij, CWA; Heus, HA; Hilbers, CW			NMR structure of a classical pseudoknot: Interplay of single- and double-stranded RNA	SCIENCE			English	Article							MOSAIC-VIRUS RNA; IMPROVED SENSITIVITY; VIRAL RNAS; TYMV-RNA; C-13; SPECTROSCOPY; PROTEINS; RIBOZYME; PROTONS; VALINE	Pseudoknot formation folds the 3' ends of many plant viral genomic RNAs into structures that resemble transfer RNA in global folding and in their reactivity to transfer RNA-specific proteins. The solution structure of the pseudoknotted T arm and acceptor arm of the transfer RNA-like structure of turnip yellow mosaic virus (TYMV) was determined by nuclear magnetic resonance (NMR) spectroscopy. The molecule is stabilized by the hairpin formed by the 5' end of the RNA, and by the intricate interactions related to the loops of the pseudoknot. Loop 1 spans the major groove of the helix with only two of its four nucleotides. Loop 2, which crosses the minor groove, interacts closely with its opposing helix, in particular through hydrogen bonds with a highly conserved adenine. The structure resulting from this interaction between the minor groove and single-stranded RNA at helical junctions displays internal mobility, which may be a general feature of RNA pseudoknots that regulates their interaction with proteins or other RNA molecules.	Univ Nijmegen, Biophys Chem Lab, Nijmegen SON Res Ctr Mol Struct Design & Synth, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	Hilbers, CW (corresponding author), Univ Nijmegen, Biophys Chem Lab, Nijmegen SON Res Ctr Mol Struct Design & Synth, Toernooiveld, NL-6525 ED Nijmegen, Netherlands.		van der Graaf, Marinette/D-4086-2009; Heus, Hans/F-9696-2015	Heus, Hans/0000-0001-7256-4241				BARSUKOV IL, 1993, NMR MACROMOLECULES P, P315; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BRIERLEY I, 1995, J GEN VIROL, V76, P1885, DOI 10.1099/0022-1317-76-8-1885; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CHASTAIN M, 1993, BIOCHEMISTRY-US, V32, P14220, DOI 10.1021/bi00214a022; DEIMAN BAL, IN PRESS J VIROL; Du ZH, 1996, BIOCHEMISTRY-US, V35, P4187, DOI 10.1021/bi9527350; DUMAS P, 1987, J BIOMOL STRUCT DYN, V4, P707, DOI 10.1080/07391102.1987.10507674; FLORENTZ C, 1982, EMBO J, V1, P269, DOI 10.1002/j.1460-2075.1982.tb01158.x; FOLMER RHA, 1995, J BIOMOL NMR, V5, P427, DOI 10.1007/BF00182287; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Hall T C, 1979, Int Rev Cytol, V60, P1, DOI 10.1016/S0074-7696(08)61257-7; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LEGAULT P, 1995, FEBS LETT, V362, P156, DOI 10.1016/0014-5793(95)00232-X; LEGAULT P, 1994, J AM CHEM SOC, V116, P2203, DOI 10.1021/ja00084a094; MANS RMW, 1991, EUR J BIOCHEM, V201, P303, DOI 10.1111/j.1432-1033.1991.tb16288.x; MANS RMW, 1990, NUCLEIC ACIDS RES, V18, P3479, DOI 10.1093/nar/18.12.3479; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; NIKONOWICZ EP, 1992, NUCLEIC ACIDS RES, V20, P4507, DOI 10.1093/nar/20.17.4507; PINCK M, 1970, NATURE, V226, P954, DOI 10.1038/226954a0; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; PLEIJ CWA, 1994, CURR OPIN STRUC BIOL, V4, P337, DOI 10.1016/S0959-440X(94)90101-5; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; RIETVELD K, 1982, NUCLEIC ACIDS RES, V10, P1929, DOI 10.1093/nar/10.6.1929; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUDINGER J, 1992, NUCLEIC ACIDS RES, V20, P1865, DOI 10.1093/nar/20.8.1865; SCHIMMEL P, 1989, CELL, V58, P9, DOI 10.1016/0092-8674(89)90395-4; Schweisguth DC, 1997, J MOL BIOL, V267, P505, DOI 10.1006/jmbi.1996.0903; SHEN LX, 1995, J MOL BIOL, V247, P963, DOI 10.1006/jmbi.1995.0193; Simorre JP, 1995, J BIOMOL NMR, V6, P427; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; TENDAM E, 1992, BIOCHEMISTRY-US, V31, P11665, DOI 10.1021/bi00162a001; VANBELKUM A, 1989, EUR J BIOCHEM, V183, P591; VANBELKUM A, 1988, NUCLEIC ACIDS RES, V16, P1931, DOI 10.1093/nar/16.5.1931; VUISTER GW, 1993, J AM CHEM SOC, V115, P5334, DOI 10.1021/ja00065a071; Wijmenga SS, 1997, J BIOMOL NMR, V10, P337, DOI 10.1023/A:1018348123074; Yao LJ, 1997, J BIOMOL NMR, V9, P229, DOI 10.1023/A:1018618606857; YOT P, 1970, P NATL ACAD SCI USA, V67, P1345, DOI 10.1073/pnas.67.3.1345	43	128	130	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					434	438		10.1126/science.280.5362.434	http://dx.doi.org/10.1126/science.280.5362.434			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545221				2022-12-24	WOS:000073159600047
J	Jin, DY; Spencer, F; Jeang, KT				Jin, DY; Spencer, F; Jeang, KT			Human T cell leukemia virus type 1 oncoprotein tax targets the human mitotic checkpoint protein MAD1	CELL			English	Article							SPINDLE ASSEMBLY CHECKPOINT; BUDDING YEAST; I TAX; ACTIVATION; EXPRESSION; HTLV; GENE; P53; MITOSIS; LINE	In searching for cellular targets of the HTLV-I oncoprotein Tax, we identified TXBP181,which we characterized as the human homolog of yeast mitotic checkpoint MAD1 protein. Evidence supporting TXBP181 as HsMAD1 includes sequence conservation with yeast MAD1, hyperphosphorylation during S/G(2)/M phases and upon treatment of cells with nocodazole, and binding to HsMAD2. HsMAD1 functions as a homodimer. It localizes to the centrosome during metaphase and to the spindle midzone and the midbody during anaphase and telophase. Expression of either Tax or a transdominant-negative TXBP181 results in multinucleated cells, a phenotype consistent with a loss of HsMAD1 function. We propose a model of viral transformation in which Tax targets TXBP181, thereby abrogating a mitotic checkpoint.	NIAID, Mol Microbiol Lab, Bethesda, MD 20892 USA; Johns Hopkins Univ, Ctr Genet Med, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University	Jeang, KT (corresponding author), NIAID, Mol Microbiol Lab, Bethesda, MD 20892 USA.		Jeang, Kuan-Teh/A-2424-2008					Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Glotzer M, 1997, CURR OPIN CELL BIOL, V9, P815, DOI 10.1016/S0955-0674(97)80082-8; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KIKUCHI M, 1986, HEMATOL ONCOL, V4, P67, DOI 10.1002/hon.2900040109; Knecht H, 1996, ONCOGENE, V13, P947; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Laird AD, 1997, CELL SIGNAL, V9, P249, DOI 10.1016/S0898-6568(96)00176-3; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li XR, 1997, MOL CELL BIOL, V17, P2723, DOI 10.1128/MCB.17.5.2723; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Oegema K, 1997, P NATL ACAD SCI USA, V94, P4817, DOI 10.1073/pnas.94.10.4817; Pangilinan F, 1996, MOL BIOL CELL, V7, P1195, DOI 10.1091/mbc.7.8.1195; Pockwinse SM, 1997, P NATL ACAD SCI USA, V94, P3022, DOI 10.1073/pnas.94.7.3022; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P6815, DOI 10.1073/pnas.77.11.6815; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; TAGUCHI H, 1993, CANCER, V71, P133, DOI 10.1002/1097-0142(19930101)71:1<133::AID-CNCR2820710121>3.0.CO;2-G; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Wang YC, 1997, MOL CELL BIOL, V17, P620, DOI 10.1128/MCB.17.2.620; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZAJDEL MEB, 1988, ONCOGENE, V2, P579	55	447	468	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					81	91		10.1016/S0092-8674(00)81148-4	http://dx.doi.org/10.1016/S0092-8674(00)81148-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546394	hybrid			2022-12-24	WOS:000072910800012
J	Andersen, RE; Crespo, CJ; Bartlett, SJ; Cheskin, LJ; Pratt, M				Andersen, RE; Crespo, CJ; Bartlett, SJ; Cheskin, LJ; Pratt, M			Relationship of physical activity and television watching with body weight and level of fatness among children - Results from the Third National Health and Nutrition Examination Survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDHOOD WEIGHT; US ADULTS; ADOLESCENTS; OVERWEIGHT; OBESITY; EXERCISE; PREVALENCE; MORTALITY; STATEMENT; MORBIDITY	Context.-Physical inactivity contributes to weight gain in adults, but whether this relationship is true for children of different ethnic groups is not well established, Objective.-To assess participation in vigorous activity and television watching habits and their relationship to body weight and fatness in US children, Design.-Nationally representative cross-sectional survey with an in-person interview and medical examination, Setting and Participants.-Between 1988 and 1994, 4063 children aged 8 through 16 years were examined as part of the National Health and Nutrition Examination Survey III, Mexican Americans and non-Hispanic blacks were oversampled to produce reliable estimates for these groups, Main Outcome Measures.-Episodes of weekly vigorous activity and daily hours of television watched, and their relationship to body mass index and body fatness. Results.-Eighty percent of US children reported performing 3 or more bouts of vigorous activity each week, This rate was lower in non-Hispanic black and Mexican American girls (69% and 73%, respectively). Twenty percent of US children participated in 2 or fewer bouts of vigorous activity per week, and the rate was higher in girls (26%) than in boys (17%), Overall, 26% of US children watched 4 or more hours of television per day and 67% watched at least 2 hours per day, Non-Hispanic black children had the highest rates of watching 4 or more hours of television per day (42%), Boys and girls who watch 4 or more hours of television each day had greater body fat (P<.001) and had a greater body mass index (P<.001) than those who watched less than 2 hours per day, Conclusions.-Many US children watch a great deal of television and are inadequately vigorously active. Vigorous activity levels are lowest among girls, non-Hispanic blacks, and Mexican Americans, Intervention strategies to promote lifelong physical activity among US children are needed to stem the adverse health consequences of inactivity.	Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Div Gastroenterol, Baltimore, MD 21224 USA; NHLBI, Dept Hlth & Fitness, NIH, Bethesda, MD 20892 USA; Ctr Dis Control & Prevent, Phys Act & Hlth Branch, Atlanta, GA USA	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Centers for Disease Control & Prevention - USA	Andersen, RE (corresponding author), Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, 333 Cassell Dr,Suite 1640, Baltimore, MD 21224 USA.		Bartlett, Susan Joan/AAD-4103-2020; Bartlett, Susan J./J-9864-2012; Cheskin, Lawrence/AAM-1094-2021	Bartlett, Susan Joan/0000-0001-9755-2490; Cheskin, Lawrence/0000-0003-0262-1030				ABRAHAM S, 1971, HSMHA HEALTH REP, V86, P273, DOI 10.2307/4594149; Andersen RE, 1997, ANN INTERN MED, V127, P395, DOI 10.7326/0003-4819-127-5-199709010-00010; ANDERSEN RE, 1992, HLTH FITNESS CLUB LE; ANDERSEN RE, 1995, MED EXERC NUTR HLTH, V4, P57; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; [Anonymous], VITAL HLTH STAT; BRICK JM, 1997, USERS GUIDE WESVAR P; BROWN JR, 1974, USES MASS COMMUNICAT, P93; BROWNELL KD, 1992, J CONSULT CLIN PSYCH, V60, P505, DOI 10.1037/0022-006X.60.4.505; *CDCP, 1994, 1994 BRFSS SUMM PREV; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; COOPER DM, 1994, MED SCI SPORT EXER, V26, P733, DOI 10.1249/00005768-199406000-00013; Crespo CJ, 1996, ARCH INTERN MED, V156, P93, DOI 10.1001/archinte.156.1.93; DIETZ WH, 1985, PEDIATRICS, V75, P807; DIETZ WH, 1991, CURR PROBL PEDIATR, V1, P8; DIPIETRO L, 1994, INT J OBESITY, V18, P585; DURANT RH, 1994, PEDIATRICS, V94, P449; Epstein LH, 1996, MED SCI SPORT EXER, V28, P428, DOI 10.1097/00005768-199604000-00006; Epstein LH, 1997, HEALTH PSYCHOL, V16, P107, DOI 10.1037/0278-6133.16.2.107; Ezzati T M, 1992, Vital Health Stat 2, P1; Fletcher GF, 1996, CIRCULATION, V94, P857, DOI 10.1161/01.CIR.94.4.857; GUO SS, 1994, AM J CLIN NUTR, V59, P810, DOI 10.1093/ajcn/59.4.810; JEFFREY DB, 1982, HLTH ED Q, V9, P78; KANN L, 1993, PUBLIC HEALTH REP, V108, P47; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; MALINA RM, 1990, EXERCISE, FITNESS, AND HEALTH, P637; NIETO FJ, 1992, AM J EPIDEMIOL, V136, P201, DOI 10.1093/oxfordjournals.aje.a116486; PATRICK K, 1994, PHYSICIAN SPORTSMED, V22, P245; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; ROCHE AF, 1981, AM J CLIN NUTR, V34, P2831, DOI 10.1093/ajcn/34.12.2831; SALLIS JF, 1991, RES Q EXERCISE SPORT, V62, P124, DOI 10.1080/02701367.1991.10608701; SALLIS JF, 1994, PEDIATR EXERC SCI, V6, P302; SALLIS JF, 1994, HLTH FITNESS PHYS ED, P31; SAS Institute Inc, 1989, SAS STAT US GUID VER; SERDULA MK, 1993, PREV MED, V22, P167, DOI 10.1006/pmed.1993.1014; Strasburger V C, 1992, Pediatr Rev, V13, P144, DOI 10.1542/pir.13-4-144; Tanner JM, 1975, ASSESSMENT SKELETAL; TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085, DOI 10.1001/archpedi.1995.02170230039005; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; *US DEP HHS, 1991, HLTH PEOPL 2000 NAT; Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301; Williams TM, 1986, IMPACT TELEVISION NA, P143; 1994, PREVENTION, V46, P65	43	872	894	1	108	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1998	279	12					938	942		10.1001/jama.279.12.938	http://dx.doi.org/10.1001/jama.279.12.938			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZC304	9544768				2022-12-24	WOS:000072563600034
J	Jacobson, J				Jacobson, J			After the miracle	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1998	279	12					906	906		10.1001/jama.279.12.906	http://dx.doi.org/10.1001/jama.279.12.906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC304	9544753				2022-12-24	WOS:000072563600011
J	Boshuizen, HC; Izaks, GJ; van Buuren, S; Ligthart, GJ				Boshuizen, HC; Izaks, GJ; van Buuren, S; Ligthart, GJ			Blood pressure and mortality in elderly people aged 85 and older: community based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SURVIVAL; SEX	Objective: To determine whether the inverse relation between blood pressure and all cause mortality in elderly people over 85 years of age can be explained by adjusting for health status, and to determine whether high blood pressure is a risk factor for mortality when the effects of poor health are accounted for. Design: 5 to 7 year follow up of community residents aged 85 years and older. Setting: Leiden, the Netherlands. Subjects: 835 subjects whose blood pressure was recorded between 1987 and 1989. Main outcome measure: All cause mortality. Results: An inverse relation between blood pressure and all cause mortality was observed. For diastolic blood pressure crude year all cause mortality decreased from 88% (52/59) (95% confidence interval 79% to 95%) in those with diastolic blood pressures < 65 mm Hg to 59% (27/46) (44% to 72%) in those with diastolic pressures > 100 mm Hg. For systolic blood pressure crude 5 year all cause mortality decreased from 85% (95/112) (78% to 91%) in those with systolic pressures < 125 mm Hg to 59% (13/22) (38% to 78%) in those with systolic pressures > 200 min Hg. This decrease was no longer significant after adjustment for indicators of poor health. No relation existed between blood pressure and mortality from cardiovascular causes or stroke after adjustment for age and sex, but after adjustment for age, sex, and indicators of poor health there was a positive relation between diastolic blood pressure and mortality from both cardiovascular causes and stroke. Conclusion: The inverse relation between blood pressure and all cause mortality in elderly people over 85 is associated with health status.	TNO Prevent & Hlth, Div Publ Hlth & Prevent, Leiden, Netherlands; Leiden Univ, Dept Gen Internal Med, Sect Gerontol & Geriatr, Med Ctr, Leiden, Netherlands	Netherlands Organization Applied Science Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Boshuizen, HC (corresponding author), TNO Prevent & Hlth, Div Publ Hlth & Prevent, Leiden, Netherlands.	HC.Boshuizen@PG.TNO.NL	Izaks, Gerbrand/F-5089-2014; Boshuizen, Hendriek/M-3415-2014; Boshuizen, Hendriek C/B-3718-2014	Izaks, Gerbrand/0000-0003-3213-7637; Boshuizen, Hendriek/0000-0002-3916-9095; van Buuren, Stef/0000-0003-1098-2119	NATIONAL INSTITUTE ON AGING [R01AG006354] Funding Source: NIH RePORTER; NIA NIH HHS [AG 06354] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMERY A, 1986, LANCET, V2, P589; [Anonymous], 1991, JAMA, V265, P3255; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GLYNN RJ, 1995, LANCET, V345, P825, DOI 10.1016/S0140-6736(95)92964-9; Guo ZC, 1997, AM J PUBLIC HEALTH, V87, P623, DOI 10.2105/AJPH.87.4.623; HEIKINHEIMO RJ, 1990, J HYPERTENS, V8, P361, DOI 10.1097/00004872-199004000-00010; HOLME I, 1976, ACTA MED SCAND, V200, P229; Izaks GJ, 1997, J AM GERIATR SOC, V45, P56, DOI 10.1111/j.1532-5415.1997.tb00978.x; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; LAGAAY AM, 1992, BRIT MED J, V304, P1091, DOI 10.1136/bmj.304.6834.1091; LANGER RD, 1991, AM J EPIDEMIOL, V134, P29, DOI 10.1093/oxfordjournals.aje.a115990; LIGTHART GJ, 1984, MECH AGEING DEV, V28, P47, DOI 10.1016/0047-6374(84)90152-0; MATTILA K, 1988, BRIT MED J, V296, P887, DOI 10.1136/bmj.296.6626.887; RAJALA S, 1983, LANCET, V2, P520; WeverlingRijnsburger AWE, 1997, LANCET, V350, P1119, DOI 10.1016/S0140-6736(97)04430-9	16	152	158	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	1998	316	7147					1780	+		10.1136/bmj.316.7147.1780	http://dx.doi.org/10.1136/bmj.316.7147.1780			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624064	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000074286300024
J	Richards, SH; Coast, J; Gunnell, DJ; Peters, TJ; Pounsford, J; Darlow, MA				Richards, SH; Coast, J; Gunnell, DJ; Peters, TJ; Pounsford, J; Darlow, MA			Randomised controlled trial comparing effectiveness and acceptability of an early discharge, hospital at home scheme with acute hospital care	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; STATE	Objective: to compare effectiveness and acceptability of early discharge to a hospital at home scheme with that of routine discharge from acute hospital. Design: Pragmatic randomised controlled trial. Setting: Acute hospital wards and community in north of Bristol, with a catchment population of about 224 000 people. Subjects: 241 hospitalised but medically stable elderly patients who fulfilled criteria for early discharge to hospital at home scheme and who consented to participate. Interventions: Patients' received hospital at home care or routine hospital care. Main outcome measures: Patients' quality of life, satisfaction, and physical functioning assessed at 4 weeks and 3 months after randomisation to treatment; length of stay in hospital and in hospital at home scheme after randomisation; mortality at 3 months. Results: There were no significant differences in patient mortality, quality of life, and physical functioning between the two arms of the trial at 4 weeks or 3 months. Only one of 11 measures of patient satisfaction was significantly different: hospital at home patients perceived higher levels of involvement in decisions. Length of stay for those receiving routine hospital care was 62% (95% confidence interval 51% to 75%) of length of stay in hospital at home scheme. Conclusions: The early discharge hospital at home scheme was similar to routine hospital discharge in terms of effectiveness and acceptability. Increased length of stay associated with the scheme must be interpreted with caution because of different organisational characteristics of the services.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Frenchay Hosp, Day Hosp, Bristol BS16 1LE, Avon, England; Hosp Home, Downend Clin, Bristol BS16 5TW, Avon, England	University of Bristol	Richards, SH (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	suzanne.richards@bris.ac.uk	Gunnell, David/ABE-6653-2020	Gunnell, David/0000-0002-0829-6470; Richards, Suzanne/0000-0003-1416-0569; Peters, Tim/0000-0003-2881-4180; Coast, Joanna/0000-0002-3537-5166				Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Closset J, 1995, ACTA GASTRO-ENT BELG, V58, P373; Coast J, 1998, BRIT MED J, V316, P1802, DOI 10.1136/bmj.316.7147.1802; Coast J, 1996, BRIT MED J, V312, P162; Collin C, 1988, Int Disabil Stud, V10, P61; COSTAIN D, 1992, HOSP HOME CARE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fulop NJ, 1997, J ROY SOC MED, V90, P212, DOI 10.1177/014107689709000408; GOULD MM, 1995, BR J HLTH CARE MANAG, V1, P809; HENDEE WR, 1990, JAMA-J AM MED ASSOC, V263, P1241; Hensher M, 1996, J ROY SOC MED, V89, P548, DOI 10.1177/014107689608901003; KNOWELDEN J, 1991, J PUBLIC HEALTH MED, V13, P182, DOI 10.1093/oxfordjournals.pubmed.a042616; MAHONEY F I, 1965, Md State Med J, V14, P61; Marks L, 1990, HOME HOSP CARE REDRA; OCATHAIN A, 1994, J PUBLIC HEALTH MED, V16, P205, DOI 10.1093/oxfordjournals.pubmed.a042958; *OFF POP CENS SURV, 1994, GEN HOUS SURV RES 19; Peters TJ, 1998, J EPIDEMIOL COMMUN H, V52, P59, DOI 10.1136/jech.52.1.59; PRYOR GA, 1989, J BONE JOINT SURG BR, V71, P471, DOI 10.1302/0301-620X.71B3.2722942; SCHULTEN JHG, 1992, FUNCTIONAL STATUS AS	19	100	102	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1796	1801		10.1136/bmj.316.7147.1796	http://dx.doi.org/10.1136/bmj.316.7147.1796			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624070	Green Published			2022-12-24	WOS:000074286300029
J	Rizzuto, R; Pinton, P; Carrington, W; Fay, FS; Fogarty, KE; Lifshitz, LM; Tuft, RA; Pozzan, T				Rizzuto, R; Pinton, P; Carrington, W; Fay, FS; Fogarty, KE; Lifshitz, LM; Tuft, RA; Pozzan, T			Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses	SCIENCE			English	Article							CALCIUM LOADS; INTACT-CELLS; LIVING CELLS; HOMEOSTASIS; AEQUORIN; NEURONS	The spatial relation between mitochondria and endoplasmic reticulum (ER) in living HeLa cells was analyzed at high resolution in three dimensions with two differently colored, specifically targeted green fluorescent proteins. Numerous close contacts were observed between these organelles, and mitochondria in situ formed a largely interconnected, dynamic network. A Ca2+-sensitive photoprotein targeted to the outer face of the inner mitochondrial membrane showed that, upon opening of the inositol 1,4,5-triphosphate (IP3)-gated channels of the ER, the mitochondrial surface was exposed to a higher concentration of Ca2+ than was the bulk cytosol. These results emphasize the importance of cell architecture and the distribution of organelles in regulation of Ca2+ signaling.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Natl Res Council, Ctr Study Biomembranes, I-35121 Padua, Italy; Univ Massachusetts, Med Ctr, Biomed Imaging Grp, Worcester, MA 01605 USA	University of Padua; University of Padua; University of Massachusetts System; University of Massachusetts Worcester	Rizzuto, R (corresponding author), Univ Padua, Dept Biomed Sci, Via Colombo 3, I-35121 Padua, Italy.	rizzuto@civ.bio.unipd.it	Pinton, Paolo/J-8025-2012; Rizzuto, Rosario/B-6312-2008	Pinton, Paolo/0000-0001-7108-6508; Rizzuto, Rosario/0000-0001-7044-5097	NCRR NIH HHS [RR09799] Funding Source: Medline; NHLBI NIH HHS [HL14523] Funding Source: Medline; Telethon [845, 850] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009799] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL014523, R01HL014523] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKEEVA LE, 1978, BIOCHIM BIOPHYS ACTA, V501, P349, DOI 10.1016/0005-2728(78)90104-4; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; BROWN LJ, 1994, J BIOL CHEM, V269, P14363; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; CAMPBELL CL, 1994, MOL BIOL CELL, V5, P899, DOI 10.1091/mbc.5.8.899; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; DAVISON MT, 1977, J GEN MICROBIOL, V98, P147, DOI 10.1099/00221287-98-1-147; Drummond RM, 1996, PFLUG ARCH EUR J PHY, V431, P473, DOI 10.1007/s004240050025; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KIEDROWSKI L, 1995, MOL PHARMACOL, V47, P140; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; MacDonald MJ, 1996, ARCH BIOCHEM BIOPHYS, V326, P79, DOI 10.1006/abbi.1996.0049; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Rizzuto R, 1995, METHOD ENZYMOL, V260, P417, DOI 10.1016/0076-6879(95)60155-4; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; RIZZUTO R, IN PRESS TRENDS CELL; ROBBGASPERS LD, UNPUB; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; WERTH JL, 1994, J NEUROSCI, V14, P348; WHITE RJ, 1995, J NEUROSCI, V15, P1318	35	1727	1770	6	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	1998	280	5370					1763	1766		10.1126/science.280.5370.1763	http://dx.doi.org/10.1126/science.280.5370.1763			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624056				2022-12-24	WOS:000074197800045
J	Marzuk, PM; Tardiff, K; Leon, AC; Hirsch, CS; Portera, L; Iqbal, I; Nock, MK; Hartwell, N				Marzuk, PM; Tardiff, K; Leon, AC; Hirsch, CS; Portera, L; Iqbal, I; Nock, MK; Hartwell, N			Ambient temperature and mortality from unintentional cocaine overdose	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEUROLEPTIC MALIGNANT SYNDROME; 1980 HEAT-WAVE; RECREATIONAL COCAINE; CONSCIOUS DOG; ABUSE; HYPERTHERMIA; DEATH; INTOXICATION; RHABDOMYOLYSIS; LETHALITY	Context.-Hot weather taxes cardiovascular function and is associated with increased deaths from heart disease. Cocaine can cause hypertension, tachycardia, coronary vasospasm, arrhythmias, and increased core temperature. Objective.-To determine the association between mortality from cocaine overdose and hot weather. Setting.-New York, NY. Design.-Retrospective review of medical examiner cases from 1990 through 1995. Subjects.-All fatal unintentional cocaine overdoses from 1990 through 1992 (n=1382) and all hyperthermia deaths of cocaine users (n = 10) were used to identify a maximum daily temperature threshold above which mortality from cocaine intoxication increased. The study population consisted of all fatal unintentional cocaine overdoses from 1993 through 1995 (n = 2008) and 4 contemporaneous comparison groups that included fatal unintentional opiate overdoses (n = 793), all other fatal unintentional overdoses (n = 85), and a subset of homicides (n = 4638) and fatalities from motor vehicle crashes (n = 815). Main Outcome Measures.-The number of overdose deaths and the proportion of homicides and traffic fatalities with a positive cocaine toxicology test result on days with a maximum temperature above or below the temperature threshold. Results.-A threshold temperature of 31.1 degrees C (88 degrees F) was identified, above which the mean daily number of fatal cocaine overdoses increased steadily. On days with a maximum daily temperature of 31.1 degrees C (88 degrees F) or higher ("hot days"), the mean daily number of cocaine overdose deaths was 2.34 (SD = 1.68), which was 33% higher than the mean on days with a maximum temperature of less than 31.1 degrees C (88 degrees F) (mean=1.76 [SD=1.37] (P<.001). In contrast, the mean number of opiate overdose deaths per day was 0.81 (SD = 0.94) on hot days and 0.71 (SD = 0.86) on other days (P=.28). For other drug overdose deaths, the mean number of deaths per day was 0.08 (SD = 0.28) on hot days and 0.08 (SD = 0.28) on other days (P=.69). Among homicides, the proportion with a positive cocaine toxicology test result was 18.9% on hot days and 19.5% on other days (P=.69), and among traffic fatalities, the proportions with positive cocaine toxicology test results were 9.5% on hot days and 10.3% on other days (P=.91). Conclusions.-High ambient temperature is associated with a significant increase in mortality from cocaine overdose. Based on our comparison groups, the increase is not explained by changes in cocaine use among the general population. Although cocaine use is dangerous on all days, it appears to be even more dangerous on hot days.	Cornell Univ Med Coll, Dept Psychiat, Epidemiol Sect, New York, NY USA; Cornell Univ Med Coll, Dept Publ Hlth, New York, NY USA; Off Chief Med Examiner, New York, NY USA; NYU, Sch Med, Dept Forens Med, New York, NY USA	Cornell University; Cornell University; New York University	Marzuk, PM (corresponding author), Cornell Univ, Med Ctr, New York Hosp, Dept Psychiat, 525 E 68th St, New York, NY 10021 USA.		Nock, Matthew/AAE-8330-2019		NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006534] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 06534] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ANDERS C, 1995, MMWR-MORBID MORTAL W, V44, P465; APPLEGATE WB, 1981, J AM GERIATR SOC, V29, P337, DOI 10.1111/j.1532-5415.1981.tb01238.x; BAUWENS JE, 1989, WESTERN J MED, V150, P210; BUECHLEY RW, 1972, ENVIRON RES, V5, P85, DOI 10.1016/0013-9351(72)90022-9; CALLAWAY CW, 1994, ANN EMERG MED, V24, P68, DOI 10.1016/S0196-0644(94)70165-2; CATRAVAS JD, 1978, ARCH INT PHARMACOD T, V235, P328; CATRAVAS JD, 1981, J PHARMACOL EXP THER, V217, P350; CLARKE JF, 1972, ENVIRON RES, V5, P93, DOI 10.1016/0013-9351(72)90023-0; COX B, 1978, J PHYSIOL-LONDON, V282, P471, DOI 10.1113/jphysiol.1978.sp012476; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; DARAS M, 1995, ACTA NEUROL SCAND, V92, P161; ELLIS FP, 1972, ENVIRON RES, V5, P1, DOI 10.1016/0013-9351(72)90019-9; FISCHMAN MW, 1976, ARCH GEN PSYCHIAT, V33, P983; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; JONES TS, 1982, JAMA-J AM MED ASSOC, V247, P3327, DOI 10.1001/jama.247.24.3327; KALKSTEIN LS, 1993, LANCET, V342, P1397, DOI 10.1016/0140-6736(93)92757-K; KALKSTEIN LS, 1989, ANN ASSOC AM GEOGR, V79, P44, DOI 10.1111/j.1467-8306.1989.tb00249.x; KALKSTEIN LS, 1988, IMPACT PREDICTED CLI, V41; KOSTEN TR, 1988, AM J DRUG ALCOHOL AB, V14, P335, DOI 10.3109/00952998809001555; LOGHMANEE F, 1986, AM J FOREN MED PATH, V7, P246, DOI 10.1097/00000433-198607030-00012; MARZUK PM, 1995, NEW ENGL J MED, V332, P1753, DOI 10.1056/NEJM199506293322606; Marzuk PM, 1997, AM J DRUG ALCOHOL AB, V23, P221, DOI 10.3109/00952999709040943; *OFF APPL STUD, 1993, SMA PUBL; *OFF APPL STUD, 1996, SMA PUBL; *OFF APPL STUD, 1994, ANN EM ROOM DAT 19 1, pA12; ROBERTS JR, 1984, AM J EMERG MED, V2, P373, DOI 10.1016/0735-6757(84)90178-5; ROTH D, 1988, NEW ENGL J MED, V319, P673, DOI 10.1056/NEJM198809153191103; SEMANZA JC, 1996, NEW ENGL J MED, V335, P84; SPRANG CL, 1979, CHEST, V75, P362; WETLI CV, 1985, J FORENSIC SCI, V30, P873	31	75	77	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1795	1800		10.1001/jama.279.22.1795	http://dx.doi.org/10.1001/jama.279.22.1795			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR635	9628710	Green Published, Bronze			2022-12-24	WOS:000073998500031
J	Serpell, MG; Haldane, GJ; Jamieson, DRS; Carson, D				Serpell, MG; Haldane, GJ; Jamieson, DRS; Carson, D			Prevention of headache after lumbar puncture: questionnaire survey of neurologists and neurosurgeons in United Kingdom	BRITISH MEDICAL JOURNAL			English	Article							NEEDLE		Univ Glasgow, Western Infirm, Dept Anaesthesia, Glasgow G11 6NT, Lanark, Scotland; So Gen Hosp NHS Trust, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland; Ulster Hosp, Dept Anaesthesia, Belfast BT16 0RH, Antrim, North Ireland	University of Glasgow; University of Glasgow	Serpell, MG (corresponding author), Univ Glasgow, Western Infirm, Dept Anaesthesia, Glasgow G11 6NT, Lanark, Scotland.							CARBAAT PAT, 1981, LANCET, V2, P1133; Carson D, 1996, NEUROLOGY, V47, P33, DOI 10.1212/WNL.47.1.33; KUNTZ KM, 1992, NEUROLOGY, V42, P1884, DOI 10.1212/WNL.42.10.1884; MIHIC D N, 1986, Regional-Anaesthesie, V9, P54; TOURTELLOTTE WW, 1972, HEADACHE, V12, P73, DOI 10.1111/j.1526-4610.1972.hed1202073.x	5	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1709	1710		10.1136/bmj.316.7146.1709	http://dx.doi.org/10.1136/bmj.316.7146.1709			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614018	Green Accepted, Green Submitted, Bronze, Green Published			2022-12-24	WOS:000074129500020
J	Cooper, MK; Porter, JA; Young, KE; Beachy, PA				Cooper, MK; Porter, JA; Young, KE; Beachy, PA			Teratogen-mediated inhibition of target tissue response to Shh signaling	SCIENCE			English	Article							MOTOR-NEURON INDUCTION; A REDUCTASE-ACTIVITY; SONIC-HEDGEHOG; CHOLESTEROL-BIOSYNTHESIS; FLOOR PLATE; GENE; CELLS; PROGESTERONE; HOMEOSTASIS; AUTOPROTEOLYSIS	Veratrum alkaloids and distal inhibitors of cholesterol biosynthesis have been studied for more than 30 years as potent teratogens capable of inducing cyclopia and other birth defects. Here, it is shown that these compounds specifically block the Sonic hedgehog (Shh) signaling pathway. These teratogens did not prevent the sterol modification of Shh during autoprocessing but rather inhibited the response of target tissues to Shh, possibly acting through the sterol sensing domain within the Patched protein regulator of Shh response.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University	Beachy, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA.							ALTABA AR, 1995, DEV BIOL, V170, P299; AUFENANGER J, 1986, BIOCHEM PHARMACOL, V35, P911, DOI 10.1016/0006-2952(86)90076-6; Beachy PA, 1997, COLD SPRING HARB SYM, V62, P191; BELL JJ, 1976, J BIOL CHEM, V251, P1745; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; BINNS W, 1963, AM J VET RES, V24, P1164; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CAPDEVILA J, 1994, DEVELOPMENT, V120, P987; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COHEN MM, 1992, J CRAN GENET DEV BIO, V12, P196; COOPER MD, UNPUB; Dehart DB, 1997, AM J MED GENET, V68, P328, DOI 10.1002/(SICI)1096-8628(19970131)68:3<328::AID-AJMG15>3.0.CO;2-V; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; Gaffield W, 1996, J NAT TOXINS, V5, P25; GIBSON KM, 1990, J LIPID RES, V31, P515; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KEELER RF, 1968, TERATOLOGY, V1, P5, DOI 10.1002/tera.1420010103; Kelley RI, 1996, AM J MED GENET, V66, P478, DOI 10.1002/(SICI)1096-8628(19961230)66:4<478::AID-AJMG22>3.0.CO;2-Q; KRAML M, 1964, BIOCHEM BIOPH RES CO, V15, P455, DOI 10.1016/0006-291X(64)90485-1; Lange Y, 1996, J LIPID RES, V37, P534; Lange Y, 1996, TRENDS CELL BIOL, V6, P205, DOI 10.1016/0962-8924(96)20016-9; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MARTI E, 1995, DEVELOPMENT, V121, P2537; Metherall JE, 1996, J BIOL CHEM, V271, P2627, DOI 10.1074/jbc.271.5.2627; MILLER SC, 1984, J LIPID RES, V25, P991; POPJAK G, 1989, J BIOL CHEM, V264, P6230; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; ROUX C, 1966, CR SOC BIOL, V160, P1353; ROUX CHARLES, 1964, ARCH FRANC PEDIAT, V21, P451; Rubenstein JLR, 1998, CURR OPIN NEUROBIOL, V8, P18, DOI 10.1016/S0959-4388(98)80004-4; STEFANSSON S, 1995, J BIOL CHEM, V270, P19417, DOI 10.1074/jbc.270.33.19417; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; Wang B., UNPUB; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YOSHIKAWA H, 1991, BRAIN DEV-JPN, V13, P115, DOI 10.1016/S0387-7604(12)80118-5	47	729	771	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1603	1607		10.1126/science.280.5369.1603	http://dx.doi.org/10.1126/science.280.5369.1603			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616123				2022-12-24	WOS:000074061200041
J	Rosenmund, C; Stern-Bach, Y; Stevens, CF				Rosenmund, C; Stern-Bach, Y; Stevens, CF			The tetrameric structure of a glutamate receptor channel	SCIENCE			English	Article							HIPPOCAMPAL-NEURONS; ACID RECEPTORS; BINDING-SITES; RAT-BRAIN; DESENSITIZATION; CONDUCTANCE; LOCALIZATION; ACTIVATION; KINETICS; GLYCINE	The subunit stoichiometry of several ligand-gated ion channel receptors is still unknown. A counting method was developed to determine the number of subunits in one family of brain glutamate receptors, Successful application of this method in an HEK cell line provides evidence that ionotropic glutamate receptors share a tetrameric structure with the voltage-gated potassium channels. The average conductance of these channels depends on how many subunits are occupied by an agonist.	Salk Inst, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Max Planck Inst Biophys Chem, Workgrp Cellular Neurobiol, Gottingen, Germany; Hebrew Univ Jerusalem, Haddassah Dent Sch, Dept Anat & Embryol, Jerusalem, Israel	Howard Hughes Medical Institute; Salk Institute; Max Planck Society; Hebrew University of Jerusalem	Stevens, CF (corresponding author), Salk Inst, Howard Hughes Med Inst, La Jolla, CA 92093 USA.		Rosenmund, Christian/AAC-3596-2020	Rosenmund, Christian/0000-0002-3905-2444	NINDS NIH HHS [NS 12961] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS012961] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENVENISTE M, 1991, BIOPHYS J, V59, P560, DOI 10.1016/S0006-3495(91)82272-X; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BROSE N, 1993, J BIOL CHEM, V268, P22663; CHAPMAN L, 1997, BIOPHYS J, V72, P708; Clements JD, 1998, J NEUROSCI, V18, P119; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; DUDEL J, 1990, BIOPHYS J, V57, P533, DOI 10.1016/S0006-3495(90)82569-8; FerrerMontiel AV, 1996, P NATL ACAD SCI USA, V93, P2741, DOI 10.1073/pnas.93.7.2741; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KISKIN NI, 1986, NEUROSCI LETT, V63, P225, DOI 10.1016/0304-3940(86)90360-5; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; Mano I, 1998, NEUROREPORT, V9, P327, DOI 10.1097/00001756-199801260-00027; Mano I., 1996, Society for Neuroscience Abstracts, V22, P726; PARTIN KM, 1994, MOL PHARMACOL, V46, P129; PREMKUMAR LS, 1997, J GEN PHYSIOL, V110, P48; RAFTERY MA, 1980, SCIENCE, V208, P1454, DOI 10.1126/science.7384786; ROSENMUND C, 1995, J NEUROSCI, V15, P2788; Rosenmund C., 1996, Biophysical Journal, V70, pA251; RUIZ L, 1997, NATURE, V389, P389; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Sutcliffe MJ, 1996, BIOPHYS J, V70, P1575, DOI 10.1016/S0006-3495(96)79724-2; SWANSON T, 1997, J NEUROSCI, V17, P58; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TAYLOR WR, 1995, J PHYSIOL-LONDON, V483, P567, DOI 10.1113/jphysiol.1995.sp020607; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882; WU TY, 1994, BIOCHEM J, V300, P365, DOI 10.1042/bj3000365; YAMADA KA, 1993, J NEUROSCI, V13, P3904	35	608	626	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1596	1599		10.1126/science.280.5369.1596	http://dx.doi.org/10.1126/science.280.5369.1596			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616121	Green Published			2022-12-24	WOS:000074061200039
J	Ridge, JP; Di Rosa, F; Matzinger, P				Ridge, JP; Di Rosa, F; Matzinger, P			A conditioned dendritic cell can be a temporal bridge between a CD4(+) T-helper and a T-killer cell	NATURE			English	Article							ANTIGEN-PRESENTING CELLS; INVIVO; TOLERANCE; INDUCTION; RESPONSES; ABSENCE; REQUIREMENTS; GENERATION; ACTIVATION; MECHANISM	To generate an immune response, antigen-specific T-helper and T-killer cells must find each other and, because they cannot detect each other's presence, they are brought together by an antigen-loaded dendritic cell that displays antigens to both(1-3). This three-cell interaction, however, seems nearly impossible because all three cell types are rare and migratory. Here we provide a potential solution to this conundrum, We found that the three cells need not meet simultaneously but that the helper cell can first engage and 'condition' the dendritic cell, which then becomes empowered to stimulate a killer cell. The first step (help) can be bypassed by modulation of the surface molecule CD40, or by viral infection of dendritic cells. These results may explain the longstanding paradoxical observation that responses to some viruses are helper-independent, and they evoke the possibility that dendritic cells may take on different functions in response to different conditioning signals.	NIAID, Ghost Lab, Sect T Cell Tolerance & Memory, Lab Cellular & Mol Immunol,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Ridge, JP (corresponding author), NIAID, Ghost Lab, Sect T Cell Tolerance & Memory, Lab Cellular & Mol Immunol,NIH, Bldg 4 Room 111,9000 Rockville Pike, Bethesda, MD 20892 USA.	jridge@atlas.niaid.nih.gov	Di Rosa, Francesca/J-8116-2014; Di Rosa, Francesca/AAW-8612-2020	Di Rosa, Francesca/0000-0003-0252-9138				AHMED R, 1988, J VIROL, V62, P2102, DOI 10.1128/JVI.62.6.2102-2106.1988; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Bennett SRM, 1997, J EXP MED, V186, P65, DOI 10.1084/jem.186.1.65; BOOG CJP, 1985, NATURE, V318, P59, DOI 10.1038/318059a0; BULLER RML, 1987, NATURE, V328, P77, DOI 10.1038/328077a0; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GUERDER S, 1992, J EXP MED, V176, P553, DOI 10.1084/jem.176.2.553; GUERDER S, 1989, COLD SPRING HARB SYM, V54, P799; HOU S, 1995, J VIROL, V69, P1429, DOI 10.1128/JVI.69.3.1429-1434.1995; JANEWAY CA, 1989, COLD SH Q B, V54, P1; KATONA IM, 1991, J IMMUNOL, V146, P4215; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; Liu LM, 1997, ADV EXP MED BIOL, V417, P375; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; MITCHISON NA, 1987, EUR J IMMUNOL, V17, P1579, DOI 10.1002/eji.1830171109; NONACS R, 1992, J EXP MED, V176, P519, DOI 10.1084/jem.176.2.519; PALIARD X, 1988, J IMMUNOL, V141, P849; REES MA, 1990, P NATL ACAD SCI USA, V87, P2765, DOI 10.1073/pnas.87.7.2765; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; SAELAND S, 1993, J EXP MED, V178, P113, DOI 10.1084/jem.178.1.113; SIMPSON E, 1977, IMMUNOL REV, V35, P59, DOI 10.1111/j.1600-065X.1977.tb00235.x; STAVNEZER J, 1995, J IMMUNOL, V155, P1647; TRIPP RA, 1995, J IMMUNOL, V155, P2955; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P1031, DOI 10.1002/eji.1830220423; WU Y, 1994, CURR BIOL, V4, P499, DOI 10.1016/S0960-9822(00)00110-X; Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862; YONG JL, 1995, IMMUNITY, V2, P239	30	1947	2102	1	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					474	478		10.1038/30989	http://dx.doi.org/10.1038/30989			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624003				2022-12-24	WOS:000074020000046
J	Schreiber-Agus, N; Meng, Y; Hoang, T; Hou, H; Chen, K; Greenberg, R; Cordon-Cardo, C; Lee, HW; DePinho, RA				Schreiber-Agus, N; Meng, Y; Hoang, T; Hou, H; Chen, K; Greenberg, R; Cordon-Cardo, C; Lee, HW; DePinho, RA			Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth	NATURE			English	Article							TRANSGENIC MICE; PROSTATE-CANCER; C-MYC; REPRESSOR SIN3; MAX; MODELS; MOUSE; GENE; DIFFERENTIATION; TRANSFORMATION	Mxi1 belongs to the Mad (Mxi1) family of proteins, which function as potent antagonists of Myc oncoproteins(1-4). This antagonism relates partly to their ability to compete with Myc for the protein Max and for consensus DNA binding sites and to recruit transcriptional co-repressors(4-6). Mad(Mxi1) proteins have been suggested to be essential in cellular growth control and/or in the induction and maintenance of the differentiated state(6-7) Consistent with these roles, mxi1 may be the tumour-suppressor gene that resides at region 24-26 of the long arm of chromosome 10. This region is a cancer hotspot, and mutations here may be involved in several cancers, including prostate adenocarcinoma(8-10). Here we show that mice lacking Mxi1 exhibit progressive, multisystem abnormalities. These mice also show increased susceptibility to tumorigenesis either following carcinogen treatment or when also deficient in Ink4a. This cancer-prone phenotype may correlate with the enhanced ability of several mxi1-deficient cell types, including prostatic epithelium, to proliferate. Our results show that Mxi1 is involved in the homeostasis of differentiated organ systems, acts as a tumour suppressor in vivo and engages the Myc network in functionally relevant manner.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center	DePinho, RA (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	depinho@aecom.yu.edu		DePinho, Ronald/0000-0002-5625-577X				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; COWLEY BD, 1991, J AM SOC NEPHROL, V1, P1048; Dedeoglu IO, 1996, PEDIATR PATHOL LAB M, V16, P941, DOI 10.1080/15513819609168717; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; EDELHOFF S, 1994, ONCOGENE, V9, P665; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Gerlach C, 1997, LAB INVEST, V77, P697; GRAY IC, 1995, CANCER RES, V55, P4800; HARRIS AW, 1988, CURR TOP MICROBIOL, V141, P82; HECKER E, 1992, J CANCER RES CLIN, V118, P321, DOI 10.1007/BF01208624; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Jenkins RB, 1997, CANCER RES, V57, P524; Kawamata N, 1996, PROSTATE, V29, P191, DOI 10.1002/1097-0045(199609)29:3<191::AID-PROS2990290305>3.0.CO;2-1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; PROCHOWNIK EV, IN PRESS GENES CHROM; RAIMONDI SC, 1988, BLOOD, V72, P1560; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHREIBERAGUS N, IN PRESS BIOESSAYS; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAPIRO DN, 1994, GENOMICS, V23, P282, DOI 10.1006/geno.1994.1496; THOMPSON TC, 1993, CANCER, V71, P1165, DOI 10.1002/1097-0142(19930201)71:3+<1165::AID-CNCR2820711440>3.0.CO;2-U; TRUDEL M, 1991, KIDNEY INT, V39, P665, DOI 10.1038/ki.1991.80; WECHSLER DS, 1994, GENOMICS, V21, P669, DOI 10.1006/geno.1994.1336; YUKAWA K, 1989, J EXP MED, V170, P711, DOI 10.1084/jem.170.3.711; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	30	164	170	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 4	1998	393	6684					483	487		10.1038/31008	http://dx.doi.org/10.1038/31008			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624006				2022-12-24	WOS:000074020000049
J	Weeks, JC; Cook, EF; O'Day, SJ; Petersen, LM; Wenger, N; Reding, D; Harrell, FE; Kussin, P; Dawson, NV; Connors, AF; Lynn, J; Phillips, RS				Weeks, JC; Cook, EF; O'Day, SJ; Petersen, LM; Wenger, N; Reding, D; Harrell, FE; Kussin, P; Dawson, NV; Connors, AF; Lynn, J; Phillips, RS			Relationship between cancer patients' predictions of prognosis and their treatment preferences	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVANCE DIRECTIVES; CARDIOPULMONARY-RESUSCITATION; BREAST-CANCER; SURVIVAL; LIFE; CARE; DECISIONS; DOCTORS; TRUTH	Context.-Previous studies have documented that cancer patients tend to overestimate the probability of long-term survival. If patient preferences about the trade-offs between the risks and benefits associated with alternative treatment strategies are based on inaccurate perceptions of prognosis, then treatment choices may not reflect each patient's true values. Objective.-To test the hypothesis that among terminally ill cancer patients an accurate understanding of prognosis is associated with a preference for therapy that focuses on comfort over attempts at life extension. Design.-Prospective cohort study. Setting.-Five teaching hospitals in the United States. Patients.-A total of 917 adults hospitalized with stage III or IV non-small cell lung cancer or colon cancer metastatic to liver in phases 1 and 2 of the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT), Main Outcome Measures.-Proportion of patients favoring life-extending therapy over therapy focusing on relief of pain and discomfort, patient and physician estimates of the probability of 6-month survival, and actual 6-month survival, Results.-Patients who thought they were going to live for at least 6 months were more likely (odds ratio [OR], 2.6; 95% confidence interval [CI], 1.8-3.7) to favor life-extending therapy over comfort care compared with patients who thought there was at least a 10% chance that they would not live 6 months. This OR was highest (8.5; 95% CI, 3.0-24.0) among patients who estimated their 6-month survival probability at greater than 90% but whose physicians estimated it at 10% or less. Patients overestimated their chances of surviving 6 months, while physicians estimated prognosis quite accurately. Patients who preferred life-extending therapy were more likely to undergo aggressive treatment, but controlling for known prognostic factors, their 6-month survival was no better. Conclusions.-Patients with metastatic colon and lung cancer overestimate their survival probabilities and these estimates may influence their preferences about medical therapies.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Med, Clin Epidemiol Sect, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Univ Calif Los Angeles, Med Ctr, Dept Med, Los Angeles, CA 90024 USA; Marshfield Clin Fdn Med Res & Educ, Marshfield, WI 54449 USA; Univ Virginia, Sch Med, Dept Hlth Evaluat Sci, Div Biostat & Epidemiol, Charlottesville, VA 22908 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Case Western Reserve Univ, Dept Med, Metrohlth Med Ctr, Cleveland, OH 44106 USA; George Washington Univ, Ctr Improve Care Dying, Washington, DC USA; Beth Israel Hosp, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Marshfield Clinic; University of Virginia; Duke University; Case Western Reserve University; MetroHealth System; George Washington University; Harvard University; Beth Israel Deaconess Medical Center	Weeks, JC (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	jane_weeks@dci.harvard.edu		Connors, Alfred F./0000-0001-7123-3360				Bernheim JL, 1987, MONOGR SER EUR ORGAN, V17, P285; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; Dawson N. V., 1995, JGIM, V10, P41; EIDINGER RN, 1984, CANCER, V53, P2736, DOI 10.1002/1097-0142(19840615)53:12<2736::AID-CNCR2820531233>3.0.CO;2-W; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FORROW L, 1988, JAMA-J AM MED ASSOC, V259, P3161, DOI 10.1001/jama.259.21.3161; GOODMAN LA, 1972, J AM STAT ASSOC, V67, P415, DOI 10.2307/2284396; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HOLCOMBE RF, 1994, NEW ENGL J MED, V331, P811; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KATZ S, 1976, INT J HEALTH SERV, V6, P493, DOI 10.2190/UURL-2RYU-WRYD-EY3K; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; MCQUELLON RP, 1995, J CLIN ONCOL, V13, P858, DOI 10.1200/JCO.1995.13.4.858; Mezey M, 1996, J AM GERIATR SOC, V44, P144, DOI 10.1111/j.1532-5415.1996.tb02430.x; MIYAJI NT, 1993, SOC SCI MED, V36, P249, DOI 10.1016/0277-9536(93)90008-R; MIYAJI NT, 1994, NEW ENGL J MED, V331, P810; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; MURPHY DJ, 1990, J CLIN EPIDEMIOL S, V43, pS1; Phillips RS, 1996, J GEN INTERN MED, V11, P387, DOI 10.1007/BF02600183; PRONZATO P, 1994, SUPPORT CARE CANCER, V2, P242, DOI 10.1007/BF00365729; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; SIMINOFF LA, 1989, J CLIN ONCOL, V7, P1192, DOI 10.1200/JCO.1989.7.9.1192; SINGER PA, 1995, SOC SCI MED, V41, P1517, DOI 10.1016/0277-9536(95)00057-E; SINGER PA, 1991, J CLIN ONCOL, V9, P328, DOI 10.1200/JCO.1991.9.2.328; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; STEELE GD, 1994, CANCER, V74, P1979, DOI 10.1002/1097-0142(19941001)74:7<1979::AID-CNCR2820740725>3.0.CO;2-J; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; YELLEN SB, 1996, 4 INT SOC BEH MED MA	31	891	893	1	34	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1709	1714		10.1001/jama.279.21.1709	http://dx.doi.org/10.1001/jama.279.21.1709			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624023	Bronze			2022-12-24	WOS:000073878700031
J	Cibelli, JB; Stice, SL; Golueke, PJ; Kane, JJ; Jerry, J; Blackwell, C; de Leon, FAP; Robl, JM				Cibelli, JB; Stice, SL; Golueke, PJ; Kane, JJ; Jerry, J; Blackwell, C; de Leon, FAP; Robl, JM			Cloned transgenic calves produced from nonquiescent fetal fibroblasts	SCIENCE			English	Article							TRANSPLANT RABBIT EMBRYOS; CELL-CYCLE STAGE; NUCLEAR TRANSFER; LIVESTOCK	An efficient system for genetic modification and large-scale cloning of cattle is of importance for agriculture, biotechnology, and human medicine. Here, actively dividing fetal fibroblasts were genetically modified with a marker gene, a clonal line was selected, and the cells were fused to enucleated mature oocytes. Out of 28 embryos transferred to 11 recipient cows, three healthy, identical, transgenic calves were generated. Furthermore, the life-span of near senescent fibroblasts could be extended by nuclear transfer, as indicated by population doublings in fibroblast lines derived from a 40-day-old fetal clone. With the ability to extend the life-span of these primary cultured cells, this system would be useful for inducing complex genetic modifications in cattle.	Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; Adv Cell Technol Inc, Worcester, MA 01605 USA; Coll Agr Food & Environm Sci, St Paul, MN 55108 USA	University of Massachusetts System; University of Massachusetts Amherst	Robl, JM (corresponding author), Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA.			Cibelli, Jose/0000-0002-2176-3854; Ponce de Leon, Federico/0000-0001-8645-553X				BONDIOLI KR, 1993, MOL REPROD DEV, V36, P274, DOI 10.1002/mrd.1080360229; CLEMENTSENGEWALD A, 1992, BERL MUNCH TIERARZTL, V105, P15; COLLAS P, 1992, BIOL REPROD, V46, P501, DOI 10.1095/biolreprod46.3.501; COLLAS P, 1992, BIOL REPROD, V46, P492, DOI 10.1095/biolreprod46.3.492; FIEDRICH G, 1991, GENE DEV, V5, P1513; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; PURSEL VG, 1993, J ANIM SCI, V71, P10, DOI 10.2527/1993.71suppl_310x; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; SAITO S, 1992, ROUX ARCH DEV BIOL, V201, P134, DOI 10.1007/BF00188711; Stice SL, 1996, BIOL REPROD, V54, P100, DOI 10.1095/biolreprod54.1.100; SUSKOPARRISH JL, 1994, DEV BIOL, V166, P729, DOI 10.1006/dbio.1994.1351; Walker SK, 1996, THERIOGENOLOGY, V45, P111, DOI 10.1016/0093-691X(95)00360-K; WALL RJ, 1992, J CELL BIOCHEM, V49, P113, DOI 10.1002/jcb.240490203; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	15	996	1261	0	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 22	1998	280	5367					1256	1258		10.1126/science.280.5367.1256	http://dx.doi.org/10.1126/science.280.5367.1256			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596577				2022-12-24	WOS:000073852500046
J	Shajahan, PM; Cavanagh, JTO				Shajahan, PM; Cavanagh, JTO			Admission for depression among men in Scotland, 1980-95: retrospective study	BRITISH MEDICAL JOURNAL			English	Article									Royal Edinburgh Hosp, MRC, Brain Metab Unit, Edinburgh EH10 5HF, Midlothian, Scotland; Univ Edinburgh, Royal Edinburgh Hosp, Dept Psychiat, Edinburgh EH10 5HF, Midlothian, Scotland	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Shajahan, PM (corresponding author), Royal Edinburgh Hosp, MRC, Brain Metab Unit, Edinburgh EH10 5HF, Midlothian, Scotland.							BECK P, 1994, BRIT MED J, V308, P789, DOI 10.1136/bmj.308.6931.789; GEDDES JR, 1993, BRIT J PSYCHIAT, V163, P620, DOI 10.1192/bjp.163.5.620; POUNDER DJ, 1991, FORENSIC SCI INT, V51, P79, DOI 10.1016/0379-0738(91)90207-Y; WEISSMAN MM, 1993, J AFFECT DISORDERS, V29, P77, DOI 10.1016/0165-0327(93)90025-F	4	9	9	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1998	316	7143					1496	1497		10.1136/bmj.316.7143.1496	http://dx.doi.org/10.1136/bmj.316.7143.1496			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZP020	9582135	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000073707700024
J	Ebinu, JO; Bottorff, DA; Chan, EYW; Stang, SL; Dunn, RJ; Stone, JC				Ebinu, JO; Bottorff, DA; Chan, EYW; Stang, SL; Dunn, RJ; Stone, JC			RasGRP, a Ras guanyl nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs	SCIENCE			English	Article							EXCHANGE FACTOR; KINASE-C; ACTIVATION; RECEPTORS; NEURONS; CLONING; PATHWAY; GRF	RasGRP, a guanyl nucleotide-releasing protein for the small guanosine triphosphatase Ras, was characterized. Besides the catalytic domain, RasGRP has an atypical pair of "EF hands" that bind calcium and a diacylglycerol (DAG)-binding domain. RasGRP activated Ras and caused transformation in fibroblasts. A DAG analog caused sustained activation of Ras-Erk signaling and changes in cell morphology. Signaling was associated with partitioning of RasGRP protein into the membrane fraction. Sustained ligand-induced signaling and membrane partitioning were absent when the DAG-binding domain was deleted. RasGRP is expressed in the nervous system, where it may couple changes in DAG and possibly calcium concentrations to Ras activation.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Montreal Gen Hosp, Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada	University of Alberta; McGill University	Stone, JC (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.		Chan, Edmond Y.W./A-1940-2013	Chan, Edmond Y.W./0000-0001-9777-0252				AITKEN A, 1984, EUR J BIOCHEM, V139, P663, DOI 10.1111/j.1432-1033.1984.tb08055.x; AMBAR I, 1993, EUR J PHARM-MOLEC PH, V245, P31, DOI 10.1016/0922-4106(93)90166-7; ARIS JP, 1993, BIOCHIM BIOPHYS ACTA, V1174, P171, DOI 10.1016/0167-4781(93)90111-P; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BORASIO GD, 1989, NEURON, V2, P1087; BOTTORFF D, 1995, MOL CELL BIOL, V15, P5113; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; Chan E., UNPUB; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; EBINU JO, UNPUB; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; Leonardsen L, 1996, ONCOGENE, V13, P2177; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; Stang S, 1997, MOL CELL BIOL, V17, P3047, DOI 10.1128/MCB.17.6.3047; STONE JC, 1993, MOL CELL BIOL, V13, P7311, DOI 10.1128/MCB.13.12.7311; STONE JC, 1991, MOL CELL BIOL, V11, P6158, DOI 10.1128/MCB.11.12.6158; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TANAKA Y, 1986, J BIOCHEM-TOKYO, V99, P257, DOI 10.1093/oxfordjournals.jbchem.a135467; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704	31	532	547	3	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1082	1086		10.1126/science.280.5366.1082	http://dx.doi.org/10.1126/science.280.5366.1082			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9582122				2022-12-24	WOS:000073663600048
J	Howe, JR; Roth, S; Ringold, JC; Summers, RW; Jarvinen, HJ; Sistonen, P; Tomlinson, IPM; Houlston, RS; Bevan, S; Mitros, FA; Stone, EM; Aaltonen, LA				Howe, JR; Roth, S; Ringold, JC; Summers, RW; Jarvinen, HJ; Sistonen, P; Tomlinson, IPM; Houlston, RS; Bevan, S; Mitros, FA; Stone, EM; Aaltonen, LA			Mutations in the SMAD4/DPC4 gene in juvenile polyposis	SCIENCE			English	Article							TUMOR-SUPPRESSOR GENE; COLORECTAL CANCERS; DPC4 GENE; CARCINOMA	Familial juvenile polyposis is an autosomal dominant disease characterized by a predisposition to hamartomatous polyps and gastrointestinal cancer. Here it is shown that a subset of juvenile polyposis families carry germ line mutations in the gene SMAD4 (also known as DPC4), located on chromosome 18q21.1, that encodes a critical cytoplasmic mediator in the transforming growth factor-beta signaling pathway. The mutant SMAD4 proteins are predicted to be truncated at the carboxyl-terminus and lack sequences required for normal function. These results confirm an important role for SMAD4 in the development of gastrointestinal tumors.	Univ Iowa, Coll Med, Dept Surg, Iowa City, IA 52242 USA; Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Iowa, Coll Med, Dept Med, Iowa City, IA 52242 USA; Univ Helsinki, Cent Hosp, Dept Surg 2, FIN-00290 Helsinki, Finland; Finnish Red Cross & Blood Transfus Serv, Helsinki 00130, Finland; Imperial Canc Res Fund, Mol Populat Genet Lab, London WC2A 3PX, England; Inst Canc Res, Sect Can Genet, Surrey SM2 5NG, England; Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Ophthalmol, Iowa City, IA 52242 USA	University of Iowa; University of Helsinki; University of Iowa; University of Helsinki; Helsinki University Central Hospital; Cancer Research UK; University of London; Institute of Cancer Research - UK; University of Iowa; University of Iowa	Howe, JR (corresponding author), Univ Iowa, Coll Med, Dept Surg, Iowa City, IA 52242 USA.		Aaltonen, Lauri/A-5375-2010	Aaltonen, Lauri/0000-0001-6839-4286; Bevan, Steve/0000-0003-0490-6830; Stone, Edwin M./0000-0003-3343-4414; Howe, James/0000-0001-5312-5972; Houlston, Richard/0000-0002-5268-0242				AALTONEN LA, UNPUB; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Eng C, 1998, AM J HUM GENET, V62, P1020, DOI 10.1086/301847; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Grau AM, 1997, CANCER RES, V57, P3929; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; HOWE JM, UNPUB; Howe JR, 1998, AM J HUM GENET, V62, P1129, DOI 10.1086/301840; Howe JR, 1997, HISTOL HISTOPATHOL, V12, P595; JARVINEN H, 1984, GUT, V25, P792, DOI 10.1136/gut.25.7.792; Jass J.R., 1994, FAMILIAL ADENOMATOUS, P203; Kim SK, 1996, CANCER RES, V56, P2519; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Li DM, 1997, CANCER RES, V57, P2124; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Marsh DJ, 1997, CANCER RES, V57, P5017; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Moskaluk CA, 1997, DIAGN MOL PATHOL, V6, P85, DOI 10.1097/00019606-199704000-00003; Olschwang S, 1998, NAT GENET, V18, P12, DOI 10.1038/ng0198-12; REGGINS GJ, 1997, J NEG OBS GEN ONCOL, V1, P1; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; STEMPER TJ, 1975, ANN INTERN MED, V83, P639, DOI 10.7326/0003-4819-83-5-639; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Wrana J, 1997, NATURE, V388, P28, DOI 10.1038/40290; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1	30	672	697	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1086	1088		10.1126/science.280.5366.1086	http://dx.doi.org/10.1126/science.280.5366.1086			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9582123				2022-12-24	WOS:000073663600049
J	Klein, JL; Millman, GC				Klein, JL; Millman, GC			Prospective, hospital based study of fever in children in the United Kingdom who had recently spent time in the tropics	BRITISH MEDICAL JOURNAL			English	Article									Northwick Pk & St Marks NHS Trust, Childrens Serv Directorate, Harrow HA1 3UJ, Middx, England	Imperial College London	Klein, JL (corresponding author), 177 Purves Rd,Kensal Rise, London NW10 5TH, England.							Brabin BJ, 1997, ARCH DIS CHILD, V77, P76, DOI 10.1136/adc.77.1.76; DOHERTY JF, 1995, QJM-INT J MED, V88, P277; SHINGADIA D, 1996, CURR PAEDIAT, V6, P108	3	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1998	316	7142					1425	1426		10.1136/bmj.316.7142.1425	http://dx.doi.org/10.1136/bmj.316.7142.1425			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN495	9572752	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000073651600028
J	Bray, D; Levin, MD; Morton-Firth, CJ				Bray, D; Levin, MD; Morton-Firth, CJ			Receptor clustering as a cellular mechanism to control sensitivity	NATURE			English	Article							BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; COVALENT MODIFICATION; FLAGELLAR MOTOR; PHOSPHORYLATION; CHEMORECEPTOR; COMPLEX; PROTEIN; CHEY	Chemotactic bacteria such as Escherichia coli can detect and respond to extremely low concentrations of attractants, concentrations of less than 5 nM in the case of aspartate(1), They also sense gradients of attractants extending over five orders of magnitude in concentration (up to 1 mM aspartate)(2,3). Here we consider the possibility that this combination of sensitivity and range of response depends on the clustering of chemotactic receptors on the surface of the bacterium(4). We examine what will happen if ligand binding changes the activity of a receptor, propagating this change in activity to neighbouring receptors in a cluster(5,6). Calculations based on these assumptions show that sensitivity to extracellular ligands increases with the extent of spread of activity through an array of receptors, but that the range of concentrations over which the array works is severely diminished. However, a combination of low threshold of response and wide dynamic range can be attained if the cell has both clusters and single receptors on its surface, particularly if the extent of activity spread can adapt to external conditions. A mechanism of this kind can account quantitatively for the sensitivity and response range of E. coli to aspartate.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	University of Cambridge	Bray, D (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	d.bray@zoo.cam.ac.uk						AKSAMIT RR, 1975, J BACTERIOL, V123, P1000, DOI 10.1128/JB.123.3.1000-1005.1975; BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; BERG HC, 1975, P NATL ACAD SCI USA, V72, P3235, DOI 10.1073/pnas.72.8.3235; BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; EISENBACH M, 1990, MOL MICROBIOL, V4, P161, DOI 10.1111/j.1365-2958.1990.tb00584.x; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; HAZELBAUER GL, 1981, J BACTERIOL, V145, P43, DOI 10.1128/JB.145.1.43-49.1981; KHAN S, 1993, BIOPHYS J, V65, P2368, DOI 10.1016/S0006-3495(93)81317-1; KUO SC, 1989, J BACTERIOL, V171, P6279, DOI 10.1128/jb.171.11.6279-6287.1989; Levin MD, 1998, BIOPHYS J, V74, P175, DOI 10.1016/S0006-3495(98)77777-X; Li JY, 1997, BIOCHEMISTRY-US, V36, P11851, DOI 10.1021/bi971510h; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MADDOCK JR, 1993, SCIENCE, V259, P1717; MESIBOV R, 1973, J GEN PHYSIOL, V62, P203, DOI 10.1085/jgp.62.2.203; NINFA EG, 1991, J BIOL CHEM, V266, P9764; PARKINSON JS, 1993, SCIENCE, V259, P1701, DOI 10.1126/science.8456297; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SEGALL JE, 1986, P NATL ACAD SCI USA, V83, P8987, DOI 10.1073/pnas.83.23.8987; STEWART RC, 1993, J BIOL CHEM, V268, P1921; STOCK A, 1985, P NATL ACAD SCI USA, V82, P7989, DOI 10.1073/pnas.82.23.7989; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; Wu JG, 1996, BIOCHEMISTRY-US, V35, P4984, DOI 10.1021/bi9530189; YONEKAWA H, 1986, FEBS LETT, V198, P21, DOI 10.1016/0014-5793(86)81176-0	27	506	512	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1998	393	6680					85	88		10.1038/30018	http://dx.doi.org/10.1038/30018			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590695				2022-12-24	WOS:000073497500053
J	Croft, PR; Macfarlane, GJ; Papageorgiou, AC; Thomas, E; Silman, AJ				Croft, PR; Macfarlane, GJ; Papageorgiou, AC; Thomas, E; Silman, AJ			Outcome of low back pain in general practice: a prospective study	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To investigate the claim that 90% of episodes of low back pain that present to general practice have resolved within one month. Design: Prospective study of all adults consulting in general practice because of low back pain over 12 months with follow up at 1 week, 3 months, and 12 months after consultation. Setting: Two general practices in south Manchester. Subjects: 490 subjects (203 men, 287 women) aged 18-75 years. Main outcome measures: Proportion of patients who have ceased to consult with low back pain after 3 months; proportion of patients who are free of pain and back related disability at 3 and 12 months. Results: Annual cumulative consultation late among adults in the practices was 6.4%. Of the 463 patients who consulted with a new episode of low back pain, 275 (59%) had only a single consultation, and 150 (32%) had repeat consultations confined to the 3 months after initial consultation. However, of those interviewed at 3 and 12 months follow up, only 39/188 (21%) and 42/170 (25%) respectively had completely recovered in terms of pain and disability. Conclusions: The results are consistent with the interpretation that 90% of patients with low back pain in primary care will have stopped consulting with symptoms within three months. However most will still be experiencing low back pain and related disability one year after consultation.	Univ Manchester, Sch Epidemiol & Hlth Sci, ARC Epidemiol Res Unit, Manchester M13 9PT, Lancs, England; Keele Univ, Postgrad Med Sch, Ind & Community Hlth Res Ctr, Stoke On Trent ST4 7QB, Staffs, England	University of Manchester; Keele University	Macfarlane, GJ (corresponding author), Univ Manchester, Sch Epidemiol & Hlth Sci, ARC Epidemiol Res Unit, Stopford Bldg, Manchester M13 9PT, Lancs, England.		Macfarlane, Gary J/I-9521-2014	Macfarlane, Gary J/0000-0003-2322-3314				Clinical Standards Advisory Group, 1994, EP REV EP COST BACK; COSTE J, 1994, BRIT MED J, V308, P577, DOI 10.1136/bmj.308.6928.577; DEYO RA, 1993, SPINE, V18, P2153, DOI 10.1097/00007632-199311000-00002; DIXON ASJ, 1973, RHEUM REHABILITATION, V12, P165; Kohlmann T, 1996, Rehabilitation (Stuttg), V35, pI; MASON V, 1994, PREVALENCE BACK PAIN; MCCORMICK A, 1995, MORBIDITY STAT G MB5; *OFF POP CENS SURV, 1994, OPCS MON MB5 94 1 MO; PAPAGEORGIOU AC, 1995, SPINE, V20, P1889, DOI 10.1097/00007632-199509000-00009; Papageorgiou AC, 1996, PAIN, V66, P181, DOI 10.1016/0304-3959(96)03022-9; ROLAND MO, 1983, BRIT MED J, V286, P523, DOI 10.1136/bmj.286.6364.523; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002; WALSH K, 1992, J EPIDEMIOL COMMUN H, V46, P227, DOI 10.1136/jech.46.3.227	13	458	461	3	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1998	316	7141					1356	1359		10.1136/bmj.316.7141.1356	http://dx.doi.org/10.1136/bmj.316.7141.1356			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL882	9563990	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000073483000021
J	Lie, RT; Rasmussen, S; Brunborg, H; Gjessing, HK; Lie-Nielsen, E; Irgens, LM				Lie, RT; Rasmussen, S; Brunborg, H; Gjessing, HK; Lie-Nielsen, E; Irgens, LM			Fetal and maternal contributions to risk of pre-eclampsia: population based study	BRITISH MEDICAL JOURNAL			English	Article							PREECLAMPSIA; PREGNANCY; HYPERTENSION; GENE; ANGIOTENSINOGEN; ASSOCIATION; RECURRENCE; MOTHER; FETUS	Objective: To use familial patterns of recurrence of pre-eclampsia to investigate whether paternal genes expressed in the fetus contribute to the mother's risk of pre-eclampsia and whether mother's susceptibility to pre-eclampsia is related to maternal inheritance by mitochondrial DNA. Design: Linked data on pregnancies of different women who had children with the same father, and subsequently linked data on pregnancies of half sisters who either had same mother and different fathers or had same father and different mothers. Setting: Population based data from the Medical Birth Registry of Norway covering all births since 1967 (about 1.7 million) and the Norwegian Central Population Register. Main outcome measures: Relative risk of pre-eclampsia after a previous pre-eclamptic pregnancy in the family. Relative risks approximated by odds ratios. Results: If a woman becomes pregnant by a man who has already fathered a pre-eclamptic pregnancy in a different woman her risk of developing pre-eclampsia is 1.8 (95% confidence interval 1.2 to 2.6). If the woman has a half sister who had pre-eclampsia and with whom she shares the same mother but different fathers the risk of pre-eclampsia is 1.6 (0.9 to 2.6). If the two sisters have the same father but different mothers the risk is 1.8 (1.01 to 2.9). Conclusions: Both the mother and the fetus contribute to the risk of pre-eclampsia, the contribution of the fetus being affected by paternal genes. Mitochondrial genes, which are transmitted by mothers, do not seem to contribute to the risk.	Univ Bergen, Haukeland Hosp, Div Med Stat, N-5021 Bergen, Norway; Haukeland Hosp, Med Birth Registry Norway, N-5021 Bergen, Norway; Stat Norway, N-0033 Oslo, Norway	University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; Statistics Norway	Lie, RT (corresponding author), Univ Bergen, Haukeland Hosp, Div Med Stat, Hansens Bldg, N-5021 Bergen, Norway.	rolv.lie@smis.uib.no	Gjessing, Hakon K/A-5871-2012					ADAMS EM, 1961, LANCET, V2, P1375; ARNGRIMSSON R, 1993, NAT GENET, V4, P114, DOI 10.1038/ng0693-114; ARNGRIMSSON R, 1990, BRIT J OBSTET GYNAEC, V97, P762, DOI 10.1111/j.1471-0528.1990.tb02569.x; CHESLEY LC, 1986, BRIT J OBSTET GYNAEC, V93, P898, DOI 10.1111/j.1471-0528.1986.tb08006.x; ENGELMAN L, 1990, BMDP STAT SOFTWARE; Folgero T, 1996, AM J OBSTET GYNECOL, V174, P1626, DOI 10.1016/S0002-9378(96)70619-1; HAIG D, 1993, Q REV BIOL, V68, P495, DOI 10.1086/418300; KILPATRICK DC, 1990, TISSUE ANTIGENS, V35, P178, DOI 10.1111/j.1399-0039.1990.tb01776.x; LIE RT, 1994, NEW ENGL J MED, V331, P1, DOI 10.1056/NEJM199407073310101; LISTON WA, 1991, BRIT J OBSTET GYNAEC, V98, P1079, DOI 10.1111/j.1471-0528.1991.tb15358.x; LOUDON I, 1991, BRIT J OBSTET GYNAEC, V98, P853, DOI 10.1111/j.1471-0528.1991.tb13505.x; MACGILLIVRAY I, 1958, J OBSTET GYNAECOL, V65, P536; Olsen J, 1997, EPIDEMIOLOGY, V8, P6, DOI 10.1097/00001648-199701000-00001; Olson JM, 1996, GENET EPIDEMIOL, V13, P489, DOI 10.1002/(SICI)1098-2272(1996)13:5<489::AID-GEPI5>3.0.CO;2-Y; ROBILLARD PY, 1994, LANCET, V344, P973, DOI 10.1016/S0140-6736(94)91638-1; SAFTLAS AF, 1990, AM J OBSTET GYNECOL, V163, P460, DOI 10.1016/0002-9378(90)91176-D; SHANKLIN DR, 1990, AM J OBSTET GYNECOL, V163, P943, DOI 10.1016/0002-9378(90)91102-I; SIBAI BM, 1991, AM J OBSTET GYNECOL, V165, P1408; Takimoto E, 1996, SCIENCE, V274, P995, DOI 10.1126/science.274.5289.995; Trupin LS, 1996, EPIDEMIOLOGY, V7, P240, DOI 10.1097/00001648-199605000-00004; VINATIER D, 1995, EUR J OBSTET GYN R B, V61, P85, DOI 10.1016/0301-2115(95)02106-H	21	330	341	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1998	316	7141					1343	1347		10.1136/bmj.316.7141.1343	http://dx.doi.org/10.1136/bmj.316.7141.1343			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL882	9563982	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000073483000014
J	Hourihane, JO; Roberts, SA; Warner, JO				Hourihane, JO; Roberts, SA; Warner, JO			Resolution of peanut allergy: case-control study	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL COURSE; HYPERSENSITIVITY; CHILDREN; MILK	Objectives: To determine whether there are any differences between children who remain mildly or moderately allergic to peanut and children with similar histories but a negative reaction on challenge with peanut Design: Case-controls matched for age and sex. Setting: Children's day wards in two teaching hospitals. Intervention: Open food challenge with peanut. Subjects: 15 children with resolved peanut allergy (resolvers) and 15 with persistent allergy (persisters). Main outcome measure: Reaction on challenge with peanut, serum total and peanut specific IgE concentrations. Results: The groups had a similar median age at first reaction to peanut (11 months, range 5-38) and similar symptoms. Allergy to other foods was less common in resolvers (2/15) than persisters (9/15) (P = 0.02). On skin prick testing with peanut all 13 resolvers tested but only 3/14 persisters had a weal of < 6 mm CP < 0.0001). Total and peanut specific IgE concentrations did not differ much between the groups. Conclusion: Appropriately trained clinicians must be prepared to challenge preschool children with peanut as some will be tolerant despite a history of reactions to peanut and a positive skin prick test with peanut Preschool children whose apparent peanut allergy is refuted by food challenge show allergy to other foods less often than those in whom peanut allergy persists. The size of weal on skin prick testing to peanut predicts reactivity but not severity on peanut challenge.	Univ Southampton, Southampton SO16 6YD, Hants, England; Univ S Manchester Hosp, Withington Hosp, Manchester M20 2LR, Lancs, England	University of Southampton; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Hourihane, JO (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.		Warner, John/AAF-9587-2020					BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; Cooke SK, 1997, J IMMUNOL, V159, P2026; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; Ewan PW, 1996, BRIT MED J, V312, P1074; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P1101; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; HOST A, 1997, J ALLERGY CLIN IMM 2, V99, pS491; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sporik R, 1996, BRIT MED J, V313, P1477, DOI 10.1136/bmj.313.7070.1477c; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514	15	203	206	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1998	316	7140					1271	1275		10.1136/bmj.316.7140.1271	http://dx.doi.org/10.1136/bmj.316.7140.1271			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554896	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000073335900020
J	Meier, DE; Emmons, CA; Wallenstein, S; Quill, T; Morrison, RS; Cassel, CK				Meier, DE; Emmons, CA; Wallenstein, S; Quill, T; Morrison, RS; Cassel, CK			A national survey of physician-assisted suicide and euthanasia in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ONCOLOGISTS; ATTITUDES; DEATH; ILL	Background Although there have been many studies of physician-assisted suicide and euthanasia in the United States, national data are lacking. Methods In 1996, we mailed questionnaires to a stratified probability sample of 3102 physicians in the 10 specialties in which doctors are most likely to receive requests from patients for assistance with suicide or euthanasia. We weighted the results to obtain nationally representative data. Results We received 1902 completed questionnaires (response rate, 61 percent). Eleven percent of the physicians said that under current legal constraints; there were circumstances in which they would be willing to hasten a patient's death by prescribing medication, and 7 percent said that they would provide a lethal injection; 36 percent and 24 percent, respectively, said that they would do so if it were legal. Since entering practice, 18.3 percent of the physicians (unweighted number, 320) reported having received a request from a patient for assistance with suicide and 11.1 percent (unweighted number, 196) had received a request for a lethal injection. Sixteen percent of the physicians receiving such requests (unweighted number, 42), or 3.3 percent of the entire sample, reported that they had written at least one prescription to be used to hasten death, and 4.7 percent (unweighted number, 59), said that they had administered at least one lethal injection. Conclusions A substantial proportion of physicians in the United States in the specialties surveyed report that they receive requests for physician-assisted suicide and euthanasia, and about 6 percent have complied with such requests at least once. (C)1998, Massachusetts Medical Society.	Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Biomath Sci, New York, NY 10029 USA; Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Chicago	Meier, DE (corresponding author), Mt Sinai Sch Med, Dept Geriatr & Adult Dev, Box 1070, New York, NY 10029 USA.				NINR NIH HHS [1RO3NR03109] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCH [R03NR003109] Funding Source: NIH RePORTER	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; CARSON R, 1992, HASTINGS CENT REP, V22, P7, DOI 10.2307/3562559; CHRISTAKIS NA, 1995, AM J PUBLIC HEALTH, V85, P367, DOI 10.2105/AJPH.85.3.367; CRANE D, 1977, SANCTITY SOCIAL LIFE; DOUKAS DJ, 1995, J CLIN ONCOL, V13, P1055, DOI 10.1200/JCO.1995.13.5.1055; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Ganzini L, 1997, NEW ENGL J MED, V336, P1824, DOI 10.1056/NEJM199706193362511; Hendin H, 1997, JAMA-J AM MED ASSOC, V277, P1720, DOI 10.1001/jama.277.21.1720; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; JOBE JB, 1989, AM J PUBLIC HEALTH, V79, P1053, DOI 10.2105/AJPH.79.8.1053; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; McKeogh M, 1997, NEW ENGL J MED, V337, P56, DOI 10.1056/NEJM199707033370118; Meier DE, 1997, ANN INTERN MED, V127, P225, DOI 10.7326/0003-4819-127-3-199708010-00008; MEIER DE, 1993, PHYSICIAN ASSISTED D; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; Ryan CJ, 1996, NEW ENGL J MED, V334, P326, DOI 10.1056/NEJM199602013340512; Slome LR, 1997, NEW ENGL J MED, V336, P417, DOI 10.1056/NEJM199702063360606; TAYLOR H, 1995, DOCTOR ASSISTED SUCI	22	366	367	2	69	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1998	338	17					1193	1201		10.1056/NEJM199804233381706	http://dx.doi.org/10.1056/NEJM199804233381706			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ376	9554861				2022-12-24	WOS:000073208400006
J	Matsuoka, K; Orci, L; Amherdt, M; Bednarek, SY; Hamamoto, S; Schekman, R; Yeung, T				Matsuoka, K; Orci, L; Amherdt, M; Bednarek, SY; Hamamoto, S; Schekman, R; Yeung, T			COPII-coated vesicle formation reconstituted with purified coat proteins and chemically defined liposomes	CELL			English	Article							GTP-BINDING PROTEIN; ENDOPLASMIC-RETICULUM; PHOSPHATIDYLINOSITOL 4-KINASE; SACCHAROMYCES-CEREVISIAE; MEMBRANE GLYCOPROTEIN; GOLGI-APPARATUS; YEAST; TRANSPORT; COMPLEX; SEC23P	COPII vesicle formation requires only three coat assembly subunits: Sar1p, Sec13/31p, and Sec23/24p. PI 4-phosphate or PI 4,5-bisphosphate is required for the binding of these proteins to liposomes. The GTP-bound form of Sar1p recruits Sec23/24p to the liposomes as well as to the ER membranes, and this Sar1p-Sec23/24p complex is required for the binding of Sec13/31p. Ultrastructural analysis shows that the binding of COPII coat proteins to liposomes results in coated patches, coated buds, and coated vesicles of 50-90 nm in diameter. Budding proceeds without rupture of the donor liposome or vesicle product. These observations suggest that the assembly of the COPII coat on the ER occurs by a sequential binding of coat proteins to specific lipids and that this assembly promotes the budding of COPII-coated vesicles.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Geneva, Sch Med, Dept Morphol, CH-1211 Geneva 4, Switzerland	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Geneva	Schekman, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.		Matsuoka, Ken/E-3215-2010; Taylor, Graham/A-4027-2012					Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bednarek SY, 1996, TRENDS CELL BIOL, V6, P468, DOI 10.1016/0962-8924(96)84943-9; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MATSUOKA K, 1995, J CELL BIOL, V130, P1307, DOI 10.1083/jcb.130.6.1307; Nakagawa T, 1996, BIOCHEM J, V320, P643, DOI 10.1042/bj3200643; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Salama NR, 1997, MOL BIOL CELL, V8, P205, DOI 10.1091/mbc.8.2.205; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shaywitz DA, 1997, J BIOL CHEM, V272, P25413, DOI 10.1074/jbc.272.41.25413; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; WAGNER S, 1994, YEAST, V10, P1429, DOI 10.1002/yea.320101106; Waksman M, 1997, J BIOL CHEM, V272, P36; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124; Yeung T, 1995, J BIOL CHEM, V270, P30567, DOI 10.1074/jbc.270.51.30567; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	48	498	509	0	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					263	275		10.1016/S0092-8674(00)81577-9	http://dx.doi.org/10.1016/S0092-8674(00)81577-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568718	Bronze			2022-12-24	WOS:000073174000012
J	McKeegan, KD; Leshin, LA; Russell, SS; MacPherson, GJ				McKeegan, KD; Leshin, LA; Russell, SS; MacPherson, GJ			Oxygen isotopic abundances in calcium-aluminum-rich inclusions from ordinary chondrites: Implications for nebular heterogeneity	SCIENCE			English	Article							SOLAR NEBULA; CARBONACEOUS CHONDRITES; ALLENDE INCLUSIONS; METEORITES; ORIGIN; COMPONENT; ANOMALIES; AL-26	The oxygen isotopic compositions of two calcium-aluminum-rich inclusions (CAIs) from the unequilibrated ordinary chondrite meteorites Quinyambie and Semarkona are enriched in O-16 by an amount similar to that in CAIs from carbonaceous chondrites. This may indicate that most CAIs formed in a restricted region of the solar nebula and were then unevenly distributed throughout the various chondrite accretion regions. The Semarkona CAI is isotopically homogeneous and contains highly O-16-enriched melilite, supporting the hypothesis that all CAI minerals were originally O-16-rich, but that in most carbonaceous chondrite inclusions some minerals exchanged oxygen isotopes with an external reservoir following crystallization.	Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Smithsonian Inst, Museum Natl Hist Nat, Dept Mineral Sci, Washington, DC 20560 USA	University of California System; University of California Los Angeles; Smithsonian Institution; Smithsonian National Museum of Natural History	McKeegan, KD (corresponding author), Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA.	kdm@ess.ucla.edu	McKeegan, Kevin D/A-4107-2008	McKeegan, Kevin D/0000-0002-1827-729X; Russell, Sara/0000-0001-5531-7847				BISCHOFF A, 1984, GEOCHIM COSMOCHIM AC, V48, P693, DOI 10.1016/0016-7037(84)90096-6; BLANDER M, 1975, GEOCHIM COSMOCHIM AC, V39, P1605, DOI 10.1016/0016-7037(75)90083-6; BOYNTON WV, 1975, GEOCHIM COSMOCHIM AC, V39, P569, DOI 10.1016/0016-7037(75)90003-4; CHEN JH, 1981, EARTH PLANET SC LETT, V52, P1, DOI 10.1016/0012-821X(81)90202-8; Choi BG, 1997, METEORIT PLANET SCI, V32, pA28; Clayton R. N., 1983, CHONDRULES THEIR ORI, P37; CLAYTON RN, 1977, GEOPHYS RES LETT, V4, P295, DOI 10.1029/GL004i007p00295; CLAYTON RN, 1977, EARTH PLANET SC LETT, V34, P209, DOI 10.1016/0012-821X(77)90005-X; CLAYTON RN, 1991, GEOCHIM COSMOCHIM AC, V55, P2317, DOI 10.1016/0016-7037(91)90107-G; CLAYTON RN, 1993, ANNU REV EARTH PL SC, V21, P115, DOI 10.1146/annurev.earth.21.1.115; CLAYTON RN, 1978, EARTH PLANET SC LETT, V40, P168, DOI 10.1016/0012-821X(78)90087-0; CLAYTON RN, 1973, SCIENCE, V182, P485, DOI 10.1126/science.182.4111.485; CLAYTON RN, 1976, EARTH PLANET SC LETT, V30, P10, DOI 10.1016/0012-821X(76)90003-0; CLAYTON RN, 1983, EARTH PLANET SC LETT, V62, P1, DOI 10.1016/0012-821X(83)90066-3; CLAYTON RN, 1986, TERRA COGNITA, V6, P130; Engrand C, 1997, METEORIT PLANET SCI, V32, pA39; FAHEY AJ, 1988, THESIS WASHINGTON U; GOSWAMI JN, 1997, LUNAR PLANET SCI, V28, P349; GRAHAM A. L., 1985, CATALOGUE METEORITES; KIMURA M, 1993, GEOCHIM COSMOCHIM AC, V57, P2329, DOI 10.1016/0016-7037(93)90573-F; Leshin LA, 1997, GEOCHIM COSMOCHIM AC, V61, P835, DOI 10.1016/S0016-7037(96)00374-2; MacPherson G.J., 1988, METEORITES EARLY SOL, P746; MACPHERSON GJ, 1995, METEORITICS, V30, P365, DOI 10.1111/j.1945-5100.1995.tb01141.x; MAYEDA TK, 1986, LUNAR PLANET SCI, V17, P526; McKeegan K.D., 1996, METEORIT PLANET SCI, V31, pA86; MCKEEGAN KD, 1987, SCIENCE, V237, P1468, DOI 10.1126/science.237.4821.1468; PODOSEK FA, 1994, METEORITICS, V29, P6, DOI 10.1111/j.1945-5100.1994.tb00649.x; PODOSEK FA, 1991, GEOCHIM COSMOCHIM AC, V55, P1083, DOI 10.1016/0016-7037(91)90165-2; ROWE MW, 1994, GEOCHIM COSMOCHIM AC, V58, P5341, DOI 10.1016/0016-7037(94)90317-4; Russell SS, 1997, METEORIT PLANET SCI, V32, pA111; Russell SS, 1996, SCIENCE, V273, P757, DOI 10.1126/science.273.5276.757; RYERSON FJ, 1994, GEOCHIM COSMOCHIM AC, V58, P3713, DOI 10.1016/0016-7037(94)90161-9; SAXTON JM, 1995, METEORITICS, V30, P571; Sears D.W.G., 1988, METEORITES EARLY SOL, P3; SHENG YJ, 1991, GEOCHIM COSMOCHIM AC, V55, P581, DOI 10.1016/0016-7037(91)90014-V; Shu FH, 1996, SCIENCE, V271, P1545, DOI 10.1126/science.271.5255.1545; SLODZIAN G, 1987, CAMECA NEWS      MAY, P1; Tilton G. G., 1988, METEORITES EARLY SOL, P259; VALLEY JW, IN PRESS SOC EC GEOL, V7	39	111	112	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1998	280	5362					414	418		10.1126/science.280.5362.414	http://dx.doi.org/10.1126/science.280.5362.414			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545215				2022-12-24	WOS:000073159600041
J	Zhang, ZL; Huang, LS; Shulmeister, VM; Chi, YI; Kim, KK; Hung, LW; Crofts, AR; Berry, EA; Kim, SH				Zhang, ZL; Huang, LS; Shulmeister, VM; Chi, YI; Kim, KK; Hung, LW; Crofts, AR; Berry, EA; Kim, SH			Electron transfer by domain movement in cytochrome bc(1)	NATURE			English	Article							CYTOCHROME-C OXIDOREDUCTASE; IRON-SULFUR PROTEIN; HEART UBIQUINOL; COMPLEX; SITE; CRYSTALLIZATION; MITOCHONDRIA; RESOLUTION; REDUCTASE; SUBUNIT	The cytochrome bc(1) is one of the three major respiratory enzyme complexes residing in the inner mitochondrial membrane. Cytochrome bc(1) transfers electrons from ubiquinol to cytochrome c and uses the energy thus released to form an electrochemical gradient across the inner membrane. Our X-ray crystal structures of the complex from chicken, cow and rabbit In both the presence and absence of inhibitors of quinone oxidation, reveal two different locations for the extrinsic domain of one component of the enzyme, an Iron-sulphur protein. One location Is close enough to the supposed quinol oxidation site to allow reduction of the Fe-S protein by ubiquinol. The other site is close enough to cytochrome cl to allow oxidation of the Fe-S protein by the cytochrome. As neither location will allow both reactions to proceed at a suitable rate, the reaction mechanism must involve movement of the extrinsic domain of the Fe-S component In order to shuttle electrons from ubiquinol to cytochrome c(1). Such a mechanism has not previously been observed in redox protein complexes.	Univ Calif Berkeley, EO Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Grad Grp Biophys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Illinois, Ctr Biophys & Comptat Biol, Urbana, IL 61801 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Illinois System; University of Illinois Urbana-Champaign	Berry, EA (corresponding author), Univ Calif Berkeley, EO Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA.		Zhang, Zhaolei/G-2369-2017	Huang, Li-Shar/0000-0003-1427-2544				AMBLER RP, 1991, BIOCHIM BIOPHYS ACTA, V1058, P42, DOI 10.1016/S0005-2728(05)80266-X; [Anonymous], 1985, ENZYMES BIOL MEMBRAN, DOI DOI 10.1007/978-1-4684-4604-3_10; BEAUTEMENT K, 1991, PESTIC SCI, V31, P499, DOI 10.1002/ps.2780310406; BERRY EA, 1992, J MOL BIOL, V224, P1161, DOI 10.1016/0022-2836(92)90476-Z; BERRY EA, 1995, ACTA CRYSTALLOGR D, V51, P235, DOI 10.1107/S0907444994010486; BERRY EA, 1991, J BIOL CHEM, V266, P9064; BRANDT U, 1993, J BIOL CHEM, V268, P8387; BROGER C, 1983, EUR J BIOCHEM, V131, P349, DOI 10.1111/j.1432-1033.1983.tb07269.x; CLOUGH JM, 1995, CHEM BRIT, V31, P466; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; CROFTS AR, 1997, IN PRESS PHOTOTROPHI; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; HINKLE PC, 1991, BIOCHEMISTRY-US, V30, P3576, DOI 10.1021/bi00228a031; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, P CCP4 STUD WEEK MOL, P91; KIM CH, 1983, J BIOL CHEM, V258, P3543; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBOTA T, 1991, J MOL BIOL, V221, P379, DOI 10.1016/0022-2836(91)80059-4; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; LINK TA, FRONTIERS CELLULAR B; LINK TA, 1987, CYTOCHROME SYSTEMS M, P289; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MOSER CC, 1995, J BIOENERG BIOMEMBR, V27, P263, DOI 10.1007/BF02110096; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; RAYMENT I, 1983, ACTA CRYSTALLOGR A, V39, P102, DOI 10.1107/S0108767383000197; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; SAUTER H, 1996, CROP PROTECTION AGEN, P50; Schagger H, 1995, METHOD ENZYMOL, V260, P82, DOI 10.1016/0076-6879(95)60132-5; SCHLAGGER H, 1986, METHOD ENZYMOL, V126, P224; *SERC UK COLL COMP, 1995, ACTA CRYSTALLOGR D, V50, P760; SLATER EC, 1973, BIOCHIM BIOPHYS ACTA, V301, P129, DOI 10.1016/0304-4173(73)90002-5; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; STONEHUERNER J, 1985, J BIOL CHEM, V260, P5392; VANDOREN SR, 1993, BIOCHEMISTRY-US, V32, P628, DOI 10.1021/bi00053a031; WEISS H, 1987, CHEM SCRIPTA, V27B, P73; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YUE WH, 1991, BIOCHEMISTRY-US, V30, P2303, DOI 10.1021/bi00223a002	42	923	944	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 16	1998	392	6677					677	684		10.1038/33612	http://dx.doi.org/10.1038/33612			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565029				2022-12-24	WOS:000073129000047
J	Friedmann, PD; Saitz, R; Samet, JH				Friedmann, PD; Saitz, R; Samet, JH			Management of adults recovering from alcohol or other drug problems - Relapse prevention in primary care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED TRIAL; SUBSTANCE-ABUSE; PREVALENCE; DEPENDENCE; DEPRESSION; ADDICTION; PHYSICIAN; DRINKING	Patients recovering from substance use disorders are commonly seen in the primary care setting, and relapse is a serious long-term problem for these patients. Extrapolating from therapeutic strategies effective in specialty addiction treatment settings, this article outlines a practical approach to relapse prevention in the primary care setting. Working within a supportive patient-physician relationship, the primary care physician can help recovering patients decrease their susceptibility to relapse, recognize and manage high-risk situations, and use available self-help, pharmacological, and specialty resources, Drawing on the therapeutic relationship and skills they already possess, primary care physicians can have an important, productive, and satisfying role in the long-term management of patients in recovery from alcohol or other drug problems.	Univ Chicago, Pritzker Sch Med, Dept Med, Gen Internal Med Sect, Chicago, IL 60637 USA; Boston Univ, Sch Med, Boston Med Ctr, Dept Med,Sect Gen Internal Med,Clin Addict Res & E, Boston, MA 02118 USA	University of Chicago; Boston Medical Center; Boston University	Friedmann, PD (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Med, Gen Internal Med Sect, 5841 S Maryland Ave,MC2007, Chicago, IL 60637 USA.	pfriedman@medicine.bsd.uchicago.edu		/0000-0002-2535-1427; Samet, Jeffrey/0000-0002-0897-3400	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010019, K08DA000320] Funding Source: NIH RePORTER; NIAAA NIH HHS [5R01-AA10870] Funding Source: Medline; NIDA NIH HHS [1K08-DA00320, 5R01-DA10019] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		*ALC AN WORLD SERV, 1952, 12 STEPS 12 TRAD; *ALC AN WORLD SERV, 1975, ALC AN; *ALC AN WORLD SERV, 1975, LIV SOB; Allen J, 1997, ADDICTION, V92, P1671; Allen JP, 1997, J STUD ALCOHOL, V58, P7; *AM SOC ADD MED, 1997, ASAM NEWS, V17, P17; Babor TF, 1996, AM J PUBLIC HEALTH, V86, P948; Barnes HN, 1997, MED CLIN N AM, V81, P867, DOI 10.1016/S0025-7125(05)70553-8; BARNES HN, 1995, SUBST ABUSE, V16, P31; BIGBY JA, 1987, ALCOHOLISM GUIDE PRI, P66; BUCHSBAUM DG, 1995, ARCH INTERN MED, V155, P104, DOI 10.1001/archinte.155.1.104; Carroll KM, 1996, EXP CLIN PSYCHOPHARM, V4, P46, DOI 10.1037/1064-1297.4.1.46; COLLETTI G, 1980, J CONSULT CLIN PSYCH, V48, P665, DOI 10.1037/0022-006X.48.5.665; Connors GJ, 1996, ADDICTION, V91, pS173, DOI 10.1111/j.1360-0443.1996.tb02337.x; Connors GJ, 1996, ADDICTION, V91, pS5, DOI 10.1111/j.1360-0443.1996.tb02323.x; Connors GJ, 1996, ADDICTION, V91, pS191, DOI 10.1111/j.1360-0443.1996.tb02338.x; DALEY DC, 1989, RELAPSE CONCEPTUAL R, P3; DEJONG W, 1994, DHHS PUBLICATION; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; FLITCRAFT AH, 1994, AM MED ASS DIAGNOSTI; GORSKI T.T, 1988, STAYING SOBER WORKBO; GORSKI TT, 1989, RELAPSE CONCEPTUAL R, P153; GORSKI TT, 1991, ADDICT RECOVERY, V3, P17; HASIN DS, 1990, ARCH INTERN MED, V150, P397, DOI 10.1001/archinte.150.2.397; HAWKINS JD, 1985, INT J ADDICT, V20, P917, DOI 10.3109/10826088509047759; Hirschfeld RMA, 1997, NEW ENGL J MED, V337, P910, DOI 10.1056/NEJM199709253371307; HOFFMANN NG, 1996, COMMITTEE BENEFITS P; HUNT WA, 1971, J CLIN PSYCHOL, V27, P455, DOI 10.1002/1097-4679(197110)27:4<455::AID-JCLP2270270412>3.0.CO;2-R; Institute of Medicine, 1997, DISP MYTHS ADD; KIMBALL HR, 1994, JAMA-J AM MED ASSOC, V271, P315, DOI 10.1001/jama.271.4.315; KRISTENSON H, 1983, ALCOHOL CLIN EXP RES, V7, P203, DOI 10.1111/j.1530-0277.1983.tb05441.x; KURTZ E, 1982, J STUD ALCOHOL, V43, P38, DOI 10.15288/jsa.1982.43.38; Larson MJ, 1997, MED CLIN N AM, V81, P1053, DOI 10.1016/S0025-7125(05)70563-0; Liebschutz JM, 1997, ARCH INTERN MED, V157, P1093, DOI 10.1001/archinte.157.10.1093; Marlatt G.A, 2005, RELAPSE PREVENTION M; Mason BJ, 1996, JAMA-J AM MED ASSOC, V275, P761, DOI 10.1001/jama.275.10.761; MCAULIFFE WE, 1990, J PSYCHOACTIVE DRUGS, V22, P197, DOI 10.1080/02791072.1990.10472544; MCCRADY BS, 1996, TREATING SUBSTANCE A, P117; MCLELLAN AT, 1983, ARCH GEN PSYCHIAT, V40, P620; Miller W.R., 2013, MOTIVATIONAL INTERVI, V3rd ed.; Miller WR, 1996, ADDICTION, V91, pS15, DOI 10.1111/j.1360-0443.1996.tb02324.x; *NARC AN WORLD SER, 1983, NARC AN; *NAT I ALC AB ALC, 1995, NIH PUBL; NOWINSKI J, 1995, DHHS PUBLICATION, V1; O'Connor P. G., 1996, JGIM, V11, P53; O'Connor PG, 1997, AM J MED, V103, P477, DOI 10.1016/S0002-9343(97)00271-4; OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66; OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2; OFARELL TJ, 1993, TREATING ALCOHOL PRO; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; ROBINS LN, 1984, ARCH GEN PSYCHIAT, V41, P949; ROUNSAVILLE BJ, 1987, ARCH GEN PSYCHIAT, V44, P505; Saitz R, 1997, AM J DRUG ALCOHOL AB, V23, P343, DOI 10.3109/00952999709016881; Saitz R, 1997, MED CLIN N AM, V81, P881, DOI 10.1016/S0025-7125(05)70554-X; Samet J. H., 1995, JGIM, V10, P48; Samet JH, 1996, ARCH INTERN MED, V156, P2287, DOI 10.1001/archinte.156.20.2287; Sobell LC, 1996, AM J PUBLIC HEALTH, V86, P966, DOI 10.2105/AJPH.86.7.966; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; WALLACE BC, 1989, J SUBST ABUSE TREAT, V6, P95, DOI 10.1016/0740-5472(89)90036-6; Warner EA, 1997, MED CLIN N AM, V81, P909, DOI 10.1016/S0025-7125(05)70555-1; Wilk AI, 1997, J GEN INTERN MED, V12, P274; Ziedonis D, 1997, MED CLIN N AM, V81, P1017, DOI 10.1016/S0025-7125(05)70561-7; ZIEDONIS DM, 1991, PSYCHOPHARMACOL BULL, V27, P337	63	89	90	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1998	279	15					1227	1231		10.1001/jama.279.15.1227	http://dx.doi.org/10.1001/jama.279.15.1227			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZG133	9555766				2022-12-24	WOS:000072969400039
J	Ditzel, L; Lowe, J; Stock, D; Stetter, KO; Huber, H; Huber, R; Steinbacher, S				Ditzel, L; Lowe, J; Stock, D; Stetter, KO; Huber, H; Huber, R; Steinbacher, S			Crystal structure of the thermosome, the archaeal chaperonin and homolog of CCT	CELL			English	Article							T-COMPLEX POLYPEPTIDE-1; GROEL-GROES COMPLEXES; MOLECULAR CHAPERONE; CYTOPLASMIC CHAPERONIN; HEAT-SHOCK; THERMOPHILIC ARCHAEBACTERIUM; SULFOLOBUS-SOLFATARICUS; PROTEIN SUBSTRATE; BINDING DOMAINS; ATP HYDROLYSIS	We have determined to 2.6 Angstrom resolution the crystal structure of the thermosome, the archaeal group II chaperonin from T. acidophilum. The hexadecameric homolog of the eukaryotic chaperonin CCT/TRiC shows an (alpha beta)(4)(alpha beta)(4) subunit assembly. Domain folds are homologous to GroEL but form a novel type of inter-ring contact. The domain arrangement resembles the GroEL-GroES cis-ring. Parts of the apical domains form a lid creating a closed conformation. The lid substitutes for a GroES-like cochaperonin that is absent in the CCT/TRiC system. The central cavity has a polar surface implicated in protein folding. Binding of the transition state analog MS-ADP-AIF(3) suggests that the closed conformation corresponds to the ATP form.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Regensburg, Inst Mikrobiol, D-93053 Regensburg, Germany	Max Planck Society; University of Regensburg	Steinbacher, S (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.		Löwe, Jan/B-3882-2011; Löwe, Jan/X-6998-2019	Lowe, Jan/0000-0002-5218-6615				Andra S, 1996, FEBS LETT, V379, P127, DOI 10.1016/0014-5793(95)01493-4; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Coyle JE, 1997, FOLD DES, V2, pR93, DOI 10.1016/S1359-0278(97)00046-1; DARLAND G, 1971, J GEN MICROBIOL, V67, P9, DOI 10.1099/00221287-67-1-9; Dobrzynski JK, 1996, BIOCHEMISTRY-US, V35, P15870, DOI 10.1021/bi961114j; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GUAGLIARDI A, 1994, PROTEIN SCI, V3, P1436, DOI 10.1002/pro.5560030910; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KNAPP S, 1994, J MOL BIOL, V242, P397; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1991, RECENT CHANGES MOSFL; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; MARCO S, 1994, FEBS LETT, V341, P152, DOI 10.1016/0014-5793(94)80447-8; MARCO S, 1994, BIOPHYS J, V67, P364, DOI 10.1016/S0006-3495(94)80489-8; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Nitsch M, 1997, J MOL BIOL, V267, P142, DOI 10.1006/jmbi.1996.0849; PHIPPS BM, 1993, NATURE, V361, P475, DOI 10.1038/361475a0; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; TURK D, 1992, THESIS TU MUNCHEN; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; WALDMANN T, 1995, EUR J BIOCHEM, V227, P848, DOI 10.1111/j.1432-1033.1995.tb20210.x; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Willison KR, 1994, BIOL HEAT SHOCK PROT, P299; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; YIFRACH O, 1994, J MOL BIOL, V243, P397, DOI 10.1006/jmbi.1994.1667	80	362	371	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1998	93	1					125	138		10.1016/S0092-8674(00)81152-6	http://dx.doi.org/10.1016/S0092-8674(00)81152-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546398	Bronze			2022-12-24	WOS:000072910800016
J	Hertz, R; Magenheim, J; Berman, I; Bar-Tana, J				Hertz, R; Magenheim, J; Berman, I; Bar-Tana, J			Fatty acyl-CoA thioesters are ligands of hepatic nuclear factor-4 alpha	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATION; ESCHERICHIA-COLI; ACID; PROLIFERATORS; PROTEINS; PROMOTER; BINDING; LIPIDS; GENE	Dietary fatty acids specifically modulate the onset and progression of various diseases, including cancer(1,2), atherogenesis(3), hyperlipidaemia(4), insulin resistance(5) and hypertension(6), as well as blood coagulability and fibrinolytic defects(7); their effects depend on their chain length and degree of saturation. Hepatocyte nuclear factor-4 alpha (ref. 8) (HNF-4 alpha) is an orphan transcription factor of the superfamily of nuclear receptors and controls the expression of genes (reviewed in ref. 9) that govern the pathogenesis and course of some of these diseases. Here we show that long-chain fatty acids directly modulate the transcriptional activity of HNF-4 alpha by binding as their acyl-CoA thioesters to the ligand-binding domain of HNF-4 alpha, This binding may shift the oligomeric-dimeric equilibrium of HNF-4 alpha or may modulate the affinity of HNF-4 alpha for its cognate promoter element, resulting in either activation or inhibition of HNF-4 alpha transcriptional activity as a function of chain length and the degree of saturation of the fatty acyl-CoA ligands, In addition to their roles as substrates to yield energy, as an energy store, or as constituents of membrane phospholipids, dietary fatty acids may affect the course of a disease by modulating the expression of HNF-4 alpha-controlled genes.	Hebrew Univ Jerusalem, Fac Med, Dept Human Nutr & Metab, IL-91010 Jerusalem, Israel	Hebrew University of Jerusalem	Bar-Tana, J (corresponding author), Hebrew Univ Jerusalem, Fac Med, Dept Human Nutr & Metab, POB 12272, IL-91010 Jerusalem, Israel.							CAVE WT, 1991, FASEB J, V5, P2160, DOI 10.1096/fasebj.5.8.1673664; CHIN JPF, 1994, PROSTAG LEUKOTR ESS, V50, P211, DOI 10.1016/0952-3278(94)90156-2; CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503; DAHLBERG E, 1980, ANAL BIOCHEM, V106, P380, DOI 10.1016/0003-2697(80)90537-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Gossett RE, 1996, LIPIDS, V31, P895, DOI 10.1007/BF02522684; GRUNDY SM, 1990, J LIPID RES, V31, P1149; HERTZ R, 1994, EUR J BIOCHEM, V221, P611, DOI 10.1111/j.1432-1033.1994.tb18773.x; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Hultin M B, 1991, Prog Hemost Thromb, V10, P215; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; KERSTEN S, 1995, P NATL ACAD SCI USA, V92, P8645, DOI 10.1073/pnas.92.19.8645; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; LEFF T, 1989, J BIOL CHEM, V264, P16132; Malik S, 1996, MOL CELL BIOL, V16, P1824; MORRIS MC, 1993, CIRCULATION, V88, P523, DOI 10.1161/01.CIR.88.2.523; NAGGERT J, 1991, BIOCHEM J, V273, P787, DOI 10.1042/bj2730787; ORI A, 1994, VIROLOGY, V204, P600, DOI 10.1006/viro.1994.1574; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; STORLIEN LH, 1987, SCIENCE, V237, P885, DOI 10.1126/science.3303333; THOLSTRUP T, 1994, AM J CLIN NUTR, V59, P371, DOI 10.1093/ajcn/59.2.371; WELSCH CW, 1992, CANCER RES, V52, pS2040; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	29	430	446	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					512	516		10.1038/33185	http://dx.doi.org/10.1038/33185			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548258				2022-12-24	WOS:000072875200063
J	Clement, K; Vaisse, C; Lahlou, N; Cabrol, S; Pelloux, V; Cassuto, D; Gourmelen, M; Dina, C; Chambaz, J; Lacorte, JM; Basdevant, A; Bougneres, P; Lebouc, Y; Froguel, P; Guy-Grand, B				Clement, K; Vaisse, C; Lahlou, N; Cabrol, S; Pelloux, V; Cassuto, D; Gourmelen, M; Dina, C; Chambaz, J; Lacorte, JM; Basdevant, A; Bougneres, P; Lebouc, Y; Froguel, P; Guy-Grand, B			A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction	NATURE			English	Article							GROWTH-HORMONE; OB/OB MICE; MOUSE; EXPRESSION; PROTEINS; CLONING; SERUM	The adipocyte-specific hormone leptin, the product of the obese (ob) gene, regulates adipose-tissue mass through hypothalamic effects on satiety and energy expenditure(1-4), Leptin acts through the leptin receptor, a single-transmembrane-domain receptor of the cytokine-receptor family(5-7). In rodents, homozygous mutations in genes encoding leptin(1) or the leptin receptor(6) cause early-onset morbid obesity, hyperphagia and reduced energy expenditure, These rodents also show hypercortisolaemia, alterations in glucose homeostasis, dyslipidaemia, and infertility due to hypogonadotropic hypogonadism(8). In humans. leptin deficiency due to a mutation in the leptin gene is associated with early-onset obesity(9), Here we describe a homozygous mutation in the human leptin receptor gene that results in a truncated leptin receptor lacking both the transmembrane and the intracellular domains, In addition to their early-onset morbid obesity, patients homozygous for this mutation have no pubertal development and their secretion of growth hormone and thyrotropin is reduced. These results indicate that leptin is an important physiological regulator of several endocrine functions in humans.	Hotel Dieu, Lab Nutr, F-75004 Paris, France; Hotel Dieu, Serv Med & Nutr, F-75004 Paris, France; Inst Pasteur, Inst Biol, CNRS, EP10, F-59000 Lille, France; Hop St Vincent de Paul, INSERM, U342, F-75674 Paris, France; Serv Endocrinol Diabete Enfant, F-75014 Paris, France; Hop Enfant Armand Trousseu, F-75012 Paris, France; INSERM, CJF 9508, F-75005 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Froguel, P (corresponding author), Hotel Dieu, Lab Nutr, Pl Parvis Notre Dame, F-75004 Paris, France.		FROGUEL, Philippe/O-6799-2017; Clément, karine/R-1120-2017; Vaisse, Christian/F-1067-2011; Dina, Christian R/D-3535-2015	FROGUEL, Philippe/0000-0003-2972-0784; Dina, Christian R/0000-0002-7722-7348				Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; BERNINI GP, 1990, CLIN ENDOCRINOL, V32, P453, DOI 10.1111/j.1365-2265.1990.tb00885.x; Bjorntorp P, 1997, NUTRITION, V13, P795, DOI 10.1016/S0899-9007(97)00191-3; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Carro E, 1997, ENDOCRINOLOGY, V138, P2203, DOI 10.1210/en.138.5.2203; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Clayton PE, 1997, CLIN ENDOCRINOL, V46, P727, DOI 10.1046/j.1365-2265.1997.2081026.x; Clement K, 1997, INT J OBESITY, V21, P556, DOI 10.1038/sj.ijo.0800440; COLEMAN DL, 1973, DIABETOLOGIA, V9, P287, DOI 10.1007/BF01221856; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Diamond FB, 1997, BIOCHEM BIOPH RES CO, V233, P818, DOI 10.1006/bbrc.1997.6538; Echwald SM, 1997, BIOCHEM BIOPH RES CO, V233, P248, DOI 10.1006/bbrc.1997.6430; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HARDOUIN S, 1989, J CLIN ENDOCR METAB, V69, P1291, DOI 10.1210/jcem-69-6-1291; Houseknecht KL, 1996, DIABETES, V45, P1638, DOI 10.2337/diabetes.45.11.1638; HUMMEL KP, 1972, BIOCHEM GENET, V7, P1, DOI 10.1007/BF00487005; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Liu CL, 1997, ENDOCRINOLOGY, V138, P3548, DOI 10.1210/en.138.8.3548; Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P1066, DOI 10.1210/jc.82.4.1066; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; TANNENBAUM GS, 1990, ENDOCRINOLOGY, V127, P3080; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; THISSEN JP, 1994, ENDOCR REV, V15, P80, DOI 10.1210/er.15.1.80; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; VIGNOLO M, 1988, EUR J PEDIATR, V147, P242, DOI 10.1007/BF00442687; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	30	1649	1711	1	110	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					398	401		10.1038/32911	http://dx.doi.org/10.1038/32911			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537324				2022-12-24	WOS:000072713600054
J	Mitchell, A				Mitchell, A			Visionaries seek UK national strategy	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					419	420		10.1038/32952	http://dx.doi.org/10.1038/32952			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537331				2022-12-24	WOS:000072713600061
J	Lumer, ED; Friston, KJ; Rees, G				Lumer, ED; Friston, KJ; Rees, G			Neural correlates of perceptual rivalry in the human brain	SCIENCE			English	Article							BINOCULAR-RIVALRY; VISUAL-PERCEPTION; ATTENTION; CORTEX; MECHANISMS; NEGLECT; FMRI; LOBE	When dissimilar images are presented to the two eyes, perception alternates spontaneously between each monocular view, a phenomenon called binocular rivalry. Functional brain imaging in humans was used to study the neural basis of these subjective perceptual changes. Cortical regions whose activity reflected perceptual transitions included extrastriate areas of the ventral visual pathway, and parietal and frontal regions that have been implicated in spatial attention; whereas the extrastriate areas were also engaged by nonrivalrous perceptual changes, activity in the frontoparietal cortex was specifically associated with perceptual alternation only during rivalry. These results suggest that frontoparietal areas play a central role in conscious perception, biasing the content of visual awareness toward abstract internal representations of visual scenes, rather than simply toward space.	UCL, Inst Neurol, Wellcome Dept Cognit Neurol, London WC1N 3BG, England	University of London; University College London	Lumer, ED (corresponding author), UCL, Inst Neurol, Wellcome Dept Cognit Neurol, Queen Sq, London WC1N 3BG, England.	elumer@fil.ion.ucl.ac.uk	Rees, Geraint/C-1493-2008; Friston, Karl/D-9230-2011	Rees, Geraint/0000-0002-9623-7007; Friston, Karl/0000-0001-7984-8909	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andrews TJ, 1997, P NATL ACAD SCI USA, V94, P9905, DOI 10.1073/pnas.94.18.9905; BLAKE R, 1989, PSYCHOL REV, V96, P145, DOI 10.1037/0033-295X.96.1.145; BORSELLINO A, 1972, KYBERNETIK, V10, P139, DOI 10.1007/BF00290512; CORBETTA M, 1995, SCIENCE, V270, P802, DOI 10.1126/science.270.5237.802; Corbetta M, 1998, P NATL ACAD SCI USA, V95, P831, DOI 10.1073/pnas.95.3.831; CORBETTA M, 1991, J NEUROSCI, V11, P2383; CORBETTA M, 1993, J NEUROSCI, V13, P1202; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; Crick F, 1996, NATURE, V379, P485, DOI 10.1038/379485a0; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193; Fink GR, 1996, NATURE, V382, P626, DOI 10.1038/382626a0; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; Friston K.J., 1994, HUMAN BRAIN MAPPING, V2, P211, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; FRISTON KJ, 1995, NEUROIMAGE, V2, P157, DOI 10.1006/nimg.1995.1018; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; HEILMAN KM, 1980, NEUROLOGY, V30, P327, DOI 10.1212/WNL.30.3.327; HEINZE HJ, 1994, NATURE, V372, P543, DOI 10.1038/372543a0; HELMHOLTZ, 1911, TREATISE PHYSL OPTIC; Holmes AP, 1997, NEUROIMAGE, V5, pS480; HUMPHREYS GW, 1994, NATURE, V372, P357, DOI 10.1038/372357a0; Husain M, 1996, J NEUROL, V243, P652, DOI 10.1007/BF00878662; Josephs O, 1997, HUM BRAIN MAPP, V5, P243, DOI 10.1002/(SICI)1097-0193(1997)5:4<243::AID-HBM7>3.0.CO;2-3; Kanwisher N, 1997, J NEUROSCI, V17, P4302; LANSING RW, 1964, SCIENCE, V146, P1325, DOI 10.1126/science.146.3649.1325; Leopold DA, 1996, NATURE, V379, P549, DOI 10.1038/379549a0; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; Logothetis NK, 1996, NATURE, V380, P621, DOI 10.1038/380621a0; LOGOTHETIS NK, 1996, ANNU REV NEUROSCI, V19, P557; MALACH R, 1995, P NATL ACAD SCI USA, V92, P8135, DOI 10.1073/pnas.92.18.8135; MAUNSELL JHR, 1995, SCIENCE, V270, P764, DOI 10.1126/science.270.5237.764; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; POGGIO GF, 1988, J NEUROSCI, V8, P4531; Rees G, 1997, SCIENCE, V278, P1616, DOI 10.1126/science.278.5343.1616; Rosen BR, 1998, P NATL ACAD SCI USA, V95, P773, DOI 10.1073/pnas.95.3.773; SCALAIDHE SPO, 1997, SCIENCE, V278; Talairach J., 1988, COPLANAR STEREOTAXIC; Ungerleider Leslie G., 1994, Current Opinion in Neurobiology, V4, P157, DOI 10.1016/0959-4388(94)90066-3; VANESSEN DC, 1994, NEURON, V13, P1, DOI 10.1016/0896-6273(94)90455-3; WALKER P, 1978, PSYCHOL BULL, V85, P376, DOI 10.1037/0033-2909.85.2.376; Wolfe JM, 1996, NATURE, V380, P587, DOI 10.1038/380587a0	41	546	552	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1930	1934		10.1126/science.280.5371.1930	http://dx.doi.org/10.1126/science.280.5371.1930			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632390				2022-12-24	WOS:000074323800062
J	Rogers, A; Entwistle, V; Pencheon, D				Rogers, A; Entwistle, V; Pencheon, D			Managing demand - A patient led NHS: Managing demand at the interface between lay and primary care	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; MEDICATION; SERVICES; ILLNESS		Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Univ York, NHS Ctr Reviews & Disseminat, York YO1 5DD, N Yorkshire, England; Univ Forvie Site, Inst Publ Hlth, Cambridge CB2 2SR, England	University of Manchester; University of York - UK; University of Cambridge	Rogers, A (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.		Entwistle, Vikki Ann/I-9266-2019	Entwistle, Vikki Ann/0000-0002-0856-4025				ALONZO AA, 1984, SOC SCI MED, V19, P499, DOI 10.1016/0277-9536(84)90045-5; ANCTIL B, 1996, JOINT COMMISSION J Q, V2, P345; BALXTER M, 1986, J ROY COLL GEN PRACT, V33, P256; Blenkinsopp A, 1996, BRIT MED J, V312, P629; Coulter A, 1997, J Health Serv Res Policy, V2, P112; DEAN K, 1986, SOC SCI MED, V22, P275, DOI 10.1016/0277-9536(86)90076-6; DEAN K, 1986, HLTH PROMOTION, V2, P133; EYLES J, 1990, SOCIAL EFFECTS HLTH; FLEMING GV, 1984, MED CARE, V22, P950, DOI 10.1097/00005650-198410000-00007; Free C, 1998, BRIT MED J, V316, P380, DOI 10.1136/bmj.316.7128.380; FREWER LJ, 1994, PUBLIC UNDERST SCI, V2, P112; Gurwitz JH, 1995, HEALTH SERV RES, V30, P672; Hassell K, 1997, FAM PRACT, V14, P498, DOI 10.1093/fampra/14.6.498; HOPTON JL, 1995, BRIT MED J, V310, P1369, DOI 10.1136/bmj.310.6991.1369; JESSON J, 1994, ETHNIC MINORITY CONS, P66; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Macfarlane JT, 1997, BRIT J GEN PRACT, V47, P719; PEARSON M, 1993, HEALTH SOC CARE COMM, V1, P11; ROGERS A, IN PRESS HLTH PLACE; ROGERS A, IN PRESS DEMANDING P; *SECR STAT HLTH, 1998, NEW NHS; Shipman C, 1997, FAM PRACT, V14, P503, DOI 10.1093/fampra/14.6.503; STACEY M, 1984, ECON IND DEMOCRACY, V5, P157, DOI 10.1177/0143831X8452002	24	37	37	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1816	+		10.1136/bmj.316.7147.1816	http://dx.doi.org/10.1136/bmj.316.7147.1816			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZV258	9624078	Green Published			2022-12-24	WOS:000074286300035
J	Cullum, CM; Rosenberg, RN				Cullum, CM; Rosenberg, RN			Memory loss - When is it Alzheimer disease?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINI-MENTAL-STATE		Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Alzheimers Dis Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cullum, CM (corresponding author), Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Cullum, C. Munro/AAC-2496-2019	Cullum, C. Munro/0000-0001-9706-5465	NIA NIH HHS [P30-AG-12300-05] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG012300] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1996, Neurology, V47, P592; Bonte FJ, 1997, RADIOLOGY, V202, P793, DOI 10.1148/radiology.202.3.9051035; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Cullum C M, 1995, J Int Neuropsychol Soc, V1, P100; CULLUM CM, 1993, J CLIN EXP NEUROPSYC, V15, P321, DOI 10.1080/01688639308402566; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Geldmacher DS, 1997, NEUROLOGY, V48, pS2, DOI 10.1212/WNL.48.5_Suppl_6.2S; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; MORRISONBOGORAD M, 1997, MOL GENETIC BASIS NE, P581; NAUGLE RI, 1998, INTRO CLIN NEUROPSYC; Rosenberg RN, 1997, JAMA-J AM MED ASSOC, V278, P1282, DOI 10.1001/jama.278.15.1282; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Small GW, 1997, JAMA-J AM MED ASSOC, V278, P1363, DOI 10.1001/jama.278.16.1363	13	8	8	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1689	1690		10.1001/jama.279.21.1689	http://dx.doi.org/10.1001/jama.279.21.1689			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624014				2022-12-24	WOS:000073878700010
J	Cadigan, KM; Fish, MP; Rulifson, EJ; Nusse, R				Cadigan, KM; Fish, MP; Rulifson, EJ; Nusse, R			Wingless repression of Drosophila frizzled 2 expression shapes the wingless morphogen gradient in the wing	CELL			English	Article							IMAGINAL DISKS; SIGNALING PATHWAY; NERVOUS-SYSTEM; BODY PATTERN; CELL FATE; HEDGEHOG; PROTEIN; POLARITY; RECEPTOR; ENCODES	In Drosophila wing imaginal discs, the Wingless (Wg) protein acts as a morphogen, emanating from the dorsal/ventral (D/V) boundary of the disc to directly define cell identities along the D/V axis at short and long range. Here, we show that high levels of a Wg receptor, Drosophila frizzled 2 (Dfz2), stabilize Wg, allowing it to reach cells far from its site of synthesis. Wg signaling represses Dfz2 expression, creating a gradient of decreasing Wg stability moving toward the D/V boundary. This repression of Dfz2 is crucial for the normal shape of Wg morphogen gradient as well as the response of cells to the Wg signal. In contrast to other ligand-receptor relationships where the receptor limits diffusion of the ligand, Dfz2 broadens the range of Wg action by protecting it from degradation.	Stanford Univ, Med Ctr, Dept Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Nusse, R (corresponding author), Stanford Univ, Med Ctr, Dept Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA.			Cadigan, Ken/0000-0003-2431-1703				BAKER NE, 1988, DEVELOPMENT, V102, P489; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BLAIR SS, 1994, DEV BIOL, V162, P229, DOI 10.1006/dbio.1994.1081; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadigan KM, 1996, DEVELOPMENT, V122, P2801; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CASANOVA J, 1995, GENE DEV, V9, P2539, DOI 10.1101/gad.9.20.2539; CASANOVA J, 1993, NATURE, V362, P152, DOI 10.1038/362152a0; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; COUSO JP, 1994, DEVELOPMENT, V120, P621; Freeman M, 1997, DEVELOPMENT, V124, P261; Golembo M, 1996, DEVELOPMENT, V122, P223; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hajnal A, 1997, GENE DEV, V11, P2715, DOI 10.1101/gad.11.20.2715; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOPPLER S, 1995, EMBO J, V14, P5016, DOI 10.1002/j.1460-2075.1995.tb00184.x; Hulme E. C., 1992, RECEPTOR LIGAND INTE, P63; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Kozopas KM, 1998, GENE DEV, V12, P1155, DOI 10.1101/gad.12.8.1155; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lawrence PA, 1996, DEVELOPMENT, V122, P4095; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Neumann CJ, 1996, DEVELOPMENT, V122, P1781; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; Pai LM, 1997, DEVELOPMENT, V124, P2255; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; Pignoni F, 1997, DEVELOPMENT, V124, P271; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Rulifson EJ, 1996, NATURE, V384, P72, DOI 10.1038/384072a0; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SLACK JMW, 1987, TRENDS BIOCHEM SCI, V12, P200, DOI 10.1016/0968-0004(87)90094-6; SLACK JMW, 1987, EGG EMBRYO REGIONAL; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; VINCENT JP, 1994, CELL, V77, P909, DOI 10.1016/0092-8674(94)90139-2; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; XU T, 1993, DEVELOPMENT, V117, P1223; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	58	265	268	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					767	777		10.1016/S0092-8674(00)81438-5	http://dx.doi.org/10.1016/S0092-8674(00)81438-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630221	Bronze			2022-12-24	WOS:000073956700013
J	Probst, FJ; Fridell, RA; Raphael, Y; Saunders, TL; Wang, AH; Liang, Y; Morell, RJ; Touchman, JW; Lyons, RH; Noben-Trauth, K; Friedman, TB; Camper, SA				Probst, FJ; Fridell, RA; Raphael, Y; Saunders, TL; Wang, AH; Liang, Y; Morell, RJ; Touchman, JW; Lyons, RH; Noben-Trauth, K; Friedman, TB; Camper, SA			Correction of deafness in shaker-2 mice by an unconventional myosin in a BAC transgene	SCIENCE			English	Article							HAIR-CELLS; MOUSE; GENE; ALIGNMENT; ACTIN	The shaker-2 mouse mutation, the homolog of human DFNB3, causes deafness and circling behavior. A bacterial artificial chromosome (BAC) transgene from the shaker-2 critical region corrected the vestibular defects, deafness, and inner ear morphology of shaker-2 mice. An unconventional myosin gene, Myo15, was discovered by DNA sequencing of this BAG. Shaker-2 mice were found to have an amino acid substitution at a highly conserved position within the motor domain of this myosin, Auditory hair cells of shaker-2 mice have very short stereocilia and a long actin-containing protrusion extending from their basal end. This histopathology suggests that Myo15 is necessary for actin organization in the hair cells of the cochlea.	NIDOCD, NIH, Rockville, MD 20850 USA; Michigan State Univ, Grad Program Genet, E Lansing, MI 48824 USA; Univ Michigan, Kresge Hearing Res Inst, Ann Arbor, MI 48109 USA; Natl Human Genome Res Inst, Bethesda, MD 20892 USA; NIH, Intramural Sequencing Ctr, Rockville, MD 20850 USA; Univ Michigan, DNA Sequencing Core Facil, Ann Arbor, MI 48109 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Michigan State University; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Michigan System; University of Michigan	Camper, SA (corresponding author), Univ Michigan, Dept Human Genet, 4701 MSRB 111,1500 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	scamper@umich.edu	Morell, Robert James/Q-2042-2019	Camper, Sally/0000-0001-8556-3379; Morell, Robert/0000-0003-1537-7356; Saunders, Thom/0000-0003-2015-101X	NIDCD NIH HHS [Z01 DC 00035, Z01 DC 02407, Z01 DC 00038] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002407] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; DEOL MS, 1954, J GENET, V52, P562, DOI 10.1007/BF02985081; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DOBROVOLSKAIA-ZAVASDKAIA N., 1928, ARCH BIOL, V38, P457; FRIEDMAN TB, 1995, NAT GENET, V9, P86, DOI 10.1038/ng0195-86; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Hogan B, 1994, MANIPULATING MOUSE E; KOHMAN D, 1998, 21 MIDW RES M ASS RE; Liang Y, 1998, AM J HUM GENET, V62, P904, DOI 10.1086/301786; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; PORTER JA, 1993, J CELL BIOL, V122, P601, DOI 10.1083/jcb.122.3.601; PROBST, UNPUB; RAPHAEL Y, 1994, HEARING RES, V76, P173, DOI 10.1016/0378-5955(94)90098-1; RAPHAEL Y, 1991, CELL MOTIL CYTOSKEL, V18, P215, DOI 10.1002/cm.970180307; Self T, 1998, DEVELOPMENT, V125, P557; Snell GD, 1939, J HERED, V30, P447, DOI 10.1093/jhered/30.10.447; SOBIN A, 1982, ARCH OTO-RHINO-LARYN, V236, P1, DOI 10.1007/BF00464051; SOBIN A, 1981, ADV OTORHINOLARYNGOL, V25, P12; STEEL K, COMMUNICATION; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wakabayashi Y, 1997, BIOCHEM BIOPH RES CO, V234, P107, DOI 10.1006/bbrc.1997.6595; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WILSON REK, 1997, ANAL DNA, P398	30	323	338	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 29	1998	280	5368					1444	1447		10.1126/science.280.5368.1444	http://dx.doi.org/10.1126/science.280.5368.1444			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9603735				2022-12-24	WOS:000073883400058
J	Wang, AH; Liang, Y; Fridell, RA; Probst, FJ; Wilcox, ER; Touchman, JW; Morton, CC; Morell, RJ; Noben-Trauth, K; Camper, SA; Friedman, TB				Wang, AH; Liang, Y; Fridell, RA; Probst, FJ; Wilcox, ER; Touchman, JW; Morton, CC; Morell, RJ; Noben-Trauth, K; Camper, SA; Friedman, TB			Association of unconventional myosin MYO15 mutations with human nonsyndromic deafness DFNB3	SCIENCE			English	Article							GENE; MOUSE	DFNB3, a locus for nonsyndromic sensorineural recessive deafness, maps to a 3-centimorgan interval on human chromosome 17p11.2, a region that shows conserved synteny with mouse shaker-2. A human unconventional myosin gene, MYO15, was identified by combining functional and positional cloning approaches in searching for shaker-2 and DFNB3. MYO15 has at least 50 exons spanning 36 kilobases. Sequence analyses of these exons in affected individuals from three unrelated DFNB3 families revealed two missense mutations and one nonsense mutation that cosegregated with congenital recessive deafness.	NIDOCD, Genet Mol Lab, NIH, Rockville, MD 20850 USA; Michigan State Univ, Grad Program Genet, E Lansing, MI 48824 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; NIH, Intramural Sequencing Ctr, Rockville, MD 20850 USA; NIH, Natl Human Genome Res Inst, Bethesda, MD 20892 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Michigan State University; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Friedman, TB (corresponding author), NIDOCD, Genet Mol Lab, NIH, Rockville, MD 20850 USA.	tfriedman@pop.nidcd.nih.gov	Morell, Robert James/Q-2042-2019	Camper, Sally/0000-0001-8556-3379; Morell, Robert/0000-0003-1537-7356	NIDCD NIH HHS [Z01 DC 00035-01, R01 DC 03402, Z01 DC 00038-01] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003402] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; Baker JP, 1997, J MOL BIOL, V272, P523, DOI 10.1006/jmbi.1997.1232; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Chen K-S, 1996, MENTAL RETARD DEV DI, V2, P122; Chen ZY, 1996, GENOMICS, V36, P440, DOI 10.1006/geno.1996.0489; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Crozet F, 1997, GENOMICS, V40, P332, DOI 10.1006/geno.1996.4526; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FRIEDMAN TB, 1995, NAT GENET, V9, P86, DOI 10.1038/ng0195-86; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Hasson T, 1996, GENOMICS, V36, P431, DOI 10.1006/geno.1996.0488; Houdusse A, 1996, STRUCTURE, V4, P1475, DOI 10.1016/S0969-2126(96)00154-2; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Li XC, 1998, NAT GENET, V18, P215, DOI 10.1038/ng0398-215; Liang Y, 1998, AM J HUM GENET, V62, P904, DOI 10.1086/301786; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Maquat LE, 1996, AM J HUM GENET, V59, P279; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NANCE WE, 1975, OTOLARYNG CLIN N AM, V8, P19; PORTER JA, 1993, J CELL BIOL, V122, P601, DOI 10.1083/jcb.122.3.601; Probst FJ, 1998, SCIENCE, V280, P1444, DOI 10.1126/science.280.5368.1444; PUSTELL J, 1984, NUCLEIC ACIDS RES, V12, P643, DOI 10.1093/nar/12.1Part2.643; Sellers JR, 1996, J MUSCLE RES CELL M, V17, P7, DOI 10.1007/BF00140320; Titus MA, 1997, TRENDS CELL BIOL, V7, P119, DOI 10.1016/S0962-8924(97)01019-2; VANCAMP G, 1998, HEREDITARY HEARING L; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WILSON REK, 1997, ANAL DNA, P398	35	332	343	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 29	1998	280	5368					1447	1451		10.1126/science.280.5368.1447	http://dx.doi.org/10.1126/science.280.5368.1447			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9603736	Green Submitted			2022-12-24	WOS:000073883400059
J	Wheeler, GL; Jones, MA; Smirnoff, N				Wheeler, GL; Jones, MA; Smirnoff, N			The biosynthetic pathway of vitamin C in higher plants	NATURE			English	Article							ASCORBIC-ACID BIOSYNTHESIS; L-SORBOSONE; L-FUCOSE; DEHYDROGENASE; METABOLISM; GALACTOSE; MANNOSE; ENZYME; ROOTS; LEAF	Vitamin C (L-ascorbic acid) has important antioxidant and metabolic functions in both plants and animals, but humans, and a few other animal species, have lost the capacity to synthesize it(1). Plant-derived ascorbate is thus the major source of vitamin C in the human diet. Although the biosynthetic pathway of L-ascorbic acid in animals is well understood(2), the plant pathway has remained unknown(3)-one of the few primary plant metabolic pathways for which this is the case. L-ascorbate is abundant in plants (found at concentrations of 1-5 mM in leaves and 25 mM in chloroplasts(3,4)) and may have roles in photosynthesis and transmembrane electron transport(3-5). We found that D-mannose and I.-galactose are efficient precursors for ascorbate synthesis and are interconverted by GDP-D-mannose-3,5-epimerase. We have identified an enzyme in pea and Arabidopsis thaliana, L-galactose dehydrogenase, that catalyses oxidation of L-galactose to L-galactono-1,4-lactone. We propose an ascorbate biosynthesis pathway involving GDP-D-mannose, GDP-L-galactose, L-galactose and L-galactono-1,4-lactone, and have synthesized ascorbate from GDP-D-mannose by way of these intermediates in vitro. The definition of this biosynthetic pathway should allow engineering of plants for increased ascorbate production, thus increasing their nutritional value and stress tolerance.	Univ Exeter, Sch Biol Sci, Hatherly Labs, Exeter EX4 4PS, Devon, England	University of Exeter	Smirnoff, N (corresponding author), Univ Exeter, Sch Biol Sci, Hatherly Labs, Prince Wales Rd, Exeter EX4 4PS, Devon, England.	N.Smirnoff@exeter.ac.uk	Smirnoff, Nicholas/GZN-1978-2022; Wheeler, Glen L/E-5034-2011	Smirnoff, Nicholas/0000-0001-5630-5602; 				ANDREWS MA, 1989, CARBOHYD RES, V194, P1, DOI 10.1016/0008-6215(89)85001-3; BARBER GA, 1971, ARCH BIOCHEM BIOPHYS, V147, P619, DOI 10.1016/0003-9861(71)90420-6; BARBER GA, 1979, J BIOL CHEM, V254, P7600; BAYDOUN EAH, 1988, J PLANT PHYSIOL, V132, P484, DOI 10.1016/S0176-1617(88)80068-3; BURNS J. J., 1967, Metabolic Pathways, V1, P394; CHEN YT, 1953, BIOCHEM J, V55, P821, DOI 10.1042/bj0550821; Conklin PL, 1996, P NATL ACAD SCI USA, V93, P9970, DOI 10.1073/pnas.93.18.9970; Conklin PL, 1997, PLANT PHYSIOL, V115, P1277, DOI 10.1104/pp.115.3.1277; CONTER PF, 1984, CAN J MICROBIOL, V30, P753, DOI 10.1139/m84-115; Dawson R. M. C., 1991, DATA BIOCH RES, V3rd, P363; Feingold D. S., 1982, ENCY PLANT PHYSL A, V13A, P3; Foyer C. H., 1993, ANTIOXIDANTS HIGHER, P31; GHEBREGZABHER M, 1976, J CHROMATOGR, V127, P133, DOI 10.1016/S0021-9673(00)80168-5; HARRIS GC, 1986, PLANT PHYSIOL, V82, P1081, DOI 10.1104/pp.82.4.1081; HOREMANS N, 1994, PLANT PHYSIOL, V104, P1455, DOI 10.1104/pp.104.4.1455; Kim ST, 1996, BBA-PROTEIN STRUCT M, V1297, P1, DOI 10.1016/0167-4838(96)00077-5; LOEWUS FA, 1987, CRC CR REV PLANT SCI, V5, P101, DOI 10.1080/07352688709382235; LOEWUS FA, 1963, PHYTOCHEMISTRY, V2, P109, DOI 10.1016/S0031-9422(00)82971-4; LOEWUS MW, 1990, PLANT PHYSIOL, V94, P1492, DOI 10.1104/pp.94.3.1492; MAIER E, 1982, METHOD ENZYMOL, V89, P176; MAPSON LW, 1956, BIOCHEM J, V64, P13, DOI 10.1042/bj0640013; MAPSON LW, 1958, BIOCHEM J, V68, P395, DOI 10.1042/bj0680395; NISHIKIMI M, 1994, J BIOL CHEM, V269, P13685; OBA K, 1995, J BIOCHEM, V117, P120, DOI 10.1093/oxfordjournals.jbchem.a124697; ROBERTS RM, 1973, PHYTOCHEMISTRY, V12, P2679, DOI 10.1016/0031-9422(73)85079-4; ROBERTS RM, 1971, ARCH BIOCHEM BIOPHYS, V145, P685, DOI 10.1016/S0003-9861(71)80029-2; SAITO K, 1990, PLANT PHYSIOL, V94, P1496, DOI 10.1104/pp.94.3.1496; SCHACHTER H, 1969, J BIOL CHEM, V244, P4785; Smirnoff N, 1996, ANN BOT-LONDON, V78, P661, DOI 10.1006/anbo.1996.0175	29	772	918	8	168	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 28	1998	393	6683					365	369		10.1038/30728	http://dx.doi.org/10.1038/30728			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620799				2022-12-24	WOS:000073883600054
J	Goyder, EC; McNally, PG; Drucquer, M; Spiers, N; Botha, JL				Goyder, EC; McNally, PG; Drucquer, M; Spiers, N; Botha, JL			Shifting of care for diabetes from secondary to primary care, 1990-5: review of general practices	BRITISH MEDICAL JOURNAL			English	Review									Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England; Leicester Royal Infirm NHS Trust, Dept Endocrinol & Diabet, Leicester LE1 5WW, Leics, England; S Wigston Hlth Ctr, Leicester LE8 2SE, Leics, England	University of Leicester	Goyder, EC (corresponding author), Univ Sydney, Dept Publ Hlth & Community Med, Edward Ford Bldg A27, Sydney, NSW 2006, Australia.		Goyder, Elizabeth E/A-2146-2010	Goyder, Elizabeth E/0000-0003-3691-1888				Alexander WD, 1997, LANCET, V349, P578, DOI 10.1016/S0140-6736(97)80134-1; Krans H., 1992, DIABETES CARE RES EU; LEESE B, 1995, BRIT MED J, V311, P546, DOI 10.1136/bmj.311.7004.546; LOWY A, 1993, BRIT MED J, V307, P413, DOI 10.1136/bmj.307.6901.413; Marks L., 1996, COUNTING COST REAL I	5	50	51	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1998	316	7143					1505	1506		10.1136/bmj.316.7143.1505	http://dx.doi.org/10.1136/bmj.316.7143.1505			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP020	9582142	Green Published			2022-12-24	WOS:000073707700032
J	Colasanti, J; Yuan, Z; Sundaresan, V				Colasanti, J; Yuan, Z; Sundaresan, V			The indeterminate gene encodes a zinc finger protein and regulates a leaf-generated signal required for the transition to flowering in maize	CELL			English	Article							FLORAL MERISTEM IDENTITY; SHOOT APICAL MERISTEM; NICOTIANA-TABACUM; ARABIDOPSIS; TIME; MORPHOGENESIS; PATTERNS; HOMOLOG; CLONING; PLANTS	Flowering in plants is a consequence of the transition of the shoot apex from vegetative to reproductive growth in response to environmental and internal signals. The indeterminate 1 gene (id1) controls the transition to flowering in maize. We show by cloning the id1 gene that it encodes a protein with zinc finger motifs, suggesting that the id1 gene product functions as a transcriptional regulator of the floral transition, id1 mRNA expression studies and analyses of transposon-induced chimeric plants indicate that id1 acts non-cell-autonomously to regulate the production of a transmissible signal in the leaf that elicits the transformation of the shoot apex to reproductive development. These results provide molecular and genetic data consistent with the florigen hypothesis derived from classical plant physiology studies.	Univ Calif Berkeley, USDA, Ctr Plant Gene Express, Albany, CA 94710 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Natl Univ Singapore, Inst Mol Agrobiol, Singapore 117604, Singapore	United States Department of Agriculture (USDA); University of California System; University of California Berkeley; Cold Spring Harbor Laboratory; National University of Singapore	Colasanti, J (corresponding author), Univ Calif Berkeley, USDA, Ctr Plant Gene Express, Albany, CA 94710 USA.			Sundaresan, Venkatesan/0000-0002-4670-0630				Aukerman MJ, 1996, SEMIN CELL DEV BIOL, V7, P427, DOI 10.1006/scdb.1996.0053; BATTEY NH, 1990, BOT REV, V56, P162, DOI 10.1007/BF02858534; BERNIER G, 1988, ANNU REV PLANT PHYS, V39, P175, DOI 10.1146/annurev.arplant.39.1.175; Blazquez MA, 1997, DEVELOPMENT, V124, P3835; Chen J., 1994, MAIZE HDB, P526, DOI [10.1007/978-1-4612-2694-9_85, DOI 10.1007/978-1-4612-2694-9_85]; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COLASANTI J, 1991, P NATL ACAD SCI USA, V88, P3377, DOI 10.1073/pnas.88.8.3377; COLASANTI J, 1992, MAIZE GENET COOP NEW, V66, P30; COUPLAND G, 1995, TRENDS GENET, V11, P393, DOI 10.1016/S0168-9525(00)89122-2; DAWE RK, 1990, DEV BIOL, V142, P233, DOI 10.1016/0012-1606(90)90167-H; FISHER JE, 1972, BOT GAZ, V133, P78, DOI 10.1086/336618; GALINAT WC, 1951, AM J BOT, V38, P38, DOI 10.2307/2437990; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; HAKE S, 1989, EMBO J, V8, P15, DOI 10.1002/j.1460-2075.1989.tb03343.x; Irish E, 1997, PLANT J, V11, P63, DOI 10.1046/j.1365-313X.1997.11010063.x; IRISH EE, 1991, DEVELOPMENT, V112, P891; IRISH EE, 1988, PLANTA, V175, P9, DOI 10.1007/BF00402876; JACKSON D, 1994, DEVELOPMENT, V120, P405; Jackson D., 1991, MOL PLANT PATHOLOGY, P163; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; KUHN C, 1995, MOL GEN GENET, V247, P759, DOI 10.1007/BF00290408; Lang A., 1965, ENCYCL PLANT PHYSIOL, VVolume XV/1, P1380; LEE I, 1994, PLANT CELL, V6, P75, DOI 10.1105/tpc.6.1.75; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; MARTIENSSEN RA, 1989, EMBO J, V8, P1633, DOI 10.1002/j.1460-2075.1989.tb03553.x; Martinez-Zapater JM, 1994, ARABIDOPSIS, P403; McClintock B., 1949, CARNEGIE I WASHINGTO, V48, P142; MCCLINTOCK B, 1955, CARNEGIE I WASH YB, V54, P242; MCDANIEL CN, 1988, PLANTA, V175, P13, DOI 10.1007/BF00402877; McDaniel CN, 1996, PLANT J, V9, P55, DOI 10.1046/j.1365-313X.1996.09010055.x; Okamuro JK, 1996, P NATL ACAD SCI USA, V93, P13831, DOI 10.1073/pnas.93.24.13831; ONEILL SD, 1992, PHOTOCHEM PHOTOBIOL, V56, P789, DOI 10.1111/j.1751-1097.1992.tb02235.x; Pouteau S, 1997, DEVELOPMENT, V124, P3343; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; RAIKHEL N, 1992, PLANT PHYSIOL, V100, P1627, DOI 10.1104/pp.100.4.1627; Sambrook JFE, 1989, MOL CLONING LAB MANU; Scott L, 1996, GENETICS, V142, P237; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; SINGER SR, 1986, DEV BIOL, V118, P587, DOI 10.1016/0012-1606(86)90028-X; SINGLETON WR, 1946, J HERED, V37, P61, DOI 10.1093/oxfordjournals.jhered.a105582; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; Weller JL, 1997, TRENDS PLANT SCI, V2, P412, DOI 10.1016/S1360-1385(97)85580-X	43	223	257	2	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1998	93	4					593	603		10.1016/S0092-8674(00)81188-5	http://dx.doi.org/10.1016/S0092-8674(00)81188-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604934	Bronze			2022-12-24	WOS:000073722200012
J	Fauman, EB; Cogswell, JP; Lovejoy, B; Rocque, WJ; Holmes, W; Montana, VG; Piwnica-Worms, H; Rink, MJ; Saper, MA				Fauman, EB; Cogswell, JP; Lovejoy, B; Rocque, WJ; Holmes, W; Montana, VG; Piwnica-Worms, H; Rink, MJ; Saper, MA			Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A	CELL			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; KINASE ACTIVATION; PHOSPHORYLATION; DEPHOSPHORYLATION; P34CDC2; TRANSITION; P34(CDC2); MECHANISM; RHODANESE; MITOSIS	Cdc25 phosphatases activate the cell division kinases throughout the cell cycle. The 2.3 Angstrom structure of the human Cdc25A catalytic domain reveals a small alpha/beta domain with a fold unlike previously described phosphatase structures but identical to rhodanese, a sulfur-transfer protein. Only the active-site loop, containing the Cys-(X)(5)-Arg motif, shows similarity to the tyrosine phosphatases. In some crystals, the catalytic Cys-430 forms a disulfide bond with the invariant Cys-384, suggesting that Cdc25 may be self-inhibited during oxidative stress. Asp-383, previously proposed to be the general acid, instead serves a structural role, forming a conserved buried salt-bridge. We propose that Glu-431 may act as a general acid. Structure-based alignments suggest that the noncatalytic domain of the MAP kinase phosphatases will share this topology, as will ACR2, a eukaryotic arsenical resistance protein.	Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Glaxo Wellcome Inc, Dept Funct Genet, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Struct Chem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Mol Sci, Res Triangle Pk, NC 27709 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, Howard Hughes Med Inst, St Louis, MO 63110 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Howard Hughes Medical Institute; Washington University (WUSTL)	Fauman, EB (corresponding author), Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA.		Fauman, Eric/AAC-8275-2020; Piwnica-Worms, Helen/C-5214-2012	Fauman, Eric/0000-0002-9739-0249	NIAID NIH HHS [AI34095] Funding Source: Medline; NIGMS NIH HHS [GM47017] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047017] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Bobrowicz P, 1997, YEAST, V13, P819, DOI 10.1002/(SICI)1097-0061(199707)13:9<819::AID-YEA142>3.0.CO;2-Y; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Collaborative Computational Project, 1994, ACTA CRYST D, V50, P760; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Eckstein JW, 1996, PROTEIN SCI, V5, P5; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Gladysheva T, 1996, J BIOL CHEM, V271, P33256, DOI 10.1074/jbc.271.52.33256; Gliubich F, 1996, J BIOL CHEM, V271, P21054, DOI 10.1074/jbc.271.35.21054; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; Ramponi G, 1997, BBA-PROTEIN STRUCT M, V1341, P137, DOI 10.1016/S0167-4838(97)00087-3; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Wysocki R, 1997, J BIOL CHEM, V272, P30061, DOI 10.1074/jbc.272.48.30061; Xu X, 1996, J BIOL CHEM, V271, P5118; Yamauchi A, 1997, BLOOD, V89, P4092, DOI 10.1182/blood.V89.11.4092; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	51	262	268	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					617	625		10.1016/S0092-8674(00)81190-3	http://dx.doi.org/10.1016/S0092-8674(00)81190-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604936	Bronze			2022-12-24	WOS:000073722200014
J	Fisk, GJ; Thummel, CS				Fisk, GJ; Thummel, CS			The DHR78 nuclear receptor is required for ecdysteroid signaling during the onset of Drosophila metamorphosis	CELL			English	Article							STEROID-HORMONE ECDYSONE; RETINOID-X-RECEPTOR; BROAD-COMPLEX; GENE-EXPRESSION; MANDUCA-SEXTA; MOLECULAR ANALYSIS; PUPAL DEVELOPMENT; TOBACCO HORNWORM; SALIVARY-GLANDS; INDUCIBLE GENE	Pulses of ecdysteroids direct Drosophila through its life cycle by activating stage- and tissue-specific genetic regulatory hierarchies. Here we show that an orphan nuclear receptor, DHR78, functions at the top of the ecdysteroid regulatory hierarchies. Null mutations in DHR78 lead to lethality during the third larval instar with defects in ecdysteroid-triggered developmental responses. Consistent with these phenotypes, DHR78 mutants fail to activate the mid-third instar regulatory hierarchy that prepares the animal for metamorphosis. DHR78 protein is bound to many ecdysteroid-regulated puff loci, suggesting that DHR78 directly regulates puff gene expression. In addition, ectopic expression of DHR78 has no effects on development, indicating that its activity is regulated posttranslationally. We propose that DHR78 is a ligand-activated receptor that plays a central role in directing the onset of Drosophila metamorphosis.	Univ Utah, Dept Human Genet, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Thummel, CS (corresponding author), Univ Utah, Dept Human Genet, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA.				NIGMS NIH HHS [5T32GM07464] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007464] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRES AJ, 1994, METHOD CELL BIOL, V44, P565, DOI 10.1016/S0091-679X(08)60932-2; ANDRES AJ, 1993, DEV BIOL, V160, P388, DOI 10.1006/dbio.1993.1315; ANDREW DJ, 1994, DROSOPHILA MELANOGAS, P354; Arias A.M., 1993, DEV DROSOPHILA, P609; Ashburner M, 1972, Results Probl Cell Differ, V4, P101; ASHBURNER M, 1974, DEV BIOL, V39, P141, DOI 10.1016/S0012-1606(74)80016-3; BELYAEVA ES, 1980, CHROMOSOMA, V81, P281, DOI 10.1007/BF00285954; Bender M, 1997, CELL, V91, P777, DOI 10.1016/S0092-8674(00)80466-3; BERREUR P, 1984, GEN COMP ENDOCR, V54, P76, DOI 10.1016/0016-6480(84)90201-6; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BOLLENBACHER WE, 1975, DEV BIOL, V44, P46, DOI 10.1016/0012-1606(75)90375-9; BOYD L, 1991, DEVELOPMENT, V112, P981; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CALVEZ B, 1976, FEBS LETT, V71, P57, DOI 10.1016/0014-5793(76)80898-8; Champlin DT, 1998, DEVELOPMENT, V125, P269; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; CLEVER U, 1964, SCIENCE, V146, P794, DOI 10.1126/science.146.3645.794; Crossgrove K, 1996, DEV BIOL, V180, P745, DOI 10.1006/dbio.1996.0343; DAVIES MJ, 1995, CARDIOL ELDER, V3, P161; DIBELLO PR, 1991, GENETICS, V129, P385; DOMINICK OS, 1985, J EXP BIOL, V117, P45; FISK GJ, 1995, P NATL ACAD SCI USA, V92, P10604, DOI 10.1073/pnas.92.23.10604; FLETCHER JC, 1995, GENETICS, V141, P1025; FLETCHER JC, 1995, DEVELOPMENT, V121, P1455; FLETCHER JC, 1995, DEVELOPMENT, V121, P1411; Gilbert Lawrence I., 1996, P59; GUAY PS, 1991, GENETICS, V129, P169; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; HENRICH VC, 1994, DEV BIOL, V165, P38, DOI 10.1006/dbio.1994.1232; HIROMI Y, 1993, DEVELOPMENT, V118, P1123; Horner M., 1997, DROS INF SERV, V80, P35; IMAM F, 1996, THESIS STANFORD U ST; KARIM FD, 1992, EMBO J, V11, P4083, DOI 10.1002/j.1460-2075.1992.tb05501.x; KARIM FD, 1991, GENE DEV, V5, P1067, DOI 10.1101/gad.5.6.1067; KARIM FD, 1993, DEVELOPMENT, V118, P977; Karim FD, 1996, GENETICS, V143, P315; KARLSON P, 1984, BIOSYNTHESIS METABOL, P162; KISS I, 1988, GENETICS, V118, P247; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOELLE MR, 1992, P NATL ACAD SCI USA, V89, P6167, DOI 10.1073/pnas.89.13.6167; KOELLE MR, 1992, THESIS STANFORD U ST; KOOLMAN J, 1980, PROGR ECDYSONE RES, V7, P187; KOZLOVA T, 1998, IN PRESS GENETICS; Lam GT, 1997, DEVELOPMENT, V124, P1757; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MEYEROWITZ EM, 1987, TRENDS GENET, V3, P288, DOI 10.1016/0168-9525(87)90270-8; MOUGNEAU E, 1993, MOL CELL BIOL, V13, P184, DOI 10.1128/MCB.13.1.184; NAKANISHI Y, 1983, P NATL ACAD SCI-BIOL, V80, P2971, DOI 10.1073/pnas.80.10.2971; NOIROT C, 1982, INSECT ULTRASTRUCTUR, V1, P351; OHTAKI T, 1986, J INSECT PHYSIOL, V32, P635, DOI 10.1016/0022-1910(86)90093-4; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; ORO AE, 1992, DEVELOPMENT, V115, P449; RESTIFO LL, 1992, ROUX ARCH DEV BIOL, V201, P221, DOI 10.1007/BF00188753; RICHARDS G, 1981, BIOL REV, V56, P501, DOI 10.1111/j.1469-185X.1981.tb00358.x; RICHARDS G, 1981, MOL CELL ENDOCRINOL, V21, P181, DOI 10.1016/0303-7207(81)90013-7; Riddiford L., 1993, DEV DROSOPHILA MELAN, V2, P899; RIDDIFORD LM, 1978, GEN COMP ENDOCR, V34, P438, DOI 10.1016/0016-6480(78)90284-8; RIDDIFORD LM, 1986, DEV BIOL, V118, P82, DOI 10.1016/0012-1606(86)90075-8; Russell SRH, 1996, GENETICS, V144, P159; RYERSE JS, 1978, J INSECT PHYSIOL, V24, P541, DOI 10.1016/0022-1910(78)90056-2; SCHWARTZ MB, 1984, DEV BIOL, V103, P85, DOI 10.1016/0012-1606(84)90010-1; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SLATIS HM, 1959, GENETICS, V44, P536; SLITER TJ, 1992, GENETICS, V130, P555; SMITH WA, 1982, J INSECT PHYSIOL, V28, P797, DOI 10.1016/0022-1910(82)90141-X; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; SUTHERLAND JD, 1995, P NATL ACAD SCI USA, V92, P7966, DOI 10.1073/pnas.92.17.7966; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; TALBOT WS, 1993, THESIS STANFORD U ST; Thummel CS, 1996, TRENDS GENET, V12, P306, DOI 10.1016/0168-9525(96)10032-9; Thummel CS, 1992, DROS INF SERV, V71, P150; Urness LD, 1995, EMBO J, V14, P6239, DOI 10.1002/j.1460-2075.1995.tb00314.x; VONKALM L, 1994, EMBO J, V13, P3505, DOI 10.1002/j.1460-2075.1994.tb06657.x; Wassarman P., 1997, ADV DEV BIO, P81; White KP, 1997, SCIENCE, V276, P114, DOI 10.1126/science.276.5309.114; WIGGLESWORTH VB, 1976, INSECT DEV, V8, P186; WOODARD CT, 1994, CELL, V79, P607, DOI 10.1016/0092-8674(94)90546-0; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; ZELHOF AC, 1995, MOL CELL BIOL, V15, P6736; ZELHOF AC, 1995, P NATL ACAD SCI USA, V92, P10477, DOI 10.1073/pnas.92.23.10477	86	49	49	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1998	93	4					543	555		10.1016/S0092-8674(00)81184-8	http://dx.doi.org/10.1016/S0092-8674(00)81184-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604930	Bronze			2022-12-24	WOS:000073722200008
J	Tynell, E; Andersson, S; Lithander, E; Arneborn, M; Blomberg, J; Hansson, HB; Krook, A; Nomberg, M; Ramstedt, K; Shanwell, A; Bjorkman, A				Tynell, E; Andersson, S; Lithander, E; Arneborn, M; Blomberg, J; Hansson, HB; Krook, A; Nomberg, M; Ramstedt, K; Shanwell, A; Bjorkman, A			Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA-LYMPHOMA VIRUS; HTLV-I; TRANSMISSION; TRANSFUSION; ANTIBODIES; RECIPIENTS; PREVALENCE; JAPAN	Objective: To analyse the cost effectiveness of a national programme to screen blood donors for infection with the human T cell leukaemia/lymphoma virus. Design: Three models for calculating the costs and benefits of screening were developed. The first model analysed the cost of continuously testing all donations; the second analysed the cost of initially testing nerv blood dollars and then retesting them after five years; the third analysed the cost of testing donors only at the time of their first donation, Patients who had received blood components from donors confirmed to be infected with the virus were offered testing. Setting: Sweden. Main outcome measures: Prevalence of infection with the virus among blood donors, the risk of transmission of the virus, screening costs, and the outcome of infection. Results: 648 497 donations were tested for the virus; 1625 samples tested positive by enzyme linked immunosorbent assay, 6 were confirmed positive by western blotting. The prevalence of infection with the virus was 2/100 000 donors. 35 patients who had received blood infected with the virus were tested; 3 were positive. The cost of testing every donation was calculated to be $3.02m (pound 1.88m); this is 18 times higher than the cost of testing new donors only, and only 1 additional positive donor would be discovered in 7 years. Regardless of the model used, screening was estimated to prevent only 1 death every 200 years at a minimum cost of $36m (pound 22.5m). Conclusion: Based on these estimates the Swedish National Board of Health and Welfare decided that only new blood donors would be screened for infection with the virus.	Danderyd Univ Hosp, Karolinska Inst, Div Infect Dis, Danderyd, Sweden; Swedish Inst Infect Dis, Stockholm, Sweden; Karolinska Inst, Stockholm, Sweden; Natl Board Hlth & Welf, Stockholm, Sweden; Univ Lund, Dept Med Microbiol, Sect Virol, Lund, Sweden; Univ Hosp MAS, Reg Ctr Communicable Dis Control, Malmo, Sweden; Huddinge Univ Hosp, Karolinska Inst, Div Infect Dis, S-14186 Huddinge, Sweden; South Hosp, Div Transfus Med, Stockholm, Sweden	Danderyds Hospital; Karolinska Institutet; Swedish Institute for Infectious Disease Control; Karolinska Institutet; National Board of Health & Welfare; Lund University; Lund University; Skane University Hospital; Karolinska Institutet	Tynell, E (corresponding author), Danderyd Univ Hosp, Karolinska Inst, Div Infect Dis, Danderyd, Sweden.	elsa.tynell@inf.ds.sll.se	Krook, Anna/K-1192-2015	Krook, Anna/0000-0002-0891-0258; Blomberg, Jonas/0000-0001-6492-2491				ANDERSSON S, 1994, 10 INT C AIDS STD YO; BOHNCHRISTANSEN C, 1995, J ACQ IMMUN DEF SYND, V10, P251; BRENNAN M, 1993, BRIT MED J, V307, P1235, DOI 10.1136/bmj.307.6914.1235; COUROUCE AM, 1993, AIDS, V7, P841, DOI 10.1097/00002030-199306000-00013; DALGLEISH AG, 1993, BRIT MED J, V307, P1224, DOI 10.1136/bmj.307.6914.1224; DEFER C, 1995, TRANSFUSION, V35, P506; DONEGAN E, 1994, TRANSFUSION, V34, P478, DOI 10.1046/j.1537-2995.1994.34694295061.x; Goubau P, 1996, J ACQ IMMUN DEF SYND, V13, P68; IWATA K, 1994, JPN J CANCER RES, V85, P231, DOI 10.1111/j.1349-7006.1994.tb02087.x; KAGESON P, 1993, GETTING PRICES RIGHT, P114; KAJIYAMA W, 1986, J INFECT DIS, V154, P851, DOI 10.1093/infdis/154.5.851; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KAMIHIRA S, 1987, VOX SANG, V52, P43, DOI 10.1111/j.1423-0410.1987.tb02987.x; Krook A, 1997, J ACQ IMMUN DEF SYND, V15, P381, DOI 10.1097/00042560-199708150-00009; KWOK S, 1990, TRANSFUSION, V30, P491, DOI 10.1046/j.1537-2995.1990.30690333477.x; LEE HH, 1991, LANCET, V337, P1435, DOI 10.1016/0140-6736(91)93126-T; MURPHY E, 1990, HUMAN RETROVIROLOGY, P290; Nyambi Phillipe N., 1995, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, V10, P258; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; OSAME M, 1987, ANN NEUROL, V21, P117, DOI 10.1002/ana.410210203; PILLONEL J, 1995, J ACQ IMMUN DEF SYND, V10, P251; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SULLIVAN MT, 1991, ARCH INTERN MED, V151, P2043, DOI 10.1001/archinte.151.10.2043; Tajima K., 1995, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, V10, P285; YAMAGUCHI K, 1994, LANCET, V343, P213, DOI 10.1016/S0140-6736(94)90994-6; ZAAIJER HL, 1994, TRANSFUSION, V34, P1; 1988, MMWR MORB MORTAL WKL, V37, P736; 1966, ECONOMIST       0316, P29; 1992, WHO WKLY EPIDEMIOLOG, V29, P213	29	31	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1998	316	7142					1417	1422		10.1136/bmj.316.7142.1417	http://dx.doi.org/10.1136/bmj.316.7142.1417			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN495	9572750	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000073651600025
J	Pier, GB; Grout, M; Zaidi, T; Meluleni, G; Mueschenborn, SS; Banting, G; Ratcliff, R; Evans, MJ; Colledge, WH				Pier, GB; Grout, M; Zaidi, T; Meluleni, G; Mueschenborn, SS; Banting, G; Ratcliff, R; Evans, MJ; Colledge, WH			Salmonella typhi uses CFTR to enter intestinal epithelial cells	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; FIBROSIS MOUSE MODEL; GENE; INVASION; MURINE	Homozygous mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) cause cystic fibrosis (CF). In the heterozygous state, increased resistance to infectious diseases may maintain mutant CFTR alleles at high levels in selected populations'. Here we investigate whether typhoid fever could be one such disease. The disease is initiated when Salmonella typhi enters gastrointestinal epithelial cells for submucosal translocation(2). We found that S, typhi but not the related murine pathogen S. typhimurium, uses CFTR for entry into epithelial cells. Cells expressing wild-type CFTR internalized more S. typhi than isogenic cells expressing the most common CFTR mutation, a phenylalanine deleted at residue 508 (Delta 508). Monoclonal antibodies and synthetic peptides containing a sequence corresponding to the first predicted extracellular domain of CFTR inhibited uptake of S. typhi. Heterozygous Delta F508 Cftr mice translocated 86% fewer S. typhi into the gastrointestinal submucosa than wild-type Cftr mice; no translocation occurred in Delta F508 Cftr homozygous mice. The Cftr genotype had no effect on the translocation of S. typhimurium. Immunoelectron microscopy revealed that more CFTR bound to S. typhi in the submucosa of Cftr wild-type mice than in Delta F508 heterozygous mice. We conclude that diminished levels of CFTR in heterozygotes may decrease susceptibility to typhoid fever.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; Univ Bristol, Mol Recognit Ctr, Dept Biochem & Biotechnol & Biol Sci Res Council, Bristol BS8 1TD, Avon, England; Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England; Univ Cambridge, Wellcome CRC Inst Canc & Dev Biol, Cambridge CB2 1QR, England; Univ Cambridge, Dept Genet, Cambridge CB2 1QR, England	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Bristol; University of Cambridge; University of Cambridge; University of Cambridge	Pier, GB (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA.	gpier@channing.harvard.edu	Colledge, William/X-4976-2019; Pier, Gerald/AAO-2692-2021	Colledge, William/0000-0002-9603-4429; Pier, Gerald/0000-0002-9112-2331; Banting, George/0000-0001-8249-1621	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALPUCHEARANDA CM, 1995, INFECT IMMUN, V63, P4456, DOI 10.1128/IAI.63.11.4456-4462.1995; Beatty WL, 1997, INFECT IMMUN, V65, P4395, DOI 10.1128/IAI.65.11.4395-4404.1997; BERTRANPETIT J, 1996, VARIATION HUMAN GENO, P97; CHENG SH, 1995, AM J PHYSIOL-LUNG C, V268, pL615, DOI 10.1152/ajplung.1995.268.4.L615; COLLEDGE WH, 1995, NAT GENET, V10, P445, DOI 10.1038/ng0895-445; CUTHBERT AW, 1995, J PHYSIOL-LONDON, V482, P449, DOI 10.1113/jphysiol.1995.sp020531; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FLEISZIG SMJ, 1995, INFECT IMMUN, V63, P4072, DOI 10.1128/IAI.63.10.4072-4077.1995; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; Ishibashi Y, 1996, MICROB PATHOGENESIS, V21, P435, DOI 10.1006/mpat.1996.0074; JONES BD, 1994, J EXP MED, V180, P15, DOI 10.1084/jem.180.1.15; Jones BD, 1996, ANNU REV IMMUNOL, V14, P533, DOI 10.1146/annurev.immunol.14.1.533; MILLS SD, 1994, MICROB PATHOGENESIS, V17, P409, DOI 10.1006/mpat.1994.1086; OLSEN JC, 1992, HUM GENE THER, V3, P253, DOI 10.1089/hum.1992.3.3-253; ORIORDAN CR, 1995, J BIOL CHEM, V270, P17033, DOI 10.1074/jbc.270.28.17033; PASCOPELLA L, 1995, INFECT IMMUN, V63, P4329, DOI 10.1128/IAI.63.11.4329-4335.1995; Pier GB, 1997, P NATL ACAD SCI USA, V94, P12088, DOI 10.1073/pnas.94.22.12088; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; POLLITZNER R, 1959, CHOLERA; ROMEO G, 1989, HUM GENET, V84, P1, DOI 10.1007/BF00210660; ROSNER B, 1990, FUNDAMENTALS BIOSTAT, P498; TSUI LC, 1995, AM J RESP CRIT CARE, V151, pS47, DOI 10.1164/ajrccm/151.3_Pt_2.S47; VANHEYNINGEN WE, 1983, CHOLERA AM SCI ENCOU, P1; WALKER J, 1995, J CELL SCI, V108, P2433	25	244	256	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1998	393	6680					79	82		10.1038/30006	http://dx.doi.org/10.1038/30006			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590693				2022-12-24	WOS:000073497500051
J	Marciniak, TA; Ellerbeck, EF; Radford, MJ; Kresowik, TF; Gold, JA; Krumholz, HM; Kiefe, CI; Allman, RM; Vogel, RA; Jencks, SF				Marciniak, TA; Ellerbeck, EF; Radford, MJ; Kresowik, TF; Gold, JA; Krumholz, HM; Kiefe, CI; Allman, RM; Vogel, RA; Jencks, SF			Improving the quality of care for Medicare patients with acute myocardial infarction - Results from the Cooperative Cardiovascular Project	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUIDELINES; MANAGEMENT; ASSURANCE	Context.-Medicare has a legislative mandate for quality assurance, but the effectiveness of its population-based quality improvement programs has been difficult to establish. Objective.-To improve the quality of care for Medicare patients with acute myocardial infarction. Design.-Quality improvement project with baseline measurement, feedback, remeasurement, and comparison samples. Setting.-All acute care hospitals in the United States. Patients.-Preintervention and postintervention samples included all Medicare patients in Alabama, Connecticut, Iowa, and Wisconsin discharged with principal diagnoses of acute myocardial infarctions during 2 periods, June 1992 through December 1992 and August 1995 through November 1995, Indicator comparisons were made with a random sample of Medicare patients in the rest of the nation discharged with acute myocardial infarctions from August 1995 through November 1995, Mortality comparisons involved all Medicare patients nationwide with inpatient claims for acute myocardial infarctions during 2 periods, June 1992 through May 1993 and August 1995 through July 1996. Intervention.-Data feedback by peer review organizations. Main Outcome Measures.-Quality indicators derived from clinical practice guidelines, length of stay, and mortality. Results.-Performance on all quality indicators improved significantly in the 4 pilot states. Administration of aspirin during hospitalization in patients without contraindications improved from 84% to 90% (P<.001), and prescription of beta-blockers at discharge improved from 47% to 68% (P<.001), Mortality at 30 days decreased from 18.9% to 17.1% (P=.005) and at 1 year from 32.3% to 29.6% (P<.001). These improvements in quality occurred during a period when median length of stay decreased from 8 days to 6 days. Performance on all quality indicators except reperfusion was better in the pilot states than in the rest of the nation in 1995, and the differences were statistically significant for aspirin use at discharge (P<.001), beta-blocker use (P<.001), and smoking cessation counseling (P=.02), Postinfarction mortality was not significantly different between the pilot states and the rest of the nation during the baseline period, although it was slightly but significantly better in the pilot states during the follow-up period (absolute mortality difference at 1 year, 0.9%, P=.004). Conclusions.-The quality of care for Medicare patients with acute myocardial infarction has improved in the Cooperative Cardiovascular Project pilot states. Performance on the defined quality indicators appeared to be better in the pilot states than in the rest of the nation in 1995 and was associated with reduced mortality.	US Hlth Care Financing Adm, Baltimore, MD 21244 USA; Iowa Fdn Med Care, Des Moines, IA USA; Univ Kansas, Med Ctr, Kansas City, KS 66103 USA; Connecticut Peer Review Org, Middletown, CT USA; Univ Connecticut, Div Cardiol, Farmington, CT USA; Univ Iowa, Dept Surg, Iowa City, IA 52242 USA; MetaStar Inc, Madison, WI USA; Med Coll Wisconsin, Dept Prevent Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Hlth Policy Inst, Milwaukee, WI 53226 USA; Yale Univ, Sch Med, Cardiovasc Sect, New Haven, CT USA; Alabama Qual Assurance Fdn, Birmingham, AL USA; Dept Vet Affairs, Birmingham, AL USA; Univ Alabama, Div Prevent Med, Birmingham, AL USA; Univ Alabama, Ctr Aging, Birmingham, AL USA; Univ Maryland, Dept Cardiol, Baltimore, MD 21201 USA	University of Kansas; University of Kansas Medical Center; University of Connecticut; University of Iowa; Medical College of Wisconsin; Medical College of Wisconsin; Yale University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University System of Maryland; University of Maryland Baltimore	Marciniak, TA (corresponding author), US Hlth Care Financing Adm, 7500 Secur Blvd,Bldg S2-11-07, Baltimore, MD 21244 USA.	tmarciniak@hcfa.gov	Ellerbeck, Edward/I-8438-2014; Allman, Richard M/D-5964-2011; Allman, Richard M./O-1693-2019; , Harlan/AAI-2875-2020	Ellerbeck, Edward/0000-0002-7774-2729; Allman, Richard M./0000-0002-1850-6515; Radford, Martha/0000-0001-7503-9557; Kresowik, Timothy/0000-0003-4163-1573				Angell M, 1996, NEW ENGL J MED, V335, P883, DOI 10.1056/NEJM199609193351209; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Fleiss JL., 1981, STAT METHODS RATES P, V2, P22; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; Ghali WA, 1997, JAMA-J AM MED ASSOC, V277, P379, DOI 10.1001/jama.277.5.379; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; Kerr EA, 1996, JAMA-J AM MED ASSOC, V276, P1236, DOI 10.1001/jama.276.15.1236; LAMBERTHUBER DA, 1994, CLIN PERFORMANCE QUA, V2, P219; Meehan TP, 1996, JOINT COMM J QUAL IM, V22, P751, DOI 10.1016/S1070-3241(16)30280-2; National Heart Attack Alert Program Coordinating Committee, 1993, EM DEP RAP ID TREATM; Normand SLT, 1996, JAMA-J AM MED ASSOC, V275, P1322, DOI 10.1001/jama.275.17.1322; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; *SAS I INC, 1996, SAS COMP SOFTW REL 6; *TEX STAT CORP, 1995, STAT STAT SOFTW REL	16	412	412	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1998	279	17					1351	1357		10.1001/jama.279.17.1351	http://dx.doi.org/10.1001/jama.279.17.1351			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK758	9582042				2022-12-24	WOS:000073359800026
J	Nightingale, SL				Nightingale, SL			Advisory on medical telemetry system interference problem	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1998	279	17					1339	1339		10.1001/jama.279.17.1339	http://dx.doi.org/10.1001/jama.279.17.1339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK758	9582030				2022-12-24	WOS:000073359800007
J	Stams, T; Niranjanakumari, S; Fierke, CA; Christianson, DW				Stams, T; Niranjanakumari, S; Fierke, CA; Christianson, DW			Ribonuclease P protein structure: Evolutionary origins in the translational apparatus	SCIENCE			English	Article							GEL RETARDATION ANALYSIS; ELONGATION-FACTOR-G; COLI RNASE-P; 4.5 S-RNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; M1 RNA; MAGNESIUM-IONS; CATALYTIC RNA; NUCLEOTIDE-SEQUENCE	The crystal structure of Bacillus subtilis ribonuclease P protein is reported at 2.6 angstroms resolution. This protein binds to ribonuclease P RNA to form a ribonucleoprotein holoenzyme with optimal catalytic activity. Mutagenesis and biochemical data indicate that an unusual left-handed beta alpha beta crossover connection and a large central cleft in the protein form conserved RNA binding sites; a metal binding loop may comprise a third RNA binding site. The unusual topology is partly shared with ribosomal protein S5 and the ribosomal translocase elongation factor G, which suggests evolution from a common RNA binding ancestor in the primordial translational apparatus.	Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	University of Pennsylvania; Duke University	Christianson, DW (corresponding author), Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA.	chris@xtal.chem.upenn.edu	Stams, Travis/R-5730-2019		NIGMS NIH HHS [GM55387] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAER MF, 1989, J BACTERIOL, V171, P6862, DOI 10.1128/jb.171.12.6862-6866.1989; Beebe JA, 1996, BIOCHEMISTRY-US, V35, P10493, DOI 10.1021/bi960870m; BOTHWELL ALM, 1976, J BIOL CHEM, V251, P7709; Brown JW, 1998, NUCLEIC ACIDS RES, V26, P351, DOI 10.1093/nar/26.1.351; BROWN S, 1989, J MOL BIOL, V209, P79, DOI 10.1016/0022-2836(89)90171-X; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Czworkowski J, 1997, BIOCHEMISTRY-US, V36, P10327, DOI 10.1021/bi970610k; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; GARDINER KJ, 1985, J BIOL CHEM, V260, P5415; Gopalan V, 1997, J MOL BIOL, V267, P818, DOI 10.1006/jmbi.1997.0906; GUERRIERTAKADA C, 1984, SCIENCE, V223, P285, DOI 10.1126/science.6199841; GUERRIERTAKADA C, 1986, BIOCHEMISTRY-US, V25, P1509, DOI 10.1021/bi00355a006; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HANSEN FG, 1985, GENE, V38, P85, DOI 10.1016/0378-1119(85)90206-9; HARDT WD, 1993, NUCLEIC ACIDS RES, V21, P3521, DOI 10.1093/nar/21.15.3521; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIRSEBOM LA, 1995, MOL MICROBIOL, V17, P411, DOI 10.1111/j.1365-2958.1995.mmi_17030411.x; KIRSEBOM LA, 1989, J MOL BIOL, V207, P837, DOI 10.1016/0022-2836(89)90250-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurz JC, 1998, BIOCHEMISTRY-US, V37, P2393, DOI 10.1021/bi972530m; Loria A, 1997, BIOCHEMISTRY-US, V36, P6317, DOI 10.1021/bi970115o; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURZIN AG, 1995, NAT STRUCT BIOL, V2, P25, DOI 10.1038/nsb0195-25; NIRANJANAKUMARI S, UNPUB; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; OTWINOWSKI Z, 1994, ACTA CRYSTALLOGR D, V50, P760; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PACE NR, 1995, J BACTERIOL, V177, P1919, DOI 10.1128/jb.177.8.1919-1928.1995; PAN T, 1995, BIOCHEMISTRY-US, V34, P902, DOI 10.1021/bi00003a024; PECKMILLER KA, 1991, J MOL BIOL, V221, P1; PERREAULT JP, 1992, J MOL BIOL, V226, P399, DOI 10.1016/0022-2836(92)90955-J; PERREAULT JP, 1993, J MOL BIOL, V230, P750, DOI 10.1006/jmbi.1993.1197; RAMAKRISHNAN V, 1992, NATURE, V358, P768, DOI 10.1038/358768a0; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P341; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SURRATT CK, 1990, J BIOL CHEM, V265, P22513; SVARD SG, 1993, NUCLEIC ACIDS RES, V21, P427, DOI 10.1093/nar/21.3.427; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1399, DOI 10.1021/bi00172a016; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1406, DOI 10.1021/bi00172a017; TALLSJO A, 1993, NUCLEIC ACIDS RES, V21, P51, DOI 10.1093/nar/21.1.51; Westhof E, 1996, J MOL BIOL, V258, P600, DOI 10.1006/jmbi.1996.0272; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	52	137	142	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1998	280	5364					752	755		10.1126/science.280.5364.752	http://dx.doi.org/10.1126/science.280.5364.752			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563955				2022-12-24	WOS:000073415600053
J	Garcia-Cardena, G; Fan, R; Shah, V; Sorrentino, R; Cirino, G; Papapetropoulos, A; Sessa, WC				Garcia-Cardena, G; Fan, R; Shah, V; Sorrentino, R; Cirino, G; Papapetropoulos, A; Sessa, WC			Dynamic activation of endothelial nitric oxide synthase by Hsp90	NATURE			English	Article							RECEPTOR TYROSINE KINASE; PALMITOYLATION; DROSOPHILA; SEVENLESS; PATHWAYS; CELLS	Heat-shock protein 90 (Hsp90) coordinates the trafficking and regulation of diverse signalling proteins, but its precise role in regulating specific cellular targets is not known(1,2). Here we show that Hsp90 associates with endothelial nitric oxide synthase (eNOS) and is rapidly recruited to the eNOS complex by agonists that stimulate production of nitric oxide, namely vascular endothelial growth factor, histamine and fluid shear stress. Moreover, the binding of Hsp90 to eNOS enhances the activation of eNOS. Inhibition of signalling through Hsp90 attenuates both agonist-stimulated production of nitric oxide and endothelium-dependent relaxation of isolated blood vessels. Our results indicate that Hsp90 facilitates signalling mediated by growth-factor, G-protein and mechanotransduction pathways that lead to the activation of eNOS. These observations indicate that in addition to its role as a molecular chaperone involved in protein folding and maturation, Hsp90 may also be recruited to cellular targets depending on the activation state of the cell.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Mol Cardiobiol Program, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Med, New Haven, CT 06536 USA; Univ Naples Federico II, Dipartimento Farmacol Sperimentale, I-80131 Naples, Italy	Yale University; Yale University; Yale University; University of Naples Federico II	Sessa, WC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.	william.sessa@yale.edu	Garcia-Cardena, Guillermo/Q-6649-2019; Sessa, William C/B-6844-2011; Andreas, Papapetropoulos/AAJ-3089-2020	Sessa, William C/0000-0001-5759-1938; Papapetropoulos, Andreas/0000-0002-4253-5930; Cirino, Giuseppe/0000-0003-3954-4083; SORRENTINO, RAFFAELLA/0000-0002-0284-5424				BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GIMBRONE MA, 1976, PROGR HEMOSTASIS THR, P1; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; MONCADA S, 1991, PHARMACOL REV, V43, P109; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; NAGAO T, 1992, AM J PHYSIOL, V263, pH1090, DOI 10.1152/ajpheart.1992.263.4.H1090; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SESSA WC, 1994, J VASC RES, V31, P131, DOI 10.1159/000159039; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; vanderStraten A, 1997, EMBO J, V16, P1961, DOI 10.1093/emboj/16.8.1961; VENEMA VJ, 1996, BIOCHEM BIOPH RES CO, V155, P801; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	30	834	859	3	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1998	392	6678					821	824		10.1038/33934	http://dx.doi.org/10.1038/33934			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9580552				2022-12-24	WOS:000073241200055
J	Stenager, EN; Madsen, C; Stenager, E; Boldsen, J				Stenager, EN; Madsen, C; Stenager, E; Boldsen, J			Suicide in patients with stroke: epidemiological study	BRITISH MEDICAL JOURNAL			English	Article									Odense Municipal Dept Social Med, DK-5000 Odense C, Denmark; Odense Univ Hosp, Dept Neurol, DK-5000 Odense, Denmark; Esbjerg Cent Sygehus, Dept Neurol, Esbjerg, Denmark; Odense Univ, Inst Community Hlth, DK-5000 Odense C, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark	Stenager, EN (corresponding author), Odense Municipal Dept Social Med, Vindegade 18, DK-5000 Odense C, Denmark.		Stenager, Egon/AAU-4463-2020; Stenager, Egon/O-2275-2017					ANDERSEN G, 1995, ACTA PSYCHIAT SCAND, V92, P193, DOI 10.1111/j.1600-0447.1995.tb09567.x; HOUSE A, 1991, BRIT J PSYCHIAT, V158, P83, DOI 10.1192/bjp.158.1.83; ROBINS M, 1981, STROKE S1, V12, P45; STENAGER EN, 1992, ARCH NEUROL-CHICAGO, V49, P1296, DOI 10.1001/archneur.1992.00530360098025; Stenager EN, 1997, DIS PAIN SUICIDAL BE	5	84	85	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1206	1206		10.1136/bmj.316.7139.1206	http://dx.doi.org/10.1136/bmj.316.7139.1206			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9583928	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000073224100022
J	Wu, GQ; D'Agati, V; Cai, YQ; Markowitz, G; Park, JH; Reynolds, DM; Maeda, Y; Le, TC; Hou, H; Kucherlapati, R; Edelmann, W; Somlo, S				Wu, GQ; D'Agati, V; Cai, YQ; Markowitz, G; Park, JH; Reynolds, DM; Maeda, Y; Le, TC; Hou, H; Kucherlapati, R; Edelmann, W; Somlo, S			Somatic inactivation of Pkd2 results in polycystic kidney disease	CELL			English	Article							PROTEIN; GENE; CELLS; PATTERN; ENCODES; PRODUCT; ADULT; FETAL	Germline mutations in PKD2 cause autosomal dominant polycystic kidney disease. We have introduced a mutant exon 1 in tandem with the wild-type exon 1 at the mouse Pkd2 locus. This is an unstable allele that undergoes somatic inactivation by intragenic homologous recombination to produce a true null allele. Mice heterozygous and homozygous for this mutation, as well as Pkd(+/-) mice, develop polycystic kidney and liver lesions that are indistinguishable from the human phenotype. In all cases, renal cysts arise from renal tubular cells that lose the capacity to produce Pkd2 protein. Somatic loss of Pkd2 expression is both necessary and sufficient for renal cyst formation in ADPKD, suggesting that PKD2 occurs by a cellular recessive mechanism.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Columbia University	Somlo, S (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Kucherlapati, Raju/ABC-8807-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048383] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48383] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brasier JL, 1997, J CLIN INVEST, V99, P194, DOI 10.1172/JCI119147; BURN TC, 1995, HUM MOL GENET, V4, P575, DOI 10.1093/hmg/4.4.575; CALVET JP, 1993, KIDNEY INT, V43, P101, DOI 10.1038/ki.1993.17; Chen KS, 1997, NAT GENET, V17, P154, DOI 10.1038/ng1097-154; DAGATI V, 1992, J AM SOC NEPHROL, V3, P975; DAOUST MC, 1995, GENOMICS, V25, P733, DOI 10.1016/0888-7543(95)80020-M; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; EVAN AP, 1992, CYSTIC KIDNEY, P22; EVERSON GT, 1993, AM J KIDNEY DIS, V22, P520, DOI 10.1016/S0272-6386(12)80923-1; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; GABOW PA, 1997, DIS KIDNEY, P521; Geng L, 1996, J CLIN INVEST, V98, P2674, DOI 10.1172/JCI119090; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Griffin MD, 1996, P ASSOC AM PHYSICIAN, V108, P185; Harris PC, 1997, NEPHROL DIAL TRANSPL, V12, P1089, DOI 10.1093/ndt/12.6.1089; HASTY P, 1991, MOL CELL BIOL, V11, P4509, DOI 10.1128/MCB.11.9.4509; Hayashi T, 1997, GENOMICS, V44, P131, DOI 10.1006/geno.1997.4851; HOYER JR, 1979, KIDNEY INT, V16, P279, DOI 10.1038/ki.1979.130; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; IbraghimovBeskrovnaya O, 1997, P NATL ACAD SCI USA, V94, P6397, DOI 10.1073/pnas.94.12.6397; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; Laitinen L, 1987, J HISTOCHEM CYTOCHEM, V35, P55, DOI 10.1177/35.1.3794309; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Ong ACM, 1997, LANCET, V349, P1039, DOI 10.1016/S0140-6736(05)62286-6; Palsson R, 1996, MOL MED, V2, P702, DOI 10.1007/BF03401654; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; Peral B, 1996, AM J HUM GENET, V58, P86; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; Peters DJM, 1996, LAB INVEST, V75, P221; Qian F, 1997, AM J HUM GENET, V61, P1000, DOI 10.1086/301618; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; RAVINE D, 1992, LANCET, V340, P1330, DOI 10.1016/0140-6736(92)92503-8; Roelfsema JH, 1997, AM J HUM GENET, V61, P1044, DOI 10.1086/301600; SIROTKIN AM, 1995, P NATL ACAD SCI USA, V92, P6434, DOI 10.1073/pnas.92.14.6434; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; vanAdelsberg J, 1997, AM J PHYSIOL-RENAL, V272, pF602, DOI 10.1152/ajprenal.1997.272.5.F602; Veldhuisen B, 1997, AM J HUM GENET, V61, P547, DOI 10.1086/515497; Ward CJ, 1996, P NATL ACAD SCI USA, V93, P1524, DOI 10.1073/pnas.93.4.1524; WARD CJ, 1994, CELL, V77, P881; Wu GQ, 1997, GENOMICS, V45, P220, DOI 10.1006/geno.1997.4920	44	416	424	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					177	188		10.1016/S0092-8674(00)81570-6	http://dx.doi.org/10.1016/S0092-8674(00)81570-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568711	hybrid			2022-12-24	WOS:000073174000005
J	Ahmad, M; Jarillo, JA; Smirnova, O; Cashmore, AR				Ahmad, M; Jarillo, JA; Smirnova, O; Cashmore, AR			Cryptochrome blue-light photoreceptors of Arabidopsis implicated in phototropism	NATURE			English	Article							INHIBITED HYPOCOTYL ELONGATION; THALIANA; MUTATIONS; PROTEIN; MUTANTS; GENE; DEPENDENCE; ENCODES	Phototropism-bending towards the light-is one of the best known plant tropic responses(1,2) Despite being reported by Darwin and others(3,4) over a century ago to be specifically under the control of blue light, the photoreceptors mediating phototropism have remained unknown. We have characterized a blue-light photoreceptor from Arabidopsis named CRY1 for cryptochrome 1 (ref, 5); this photoreceptor is a flavoprotein that mediates numerous blue-light-dependent responses(6). In Arabidopsis, HY4 (the gene encoding CRY1) is a member of a small gene family that also encodes a related photoreceptor, CRY2 (refs 7, 8), which shares considerable functional overlap with CRY1 (ref, 9). Here we report that mutant plants lacking both the CRY1 and the CRY2 blue-light photoreceptors are deficient in the phototropic response. Transgenic Arabidopsis plants overexpressing CRY1 or CRY2 show enhanced phototropic curvature. We conclude that cryptochrome is one of the photoreceptors mediating phototropism in plants.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA	University of Pennsylvania	Ahmad, M (corresponding author), Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA.	mahmad@mail.sas.upenn.edu		Ahmad, Margaret/0000-0003-4524-5813; Jarillo, Jose Antonio/0000-0002-2963-7641				AHMAD M, 1995, PLANT J, V8, P653, DOI 10.1046/j.1365-313X.1995.08050653.x; Ahmad M, 1998, PLANT CELL, V10, P197, DOI 10.1105/tpc.10.2.197; Ahmad M, 1997, PLANT J, V11, P421, DOI 10.1046/j.1365-313X.1997.11030421.x; Ahmad M, 1996, PLANT MOL BIOL, V30, P851, DOI 10.1007/BF00020798; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Bagnall DJ, 1996, PLANTA, V200, P278, DOI 10.1007/BF00208319; DARWIN C, 1981, POWER MOVEMENT PLANT; Hoffman PD, 1996, MOL GEN GENET, V253, P259, DOI 10.1007/s004380050321; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; IINO M, 1990, PLANT CELL ENVIRON, V13, P633, DOI 10.1111/j.1365-3040.1990.tb01080.x; Janoudi AK, 1997, PHYSIOL PLANTARUM, V101, P278, DOI 10.1034/j.1399-3054.1997.1010204.x; Janoudi AK, 1997, PLANT PHYSIOL, V113, P975, DOI 10.1104/pp.113.3.975; KHURANA J P, 1989, Planta (Heidelberg), V178, P400, DOI 10.1007/BF00391868; Koncz C., 1992, METHODS ARABIDOPSIS; KONJEVIC R, 1989, P NATL ACAD SCI USA, V86, P9876, DOI 10.1073/pnas.86.24.9876; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; Lin C., 1996, PLANT PHYSIOL, V110, P1047; Lin CT, 1996, PLANT J, V10, P893, DOI 10.1046/j.1365-313X.1996.10050893.x; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; LISCUM E, 1995, PLANT CELL, V7, P473, DOI 10.1105/tpc.7.4.473; Liscum E, 1996, PLANT PHYSIOL, V112, P291, DOI 10.1104/pp.112.1.291; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; POFF LK, 1994, ARABIDOPSIS, P639; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; SACHS J, 1864, BOT Z, P353; SHROPSHIRE W, 1958, PLANT PHYSIOL, V33, P360, DOI 10.1104/pp.33.5.360; SMALL GD, 1995, PLANT MOL BIOL, V28, P443, DOI 10.1007/BF00020393; YOUNG JC, 1992, PLANTA, V188, P106, DOI 10.1007/BF00198946	28	126	141	1	38	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 16	1998	392	6677					720	723		10.1038/33701	http://dx.doi.org/10.1038/33701			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565033				2022-12-24	WOS:000073129000060
J	Preiss, T; Hentze, MW				Preiss, T; Hentze, MW			Dual function of the messenger RNA cap structure in poly(A)-tail-promoted translation in yeast	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; INTERNAL INITIATION; POLY(A) TAIL	The messenger RNA 3' poly(A) tail critically affects the initiation and control of translation in eukaryotes(1-3). By analogy to elements involved in transcription initiation, the poly(A) tail has been described as a 'translational enhancer' that enhances the 'translational promoter' activity of the mRNA 5'-cap structure(3,4). Elongation or shortening of the poly(A) tail regulates translation during development(2). Here we show, using cell-free and in vivo translation analyses in SRccharomyces cerevisiae, that the poly(A) tail can act as an independent 'translational promoter: delivering ribosomes to uncapped mRNAs even if their 5' end is blocked. When mRNAs compete for ribosome binding, neither the cap structure nor the poly(A) tail alone is enough to drive efficient translation, but together they synergize and direct ribosome entry to the 5' end. The cap structure both promotes ribosome recruitment, together with the poly(A) tail, and tethers recruited ribosomes to the 5' end, Correct choice of translation initiation codons and the function of translational regulators acting on the 5' untranslated region are thus ensured by the functional interaction of the poly(A) tail with the cap structure.	European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Hentze, MW (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Preiss, Thomas/F-7355-2010; Hentze, Matthias W/V-3980-2017	Preiss, Thomas/0000-0001-6273-784X; Hentze, Matthias W/0000-0002-4023-7876				EVERETT JG, 1992, YEAST, V8, P1007, DOI 10.1002/yea.320081203; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; JOHANSSON HE, 1994, NUCLEIC ACIDS RES, V22, P4591, DOI 10.1093/nar/22.22.4591; MASSON DC, 1995, MOL CELL BIOL, V15, P2763; Muckenthaler M, 1997, RNA, V3, P983; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Proweller A, 1997, J BIOL CHEM, V272, P6004, DOI 10.1074/jbc.272.9.6004; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Wickens M., 1996, TRANSLATIONAL CONTRO, P411	19	215	248	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					516	520		10.1038/33192	http://dx.doi.org/10.1038/33192			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548259				2022-12-24	WOS:000072875200064
J	Romo, R; Hernandez, A; Zainos, A; Salinas, E				Romo, R; Hernandez, A; Zainos, A; Salinas, E			Somatosensory discrimination based on cortical microstimulation	NATURE			English	Article							PSYCHOPHYSICAL MEASUREMENTS; AREA MT; MONKEYS; PERFORMANCE; FREQUENCY; DIRECTION; NEURONS; EVENTS	The sensation of flutter is produced when mechanical vibrations in the range of 5-50 Hz are applied to the skin(1-3). A flutter stimulus activates neurons in the primary somatosensory cortex (S1) that somatotopically map to the site of stimulation(4,5). A subset of these neurons-those with quickly adapting properties, associated with Meissner's corpuscles-are strongly entrained by periodic flutter vibrations, firing with a probability that oscillates at the input frequency(1,6) Hence, quickly adapting neurons provide a dynamic representation of such flutter stimuli. However, are these neurons directly involved in the perception of flutter? Here we investigate this in monkeys trained to discriminate the difference in frequency between two flutter stimuli delivered sequentially on the fingertips(1,7). Microelectrodes were inserted into area 3b of S1 and the second stimulus was substituted with a train of injected current pulses. Animals reliably indicated whether the frequency of the second (electrical) signal was higher or lower than that of the first (mechanical) signal, even though both frequencies changed from trial to trial. Almost identical results were obtained with periodic and aperiodic stimuli of equal average frequencies. Thus, the quickly adapting neurons in area 3b activate the circuit leading to the perception of flutter. Furthermore, as far as can be psychophysically quantified during discrimination, the neural code underlying the sensation of flutter can be finely manipulated, to the extent that the behavioural responses produced by natural and artificial stimuli are indistinguishable.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Romo, R (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico.			Salinas, Emilio/0000-0001-7411-5693; zainos, antonio/0000-0001-6137-1794; romo, ranulfo/0000-0003-3529-3635				BAIR W, 1994, J NEUROSCI, V14, P2870; Hernandez A, 1997, J NEUROSCI, V17, P6391; LAMOTTE RH, 1979, J NEUROPHYSIOL, V42, P400, DOI 10.1152/jn.1979.42.2.400; LAMOTTE RH, 1975, J NEUROPHYSIOL, V38, P539, DOI 10.1152/jn.1975.38.3.539; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; MOUNTCASTLE VB, 1990, J NEUROSCI, V10, P3032; MOUNTCASTLE VB, 1991, J NEUROSCI METH, V36, P77, DOI 10.1016/0165-0270(91)90140-U; POWELL TPS, 1959, B JOHNS HOPKINS HOSP, V105, P133; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1071, DOI 10.1152/jn.1992.67.5.1071; SALZMAN CD, 1990, NATURE, V346, P174, DOI 10.1038/346174a0; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; SUR M, 1984, J NEUROPHYSIOL, V51, P724, DOI 10.1152/jn.1984.51.4.724; TALBOT WH, 1968, J NEUROPHYSIOL, V31, P301, DOI 10.1152/jn.1968.31.2.301; Vallbo Ake B., 1995, P237; Zainos A, 1997, EXP BRAIN RES, V115, P357, DOI 10.1007/PL00005704; [No title captured]; [No title captured]	17	336	348	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					387	390		10.1038/32891	http://dx.doi.org/10.1038/32891			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537321				2022-12-24	WOS:000072713600051
J	Rizzuto, CD; Wyatt, R; Hernandez-Ramos, N; Sun, Y; Kwong, PD; Hendrickson, WA; Sodroski, J				Rizzuto, CD; Wyatt, R; Hernandez-Ramos, N; Sun, Y; Kwong, PD; Hendrickson, WA; Sodroski, J			A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; AMINO-ACID CHANGES; ENVELOPE GLYCOPROTEIN; INFLUENZA HEMAGGLUTININ; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; VARIABLE LOOP; FUSION; INFECTION; PEPTIDE	The entry of primate immunodeficiency viruses into target cells depends on a sequential interaction of the gp120 envelope glycoprotein with the cellular receptors, CD4 and members of the chemokine receptor family. The gp120 third variable (V3) loop has been implicated in chemokine receptor binding, but the use of the CCR5 chemokine receptor by diverse primate immunodeficiency viruses suggests the involvement of an additional, conserved gp120 element. Through the use of gp120 mutants, a highly conserved gp120 structure was shown to be critical for CCR5 binding. This structure is located adjacent to the V3 loop and contains neutralization epitopes induced by CD4 binding. This conserved element may be a useful target for pharmacologic or prophylactic intervention in human immunodeficiency virus (HIV) infections.	Harvard Univ, Sch Med, Dept Pathol, Dana Farber Canc Inst,Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Columbia University; Howard Hughes Medical Institute; Harvard University; Harvard T.H. Chan School of Public Health	Sodroski, J (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Dana Farber Canc Inst,Dept Canc Immunol & AIDS, Boston, MA 02115 USA.				NIAID NIH HHS [AI 40895, AI 41851] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041851, R01AI040895] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARILLO A, 1996, J VIROL, V70, P1301; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; CONNOLLY ML, 1987, J MOL GRAPHICS, V5, P103; CORDONNIER A, 1989, NATURE, V340, P571, DOI 10.1038/340571a0; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FUJITA K, 1992, J VIROL, V66, P4445, DOI 10.1128/JVI.66.7.4445-4451.1992; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; JIANG SB, 1993, BIOCHEM BIOPH RES CO, V195, P533, DOI 10.1006/bbrc.1993.2078; KELLER R, 1993, J VIROL, V67, P6253, DOI 10.1128/JVI.67.10.6253-6258.1993; KIRCHHOFF F, 1995, VIROLOGY, V213, P179, DOI 10.1006/viro.1995.1558; KWONG P, IN PRESS NATURE; KWONG P, UNPUB; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; Martin KA, 1997, SCIENCE, V278, P1470, DOI 10.1126/science.278.5342.1470; MOORE JP, 1993, J VIROL, V67, P4785, DOI 10.1128/JVI.67.8.4785-4796.1993; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; MORRISON HG, 1993, VIROLOGY, V195, P167, DOI 10.1006/viro.1993.1357; MYERS G, 1996, HUMAN RETROVIRUSES A; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; POSNER MR, 1991, J IMMUNOL, V146, P4325; Rabut GEE, 1998, J VIROL, V72, P3464, DOI 10.1128/JVI.72.4.3464-3468.1998; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; RIZZUTO C, UNPUB; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Speck RF, 1997, J VIROL, V71, P7136, DOI 10.1128/JVI.71.9.7136-7139.1997; Sullivan N, 1998, J VIROL, V72, P4694, DOI 10.1128/JVI.72.6.4694-4703.1998; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; WYATT R, 1992, J VIROL, V66, P6997, DOI 10.1128/JVI.66.12.6997-7004.1992; WYATT R, IN PRESS NATURE	49	737	776	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1949	1953		10.1126/science.280.5371.1949	http://dx.doi.org/10.1126/science.280.5371.1949			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632396				2022-12-24	WOS:000074323800068
J	Pablos-Mendez, A; Raviglione, MC; Laszlo, A; Binkin, N; Rieder, HL; Bustreo, F; Cohn, DL; Lambregts-van Weezenbeek, CSB; Kim, SJ; Chaulet, P; Nunn, P				Pablos-Mendez, A; Raviglione, MC; Laszlo, A; Binkin, N; Rieder, HL; Bustreo, F; Cohn, DL; Lambregts-van Weezenbeek, CSB; Kim, SJ; Chaulet, P; Nunn, P		World Hlth Org Int Union TB Lung Dis Working G	Global surveillance for antituberculosis-drug resistance, 1994-1997	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEW-YORK-CITY; DIRECTLY OBSERVED THERAPY; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; HIV-INFECTION; OUTBREAK; TRANSMISSION; EPIDEMIOLOGY; EMERGENCE; MORTALITY	Background Drug-resistant tuberculosis threatens efforts to control the disease. This report describes the prevalence of resistance to four first-line drugs in 35 countries participating in the World Health Organization-lnternational Union against Tuberculosis and Lung Disease Global Project on Anti-Tuberculosis Drug Resistance Surveillance between 1994 and 1997. Methods The data are from cross-sectional surveys and surveillance reports. Participating countries followed guidelines to ensure the use of representative samples, accurate histories of treatment, standardized laboratory methods, and common definitions. A network of reference laboratories provided quality assurance. The median number of patients studied in each country or region was 555 (range, 59 to 14,344). Results Among patients with no prior treatment, a median of 9.9 percent of Mycobacterium tuberculosis strains were resistant to at least one drug (range, 2 to 41 percent); resistance to isoniazid (7.3 percent) or streptomycin (6.5 percent) was more common than resistance to rifampin (1.8 percent) or ethambutol (1.0 percent). The prevalence of primary multidrug resistance was 1.4 percent (range, 0 to 14.4 percent). Among patients with histories of treatment for one month or less, the prevalence of resistance to any of the four drugs was 36.0 percent (range, 5.3 to 100 percent), and the prevalence of multidrug resistance was 13 percent (range, 0 to 54 percent). The overall prevalences were 12.6 percent for single-drug resistance (range, 2.3 to 42.4 percent) and 2.2 percent for multidrug resistance (range, 0 to 22.1 percent). Particularly high prevalences of multidrug resistance were found in the former Soviet Union, Asia, the Dominican Republic, and Argentina. Conclusions Resistance to antituberculosis drugs was found in all 35 countries and regions surveyed, suggesting that it is a global problem. (C) 1998, Massachusetts Medical Society.	Columbia Univ Coll Phys & Surg, Div Gen Med, New York, NY 10032 USA; Columbia Univ, Div Epidemiol, New York, NY 10032 USA; WHO, Global TB Program, CH-1211 Geneva, Switzerland; Lab Ctr Dis Control, Ottawa, ON K1A 0L2, Canada; Int Union TB & Lung Dis, Paris, France; Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA; Denver Publ Hlth Dept, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Royal Netherlands TB Assoc, The Hague, Netherlands; Korean Inst TB, Seoul, South Korea	Columbia University; Columbia University; World Health Organization; Centers for Disease Control & Prevention - USA; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Pablos-Mendez, A (corresponding author), Columbia Univ Coll Phys & Surg, Div Gen Med, 622 W 168th St,PH-9E-105, New York, NY 10032 USA.			RAVIGLIONE, Mario/0000-0002-9331-2067				ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BARNES PF, 1987, AM REV RESPIR DIS, V136, P325, DOI 10.1164/ajrccm/136.2.325; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Boulahbal F, 1989, Bull Int Union Tuberc Lung Dis, V64, P23; BOUVET E, 1991, B EPIDEMIOLOGIQUE HE, V45, P196; CANETTI G, 1965, AM REV RESPIR DIS, V92, P687; CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21; Chaulet P, 1995, TUBERCLE LUNG DIS, V76, P487, DOI 10.1016/0962-8479(95)90523-5; CHAULET P, 1993, ANN I PASTEUR, V4, P181; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; Cohn DL, 1997, CLIN INFECT DIS, V24, pS121, DOI 10.1093/clinids/24.Supplement_1.S121; COHN ML, 1959, J CLIN INVEST, V38, P1349, DOI 10.1172/JCI103910; CONINX R, 1997, INT J TUBERC LUNG S1, V1, pS43; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; CROFTON J, 1948, BMJ-BRIT MED J, V2, P1009, DOI 10.1136/bmj.2.4588.1009; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; FRIEDEN TR, 1993, NEW ENGL J MED, V329, P148; Fujiwara PI, 1997, CLIN CHEST MED, V18, P135, DOI 10.1016/S0272-5231(05)70363-4; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; *HONG KONG GOV TUB, 1964, TUBERCLE, V45, P77; KENNEDY N, 1993, BRIT MED J, V306, P514, DOI 10.1136/bmj.306.6876.514; KIM SJ, 1992, TUBERCLE LUNG DIS, V73, P219, DOI 10.1016/0962-8479(92)90090-7; Kim SJ, 1997, INT J TUBERC LUNG D, V1, P302; KOCHI A, 1993, RES MICROBIOL, V144, P104, DOI 10.1016/0923-2508(93)90023-U; LAMBREGTSVANWEC.CS, 1997, EUR RESP MONOGR, V2, P298; Laszlo A, 1997, INT J TUBERC LUNG D, V1, P231; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; MONNO L, 1991, LANCET, V337, P852, DOI 10.1016/0140-6736(91)92559-K; Morcillo N, 1996, MEDICINA-BUENOS AIRE, V56, P45; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PablosMendez A, 1996, JAMA-J AM MED ASSOC, V276, P1223, DOI 10.1001/jama.276.15.1223; PABLOSMENDEZ A, 1997, PUBLICATION WHO GTB; *PHS COOP INV, 1964, AM RESP DIS, V89, P327; RAVIGLIONE MC, 1994, TUBERCLE LUNG DIS, V75, P400, DOI 10.1016/0962-8479(94)90113-9; Raviglione MC, 1997, LANCET, V350, P624, DOI 10.1016/S0140-6736(97)04146-9; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; SIDDIQI SH, 1989, BACTECT TB SYSTEM PR; SKINNER C, 1994, THORAX, V49, P1193, DOI 10.1136/thx.49.12.1193; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; STYBLO K, 1967, B WORLD HEALTH ORGAN, V37, P819; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; *WHO, 1961, WHO TECH REP SER, V210, P3; *WHO, 1994, WHO PUBL; WHO, 1997, OBESITY PREVENTING M; *WHO, 1983, MAN BACT TUB; Zhao FZ, 1996, LANCET, V347, P358, DOI 10.1016/S0140-6736(96)90537-1; 1991, MMWR MORB MORTAL WKL, V40, P585; 1996, MMWR MORB MORTAL WKL, V45, P330	56	684	719	0	55	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1998	338	23					1641	1649		10.1056/NEJM199806043382301	http://dx.doi.org/10.1056/NEJM199806043382301			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR451	9614254	Bronze			2022-12-24	WOS:000073978000001
J	Minkoff, H; O'Sullivan, MJ				Minkoff, H; O'Sullivan, MJ			The case for rapid HIV testing during labor	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; MOTHER-TO-INFANT; COCAINE USE; ZIDOVUDINE TREATMENT; TRANSMISSION; TYPE-1; INFECTION; CITY; WOMEN; ASSOCIATION		Maimonides Hosp, Dept Obstet & Gynecol, Brooklyn, NY 11219 USA; SUNY, Hlth Sci Ctr, Brooklyn, NY USA; Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA	Maimonides Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; SUNY Maritime College; University of Miami	Minkoff, H (corresponding author), Maimonides Hosp, Dept Obstet & Gynecol, 4800 10th Ave, Brooklyn, NY 11219 USA.	hminkoff@maimonidesmed.org						BIRKHEAD GS, 1998, 5 C RETR FEBR 1 5 19; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; Centers for Disease Control, 1994, MMWR, V43, P1; Centers for Disease Control and Prevention, 1995, MMWR-MORBID MORTAL W, V44, P1; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 1996, J INFECT DIS, V174, P1207, DOI 10.1093/infdis/174.6.1207; *CTR DIS CONTR, 1991, MMWR-MORBID MORTAL W, V40, P1; *CTR DIS CONTR PRE, 1996, MMWR-MORBID MORTAL W, V46, P468; DEROSSI A, 1993, AIDS, V7, P1528, DOI 10.1097/00002030-199311000-00020; DULIEGE AM, 1995, J PEDIATR-US, V126, P625, DOI 10.1016/S0022-3476(95)70365-9; DUNN DT, 1995, AIDS, V9, pF9; Fiscus Susan A., 1996, JAMA (Journal of the American Medical Association), V275, P1483, DOI 10.1001/jama.275.19.1483; GOEDERT JJ, 1989, LANCET, V2, P1351; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; Irwin K, 1996, ANN INTERN MED, V125, P471, DOI 10.7326/0003-4819-125-6-199609150-00007; Mayaux MJ, 1996, JAMA-J AM MED ASSOC, V275, P606, DOI 10.1001/jama.275.8.606; MAYERS MM, 1991, PEDIATRICS, V88, P1248; McCalla S, 1995, AM J PUBLIC HEALTH, V85, P1695, DOI 10.2105/AJPH.85.12.1695; MINKOFF HL, 1990, AM J OBSTET GYNECOL, V163, P521, DOI 10.1016/0002-9378(90)91188-I; NANDA D, 1990, NEW YORK STATE J MED, V90, P488; Rouzioux C, 1995, AM J EPIDEMIOL, V142, P1330, DOI 10.1093/oxfordjournals.aje.a117601; SIMMONDS RJ, 1996, P 11 INT C AIDS JUL; SPEILBERG F, 1996, ANN INTERN MED, V125, P509; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Stetler HC, 1997, AIDS, V11, P369, DOI 10.1097/00002030-199703110-00015	25	41	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1743	1744		10.1001/jama.279.21.1743	http://dx.doi.org/10.1001/jama.279.21.1743			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624029				2022-12-24	WOS:000073878700037
J	Takahashi, N; Nishida, H; Kato, H; Imanishi, K; Sakata, Y; Uchiyama, T				Takahashi, N; Nishida, H; Kato, H; Imanishi, K; Sakata, Y; Uchiyama, T			Exanthematous disease induced by toxic shock syndrome toxin 1 in the early neonatal period	LANCET			English	Article							HUMAN T-CELLS; STAPHYLOCOCCAL ENTEROTOXIN-B; CLASS-II MOLECULES; YERSINIA-PSEUDOTUBERCULOSIS; BACTERIAL SUPERANTIGEN; PATHOLOGIC FINDINGS; ACCESSORY CELLS; MICE; STIMULATION; ACTIVATION	Background We have seen a number of patients who developed systemic exanthema and thrombocytopenia in the first week of life. Although nearly 100% of the patients were cariers of meticillin-resistant Staphylococcus aureus (MRSA), no clear link between MRSA and this exanthematous disease has yet been made. Methods 20 neonates with exanthema and thrombocytopenia were selected for study. To see whether superantigenic exotoxins from MRSA are involved in the pathogensis of the exanthematous disease, we studied the production of these exotoxins by MRSA isolates from the neonates. We studied the expression of T-cell-receptor VP and CD45R0 in T cells taken from four of the neonates. We also analysed the DNA sequences of 16 cloned V beta 2-positive T-cell-receptor-chain genes taken from two of the neonates. Findings Although most of the patients recovered within 5 days of onset of the exanthematous disease without any active treatment, two preterm infants died in the recovery phase. All patients showed colonisation by MRSA. The MRSA produced toxic shock syndrome toxin-1 (TSST-1). The number of T cells positive for T-cell-receptor V beta 2, reactive to TSST-1, was increased in the four patients studied (p<0.0001), and these T cells expressed CD45R0 (p=0.0185). None of the V beta 2 clones had the same junctional sequences. Interpretation The polyclonal expansion of V beta 2-positive T cells in patients colonised by TSST-1-producing MRSA suggests that the pathogenic micro-organism of this neonatal exanthematous disease is S aureus, mainly MRSA, and that in its pathogenesis it activates T cells by TSST-1. Although the pathogenesis of both this exanthematous disease and toxic shock syndrome are fundamentally the same, a diagnosis of toxic shock syndrome cannot be made in this case, based on the clinical criteria for toxic shock syndrome. We propose neonatal toxic-shock-syndrome-like exanthematous disease (NTED) as the name for this disease.	Tokyo Womens Univ, Sch Med, Maternal & Perinatal Ctr, Shinjuku Ku, Tokyo 1628666, Japan; Tokyo Womens Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo 1628666, Japan		Takahashi, N (corresponding author), Tokyo Womens Univ, Sch Med, Maternal & Perinatal Ctr, Shinjuku Ku, 8-1 Kawadacho, Tokyo 1628666, Japan.							Abe J, 1997, J CLIN INVEST, V99, P1823, DOI 10.1172/JCI119349; ABE J, 1993, J IMMUNOL, V151, P4183; AKATSUKA H, 1994, CLIN EXP IMMUNOL, V96, P422; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; GUTTERMAN JU, 1980, ANN INTERN MED, V93, P399, DOI 10.7326/0003-4819-93-3-399; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KAWAMURA M, 1995, ACTA PAEDIATR, V84, P10, DOI 10.1111/j.1651-2227.1995.tb13475.x; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; Kuroda K, 1996, J IMMUNOL, V157, P1422; LARKIN SM, 1982, ANN INTERN MED, V96, P858, DOI 10.7326/0003-4819-96-6-858; LOTZE MT, 1985, J IMMUNOL, V135, P2865; MAKIMOTO A, 1996, J JPN PEDIAT SOC, V100, P609; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MATSUO Y, 1997, J JPN SOC PREMATURE, V9, P86; MIYOSHIAKIYAMA T, 1995, J IMMUNOL, V154, P5228; OKADA T, 1997, J JPN PEDIAT SOC, V101, P631; PARIS AL, 1982, ANN INTERN MED, V96, P852, DOI 10.7326/0003-4819-96-6-852; PARSONNET J, 1987, INFECT IMMUN, V55, P1070, DOI 10.1128/IAI.55.5.1070-1076.1987; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; SAKATA Y, 1997, JPN J OBSTET GYNECOL, V7, pS107; SCHATTNER A, 1981, LANCET, V2, P497; TAKAHASHI N, 1995, J IMMUNOL, V155, P5213; Takahashi N, 1997, ARCH DIS CHILD-FETAL, V77, pF79; Takahashi N., 1995, ACTA NEONAT JPN, V31, P371; TAUCHI M, 1993, J JPN PEDIAT SOC, V97, P1184; TODD J K, 1988, Clinical Microbiology Reviews, V1, P432; UCHIYAMA T, 1993, J IMMUNOL, V151, P4407; UCHIYAMA T, 1994, MICROBIOL IMMUNOL, V38, P245, DOI 10.1111/j.1348-0421.1994.tb01772.x; UCHIYAMA T, 1989, J IMMUNOL, V143, P3175; UCHIYAMA T, 1989, EUR J IMMUNOL, V19, P1803, DOI 10.1002/eji.1830191007; UCHIYAMA T, 1987, CLIN EXP IMMUNOL, V68, P638; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YAMANISHI K, 1988, LANCET, V1, P1065	35	80	82	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1614	1619		10.1016/S0140-6736(97)11125-4	http://dx.doi.org/10.1016/S0140-6736(97)11125-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620715				2022-12-24	WOS:000074026600008
J	Guttman, DS; Charlesworth, D				Guttman, DS; Charlesworth, D			An X-linked gene with a degenerate Y-linked homologue in a dioecious plant	NATURE			English	Article							DOSAGE COMPENSATION; SEX DETERMINATION; MELANDRIUM-ALBUM; FLOWERING PLANTS; EVOLUTION; CHROMOSOMES; EXPRESSION; OVERLAP; SILENE; MODEL	Most flowering plants are hermaphroditic, having flowers with both male and female parts. Less than 4% of plant species are dioecious (with individuals of separate sexes), and many of these species have chromosome-mediated sex determination. The taxonomic distribution of separate sexes and chromosomal sex-determination systems in the flowering planes indicates that plant sex chromosomes have evolved recently through replicated, independent events(1-4), contrasting with the ancient origins of mammalian and insect sex chromosomes. Plant sex chromosomes, therefore, offer opportunities to study the most interesting early stages of the evolution of sex chromosomes. Here we show that a gene encoding a male-specific protein is linked to the X chromosome in the dioecious plant Silene latifolia, and that it has a degenerate homologue in the non-pairing region of the Y chromosome. The Y-linked locus has degenerated as a result of nucleotide deletion and the accumulation of repetitive sequences. We have identified both the first X-linked gene and the first pair of homologous sex-linked loci to be found in plants. The homology between the active X-linked locus and the degenerate Y-linked locus supports a common ancestry for these two loci.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago	Guttman, DS (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 1103 E 57th St, Chicago, IL 60637 USA.		Guttman, David S/A-7839-2011; Charlesworth, Deborah/F-3071-2011	Guttman, David S/0000-0001-8479-3869; 				CHARLESWORTH B, 1978, AM NAT, V112, P975, DOI 10.1086/283342; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; CHARLESWORTH B, 1978, P NATL ACAD SCI USA, V75, P5618, DOI 10.1073/pnas.75.11.5618; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; Charlesworth D., 1985, EVOLUTION ESSAYS HON, P237; Darwin, 1876, EFFECTS CROSS SELF F; Desfeux C, 1996, P ROY SOC B-BIOL SCI, V263, P409, DOI 10.1098/rspb.1996.0062; Donnison IS, 1996, GENETICS, V144, P1893; GRANT S, 1994, DEV GENET, V15, P214, DOI 10.1002/dvg.1020150304; GRAVES JAM, 1995, BIOESSAYS, V17, P311, DOI 10.1002/bies.950170407; Guttman DS, 1996, J CLIN MICROBIOL, V34, P652, DOI 10.1128/JCM.34.3.652-656.1996; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; JUKES T H, 1969, P21; Matsunaga S, 1996, PLANT J, V10, P679, DOI 10.1046/j.1365-313X.1996.10040679.x; MAYER SS, 1992, EVOLUTION, V46, P207, DOI 10.1111/j.1558-5646.1992.tb01995.x; Nei M., 1987, MOL EVOLUTIONARY GEN, P1, DOI DOI 10.7312/NEI-92038; PEDERSEN S, 1987, THEOR APPL GENET, V75, P200, DOI 10.1007/BF00249164; REJON CR, 1994, HEREDITY, V72, P209, DOI 10.1038/hdy.1994.28; STINSON JR, 1987, PLANT PHYSIOL, V83, P442, DOI 10.1104/pp.83.2.442; TANKSLEY SD, 1981, SCIENCE, V213, P453, DOI 10.1126/science.213.4506.453; VANNIGTE.G, 1966, GENETICA, V37, P281, DOI 10.1007/BF01547140; VANNIGTEVECHT G, 1966, GENETICA, V37, P307, DOI 10.1007/BF01547141; VYSKOT B, 1993, MOL GEN GENET, V239, P219, DOI 10.1007/BF00281621; WESTERGAARD M, 1958, ADV GENET, V9, P217, DOI 10.1016/S0065-2660(08)60163-7; ZUK J, 1969, CHROMOSOMES TODAY, V2, P183	25	110	118	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					263	266		10.1038/30492	http://dx.doi.org/10.1038/30492			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607762				2022-12-24	WOS:000073761000052
J	Schuppel, R; Buchele, G; Batz, L; Koenig, W				Schuppel, R; Buchele, G; Batz, L; Koenig, W			Sex differences in selection of pacemakers: retrospective observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-ARTERY DISEASE; GENDER DIFFERENCES; SINGLE-CHAMBER; WOMEN; BIAS; PRESCRIPTION; MANAGEMENT; SURVIVAL; MEN; AGE	Objective: To evaluate the effect of patients' sex on selection of pacemakers. Design: Retrospective univariate and multivariate analysis of a large database. Setting: German central pacemaker register. Subjects: Records collected at the register for 1992 and 1993 (n=31 913), covering 64% of all implantations in Germany. Main outcome measure: Probability of receiving a single chamber, dual chamber, or rate responsive pacemaker in relation to sex. Results: Univariate analysis showed that women were more likely to receive single chamber pacemakers and less likely to receive dual chamber or rate responsive systems than men. After demographic and clinical variables were controlled for, women were still more likely to receive a single chamber system (atrial pacing: odds ratio 0.89, 95% confidence interval 0.74 to 1.07; ventricular pacing: 0.85, 0.80 to 0.92) and less likely to receive a dual chamber (1.20, 1.12 to 1.30) or a rate responsive system (1.26, 1.17 to 1.37) than men. Conclusions: The data suggest sex differences in the selection of a pacemaker system which cannot be explained by the underlying cardiac disorder. Further research is needed to evaluate why guidelines for implanting pacemakers are not better adhered to.	Univ Ulm, Dept Psychotherapy & Psychosomat, Med Ctr, D-89081 Ulm, Germany; Univ Ulm, Dept Biometry & Med Documentat, D-89075 Ulm, Germany; Univ Giessen, Inst Med Technol, D-36392 Giessen, Germany; Univ Ulm, Med Ctr, Dept Internal Med 2, Ulm, Germany	Ulm University; Ulm University; Justus Liebig University Giessen; Ulm University	Schuppel, R (corresponding author), Univ Ulm, Dept Psychotherapy & Psychosomat, Med Ctr, D-89081 Ulm, Germany.							Aggarwal RK, 1996, HEART, V75, P518, DOI 10.1136/hrt.75.5.518; ALPERT MA, 1987, AM HEART J, V113, P958, DOI 10.1016/0002-8703(87)90057-3; ARMITAGE KJ, 1979, JAMA-J AM MED ASSOC, V241, P2186, DOI 10.1001/jama.241.20.2186; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; CLARKE M, 1991, BRIT HEART J, V66, P185; *EUR WORK GROUP CA, 1987, EUR HEART J SUPPL, V8, P21; FORCINITO M, 1991, J AM COLL CARDIOL, V18, P1, DOI 10.1016/S0735-1097(10)80209-8; GREENSPAN AM, 1988, NEW ENGL J MED, V318, P158, DOI 10.1056/NEJM198801213180306; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; HORTON HL, 1995, ARCH INTERN MED, V155, P2342, DOI 10.1001/archinte.155.21.2342; IRNICH W, 1994, HERZSCHRITTMACHER, V14, P239; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; LAMAS GA, 1995, CIRCULATION, V91, P1063, DOI 10.1161/01.CIR.91.4.1063; LAMAS GA, 1992, CIRCULATION, V86, P449; LAU CP, 1994, PACE, V17, P1838, DOI 10.1111/j.1540-8159.1994.tb03759.x; MARK DB, 1994, NEW ENGL J MED, V330, P1101, DOI 10.1056/NEJM199404213301601; PROCTOR EE, 1991, AM HEART J, V122, P728, DOI 10.1016/0002-8703(91)90518-M; RAY SG, 1992, BRIT HEART J, V68, P531; SHAW LJ, 1994, ANN INTERN MED, V120, P559, DOI 10.7326/0003-4819-120-7-199404010-00005; STANGL K, 1990, HERZSCHRITIMACHER EL, V1, P42; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406	24	17	17	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 16	1998	316	7143					1492	1494		10.1136/bmj.316.7143.1492	http://dx.doi.org/10.1136/bmj.316.7143.1492			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP020	9582133	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000073707700021
J	Irving, BA; Alt, FW; Killeen, N				Irving, BA; Alt, FW; Killeen, N			Thymocyte development in the absence of pre-T cell receptor extracellular immunoglobulin domains	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; ANTIGEN RECEPTOR; MUTANT MICE; ALPHA-BETA; DEFICIENT MICE; CHAIN; EXPRESSION; GENE; LCK; DIFFERENTIATION	Immature thymocytes express a pre-T cell receptor (pre-TCR) composed of the TCR beta chain paired with pre-T alpha. Signals from this receptor are essential for passage of thymocytes through a key developmental checkpoint in the thymus. These signals were efficiently delivered in vivo by a truncated form of the murine pre-TCR that lacked all of its extracellular immunoglobulin domains. De novo expression of the truncated pre-TCR or an intact alpha beta TCR was sufficient to activate characteristic TCR signaling pathways in a T cell line. These findings support the view that recognition of an extracellular ligand is not required for pre-TCR function.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Genet & Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA	University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Killeen, N (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.							Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; CORCOS D, 1995, CURR BIOL, V5, P1140, DOI 10.1016/S0960-9822(95)00230-2; CROMPTON T, 1994, EUR J IMMUNOL, V24, P1903, DOI 10.1002/eji.1830240828; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; Hedrick Stephen M., 1993, P383; Hogan B, 1994, MANIPULATING MOUSE E; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, UNPUB; JACOBS H, 1994, EUR J IMMUNOL, V24, P934, DOI 10.1002/eji.1830240423; KERSH GJ, 1995, J IMMUNOL, V154, P5706; Krotkova A, 1997, J EXP MED, V186, P767, DOI 10.1084/jem.186.5.767; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; MANOLIOS N, 1994, EUR J IMMUNOL, V24, P84, DOI 10.1002/eji.1830240114; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1995, P NATL ACAD SCI USA, V92, P7420, DOI 10.1073/pnas.92.16.7420; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; OShea CC, 1997, IMMUNITY, V7, P591, DOI 10.1016/S1074-7613(00)80380-5; Papavasiliou F, 1997, CURR OPIN IMMUNOL, V9, P233, DOI 10.1016/S0952-7915(97)80141-0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; Shaffer AL, 1997, J IMMUNOL, V159, P1265; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1994, INT IMMUNOL, V6, P995, DOI 10.1093/intimm/6.7.995; Swat W, 1996, P NATL ACAD SCI USA, V93, P4683, DOI 10.1073/pnas.93.10.4683; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9	43	151	152	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 8	1998	280	5365					905	908		10.1126/science.280.5365.905	http://dx.doi.org/10.1126/science.280.5365.905			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572735				2022-12-24	WOS:000073532900042
J	Kristensen, P; Judge, ME; Thim, L; Ribel, U; Christjansen, KN; Wulff, BS; Clausen, JT; Jensen, PB; Madsen, OD; Vrang, N; Larsen, PJ; Hastrup, S				Kristensen, P; Judge, ME; Thim, L; Ribel, U; Christjansen, KN; Wulff, BS; Clausen, JT; Jensen, PB; Madsen, OD; Vrang, N; Larsen, PJ; Hastrup, S			Hypothalamic CART is a new anorectic peptide regulated by leptin	NATURE			English	Article							MESSENGER-RIBONUCLEIC-ACID; NEUROPEPTIDE-Y; RNA; POLYPEPTIDE; AMPHETAMINE; COCAINE; MOUSE; RATS; FOOD; MICE	The mammalian hypothalamus strongly influences ingestive behaviour through several different signalling molecules and receptor systems(1-4). Here we show that CART (cocaine-and amphetamine-regulated transcript), a brain-located peptide(5-8), is a satiety factor and is closely associated with the actions of two important regulators of food intake, leptin and neuropeptide Y. Food-deprived animals show a pronounced decrease in expression of CART messenger RNA in the arcuate nucleus. In animal models of obesity with disrupted leptin signalling, CART mRNA is almost absent from the arcuate nucleus. Peripheral administration of leptin to obese mice stimulates CART mRNA expression. When injected intracerebroventricularly into rats, recombinant CART peptide inhibits both normal and starvation-induced feeding, and completely blocks the feeding response induced by neuropeptide Y. An antiserum against CART increases feeding in normal rats, indicating that CART may be an endogenous inhibitor of food intake in normal animals.	Novo Nordisk AS, Hlth Care Discovery, DK-2880 Bagsvaerd, Denmark; Hagedorn Res Inst, DK-2820 Gentofte, Denmark; Univ Copenhagen, Dept Anat, DK-2200 Copenhagen, Denmark	Novo Nordisk; Novo Nordisk; Hagedorn Research Institute; University of Copenhagen	Kristensen, P (corresponding author), Novo Nordisk AS, Hlth Care Discovery, Novo Alle 6A1-47, DK-2880 Bagsvaerd, Denmark.	pekr@novo.dk	Madsen, Ole D./A-7415-2011	Madsen, Ole D./0000-0002-2753-5203; Jensen, Per Bo/0000-0002-2277-1135				BERGHORN KA, 1994, J HISTOCHEM CYTOCHEM, V42, P1635, DOI 10.1177/42.12.7983364; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; Couceyro PR, 1997, J CHEM NEUROANAT, V12, P229, DOI 10.1016/S0891-0618(97)00212-3; Douglass J, 1996, GENE, V169, P241, DOI 10.1016/0378-1119(96)88651-3; DOUGLASS J, 1995, J NEUROSCI, V15, P2471; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; FENGER M, 1990, SCAND J CLIN LAB INV, V50, P229; Gautvik KM, 1996, P NATL ACAD SCI USA, V93, P8733, DOI 10.1073/pnas.93.16.8733; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/pnas.88.23.10931; Kjeldsen T, 1996, GENE, V170, P107, DOI 10.1016/0378-1119(95)00822-5; KRISTENSEN P, 1991, J HISTOCHEM CYTOCHEM, V39, P341, DOI 10.1177/39.3.1899685; SANACORA G, 1990, ENDOCRINOLOGY, V127, P730, DOI 10.1210/endo-127-2-730; SPIESS J, 1981, BIOCHEMISTRY-US, V20, P1982, DOI 10.1021/bi00510a038; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Wang Q, 1997, DIABETES, V46, P335, DOI 10.2337/diabetes.46.3.335; Whitelegge T., 1890, REC AUST MUS, V1, P41, DOI DOI 10.3853/J.0067-1975.1.1890.1224; WILDING JPH, 1993, ENDOCRINOLOGY, V132, P1939, DOI 10.1210/en.132.5.1939	20	1017	1054	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 7	1998	393	6680					72	76		10.1038/29993	http://dx.doi.org/10.1038/29993			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590691				2022-12-24	WOS:000073497500049
J	O'Neill, RJW; O'Neill, MJ; Graves, JAM				O'Neill, RJW; O'Neill, MJ; Graves, JAM			Undermethylation associated with retroelement activation and chromosome remodelling in an interspecific mammalian hybrid	NATURE			English	Article							TRANSPOSABLE ELEMENTS; METHYLATION; SPECIATION; DROSOPHILA; EVOLUTION; GENOMES; RNA	Genetic models(1,2) predict that genomic rearrangement in hybrids can facilitate reproductive isolation and the formation of new species by preventing gene flow between the parent species and hybrid (sunflowers are an example(3)). The mechanism underlying hybridization-induced chromosome remodelling is as yet unknown, although mobile element activity has been shown to be involved in DNA rearrangement in some dysgenic Drosophila hybrids(4,5), It has been proposed that DNA methylation evolved as a means of repressing the movement of mobile elements (the host defence model(6,7)). If such a protective mechanism were to fail, mobile elements could be activated, and could cause major and rapid genome alterations(8,9), Here we demonstrate the occurrence of genome-wide undermethylation, retroviral element amplification and chromosome remodelling in an interspecific mammalian hybrid (Macropus eugenii X Wallabia bicolor). Atypically extended centromeres of Macropus eugenii derived autosomes in the hybrid were composed primarily of an unmethylated, amplified retroviral element not detectable in either parent species. These results, taken with the observation of deficient methylation and de novo chromosome change in other mammalian hybrids, indicate that the failure of DNA methylation and subsequent mobile-element activity in hybrids could facilitate rapid karyotypic evolution.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; La Trobe Univ, Dept Genet & Human Variat, Bundoora, Vic 3083, Australia	Princeton University; La Trobe University	O'Neill, RJW (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.		Graves, Jennifer A.M./A-1387-2008	Graves, Jennifer/0000-0001-6480-7856				ARNAULT C, 1994, GENETICA, V93, P149, DOI 10.1007/BF01435247; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; Curcio MJ, 1996, TRENDS GENET, V12, P436; ENGELS WR, 1984, GENETICS, V107, P657; GRANT V, 1958, COLD SPRING HARB SYM, V23, P337, DOI 10.1101/SQB.1958.023.01.034; GRAUR D, 1985, J MOL EVOL, V21, P221, DOI 10.1007/BF02102356; HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; JAENISCH R, 1985, P NATL ACAD SCI USA, V82, P1451, DOI 10.1073/pnas.82.5.1451; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LOEBEL DA, 1993, CHROMOSOMA, V102, P81, DOI 10.1007/BF00356024; PETROV DA, 1995, P NATL ACAD SCI USA, V92, P8050, DOI 10.1073/pnas.92.17.8050; RIESEBERG LH, 1995, NATURE, V375, P313, DOI 10.1038/375313a0; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHEMPP W, 1983, HUM GENET, V63, P171, DOI 10.1007/BF00291539; SMITH MJ, 1979, AUST J ZOOL, V27, P959, DOI 10.1071/ZO9790959; SUNKEL CE, 1995, CURR OPIN GENET DEV, V5, P756, DOI 10.1016/0959-437X(95)80008-S; TEMPLETON AR, 1981, ANNU REV ECOL SYST, V12, P23, DOI 10.1146/annurev.es.12.110181.000323; Toder R, 1996, CHROMOSOME RES, V4, P295, DOI 10.1007/BF02263680; Toder R, 1997, MAMM GENOME, V8, P418, DOI 10.1007/s003359900459; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; WICHMAN HA, 1992, GENETICA, V86, P287, DOI 10.1007/BF00133727; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	24	354	359	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1998	393	6680					68	72		10.1038/29985	http://dx.doi.org/10.1038/29985			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590690				2022-12-24	WOS:000073497500048
J	Gaist, D; Tsiropoulos, I; Sindrup, SH; Hallas, J; Ramussen, BK; Kragstrup, J; Gram, LF				Gaist, D; Tsiropoulos, I; Sindrup, SH; Hallas, J; Ramussen, BK; Kragstrup, J; Gram, LF			Inappropriate use of sumatriptan: population based register and interview study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Odense Univ, Inst Med Biol, Dept Clin Pharmacol, DK-5000 Odense C, Denmark; Odense Univ Hosp, Dept Neurol, DK-5000 Odense, Denmark; Hillerod Hosp, Dept Neurol, Hillerod, Denmark; Odense Univ, Gen Practice Res Unit, Odense, Denmark	University of Southern Denmark; University of Southern Denmark; Odense University Hospital; University of Copenhagen; University of Southern Denmark	Gaist, D (corresponding author), Odense Univ, Inst Med Biol, Dept Clin Pharmacol, DK-5000 Odense C, Denmark.	d.gaist@winsloew.ou.dk	Gaist, David/I-4397-2014	Gaist, David/0000-0001-5205-7007; Sindrup, Soren/0000-0003-0357-8628				Gaist D, 1997, DAN MED BULL, V44, P445; Gaist D, 1997, BRIT J CLIN PHARMACO, V43, P429, DOI 10.1046/j.1365-2125.1997.00582.x; Gaist D, 1996, EUR J CLIN PHARMACOL, V50, P161, DOI 10.1007/s002280050086; RUSSELL MB, 1992, CEPHALALGIA, V12, P369, DOI 10.1111/j.1468-2982.1992.00369.x; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x	5	44	44	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 2	1998	316	7141					1352	1353		10.1136/bmj.316.7141.1352	http://dx.doi.org/10.1136/bmj.316.7141.1352			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL882	9563984	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000073483000017
J	Parganas, E; Wang, D; Stravopodis, D; Topham, DJ; Marine, JC; Teglund, S; Vanin, EF; Bodner, S; Colamonici, OR; van Deursen, JM; Grosveld, G; Ihle, JN				Parganas, E; Wang, D; Stravopodis, D; Topham, DJ; Marine, JC; Teglund, S; Vanin, EF; Bodner, S; Colamonici, OR; van Deursen, JM; Grosveld, G; Ihle, JN			Jak2 is essential for signaling through a variety of cytokine receptors	CELL			English	Article							PROTEIN-TYROSINE KINASE; STIMULATING FACTOR-RECEPTOR; TRANSCRIPTION FACTOR GATA-1; MICE LACKING JAK3; ERYTHROPOIETIN RECEPTOR; LYMPHOID DEVELOPMENT; INTERFERON-ALPHA/BETA; TRANSDUCTION PATHWAY; G-CSF; ACTIVATION	A variety of cytokines activate receptor-associated members of the Janus family of protein tyrosine kinases (Jaks). To assess the role of Jak2, we have derived Jak2-deficient mice. The mutation causes an embryonic lethality due to the absence of definitive erythropoiesis. Fetal liver myeloid progenitors, although present based on the expression of lineage specific markers, fail to respond to erythropoietin, thrombopoietin, interleukin-3 (IL-3), or granulocyte/macrophage colony-stimulating factor. In contrast, the response to granulocyte specific colony-stimulating factor is unaffected. Jak2-deficient fibroblasts failed to respond to interferon gamma (IFN gamma), although the responses to IFN alpha/beta and IL-6 were unaffected. Lastly, reconstitution experiments demonstrate that Jak2 is not required for the generation of lymphoid progenitors, their amplification, or functional differentiation. Therefore, Jak2 plays a critical, nonredundant role in the function of a specific group of cytokines receptors.	St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Expt Hematol, Memphis, TN 38105 USA; Univ Tennessee, Sch Med, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Sch Med, Dept Pathol, Memphis, TN 38105 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Ihle, JN (corresponding author), St Jude Childrens Res Hosp, Howard Hughes Med Inst, 332 N Lauderdale St, Memphis, TN 38105 USA.		Marine, Jean Christophe/J-2237-2015; Wang, Demin/AAX-4449-2020; Marine, Jean-Christophe/K-3292-2016	Wang, Demin/0000-0001-5549-3795; Marine, Jean-Christophe/0000-0003-2433-9837; Stravopodis, Dimitrios/0000-0002-9535-2134	NCI NIH HHS [CA21765] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDUS T, 1988, EUR J IMMUNOL, V18, P739, DOI 10.1002/eji.1830180513; ARTGETSINGER LS, 1993, CELL, V74, P237; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; Barge RMY, 1996, BLOOD, V87, P2148, DOI 10.1182/blood.V87.6.2148.bloodjournal8762148; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HANAZONO Y, 1993, BLOOD, V81, P3193; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; Hogan B, 1994, MANIPULATING MOUSE E; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kieran MW, 1996, P NATL ACAD SCI USA, V93, P9126, DOI 10.1073/pnas.93.17.9126; Leonard WJ, 1995, IMMUNOL REV, V148, P97, DOI 10.1111/j.1600-065X.1995.tb00095.x; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MACHIDE M, 1995, ONCOGENE, V11, P619; MANO H, 1995, BLOOD, V85, P343; MIYAKAWA Y, 1995, BLOOD, V86, P23, DOI 10.1182/blood.V86.1.23.bloodjournal86123; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PERKINS AC, 1995, NATURE, V375, P318; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAUPRICH P, 1995, BLOOD, V86, P4500, DOI 10.1182/blood.V86.12.4500.bloodjournal86124500; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Shimoda K, 1997, BLOOD, V90, P597, DOI 10.1182/blood.V90.2.597.597_597_604; SHIMODA K, 1994, BIOCHEM BIOPH RES CO, V203, P922, DOI 10.1006/bbrc.1994.2270; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TORIGOE T, 1992, LEUKEMIA, V6, pS94; TORIGOE T, 1992, BLOOD, V80, P617; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsubokawa M, 1997, EUR J BIOCHEM, V249, P792, DOI 10.1111/j.1432-1033.1997.t01-2-00792.x; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VANDEURSEN J, 1991, NUCLEIC ACIDS RES, V19, P2637, DOI 10.1093/nar/19.10.2637; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wollert KC, 1997, J MOL MED-JMM, V75, P492, DOI 10.1007/s001090050134; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	55	846	953	1	27	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1998	93	3					385	395		10.1016/S0092-8674(00)81167-8	http://dx.doi.org/10.1016/S0092-8674(00)81167-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590173	Bronze			2022-12-24	WOS:000073471500014
J	Pancioli, AM; Broderick, J; Kothari, R; Brott, T; Tuchfarber, A; Miller, R; Khoury, J; Jauch, E				Pancioli, AM; Broderick, J; Kothari, R; Brott, T; Tuchfarber, A; Miller, R; Khoury, J; Jauch, E			Public perception of stroke warning signs and knowledge of potential risk factors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; URGENT THERAPY; PREVENTION; MINUTES; TRIAL	Context.-Decreasing the time from stroke onset to hospital arrival and improving control of stroke risk factors depend on public knowledge of stroke warning signs and risk factors. Objective.-To assess current public knowledge of stroke warning signs and risk factors. Design.-A population-based telephone interview survey using random digit dialing conducted in 1995. Setting.-The Greater Cincinnati, Ohio, metropolitan area, the population of which is similar to that of the United States overall in age, sex, percentage of blacks, and economic status. Participants.-Respondents with age, race, and sex that matched the population of patients with acute stroke. Main Outcome Measures.-Knowledge of risk factors for stroke and warning signs of stroke as defined by the National Institute of Neurological Disorders and Stroke. Results.-Telephone calls were made to 17 634 households, which yielded 2642 demographically eligible individuals. Interviews were completed by 1880 respondents (response rate, 71.2%). A total of 1066 respondents (57%) correctly listed at least 1 of the 5 established stroke warning signs, and of all respondents, 1274 (68%) correctly listed at least 1 of the established stroke risk factors. Of the respondents, 469 (57%) of 818 respondents with a history of hypertension listed hypertension, 142 (35%) of 402 respondents who were current smokers listed smoking, and 32 (13%) of 255 respondents with diabetes listed diabetes as a risk factor for stroke. Compared with those younger than 75 years, respondents 75 years or older were less likely to correctly list at least 1 stroke warning sign (60% vs 47%, respectively; P<.001) and were less likely to list at least 1 stroke risk factor (72% vs 56%, respectively; P<.001). Conclusion.-Considerable education is needed to increase the public's awareness of the warning signs and risk factors for stroke. Respondents with self-reported risk factors for stroke are largely unaware of their increased risk The population at greatest risk for stroke, the very elderly, are the least knowledgeable about stroke warning signs and risk factors.	Univ Cincinnati, Coll Med, Dept Emergency Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Inst Policy Res, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Pancioli, AM (corresponding author), Univ Cincinnati, Coll Med, Dept Emergency Med, 231 Bethesda Ave,POB 670769, Cincinnati, OH 45267 USA.	Arthur.Pancioli@uc.edu	Khoury, Jane/O-2068-2015	Jauch, Edward/0000-0002-3533-4364	NINDS NIH HHS [R0-1 NS30678-04] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030678] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARSAN WG, 1994, STROKE, V25, P2132, DOI 10.1161/01.STR.25.11.2132; BONNER LL, 1995, NEW ENGL J MED, V333, P1392; BRODERICK J, 1993, ANN EMERG MED, V22, P1438, DOI 10.1016/S0196-0644(05)81993-6; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; BRODERICK JP, 1992, NEW ENGL J MED, V326, P733, DOI 10.1056/NEJM199203123261103; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; Brott T, 1996, ARCH NEUROL-CHICAGO, V53, P1305, DOI 10.1001/archneur.1996.00550120117025; BROTT TG, 1992, STROKE, V23, P632, DOI 10.1161/01.STR.23.5.632; Brown RD, 1996, STROKE, V27, P373; Ezzati TM, 1992, VITAL HLTH STAT 2, V2, P1; Feinberg WM, 1996, CURR OPIN NEUROL, V9, P46, DOI 10.1097/00019052-199602000-00010; FREY JH, 1989, SURVEY RES TELEPHONE, P90; GORELICK PB, 1995, ARCH NEUROL-CHICAGO, V52, P347, DOI 10.1001/archneur.1995.00540280029015; HALEY EC, 1992, STROKE, V23, P641, DOI 10.1161/01.STR.23.5.641; HALEY EC, 1993, STROKE, V24, P1000, DOI 10.1161/01.STR.24.7.1000; Kothari R, 1997, STROKE, V28, P1871, DOI 10.1161/01.STR.28.10.1871; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MATCHAR DB, 1994, ANN INTERN MED, V121, P54; *NAT I NEUR DIS ST, 1997, BRAIN ATT STROK WARN; *NAT STROK ASS, 1994, BRAIN RISK UND PREV; National Stroke Association, 1996, AW KNOWL STROK PREV; *US BUR CENS, 1993, POP HOUS CHAR CENS T; Whisnant JP, 1997, STROKE, V28, P1840, DOI 10.1161/01.STR.28.9.1840; Williams LS, 1997, STROKE, V28, P912, DOI 10.1161/01.STR.28.5.912	24	368	382	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 29	1998	279	16					1288	1292		10.1001/jama.279.16.1288	http://dx.doi.org/10.1001/jama.279.16.1288			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH270	9565010				2022-12-24	WOS:000073090300035
J	Nagy, L; Tontonoz, P; Alvarez, JGA; Chen, HW; Evans, RM				Nagy, L; Tontonoz, P; Alvarez, JGA; Chen, HW; Evans, RM			Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR gamma	CELL			English	Article							LOW-DENSITY-LIPOPROTEIN; MONOCYTE-DERIVED MACROPHAGES; NECROSIS-FACTOR-ALPHA; ADIPOCYTE DIFFERENTIATION; ATHEROSCLEROTIC LESIONS; CHOLESTEROL DEPOSITION; POTENTIAL ROLE; MESSENGER-RNA; RECEPTOR; INTERLEUKIN-1-BETA	Macrophage uptake of oxidized low-density lipoprotein (oxLDL) is thought to play a central role in foam cell formation and the pathogenesis of atherosclerosis. We demonstrate here that oxLDL activates PPAR gamma-dependent transcription through a novel signaling pathway involving scavenger receptor-mediated particle uptake. Moreover, we identify two of the major oxidized lipid components of oxLDL, 9-HODE and 13-HODE, as endogenous activators and ligands of PPAR gamma. Our data suggest that the biologic effects of oxLDL are coordinated by two sets of receptors, one on the cell surface, which binds and internalizes the particle, and one in the nucleus, which is transcriptionally activated by its component lipids. These results suggest that PPAR gamma may be a key regulator of foam cell gene expression.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	Salk Institute; Howard Hughes Medical Institute; University of California System; University of California San Diego	Evans, RM (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Nagy, Laszlo/A-3814-2008; Evans, Ronald/AAF-4001-2019	Nagy, Laszlo/0000-0001-6653-2155; Evans, Ronald/0000-0002-9986-5965				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUJA LM, 1983, ARTERIOSCLEROSIS, V3, P87, DOI 10.1161/01.ATV.3.1.87; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; FONG LG, 1991, J LIPID RES, V32, P1899; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GLAVIND J, 1952, ACTA PATHOL MIC SC, V30, P1; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAMILTON TA, 1990, J IMMUNOL, V144, P2343; HAMILTON TA, 1995, J CLIN INVEST, V95, P2020, DOI 10.1172/JCI117887; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; HARLAND WA, 1971, ATHEROSCLEROSIS, V13, P239, DOI 10.1016/0021-9150(71)90026-8; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Huh HY, 1996, BLOOD, V87, P2020; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KU G, 1992, J BIOL CHEM, V267, P14183; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEHR HA, 1993, LAB INVEST, V68, P388; LENZ ML, 1990, J LIPID RES, V31, P1043; LIPTON BA, 1995, J LIPID RES, V36, P2232; MALDEN LT, 1991, J BIOL CHEM, V266, P13901; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; Ohlsson BG, 1996, J CLIN INVEST, V98, P78, DOI 10.1172/JCI118780; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SIMON TC, 1989, ATHEROSCLEROSIS, V75, P31, DOI 10.1016/0021-9150(89)90204-9; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; THOMAS CE, 1991, J PHARMACOL EXP THER, V256, P1182; THOMAS CE, 1994, J LIPID RES, V35, P417; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	48	1507	1563	0	72	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1998	93	2					229	240		10.1016/S0092-8674(00)81574-3	http://dx.doi.org/10.1016/S0092-8674(00)81574-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568715	Bronze			2022-12-24	WOS:000073174000009
J	Wang, F; Nemes, A; Mendelsohn, M; Axel, R				Wang, F; Nemes, A; Mendelsohn, M; Axel, R			Odorant receptors govern the formation of a precise topographic map	CELL			English	Article							OCULAR DOMINANCE COLUMNS; RABBIT OLFACTORY-BULB; MITRAL TUFTED CELLS; IMPULSE ACTIVITY; GENE-EXPRESSION; MESSENGER-RNA; IN-VITRO; ORGANIZATION; EPITHELIUM; RAT	Olfactory neurons expressing a given odorant receptor project with precision to 2 of the 1800 glomeruli within the olfactory bulb to create a topographic map of odor quality. We demonstrate that deletions or nonsense mutations in the P2 odorant receptor gene cause the axons of these cells to wander rather than converge on a specific glomerulus. Receptor substitution experiments that replace the P2 gene with the coding region of the P3 gene result in the projection of P3-->P2 axons to a glomerulus touching the wildtype P3 glomerulus. These data, along with additional receptor substitutions, indicate that the odorant receptor plays an instructive role in the establishment of the topographic map.	Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute	Axel, R (corresponding author), Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA.			Axel, Richard/0000-0002-3141-4076	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER; NIMH NIH HHS [5 P50 MH50733] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; Drescher U, 1997, CURR OPIN NEUROBIOL, V7, P75, DOI 10.1016/S0959-4388(97)80123-7; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Friedrich RW, 1997, NEURON, V18, P737, DOI 10.1016/S0896-6273(00)80314-1; GALLI L, 1988, SCIENCE, V242, P90, DOI 10.1126/science.3175637; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HARRIS WA, 1986, NATURE, V320, P266, DOI 10.1038/320266a0; HARRIS WA, 1989, NATURE, V339, P218, DOI 10.1038/339218a0; HOLT CE, 1993, J NEUROBIOL, V24, P1400, DOI 10.1002/neu.480241011; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; IMAMURA K, 1992, J NEUROPHYSIOL, V68, P1986, DOI 10.1152/jn.1992.68.6.1986; Joerges J, 1997, NATURE, V387, P285, DOI 10.1038/387285a0; KADOWAKI T, 1990, P NATL ACAD SCI USA, V87, P658, DOI 10.1073/pnas.87.2.658; KATOH K, 1993, J NEUROPHYSIOL, V70, P2161, DOI 10.1152/jn.1993.70.5.2161; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KAUER JS, 1987, BRAIN RES, V418, P255, DOI 10.1016/0006-8993(87)90093-X; KING AJ, 1991, TRENDS NEUROSCI, V14, P31, DOI 10.1016/0166-2236(91)90181-S; LANCET D, 1982, P NATL ACAD SCI-BIOL, V79, P670, DOI 10.1073/pnas.79.2.670; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; SAUCIER D, 1986, BRAIN RES BULL, V16, P455, DOI 10.1016/0361-9230(86)90173-5; SAUER B, 1990, New Biologist, V2, P441; SCHOENFELD TA, 1994, BRAIN RES BULL, V34, P183, DOI 10.1016/0361-9230(94)90059-0; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STEWART CL, 1993, METHOD ENZYMOL, V225, P823; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STROTMANN J, 1994, CELL TISSUE RES, V278, P11, DOI 10.1007/s004410050189; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; STRYKER MP, 1986, J NEUROSCI, V6, P2117; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; vanHoof A, 1996, PLANT J, V10, P415, DOI 10.1046/j.1365-313x.1996.10030415.x; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Woolsey T.A., 1990, P461; Yoshihara Y, 1997, J NEUROSCI, V17, P5830	51	484	494	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					47	60		10.1016/S0092-8674(00)81145-9	http://dx.doi.org/10.1016/S0092-8674(00)81145-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546391	hybrid			2022-12-24	WOS:000072910800009
J	Weiner, JH; Bilous, PT; Shaw, GM; Lubitz, SP; Frost, L; Thomas, GH; Cole, JA; Turner, RJ				Weiner, JH; Bilous, PT; Shaw, GM; Lubitz, SP; Frost, L; Thomas, GH; Cole, JA; Turner, RJ			A novel and ubiquitous system for membrane targeting and secretion of cofactor-containing proteins	CELL			English	Article							DIMETHYL-SULFOXIDE REDUCTASE; ENGINEERED 3FE-4S CLUSTER; COLI FUMARATE REDUCTASE; GROWN ESCHERICHIA-COLI; DIMETHYLSULFOXIDE REDUCTASE; NITRITE REDUCTION; DMSO REDUCTASE; IDENTIFICATION; MOLYBDOENZYME; PURIFICATION	We report the identification of the proteins encoded by the mttABC operon (formerly yigTUW), which mediate a novel Sec-independent membrane targeting and translocation system in Escherichia coli that interacts with cofactor-containing redox proteins having a S/TRRXFLK "twin arginine" leader motif. A pleiotropic-negative mutant in mttA prevents the periplasmic localization of twin arginine redox enzymes, including nitrate reductase (NapA) and trimethylamine N-oxide reductase (TorA). The mutation also prevents the correct localization of the integral membrane molybdoenzyme dimethylsulfoxide reductase (DmsABC). The DmsA subunit has a twin arginine leader. Proteins with a Sec-dependent leader or which assemble spontaneously in the membrane are not affected by this mutation. MttA, B, and C are members of a large family of related sequences extending from archaebacteria to higher eukaryotes.	Univ Alberta, Dept Biochem, MRC, Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Sci Biol, Edmonton, AB T6G 2E1, Canada; Univ Birmingham, Sch Biochem, Birmingham B15 2TT, W Midlands, England	University of Alberta; University of Alberta; University of Birmingham	Weiner, JH (corresponding author), Univ Alberta, Dept Biochem, MRC, Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada.		Turner, Raymond J./M-3961-2015; Thomas, Gavin H/E-5753-2011; Frost, Laura/A-2639-2014	Turner, Raymond J./0000-0002-9263-0776; Thomas, Gavin H/0000-0002-9763-1313; Frost, Laura/0000-0002-8433-8230				Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; BERLYN MKB, 1996, ESCHERICHIA COLI SAL, P1715; BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; BILOUS PT, 1985, J BACTERIOL, V162, P1151, DOI 10.1128/JB.162.3.1151-1155.1985; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BROOMESMITH JK, 1986, GENE, V49, P341, DOI 10.1016/0378-1119(86)90370-7; Cole J, 1996, FEMS MICROBIOL LETT, V136, P1; DARWIN A, 1993, MOL MICROBIOL, V9, P1255, DOI 10.1111/j.1365-2958.1993.tb01255.x; DARWIN A, 1993, J GEN MICROBIOL, V139, P1829, DOI 10.1099/00221287-139-8-1829; DICKIE P, 1979, CAN J BIOCHEM CELL B, V57, P813, DOI 10.1139/o79-101; DOUNG F, 1997, CELL, V91, P567; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FROST L, 1989, MOL GEN GENET, V218, P152, DOI 10.1007/BF00330578; Grove J, 1996, MOL MICROBIOL, V19, P467, DOI 10.1046/j.1365-2958.1996.383914.x; HUSSAIN H, 1994, MOL MICROBIOL, V12, P153, DOI 10.1111/j.1365-2958.1994.tb01004.x; LATOUR DJ, 1987, J GEN MICROBIOL, V133, P597; LEMIRE BD, 1986, METHOD ENZYMOL, V126, P377; LEMIRE BD, 1983, J BACTERIOL, V155, P391, DOI 10.1128/JB.155.1.391-397.1983; LEMIRE BD, 1982, J BACTERIOL, V152, P1126; MCEWAN AG, 1994, ANTON LEEUW INT J G, V66, P151, DOI 10.1007/BF00871637; MCEWAN AG, 1984, ARCH MICROBIOL, V137, P344, DOI 10.1007/BF00410732; MCEWAN AG, 1991, BIOCHEM J, V274, P305, DOI 10.1042/bj2740305; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NEWMAN BM, 1978, J GEN MICROBIOL, V106, P1; ROTHERY RA, 1995, J BACTERIOL, V177, P2057, DOI 10.1128/jb.177.8.2057-2063.1995; Rothery RA, 1996, BIOCHEMISTRY-US, V35, P3247, DOI 10.1021/bi951584y; ROTHERY RA, 1993, BIOCHEMISTRY-US, V32, P5855, DOI 10.1021/bi00073a019; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; SAMBASIVARAO D, 1991, J BACTERIOL, V173, P5935, DOI 10.1128/jb.173.19.5935-5943.1991; SAMBASIVARAO D, 1990, J BACTERIOL, V172, P5938, DOI 10.1128/jb.172.10.5938-5948.1990; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; SimalaGrant JL, 1996, MICROBIOL-SGM, V142, P3231, DOI 10.1099/13500872-142-11-3231; ThonyMeyer L, 1997, EUR J BIOCHEM, V246, P794, DOI 10.1111/j.1432-1033.1997.t01-1-00794.x; Turner RJ, 1997, PROTEIN ENG, V10, P285, DOI 10.1093/protein/10.3.285; WEINER JH, 1992, BIOCHIM BIOPHYS ACTA, V1102, P1, DOI 10.1016/0167-4838(92)90493-W; WEINER JH, 1971, J BIOL CHEM, V246, P6933; WEINER JH, 1993, J BIOL CHEM, V268, P3238	41	399	422	0	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					93	101		10.1016/S0092-8674(00)81149-6	http://dx.doi.org/10.1016/S0092-8674(00)81149-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546395	Bronze			2022-12-24	WOS:000072910800013
J	Craig, AWB; Haghighat, A; Yu, ATK; Sonenberg, N				Craig, AWB; Haghighat, A; Yu, ATK; Sonenberg, N			Interaction of polyadenylate-binding protein with the eIF4G homologue PAIP enhances translation	NATURE			English	Article							POLY(A)-BINDING PROTEIN; INITIATION; RNA; MOTIF	In the initiation of translation in eukaryotes, binding of the small ribosomal subunit to the messenger RNA results from recognition of the 5' cap structure (m(7)GpppX) of the mRNA by the cap-binding complex eIF4F(1). eIF4F is itself a three-subunit complex comprising the cap-binding protein eIF4E(2), eIF4A, an ATP-dependent RNA helicase(3), and eIF4G, which interacts with both eIF4A and eIF4E and enhances cap binding by eIF4E(4). The mRNA 3' polyadenylate tail and the associated poly(A)-binding protein (PABP) also regulate translational initiation(5), probably by interacting with the 5' end of the mRNA(6,7). In yeast(8,9) and plants(10), PABP interacts with eIF4G(8,9) but no such interaction has been reported in mammalian cells. Here, we describe a new human PABP-interacting protein, PAIP-1, whose sequence is similar to the central portion of eIF4G and which interacts with eIE4A. Overexpression of PAIP-1 in COS-7 cells stimulates translation, perhaps by providing a physical link between the mRNA termini.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Sonenberg, N (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.		Craig, Andrew/G-2312-2017; Craig, Andrew/AAC-6923-2019	Craig, Andrew/0000-0002-2039-2393; Craig, Andrew/0000-0002-2039-2393				ASSELBERGS FAM, 1978, EUR J BIOCHEM, V88, P483, DOI 10.1111/j.1432-1033.1978.tb12473.x; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; DONZE O, 1995, NUCLEIC ACIDS RES, V23, P861, DOI 10.1093/nar/23.5.861; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; MADER S, 1995, MOL CELL BIOL, V15, P4990; Merrick WC., 1996, TRANSLATION CONTROL, P31; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Sachs AB, 1997, TRENDS BIOCHEM SCI, V22, P189, DOI 10.1016/S0968-0004(97)01051-7; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SONENBERG N, 1979, P NATL ACAD SCI USA, V76, P4345, DOI 10.1073/pnas.76.9.4345; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321; YAN RQ, 1992, J BIOL CHEM, V267, P23226; YANG HD, 1995, MOL CELL BIOL, V15, P6770	29	309	323	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					520	523		10.1038/33198	http://dx.doi.org/10.1038/33198			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548260				2022-12-24	WOS:000072875200065
J	Steinberg-Yfrach, G; Rigaud, JL; Durantini, EN; Moore, AL; Gust, D; Moore, TA				Steinberg-Yfrach, G; Rigaud, JL; Durantini, EN; Moore, AL; Gust, D; Moore, TA			Light-driven production of ATP catalysed by F0F1-ATP synthase in an artificial photosynthetic membrane	NATURE			English	Article							RECONSTITUTION PROCEDURE; LIPOSOMES; BACTERIORHODOPSIN; CHLOROPLASTS; CF0F1; SITE; ENERGY	Energy-transducing membranes of living organisms couple spontaneous to non-spontaneous processes through the intermediacy of protonmotive force (p.m.f.)-an imbalance in electrochemical potential of protons across the membrane, In most organisms, p.m.f. is generated by redox reactions that are either photochemically driven, such as those in photosynthetic reaction centres, or intrinsically spontaneous, such as those of oxidative phosphorylation in mitochondria. Transmembrane proteins (such as the cytochromes and complexes I, III and IV in the electron-transport chain in the inner mitochondrial membrane) couple the redox reactions to proton translocation, thereby conserving a fraction of the redox chemical potential as p.m.f. Many transducer proteins couple p.m.f. to the performance of biochemical work, such as biochemical synthesis and mechanical and transport processes, Recently, an artificial photosynthetic membrane was reported in which a photocyclic process was used to transport protons across a liposomal membrane, resulting in acidification of the Liposome's internal volume(1), If significant p.m.f. is generated in this system, then incorporating an appropriate transducer into the liposomal bilayer should make it possible to drive a non-spontaneous chemical process, Here we report the incorporation of F0F1-ATP synthase into liposomes containing the components of the proton-pumping photocycle, Irradiation of this artificial membrane,vith visible Light results in the uncoupler-and inhibitor-sensitive synthesis of adenosine triphosphate (ATP) against an ATP chemical potential of similar to 12 kcal mol(-1), with a quantum yield of more than 7%, This system mimics the process by which photosynthetic bacteria convert light energy into ATP chemical potential.	Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Arizona State Univ, Ctr Study Early Events Photosynthesis, Tempe, AZ 85287 USA; Inst Curie, CNRS, UMR 168, Sect Rech, F-75231 Paris, France; CEA, LCR, F-75231 Paris 05, France	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; CEA	Moore, TA (corresponding author), Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA.			Durantini, Edgardo N./0000-0001-8901-7543				Cladera J, 1996, J BIOENERG BIOMEMBR, V28, P503, DOI 10.1007/BF02110440; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1016, P29, DOI 10.1016/0005-2728(90)90003-M; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; GUST D, 1993, ACCOUNTS CHEM RES, V26, P198, DOI 10.1021/ar00028a010; HANGARTER RP, 1982, BIOCHIM BIOPHYS ACTA, V681, P397, DOI 10.1016/0005-2728(82)90181-5; PETITOU M, 1978, ANAL BIOCHEM, V91, P350, DOI 10.1016/0003-2697(78)90849-7; Pitard B, 1996, EUR J BIOCHEM, V235, P779, DOI 10.1111/j.1432-1033.1996.t01-1-00779.x; RICHARD P, 1990, EUR J BIOCHEM, V193, P921, DOI 10.1111/j.1432-1033.1990.tb19418.x; RICHARD P, 1992, EUR J BIOCHEM, V210, P287, DOI 10.1111/j.1432-1033.1992.tb17419.x; RICHARD P, 1995, J BIOL CHEM, V270, P21571, DOI 10.1074/jbc.270.37.21571; SCHMIDT G, 1985, BIOCHIM BIOPHYS ACTA, V808, P46, DOI 10.1016/0005-2728(85)90026-X; SIGALAT C, 1995, FEBS LETT, V368, P253, DOI 10.1016/0014-5793(95)00664-U; SteinbergYfrach G, 1997, NATURE, V385, P239, DOI 10.1038/385239a0	13	392	395	5	169	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					479	482		10.1038/33116	http://dx.doi.org/10.1038/33116			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548252				2022-12-24	WOS:000072875200053
J	Tudor-Smith, C; Nutbeam, D; Moore, L; Catford, J				Tudor-Smith, C; Nutbeam, D; Moore, L; Catford, J			Effects of the Heartbeat Wales programme over five years on behavioural risks for cardiovascular disease: quasi-experimental comparison of result from Wales and a matched reference area	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-PROGRAM; INTERVENTION; EDUCATION; SMOKING	Objective: To assess the net 5 year effects of intervention of a community based demonstration project, the Heartbeat Wales programme, on modifiable behavioural risks for prevention of cardiovascular disease. Design and setting: Quasi-experimental design comparing results from two independent cross sectional population surveys conducted in 1985 and 1990 in Wales and a matched reference area in north east England. Subjects: Random, stratified samples of people aged 18-64 years (18 538 in 1985 and 13 045 in 1990) in Wales and in north east England (1483 and 4534, respectively). Intervention: A coordinated range of activities for heart health promotion in Wales entailing public education campaigns along with supportive policy and infrastructure change. In the reference area no additional community heart health promotion was planned, though considerable activity did take place, "contaminating" the reference area. Main outcome measures: Fifteen self reported behavioural indicators relating to dietary choice, smoking, frequency of exercise, and weight. Results: Positive changes (for health) in behavioural outcomes were observed among the population in Wales, including a reduction in reported smoking prevalence and improvements in dietary choice. There was no net intervention effect for the programme over and above observed change in the reference area. Conclusions: No definite conclusions can be drawn concerning the efficacy of the programme in terms of behavioural outcomes. With hindsight, the difficulties of evaluating such a complex multifaceted intervention were underestimated. Further debate on the most appropriate methods for assessing the effectiveness of community based health promotion programmes is called for.	Hlth Promot Wales, Cardiff CF4 5DZ, S Glam, Wales; Univ Sydney, Dept Publ Hlth & Community Med, Sydney, NSW 2006, Australia; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Deakin Univ, Burwood, Vic 3125, Australia	University of Sydney; University of Bristol; Deakin University	Tudor-Smith, C (corresponding author), Hlth Promot Wales, Cardiff CF4 5DZ, S Glam, Wales.		Nutbeam, Don/AAU-1571-2021	Moore, Laurence/0000-0003-2182-823X; Nutbeam, Don/0000-0001-6497-2827				BENNETT N, 1996, LIVING BRITAIN RESUL; Black N, 1996, BRIT MED J, V312, P1215; BOAZ A, 1995, CORONARY HEART DIS S; CARLETON RA, 1995, AM J PUBLIC HEALTH, V85, P777, DOI 10.2105/AJPH.85.6.777; CATFORD J, 1992, COMMUNITY PREVENTION, P164; CHAPMAN S, 1993, BRIT MED J, V307, P429, DOI 10.1136/bmj.307.6901.429; CLARKSON J, 1991, J NUTR HLTH, V7, P101; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; GREEN LW, 1993, PROMOTION ED, P11; LUEPKER RV, 1994, AM J PUBLIC HEALTH, V84, P1383, DOI 10.2105/AJPH.84.9.1383; *MIN AGR FISH FOOD, 1970, HOUS FOOD CONS EXP; MURPHY S, 1994, J NUTR HLTH, V9, P317; NUTBEAM D, 1990, PUBLIC HEALTH, V104, P353, DOI 10.1016/S0033-3506(05)80528-1; NUTBEAM D, 1993, J EPIDEMIOL COMMUN H, V47, P127, DOI 10.1136/jech.47.2.127; Nutbeam D., 1996, HEALTH PROMOT J AUST, V6, P58; PHILLIPS CJ, 1993, J EPIDEMIOL COMMUN H, V47, P215, DOI 10.1136/jech.47.3.215; PULLEN E, 1992, J EPIDEMIOL COMMUN H, V46, P455, DOI 10.1136/jech.46.4.455; PUSKA P, 1995, N KARELIA PROJECT 20; ROBERTS RJ, 1995, PUBLIC HEALTH, V109, P275, DOI 10.1016/S0033-3506(95)80205-3; ROSE G, 1984, CORONARY HEART DIS P; Shah BV, 1997, SOFTWARE STAT ANAL C; SMITH C, 1990, Health Education Research, V5, P381, DOI 10.1093/her/5.3.381; Smith C, 1994, Health Trends, V26, P18; Speller V, 1997, BRIT MED J, V315, P361; SUSSER M, 1995, AM J PUBLIC HEALTH, V85, P156, DOI 10.2105/AJPH.85.2.156; *WHO EXP COMM, 1982, WHO TECH REP SER, V678; WINKLEBY MA, 1994, AM J PUBLIC HEALTH, V84, P1369, DOI 10.2105/AJPH.84.9.1369; [No title captured]; [No title captured]	29	78	79	2	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					818	822		10.1136/bmj.316.7134.818	http://dx.doi.org/10.1136/bmj.316.7134.818			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZC488	9549451	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000072584300026
J	Mullins, RJ; Mann, NC; Hedges, JR; Worrall, W; Helfand, M; Zechnich, AD; Jurkovich, GJ				Mullins, RJ; Mann, NC; Hedges, JR; Worrall, W; Helfand, M; Zechnich, AD; Jurkovich, GJ			Adequacy of hospital discharge status as a measure of outcome among injured patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY 18-22, 1997	WASHINGTON, D.C.	Soc Acad Emergency Med			TRAUMA SYSTEM; MAJOR TRAUMA; MORTALITY; DEATH; CARE; COMORBIDITIES; INSTITUTION; DATABASES; ACCURACY; BIAS	Context.-Crude mortality rates at the time of hospital discharge are commonly used to assess the quality of care provided to patients hospitalized following trauma. Objectives.-To evaluate the adequacy of hospital death rates as an outcome measure following trauma and to determine the influence of noninjury illness as a cause of hospital death and the frequency of postdischarge death. Design.-Retrospective cohort analyses using hospital discharge data for injured patients cross-linked to death certificate data that provided 1 year of followup for all patients discharged alive. Patients.-A total of 90 048 injured patients admitted to all acute care hospitals in the state of Washington from 1991 through 1993 and discharged with at least 1 diagnosis coded in the International Classification of Diseases, Ninth Revision, Clinical Modification to indicate trauma. Main Outcome Measures.-Death in the hospital and death within 30 days of hospital discharge. Results.-Among 1912 injured patients with in-hospital deaths, 825 death certificates (43%) listed a noninjury cause of death, The overall mortality rate at hospital discharge was 21.2 per 100 000 hospitalized injured patients, and was 12.1 per 100 000 for trauma deaths and 9.1 per 100 000 for those designated as nontrauma deaths. Patients with trauma-related death designations were younger (mean age, 51.5 years vs 77.9 years), had shorter lengths of stay (median stay, 2 days vs 5 days), and sustained more severe injures (P<.001). Including the 1273 deaths that occurred within 30 days of hospital discharge increased rates for trauma-designated deaths to 14.1 per 100 000 and increased rates for nontrauma-designated deaths to 21.3 per 100 000. Conclusions.-Hospital discharge death rates are incomplete measures of death frequency for injured patients. Designation of the cause of death, especially among older, hospitalized, injured patients often reflects preexisting medical conditions. Adequate assessment of mortality following trauma requires measurement of the frequency of death following hospital discharge.	Oregon Hlth & Sci Univ, Sch Med, Dept Surg, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Sch Med, Dept Emergency Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Sch Med, Div Hlth Informat & Outcomes Res, Portland, OR 97201 USA; Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; University of Washington; University of Washington Seattle	Mullins, RJ (corresponding author), Oregon Hlth & Sci Univ, Sch Med, Dept Surg, L223A,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	mullinsr@ohsu.edu	Hedges, Jerris/AAC-1847-2021		PHS HHS [R49/CCR-006283] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON RN, 1997, MON VITAL STAT REP, V45, P17; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; DEYO RA, 1994, SPINE, V19, pS2083; FINELLI FC, 1989, J TRAUMA, V29, P541, DOI 10.1097/00005373-198905000-00001; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; GARNICK DW, 1995, HEALTH SERV RES, V29, P679; Gubler KD, 1997, ARCH SURG-CHICAGO, V132, P1010; IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; JONES DR, 1982, INT J EPIDEMIOL, V11, P276, DOI 10.1093/ije/11.3.276; JONES JM, 1995, J TRAUMA, V38, P123, DOI 10.1097/00005373-199501000-00029; Kleinbaum DG, 1996, SURVIVAL ANAL SELF L; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Messite J, 1996, JAMA-J AM MED ASSOC, V275, P794, DOI 10.1001/jama.275.10.794; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; MULLINS RJ, 1994, JAMA-J AM MED ASSOC, V271, P1919, DOI 10.1001/jama.271.24.1919; MULLINS RJ, 1995, J TRAUMA, V39, P941, DOI 10.1097/00005373-199511000-00020; NORUSIS MJ, 1996, SPSS VERSION 6 01 WI; Osler T, 1996, J TRAUMA, V41, P380, DOI 10.1097/00005373-199609000-00002; POLLOCK DA, 1993, JAMA-J AM MED ASSOC, V269, P1525, DOI 10.1001/jama.269.12.1525; ROMANO PS, 1992, AM J EPIDEMIOL, V136, P863, DOI 10.1093/aje/136.7.863; SHACKFORD SR, 1986, J TRAUMA, V26, P812, DOI 10.1097/00005373-198609000-00006; Winer B. J., 1971, STAT PRINCIPLES EXPT, V2	25	101	101	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1727	1731		10.1001/jama.279.21.1727	http://dx.doi.org/10.1001/jama.279.21.1727			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZQ544	9624026	Bronze			2022-12-24	WOS:000073878700034
J	Mason, AL; Xu, LZ; Guo, LS; Munoz, S; Jaspan, JB; Bryer-Ash, M; Cao, Y; Sander, DM; Shoenfeld, Y; Ahmed, A; Van de Water, J; Gershwin, ME; Garry, RF				Mason, AL; Xu, LZ; Guo, LS; Munoz, S; Jaspan, JB; Bryer-Ash, M; Cao, Y; Sander, DM; Shoenfeld, Y; Ahmed, A; Van de Water, J; Gershwin, ME; Garry, RF			Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders	LANCET			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; HEPATITIS-C VIRUS; LIVER-TRANSPLANTATION; SJOGRENS-SYNDROME; GRAVES-DISEASE; AUTOANTIBODIES; RECURRENCE; PROTEINS; PARTICLE	Background Retroviruses have been implicated in the aetiology of various autoimmune diseases. We used immunoblots as a surrogate test to find out whether retroviruses play a part in the development of primary biliary cirrhosis. Methods We did western blot tests for HIV-1 and the human intracisternal A-type particle (HIAP), on serum samples from 77 patients with primary biliary cirrhosis, 126 patients with chronic liver disease, 48 patients with systemic lupus erythematosus, and 25 healthy volunteers. Findings HIV-1 p24 gag seroreactivity was found in 27 (35%) of 77 patients with primary biliary cirrhosis, 14 (29%) of 48 patients with systemic lupus erythematosus, 14 (50%) of 28 patients with chronic viral hepatitis, and nine (39%) of 23 patients with either primary sclerosing cholangitis or biliary atresia, compared with only one (4%) of 24 patients with alcohol-related liver disease or alpha(1)-antitrypsin-deficiency liver disease, and only one (4%) of 25 healthy volunteers (p=0.003). Western blot reactivity to more than two HIAP proteins was found in 37 (51%) of patients with primary biliary cirrhosis, in 28 (58%) of patients with systemic lupus erythematosus, in 15 (20%) of patients with chronic viral hepatitis, and in four (17%) of those with other biliary diseases. None of the 23 patients with either alcohol-related liver disease or alpha(1)-antitrypsin deficiency, and only one of the healthy controls showed the same reactivity to HIAP proteins (p<0.0001). Our results showed a strong association between HIAP seroreactivity and the detection of autoantibodies to double-stranded DNA. HIAP seroreactivity was also strongly associated with the detection of mitochondrial, nuclear, and extractable nuclear antigens. Interpretation The HIV-1 and HIAP antibody reactivity found in patients with primary biliary cirrhosis and other biliary disorders may be attributable either to an autoimmune response to antigenically related cellular proteins or to an immune response to uncharacterised viral proteins that share antigenic determinants with these retroviruses.	Alton Ochsner Med Fdn & Ochsner Clin, Sect Gastroenterol & Hepatol, New Orleans, LA 70121 USA; Albert Einstein Med Ctr, Ctr Liver Dis, Philadelphia, PA 19141 USA; Tulane Univ, Med Ctr, Sch Med, Dept Med, New Orleans, LA USA; Tulane Univ, Med Ctr, Sch Med, Dept Microbiol & Immunol, New Orleans, LA USA; Univ Tennessee, Coll Med, Dept Med, Memphis, TN USA; Chaim Sheba Med Ctr, Dept Med B, Autoimmune Dis Res Unit, IL-52621 Tel Hashomer, Israel; Specialty Labs Inc, Santa Monica, CA USA; Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, Davis, CA USA	Ochsner Health System; Yeshiva University; Tulane University; Tulane University; University of Tennessee System; University of Tennessee Health Science Center; Chaim Sheba Medical Center; University of California System; University of California Davis	Mason, AL (corresponding author), Alton Ochsner Med Fdn & Ochsner Clin, Richard Freeman Res Inst, 1520 Jefferson Highway, New Orleans, LA 70121 USA.		Mason, Andrew/D-2938-2013	Mason, Andrew/0000-0002-0470-9522; Garry, Robert/0000-0002-5683-3250	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039588, R01DK039588] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE10862-03] Funding Source: Medline; NIDDK NIH HHS [DK39588] Funding Source: Medline; PHS HHS [A101467-01] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARKA N, 1995, CLIN DIAGN LAB IMMUN, V2, P469, DOI 10.1128/CDLI.2.4.469-472.1995; CELLO JP, 1989, AM J MED, V86, P539, DOI 10.1016/0002-9343(89)90381-1; CHA S, 1993, P NATL ACAD SCI USA, V90, P2527, DOI 10.1073/pnas.90.6.2527; Conrad B, 1997, CELL, V90, P303, DOI 10.1016/S0092-8674(00)80338-4; DORNER T, 1994, SCAND J GASTROENTERO, V29, P655, DOI 10.3109/00365529409092488; GARRY RF, 1990, SCIENCE, V250, P1127, DOI 10.1126/science.1701273; GARRY RF, 1995, RETROVIRUSES THEIR R; HADDAD J, 1992, LANCET, V339, P321, DOI 10.1016/0140-6736(92)91645-O; Jaspan JB, 1996, J CLIN ENDOCR METAB, V81, P2271, DOI 10.1210/jc.81.6.2271; JASPAN JB, 1995, AUTOIMMUNITY, V20, P135, DOI 10.3109/08916939509001938; KONIKOFF F, 1989, HEPATO-GASTROENTEROL, V36, P341; MUNOZ SJ, 1988, GASTROENTEROLOGY, V94, pA574; NEUBERGER J, 1982, NEW ENGL J MED, V306, P1, DOI 10.1056/NEJM198201073060101; Perron H, 1997, P NATL ACAD SCI USA, V94, P7583, DOI 10.1073/pnas.94.14.7583; PIRISI M, 1994, SCAND J GASTROENTERO, V29, P942; RODRIGUEZCUARTERO A, 1994, INFECTION, V22, P415, DOI 10.1007/BF01715500; Sherlock S, 1993, PRIMARY BILIARY CIRR; SWAAK T, 1985, ANN RHEUM DIS, V44, P245, DOI 10.1136/ard.44.4.245; TALAL N, 1990, J CLIN INVEST, V85, P1866, DOI 10.1172/JCI114647; TALAL N, 1990, ARTHRITIS RHEUM, V33, P741; VANDEWATER J, 1989, NEW ENGL J MED, V320, P1377, DOI 10.1056/NEJM198905253202104; VandeWater J, 1996, HEPATOLOGY, V24, P1079	22	125	129	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1620	1624		10.1016/S0140-6736(97)10290-2	http://dx.doi.org/10.1016/S0140-6736(97)10290-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620716				2022-12-24	WOS:000074026600009
J	Rosen, RC				Rosen, RC			Sildenafil: medical advance or media event?	LANCET			English	Editorial Material							IMPOTENCE		Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Rosen, RC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA.							ALTHOF SE, 1989, J SEX MARITAL THER, V15, P121; Boolell M, 1996, BRIT J UROL, V78, P257, DOI 10.1046/j.1464-410X.1996.10220.x; Burnett AL, 1998, GERIATRICS, V53, P34; DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; FuglMeyer AR, 1997, INT J IMPOT RES, V9, P141, DOI 10.1038/sj.ijir.3900269; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Laumann E. O., 1994, SOCIAL ORG SEXUALITY; LUE TF, 1990, WORLD J UROL, V8, P67, DOI 10.1007/BF01576350; Moreland RB, 1998, LIFE SCI, V62, pPL309, DOI 10.1016/S0024-3205(98)00158-1; Rosen RC, 1996, CLIN PSYCHOL REV, V16, P497, DOI 10.1016/0272-7358(96)00032-3; TAUB HC, 1993, UROLOGY, V42, P698, DOI 10.1016/0090-4295(93)90538-L	12	28	28	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	1998	351	9116					1599	1600		10.1016/S0140-6736(05)77682-0	http://dx.doi.org/10.1016/S0140-6736(05)77682-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620710				2022-12-24	WOS:000074026600003
J	Peet, DJ; Turley, SD; Ma, WZ; Janowski, BA; Lobaccaro, JMA; Hammer, RE; Mangelsdorf, DJ				Peet, DJ; Turley, SD; Ma, WZ; Janowski, BA; Lobaccaro, JMA; Hammer, RE; Mangelsdorf, DJ			Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha	CELL			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; 7-ALPHA-HYDROXYLASE GENE; HYPERCHOLESTEROLEMIA; BIOSYNTHESIS; PATHWAY; LIVER; FLUX; DIFFERENTIATION; SUPERFAMILY; ACTIVATION	We demonstrate that mice lacking the oxysterol receptor, LXR alpha, lose their ability to respond normally to dietary cholesterol and are unable to tolerate any amount of cholesterol in excess of that which they synthesize de novo. When fed diets containing cholesterol, LXR alpha (-/-) mice fair to induce transcription of the gene encoding cholesterol 7 alpha-hydroxylase (Cyp7a), the rate-limiting enzyme in bile acid synthesis. This defect is associated with a rapid accumulation of large amounts of cholesterol in the liver that eventually leads to impaired hepatic function. The regulation of several other crucial lipid metabolizing genes is also altered in LXR alpha (-/-) mice. These results demonstrate the existence of a physiologically significant feed-forward regulatory pathway for sterol metabolism and establish the role of LXR alpha as the major sensor of dietary cholesterol.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mangelsdorf, DJ (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia.		Lobaccaro, Jean-Marc/Q-3926-2019; Peet, Daniel/AAE-6698-2020; Lobaccaro, Jean-Marc A./U-1928-2019	Lobaccaro, Jean-Marc/0000-0001-9890-2392; Peet, Daniel/0000-0002-6085-8936; Mangelsdorf, David/0000-0002-4355-0796; Hammer, Robert E./0000-0001-5487-7551	NHLBI NIH HHS [HL09610] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL009610, R37HL009610] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYOSHI T, 1986, J LIPID RES, V27, P915; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; Breslow JL, 1996, SCIENCE, V272, P685, DOI 10.1126/science.272.5262.685; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BUCOLO G, 1973, CLIN CHEM, V19, P476; Carey Martin C., 1994, P719; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; COHEN BI, 1977, J LIPID RES, V18, P223; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; LAVY U, 1977, J LIPID RES, V18, P232; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LEHRMAN MA, 1987, J BIOL CHEM, V262, P3354; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MORI T, 1991, P NATL ACAD SCI USA, V88, P4338, DOI 10.1073/pnas.88.10.4338; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; RUDLING M, 1992, J LIPID RES, V33, P493; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; SHEFER S, 1991, J BIOL CHEM, V266, P2693; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; SHINAR DM, 1994, GENE, V147, P273, DOI 10.1016/0378-1119(94)90080-9; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; SPENCER TA, 1985, J BIOL CHEM, V260, P3391; SPENCER TA, 1994, ACCOUNTS CHEM RES, V27, P83, DOI 10.1021/ar00039a004; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Turley SD, 1997, HEPATOLOGY, V25, P797, DOI 10.1002/hep.510250403; TURLEY SD, 1988, LIVER BIOL PATHOBIOL, P617; UCHIDA K, 1980, J BIOCHEM, V87, P187, DOI 10.1093/oxfordjournals.jbchem.a132724; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; WILLY PJ, 1998, HORMONES SIGNALING, V1, P307; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	43	1197	1276	1	50	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					693	704		10.1016/S0092-8674(00)81432-4	http://dx.doi.org/10.1016/S0092-8674(00)81432-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630215	Bronze			2022-12-24	WOS:000073956700007
J	Kengaku, M; Capdevila, J; Rodriguez-Esteban, C; De La Pena, J; Johnson, RL; Belmonte, JCI; Tabin, CJ				Kengaku, M; Capdevila, J; Rodriguez-Esteban, C; De La Pena, J; Johnson, RL; Belmonte, JCI; Tabin, CJ			Distinct WNT pathways regulating AER formation and dorsoventral polarity in the chick limb bud	SCIENCE			English	Article							TRANSCRIPTION FACTOR LEF-1; BETA-CATENIN; VERTEBRATE LIMB; XENOPUS EMBRYOS; GENE-EXPRESSION; SONIC-HEDGEHOG; CELL FATE; AXIS; INDUCTION; DOMAINS	The apical ectodermal ridge (AER) is an essential structure for vertebrate limb development. Wnt3a is expressed during the induction of the chick AER, and misexpression of Wnt3a induces ectopic expression of AER-specific genes in the limb ectoderm. The genes beta-catenin and Lef1 can mimic the effect of Wnt3a, and blocking the intrinsic Lef1 activity disrupts AER formation. Hence, Wnt3a functions in AER formation through the beta-catenin/LEF1 pathway. In contrast, neither beta-catenin nor Lef1 affects the Wnt7a-regulated dorsoventral polarity of the limb. Thus, two related Wnt genes elicit distinct responses in the same tissues by using different intracellular pathways.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Salk Institute; Harvard University; Harvard Medical School; University of Texas System; UTMD Anderson Cancer Center	Belmonte, JCI (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DU SJ, 1995, MOL CELL BIOL, V15, P2625; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GASTROP J, 1992, EUR J IMMUNOL, V22, P1327, DOI 10.1002/eji.1830220531; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Greco TL, 1996, GENE DEV, V10, P313, DOI 10.1101/gad.10.3.313; HOLLYDAY M, 1995, MECH DEVELOP, V52, P9, DOI 10.1016/0925-4773(95)00385-E; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; KENGAKU M, UNPUB; KENGAKU M, 1998, COLD SPRING HARBOR L, V12, P421; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; MCGREW LL, 1995, DEV BIOL, V172, P337, DOI 10.1006/dbio.1995.0027; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; Noramly S, 1996, DEV BIOL, V179, P339, DOI 10.1006/dbio.1996.0265; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; ROS MA, 1992, DEVELOPMENT, V116, P811; Ros MA, 1997, DEVELOPMENT, V124, P1821; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SAWAI S, 1990, MOL CELL BIOL, V10, P2017, DOI 10.1128/MCB.10.5.2017; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vogel A, 1996, DEVELOPMENT, V122, P1737; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; YOKOUCHI Y, 1991, DEVELOPMENT, V113, P431; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	46	355	363	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 22	1998	280	5367					1274	1277		10.1126/science.280.5367.1274	http://dx.doi.org/10.1126/science.280.5367.1274			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596583				2022-12-24	WOS:000073852500052
J	Dwyer, ND; Troemel, ER; Sengupta, P; Bargmann, CI				Dwyer, ND; Troemel, ER; Sengupta, P; Bargmann, CI			Odorant receptor localization to olfactory cilia is mediated by ODR-4, a novel membrane-associated protein	CELL			English	Article							ACHIEVE BASOLATERAL LOCALIZATION; DOMINANT RETINITIS-PIGMENTOSA; CYCLOPHILIN HOMOLOG NINAA; CANINE KIDNEY-CELLS; CAENORHABDITIS-ELEGANS; C-ELEGANS; MICROSCOPY; CHAPERONE; RHODOPSIN; TRANSPORT	Seven transmembrane domain receptors can be localized to different parts of the plasma membrane or to different intracellular compartments in a receptor-specific and cell type-specific fashion. We show here that the C. elegans genes odr-4 and odr-8 are required for localization of a subset of seven transmembrane domain odorant receptors to the cilia of olfactory neurons. Other cilia-signaling proteins, including ion channels, a G alpha protein, and even other receptor types, are localized via an odr-4/odr-8-independent pathway. odr-4 encodes a novel membrane protein that is expressed exclusively on intracellular membranes of chemosensory neurons, where it acts cell-autonomously to facilitate odorant receptor folding or localization.	Univ Calif San Francisco, Howard Hughes Med Inst, Program Dev Biol, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Genet Program, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bargmann, CI (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Program Dev Biol, Dept Anat, San Francisco, CA 94143 USA.			Bargmann, Cornelia/0000-0002-8484-0618; Dwyer, Noelle/0000-0002-1995-7203				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Bohm SK, 1997, J BIOL CHEM, V272, P2363; BRENNER S, 1974, GENETICS, V77, P71; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; Chou JH, 1996, COLD SPRING HARB SYM, V61, P157; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; Colbert HA, 1997, J NEUROSCI, V17, P8259; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; HEIN L, 1995, NEUROPHARMACOLOGY, V34, P357, DOI 10.1016/0028-3908(95)00018-2; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Mombaerts P, 1996, COLD SPRING HARB SYM, V61, P135; Ng GYK, 1997, ENDOCRINOLOGY, V138, P4199, DOI 10.1210/en.138.10.4199; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sambrook JFE, 1989, MOL CLONING LAB MANU; Saunders C, 1996, J BIOL CHEM, V271, P995, DOI 10.1074/jbc.271.2.995; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1994, J NEUROSCI, V14, P5818; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; WILLIAMS BD, 1992, GENETICS, V131, P609; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wozniak M, 1997, J RECEPT SIGNAL TR R, V17, P373, DOI 10.3109/10799899709036615; Wozniak M, 1996, J BIOL CHEM, V271, P5017; Yu R, 1997, MOL PHARMACOL, V51, P785, DOI 10.1124/mol.51.5.785; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P12162, DOI 10.1073/pnas.94.22.12162	46	197	211	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1998	93	3					455	466		10.1016/S0092-8674(00)81173-3	http://dx.doi.org/10.1016/S0092-8674(00)81173-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590179	Bronze			2022-12-24	WOS:000073471500020
J	Epstein, R; Kanwisher, N				Epstein, R; Kanwisher, N			A cortical representation of the local visual environment	NATURE			English	Article							SPATIAL REORIENTATION; LANDMARK STABILITY	Medial temporal brain regions such as the hippocampal formation and parahippocampal cortex have been generally implicated in navigation(1-6) and visual memory(7-9). However, the specific function of each of these regions is not yet clear, Here we present evidence that a particular area within human parahippocampal cortex is involved in a critical component of navigation: perceiving the local visual environment, This region, which we name the 'parahippocampal place area' (PPA), responds selectively and automatically in functional magnetic resonance imaging (fMRI) to passively viewed scenes, but only weakly to single objects and not at all to faces, The critical factor for this activation appears to be the presence in the stimulus of information about the layout of local space. The response in the PPA to scenes with spatial layout but no discrete objects (empty rooms) is as strong as the response to complex meaningful scenes containing multiple objects (the same rooms furnished) and over twice as strong as the response to arrays of multiple objects without three-dimensional spatial context (the furniture from these rooms on a blank background). This response is reduced if the surfaces in the scene are rearranged so that they no longer define a coherent space, We propose that the PPA represents places by encoding the geometry of the local environment.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Epstein, R (corresponding author), MIT, Dept Brain & Cognit Sci, E10-238,79 Amherst St, Cambridge, MA 02139 USA.	epstein@psyche.mit.edu	Kennedy, Kristen M/B-4699-2008; Epstein, Russell/G-4517-2013	Kennedy, Kristen M/0000-0001-5373-9026; 				Aguirre GK, 1998, P NATL ACAD SCI USA, V95, P839, DOI 10.1073/pnas.95.3.839; Aguirre GK, 1997, J NEUROSCI, V17, P2512; Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; BIEGLER R, 1993, NATURE, V361, P631, DOI 10.1038/361631a0; BOHBOT V, IN PRESS NEUROPSYCHO; CHENG K, 1986, COGNITION, V23, P149, DOI 10.1016/0010-0277(86)90041-7; Fodor J. A, 1983, MODULARITY MIND; Gabrieli JDE, 1997, SCIENCE, V276, P264, DOI 10.1126/science.276.5310.264; GAFFAN D, 1994, J COGNITIVE NEUROSCI, V6, P305, DOI 10.1162/jocn.1994.6.4.305; Gallistel C. R., 1990, ORG LEARNING; HABIB M, 1987, CORTEX, V23, P73, DOI 10.1016/S0010-9452(87)80020-5; Hermer L, 1996, COGNITION, V61, P195, DOI 10.1016/S0010-0277(96)00714-7; HERMER L, 1994, NATURE, V370, P57, DOI 10.1038/370057a0; ISHAI A, 1997, NEUROIMAGE, V5, pS149; Kanwisher N, 1997, J NEUROSCI, V17, P4302; KNIERIM JJ, 1995, J NEUROSCI, V15, P1648, DOI 10.1523/JNEUROSCI.15-03-01648.1995; LANDIS T, 1986, ARCH NEUROL-CHICAGO, V43, P132, DOI 10.1001/archneur.1986.00520020026011; Maguire EA, 1996, P ROY SOC B-BIOL SCI, V263, P1745, DOI 10.1098/rspb.1996.0255; Maguire EA, 1997, J NEUROSCI, V17, P7103; MAGUIRE EA, 1996, NEUROPSYCHOLOGIA, V34, P994; MARGULES J, 1988, ANIM LEARN BEHAV, V16, P404, DOI 10.3758/BF03209379; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Rolls ET, 1997, EUR J NEUROSCI, V9, P1789, DOI 10.1111/j.1460-9568.1997.tb01538.x; Stern CE, 1996, P NATL ACAD SCI USA, V93, P8660, DOI 10.1073/pnas.93.16.8660	24	1992	2018	6	176	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					598	601		10.1038/33402	http://dx.doi.org/10.1038/33402			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZG300	9560155				2022-12-24	WOS:000072987200058
J	Fisher, K; Hanspal, RS				Fisher, K; Hanspal, RS			Phantom pain, anxiety depression, and their relation in consecutive patients with amputated limbs: case reports	BRITISH MEDICAL JOURNAL			English	Article									Royal Natl Orthopaed Hosp Trust, Disablement Serv Ctr, Stanmore HA7 4LP, Middx, England	University of London; University College London; Royal National Orthopaedic Hospital NHS Trust	Fisher, K (corresponding author), Royal Natl Orthopaed Hosp Trust, Disablement Serv Ctr, Brockley Hill, Stanmore HA7 4LP, Middx, England.							KATZ J, 1990, PAIN, V43, P319, DOI 10.1016/0304-3959(90)90029-D; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; PARKES CM, 1973, J PSYCHOSOM RES, V17, P97, DOI 10.1016/0022-3999(73)90010-X; Sherman R, 1995, J MILIT PSYCHOL, V7, P28; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	5	34	37	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					903	904		10.1136/bmj.316.7135.903	http://dx.doi.org/10.1136/bmj.316.7135.903			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZD691	9552839	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000072713300029
J	del Pozo, JC; Timpte, C; Tan, S; Callis, J; Estelle, M				del Pozo, JC; Timpte, C; Tan, S; Callis, J; Estelle, M			The ubiquitin-related protein RUB1 and auxin response in Arabidopsis	SCIENCE			English	Article							THALIANA; GENES	The AXR1 (auxin-resistant) protein, which has features of the ubiquitin-activating enzyme E1, is required for normal response to the plant hormone auxin in Arabidopsis thaliana. ECR1 functions together with AXR1 to activate members of the RUB/NEDD8 family of ubiquitin-related proteins. Extracts from mutant seedlings lacking AXR1 did not promote formation of the RUB-ECR1 thiolester, indicating that AXR1 is the major activity in this tissue. AXR1 was localized primarily to the nucleus of dividing and elongating cells, suggesting that the targets of RUB modification are nuclear. These results indicate that auxin response depends on RUB modification of one or more nuclear proteins.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	Indiana University System; Indiana University Bloomington; University of California System; University of California Davis	Estelle, M (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.		del Pozo, Juan C/K-7978-2014	del Pozo, Juan C/0000-0002-4113-457X; Callis, Judy/0000-0002-0622-078X	NIGMS NIH HHS [GM43644] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CALLIS J, 1995, GENETICS, V139, P921; Cernac A, 1997, DEVELOPMENT, V124, P1583; Chow NW, 1996, J BIOL CHEM, V271, P11339, DOI 10.1074/jbc.271.19.11339; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; EVANS ML, 1984, ENCY PLANT PHYSL, V10, P23; GRAY WM, IN PRESS CURR OPIN B; HAAS AL, 1997, FASEB J, V11, P125; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; HANDELI S, COMMUNICATION; HOBBIE L, 1994, PLANT CELL ENVIRON, V17, P525, DOI 10.1111/j.1365-3040.1994.tb00147.x; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; KLEE H, 1990, ANN REV PLANT PHYSL, V42, P1529; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; MAHAJAN R, 1997, CELL, V88, P197; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; PERKY SE, 1996, PLANT CELL, V8, P1977; Ruegger M, 1998, GENE DEV, V12, P198, DOI 10.1101/gad.12.2.198; Shayeghi M, 1997, NUCLEIC ACIDS RES, V25, P1162, DOI 10.1093/nar/25.6.1162; Tan S., UNPUB; TIMPTE C, 1995, PLANT J, V8, P561, DOI 10.1046/j.1365-313X.1995.8040561.x	25	179	189	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1760	1763		10.1126/science.280.5370.1760	http://dx.doi.org/10.1126/science.280.5370.1760			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624055				2022-12-24	WOS:000074197800044
J	Adolphs, R; Tranel, D; Damasio, AR				Adolphs, R; Tranel, D; Damasio, AR			The human amygdala in social judgment	NATURE			English	Article							FACIAL EXPRESSIONS; DAMAGE; RECOGNITION; LESIONS; EMOTION; FEAR	Studies in animals have implicated the amygdala in emotional(1-3) and social(4-6) behaviours, especially those related to fear and aggression. Although lesion(7-10) and functional imaging(11-13) studies in humans have demonstrated the amygdala's participation in recognizing emotional facial expressions, its role in human social behaviour has remained unclear. We report here our investigation into the hypothesis that the human amygdala is required for accurate social judgments of other individuals on the basis of their facial appearance. We asked three subjects with complete bilateral amygdala damage to judge faces of unfamiliar people with respect to two attributes important in real-life social encounters: approachability and trustworthiness. All three subjects judged unfamiliar individuals to be more approachable and more trustworthy than did control subjects. The impairment was most striking for faces to which normal subjects assign the most negative ratings: unapproachable and untrustworthy looking individuals. Additional investigations revealed that the impairment does not extend to judging verbal descriptions of people. The amygdala appears to be an important component of the neural systems that help retrieve socially relevant knowledge on the basis of facial appearance.	Univ Iowa, Coll Med, Dept Neurol, Div Cognit Neurosci, Iowa City, IA 52242 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA	University of Iowa; Salk Institute	Adolphs, R (corresponding author), Univ Iowa, Coll Med, Dept Neurol, Div Cognit Neurosci, 200 Hawkins Dr, Iowa City, IA 52242 USA.	ralph-adolphs@uiowa.edu	Damasio, Antonio/AAD-1342-2019; Tudusciuc, Oana/C-1339-2011	Tranel, Daniel/0000-0002-1338-1389				ADOLPHS R, 1995, J NEUROSCI, V15, P5879; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; ANDERSON NH, 1968, J PERS SOC PSYCHOL, V9, P272, DOI 10.1037/h0025907; BLANCHARD DC, 1972, J COMP PHYSIOL PSYCH, V81, P281, DOI 10.1037/h0033521; Breiter HC, 1996, NEURON, V17, P875, DOI 10.1016/S0896-6273(00)80219-6; Broks P, 1998, NEUROPSYCHOLOGIA, V36, P59, DOI 10.1016/S0028-3932(97)00105-X; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; DDAMASIO AR, 1995, NEUROSCIENTIST, V1, P19; Ekman P., 1976, PICTURES FACIAL AFFE; Frank RJ, 1997, NEUROIMAGE, V5, P13, DOI 10.1006/nimg.1996.0250; KLING A, 1979, EXP NEUROL, V66, P88, DOI 10.1016/0014-4886(79)90065-7; KLING A S, 1992, P353; LeDoux J. E., 1996, EMOTIONAL BRAIN; LEWICKI P, 1992, AM PSYCHOL, V47, P796, DOI 10.1037/0003-066X.47.6.796; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; Morris JS, 1998, BRAIN, V121, P47, DOI 10.1093/brain/121.1.47; NAHM FKD, 1993, NEUROPSYCHOLOGIA, V31, P727, DOI 10.1016/0028-3932(93)90125-J; ROSVOLD HE, 1954, J COMP PHYSIOL PSYCH, V47, P173, DOI 10.1037/h0058870; Saarni C., 1998, P237; TRANEL D, 1990, ARCH NEUROL-CHICAGO, V47, P349, DOI 10.1001/archneur.1990.00530030131029; TRANEL D, 1996, NEUROPSYCHOLOGICAL A, P81; WEISKRANTZ L, 1956, J COMP PHYSIOL PSYCH, V49, P381, DOI 10.1037/h0088009; YOUNG AW, 1995, BRAIN, V118, P15, DOI 10.1093/brain/118.1.15	24	861	875	3	112	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					470	474		10.1038/30982	http://dx.doi.org/10.1038/30982			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZR842	9624002				2022-12-24	WOS:000074020000045
J	Muhua, L; Adames, NR; Murphy, MD; Shields, CR; Cooper, JA				Muhua, L; Adames, NR; Murphy, MD; Shields, CR; Cooper, JA			A cytokinesis checkpoint requiring the yeast homologue of an APC binding protein	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; SPINDLE ORIENTATION; GENE; MICROTUBULES; DYNEIN; MUTANT	Checkpoint controls ensure that events of the cell-division cycle are completed with fidelity and in the correct order. In budding yeast with a mutation in the motor protein dynein, the mitotic spindle is often misaligned and therefore slow to enter the neck between mother cell and budding daughter cell. When this occurs, cytokinesis (division of the cytoplasm into two) is delayed until the spindle is properly positioned(1). Here we describe mutations that abolish this delay, indicating the existence of a new checkpoint mechanism. One mutation lies in the gene encoding the yeast homologue of EB1, a human protein that binds the adenomatous polyposis coli (APC) protein, a tumour suppressor. EB1 is located on microtubules of the mitotic spindle and is important in spindle assembly. EB1 may therefore, by associating with microtubules, contribute to the sensor mechanism that activates the checkpoint. Another mutation affects Stt4, a phosphatidylinositol-4-OH kinase. Cold temperature is an environmental stimulus that causes misalignment of the mitotic spindle in yeast and appears to activate this checkpoint mechanism.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Cooper, JA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.		Adames, Neil/S-1460-2017; Adames, Neil/C-8863-2012; Cooper, John/E-9389-2012; Cooper, John/D-4448-2014	Adames, Neil/0000-0003-4331-9348; Adames, Neil/0000-0003-4331-9348; Cooper, John/0000-0002-0933-4571	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047337] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM047337, R01 GM047337-07] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; MCMILLAN JN, 1994, J CELL BIOL, V125, P143, DOI 10.1083/jcb.125.1.143; MUHUA L, 1994, CELL, V78, P669, DOI 10.1016/0092-8674(94)90531-2; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SMITH KJ, 1994, CANCER RES, V54, P3672; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; SU LK, 1995, CANCER RES, V55, P2972; SULLIVAN DS, 1992, J CELL BIOL, V119, P379, DOI 10.1083/jcb.119.2.379; Waddle JA, 1996, J CELL BIOL, V132, P861, DOI 10.1083/jcb.132.5.861; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; YEH E, 1995, J CELL BIOL, V130, P687, DOI 10.1083/jcb.130.3.687; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	19	136	138	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					487	491		10.1038/31014	http://dx.doi.org/10.1038/31014			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624007	Green Accepted			2022-12-24	WOS:000074020000050
J	Cnattingius, S; Haglund, B; Kramer, MS				Cnattingius, S; Haglund, B; Kramer, MS			Differences in late fetal death rates in association with determinants of small for gestational age fetuses: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							INTRAUTERINE GROWTH-RETARDATION; RISK-FACTORS; MATERNAL AGE; STILLBIRTH; BIRTH; MALFORMATIONS; COMPLICATIONS; ANTEPARTUM; DURATION; SMOKING	Objective: To examine differences in late fetal death rates in association with determinants of small for gestational age fetuses. Design: Population based cohort study. Subjects: 1 026 249 pregnancies without congenital malformations. Setting: Sweden 1983-92. Main outcome measure: Late fetal death rate. Results: Depending on underlying determinants late fetal death rates were greatly increased in extremely small for gestational age fetuses (range 16 to 45 per 1000) compared with non-small for gestational age fetuses (1.4 to 4.6). In extremely small for gestational age fetuses late fetal death rates were increased from 31 per 1000 in mothers aged less than 35 years to 45 per 1000 in older mothers, and from 22 per 1000 in women < 155 cm in height to 33 per 1000 in women greater than or equal to 175 cm tall. Late fetal death rates were also higher in extremely small for gestational age fetuses in singleton compared with twin pregnancies and in non-hypertensive pregnancies compared with pregnancies complicated by severe pre-eclampsia or other hypertensive disorders. Slightly higher late fetal death rates were observed in nulliparous compared with parous women and in non-smokers compared with smokers. Conclusions: Although the risk of late fetal death is greatly increased in fetuses that are extremely small for gestational age the risk is strongly modified by underlying determinants-for example, there is a lower risk of late fetal death in a small for gestational age fetus if the mother is of short stature, has a twin pregnancy, or has hypertension.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Natl Board Hlth & Welf, Ctr Epidemiol, Stockholm, Sweden; McGill Univ, Fac Med, Dept Pediat, Montreal, PQ, Canada	Karolinska Institutet; National Board of Health & Welfare; McGill University	Cnattingius, S (corresponding author), Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden.							ABDELLA TN, 1984, OBSTET GYNECOL, V63, P365; Aberg A, 1992, Int J Technol Assess Health Care, V8 Suppl 1, P20; ALESSANDRI LM, 1992, BRIT J OBSTET GYNAEC, V99, P711, DOI 10.1111/j.1471-0528.1992.tb13868.x; BARROS FC, 1992, PEDIATRICS, V90, P238; Cnattingius S, 1998, NEW ENGL J MED, V338, P147, DOI 10.1056/NEJM199801153380302; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; CNATTINGIUS S, 1990, International Journal of Feto-Maternal Medicine, V3, P15; Cnattingius S, 1997, AM J EPIDEMIOL, V145, P319; GARDOSI J, 1992, LANCET, V339, P283, DOI 10.1016/0140-6736(92)91342-6; GENEST DR, 1992, OBSTET GYNECOL, V80, P575; Haglund B, 1993, Paediatr Perinat Epidemiol, V7, P33, DOI 10.1111/j.1365-3016.1993.tb00599.x; HEINRICH UE, 1992, BAILLIERE CLIN ENDOC, V6, P589, DOI 10.1016/S0950-351X(05)80114-4; Hogberg U, 1997, ACTA OBSTET GYN SCAN, V76, P907, DOI 10.3109/00016349709034900; KHOURY MJ, 1988, PEDIATRICS, V82, P83; KRAMER MS, 1990, PEDIATRICS, V86, P18; KRAMER MS, 1987, PEDIATRICS, V80, P502; Lang JM, 1996, EPIDEMIOLOGY, V7, P369, DOI 10.1097/00001648-199607000-00006; LITTLE RE, 1993, AM J EPIDEMIOL, V137, P1177, DOI 10.1093/oxfordjournals.aje.a116620; NAEYE RL, 1983, OBSTET GYNECOL, V61, P210; NAEYE RL, 1979, EARLY HUM DEV, V3, P229, DOI 10.1016/0378-3782(79)90031-8; OUNSTED M, 1981, EARLY HUM DEV, V5, P367, DOI 10.1016/0378-3782(81)90017-7; Radestad I, 1996, BRIT MED J, V312, P1505, DOI 10.1136/bmj.312.7045.1505; RAYMOND EG, 1994, BRIT J OBSTET GYNAEC, V101, P301, DOI 10.1111/j.1471-0528.1994.tb13614.x; RAYMOND EG, 1993, ACTA OBSTET GYN SCAN, V72, P633, DOI 10.3109/00016349309021156; RYDHSTROM H, 1994, ACTA OBSTET GYN SCAN, V73, P779, DOI 10.3109/00016349409072504; SANDERSON DA, 1994, BRIT J OBSTET GYNAEC, V101, P310, DOI 10.1111/j.1471-0528.1994.tb13616.x; Sciscione AC, 1996, AM J OBSTET GYNECOL, V175, P544; SNIJDERS RJM, 1993, AM J OBSTET GYNECOL, V168, P547, DOI 10.1016/0002-9378(93)90491-Z; Wennergren M, 1992, Int J Technol Assess Health Care, V8 Suppl 1, P147; YUDKIN PL, 1987, LANCET, V1, P1192; 1990, AM J OBSTET GYNECOL, V163, P1689	31	124	125	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1998	316	7143					1483	1487		10.1136/bmj.316.7143.1483	http://dx.doi.org/10.1136/bmj.316.7143.1483			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP020	9582131	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000073707700019
J	McNamee, D				McNamee, D			Cancer hopes and setbacks	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1450	1450		10.1016/S0140-6736(05)78868-1	http://dx.doi.org/10.1016/S0140-6736(05)78868-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605800				2022-12-24	WOS:000073707300006
J	Smith, SS; Gong, QH; Hsu, FC; Markowitz, RS; ffrench-Mullen, JMH; Li, HS				Smith, SS; Gong, QH; Hsu, FC; Markowitz, RS; ffrench-Mullen, JMH; Li, HS			GABA(A) receptor alpha 4 subunit suppression prevents withdrawal properties of an endogenous steroid	NATURE			English	Article							A RECEPTOR; RAT-BRAIN; PROGESTERONE; METABOLITES; DEPENDENCE; ETHANOL; WOMEN; MODEL	The hormone progesterone is readily converted to 3 alpha-OH-5 alpha-pregnan-20-one (3 alpha,5 alpha-THP) in the brains of males and females(1,2), In the brain, 3 alpha,5 alpha-THP acts like a sedative(3-5), decreasing anxiety and reducing seizure activity, by enhancing the function of GABA (gamma-aminobutyric acid)(6-8), the brain's major inhibitory neurotransmitter, Symptoms of premenstrual syndrome (PMS), such as anxiety(9) and seizure(10,11) susceptibility, are associated with sharp declines in circulating levels of progesterone and, consequently, of levels of 3 alpha,5 alpha-THP in the brain. Abrupt discontinuation of use of sedatives such as benzodiazepines(12) and ethanol(13) can also produce PMS-like withdrawal symptoms. Here we report a progesterone-withdrawal paradigm, designed to mimic PMS and post-partum syndrome in a rat model. In this model, withdrawal of progesterone leads to increased seizure susceptibility and insensitivity to benzodiazepine sedatives through an effect on gene transcription. Specifically, this effect was due to reduced levels of 3 alpha,5 alpha-THP which enhance transcription of the gene encoding the alpha 4 subunit of the GABA(A) receptor. We also find that increased susceptibility to seizure after progesterone withdrawal is due to a sixfold decrease in the decay time for GABA currents and consequent decreased inhibitory function. Blockade of the alpha 4 gene transcript prevents these withdrawal properties. PMS symptoms may therefore be attributable, in part, to alterations in expression of GABA(A) receptor subunits as a result of progesterone withdrawal.	Allegheny Univ Hlth Sci, Dept Neurobiol & Anat, EPPI, Philadelphia, PA 19129 USA; Zeneca Inc, Zeneca Pharmaceut, RIN Biosci, Wilmington, DE 19850 USA	AstraZeneca	Smith, SS (corresponding author), Allegheny Univ Hlth Sci, Dept Neurobiol & Anat, EPPI, 3200 Henry Ave, Philadelphia, PA 19129 USA.			Smith, Sheryl/0000-0003-4308-3267				ATOR NA, 1993, EUR J PHARMACOL, V241, P237, DOI 10.1016/0014-2999(93)90208-Y; BACKSTROM T, 1984, ACTA NEUROL SCAND, V69, P240; BELELLI D, 1989, EUR J PHARMACOL, V166, P325, DOI 10.1016/0014-2999(89)90077-0; BITRAN D, 1991, BRAIN RES, V561, P157, DOI 10.1016/0006-8993(91)90761-J; Brot MD, 1997, EUR J PHARMACOL, V325, P1, DOI 10.1016/S0014-2999(97)00096-4; BUCK KJ, 1990, J PHARMACOL EXP THER, V253, P713; COSTA AMN, 1995, J NEUROPHYSIOL, V74, P464, DOI 10.1152/jn.1995.74.1.464; DENNERSTEIN L, 1985, BRIT MED J, V290, P1617, DOI 10.1136/bmj.290.6482.1617; Devaud LL, 1997, J NEUROCHEM, V69, P126; FILE SE, 1990, NEUROSCI BIOBEHAV R, V14, P135, DOI 10.1016/S0149-7634(05)80214-3; FRIEDMAN L, 1993, MOL PHARMACOL, V44, P191; GALLO MA, 1993, PHARMACOL BIOCHEM BE, V46, P897, DOI 10.1016/0091-3057(93)90219-J; HERZOG AG, 1995, NEUROLOGY, V45, P1660, DOI 10.1212/WNL.45.9.1660; Holt RA, 1996, NEUROPHARMACOLOGY, V35, P1457, DOI 10.1016/S0028-3908(96)00064-0; KERN W, 1994, J NEUROCHEM, V62, P764; KOKKA N, 1993, ALCOHOL CLIN EXP RES, V17, P525, DOI 10.1111/j.1530-0277.1993.tb00793.x; LAU EC, 1993, J STEROID BIOCHEM, V46, P751, DOI 10.1016/0960-0760(93)90315-N; LAVOIE AM, 1997, BIOPHYS J, V73, P1; Mahmoudi M, 1997, J NEUROCHEM, V68, P2485; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MOSSIER B, 1994, J BIOL CHEM, V269, P25777; PURDY RH, 1991, P NATL ACAD SCI USA, V88, P4553, DOI 10.1073/pnas.88.10.4553; SMITH SS, 1994, PROG NEUROBIOL, V44, P55, DOI 10.1016/0301-0082(94)90057-4; SMITH SS, 1987, BRAIN RES, V400, P353, DOI 10.1016/0006-8993(87)90634-2; Sundstrom I, 1997, PSYCHONEUROENDOCRINO, V22, P25, DOI 10.1016/S0306-4530(96)00035-2; TWYMAN RE, 1992, J PHYSIOL-LONDON, V456, P215, DOI 10.1113/jphysiol.1992.sp019334; TYNDALE RF, 1994, J NEUROSCI, V14, P5417; Wafford KA, 1996, MOL PHARMACOL, V50, P670; WISDEN W, 1991, FEBS LETT, V289, P227, DOI 10.1016/0014-5793(91)81076-K; YU XJ, 1994, MOL PHARMACOL, V47, P603	30	462	474	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					926	930		10.1038/31948	http://dx.doi.org/10.1038/31948			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582073				2022-12-24	WOS:000073359900050
J	Rogal, AP				Rogal, AP			Brignole	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Rogal, AP (corresponding author), 200 South St, Brookline, MA 02167 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					691	692		10.7326/0003-4819-128-8-199804150-00016	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537945				2022-12-24	WOS:000073052500012
J	Schacker, TW; Hughes, JP; Shea, T; Coombs, RW; Corey, L				Schacker, TW; Hughes, JP; Shea, T; Coombs, RW; Corey, L			Biological and virologic characteristics of primary HIV infection	ANNALS OF INTERNAL MEDICINE			English	Article						human immunodeficiency virus infections; disease progression; RNA, viral; CD4 lymphocyte count; viral load	HUMAN-IMMUNODEFICIENCY-VIRUS; MULTICENTER AIDS COHORT; CLINICAL MANIFESTATIONS; IMMUNE-DEFICIENCY; TYPE-1 INFECTION; PLASMA; ZIDOVUDINE; RNA; QUANTITATION; PROGRESSION	Background: The clinical events surrounding acute HIV-1 infection have been well described, but little is known about whether the virologic course of acute HIV-1 infection influences the subsequent progression of disease. Objective: To define the virologic natural history of acute and very early HIV infection. Design: Prospective, longitudinal cohort study. Setting: University of Washington Research Clinic. Participants: 74 adults enrolled soon after acquisition of HIV (mean, 69 days). Measurements: Plasma HIV-1 RNA levels; quantitative cell cultures; CD4 cell counts; and detailed clinical assessments done at study entry, biweekly for 1 month, monthly for 2 months, and quarterly thereafter. Results: In the first 30 days after acquisition of HIV, HIV-1 RNA levels varied greatly among participants (range, 27 200 to 1.6 x 10(6) copies per mt of plasma). Levels of HIV-1 RNA decreased by a mean of 6.5% per week for the first 120 days and then increased by a mean of 0.15% per week. CD4 cell counts decreased by a mean of 5.2 cells/mm(3) per week for the first 160 days and by a mean of 1.9 cells/mm(3) per week thereafter (P < 0.01). Disease progressed faster in participants who sought medical care for their acute seroconversion syndrome (P = 0.01) and those who had high plasma HIV-1 RNA levels 120 to 365 days after acquisition (P < 0.01). Peak levels in the first 120 days were not predictive of disease progression. Conclusions: The variability in viral RNA levels associated with acute HIV-1 infection is greater than previously appreciated. Within 120 days of acquisition, plasma HIV RNA levels rapidly decrease to an inflection point, after which they gradually increase. Virus-host interactions soon after acquisition seem to have a major influence on the long-term outcome of HIV-1 disease.	Univ Washington, Dept Lab Med 357110, Seattle, WA 98195 USA; Univ Washington, Seattle, WA 98122 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Minnesota System; University of Minnesota Twin Cities; Fred Hutchinson Cancer Center	Corey, L (corresponding author), Fred Hutchinson Canc Res Ctr, 1124 Columbia St,M-115, Seattle, WA 98104 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001228] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-01228, AI-45206, AI-26657] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTELSMAN JFWM, 1990, ENDOSCOPY, V22, P184, DOI 10.1055/s-2007-1012836; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Cleveland W. S., 1992, STAT MODELS S PACIFI; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; Diggle P, 1994, ANAL LONGITUDINAL DA, VXI, P253; FISCUS SA, 1995, J INFECT DIS, V171, P305, DOI 10.1093/infdis/171.2.305; FOX R, 1987, AIDS, V1, P35; GRAHAM BS, 1995, NEW ENGL J MED, V333, P1331, DOI 10.1056/NEJM199511163332007; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HENRARD DR, 1995, J ACQ IMMUN DEF SYND, V9, P305; HO DD, 1985, ANN INTERN MED, V103, P880, DOI 10.7326/0003-4819-103-6-880; KASLOW RA, 1987, ANN INTERN MED, V107, P474, DOI 10.7326/0003-4819-107-4-474; KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LEAVITT R, 1996, 36 INT C ANT AG CHEM; LEE TH, 1994, J ACQ IMMUN DEF SYND, V7, P381; LETVIN NL, 1993, NEW ENGL J MED, V329, P1400, DOI 10.1056/NEJM199311043291908; LOES SKD, 1993, CLIN INFECT DIS, V17, P59, DOI 10.1093/clinids/17.1.59; McElrath MJ, 1996, P NATL ACAD SCI USA, V93, P3972, DOI 10.1073/pnas.93.9.3972; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MILLER RG, 1981, SURVIVAL ANAL, P7; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; Perrin L, 1996, AIDS, V10, P1233, DOI 10.1097/00002030-199609000-00009; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; PIATAK M, 1993, LANCET, V341, P1099, DOI 10.1016/0140-6736(93)92463-4; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RABENECK L, 1990, JAMA-J AM MED ASSOC, V263, P2318, DOI 10.1001/jama.263.17.2318; Revets H, 1996, J CLIN MICROBIOL, V34, P1058, DOI 10.1128/JCM.34.5.1058-1064.1996; SAIMOT AG, 1996, INT C AIDS, V11, P112; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SCHECHTER MT, 1990, AIDS, V4, P185, DOI 10.1097/00002030-199003000-00002; SINICCO A, 1993, J ACQ IMMUN DEF SYND, V6, P575; TAMELET C, 1996, INT C AIDS, V11, P113; TINDALL B, 1988, ARCH INTERN MED, V148, P945, DOI 10.1001/archinte.148.4.945; TURNBULL BW, 1976, J R STAT SOC B, V38, P290	40	225	230	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					613	+		10.7326/0003-4819-128-8-199804150-00001	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537934				2022-12-24	WOS:000073052500001
J	De Felipe, C; Herrero, JF; O'Brien, JA; Palmer, JA; Doyle, CA; Smith, AJH; Laird, JMA; Belmonte, C; Cervero, F; Hunt, SP				De Felipe, C; Herrero, JF; O'Brien, JA; Palmer, JA; Doyle, CA; Smith, AJH; Laird, JMA; Belmonte, C; Cervero, F; Hunt, SP			Altered nociception, analgesia and aggression in mice lacking the receptor for substance P	NATURE			English	Article							STRESS-INDUCED ANALGESIA; PRIMARY SENSORY NEURONS; DORSAL HORN; SPINAL-CORD; RAT; ANTAGONIST; ACTIVATION; INHIBITION; INDUCTION; LOCALIZATION	The peptide neurotransmitter substance P modulates sensitivity to pain by activating the neurokinin-1 (NK-1) receptor, which is expressed by discrete populations of neurons throughout the central nervous system(1-4). Substance P is synthesized by small-diameter sensory 'pain' fibres(5), and release of the peptide into the dorsal horn of the spinal cord following intense peripheral stimulation(6) promotes central hyperexcitability and increased sensitivity to pain(7-10). However, despite the availability of specific NK-1 antagonists(4), the function of substance P in the perception of pain remains unclear Here we investigate the effect of disrupting the gene encoding the NK-1 receptor in mice, We found that the mutant mice were healthy and fertile, but the characteristic amplification ('wind up') and intensity coding of nociceptive reflexes was absent, Although substance P did not mediate the signalling of acute pain or hyperalgesia, it was essential for the full development of stress-induced analgesia and for an aggressive response to territorial challenge, demonstrating that the peptide plays an unexpected role in the adaptive response to stress.	MRC, Mol Neurobiol Lab, Div Neurobiol, Cambridge CB2 2QH, England; Univ Miguel Hernandez, Inst Neurociencias, Alicante 03080, Spain; Univ Alcala de Henares, Fac Med, Dept Fisiol, Madrid 28871, Spain; Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN); Universidad de Alcala; University of Edinburgh	Hunt, SP (corresponding author), MRC, Mol Neurobiol Lab, Div Neurobiol, Hills Rd, Cambridge CB2 2QH, England.	hunt@mrc-lmb.cam.ac.uk	de Felipe, Carmen/D-3813-2012; HUNT, STEPHEN P/C-1646-2008	Laird, Jennifer/0000-0001-6570-3995; Herrero, Juan F./0000-0003-1986-3482				Abbadie C, 1997, PAIN, V69, P101, DOI 10.1016/S0304-3959(96)03285-X; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; CERVERO F, 1985, J PHYSIOL-LONDON, V365, P223, DOI 10.1113/jphysiol.1985.sp015768; Chapman V, 1996, J NEUROPHYSIOL, V76, P1817, DOI 10.1152/jn.1996.76.3.1817; DEFELIPE C, 1995, SCIENCE, V267, P899, DOI 10.1126/science.7531367; DUGGAN AW, 1988, BRAIN RES, V451, P261, DOI 10.1016/0006-8993(88)90771-8; HERRERO JF, 1993, BRIT J PHARMACOL, V110, P303, DOI 10.1111/j.1476-5381.1993.tb13809.x; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; Konig M, 1996, NATURE, V383, P535, DOI 10.1038/383535a0; LAIRD JMA, 1993, BRIT J PHARMACOL, V109, P713, DOI 10.1111/j.1476-5381.1993.tb13632.x; MA QP, 1995, J PHYSIOL-LONDON, V486, P769, DOI 10.1113/jphysiol.1995.sp020852; MAENO H, 1993, MOL BRAIN RES, V18, P43, DOI 10.1016/0169-328X(93)90172-L; MAGGI CA, 1993, J AUTON PHARMACOL, V13, P23, DOI 10.1111/j.1474-8673.1993.tb00396.x; MANTYH PW, 1989, J NEUROSCI, V9, P258; MAREK P, 1992, BRAIN RES, V578, P197, DOI 10.1016/0006-8993(92)90248-8; MCCARTHY PW, 1989, NEUROSCIENCE, V28, P745, DOI 10.1016/0306-4522(89)90019-5; NAKAYA Y, 1994, J COMP NEUROL, V347, P249, DOI 10.1002/cne.903470208; Nehls M, 1996, SCIENCE, V272, P886, DOI 10.1126/science.272.5263.886; Neumann S, 1996, NATURE, V384, P360, DOI 10.1038/384360a0; NOGUCHI K, 1992, J NEUROSCI, V12, P2563; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; Rupniak NMJ, 1996, PAIN, V67, P189, DOI 10.1016/0304-3959(96)03109-0; SIEGEL A, 1995, AGGRESSIVE BEHAV, V21, P49, DOI 10.1002/1098-2337(1995)21:1<49::AID-AB2480210108>3.0.CO;2-2; VANDERAH TW, 1992, J PHARMACOL EXP THER, V262, P190; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; XU XJ, 1992, EUR J PHARMACOL, V216, P337, DOI 10.1016/0014-2999(92)90428-7; YAKSH TL, 1994, TXB PAIN, P165; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	29	612	619	1	38	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 26	1998	392	6674					394	397		10.1038/32904	http://dx.doi.org/10.1038/32904			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537323				2022-12-24	WOS:000072713600053
J	Wickware, P				Wickware, P			Action at the edges in cancer research	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					417	417		10.1038/32945	http://dx.doi.org/10.1038/32945			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537329				2022-12-24	WOS:000072713600059
J	Egger, M; Low, N; Smith, GD; Lindblom, B; Herrmann, B				Egger, M; Low, N; Smith, GD; Lindblom, B; Herrmann, B			Screening for chlamydial infections and the risk of ectopic pregnancy in a county in Sweden: ecological analysis	BRITISH MEDICAL JOURNAL			English	Article							PELVIC INFLAMMATORY DISEASE; SEXUALLY-TRANSMITTED DISEASES; TRACHOMATIS INFECTION; PREVENTION; EPIDEMIOLOGY; PREVALENCE; WISCONSIN; PROGRAM	Objectives: To analyse trends in rates of genital chlamydial infection and ectopic pregnancy between 1985 and 1995 in a county in Sweden. Setting: Uppsala county where screening for chlamydial infection, treatment, and contact tracing has been widespread and where ectopic pregnancies are recorded. Methods: Rates of chlamydial infections and ectopic pregnancy between 1985 and 1995 were calculated for women aged 20-39 years. Poisson and linear regression were used to examine the association between the risk of ectopic pregnancy and the current rates of chlamydial infection and rates of chlamydial infection from up to 5 years earlier. Main outcome measures: Rates of chlamydial infection per 100 examinations, rates of ectopic pregnancy per 1000 pregnancies, rate ratios and 95% confidence intervals for an increase in chlamydial infections of 5 new cases per 100 examinations. Results: 103 870 cervical samples from women aged 15-39 years were analysed; 5648 (5.4%) were positive for chlamydia. 51 630 pregnancies were analysed; 930 (1.8%) were ectopic. Both rates declined over time. For women aged 20-24 years there was a strong correlation between the rate of ectopic pregnancy and the rate of chlamydial infection in the same year (r=0.93, P < 0.001); among older women correlations were stronger with rates of chlamydial infection occurring 1 or 2 years earlier. In Poisson regression ectopic pregnancy was most strongly associated with the current rate of chlamydial infection among women aged 20-24 (rate ratio 1.85, 95% confidence interval 1.44 to 2.38), with the rate of infection 1 year earlier among 25-29 year olds (rate ratio 1.72, 1.33 to 2.22) and 30-34 year olds (rate ratio 2.27, 1.53 to 3.37); and with the rate 2 years earlier among 35 to 39 year olds (rate ratio 2.58, 1.45 to 4.60). Conclusions: Declining rates of genital chlamydial infections have probably led to a fall in the rate of ectopic pregnancies. The timing of the decline in the rate of ectopic pregnancies varies with age. Among young women falling rates of chlamydial infection have been accompanied by an immediate reduction in the rate of ectopic pregnancy.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ London Kings Coll, Sch Med & Dent, Dept Genitourinary Med, London SE5 9RS, England; Univ Uppsala Hosp, Dept Obstet & Gynaecol, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Infect Dis & Clin Microbiol, S-75185 Uppsala, Sweden	University of Bristol; University of London; King's College London; Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital	Egger, M (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	m.egger@bristol.ac.uk	Low, Nicola/H-4718-2019; Davey Smith, George/A-7407-2013	Low, Nicola/0000-0003-4817-8986; Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132				ADDISS DG, 1993, SEX TRANSM DIS, V20, P28, DOI 10.1097/00007435-199301000-00006; CATES W, 1990, EPIDEMIOL REV, V12, P199, DOI 10.1093/oxfordjournals.epirev.a036054; CATES W, 1991, AM J OBSTET GYNECOL, V164, P1771, DOI 10.1016/0002-9378(91)90559-A; CHOW JM, 1990, JAMA-J AM MED ASSOC, V263, P3164, DOI 10.1001/jama.263.23.3164; CHOW WH, 1987, EPIDEMIOL REV, V9, P70, DOI 10.1093/oxfordjournals.epirev.a036309; COSTE J, 1994, FERTIL STERIL, V62, P289; FRANKS AL, 1990, AM J OBSTET GYNECOL, V163, P1120, DOI 10.1016/0002-9378(90)90668-W; HERRMANN B, 1995, SEX TRANSM DIS, V22, P253, DOI 10.1097/00007435-199507000-00009; HILLIS SD, 1995, FAM PLANN PERSPECT, V27, P108, DOI 10.2307/2136107; JOHNSON AM, 1994, SEXUAL ATTITUDES LIF; Kamwendo F, 1996, SEX TRANSM DIS, V23, P384, DOI 10.1097/00007435-199609000-00007; MARDH PA, 1977, NEW ENGL J MED, V296, P1377, DOI 10.1056/NEJM197706162962403; *NAT BOARD HLTH WE, 1990, AN CHLAM INF PREV ME; Padian Nancy S., 1994, Annals of Epidemiology, V4, P128, DOI 10.1016/1047-2797(94)90058-2; PIANTADOSI S, 1988, AM J EPIDEMIOL, V127, P893, DOI 10.1093/oxfordjournals.aje.a114892; RIPA KT, 1977, J CLIN MICROBIOL, V6, P328; Robinson AJ, 1996, BRIT J OBSTET GYNAEC, V103, P859, DOI 10.1111/j.1471-0528.1996.tb09901.x; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; Skjeldestad FE, 1997, ACTA OBSTET GYN SCAN, V76, P159, DOI 10.3109/00016349709050073; SUSSER M, 1994, AM J PUBLIC HEALTH, V84, P825, DOI 10.2105/AJPH.84.5.825; TAYLORROBINSON D, 1994, BMJ-BRIT MED J, V308, P150, DOI 10.1136/bmj.308.6922.150; WESTROM L, 1980, AM J OBSTET GYNECOL, V138, P880, DOI 10.1016/0002-9378(80)91077-7; XIONG X, 1995, CONTRACEPTION, V52, P23, DOI 10.1016/0010-7824(95)00120-Y	23	147	157	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1776	1780		10.1136/bmj.316.7147.1776	http://dx.doi.org/10.1136/bmj.316.7147.1776			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624063	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000074286300023
J	Darlington, TK; Wager-Smith, K; Ceriani, MF; Staknis, D; Gekakis, N; Steeves, TDL; Weitz, CJ; Takahashi, JS; Kay, SA				Darlington, TK; Wager-Smith, K; Ceriani, MF; Staknis, D; Gekakis, N; Steeves, TDL; Weitz, CJ; Takahashi, JS; Kay, SA			Closing the circadian loop: CLOCK-induced transcription of its own inhibitors per and tim	SCIENCE			English	Article							DROSOPHILA PERIOD PROTEIN; NUCLEAR ENTRY; IDENTIFICATION; COMPONENT; RECEPTOR; TIMELESS; SYSTEM; ARNT; DNA	The circadian oscillator generates a rhythmic output with a period of about 24 hours. Despite extensive studies in several model systems, the biochemical mode of action has not yet been demonstrated for any of its components. Here, the Drosophila CLOCK protein was shown to induce transcription of the circadian rhythm genes period and timeless. dCLOCK functioned as a heterodimer with a Drosophila homolog of BMAL1. These proteins acted through an E-box sequence in the period promoter. The timeless promoter contains an 18-base pair element encompassing an E-box, which was sufficient to confer dCLOCK responsiveness to a reporter gene. PERIOD and TIMELESS proteins blocked dCLOCK's ability to transactivate their promoters via the E-box. Thus, dCLOCK drives expression of period and timeless, which in turn inhibit dCLOCK's activity and close the circadian loop.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92093 USA; Scripps Res Inst, NSF, Ctr Biol Timing, La Jolla, CA 92093 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Northwestern Univ, NSF,Ctr Biol Timing, Howard Hughes Med Inst, Dept Neurobiol & Physiol, Evanston, IL 60208 USA	Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Scripps Research Institute; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University	Kay, SA (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92093 USA.		Jansen, Heiko T./A-5770-2008; Takahashi, Joseph S/E-8482-2012; Takahashi, Joseph S./Y-2781-2019; Kay, Steve A/F-6025-2011	Jansen, Heiko T./0000-0003-0178-396X; Takahashi, Joseph S/0000-0003-0384-8878; Takahashi, Joseph S./0000-0003-0384-8878; Kay, Steve A/0000-0002-0402-2878; Ceriani, Maria/0000-0001-8945-3070	NIMH NIH HHS [MH-51573] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051573] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ASHBURNER M, 1989, DROSOPHILA LAB HDB, P33; Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; DARLINGTON T, UNPUB; Dembinska ME, 1997, J BIOL RHYTHM, V12, P157, DOI 10.1177/074873049701200207; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; King DP, 1997, GENETICS, V146, P1049; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Park J.C., UNPUB; PELLEQUER JL, IN PRESS P NATL ACAD; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Rosato E, 1997, BIOESSAYS, V19, P1075, DOI 10.1002/bies.950191206; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; SIKORSKI RS, 1989, GENETICS, V122, P19; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; Stanewsky R, 1997, EMBO J, V16, P5006, DOI 10.1093/emboj/16.16.5006; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713	32	668	688	1	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1599	1603		10.1126/science.280.5369.1599	http://dx.doi.org/10.1126/science.280.5369.1599			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616122				2022-12-24	WOS:000074061200040
J	Nan, XS; Ng, HH; Johnson, CA; Laherty, CD; Turner, BM; Eisenman, RN; Bird, A				Nan, XS; Ng, HH; Johnson, CA; Laherty, CD; Turner, BM; Eisenman, RN; Bird, A			Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex	NATURE			English	Article							CHROMATIN STRUCTURE; DNA METHYLATION; CHROMOSOMAL PROTEIN; ACETYLATION; CELLS; MOUSE	Cytosine residues in the sequence 5'CpG (cytosine-guanine) are often postsynthetically methylated in animal genomes. CpG methylation is involved in long-term silencing of certain genes during mammalian development(1,2) and in repression of viral genomes(3,4). The methyl-CpG-binding proteins MeCP1 (ref. 5) and MeCP2 (ref. 6) interact specifically with methylated DNA and mediate transcriptional repression(7-9). Here we study the mechanism of repression by MeCP2, an abundant nuclear protein that is essential for mouse embryogenesis(10). MeCP2 binds tightly to chromosomes in a methylation-dependent manner(11,12). It contains a transcriptional-repression domain (TRD) that can GRAPHICS function at a distance in vitro and in vivo(9). We show that a region of MeCP2 that localizes with the TRD associates with a corepressor complex containing the transcriptional repressor mSin3A and histone deacetylases(13-19). Transcriptional repression in vivo is relieved by the deacetylase inhibitor trichostatin A(20), indicating that deacetylation of histones (and/or of other proteins) is an essential component of this repression mechanism. The data suggest that two global mechanisms of gene regulation, DNA methylation and histone deacetylation, can be linked by MeCP2.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Birmingham, Sch Med, Dept Anat, Birmingham B15 2TT, W Midlands, England; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA	University of Edinburgh; University of Birmingham; Fred Hutchinson Cancer Center	Bird, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.	A.Bird@ed.ac.uk	Ng, Huck Hui/A-1135-2009	Johnson, Colin/0000-0002-2979-8234; Bird, Adrian/0000-0002-8600-0372; Nan, Xinsheng/0000-0002-0865-7934	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; Chen ZJ, 1997, GENE DEV, V11, P2124, DOI 10.1101/gad.11.16.2124; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GROUDINE M, 1981, NATURE, V292, P311, DOI 10.1038/292311a0; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; LAHERTY CD, 1997, CELL, V89, P849; LEWIS J, 1991, FEBS LETT, V285, P155, DOI 10.1016/0014-5793(91)80795-5; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Li W, 1996, BIOCHEM J, V314, P631, DOI 10.1042/bj3140631; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1996, MOL CELL BIOL, V16, P414; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Tate P, 1996, NAT GENET, V12, P205, DOI 10.1038/ng0296-205; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	30	2605	2713	5	184	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1998	393	6683					386	389		10.1038/30764	http://dx.doi.org/10.1038/30764			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620804				2022-12-24	WOS:000073883600059
J	Conradt, B; Horvitz, HR				Conradt, B; Horvitz, HR			The C-elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; APOPTOSIS; SEQUENCE; BAX; SURVIVAL; GENETICS; ENCODES; DOMAIN; ACTIVATION; INHIBITION	Gain-of-function mutations in the Caenorhabditis elegans gene egl-1 cause the HSN neurons to undergo programmed cell death. By contrast, a loss-of-function egl-1 mutation prevents most if not all somatic programmed cell deaths. The egl-1 gene negatively regulates the ced-9 gene, which protects against cell death and is a member of the bcl-2 family. The EGL-1 protein contains a nine amino acid region similar to the Bcl-2 homology region 3 (BH3) domain but does not contain a BH1, BH2, or BH4 domain, suggesting that EGL-1 may be a member of a family of cell death activators that includes the mammalian proteins Bik, Bid, Harakiri, and Bad. The EGL-1 and CED-9 proteins interact physically. We propose that EGL-1 activates programmed cell death by binding to and directly inhibiting the activity of CED-9, perhaps by releasing the cell death activator CED-4 from a CED-9/CED-4-containing protein complex.	MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Horvitz, HR (corresponding author), MIT, Dept Biol, Howard Hughes Med Inst, 68-425,77 Massachusetts Ave, Cambridge, MA 02139 USA.		Conradt, Barbara/K-2665-2014	Conradt, Barbara/0000-0002-3731-4308				Anderson P, 1995, METHOD CELL BIOL, V48, P31; Bai C, 1996, METHOD ENZYMOL, V273, P331; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; BOYD JM, 1995, ONCOGENE, V11, P1921; BRENNER S, 1974, GENETICS, V77, P71; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; DELONG L, 1993, GENETICS, V133, P875; DESAI C, 1989, GENETICS, V121, P703; Diaz JL, 1997, J BIOL CHEM, V272, P11350; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, DEVELOPMENT, V112, P591; ELLIS RE, 1991, GENETICS, V129, P79; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Jacobson MD, 1997, TRENDS CELL BIOL, V7, P467, DOI 10.1016/S0962-8924(97)01182-3; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Mello C, 1995, METHOD CELL BIOL, V48, P451; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Ottilie S, 1997, CELL DEATH DIFFER, V4, P526, DOI 10.1038/sj.cdd.4400288; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Riddle DL, 1997, C ELEGANS; Rinkenberger JL, 1997, CURR OPIN GENET DEV, V7, P589, DOI 10.1016/S0959-437X(97)80004-4; Rose MD., 1990, METHODS YEAST GENETI; RUVKUN G, 1989, GENETICS, V121, P501; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TRENT C, 1983, GENETICS, V104, P619; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS BD, 1992, GENETICS, V131, P609; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; ZHOU H, 1997, CELL, V90, P405; Zhu JW, 1997, GENE DEV, V11, P2883, DOI 10.1101/gad.11.21.2883	63	481	500	0	35	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					519	529		10.1016/S0092-8674(00)81182-4	http://dx.doi.org/10.1016/S0092-8674(00)81182-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604928	Bronze			2022-12-24	WOS:000073722200006
J	Frenkel, LM; Mullins, JI; Learn, GH; Manns-Arcuino, L; Herring, BL; Kalish, ML; Steketee, RW; Thea, DM; Nichols, JE; Liu, SL; Harmache, A; He, X; Muthui, D; Madan, A; Hood, L; Haase, AT; Zupancic, M; Staskus, K; Wolinsky, S; Krogstad, P; Zhao, JQ; Chen, I; Koup, R; Ho, D; Korber, B; Apple, RJ; Coombs, RW; Pahwa, S; Roberts, NJ				Frenkel, LM; Mullins, JI; Learn, GH; Manns-Arcuino, L; Herring, BL; Kalish, ML; Steketee, RW; Thea, DM; Nichols, JE; Liu, SL; Harmache, A; He, X; Muthui, D; Madan, A; Hood, L; Haase, AT; Zupancic, M; Staskus, K; Wolinsky, S; Krogstad, P; Zhao, JQ; Chen, I; Koup, R; Ho, D; Korber, B; Apple, RJ; Coombs, RW; Pahwa, S; Roberts, NJ			Genetic evaluation of suspected cases of transient HIV-1 infection of infants	SCIENCE			English	Article							VIRUS; TRANSMISSION; INDIVIDUALS; ZIDOVUDINE; RESISTANCE; CLEARANCE; CHILDREN; AIDS	Detection of human immunodeficiency virus-type 1 (HIV-1) on only one or a few occasions in infants born to infected mothers has been interpreted to indicate that infection may be transient rather than persistent. Forty-two cases of suspected transient HIV-1 viremia among 1562 perinatally exposed seroreverting infants and one mother were reanalyzed. HIV-1 env sequences were not found in specimens from 20; in specimens from 6, somatic genetic analysis revealed that specimens were mistakenly attributed to an infant; and in specimens from 17, phylogenetic analysis failed to demonstrate the expected linkage between the infant's and the mother's virus. These findings argue that transient HIV-1 infection, if it exists, will only rarely be satisfactorily documented.	Univ Washington, Dept Pediat, Div Infect Dis, Seattle, WA 98105 USA; Univ Rochester, Dept Pediat, Rochester, NY 14642 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Med & Hlth Res Assoc New York City, New York, NY 10013 USA; Univ Rochester, Dept Med, Rochester, NY 14642 USA; Univ Texas, Med Branch, Dept Med & Microbiol & Immunol, Galveston, TX 77555 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA; Northwestern Univ, Dept Med, Chicago, IL 60611 USA; Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Med & Microbiol & Immunol, Los Angeles, CA 90024 USA; Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Santa Fe Inst, Los Alamos, NM 87545 USA; Roche Mol Diagnost, Alameda, CA 94501 USA; NYU, N Shore Hosp, Dept Pediat, Manhasset, NY 11030 USA	University of Washington; University of Washington Seattle; University of Rochester; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centers for Disease Control & Prevention - USA; University of Rochester; University of Texas System; University of Texas Medical Branch Galveston; University of Washington; University of Washington Seattle; University of Minnesota System; University of Minnesota Twin Cities; Northwestern University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; The Santa Fe Institute; Roche Holding; New York University	Frenkel, LM (corresponding author), Univ Washington, Dept Pediat, Div Infect Dis, 4800 Sand Point Way NE,Box 329500, Seattle, WA 98105 USA.		Krogstad, Paul/AAQ-8495-2020; Pahwa, Savita/AAA-4900-2019; HARMACHE, ABDALLAH/E-7274-2011; HARMACHE, Abdallah/AAS-2586-2021; apple, raymond J/I-4506-2012; Learn, Jerry/E-3356-2012; Herring, Belinda/M-7252-2015; Wolinsky, Steven/B-2893-2012; Liu, Shan-Lu/L-5923-2016; Learn, Gerald H/B-6934-2011	Pahwa, Savita/0000-0002-4470-4216; apple, raymond J/0000-0002-8007-0345; Liu, Shan-Lu/0000-0003-1620-3817; Learn, Gerald H/0000-0003-0434-7733; Korber, Bette/0000-0002-2026-5757; /0000-0001-8284-1505; Wolinsky, Steven/0000-0002-9625-6697; Harmache, Abdallah/0000-0002-7377-7641; Thea, Donald/0000-0002-6933-1030; Roberts Jr, Norbert J/0000-0002-4427-2986	NIAID NIH HHS [AI32910, AI27757] Funding Source: Medline; PHS HHS [UO1-27658] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757, U01AI032910] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORKOWSKY W, 1990, AIDS RES HUM RETROV, V6, P673, DOI 10.1089/aid.1990.6.673; BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; Cao YZ, 1997, NAT MED, V3, P549, DOI 10.1038/nm0597-549; CONNOR EM, 1995, PEDIATR INFECT DIS J, V14, P536, DOI 10.1097/00006454-199506000-00012; Contag CH, 1997, J VIROL, V71, P1292, DOI 10.1128/JVI.71.2.1292-1300.1997; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; DELWART EL, 1995, AIDS RES HUM RETROV, V11, P1181; FRENKEL LM, 1995, CLIN INFECT DIS, V20, P1321, DOI 10.1093/clinids/20.5.1321; FRENKEL LM, UNPUB; HOFFENBACH A, 1989, J IMMUNOL, V142, P452; HOLMES EC, 1993, J INFECT DIS, V167, P1411, DOI 10.1093/infdis/167.6.1411; JAFFE HW, 1994, ANN INTERN MED, V121, P855, DOI 10.7326/0003-4819-121-11-199412010-00005; Learn GH, 1996, J VIROL, V70, P5720, DOI 10.1128/JVI.70.8.5720-5730.1996; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LIU TM, 1995, J IMMUNOL, V154, P3147; MCCLURE MO, 1995, NATURE, V375, P637, DOI 10.1038/375637a0; McMichael A, 1996, NEW ENGL J MED, V334, P801, DOI 10.1056/NEJM199603213341215; Newell ML, 1996, LANCET, V347, P213, DOI 10.1016/S0140-6736(96)90401-8; PALUMBO P, 1995, J ACQ IMMUN DEF SYND, V10, P436, DOI 10.1097/00042560-199512000-00006; ROQUES PA, 1995, AIDS, V9, pF19; Schochetman Gerald, 1996, P25; Steketee RW, 1997, J INFECT DIS, V175, P707, DOI 10.1093/infdis/175.3.707	22	54	54	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1073	1077		10.1126/science.280.5366.1073	http://dx.doi.org/10.1126/science.280.5366.1073			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9582120				2022-12-24	WOS:000073663600046
J	Tunstall-Pedoe, H				Tunstall-Pedoe, H			Myth and paradox of coronary risk and the menopause	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION; HEART-DISEASE; CASE-FATALITY; WOMEN; POPULATION; DEATHS; HEALTH; SEX		Univ Dundee, Ninewells Hosp & Med Sch, Cardiovasc Epidemiol Unit, Dundee DD1 9SY, Scotland	University of Dundee	Tunstall-Pedoe, H (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Cardiovasc Epidemiol Unit, Dundee DD1 9SY, Scotland.							[Anonymous], 1977, MANUAL INT STAT CLAS; BarrettConnor E, 1997, CIRCULATION, V95, P252, DOI 10.1161/01.CIR.95.1.252; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; FURMAN RH, 1968, ANN NY ACAD SCI, V149, P822, DOI 10.1111/j.1749-6632.1968.tb53838.x; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; HELLER RF, 1978, BRIT MED J, V1, P472, DOI 10.1136/bmj.1.6111.472; KHAW KT, 1992, BRIT MED BULL, V48, P249, DOI 10.1093/oxfordjournals.bmb.a072546; LINDQUIST O, 1982, PREV MED, V11, P162, DOI 10.1016/0091-7435(82)90015-9; MEADE TW, 1992, BRIT MED BULL, V48, P276, DOI 10.1093/oxfordjournals.bmb.a072548; ROSENBERG L, 1981, AM J OBSTET GYNECOL, V139, P47, DOI 10.1016/0002-9378(81)90410-5; Stevenson JC, 1996, EUR J OBSTET GYN R B, V65, P39, DOI 10.1016/0028-2243(95)02301-8; TRACY RE, 1966, J CHRON DIS, V19, P1245, DOI 10.1016/0021-9681(66)90022-1; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; TUNSTALLPEDOE H, 1992, BRIT MED J, V305, P1096, DOI 10.1136/bmj.305.6861.1096-b; 1996, WRLD HLTH STAT ANN 1	17	135	136	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 9	1998	351	9113					1425	1427		10.1016/S0140-6736(97)11321-6	http://dx.doi.org/10.1016/S0140-6736(97)11321-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM665	9593428				2022-12-24	WOS:000073563400042
J	Lee, M; Lenman, M; Banas, A; Bafor, M; Singh, S; Schweizer, M; Nilsson, R; Liljenberg, C; Dahlqvist, A; Gummeson, PO; Sjodahl, S; Green, A; Stymne, S				Lee, M; Lenman, M; Banas, A; Bafor, M; Singh, S; Schweizer, M; Nilsson, R; Liljenberg, C; Dahlqvist, A; Gummeson, PO; Sjodahl, S; Green, A; Stymne, S			Identification of non-heme diiron proteins that catalyze triple bond and epoxy group formation	SCIENCE			English	Article							FATTY-ACIDS; TRANSFORMATION; MONOOXYGENASE; BIOSYNTHESIS; DESATURASE; VECTORS; ENZYME	Acetylenic bonds are present in more than 600 naturally occurring compounds. Plant enzymes that catalyze the formation of the Delta 12 acetylenic bond in 9-octadecen-12-ynoic acid and the Delta 12 epoxy group in 12,13-epoxy-9-octadecenoic acid were characterized, and two genes, similar in sequence, were cloned. When these complementary DNAs were expressed in Arabidopsis thaliana, the content of acetylenic or epoxidated fatty acids in the seeds increased from 0 to 25 or 15 percent, respectively. Both enzymes have characteristics similar to the membrane proteins containing non-heme iron that have histidine-rich motifs.	Swedish Univ Agr Sci, Dept Plant Breeding Res, S-26831 Svalov, Sweden; Svalov Welbull AB, S-26881 Svalov, Sweden; CSIRO, Canberra, ACT 2601, Australia; Inst Food Res, Norwich NR4 7UA, Norfolk, England; Univ Gothenburg, Dept Plant Physiol, S-41319 Gothenburg, Sweden	Swedish University of Agricultural Sciences; Commonwealth Scientific & Industrial Research Organisation (CSIRO); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; University of Gothenburg	Stymne, S (corresponding author), Swedish Univ Agr Sci, Dept Plant Breeding Res, S-26831 Svalov, Sweden.	sten.stymne@vf.slu.se	Green, Allan G/C-6572-2008; singh, surinder/C-9528-2009; Green, Allan/AAM-6856-2021	singh, surinder/0000-0003-4488-8147; Green, Allan/0000-0002-3248-2089; Lee, Michael/0000-0002-6643-1984; Banas, Antoni/0000-0001-9397-7627				Badami R. C., 1981, Progress in Lipid Research, V19, P119, DOI 10.1016/0163-7827(80)90002-8; BAFOR M, 1993, ARCH BIOCHEM BIOPHYS, V303, P145, DOI 10.1006/abbi.1993.1265; BAGBY MO, 1967, Patent No. 3356699; Banas A, 1996, PHYSL BIOCH MOL BIOL, P57; BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; BOHLMAN F, 1973, NATURALLY OCCURRING; BROUN P, 1996, PHYSL BIOCH MOL BIOL, P342; COLBERT JE, 1990, J AM CHEM SOC, V112, P3993, DOI 10.1021/ja00166a041; EARLE FR, 1966, LIPIDS, V1, P325, DOI 10.1007/BF02532675; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Engeseth N, 1996, PLANTA, V198, P238, DOI 10.1007/BF00206249; HAIGH WG, 1968, LIPIDS, V3, P307, DOI 10.1007/BF02530929; KOHN G, 1994, J PLANT PHYSIOL, V144, P265, DOI 10.1016/S0176-1617(11)81185-5; OKULEY J, 1994, PLANT CELL, V6, P147, DOI 10.1105/tpc.6.1.147; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Shanklin J, 1997, P NATL ACAD SCI USA, V94, P2981, DOI 10.1073/pnas.94.7.2981; SHANKLIN J, 1996, PHYSL BIOCH MOL BIOL, P6; Shu LJ, 1997, SCIENCE, V275, P515, DOI 10.1126/science.275.5299.515; STALBERG K, 1993, PLANT MOL BIOL, V23, P671, DOI 10.1007/BF00021523; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; Van De Loo Frank J., 1993, P91; VANDELOO FJ, 1995, P NATL ACAD SCI USA, V92, P6743, DOI 10.1073/pnas.92.15.6743; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7	23	198	251	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 8	1998	280	5365					915	918		10.1126/science.280.5365.915	http://dx.doi.org/10.1126/science.280.5365.915			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572738				2022-12-24	WOS:000073532900045
J	Li, WH; Llopis, J; Whitney, M; Zlokarnik, G; Tsien, RY				Li, WH; Llopis, J; Whitney, M; Zlokarnik, G; Tsien, RY			Cell-permeant caged InsP(3) ester shows that Ca2+ spike frequency can optimize gene expression	NATURE			English	Article							INOSITOL TRISPHOSPHATE; 1,4,5-TRISPHOSPHATE; RECOGNITION; RECEPTOR; SIGNALS	Inositol 1,4,5-trisphosphate (InsP(3)) releases calcium from intracellular stores and triggers complex waves and oscillations in levels of cytosolic free calcium(1-5). To determine which longer-term responses are controlled by oscillations in InsP(3) and cytosolic free calcium, it would be useful to deliver exogenous InsP(3), under spatial and temporal control, into populations of unpermeabilized cells. Here we report the 15-step synthesis of a membrane-permeant, caged InsP(3) derivative from myo-inositol. This derivative diffused into intact cells and was hydrolysed to produce a caged, metabolically stable InsP(3) derivative. This latter derivative accumulated in the cytosol at concentrations of hundreds of micromolar, without activating the InsP(3) receptor. Ultraviolet illumination uncaged an InsP(3) analogue nearly as potent as real InsP(3), and generated spikes of cytosolic free calcium, and stimulated gene expression via the nuclear factor of activated T cells(6,7). The same total amount of InsP(3) analogue elicited much more gene expression when released by repetitive flashes at 1-minute intervals than when released at 0.5- or greater than or equal to 2-minute intervals, as a single pulse, or as a slow sustained plateau, Thus, oscillations in cytosolic free calcium levels at roughly physiological rates maximize gene expression for a given amount of InsP(3).	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Aurora Biosci Corp, San Diego, CA 92121 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Tsien, RY (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Llopis, Juan/I-2622-2012	Llopis, Juan/0000-0002-9460-0642				ADAMS SR, 1993, ANNU REV PHYSIOL, V55, P755, DOI 10.1146/annurev.ph.55.030193.003543; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.ph.55.030193.002235; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HATCHARD CG, 1956, PROC R SOC LON SER-A, V235, P518, DOI 10.1098/rspa.1956.0102; HIRATA M, 1993, J BIOL CHEM, V268, P19260; HIRATA M, 1990, J BIOL CHEM, V265, P8404; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KOZIKOWSKI AP, 1993, J AM CHEM SOC, V115, P4429, DOI 10.1021/ja00064a002; Kuchtey J, 1996, J CELL PHYSIOL, V166, P643, DOI 10.1002/(SICI)1097-4652(199603)166:3<643::AID-JCP20>3.0.CO;2-6; Li WH, 1997, TETRAHEDRON, V53, P12017, DOI 10.1016/S0040-4020(97)00714-X; Oancea E, 1996, J BIOL CHEM, V271, P17253, DOI 10.1074/jbc.271.29.17253; POTTER BVL, 1995, ANGEW CHEM INT EDIT, V34, P1933, DOI 10.1002/anie.199519331; Smith GD, 1996, AM J PHYSIOL-CELL PH, V270, pC939, DOI 10.1152/ajpcell.1996.270.3.C939; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VACCA JP, 1989, TETRAHEDRON, V45, P5679, DOI 10.1016/S0040-4020(01)89510-7; WALKER JW, 1989, BIOCHEMISTRY-US, V28, P3272, DOI 10.1021/bi00434a023; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	26	741	751	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					936	941		10.1038/31965	http://dx.doi.org/10.1038/31965			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582076				2022-12-24	WOS:000073359900053
J	Ingenito, EP; Evans, RB; Loring, SH; Kaczka, DW; Rodenhouse, JD; Body, SC; Sugarbaker, DJ; Mentzer, SJ; DeCamp, MM; Reilly, JJ				Ingenito, EP; Evans, RB; Loring, SH; Kaczka, DW; Rodenhouse, JD; Body, SC; Sugarbaker, DJ; Mentzer, SJ; DeCamp, MM; Reilly, JJ			Relation between preoperative inspiratory lung resistance and the outcome of lung-volume-reduction surgery for emphysema	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PULMONARY-FUNCTION	Background Surgery to reduce lung volume has recently been reintroduced to alleviate dyspnea and improve exercise tolerance in selected patients with emphysema. A reliable means of identifying patients who are likely to benefit from this surgery is needed. Methods We measured lung resistance during inspiration, static recoil pressure at total lung capacity, static lung compliance, expiratory flow rates, and lung volumes in 29 patients with chronic obstructive lung disease before lung-volume-reduction surgery. The changes in the forced expiratory volume in one second (FEV1) six months after surgery were related to the preoperatively determined physiologic measures. A response to surgery was defined as an increase in the FEV1 of at least 0.2 liter and of at least 12 percent above base-line values. Results Of the 29 patients, 23 had some improvement in FEV1 including 15 who met the criteria for a response to surgery. Among the variables considered, only preoperative lung resistance during inspiration predicted changes in expiratory flow rates after surgery. Inspiratory lung resistance correlated significantly and inversely with improvement in FEV1 after surgery (r=-0.63, P<0.001). A preoperative criterion of an inspiratory resistance of 10 cm of water per liter per second had a sensitivity of 88 percent (14 of 16 patients) and a specificity of 92 percent (12 of 13 patients) in identifying patients who were likely to have a response to surgery. Conclusions Preoperative lung resistance during inspiration appears to be a useful measure for selecting patients with emphysema for lung-volume-reduction surgery. (C)1998, Massachusetts Medical Society.	Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Anesthesia, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center	Ingenito, EP (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.		Kaczka, David Walter/A-2984-2008; Kaczka, David W./U-2580-2018; Body, Simon/AAQ-7572-2020; Body, Simon C/O-2605-2013	Kaczka, David Walter/0000-0003-4378-5242; Kaczka, David W./0000-0003-4378-5242; Body, Simon/0000-0001-6721-7050; Body, Simon C/0000-0001-6721-7050	NHLBI NIH HHS [HL52586] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052586] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, AM J RESP CRIT CARE, V152, P2185; Bingisser R, 1996, J THORAC CARDIOV SUR, V112, P875, DOI 10.1016/S0022-5223(96)70086-7; BRANTIGAN OC, 1959, AM REV RESPIR DIS, V80, P194; Brenner M, 1996, CHEST, V110, P205, DOI 10.1378/chest.110.1.205; BROWN R, 1980, J APPL PHYSIOL, V49, P398, DOI 10.1152/jappl.1980.49.3.398; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; COOPER JD, 1995, J THORAC CARDIOV SUR, V109, P106, DOI 10.1016/S0022-5223(95)70426-4; CORBIN RP, 1979, AM REV RESPIR DIS, V120, P293; Daniel TM, 1996, ANN SURG, V223, P526, DOI 10.1097/00000658-199605000-00008; GRIMBY G, 1968, J CLIN INVEST, V47, P1455, DOI 10.1172/JCI105837; GURNEY JW, 1992, RADIOLOGY, V183, P457, DOI 10.1148/radiology.183.2.1561350; HOLOHAN TV, 1996, HEALTH TECHNOL ASSES, V10, P1; KACZKA DW, 1995, ANN BIOMED ENG, V23, P135, DOI 10.1007/BF02368321; Kotloff RM, 1996, CHEST, V110, P1399, DOI 10.1378/chest.110.6.1399; MEAD J, 1955, J CLIN INVEST, V34, P1005, DOI 10.1172/JCI103150; NAGELS J, 1950, J APPL PHYSIOL, V49, P408; Pride NB, 1986, HDB PHYSL RESP SYSTE, P659; SALAZAR E, 1964, J APPL PHYSIOL, V19, P97, DOI 10.1152/jappl.1964.19.1.97; Sciurba FC, 1996, NEW ENGL J MED, V334, P1095, DOI 10.1056/NEJM199604253341704; Slone RM, 1997, RADIOLOGY, V204, P685, DOI 10.1148/radiology.204.3.9280244; Snedecor GW, 1989, STAT METHODS; Swanson SJ, 1997, J AM COLL SURGEONS, V185, P25, DOI 10.1016/S1072-7515(97)00021-5; Wang SC, 1997, RADIOLOGY, V205, P243, DOI 10.1148/radiology.205.1.9314992; Yusen R D, 1996, Semin Thorac Cardiovasc Surg, V8, P83	24	81	83	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 23	1998	338	17					1181	1185		10.1056/NEJM199804233381703	http://dx.doi.org/10.1056/NEJM199804233381703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ376	9554858				2022-12-24	WOS:000073208400003
J	Rundlett, SE; Carmen, AA; Suka, N; Turner, BM; Grunstein, M				Rundlett, SE; Carmen, AA; Suka, N; Turner, BM; Grunstein, M			Transcriptional repression by UME6 involves deacetylation of lysine 5 of histone H4 by RPD3	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; YEAST	The histone deacetylase RPD3 can be targeted to certain genes through its interaction with DNA-binding regulatory proteins. RPD3 can then repress gene transcription(1-6). In the yeast Saccharomyces cerevisiae, association of RPD3 with the transcriptional repressors SIN3 and UME6 results in repression of reporter genes containing the UME6-binding site(3). RPD3 can deacetylate all histone HS acetylation sites in cell extracts(7). However, it is unknown how H4 proteins located at genes near UME6-binding sites are affected, nor whether the effect of RPD3 is localized to the promoter regions. Here we study the mechanism by which RPD3 represses gene activity by examining the acetylation state of histone proteins at UME6-regulated genes. We used antibodies specific for individual acetylation sites in H4 to immunoprecipitate chromatin fragments. A deletion of RPD3 or SIN3, but not of the related histone-deacetylase gene HDA1, results in increased acetylation of the lysine 5 residue of H4 in the promoters of the UME6-regulated INO1 (ref. 8), IME2! (ref. 3) and SPO13 (ref. 9) genes. As increased acetylation of this residue is not merely a consequence of gene transcription, acetylation of this site may be essential for regulating gene activity.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Birmingham, Sch Med, Dept Anat, Chromatin & Gene Express Grp, Birmingham B15 2TT, W Midlands, England	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Birmingham	Grunstein, M (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.	mg@mbi.ucla.edu						Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; CLARKE DJ, 1993, BIOCHEM J, V294, P557, DOI 10.1042/bj2940557; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; FLOMERFELT FA, 1993, J CELL PHYSIOL, V154, P573, DOI 10.1002/jcp.1041540316; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; Guthrie C, 1991, GUIDE YEAST GENETICS; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAMAN H, 1995, MOL CELL BIOL, V15, P3608; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SLEKAR KH, 1995, NUCLEIC ACIDS RES, V23, P1964, DOI 10.1093/nar/23.11.1964; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; STRICH R, 1994, GENE DEV, V8, P796, DOI 10.1101/gad.8.7.796; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	24	359	366	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1998	392	6678					831	835		10.1038/33952	http://dx.doi.org/10.1038/33952			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572144				2022-12-24	WOS:000073241200058
J	Nilson, LA; Schupbach, T				Nilson, LA; Schupbach, T			Localized requirements for windbeutel and pipe reveal a dorsoventral prepattern within the follicular epithelium of the Drosophila ovary	CELL			English	Article							DORSAL-VENTRAL POLARITY; EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; NUCLEAR-LOCALIZATION; EMBRYONIC POLARITY; TOLL GENE; GERM LINE; PROTEIN; PATTERN; CELLS	Establishment of dorsoventral polarity within the Drosophila embryo requires extraembryonic positional information generated during oogenesis. The genes windbeutel, pipe, and nudel are required within the somatic follicle cells of the ovary for production of this spatial cue. Using a novel follicle cell marker system, we have directly evaluated the effect of mutant follicle cell clones on the embryonic dorsoventral pattern. We find no spatially localized requirement for nudel activity. In contrast, windbeutel and pipe are required only within a restricted ventral region of the follicular epithelium. This ventral region can determine lateral embryonic cell fates nonautonomously, indicating that spatial information originating ventrally is subsequently refined, perhaps via diffusion, to yield the gradient of positional information that determines the embryonic dorsoventral pattern.	Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University	Schupbach, T (corresponding author), Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ 08544 USA.				NCI NIH HHS [P01 CA41086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA041086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; CHASAN R, 1992, DEVELOPMENT, V115, P607; Chasan Rebecca, 1993, P387; Chou TB, 1996, GENETICS, V144, P1673; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; HARRISON DA, 1993, CURR BIOL, V3, P424, DOI 10.1016/0960-9822(93)90349-S; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HAWLEY RJ, 1988, GENE DEV, V2, P341, DOI 10.1101/gad.2.3.341; HONG CC, 1995, CELL, V82, P785, DOI 10.1016/0092-8674(95)90475-1; Hong CC, 1996, GENETICS, V143, P1653; Huang AM, 1997, GENE DEV, V11, P1963, DOI 10.1101/gad.11.15.1963; King R. C., 1970, OVARIAN DEV DROSOPHI; Konsolaki M, 1998, GENE DEV, V12, P120, DOI 10.1101/gad.12.1.120; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MARGOLIS J, 1995, DEVELOPMENT, V121, P3797; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; ROTH S, 1994, DEVELOPMENT, V120, P2245; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1993, DEVELOPMENT, V117, P1385; RUSHLOW CA, 1989, CELL, V59, P779; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHNEIDER DS, 1994, DEVELOPMENT, V120, P1243; SCHUPACH T, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P163; SCHUPBACH T, 1989, GENETICS, V121, P101; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; Spradling Allan C., 1993, P1; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STEWARD R, 1988, CELL, V55, P487, DOI 10.1016/0092-8674(88)90035-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WIESCHAUS E, 1981, DEV BIOL, V88, P92, DOI 10.1016/0012-1606(81)90221-9; Wieschaus E., 1986, P199; XU T, 1993, DEVELOPMENT, V117, P1223	42	59	61	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					253	262		10.1016/S0092-8674(00)81576-7	http://dx.doi.org/10.1016/S0092-8674(00)81576-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568717	Bronze			2022-12-24	WOS:000073174000011
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Synthetic protease switch	SCIENCE			English	Article																		SICES H, 1996, P NATL ACAD SCI USA, V95, P2828	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					456	456						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9575087				2022-12-24	WOS:000073159600054
J	Kirsch, J; Betz, H				Kirsch, J; Betz, H			Glycine-receptor activation is required for receptor clustering in spinal neurons	NATURE			English	Article							GAMMA-AMINOBUTYRIC-ACID; DORSAL HORN NEURONS; GEPHYRIN; SYNAPSES; LOCALIZATION; SUBUNITS; PROTEIN; IDENTIFICATION; DEPOLARIZATION; EXPRESSION	The ability of nerve cells to receive up to several thousands of synaptic inputs from other neurons provides the anatomical basis for information processing in the vertebrate brain. The formation of functional synapses involves selective clustering of neurotransmitter receptors at presumptive postsynaptic regions of the neuronal plasma membrane(1-4). Receptor-associated proteins are believed to be crucial for this process. In spinal neurons, synaptic targeting of the inhibitory glycine receptor (GlyR)(5,6) depends on the expression of the anchoring protein gephyrin(7-9), Here we show that the competitive GlyR antagonist strychnine and L-type Ca2+ channel blockers inhibit the accumulation of GlyR and gephyrin at postsynaptic membrane areas in cultured rat spinal neurons. Our data are consistent with a model in which GlyR activation that results in Ca2+ influx is required for the clustering of gephyrin and GlyR at developing postsynaptic sites. Similar activity-driven mechanisms may be of general importance in synaptogenesis.	Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany	Max Planck Society	Kirsch, J (corresponding author), Max Planck Inst Brain Res, Dept Neurochem, Duetschordenstr 46, D-60528 Frankfurt, Germany.	neurochemie@mpih-frankfurt.mpg.de						ALTSCHULER RA, 1986, BRAIN RES, V369, P316, DOI 10.1016/0006-8993(86)90542-1; Bechade C, 1996, EUR J NEUROSCI, V8, P429, DOI 10.1111/j.1460-9568.1996.tb01226.x; BECKER CM, 1992, HDB EXPT PHARM, V102, P540; BETZ H, 1985, ANGEW CHEM INT EDIT, V24, P365, DOI 10.1002/anie.198503651; Boehm S, 1997, J PHYSIOL-LONDON, V504, P683, DOI 10.1111/j.1469-7793.1997.683bd.x; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; CHANGEUX JP, 1976, NATURE, V264, P705, DOI 10.1038/264705a0; Craig AM, 1996, J NEUROSCI, V16, P3166; Ehlers MD, 1996, CURR OPIN CELL BIOL, V8, P484, DOI 10.1016/S0955-0674(96)80024-X; FRITSCHY JM, 1992, P NATL ACAD SCI USA, V89, P6726, DOI 10.1073/pnas.89.15.6726; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; Goslin K., 1991, CULTURING NERVE CELL, P251; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HOCH W, 1989, NEURON, V3, P339, DOI 10.1016/0896-6273(89)90258-4; KIRSCH J, 1995, MOL CELL NEUROSCI, V6, P450, DOI 10.1006/mcne.1995.1033; Kirsch J, 1996, MOL CELL NEUROSCI, V8, P93, DOI 10.1006/mcne.1996.0048; KIRSCH J, 1991, J BIOL CHEM, V266, P22242; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; KIRSCH J, 1995, J NEUROSCI, V15, P4148; KNAUS P, 1986, J NEUROCHEM, V47, P1302; KUHSE J, 1995, CURR OPIN NEUROBIOL, V5, P318, DOI 10.1016/0959-4388(95)80044-1; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; PFEIFFER F, 1984, P NATL ACAD SCI-BIOL, V81, P7224, DOI 10.1073/pnas.81.22.7224; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; REICHLING DB, 1994, J PHYSIOL-LONDON, V476, P411, DOI 10.1113/jphysiol.1994.sp020142; Sheng M, 1997, NATURE, V386, P221, DOI 10.1038/386221a0; TRILLER A, 1985, J CELL BIOL, V101, P683, DOI 10.1083/jcb.101.2.683; Virginio C, 1997, DEV BRAIN RES, V98, P30, DOI 10.1016/S0165-3806(96)00164-2; WANG J, 1994, EUR J NEUROSCI, V6, P1275, DOI 10.1111/j.1460-9568.1994.tb00317.x	29	223	227	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 16	1998	392	6677					717	720		10.1038/33694	http://dx.doi.org/10.1038/33694			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565032				2022-12-24	WOS:000073129000059
J	Doherty, PC				Doherty, PC			Update: Immunology - The numbers game for virus-specific CD8(+) T cells	SCIENCE			English	Editorial Material							MEMORY		St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Doherty, PC (corresponding author), St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Doherty, Peter Charles/C-4185-2013	Doherty, Peter Charles/0000-0002-5028-3489				Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Busch DH, 1998, IMMUNITY, V8, P353, DOI 10.1016/S1074-7613(00)80540-3; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; Doherty PC, 1996, IMMUNOL REV, V150, P23, DOI 10.1111/j.1600-065X.1996.tb00694.x; Klenerman P, 1997, NATURE, V390, P298, DOI 10.1038/36876; KURODA MJ, IN PRESS J EXP MED; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	10	72	80	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					227	227		10.1126/science.280.5361.227	http://dx.doi.org/10.1126/science.280.5361.227			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9565533				2022-12-24	WOS:000073082400036
J	Vermeer-de Bondt, PE; Labadie, J; Rumke, HC				Vermeer-de Bondt, PE; Labadie, J; Rumke, HC			Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; INFANTS		Natl Inst Publ Hlth & Environm, Lab Clin Vaccine Res, NL-3720 BA Bilthoven, Netherlands	Netherlands National Institute for Public Health & the Environment	Vermeer-de Bondt, PE (corresponding author), Natl Inst Publ Hlth & Environm, Lab Clin Vaccine Res, POB 1, NL-3720 BA Bilthoven, Netherlands.							BARAFF LJ, 1988, PEDIATRICS, V81, P789; CODY CL, 1981, PEDIATRICS, V68, P650; HANNIK CA, 1979, P 3 NT S PERT BETH 1, P279; Howson CP, 1991, ADVERSE EFFECTS PERT; OLIN P, 1997, EFFICACY TRIAL ACELL, V2	5	27	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					902	903		10.1136/bmj.316.7135.902	http://dx.doi.org/10.1136/bmj.316.7135.902			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552838	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000072713300028
J	Wagner, A				Wagner, A			On being eighty	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1766	1766		10.1001/jama.279.22.1766-a	http://dx.doi.org/10.1001/jama.279.22.1766-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR635	9628693				2022-12-24	WOS:000073998500001
J	Nightingale, SL				Nightingale, SL			Viagra approval information on the Internet	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	10	11	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1684	1684		10.1001/jama.279.21.1684	http://dx.doi.org/10.1001/jama.279.21.1684			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624011				2022-12-24	WOS:000073878700004
J	Ye, WL; Shimamura, K; Rubenstein, JLR; Hynes, MA; Rosenthal, A				Ye, WL; Shimamura, K; Rubenstein, JLR; Hynes, MA; Rosenthal, A			FGF and Shh signals control dopaminergic and serotonergic cell fate in the anterior neural plate	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; EXPRESSION DOMAINS; SONIC HEDGEHOG; FLOOR PLATE; TYROSINE-HYDROXYLASE; MOUSE EMBRYO; RAT-BRAIN; MIDBRAIN; INDUCTION; DIFFERENTIATION	During development, distinct classes of neurons are specified in precise locations along the dorso-ventral and anterior-posterior axes of the neural tube. We provide evidence that intersections of Shh, which is expressed along the ventral neural tube, and FGF8, which is locally produced at the mid/hindbrain boundary and in the rostral forebrain, create induction sites for dopaminergic neurons in the midbrain and forebrain. The same intersection, when preceded by a third signal, FGF4, which is expressed in the primitive streak, defines an inductive center for hindbrain 5-HT neurons. These findings illustrate that cell patterning in the neural plate is a multistep process in which early inducers, which initially divide the neural plate into crude compartments, are replaced by multiple local organizing centers, which specify distinct neuronal cell types within these compartments.	Genentech Inc, Dept Neurosci, S San Francisco, CA 94080 USA; Univ Calif San Francisco, Dept Psychiat, Nina Ireland Lab Dev Neurobiol, San Francisco, CA 94143 USA	Roche Holding; Genentech; University of California System; University of California San Francisco	Rosenthal, A (corresponding author), Genentech Inc, Dept Neurosci, S San Francisco, CA 94080 USA.			Ye, Weilan/0000-0002-6219-3982; Hynes, Mary/0000-0001-6623-6727	NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH001046] Funding Source: NIH RePORTER; NIMH NIH HHS [K02 MH01046-01.18.] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ALVARADOMALLART RM, 1990, DEV BIOL, V139, P75, DOI 10.1016/0012-1606(90)90280-V; BALLYCUIF L, 1992, DEVELOPMENT, V115, P999; BALLYCUIF L, 1995, CURR OPIN GENET DEV, V5, P450, DOI 10.1016/0959-437X(95)90048-L; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cox WG, 1995, DEVELOPMENT, V121, P4349; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Dale JK, 1997, CELL, V90, P257, DOI 10.1016/S0092-8674(00)80334-7; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; Foley AC, 1997, DEVELOPMENT, V124, P2983; GARDNER CA, 1991, DEVELOPMENT, V113, P1037; GrapinBotton A, 1997, DEVELOPMENT, V124, P849; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; HORGER BA, 1995, J NEUROCHEM, V65, P770; Houart C, 1998, NATURE, V391, P788, DOI 10.1038/35853; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; Itasaki N, 1996, NEURON, V16, P487, DOI 10.1016/S0896-6273(00)80069-0; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; KENGAKU M, 1995, DEVELOPMENT, V121, P3121; LAMB TM, 1995, DEVELOPMENT, V121, P3627; LAUDER JM, 1974, J COMP NEUROL, V155, P469, DOI 10.1002/cne.901550407; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LAWSON KA, 1992, CIBA F SYMP, V165, P3; Lee SMK, 1997, DEVELOPMENT, V124, P959; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MARIN F, 1994, DEV BIOL, V163, P19, DOI 10.1006/dbio.1994.1120; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Muhr J, 1997, NEURON, V19, P487, DOI 10.1016/S0896-6273(00)80366-9; NISWANDER L, 1992, DEVELOPMENT, V114, P755; PLACZEK M, 1993, DEVELOPMENT, V117, P205; Pownall ME, 1996, DEVELOPMENT, V122, P3881; RESIBOIS A, 1992, NEUROSCIENCE, V46, P101, DOI 10.1016/0306-4522(92)90012-Q; ROGERS JH, 1992, BRAIN RES, V587, P203, DOI 10.1016/0006-8993(92)90998-O; ROWITCH DH, 1995, MECH DEVELOP, V52, P3, DOI 10.1016/0925-4773(95)00380-J; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; SASAKI H, 1993, DEVELOPMENT, V118, P47; Shimamura K, 1997, DEVELOPMENT, V124, P2709; Shimamura K, 1995, DEVELOPMENT, V121, P3923; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; SIMON H, 1995, CURR BIOL, V5, P205, DOI 10.1016/S0960-9822(95)00041-8; Smidt MP, 1997, P NATL ACAD SCI USA, V94, P13305, DOI 10.1073/pnas.94.24.13305; SPECHT LA, 1981, J COMP NEUROL, V199, P255, DOI 10.1002/cne.901990208; Storey KG, 1998, DEVELOPMENT, V125, P473; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; WANG MZ, 1995, NAT MED, V1, P1184, DOI 10.1038/nm1195-1184; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	57	703	737	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					755	766		10.1016/S0092-8674(00)81437-3	http://dx.doi.org/10.1016/S0092-8674(00)81437-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630220	Bronze			2022-12-24	WOS:000073956700012
J	Tybjaerg-Hansen, A; Steffensen, R; Meinertz, H; Schnohr, P; Nordestgaard, BG				Tybjaerg-Hansen, A; Steffensen, R; Meinertz, H; Schnohr, P; Nordestgaard, BG			Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL DEFECTIVE APOLIPOPROTEIN-B-100; RECEPTOR-BINDING; CHOLESTEROL; B-100; PRAVASTATIN; PREVENTION	Background Familial hypercholesterolemia leads to premature ischemic heart disease and is often caused by mutations in the gene for the low-density lipoprotein receptor. Mutations in the apolipoprotein B gene, which encodes a ligand for this receptor, may also result in this phenotype, Methods We studied the genotypes of 9255 women and men from the general population, 948 patients with ischemic heart disease, and 36 patients with familial hypercholesterolemia, all from Denmark, for three mutations in the apolipoprotein B gene: Arg3500Gln, Arg3531Cys, and Arg3500Trp. Results The prevalence of heterozygotes in the general population was 0.08 percent (95 percent confidence interval, 0.03 to 0.16 percent) for both the Arg3500Gln and the Arg3531Cys mutations, and 0.00 percent (95 percent confidence interval, 0.00 to 0.18 percent) for the Arg3500Trp mutation. Among carriers of the Arg3500Gln mutation, cholesterol levels were significantly higher than among noncarriers in the general population - by 100 mg per deciliter (2.6 mmol per liter) among carriers in the general population, 154 mg per deciliter (4.0 mmol per liter) among patients with ischemic heart disease, and 172 mg per deciliter (4.5 mmol per liter) among patients with familial hypercholesterolemia. Heterozygous carriers of the Arg3500Gln mutation were significantly more common among patients with ischemic heart disease (odds ratio, 7.0; 95 percent confidence interval, 2.2 to 22; P=0.003) and patients with familial hypercholesterolemia (odds ratio, 78; 95 percent confidence interval, 16 to 388; P=0.001) than in the general population. Heterozygous carriers of the Arg3531Cys mutation in the general population did not have higher-than-normal plasma cholesterol levels or an increased risk of ischemic heart disease (odds ratio; 1.4; 95 percent confidence interval, 0.2 to 11; P=0.54), Conclusions The Arg3500Gln mutation in the apolipoprotein B gene, which is responsible for familial defective apolipoprotein B-100 and is present in approximately 1 in 1000 persons in Denmark, causes severe hypercholesterolemia and increases the risk of ischemic heart disease. (C) 1998, Massachusetts Medical Society.	Univ Copenhagen, Herlev Univ Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark; Univ Copenhagen, Rigshosp, Natl Univ Hosp, Dept Med B,Div Cardiol, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Rigshosp, Natl Univ Hosp, Copenhagen City Heart Study, DK-2100 Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Tybjaerg-Hansen, A (corresponding author), Herlev Univ Hosp, Dept Clin Biochem 54M1, Herlev Ringvej 75, DK-2730 Herlev, Denmark.		Nordestgaard, Borge Gronne/ABF-1310-2020					AgerholmLarsen B, 1997, CIRCULATION, V95, P2358, DOI 10.1161/01.CIR.95.10.2358; ANDERSEN GE, 1979, ACTA PAEDIATR SCAND, V68, P541, DOI 10.1111/j.1651-2227.1979.tb05052.x; ARMITAGE P, 1987, STAT METHODS MED RES, P67; CARLETON RA, 1991, CIRCULATION, V83, P2154, DOI 10.1161/01.CIR.83.6.2154; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GAFFNEY D, 1995, ARTERIOSCL THROM VAS, V15, P1025, DOI 10.1161/01.ATV.15.8.1025; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; *GRAPHP SOFTW, 1995, STATM VERS 1 0; HANSEN PS, 1994, CLIN CHIM ACTA, V230, P101, DOI 10.1016/0009-8981(94)90093-0; HANSEN PS, 1991, J LIPID RES, V32, P1229; INNERARITY TL, 1990, J LIPID RES, V31, P1337; INNERARITY TL, 1987, P NATL ACAD SCI USA, V84, P6919, DOI 10.1073/pnas.84.19.6919; Julian DG, 1997, EUR HEART J, V18, P394; Ludwig EH, 1997, J LIPID RES, V38, P1361; MYANT NB, 1993, ATHEROSCLEROSIS, V104, P1, DOI 10.1016/0021-9150(93)90171-P; Nordestgaard BG, 1997, CIRCULATION, V96, P1737, DOI 10.1161/01.CIR.96.6.1737; PEDERSEN TR, 1994, LANCET, V344, P1383; PULLINGER CR, 1995, J CLIN INVEST, V95, P1225, DOI 10.1172/JCI117772; PYORALA K, 1994, EUR HEART J, V15, P1300; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SORIA LF, 1989, P NATL ACAD SCI USA, V86, P587, DOI 10.1073/pnas.86.2.587; SPSS, 1996, SPSS BAS 7 0 WIND US; Talmud PJ, 1996, ATHEROSCLEROSIS, V125, P135, DOI 10.1016/0021-9150(96)05838-8; TybjaergHansen A, 1997, J CLIN INVEST, V99, P3034, DOI 10.1172/JCI119499; TYBJAERGHANSEN A, 1995, SCAND J CLIN LAB INV, V55, P57; TYBJAERGHANSEN A, 1992, ATHEROSCLEROSIS, V96, P91, DOI 10.1016/0021-9150(92)90056-M; Wenham PR, 1997, ATHEROSCLEROSIS, V129, P185, DOI 10.1016/S0021-9150(96)06029-7; Wittrup HH, 1997, J CLIN INVEST, V99, P1606, DOI 10.1172/JCI119323	30	150	154	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1998	338	22					1577	1584		10.1056/NEJM199805283382203	http://dx.doi.org/10.1056/NEJM199805283382203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ350	9603795	Bronze			2022-12-24	WOS:000073852400003
J	Di Cunto, F; Topley, G; Calautti, E; Hsiao, J; Ong, L; Seth, PK; Dotto, GP				Di Cunto, F; Topley, G; Calautti, E; Hsiao, J; Ong, L; Seth, PK; Dotto, GP			Inhibitory function of p21(Cip1/WAF1) in differentiation of primary mouse keratinocytes independent of cell cycle control	SCIENCE			English	Article							P21(WAF1/CIP1) EXPRESSION; TERMINAL DIFFERENTIATION; GROWTH; P21; PROTEIN; PROGRESSION; WAF1/CIP1; CALCIUM; PCNA	The cyclin-dependent kinase inhibitor p21(Cip1/WAF1) has been implicated as an inducer of differentiation. However, although expression of p21 is increased in postmitotic cells immediately adjacent to the proliferative compartment, its expression is decreased in cells further along the differentiation program. Expression of the p21 protein was decreased in terminally differentiated primary keratinocytes of mice, and this occurred by a proteasome-dependent pathway. Forced expression of p21 in these cells inhibited the expression of markers of terminal differentiation at both the protein and messenger RNA levels. These inhibitory effects on differentiation were not observed with a carboxyl-terminal truncation mutant or with the unrelated cyclin-dependent kinase inhibitor p16(INK4a), although all these molecules exerted similar inhibition of cell growth. These findings reveal an inhibitory role of p21 in the late stages of differentiation that does not result from the effects of p21 on the cell cycle.	Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Univ Turin, Dept Genet Biol & Med Chem, Torino, Italy; NCI, Med Branch, Breast Canc Sect, Bethesda, MD 20892 USA	Harvard University; Massachusetts General Hospital; Harvard University; University of Turin; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Dotto, GP (corresponding author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, 13th St, Charlestown, MA 02129 USA.	Paolo_Dotto@cbrc.mgh.harvard.edu	Calautti, Enzo/M-8283-2018; Di Cunto, Ferdinando/K-5575-2016	Calautti, Enzo/0000-0002-4439-9709; di cunto, ferdinando/0000-0001-9367-6357	NCI NIH HHS [CA16038] Funding Source: Medline; NIAMS NIH HHS [AR39190] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039190] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Brissette JL, 1996, GENE DEV, V10, P2212, DOI 10.1101/gad.10.17.2212; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DELALLE I, 1996, SOC NEUR ABSTR, V22, P254; DICUNTO F, UNPUB; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Harper JW, 1997, CANCER SURV, V29, P91; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li LW, 1996, J INVEST DERMATOL, V106, P254, DOI 10.1111/1523-1747.ep12340654; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576	24	240	244	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1069	1072		10.1126/science.280.5366.1069	http://dx.doi.org/10.1126/science.280.5366.1069			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9582119				2022-12-24	WOS:000073663600045
J	Feray, C; Gigou, M; Samuel, D; Ducot, B; Maisonneuve, P; Reynes, M; Bismuth, A; Bismuth, H				Feray, C; Gigou, M; Samuel, D; Ducot, B; Maisonneuve, P; Reynes, M; Bismuth, A; Bismuth, H			Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation	ANNALS OF INTERNAL MEDICINE			English	Article						hepatitis C; liver transplantation; immunoglobulins; hepatitis C antibodies	VIRUS-INFECTION; IMMUNE GLOBULIN; NON-A; PREVENTION; IMMUNOPROPHYLAXIS; NEUTRALIZATION; REINFECTION; CHIMPANZEES	Background: Recurrence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection after liver transplantation is a clinical problem. Polyclonal immunoglobulins against hepatitis B surface antigen (HBIGs) prevent the recurrence of HBV infection, but no effective prophylaxis is available for HCV infection. Before screening of blood donors was introduced in France, HBIGs may have contained antibody to HCV (anti-HCV). Objective: io determine the influence of HBIG on the occurrence of hepatitis C after liver transplantation before and after 1990. Design: Retrospective cohort study. Setting: Liver transplantation unit of a university hospital. Patients: 428 consecutive patients who had liver transplantation because of cirrhosis between 1984 and 1994. Measurements: Detection of serum HCV RNA before and 1 year after transplantation and findings on liver graft biopsy. Results: Among the 218 patients who had HCV infection before transplantation, the incidence of HCV viremia after transplantation was lower in those receiving HBIG than in those not receiving HBIG (25 of 46 patients [54%] compared with 162 of 172 patients [94%]; P < 0.001). In patients receiving HBIG, the incidence of HCV viremia after transplantation was lower among those who had transplantation before March 1990 than among those who had transplantation after this date (15 of 33 patients [45%] compared with 10 of 13 patients [77%]; P = 0.05). Among the 210 patients without HCV infection before transplantation, acquired infection was significantly less frequent in those receiving HBIG than in those not receiving HBIG (18 of 68 patients [26%] compared with 40 of 86 patients [47%]; P < 0.001). Passively transmitted anti-HCV was transiently detected in patients receiving HBIG before March 1990. Multivariate analysis in patients with HCV infection before transplantation showed that the absence of HBIG and transplantation after March 1990 were independent significant risk factors for chronic hepatitis C after transplantation. Conclusions: Polyclonal immunoglobulins that are treated for viral decontamination and contain anti-HCV could prevent HCV infection.	Hop Paul Brousse, Ctr Hepatobiliare, Lab Anat Bathol & Transfus Sanguine, F-94800 Villejuif, France; Univ Paris Sud, Villejuif, France; Ctr Transfus Sanguine, Le Chesnay, France; CHU Bicetre, INSERM, U292, Le Kremlin Bicetre, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Feray, C (corresponding author), Hop Paul Brousse, Ctr Hepatobiliare, Lab Anat Bathol & Transfus Sanguine, 14 Ave Paul Vaillant Couturier, F-94800 Villejuif, France.		Feray, Cyrille/S-2559-2018	cyrille, feray/0000-0002-8627-9676				ALBERTI A, 1995, J HEPATOL, V22, P38; BJORO K, 1994, NEW ENGL J MED, V331, P1607, DOI 10.1056/NEJM199412153312402; CHOO QL, 1994, P NATL ACAD SCI USA, V91, P1294, DOI 10.1073/pnas.91.4.1294; FARCI P, 1994, P NATL ACAD SCI USA, V91, P7792, DOI 10.1073/pnas.91.16.7792; FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; FARGES O, 1994, TRANSPLANTATION, V58, P891, DOI 10.1097/00007890-199410270-00006; FARGES O, 1996, HEPATOLOGY, V5, P569; FERAY C, 1992, J CLIN INVEST, V89, P1361, DOI 10.1172/JCI115723; FERAY C, 1990, TRANSPLANTATION, V49, P1155, DOI 10.1097/00007890-199006000-00025; FERAY C, 1994, HEPATOLOGY, V20, P1137, DOI 10.1016/0270-9139(94)90748-X; KNODELL RG, 1976, LANCET, V1, P557; Krawczynski K, 1996, J INFECT DIS, V173, P822, DOI 10.1093/infdis/173.4.822; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LEFRERE JJ, 1993, LANCET, V341, P834, DOI 10.1016/0140-6736(93)90615-N; NEUHAUS P, 1994, LANCET, V344, P423; NOWAK T, 1992, J MED VIROL, V36, P209, DOI 10.1002/jmv.1890360311; SAMUEL D, 1991, LANCET, V337, P813, DOI 10.1016/0140-6736(91)92515-4; SAMUEL D, 1993, NEW ENGL J MED, V329, P1842, DOI 10.1056/NEJM199312163292503; SANCHEZQUIJANO A, 1988, LANCET, V1, P1245; SCOTTO J, 1983, HEPATOLOGY, V3, P279; SHIMIZU YK, 1994, J VIROL, V68, P1494, DOI 10.1128/JVI.68.3.1494-1500.1994; WRIGHT TL, 1992, GASTROENTEROLOGY, V103, P317, DOI 10.1016/0016-5085(92)91129-R; YAP PL, 1994, J HEPATOL, V21, P455, DOI 10.1016/S0168-8278(05)80328-9	23	106	107	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1998	128	10					810	+		10.7326/0003-4819-128-10-199805150-00003	http://dx.doi.org/10.7326/0003-4819-128-10-199805150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM889	9599192				2022-12-24	WOS:000073586500003
J	Wieczorek, E; Brand, M; Jacq, X; Tora, L				Wieczorek, E; Brand, M; Jacq, X; Tora, L			Function of TAF(II)-containing complex without TBP in transcription by RNA polymerase II	NATURE			English	Article							TATA-BINDING PROTEIN; ESTROGEN-RECEPTOR; TFIID COMPLEX; ACTIVATION FUNCTIONS; PROMOTER; PURIFICATION; INITIATION; EXPRESSION; DROSOPHILA; SUBUNITS	Initiation of transcription of a gene from a core promoter region by RNA polymerase II requires the assembly of several initiation factors to form a preinitiation complex. Assembly of this complex(1,2) is thought to be nucleated exclusively by the sequence-specific binding of the TFIID transcription factor complex, which is composed of the TATA-binding protein (TBP) and TBP-associated factors (TAF(II)s) (refs 3, 4), to the different promoters. Here we isolate and characterize a new multiprotein complex that does not contain either TBP or a TBP-like factor but is composed of several TAF(II)s and other proteins. This complex can replace TFIID on both TATA-containing and TATA-lacking promoters in in vitro transcription assays. Moreover, an anti-TBP antibody that inhibits TBP- and TFIID-dependent transcription does not inhibit activity of this new complex. These results indicate that TBP-free RNA polymerase II mediated transcription may be able to occur in mammalian cells and that multiple preinitiation complexes may play an important role in regulating gene expression.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tora, L (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch, France.		Tora, Laszlo/E-9999-2018; Wieczorek, Elżbieta/GXZ-9842-2022	Tora, Laszlo/0000-0001-7398-2250; 				Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BOAM DS, 1995, J BIOL CHEM, V270, P487; BROU C, 1993, NUCLEIC ACIDS RES, V21, P5, DOI 10.1093/nar/21.1.5; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; Chang MP, 1997, NUCLEIC ACIDS RES, V25, P4861, DOI 10.1093/nar/25.24.4861; CROWLEY TE, 1993, NATURE, V361, P557, DOI 10.1038/361557a0; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; GERARD M, 1991, J BIOL CHEM, V266, P20940; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P85; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; LAVIGNE AC, 1996, J BIOL CHEM, V271, P774; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; vanderKnaap JA, 1997, P NATL ACAD SCI USA, V94, P11827, DOI 10.1073/pnas.94.22.11827; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	29	220	228	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1998	393	6681					187	191		10.1038/30283	http://dx.doi.org/10.1038/30283			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN200	9603525				2022-12-24	WOS:000073619900054
J	Hirsch, RE; Lewis, BD; Spalding, EP; Sussman, MR				Hirsch, RE; Lewis, BD; Spalding, EP; Sussman, MR			A role for the AKT1 potassium channel in plant nutrition	SCIENCE			English	Article							RECTIFYING K+ CHANNELS; ARABIDOPSIS-THALIANA; ION-TRANSPORT; LINEAR COMPONENT; CORN ROOTS; INWARD; MECHANISM; EXPRESSION; AMMONIUM; CELLS	In plants, potassium serves an essential role as an osmoticum and charge carrier. Its uptake by roots occurs by poorly defined mechanisms. To determine the role of potassium channels in planta, we performed a reverse genetic screen and identified an Arabidopsis thaliana mutant in which the AKT1 channel gene was disrupted. Roots of this mutant lacked inward-rectifying potassium channels and displayed reduced potassium (rubidium-86) uptake. Compared with wild type, mutant plants grew poorly on media with a potassium concentration of 100 micromolar or less. These results and membrane potential measurements suggest that the AKT1 channel mediates potassium uptake from solutions that contain as little as 10 micromolar potassium.	Univ Wisconsin, Dept Hort, Ctr Biotechnol, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Biol Program, Madison, WI 53706 USA; Univ Wisconsin, Dept Bot, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Sussman, MR (corresponding author), Univ Wisconsin, Dept Hort, Ctr Biotechnol, 1575 Linden Dr, Madison, WI 53706 USA.		Spalding, Edgar P/GWC-1811-2022; Spalding, Edgar P/A-9034-2008; Spalding, Edgar P/ABF-3253-2021	Spalding, Edgar P/0000-0002-6890-4765; Spalding, Edgar P/0000-0002-6890-4765; 	NIGMS NIH HHS [GM07215] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; CAO YW, 1993, PLANT PHYSIOL, V102, P983, DOI 10.1104/pp.102.3.983; Cho MH, 1996, P NATL ACAD SCI USA, V93, P8134, DOI 10.1073/pnas.93.15.8134; EPSTEIN E, 1963, P NATL ACAD SCI USA, V49, P684, DOI 10.1073/pnas.49.5.684; GASSMANN W, 1994, PLANT PHYSIOL, V105, P1399, DOI 10.1104/pp.105.4.1399; GASSMANN W, 1993, PLANT CELL, V5, P1491, DOI 10.2307/3869732; Gaymard F, 1996, J BIOL CHEM, V271, P22863, DOI 10.1074/jbc.271.37.22863; KOCHIAN LV, 1982, PLANT PHYSIOL, V70, P1723, DOI 10.1104/pp.70.6.1723; KOCHIAN LV, 1985, PLANT PHYSIOL, V79, P771, DOI 10.1104/pp.79.3.771; Krysan PJ, 1996, P NATL ACAD SCI USA, V93, P8145, DOI 10.1073/pnas.93.15.8145; Lagarde D, 1996, PLANT J, V9, P195, DOI 10.1046/j.1365-313X.1996.09020195.x; Lewis BD, 1997, PLANT PHYSIOL, V114, P1327, DOI 10.1104/pp.114.4.1327; MAATHUIS FJM, 1993, PLANTA, V191, P302, DOI 10.1007/BF00195686; MAATHUIS FJM, 1994, P NATL ACAD SCI USA, V91, P9272, DOI 10.1073/pnas.91.20.9272; MAATHUIS FJM, 1995, PLANTA, V197, P456, DOI 10.1007/BF00196667; Roberts SK, 1995, PLANT J, V8, P811, DOI 10.1046/j.1365-313X.1995.8060811.x; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; SCHROEDER JI, 1991, P NATL ACAD SCI USA, V88, P11583, DOI 10.1073/pnas.88.24.11583; SCHROEDER JI, 1994, ANNU REV BIOPH BIOM, V23, P441, DOI 10.1146/annurev.bb.23.060194.002301; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; VALE FR, 1987, PLANT PHYSIOL, V84, P1416, DOI 10.1104/pp.84.4.1416; VALE FR, 1988, PLANTA, V173, P424, DOI 10.1007/BF00401031; Walker DJ, 1996, P NATL ACAD SCI USA, V93, P10510, DOI 10.1073/pnas.93.19.10510	23	503	564	3	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 8	1998	280	5365					918	921		10.1126/science.280.5365.918	http://dx.doi.org/10.1126/science.280.5365.918			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572739				2022-12-24	WOS:000073532900046
J	Packer, C; Tatar, M; Collins, A				Packer, C; Tatar, M; Collins, A			Reproductive cessation in female mammals	NATURE			English	Article							MENOPAUSE; LIONS; COSTS	In female mammals, fertility declines abruptly at an advanced age. The human menopause is one example, but reproductive cessation has also been documented in non-human primates, rodents, whales, dogs, rabbits, elephants and domestic livestock(1-3). The human menopause has been considered an evolutionary adaptation(4-7), assuming that elderly women avoid the increasing complications of continued childbirth to better nurture their current children and grandchildren. But an abrupt reproductive decline might be only a non-adaptive by-product of life-history patterns. Because so many individuals die from starvation, disease and predation, detrimental genetic traits can persist (or even be favoured) as long as their deleterious effects are delayed until an advanced age is reached, and, for a given pattern of mortality, there should be an age by which selection would be too weak to prevent the onset of reproductive senescence(4,5,8). We provide a systematic test of these alternatives using field data from two species in which grandmothers frequently engage in kin-directed behaviour. Both species show abrupt age-specific changes in reproductive performance that are characteristic of menopause. But elderly females do not suffer increased mortality costs of reproduction, nor do post-reproductive females enhance the fitness of grandchildren or older children. Instead, reproductive cessation appears to result from senescence.	Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA; Brown Univ, Dept Ecol & Evolut Biol, Providence, RI 02912 USA; Gombe Stream Res Ctr, Kigoma, Tanzania	University of Minnesota System; University of Minnesota Twin Cities; Brown University	Packer, C (corresponding author), Univ Minnesota, Dept Ecol Evolut & Behav, 1987 Upper Buford Circle, St Paul, MN 55108 USA.	packer@biosci.umn.edu		Tatar, Marc/0000-0003-3232-6884				Altmann J., 1970, LAB ANIM DIG, V6, P7; Caswell H, 1989, MATRIX POPULATION MO; Charlesworth B., 1980, EVOLUTION AGE STRUCT; Finch CE, 1990, LONGEVITY SENESCENCE; Gouzoules S., 1987, P299; HAMILTON WD, 1966, J THEOR BIOL, V12, P12, DOI 10.1016/0022-5193(66)90184-6; Hawkes K, 1997, CURR ANTHROPOL, V38, P551, DOI 10.1086/204646; HEINSOHN R, 1995, SCIENCE, V269, P1260, DOI 10.1126/science.7652573; Hill K, 1991, Hum Nat, V2, P313, DOI 10.1007/BF02692196; Laws R.M., 1975, ELEPHANTS THEIR HABI; Lee E, 2013, STAT METHODS SURVIVA; MCCOMB K, 1994, ANIM BEHAV, V47, P379, DOI 10.1006/anbe.1994.1052; Medawar P.B, 1952, UNIQUENESS INDIVIDUA; PACKER C, 1990, AM NAT, V136, P1, DOI 10.1086/285079; PACKER C, 1995, AM NAT, V145, P833, DOI 10.1086/285771; PACKER C, 1995, NATURE, V373, P60, DOI 10.1038/373060a0; PUSEY AE, 1994, BEHAV ECOL, V5, P362, DOI 10.1093/beheco/5.4.362; REZNICK D, 1985, OIKOS, V44, P257, DOI 10.2307/3544698; ROGERS AR, 1993, EVOL ECOL, V7, P406, DOI 10.1007/BF01237872; Stolwijk AM, 1997, FERTIL STERIL, V67, P702, DOI 10.1016/S0015-0282(97)81370-2; vanNoord PAH, 1997, FERTIL STERIL, V68, P95, DOI 10.1016/S0015-0282(97)81482-3; VAUPEL JW, 1985, AM STAT, V39, P176, DOI 10.2307/2683925; Vom Saal Frederick S., 1994, P1213; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; Wise PM, 1996, SCIENCE, V273, P67, DOI 10.1126/science.273.5271.67	25	229	234	2	111	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1998	392	6678					807	811		10.1038/33910	http://dx.doi.org/10.1038/33910			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572138				2022-12-24	WOS:000073241200051
J	Barrat, JA; Gillet, P; Lecuyer, C; Sheppard, SMF; Lesourd, M				Barrat, JA; Gillet, P; Lecuyer, C; Sheppard, SMF; Lesourd, M			Formation of carbonates in the Tatahouine meteorite	SCIENCE			English	Article							ALH84001	The Tatahouine meteorite, in southern Tunisia, shows terrestrial contamination that developed during 63 years of exposure on Earth's surface. Samples collected on the day of the fall in 1931 contained fractures, with no secondary minerals, whereas samples collected in 1994 contain calcite aggregates (70 to 150 micrometers) and rod-shaped forms (100 to 600 nanometers in length and 70 to 80 nanometers in diameter) on the fractures. Carbon isotope analysis of the carbonates within the Tatahouine meteorite [delta(13)C = -2.0 per mil Pee Dee belemnite standard (PDB)] and the underlying ground (delta(13)C = -3.2 per mil PDB) confirm their terrestrial origin.	Univ Angers, Geol Lab, F-49045 Angers, France; Ecole Normale Super Lyon, Lab Ctr Terre, CNRS, UMR 5570, F-69364 Lyon 07, France; Ecole Normale Super Lyon, Inst Univ France, F-69364 Lyon 07, France; Fac Med, CNRS, F-49045 Angers, France; Fac Med, Serv Commun Microscopie Elect, F-49045 Angers, France	Universite d'Angers; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Ecole Normale Superieure de Lyon (ENS de LYON); Institut Universitaire de France; Centre National de la Recherche Scientifique (CNRS); Universite d'Angers; Universite d'Angers	Barrat, JA (corresponding author), Univ Angers, Geol Lab, 2 Blvd Lavoisier, F-49045 Angers, France.		Jean-Alix, BARRAT/F-8035-2012; Lecuyer, Christophe/C-8297-2012; Barrat, Jean-Alix/C-8416-2017; Lecuyer, Christophe/AAO-8154-2021	Barrat, Jean-Alix/0000-0003-3158-3109; Lecuyer, Christophe/0000-0001-9513-2492				BISCHOFF WD, 1985, AM MINERAL, V70, P581; Bradley JP, 1997, NATURE, V390, P454, DOI 10.1038/37257; Clayton RN, 1996, GEOCHIM COSMOCHIM AC, V60, P1999, DOI 10.1016/0016-7037(96)00074-9; Folk RL, 1997, J SEDIMENT RES, V67, P583; GILLET P, 1993, PHYS CHEM MINER, V20, P1; GOODING JL, 1988, GEOCHIM COSMOCHIM AC, V52, P909, DOI 10.1016/0016-7037(88)90361-4; Jull AJT, 1997, J GEOPHYS RES-PLANET, V102, P1663, DOI 10.1029/96JE03111; Kerr RA, 1997, SCIENCE, V278, P1706, DOI 10.1126/science.278.5344.1706; Lacroix A, 1931, CR HEBD ACAD SCI, V193, P305; Mason B., 1992, SMITHSON CONTRIB EAR, V30, P17; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; McKay DS, 1997, NATURE, V390, P455, DOI 10.1038/37257-c1; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; Nealson KH, 1997, ANNU REV EARTH PL SC, V25, P403, DOI 10.1146/annurev.earth.25.1.403; URMOS J, 1991, AM MINERAL, V76, P641; Zolensky M., 1988, METEORITES EARLY SOL, P114	16	45	47	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					412	414		10.1126/science.280.5362.412	http://dx.doi.org/10.1126/science.280.5362.412			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545214				2022-12-24	WOS:000073159600040
J	Bolam, A; Manandhar, DS; Shrestha, P; Ellis, M; Costello, AMD				Bolam, A; Manandhar, DS; Shrestha, P; Ellis, M; Costello, AMD			The effects of postnatal health education for mothers on infant care and family planning practices in Nepal: A randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							DEVELOPING-COUNTRIES; SELF-EFFICACY; INTERVENTIONS	Objectives: To evaluate impact of postnatal health education for mothers on infant care and postnatal family planning practices in Nepal. Design: Randomised controlled trial with community follow up at 3 and 6 months post partum by interview Initial household survey of study areas to identify all pregnant women to facilitate follow up. Setting: Main maternity hospital in Kathmandu, Nepal. Follow up in urban Kathmandu and a periurban area southwest of the city. Subjects: 540 mothers randomly allocated to one of four groups: health education immediately after birth and three months later (group A), at birth only (group B), at three months only (group C), or none (group D). Interventions: Structured baseline household questionnaire; 20 minute, one to one health education at birth and three months later. Main outcome measures: Duration of exclusive breast feeding, appropriate immunisation of infant, knowledge of oral rehydration solution and need to continue breast feeding in diarrhoea, knowledge of infant signs suggesting pneumonia, uptake of postnatal family planning. Results: Mothers in groups A and B (received health education at birth) were slightly more likely to use contraception at six months after birth compared with mothers in groups C and D (no health education at birth) (odds ratio 1.62, 95% confidence interval 1.06 to 2.5). There were no other significant differences between groups with regards to infant feeding, infant care, or immunisation. Conclusions: Our findings suggest that the recommended practice of individual health education for postnatal mothers in poor communities has no impact on infant feeding, care, or immunisation, although uptake of family planning may be slightly enhanced.	Inst Child Hlth, Ctr Int Child Hlth, London WC1N 1EH, England; Matern Hosp, Mother & Infant Res Act, Kathmandu, Nepal	University of London; University College London	Costello, AMD (corresponding author), Inst Child Hlth, Ctr Int Child Hlth, 30 Guilford St, London WC1N 1EH, England.							Ad Hoc Group of the American Public Health Association, 1987, AM J PUBLIC HEALTH, V77, P89; ASHWORTH A, 1982, ARCH DIS CHILD, V57, P882, DOI 10.1136/adc.57.11.882; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BHARGAVA SK, 1990, NATL COLLABORATION S; BOLAM A, 1997, J NEPAL MED ASS, V35, P122; GYORKOS TW, 1994, CAN J PUBLIC HEALTH, V85, pS8; Hubley J. H., 1986, Health Education Research, V1, P233, DOI 10.1093/her/1.4.233; Kafatos A G, 1991, Hygie, V10, P32; KUNDI MZM, 1993, SOC SCI MED, V37, P649, DOI 10.1016/0277-9536(93)90104-C; LOEVINSOHN BP, 1990, INT J EPIDEMIOL, V19, P788, DOI 10.1093/ije/19.4.788; MAIBACH E, 1995, HEALTH EDUC RES, V10, P37, DOI 10.1093/her/10.1.37; *NAT PLANN COMM, 1995, NEP MULT IND SURV PR; NEUPANE S, 1992, STUDY BREAST FEEDING; OAKLEY A, 1995, BRIT MED J, V310, P158, DOI 10.1136/bmj.310.6973.158; PARKIN JM, 1976, ARCH DIS CHILD, V51, P259, DOI 10.1136/adc.51.4.259; PRASAD B, 1995, BRIT MED J, V310, P621, DOI 10.1136/bmj.310.6980.621; TUPASI TE, 1989, ANN TROP PAEDIATR, V9, P82, DOI 10.1080/02724936.1989.11748603; *UN CHILDR FUND, 1993, STAT WORLDS CHILDR 1; UNITED NATIONS DEVELOPMENT PROGRAM, 1996, HUM DEV REP; *WHO, 1978, ABN AT DECL; World Bank, 1993, INV HLTH WORLD DEV R; World Bank, 1990, WORLD DEV REP 1990	22	103	105	2	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					805	811		10.1136/bmj.316.7134.805	http://dx.doi.org/10.1136/bmj.316.7134.805			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZC488	9549449	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000072584300024
J	Turner, RC; Millns, H; Neil, HAW; Stratton, IM; Manley, SE; Matthews, DR; Holman, RR				Turner, RC; Millns, H; Neil, HAW; Stratton, IM; Manley, SE; Matthews, DR; Holman, RR		United Kingdom Prospective Diabet Study Grp	Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United kingdom prospective diabetes study (UKPDS : 23)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; SERUM-CHOLESTEROL CONCENTRATION; LOW-DENSITY-LIPOPROTEIN; 11-YEAR FOLLOW-UP; CARDIOVASCULAR MORTALITY; GLUCOSE-INTOLERANCE; BODY-WEIGHT; WOMEN; HYPERTRIGLYCERIDEMIA; HYPERGLYCEMIA	Objective: To evaluate baseline risk factors for coronary artery disease in patients with type 2 diabetes mellitus. Design: A stepwise selection procedure, adjusting for age and sex, was used in 2693 subjects with complete data to determine which risk factors for coronary artery disease should be included in a Cox proportional hazards model. Subjects: 3055 white patients (mean age 52) with recently diagnosed type 2 diabetes mellitus and without evidence of disease related to atheroma. Median duration of follow up was 7.9 years. 335 patients developed coronary artery disease within 10 years. Outcome measures: Angina with confirmatory abnormal electrocardiogram; non-fatal and fatal myocardial infarction. Results: Coronary artery disease was significantly associated with increased concentrations of low density lipoprotein cholesterol, decreased concentrations of high density lipoprotein cholesterol, and increased triglyceride concentration, haemoglobin A(1c), systolic blood pressure, fasting plasma glucose concentration, and a history of smoking. The estimated hazard ratios for the upper third relative to the lower third were 2.26 (95% confidence interval 1.70 to 3.00) for low density lipoprotein cholesterol, 0.55 (0.41 to 0.73) for high density lipoprotein cholesterol, 1.52 (1.15 to 2.01) for haemoglobin A(1c), and 1.82 (1.34 to 2.47) for systolic blood pressure. The estimated hazard ratio for smokers was 1.41(1.06 to 1.88). Conclusion: A quintet of potentially modifiable risk factors for coronary artery disease exists in patients with type 2 diabetes mellitus. These risk factors are increased concentrations of low density lipoprotein cholesterol, decreased concentrations of high density lipoprotein cholesterol, raised brood pressure, hyperglycaemia, and smoking.	Univ Oxford, Radcliffe Infirm, Diabet Res Labs, Dept Med, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Turner, RC (corresponding author), Univ Oxford, Radcliffe Infirm, Diabet Res Labs, Dept Med, Oxford OX2 6HE, England.	robert.turner@drl.ox.ac.uk	stratton, irene/AAZ-3627-2020; Adiels, Martin/C-9278-2011	stratton, irene/0000-0003-1172-7865; Manley, Susan/0000-0002-8298-4511				AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; BROWNLEE M, 1992, DIABETES CARE, V15, P1835, DOI 10.2337/diacare.15.12.1835; BUTLER WJ, 1985, AM J EPIDEMIOL, V121, P541; BYERS T, 1995, NEW ENGL J MED, V333, P723, DOI 10.1056/NEJM199509143331109; COLEMAN MP, 1989, PERSON YEARS PYRS FO; COX DR, 1972, J R STAT SOC B, V34, P187; CULL C, 1993, DIABETOLOGIA, V36, P1021; DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; Folsom AR, 1997, DIABETES CARE, V20, P935, DOI 10.2337/diacare.20.6.935; FONTBONNE A, 1989, DIABETOLOGIA, V32, P300, DOI 10.1007/BF00265546; GALL MA, 1995, DIABETES, V44, P1303, DOI 10.2337/diabetes.44.11.1303; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; HEYDEN S, 1980, J CHRON DIS, V33, P265, DOI 10.1016/0021-9681(80)90021-1; JARRETT RJ, 1976, LANCET, V2, P1009; KANNEL WB, 1995, MED CLIN N AM, V79, P951, DOI 10.1016/S0025-7125(16)30016-5; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; KAWAMURA M, 1994, J CLIN INVEST, V94, P771, DOI 10.1172/JCI117396; KLEIN R, 1995, DIABETES CARE, V18, P258, DOI 10.2337/diacare.18.2.258; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; LAAKSO M, 1993, CIRCULATION, V88, P1421, DOI 10.1161/01.CIR.88.4.1421; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; Lehto S, 1997, DIABETES, V46, P1354, DOI 10.2337/diabetes.46.8.1354; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANLEY SE, 1994, DIABETIC MED, V11, P534; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MODAN M, 1986, DIABETOLOGIA, V29, P82, DOI 10.1007/BF00456115; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; PEDERSEN TR, 1994, LANCET, V344, P1383; *POP CENS SURV OFF, 1994, MORT STTAT REV REG G; PYORALA K, 1995, DIABETES, V44, pA35; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SCHECTMAN G, 1993, CLIN CHEM, V39, P1495; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STENSVOLD I, 1993, BMJ-BRIT MED J, V307, P1318, DOI 10.1136/bmj.307.6915.1318; Stratton I, 1996, DIABETOLOGIA, V39, P1554, DOI 10.1007/s001250050614; STRATTON IM, 1995, DIABETES, V43, pS434; TURNER RC, 1991, DIABETOLOGIA, V34, P877; UK Prospective Diabetes Study Group, 1996, ANN INTERN MED, V124, P136; UUSITUPA MIJ, 1993, DIABETOLOGIA, V36, P1175, DOI 10.1007/BF00401063; WALTERS DP, 1994, DIABETIC MED, V11, P968, DOI 10.1111/j.1464-5491.1994.tb00255.x; World Health Organization, 1978, INT CLASS PROC MED	47	1408	1482	0	37	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 14	1998	316	7134					823	828		10.1136/bmj.316.7134.823	http://dx.doi.org/10.1136/bmj.316.7134.823			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549452	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000072584300028
J	Liu, JP; Zhu, JK				Liu, JP; Zhu, JK			A calcium sensor homolog required for plant salt tolerance	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; CALCINEURIN; YEAST; ARABIDOPSIS; ACTIVATION; ADAPTATION; RECOVERIN; CELLS	Excessive sodium (Na+) in salinized soils inhibits plant growth and development. A mutation in the SOS3 gene renders Arabidopsis thaliana plants hypersensitive to Na+-induced growth inhibition. SOS3 encodes a protein that shares significant sequence similarity with the calcineurin B subunit from yeast and neuronal calcium sensors from animals. The results suggest that intracellular calcium signaling through a calcineurin-like pathway mediates the beneficial effect of calcium on plant salt tolerance.	Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA	University of Arizona	Zhu, JK (corresponding author), Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA.		Zhu, Jian-Kang/F-7658-2011	Zhu, Jian-Kang/0000-0001-5134-731X; LIU, JIPING/0000-0002-7558-0025				[Anonymous], 1972, MINERAL NUTR PLANTS; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; CHOI S, 1995, WEEDS WORLD, V2, P17; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; EPSTEIN E, 1980, SCIENCE, V210, P399, DOI 10.1126/science.210.4468.399; GREENWAY H, 1980, ANNU REV PLANT PHYS, V31, P149, DOI 10.1146/annurev.pp.31.060180.001053; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Knight H, 1997, PLANT J, V12, P1067, DOI 10.1046/j.1365-313X.1997.12051067.x; LAHAYE PA, 1969, SCIENCE, V166, P395, DOI 10.1126/science.166.3903.395; Lauchli A, 1990, AM SOC PLANT PHYSL S; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Liu JP, 1997, P NATL ACAD SCI USA, V94, P14960, DOI 10.1073/pnas.94.26.14960; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; LYNCH J, 1989, PLANT PHYSIOL, V90, P1271, DOI 10.1104/pp.90.4.1271; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MURGUIA JR, 1995, SCIENCE, V267, P232; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; NIU XM, 1995, PLANT PHYSIOL, V109, P735, DOI 10.1104/pp.109.3.735; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; Schaad NC, 1996, P NATL ACAD SCI USA, V93, P9253, DOI 10.1073/pnas.93.17.9253; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; Wu SJ, 1996, PLANT CELL, V8, P617, DOI 10.1105/tpc.8.4.617	29	594	707	16	138	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1943	1945		10.1126/science.280.5371.1943	http://dx.doi.org/10.1126/science.280.5371.1943			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632394				2022-12-24	WOS:000074323800066
J	Feng, WJ; Ribeiro, RCJ; Wagner, RL; Nguyen, H; Apriletti, JW; Fletterick, RJ; Baxter, JD; Kushner, PJ; West, BL				Feng, WJ; Ribeiro, RCJ; Wagner, RL; Nguyen, H; Apriletti, JW; Fletterick, RJ; Baxter, JD; Kushner, PJ; West, BL			Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVATION; CRYSTAL-STRUCTURE; CONSERVED REGION; DOMAIN; PROTEIN; COMPLEX	The ligand-binding domain of nuclear receptors contains a transcriptional activation function (AF-2) that mediates hormone-dependent binding of coactivator proteins. Scanning surface mutagenesis on the human thyroid hormone receptor was performed to define the site that binds the coactivators, glucocorticoid receptor-interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1), The residues involved encircle a small surface that contains a hydrophobic cleft. Ligand activation of transcription involves formation of this surface by folding the carboxyl-terminal cr helix against a scaffold of three other helices. These features may represent general ones for nuclear receptors.	Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Brasilia, Dept Pharmaceut Sci, BR-70910900 Brasilia, DF, Brazil; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Universidade de Brasilia; University of California System; University of California San Francisco	West, BL (corresponding author), Univ Calif San Francisco, Metab Res Unit, Box 0540, San Francisco, CA 94143 USA.	kushner@itsa.ucsf.edu; west@socrates.ucsf.edu		West, Brian/0000-0002-5320-3691	NCRR NIH HHS [P41-RR01081] Funding Source: Medline; NIDDK NIH HHS [DK51281, DK09516] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051281, F32DK009516] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APRILETTI JW, 1995, PROTEIN EXPRES PURIF, V6, P363, DOI 10.1006/prep.1995.1048; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEE JW, 1992, MOL ENDOCRINOL, V6, P1867, DOI 10.1210/me.6.11.1867; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; ONATE SA, 1995, SCIENCE, V270, P1354; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Saatcioglu F, 1997, MOL CELL BIOL, V17, P4687, DOI 10.1128/MCB.17.8.4687; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WHITFIELD GK, 1995, MOL ENDOCRINOL, V9, P1166, DOI 10.1210/me.9.9.1166; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	36	477	496	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1747	1749		10.1126/science.280.5370.1747	http://dx.doi.org/10.1126/science.280.5370.1747			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624051				2022-12-24	WOS:000074197800040
J	Poloniecki, J; Valencia, O; Littlejohns, P				Poloniecki, J; Valencia, O; Littlejohns, P			Cumulative risk adjusted mortality chart for detecting changes in death rate: observational study of heart surgery	BRITISH MEDICAL JOURNAL			English	Article							STRATIFICATION; OUTCOMES	Objective: To detect changes in mortality after surgery with allowance being made for variations in case mix. Design: Observational study of postoperative mortality from January 1992 to August 1995. Setting: Regional cardiothoracic unit. Subjects: 3983 patients aged 16 and over who had open heart operations. Main outcome measures: Preoperative risk factors and postoperative mortality in hospital within 30 days were recorded for all surgical heart operations. Mortality was adjusted for case mix using a preoperative estimate of risk based on additive Parsonnet factors. The number of operations required for statistical power to detect a doubling of mortality was examined, and control limits at a nominal significance level of P = 0.01 for detection of an adverse trend were determined. Results: Total mortality of 7.0% was 26% below the Parsonnet predictor (P < 0.0001). There was a highly significant variation in annual case mix (Parsonnet scores 8.7-10.6, P < 0.0001). There was no significant variation in mortality after adjustment for case mix (odds ratio 1-1.5, P = 0.18) with monitoring by calendar year. With continuous monitoring, however, nominal 99% control limits based on 16 expected deaths were crossed on two occasions. Conclusions: Hospital league tables for mortality from heart surgery will be of limited value because year to year differences in death rate can be large (odds ratio 1.5) even when the underlying risk or case mix does not change. Statistical quality control of a single series with adjustment for case mix is the only way to take into account recent performance when informing a patient of the risk of surgery at a particular hospital. If there is an increase in the number of deaths the chances of the next patient surviving surgery can be calculated from the last 16 deaths.	St George Hosp, Sch Med, London SW17 0RE, England; St George Hosp, Reg Cardiothorac Unit, London SW17 0RE, England	St Georges University London; St Georges University London	Poloniecki, J (corresponding author), St George Hosp, Sch Med, Cranmer Terrace, London SW17 0RE, England.							Capewell S, 1996, HEART, V76, P70, DOI 10.1136/hrt.76.1.70; COPELAND GP, 1995, BRIT J SURG, V82, P408, DOI 10.1002/bjs.1800820344; DELEVAL MR, 1994, J THORAC CARDIOV SUR, V107, P914; deLeval MR, 1997, LANCET, V349, P723, DOI 10.1016/S0140-6736(96)11327-1; DYER C, 1997, GUARDIAN        0502, P10; DZIUBAN SW, 1994, ANN THORAC SURG, V58, P1871, DOI 10.1016/0003-4975(94)91730-2; ELLIS SG, 1997, CIRCULATION, V96, P2479; Irvine D, 1997, BRIT MED J, V314, P1613, DOI 10.1136/bmj.314.7094.1613; LOVEGOVE J, 1997, HEART, V77, P18; Lovegrove J, 1997, LANCET, V350, P1128, DOI 10.1016/S0140-6736(97)06507-0; NASHEF SAM, 1992, BRIT MED J, V305, P1066, DOI 10.1136/bmj.305.6861.1066; PARSONNET V, 1989, CIRCULATION, V79, P3; REESMOGG W, 1996, TIMES           0401, P16; ROCKALL TA, 1995, LANCET, V346, P346, DOI 10.1016/S0140-6736(95)92227-X; TAYLOR K, 1991, BRIT J HEALTHCA 0530, P30; TODD CJ, 1995, BRIT MED J, V310, P904, DOI 10.1136/bmj.310.6984.904	16	136	136	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1697	1700		10.1136/bmj.316.7146.1697	http://dx.doi.org/10.1136/bmj.316.7146.1697			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614015	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000074129500014
J	Geraghty, RJ; Krummenacher, C; Cohen, GH; Eisenberg, RJ; Spear, PG				Geraghty, RJ; Krummenacher, C; Cohen, GH; Eisenberg, RJ; Spear, PG			Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS; CELL-SURFACE RECEPTORS; PSEUDORABIES VIRUS; GLYCOPROTEIN-D; HEPARAN-SULFATE; PENETRATION; EXPRESSION; MEMBER; FORMS; BIND	A human member of the immunoglobulin superfamily was shown to mediate entry of several alphaherpesviruses, including herpes simplex viruses (HSV) 1 and 2, porcine pseudorabies virus (PRV), and bovine Herpesvirus 1 (BHV-1). This membrane glycoprotein is poliovirus receptor-related protein 1 (Prr1), designated here as HveC, Incubation of HSV-1 with a secreted form of HveC inhibited subsequent infection of a variety of cell lines, suggesting that HveC interacts directly with the virus. Poliovirus receptor (Pvr) itself mediated entry of PRV and BHV-1 but not of the HSV strains tested. HveC was expressed in human cells of epithelial and neuronal origin; it is the prime candidate for the coreceptor that allows both HSV-1 and HSV-2 to infect epithelial cells on mucosal surfaces and spread to cells of the nervous system.	Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Univ Penn, Sch Dent Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Oral Hlth Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA	Northwestern University; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Spear, PG (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.	p-spear@nwu.edu		Geraghty, Robert/0000-0002-0560-6509; Krummenacher, Claude/0000-0002-3492-4987	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030606, R01NS036731] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 36293] Funding Source: Medline; NINDS NIH HHS [NS-30606, NS-36731] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Babic N, 1996, J GEN VIROL, V77, P2277, DOI 10.1099/0022-1317-77-9-2277; CAMPADELLIFIUME G, 1988, J VIROL, V62, P159, DOI 10.1128/JVI.62.1.159-167.1988; CHASE CCL, 1993, VIROLOGY, V194, P365, DOI 10.1006/viro.1993.1269; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; EJERCITO PM, 1968, J GEN VIROL, V2, P357, DOI 10.1099/0022-1317-2-3-357; FRANCKE U, 1981, SOMAT CELL GENET, V7, P171; GERAGHTY RJ, UNPUB; HOGGAN MD, 1959, AM J HYG, V70, P208, DOI 10.1093/oxfordjournals.aje.a120071; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; JOHNSON DC, 1988, J VIROL, V62, P4605, DOI 10.1128/JVI.62.12.4605-4612.1988; JOHNSON DC, 1990, J VIROL, V64, P2569, DOI 10.1128/JVI.64.6.2569-2576.1990; KARGER A, 1993, VIROLOGY, V194, P654, DOI 10.1006/viro.1993.1305; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; KRUMMENACHER C, UNPUB; KRUMMENACHER C, IN PRESS J VIROL; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; LEE WC, 1993, J VIROL, V67, P5088, DOI 10.1128/JVI.67.9.5088-5097.1993; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Mettenleiter Thomas C., 1995, P367, DOI 10.1016/B978-012397570-6/50022-8; MILLER JM, 1995, AM J VET RES, V56, P870; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Nicola AV, 1998, J VIROL, V72, P3595, DOI 10.1128/JVI.72.5.3595-3601.1998; PETROVSKIS EA, 1988, J VIROL, V62, P2196, DOI 10.1128/JVI.62.6.2196-2199.1988; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SPEAR PG, 1993, SEMIN VIROL, V4, P167, DOI 10.1006/smvy.1993.1012; TERRYALLISON T, IN PRESS J VIROL; Thomas JT, 1998, J VIROL, V72, P1131, DOI 10.1128/JVI.72.2.1131-1137.1998; WARNER MW, IN PRESS VIROLOGY; Whitbeck JC, 1997, J VIROL, V71, P6083, DOI 10.1128/JVI.71.8.6083-6093.1997; Willey JC, 1996, AM J RESP CELL MOL, V14, P262, DOI 10.1165/ajrcmb.14.3.8845177	33	742	765	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1618	1620		10.1126/science.280.5369.1618	http://dx.doi.org/10.1126/science.280.5369.1618			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616127				2022-12-24	WOS:000074061200045
J	Brunet, LJ; McMahon, JA; McMahon, AP; Harland, RM				Brunet, LJ; McMahon, JA; McMahon, AP; Harland, RM			Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton	SCIENCE			English	Article							CHICK LIMB; BONE; EXPRESSION; MOUSE; GENES; REGULATORS; BMP-4; MICE	Noggin is a bone morphogenetic protein (BMP) antagonist expressed in Spemann's organizer. Murine Noggin is expressed in condensing cartilage and immature chondrocytes, as are many BMPs. In mice lacking Noggin, cartilage condensations initiated normally but developed hyperplasia, and initiation of joint development failed as measured by the expression of growth and differentiation factor-5. The maturation of cartilage and Herd expression were unaffected. Excess BMP activity in the absence of Noggin antagonism may enhance the recruitment of cells into cartilage, resulting in oversized growth plates; chondrocytes are also refractory to joint-inducing positional cues.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA; Harvard Univ, Biolabs, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	University of California System; University of California Berkeley; Harvard University	Harland, RM (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA.	harland@socrates.berkeley.edu	McMahon, Andrew P/ABE-7520-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049346] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49346] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Davis AP, 1996, DEVELOPMENT, V122, P1175; DUBOULE D, 1995, CURR OPIN GENET DEV, V5, P525, DOI 10.1016/0959-437X(95)90058-O; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; GROFF DJ, 1997, DEVELOPMENT, V124, P627; Hofmann C, 1996, DEV GENET, V19, P43, DOI 10.1002/(SICI)1520-6408(1996)19:1&lt;43::AID-DVG5&gt;3.0.CO;2-0; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; Macias D, 1997, DEVELOPMENT, V124, P1109; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Nelson CE, 1996, DEVELOPMENT, V122, P1449; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; Storm EE, 1996, DEVELOPMENT, V122, P3969; Thorogood P.V., 1983, CARTILAGE DEV DIFFER, VVol. 2, P223; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	24	646	675	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 29	1998	280	5368					1455	1457		10.1126/science.280.5368.1455	http://dx.doi.org/10.1126/science.280.5368.1455			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9603738				2022-12-24	WOS:000073883400061
J	Kalgutkar, AS; Crews, BC; Rowlinson, SW; Garner, C; Seibert, K; Marnett, LJ				Kalgutkar, AS; Crews, BC; Rowlinson, SW; Garner, C; Seibert, K; Marnett, LJ			Aspirin-like molecules that covalently inactivate cyclooxygenase-2	SCIENCE			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; SELECTIVE-INHIBITION; EPITHELIAL-CELLS; ACID; ACETYLATION; BINDING; MECHANISM; AGENTS; DRUGS; OVINE	Many of aspirin's therapeutic effects arise from its acetylation of cyclooxygenase-2 (COX-2), whereas its antithrombotic and ulcerogenic effects result from its acetylation of COX-1. Here, aspirin-like molecules were designed that preferentially acetylate and irreversibly inactivate COX-2. The most potent of these compounds was o-(acetoxyphenyl)hept-2-ynyl sulfide (APHS). Relative to aspirin, APHS was 60 times as reactive against COX-2 and 100 times as selective for its inhibition; it also inhibited COX-2 in cultured macrophages and colon cancer cells and in the rat air pouch in vivo. Such compounds may lead to the development of aspirin-like drugs for the treatment or prevention of immunological and proliferative diseases without gastrointestinal or hematologic side effects.	Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res,Canc Ctr, Ctr Mol Toxicol,Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res,Canc Ctr, Ctr Mol Toxicol,Dept Chem, Nashville, TN 37232 USA; Searle Monsanto, St Louis, MO 63167 USA	Vanderbilt University; Vanderbilt University; Monsanto	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res,Canc Ctr, Ctr Mol Toxicol,Dept Biochem, Nashville, TN 37232 USA.				NCI NIH HHS [CA47479, CA68485] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047479, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BHATTACHARYYA DK, 1995, ARCH BIOCHEM BIOPHYS, V317, P19, DOI 10.1006/abbi.1995.1130; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; Dreser M. H., 1970, PFLUGERS ARCH, V76, P306, DOI [10.1007/bf01662127, DOI 10.1007/BF01662127]; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; Kawamori T, 1998, CANCER RES, V58, P409; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MEADE EA, 1993, J BIOL CHEM, V268, P6610; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; ROTH GJ, 1975, P NATL ACAD SCI USA, V72, P3073, DOI 10.1073/pnas.72.8.3073; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; VANDEROUDERAA FJ, 1980, EUR J BIOCHEM, V109, P1; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANE JR, 1990, STROKE, V21, P12; VANE JR, 1996, SCAND J RHEUMAT S102, V25, P9, DOI DOI 10.3109/03009749609097226; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u	24	239	256	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 22	1998	280	5367					1268	1270		10.1126/science.280.5367.1268	http://dx.doi.org/10.1126/science.280.5367.1268			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596581				2022-12-24	WOS:000073852500050
J	Nevitt, MC; Ettinger, B; Black, DM; Stone, K; Jamal, SA; Ensrud, K; Segal, M; Genant, HK; Cummings, SR				Nevitt, MC; Ettinger, B; Black, DM; Stone, K; Jamal, SA; Ensrud, K; Segal, M; Genant, HK; Cummings, SR			The association of radiographically detected vertebral fractures with back pain and function: A prospective study	ANNALS OF INTERNAL MEDICINE			English	Article						spinal fractures; back pain; osteoporosis, postmenopausal; activities of daily living	RESTRICTED ACTIVITY DAYS; BONE-MINERAL DENSITY; POSTMENOPAUSAL OSTEOPOROSIS; OLDER ADULTS; WOMEN; DISABILITY; DEFORMITIES; ALENDRONATE; PREDICTORS; MANAGEMENT	Background: Vertebral fractures are a hallmark of postmenopausal osteoporosis and an important end point in trials of osteoporosis treatment, but the clinical significance of these fractures remains uncertain. Objective: To determine the association of new vertebral fractures with back pain and back-related functional limitation in older women. Design: Prospective observational study. Setting: Multicenter Study of Osteoporotic Fractures. Participants: 7223 white women aged 65 years and older. Measurements: Lateral spine radiographs were obtained at baseline and at a follow-up examination an average of 3.7 years later. Prevalent and incident radiographic vertebral fractures were assessed by quantitative morphometry. Frequency and severity of back pain, disability in doing six activities involving the back, and days of bed rest and days of limited activity due to back pain were assessed annually by questionnaire during follow-up. Results: Among women without a vertebral fracture at baseline, those with at least one incident vertebral fracture were more likely to have increased back pain (odds ratio [OR], 2.4 [95% CI, 1.7 to 3.3]) and back disability (OR, 2.6 [CI, 1.9 to 3.7]) and at least 1 day of bed rest due to back pain (OR, 6.7 [CI, 4.4 to 10.2]) and 7 days of limited activity due to back pain per year (OR, 3.8 [CI, 2.7 to 5.0]). Among women with a fracture at baseline, those with an incident vertebral fracture also had a greater risk for increased back pain (OR, 2.0 [CI, 1.4 to 2.8]) and back disability (OR, 2.2 [CI, 1.5 to 3.1]) and at least 1 day of bed rest (OR, 7.9 [CI, 4.9 to 12.9]) and 7 days of limited activity per year (OR, 3.5 [CI, 2.4 to 5.0]). Women with incident fracture had about 10 additional limited-activity days and 1 to 2 days of bed rest per year. New vertebral fractures that did not come to medical attention were associated with increased back pain and functional limitation. Conclusion: New vertebral fractures, even those not recognized clinically, are associated with substantial increases in back pain and functional limitation due to back pain in older white women. Prevention of new vertebral fractures should reduce the burden of back pain and functional limitation in women with vertebral osteoporosis.	Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94105 USA; Kaiser Permanente Med Care Program, Oakland, CA USA; Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA; Vet Affairs Med Ctr, Minneapolis, MN USA	University of California System; University of California San Francisco; Kaiser Permanente; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Nevitt, MC (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 74 New Montgomery St,Suite 600, San Francisco, CA 94105 USA.			Ensrud, Kristine/0000-0002-9069-3036	NIAMS NIH HHS [1-RO1-AR35582] Funding Source: Medline; NIA NIH HHS [5-RO1-AG05394, 1-RO1-AG05407] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005407, R01AG005394] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLACK DM, 1995, J BONE MINER RES, V10, P890; BLACK DM, 1991, J BONE MINER RES, V6, P883; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BURGER H, 1994, BRIT MED J, V309, P991, DOI 10.1136/bmj.309.6960.991; COOK DJ, 1993, ARTHRITIS RHEUM, V36, P750, DOI 10.1002/art.1780360603; COOPER C, 1991, OSTEOPOROSIS INT, V2, P48, DOI 10.1007/BF01627079; COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; CUMMINGS SR, 1995, J BONE MINER RES, V10, P518; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; ETTINGER B, 1992, J BONE MINER RES, V7, P449; ETTINGER B, 1988, MATURITAS, V10, P283, DOI 10.1016/0378-5122(88)90064-3; ETTINGER B, 1994, OSTEOPOROSIS INT, V4, P55, DOI 10.1007/BF02352262; FROST HM, 1981, ORTHOP CLIN N AM, V12, P671; Genant HK, 1996, J BONE MINER RES, V11, P984; GENANT HK, 1995, VERTEBRAL FRACTURE O; Gold DT, 1996, BONE, V18, pS185, DOI 10.1016/8756-3282(95)00500-5; Hallal J C, 1991, Geriatr Nurs, V12, P285, DOI 10.1016/S0197-4572(05)80266-6; Huang C, 1996, J BONE MINER RES, V11, P1026; KOSOROK MR, 1992, AM J PUBLIC HEALTH, V82, P1263, DOI 10.2105/AJPH.82.9.1263; LANE NE, 1993, J RHEUMATOL, V20, P1911; LEIDIG G, 1990, BONE MINER, V8, P217, DOI 10.1016/0169-6009(90)90107-Q; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; LYLES KW, 1993, AM J MED, V94, P595, DOI 10.1016/0002-9343(93)90210-G; MCCULLAGH P., 1991, GEN LINEAR MODELS; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; NICHOLSON PHF, 1993, OSTEOPOROSIS INT, V3, P300, DOI 10.1007/BF01637315; PAK CYC, 1994, ANN INTERN MED, V120, P625, DOI 10.7326/0003-4819-120-8-199404150-00001; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Ross P D, 1991, Osteoporos Int, V1, P134, DOI 10.1007/BF01625442; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919; RYAN PJ, 1994, BONE, V15, P27, DOI 10.1016/8756-3282(94)90887-7; SCHOLES D, 1991, AM J PUBLIC HEALTH, V81, P485, DOI 10.2105/AJPH.81.4.485; SPECTOR TD, 1993, J BONE MINER RES, V8, P817; WAGNER EH, 1993, J AM GERIATR SOC, V41, P241, DOI 10.1111/j.1532-5415.1993.tb06700.x; WIPF JE, 1995, MED CLIN N AM, V79, P231, DOI 10.1016/S0025-7125(16)30065-7; ZETTERBERG C, 1990, SPINE, V15, P783, DOI 10.1097/00007632-199008010-00009	38	603	614	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1998	128	10					793	+		10.7326/0003-4819-128-10-199805150-00001	http://dx.doi.org/10.7326/0003-4819-128-10-199805150-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM889	9599190				2022-12-24	WOS:000073586500001
J	Glynn, MK; Bopp, C; Dewitt, W; Dabney, P; Mokhtar, M; Angulo, FJ				Glynn, MK; Bopp, C; Dewitt, W; Dabney, P; Mokhtar, M; Angulo, FJ			Emergence of multidrug-resistant Salmonella enterica serotype typhimurium DT104 infections in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENTERITIDIS; ANIMALS; HUMANS	Background Strains of salmonella that are resistant to antimicrobial agents have become a worldwide health problem. A distinct strain of Salmonella enterica serotype typhimurium, known as definitive type 104 (DT104), is resistant to ampicillin, chloramphenicol, streptomycin, sulfonamides, and tetracycline and has become a major cause of illness in humans and animals in Europe, especially the United Kingdom. Methods To characterize typhimurium DT104 infections in the United States, we analyzed data collected by local and state health departments and public health laboratories between 1979 and 1996 in national surveys of the antimicrobial-drug resistance of salmonella. Selected typhimurium isolates with the five-drug pattern of resistance were phage typed. Results The prevalence of typhimurium isolates with the five-drug pattern of resistance increased from 0.6 percent in 1979-1980 to 34 percent in 1996. In 1994-1995, such isolates were identified in samples from 36 of the 46 surveillance sites (78 percent). Thirty-nine of 43 typhimurium isolates with the five-drug pattern of resistance identified in 1994-1995 and 1996 were phage type DT104 or a closely related phage type. Conclusions Multidrug-resistant typhimurium DT104 has become a widespread pathogen in the United States. More prudent use of antimicrobial agents in farm animals and more effective disease prevention on farms are necessary to reduce the dissemination of multidrug-resistant typhimurium DT104 and to slow the emergence of resistance to additional agents in this and other strains of salmonella. (C)1998, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; US FDA, Rockville, MD 20857 USA	Centers for Disease Control & Prevention - USA; US Food & Drug Administration (FDA)	Glynn, MK (corresponding author), Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, 1600 Clifton Rd,MS A-38, Atlanta, GA 30333 USA.							ANDERSON ES, 1977, J HYG-CAMBRIDGE, V78, P297, DOI 10.1017/S0022172400056187; ANGULO FJ, 1995, CLIN INFECT DIS, V21, pS84, DOI 10.1093/clinids/21.Supplement_1.S84; Barry AL., 1991, MANUAL CLIN MICROBIO, P117; BEAN NH, 1992, AM J PUBLIC HEALTH, V82, P1273, DOI 10.2105/AJPH.82.9.1273; Besser TE, 1997, VET REC, V140, P75; BLACK PH, 1960, NEW ENGL J MED, V262, P921, DOI 10.1056/NEJM196005052621806; BLACK PH, 1960, NEW ENGL J MED, V262, P864, DOI 10.1056/NEJM196004282621706; BLASER MJ, 1981, J INFECT DIS, V143, P743, DOI 10.1093/infdis/143.5.743; *CDCP, 1996, SALMONELLA SURVILLAN; CELUM CL, 1987, J INFECT DIS, V156, P998, DOI 10.1093/infdis/156.6.998; CHALKER RB, 1988, REV INFECT DIS, V10, P111; CODY S, 1997, 35 ANN M INF DIS SOC, P77; COHEN ML, 1986, SCIENCE, V234, P964, DOI 10.1126/science.3535069; *DIV EM OTH COMM D, 1997, WHO M BERL GERM 13 1; Fone D L, 1994, Commun Dis Rep CDR Rev, V4, pR136; FRIEDMAN CR, 1998, KINT C EM INF DIS AT, P68; Hargrett-Bean N T, 1988, MMWR CDC Surveill Summ, V37, P25; HELMICK CG, 1994, NIH PUBLICATION, P85; LEE LA, 1994, J INFECT DIS, V170, P128, DOI 10.1093/infdis/170.1.128; LEVY SB, 1976, NEW ENGL J MED, V295, P583, DOI 10.1056/NEJM197609092951103; MACDONALD KL, 1987, JAMA-J AM MED ASSOC, V258, P1496, DOI 10.1001/jama.258.11.1496; MISHU B, 1994, J INFECT DIS, V169, P547, DOI 10.1093/infdis/169.3.547; OBRIEN TF, 1982, NEW ENGL J MED, V307, P1, DOI 10.1056/NEJM198207013070101; Ramos JM, 1996, EUR J CLIN MICROBIOL, V15, P85, DOI 10.1007/BF01586193; RILEY LW, 1984, J INFECT DIS, V149, P878, DOI 10.1093/infdis/149.6.878; TAUXE RV, 1991, J FOOD PROTECT, V54, P563, DOI 10.4315/0362-028X-54.7.563; TAUXE RV, 1997, TXB INTERNAL MED, P1639; Threlfall E.J., 1997, Euro Surveill, V2, P81; THRELFALL EJ, 1993, EPIDEMIOL INFECT, V111, P189, DOI 10.1017/S0950268800056892; Wall P G, 1994, Commun Dis Rep CDR Rev, V4, pR130; 1997, MMWR MORB MORTAL WKL, V46, P308; 1996, MMWR MORB MORTAL WKL, V45, P110	32	460	473	0	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1998	338	19					1333	1338		10.1056/NEJM199805073381901	http://dx.doi.org/10.1056/NEJM199805073381901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL720	9571252				2022-12-24	WOS:000073463700001
J	Carter, CS; Braver, TS; Barch, DM; Botvinick, MM; Noll, D; Cohen, JD				Carter, CS; Braver, TS; Barch, DM; Botvinick, MM; Noll, D; Cohen, JD			Anterior cingulate cortex, error detection, and the online monitoring of performance	SCIENCE			English	Article							PET; ACTIVATION; ATTENTION; SYSTEM	An unresolved question in neuroscience and psychology is how the brain monitors performance to regulate behavior. It has been proposed that the anterior cingulate cortex (ACC), on the medial surface of the frontal lobe, contributes to performance monitoring by detecting errors. In this study, event-related functional magnetic resonance imaging was used to examine ACC function. Results confirm that this region shows activity during erroneous responses. However, activity was also observed in the same region during correct responses under conditions of increased response competition. This suggests that the ACC detects conditions under which errors are likely to occur rather than errors themselves.	Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA; Presbyterian Univ Hosp, Univ Pittsburgh Hlth Syst, Magnet Resonance Res Ctr, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Carnegie Mellon University	Carter, CS (corresponding author), Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA.	cscarter+@pitt.edu	Kennedy, Kristen M/B-4699-2008; Barch, Deanna M/G-8638-2013; Noll, Douglas C/D-8124-2014	Kennedy, Kristen M/0000-0001-5373-9026; Noll, Douglas C/0000-0002-0983-3805; Braver, Todd/0000-0002-2631-3393	NIMH NIH HHS [R01MH52864, K08MH01306] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052864, K08MH001306] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; BENCH CJ, 1992, PSYCHOL MED, V22, P607, DOI 10.1017/S003329170003806X; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Cabeza R, 1997, J COGNITIVE NEUROSCI, V9, P1, DOI 10.1162/jocn.1997.9.1.1; Carter CS, 1997, AM J PSYCHIAT, V154, P1670, DOI 10.1176/ajp.154.12.1670; Carter CS, 1995, NEUROIMAGE, V2, P264, DOI 10.1006/nimg.1995.1034; Cohen JD, 1996, PHILOS T R SOC B, V351, P1515, DOI 10.1098/rstb.1996.0138; COLES MGH, 1995, ACTA PSYCHOL, V90, P129, DOI 10.1016/0001-6918(95)00020-U; DEHAENE S, 1994, PSYCHOL SCI, V5, P303, DOI 10.1111/j.1467-9280.1994.tb00630.x; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; FALKENSTEIN M, 1995, PERSPECTIVES EVENT S, V44, P287; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; FRITH CD, 1991, NEUROPSYCHOLOGIA, V29, P1137, DOI 10.1016/0028-3932(91)90029-8; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; GHERING WJ, 1990, PSYCHOPHYSIOLOGY S, V27, pS34; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; NOLL DC, 1995, JMRI-J MAGN RESON IM, V5, P49, DOI 10.1002/jmri.1880050112; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; POSNER MI, 1994, TRENDS NEUROSCI, V17, P75, DOI 10.1016/0166-2236(94)90078-7; VOGT BA, 1992, CEREB CORTEX, V2, P435, DOI 10.1093/cercor/2.6.435-a; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024	23	2468	2522	2	174	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1998	280	5364					747	749		10.1126/science.280.5364.747	http://dx.doi.org/10.1126/science.280.5364.747			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZL268	9563953				2022-12-24	WOS:000073415600051
J	Nabel, GJ				Nabel, GJ			From rhyme to reason	NATURE			English	Editorial Material							GENE-EXPRESSION INVIVO; ARTERIAL-WALL; DELIVERY; THERAPY		Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Biol Chem, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Nabel, GJ (corresponding author), Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Internal Med, 1150 W Med Ctr Dr,4520 MSRBI, Ann Arbor, MI 48109 USA.							ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; Bach FH, 1996, IMMUNOL TODAY, V17, P379, DOI 10.1016/0167-5699(96)10024-4; Bach FH, 1997, NAT MED, V3, P944, DOI 10.1038/nm0997-944; BLAU HM, 1995, NEW ENGL J MED, V333, P1554, DOI 10.1056/NEJM199512073332308; BREM H, 1995, LANCET, V345, P1008, DOI 10.1016/S0140-6736(95)90755-6; CHANG PL, 1995, SOMAT GENET HER; CHEN KS, 1995, J NEUROSCI, V15, P2819; Ellem KAO, 1997, CANCER IMMUNOL IMMUN, V44, P10, DOI 10.1007/s002620050349; EMERICH DP, 1997, NATURE, V27, P395; Grill R, 1997, J NEUROSCI, V17, P5560; Kim S, 1997, J CLIN INVEST, V100, P1006, DOI 10.1172/JCI119611; KREMERS E, 1940, HIST PHARM, V3, P286; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; Magovern CJ, 1997, HUM GENE THER, V8, P215, DOI 10.1089/hum.1997.8.2-215; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928; Nabel GJ, 1996, P NATL ACAD SCI USA, V93, P15388, DOI 10.1073/pnas.93.26.15388; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; Parker W, 1996, IMMUNOL TODAY, V17, P373, DOI 10.1016/0167-5699(96)10028-1; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; Petsko GA, 1996, NATURE, V384, P7; Simons JW, 1997, CANCER RES, V57, P1537; Stopeck AT, 1997, J CLIN ONCOL, V15, P341, DOI 10.1200/JCO.1997.15.1.341; Tsurumi Y, 1997, CIRCULATION, V96, P382; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; WINKLER J, 1995, NATURE, V375, P484, DOI 10.1038/375484a0	26	8	9	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679		S			3	4						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK760	9579854				2022-12-24	WOS:000073360100002
J	Karkoschka, E				Karkoschka, E			Clouds of high contrast on Uranus	SCIENCE			English	Article							VOYAGER-2	Near-infrared images of Uranus taken with the Hubble Space Telescope in July and October 1997 revealed discrete clouds with contrasts exceeding 10 times the highest contrast observed before with other techniques. At visible wavelengths, these 10 clouds had lower contrasts than clouds seen by Voyager 2 in 1986. Uranus' rotational rates for southern latitudes were identical in 1986 and 1997. Clouds in northern latitudes rotate slightly more slowly than clouds in opposite southern latitudes.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	University of Arizona	Karkoschka, E (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.							BAINES KH, 1995, ICARUS, V114, P328, DOI 10.1006/icar.1995.1065; Hammel H. B., 1997, B AM ASTRON SOC, V29, P994; KARKOSCHKA E, 1993, ICARUS, V106, P428, DOI 10.1006/icar.1993.1183; LINDAL GF, 1987, J GEOPHYS RES, V92, P14987, DOI 10.1029/JA092iA13p14987; Lorenz RD, 1997, ICARUS, V127, P173, DOI 10.1006/icar.1997.5687; RAGES K, 1991, ICARUS, V89, P359, DOI 10.1016/0019-1035(91)90183-T; SMITH BA, 1986, SCIENCE, V233, P43, DOI 10.1126/science.233.4759.43	7	42	43	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					570	572		10.1126/science.280.5363.570	http://dx.doi.org/10.1126/science.280.5363.570			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554844				2022-12-24	WOS:000073242100041
J	Nakagawa, T; Roth, W; Wong, P; Nelson, A; Farr, A; Deussing, J; Villadangos, JA; Ploegh, H; Peters, C; Rudensky, AY				Nakagawa, T; Roth, W; Wong, P; Nelson, A; Farr, A; Deussing, J; Villadangos, JA; Ploegh, H; Peters, C; Rudensky, AY			Cathepsin L: Critical role in Ii degradation and CD4 T cell selection in the thymus	SCIENCE			English	Article							MHC CLASS-II; INVARIANT-CHAIN; ANTIGEN PRESENTATION; MONOCLONAL-ANTIBODY; EPITHELIAL-CELLS; MOLECULES; COMPLEXES; PEPTIDE; MICE; EXPRESSION	Degradation of invariant chain (li) is a critical step in major histocompatibility complex class II-restricted antigen presentation. Cathepsin L was found to be necessary for li degradation in cortical thymic epithelial cells (cTECs), but not in bone marrow (BM)derived antigen-presenting cells (APCs). Consequently, positive selection of CD4(+) T cells, was reduced. Because different cysteine proteinases are responsible for specific li degradation steps in cTECs and BM-derived APCs, the proteolytic environment in cells mediating positive and negative selection may be distinct. The identification of a protease involved in class II presentation in a tissue-specific manner suggests a potential means of manipulating CD4(+) T cell responsiveness in vivo.	Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; Univ Freiburg Klinikum, Abt Heamatol Onkol, D-79106 Freiburg, Germany; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Freiburg; University of Washington; University of Washington Seattle; Harvard University; Harvard Medical School	Rudensky, AY (corresponding author), Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA.	sasha@nucleus.immunol.washington.edu	Deussing, Jan M/ABB-5993-2021; Villadangos, Jose A/AAU-1404-2020	Villadangos, Jose A/0000-0001-6771-8891; Deussing, Jan/0000-0002-9329-5252				ADKINS B, 1988, IMMUNOGENETICS, V27, P180, DOI 10.1007/BF00346584; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; Bevec T, 1996, J EXP MED, V183, P1331, DOI 10.1084/jem.183.4.1331; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; Denzin LK, 1997, SCIENCE, V278, P106, DOI 10.1126/science.278.5335.106; Eastman S, 1996, EUR J IMMUNOL, V26, P385, DOI 10.1002/eji.1830260218; ENGELHARD VH, 1994, ANNU REV IMMUNOL, V12, P181, DOI 10.1146/annurev.iy.12.040194.001145; Farr A, 1996, EUR J IMMUNOL, V26, P3185, DOI 10.1002/eji.1830261252; FARR AG, 1986, ANAT REC, V216, P85, DOI 10.1002/ar.1092160115; Fineschi B, 1996, J IMMUNOL, V157, P3211; FINK PJ, 1995, ADV IMMUNOL, V59, P99, DOI 10.1016/S0065-2776(08)60630-6; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; KOCH N, 1982, NATURE, V299, P644, DOI 10.1038/299644a0; Liljedahl M, 1996, EMBO J, V15, P4817, DOI 10.1002/j.1460-2075.1996.tb00862.x; MARIC MA, 1994, P NATL ACAD SCI USA, V91, P2171, DOI 10.1073/pnas.91.6.2171; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; Martin WD, 1996, CELL, V84, P543, DOI 10.1016/S0092-8674(00)81030-2; MASON RW, 1989, BIOCHEM J, V257, P125, DOI 10.1042/bj2570125; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; MORKOWSKI S, 1995, J EXP MED, V182, P1403, DOI 10.1084/jem.182.5.1403; NAKAGAWA T, UNPUB; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; RODRIGUEZ GM, 1995, EUR J IMMUNOL, V25, P1823, DOI 10.1002/eji.1830250705; ROTH WR, UNPUB; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; SURH GD, 1997, IMMUNITY, V7, P209; Tourne S, 1997, IMMUNITY, V7, P187, DOI 10.1016/S1074-7613(00)80522-1; VANNOORT JM, 1994, EUR J IMMUNOL, V24, P2175, DOI 10.1002/eji.1830240936; Villadangos JA, 1997, J EXP MED, V186, P549, DOI 10.1084/jem.186.4.549; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411; Wong P, 1996, J IMMUNOL, V156, P2133	32	560	571	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1998	280	5362					450	453		10.1126/science.280.5362.450	http://dx.doi.org/10.1126/science.280.5362.450			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545226				2022-12-24	WOS:000073159600052
J	Bradley, DC; Chang, GC; Andersen, RA				Bradley, DC; Chang, GC; Andersen, RA			Encoding of three-dimensional structure-from-motion by primate area MT neurons	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; PERCEPTION; INTEGRATION; STEREOPSIS; MONKEY; DEPTH	We see the world as three-dimensional, but because the retinal image is flat, we must derive the third dimension, depth, from two-dimensional cues. Image movement provides one of the most potent cues for depth(1-6). For example, the shadow of a contorted wire appears flat when the wire is stationary, but rotating the wire causes motion in the shadow, which suddenly appears three-dimensional. The neural mechanism of this effect, known as 'structure-from-motion', has not been discovered. Here we study cortical area MT, a primate region that is involved in visual motion perception. Two rhesus monkeys were trained to fixate their gaze while viewing two-dimensional projections of transparent, revolving cylinders. These stimuli appear to be three-dimensional, but the surface order perceived (front as opposed to back) tends to reverse spontaneously. These reversals occur because the stimulus does not specify which surface is in front or at the back, Monkeys reported which surface order they perceived after viewing the stimulus. In many of the neurons tested, there was a reproducible change in activity that coincided with reversals of the perceived surface order, even though the stimulus remained identical. This suggests that area MT has a basic role in structure-from-motion perception.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Andersen, RA (corresponding author), CALTECH, Div Biol, 391 S Holliston Ave, Pasadena, CA 91125 USA.	andersen@vis.caltech.edu						ANDERSEN RA, 1990, NEUROSCI IN, P163; BRADDICK O, 1993, TRENDS NEUROSCI, V16, P263, DOI 10.1016/0166-2236(93)90179-P; BRADLEY DC, 1995, NATURE, V373, P609, DOI 10.1038/373609a0; HILDRETH EC, 1995, VISION RES, V35, P117, DOI 10.1016/0042-6989(94)E0068-V; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1148, DOI 10.1152/jn.1983.49.5.1148; Miles WR, 1931, AM J PSYCHOL, V43, P392, DOI 10.2307/1414610; NAWROT M, 1991, VISUAL NEUROSCI, V6, P219, DOI 10.1017/S0952523800006234; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; Ringach DL, 1996, VISION RES, V36, P1479, DOI 10.1016/0042-6989(95)00285-5; ROGERS B, 1982, VISION RES, V22, P261, DOI 10.1016/0042-6989(82)90126-2; SIEGEL RM, 1988, NATURE, V331, P259, DOI 10.1038/331259a0; SNOWDEN RJ, 1991, J NEUROSCI, V11, P2768; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; WALLACH H, 1953, J EXP PSYCHOL, V45, P205, DOI 10.1037/h0056880	15	235	237	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 16	1998	392	6677					714	717		10.1038/33688	http://dx.doi.org/10.1038/33688			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565031				2022-12-24	WOS:000073129000058
J	Glas, R; Bogyo, M; McMaster, JS; Gaczynska, M; Ploegh, HL				Glas, R; Bogyo, M; McMaster, JS; Gaczynska, M; Ploegh, HL			A proteolytic system that compensates for loss of proteasome function	NATURE			English	Article							CLASS-I MOLECULES; SACCHAROMYCES-CEREVISIAE; DEGRADATION; LACTACYSTIN; INACTIVATION; ACIDOPHILUM; INHIBITORS; PROTEINS; PEPTIDES; PATHWAY	Proteolysis is essential for the execution of many cellular functions. These include removal of incorrectly folded or damaged proteins(1), the activation of transcription factors(2), the ordered degradation of proteins involved in cell cycle control(3), and the generation of peptides destined for presentation by class I molecules of the major histocompatibility complex(4). A multisubunit protease complex, the proteasome(5), accomplishes these tasks. Here we show that in mammalian cells inactivation of the proteasome by covalent inhibitors allows the outgrowth of inhibitor-resistant cells. The growth of such adapted cells is apparently maintained by the induction of other proteolytic systems that compensate for the loss of proteasomal activity.	MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Ploegh, HL (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Bogyo, Matthew/0000-0003-3753-4412				BAI A, J IMMUNOL, V159, P2139; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HAMMERLING GJ, 1982, P NATL ACAD SCI-BIOL, V79, P4737, DOI 10.1073/pnas.79.15.4737; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILT W, 1995, MOL BIOL REP, V21, P3, DOI 10.1007/BF00990964; KETTNER C, 1981, METHOD ENZYMOL, V80, P826; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Sheaff RJ, 1996, CHEM BIOL, V3, P869, DOI 10.1016/S1074-5521(96)90174-X; Tamura T, 1996, SCIENCE, V274, P1385, DOI 10.1126/science.274.5291.1385; Vinitsky A, 1997, J IMMUNOL, V159, P554	29	225	226	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					618	622		10.1038/33443	http://dx.doi.org/10.1038/33443			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560160				2022-12-24	WOS:000072987200064
J	Niskar, AS; Kieszak, SM; Holmes, A; Esteban, E; Rubin, C; Brody, DJ				Niskar, AS; Kieszak, SM; Holmes, A; Esteban, E; Rubin, C; Brody, DJ			Prevalence of hearing loss among children 6 to 19 years of age - The Third National Health and Nutrition Examination Survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOISE	Context.-Hearing loss in children influences the development of communication and behavioral skills, but few studies in the United States have used pure-tone audiometry to derive hearing loss prevalence estimates for children. Objective.-To describe the prevalence of hearing loss among US children by sociodemographic characteristics, reported hearing loss, and audiometric screening factors. Design.-National population-based cross-sectional survey with an in-person interview and audiometric testing at 0.5 to 8 kHz. Setting/Participants.-A total of 6166 children aged 6 to 19 years completed audiometry in the mobile examination center of the Third National Health and Nutrition Examination Survey conducted between 1988 and 1994. Main Outcome Measure.-Hearing loss, defined as audiometric threshold values of at least 16-dB hearing level based on a low or high pure-tone average. Results.-A total of 14.9% of children had low-frequency or high-frequency hearing loss of at least 16-dB hearing level, 7.1% had low-frequency hearing loss of at least 16-dB hearing level, and 12.7% had high-frequency hearing loss of at least 16-dB hearing level, Most hearing loss was unilateral and slight in severity (16- to 25-dB hearing level), Of those with measured hearing loss, 10.8% were reported to have current hearing loss during the interview. Conclusions.-This analysis indicates that 14.9% of US children have low-frequency or high-frequency hearing loss of at least 16-dB hearing level in 1 or both ears, Among children in elementary, middle, and high school, audiometric screening should include low-frequency and high-frequency testing to detect hearing loss.	Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30341 USA; Univ Florida, Gainesville, FL USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; State University System of Florida; University of Florida; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Niskar, AS (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 4770 Buford Hwy NE,MS F46, Atlanta, GA 30341 USA.	abn0@cdc.gov						ANDERSON K L, 1991, Seminars in Hearing, V12, P340, DOI 10.1055/s-0028-1085507; ANDERSON KL, 1992, P ASHA AUD SUP, V21, P38; [Anonymous], 1979, JAMA-J AM MED ASSOC, V241, P2055; BARONE JA, 1987, J OCCUP ENVIRON MED, V29, P741; Barrett K.A., 1994, HDB CLIN AUDIOLOGY, P476; BEHRMAN RE, 1992, NELSON TXB PEDIAT, P1602; BROOKHOUSER PE, 1992, LARYNGOSCOPE, V102, P645, DOI 10.1288/00005537-199206000-00010; BROOKHOUSER PE, 1994, PREV MED, V23, P665, DOI 10.1006/pmed.1994.1111; Clark J G, 1981, ASHA, V23, P493; COZAD RL, 1974, J SCHOOL HEALTH, V44, P92, DOI 10.1111/j.1746-1561.1974.tb05207.x; EZZATI T, 1992, VITAL HLTH STAT, V2; Goodman A.C., 1965, ASHA, V7, P262; GULYA AJ, 1995, PRIMARY CARE MED OFF, P985; HANNER P, 1988, SCAND AUDIOL, V17, P57, DOI 10.3109/01050398809042181; Holmes A E, 1996, J Am Acad Audiol, V7, P332; Holmes AE, 1997, LANG SPEECH HEAR SER, V28, P70, DOI 10.1044/0161-1461.2801.70; JOHNSON C, 1994, NHANES 3 ANAL REPORT; KLEIN JO, 1992, SCREENING CHILDREN A, P31; Lee DJ, 1996, AM J EPIDEMIOL, V144, P442; Leske M C, 1981, ASHA, V23, P229; Naeem Z, 1996, BRIT J AUDIOL, V30, P332, DOI 10.3109/03005369609076781; *NAT CTR HLTH STAT, 1967, VIT HLTH STAT, V1; *NAT CTR HLTH STAT, 1994, VIT HLTH STAT, V1; *NAT CTR HLTH STAT, 1975, VIT HLTH STAT, V11; National Center for Health Statistics, 1988, NAT HLTH NUTR EX SUR, VIII; National Center for Health Statistics, 1996, NHANES 3 REF MAN REP; *NIH, 1990, NCI MON, P3; RIES PW, 1994, VITAL HLTH STAT, V10, P9; RYTZNER B, 1981, SCAND AUDIOL, V10, P213, DOI 10.3109/01050398109076183; *SAS I INC, 1990, SAS LANG VERS 6; SHAL BV, 1991, SUDAAN USERS MANUAL; 1987, FED REG, V52, P44117	32	266	284	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1998	279	14					1071	1075		10.1001/jama.279.14.1071	http://dx.doi.org/10.1001/jama.279.14.1071			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF216	9546565	Bronze			2022-12-24	WOS:000072875300030
J	Horton, B				Horton, B			Seeking the bigger picture in the puzzle	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					417	419		10.1038/32948	http://dx.doi.org/10.1038/32948			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537330				2022-12-24	WOS:000072713600060
J	Froelicher, VF; Lehmann, KG; Thomas, R; Goldman, S; Morrison, D; Edson, R; Lavori, P; Myers, J; Dennis, C; Shabetai, R; Do, D; Froning, J				Froelicher, VF; Lehmann, KG; Thomas, R; Goldman, S; Morrison, D; Edson, R; Lavori, P; Myers, J; Dennis, C; Shabetai, R; Do, D; Froning, J		Vet Affairs Cooperative Study Hlth Services 01	The electrocardiographic exercise test in a population with reduced workup bias: Diagnostic performance, computerized interpretation, and multivariable prediction	ANNALS OF INTERNAL MEDICINE			English	Article						exercise test; coronary angiography; sensitivity and specificity; coronary disease; image processing, computer assisted	CORONARY-ARTERY DISEASE; ST-SEGMENT DEPRESSION; PREVIOUS MYOCARDIAL-INFARCTION; AMERICAN-HEART-ASSOCIATION; TREADMILL SCORE; RATE ADJUSTMENT; RATE INDEX; ACCURACY; MEN; STANDARDS	Background: Empirical scores, computerized ST-segment measurements, and equations have been proposed as tools for improving the diagnostic performance of the exercise test. Objective: To compare the diagnostic utility of these scores, measurements, and equations with that of visual ST-segment measurements in patients with reduced workup bias. Design: Prospective analysis. Setting: 12 university-affiliated Veterans Affairs Medical Centers. Patients: 814 consecutive patients who presented with angina pectoris and agreed to undergo both exercise testing and coronary angiography. Measurements: Digital electrocardiographic recorders and angiographic calipers were used for testing at each site, and test results were sent to core laboratories. Results: Although 25% of patients had previously had testing, workup bias was reduced, as shown by comparison with a pilot study group. This reduction resulted in a sensitivity of 45% and a specificity of 85% for visual analysis. Computerized measurements and visual analysis had similar diagnostic power. Equations incorporating nonelectrocardiographic variables and either visual or computerized ST-segment measurement had similar discrimination and were superior to single ST-segment measurements. These equations correctly classified 5 more patients of every 100 tested (areas under the receiver-operating characteristic curve, 0.80 for equations and 0.68 for visual analysis; P < 0.001) in this population with a 50% prevalence of disease. Conclusions: Standard exercise tests had lower sensitivity but higher specificity in this population with reduced work-up bias than in previous studies. Computerized ST-segment measurements were similar to visual ST-segment measurements made by cardiologists. Considering more than ST-segment measurements can enhance the diagnostic power of the exercise test.	Palo Alto Vet Affairs Hlth Care Syst, Cardiol Div 111C, Palo Alto, CA 94304 USA		Froelicher, VF (corresponding author), Palo Alto Vet Affairs Hlth Care Syst, Cardiol Div 111C, 3801 Miranda Ave, Palo Alto, CA 94304 USA.			Froelicher, Victor/0000-0001-8831-4853				ASCOOP CA, 1977, BRIT HEART J, V39, P212; BERMAN JA, 1983, AM HEART J, V105, P60, DOI 10.1016/0002-8703(83)90279-X; BOBBIO M, 1991, CIRCULATION, V84, P1410, DOI 10.1161/01.CIR.84.3.1410; DECKERS JW, 1989, BRIT HEART J, V62, P438; DelCampo J, 1996, ANN NONINVAS ELECTRO, V1, P430; DETRANO R, 1987, J AM COLL CARDIOL, V10, P794, DOI 10.1016/S0735-1097(87)80272-3; DETRANO R, 1986, J AM COLL CARDIOL, V8, P836, DOI 10.1016/S0735-1097(86)80425-9; DETRY JMR, 1985, EUR HEART J, V6, P227, DOI 10.1093/oxfordjournals.eurheartj.a061846; Do D, 1997, CHEST, V111, P1742, DOI 10.1378/chest.111.6.1742; FLETCHER GF, 1995, CIRCULATION, V91, P580, DOI 10.1161/01.CIR.91.2.580; FLETCHER GF, 1990, CIRCULATION, V82, P2286, DOI 10.1161/01.CIR.82.6.2286; FROELICHER VF, 1993, EXERCISE HEART, P48; FRONING JN, 1988, J ELECTROCARDIOL, V21, pS141, DOI 10.1016/0022-0736(88)90082-9; GIANROSSI R, 1989, CIRCULATION, V80, P87, DOI 10.1161/01.CIR.80.1.87; Gibbons RJ, 1997, J AM COLL CARDIOL, V30, P260; HERBERT WG, 1991, AM HEART J, V122, P993, DOI 10.1016/0002-8703(91)90463-R; HOLLENBERG M, 1980, CIRCULATION, V61, P276, DOI 10.1161/01.CIR.61.2.276; LACHTERMAN B, 1990, CIRCULATION, V82, P44, DOI 10.1161/01.CIR.82.1.44; LACHTERMAN B, 1990, ANN INTERN MED, V112, P11, DOI 10.7326/0003-4819-112-1-11; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; MIRANDA CP, 1992, AM J CARDIOL, V69, P303, DOI 10.1016/0002-9149(92)90224-M; MORISE AP, 1995, AM HEART J, V130, P741, DOI 10.1016/0002-8703(95)90072-1; MORISE AP, 1992, AM J CARDIOL, V69, P603, DOI 10.1016/0002-9149(92)90149-S; MORRIS CK, 1993, J AM COLL CARDIOL, V22, P175, DOI 10.1016/0735-1097(93)90832-L; MYERS J, 1994, AM J CARDIOL, V73, P591, DOI 10.1016/0002-9149(94)90340-9; OKIN PM, 1995, J AM COLL CARDIOL, V25, P1726, DOI 10.1016/0735-1097(95)00085-I; PHILBRICK JT, 1989, AM J CARDIOL, V64, P1117; PRUVOST P, 1987, EUR HEART J, V8, P1287, DOI 10.1093/oxfordjournals.eurheartj.a062215; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; RIBISL PM, 1993, AM J CARDIOL, V71, P546, DOI 10.1016/0002-9149(93)90509-B; RODRIGUEZ M, 1993, AM HEART J, V126, P752, DOI 10.1016/0002-8703(93)90443-D; SHEFFIELD LT, 1969, CIRCULATION, V40, P935, DOI 10.1161/01.CIR.40.6.935; SIMOONS ML, 1977, CIRCULATION, V56, P552, DOI 10.1161/01.CIR.56.4.552; SIMOONS ML, 1977, COMPUT BIOMED RES, V10, P483, DOI 10.1016/0010-4809(77)90023-4; WILLEMS JL, 1991, NEW ENGL J MED, V325, P1767, DOI 10.1056/NEJM199112193252503; Yamada H, 1997, PROG CARDIOVASC DIS, V39, P457, DOI 10.1016/S0033-0620(97)80040-0	36	146	151	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				965	+		10.7326/0003-4819-128-12_Part_1-199806150-00001	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00001			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625682				2022-12-24	WOS:000074201300001
J	Yoshikawa, S; Shinzawa-Itoh, K; Nakashima, R; Yaono, R; Yamashita, E; Inoue, N; Yao, M; Fei, MJ; Libeu, CP; Mizushima, T; Yamaguchi, H; Tomizaki, T; Tsukihara, T				Yoshikawa, S; Shinzawa-Itoh, K; Nakashima, R; Yaono, R; Yamashita, E; Inoue, N; Yao, M; Fei, MJ; Libeu, CP; Mizushima, T; Yamaguchi, H; Tomizaki, T; Tsukihara, T			Redox-coupled crystal structural changes in bovine heart cytochrome c oxidase	SCIENCE			English	Article							MACROMOLECULAR CRYSTALLOGRAPHY; PROTEIN STRUCTURES; RESOLUTION; BINDING; OXYGEN; REFINEMENT; DYNAMICS; SOLVENT	Crystal structures of bovine heart cytochrome c oxidase in the fully oxidized, fully reduced, azide-bound, and carbon monoxide-bound states were determined at 2.30, 2.35, 2.9, and 2.8 angstrom resolution, respectively. An aspartate residue apart from the O-2 reduction site exchanges its effective accessibility to the matrix aqueous phase for one to the cytosolic phase concomitantly with a significant decrease in the pK of its carboxyl group, on reduction of the metal sites. The movement indicates the aspartate as the proton pumping site. A tyrosine acidified by a covalently linked imidazole nitrogen is a possible proton donor for the O-2 reduction by the enzyme.	Himeji Inst Technol, Dept Life Sci, Himeji, Hyogo 6781297, Japan; Japan Sci & Technol Corp, CREST, Himeji, Hyogo 6781297, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Kwansei Gakuin Univ, Fac Sci, Nishinomiya, Hyogo 662, Japan	University of Hyogo; Japan Science & Technology Agency (JST); Osaka University; Kwansei Gakuin University	Yoshikawa, S (corresponding author), Himeji Inst Technol, Dept Life Sci, Kamigohri Akoh, Himeji, Hyogo 6781297, Japan.		Yamashita, Eiki/V-6758-2019; yao, min/F-5287-2011	Yamashita, Eiki/0000-0002-4278-0039; yao, min/0000-0003-1687-5904				ANTONINI E, 1977, P NATL ACAD SCI USA, V74, P3128, DOI 10.1073/pnas.74.8.3128; ARGOS P, 1975, ACTA CRYSTALLOGR B, V32, P2975; BAKER GM, 1987, J BIOL CHEM, V262, P595; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P817, DOI 10.1006/jmbi.1994.1191; BRUDVIG GW, 1981, BIOCHEMISTRY-US, V20, P3912, DOI 10.1021/bi00516a039; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUEHNER M, 1974, J MOL BIOL, V82, P563, DOI 10.1016/0022-2836(74)90249-6; Capitanio N, 1997, BBA-BIOENERGETICS, V1318, P255, DOI 10.1016/S0005-2728(96)00143-0; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; Cotton F.A., 1980, ADV INORG CHEM; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; GIBSON QH, 1965, J BIOL CHEM, V240, P888; HAN S, 1990, P NATL ACAD SCI USA, V87, P8408, DOI 10.1073/pnas.87.21.8408; HOLMES MA, 1991, J MOL BIOL, V218, P583, DOI 10.1016/0022-2836(91)90703-9; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Kirichenko A, 1998, FEBS LETT, V423, P329, DOI 10.1016/S0014-5793(98)00117-3; Kitagawa T, 1997, PROG INORG CHEM, V45, P431; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; Mattevi A, 1991, J Mol Recognit, V4, P1, DOI 10.1002/jmr.300040102; MESSERSCHMIDT A, 1993, J MOL BIOL, V230, P997, DOI 10.1006/jmbi.1993.1215; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Puustinen A, 1997, BIOCHEMISTRY-US, V36, P13195, DOI 10.1021/bi971091o; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; Riistama S, 1997, FEBS LETT, V414, P275, DOI 10.1016/S0014-5793(97)01003-X; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; STEFFENS GCM, 1993, EUR J BIOCHEM, V213, P1149, DOI 10.1111/j.1432-1033.1993.tb17865.x; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VANGELDE.BF, 1969, BIOCHIM BIOPHYS ACTA, V189, P1, DOI 10.1016/0005-2728(69)90219-9; VERKHOVSKY MI, 1994, BIOCHEMISTRY-US, V33, P3079, DOI 10.1021/bi00176a042; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WIKSTROM M, 1996, BIOCHIM BIOPHYS ACTA, V118, P106; WILLIAMS RJP, 1995, NATURE, V376, P643, DOI 10.1038/376643a0; WILSON MT, 1981, P NATL ACAD SCI-BIOL, V78, P7115, DOI 10.1073/pnas.78.11.7115; YOSHIKAWA S, 1982, J BIOL CHEM, V257, P412; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	39	952	966	2	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1723	1729		10.1126/science.280.5370.1723	http://dx.doi.org/10.1126/science.280.5370.1723			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624044				2022-12-24	WOS:000074197800033
J	Pal, B				Pal, B			Following up outpatients by telephone: pilot study	BRITISH MEDICAL JOURNAL			English	Article									S Manchester Univ Hosp NHS Trust, Withington Hosp, Manchester M20 2LR, Lancs, England	Wythenshawe Hospital NHS Foundation Trust	Pal, B (corresponding author), S Manchester Univ Hosp NHS Trust, Withington Hosp, Manchester M20 2LR, Lancs, England.	bpal@fs1.with.man.ac.uk						HALLAM L, 1991, BRIT MED J, V302, P629, DOI 10.1136/bmj.302.6777.629; Lattimer V, 1997, BRIT MED J, V314, P198; PAL B, 1996, BR J RHEUMATOL S1, V35, pA250; RAO JN, 1994, BRIT MED J, V309, P1527, DOI 10.1136/bmj.309.6968.1527; Wootton R, 1996, BRIT MED J, V313, P1375, DOI 10.1136/bmj.313.7069.1375	5	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1998	316	7145					1647	1647		10.1136/bmj.316.7145.1647	http://dx.doi.org/10.1136/bmj.316.7145.1647			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR867	9603747	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000074022700024
J	Blum, LN; Bresolin, LB; Williams, MA				Blum, LN; Bresolin, LB; Williams, MA			Heat-related illness during extreme weather emergencies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									AMA, Council Sci Affairs, Chicago, IL 60611 USA	American Medical Association	Blum, LN (corresponding author), AMA, Council Sci Affairs, Chicago, IL 60611 USA.		Williams, Michael A./O-4075-2019	Williams, Michael A./0000-0002-7284-8014					0	35	36	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1514	1514		10.1001/jama.279.19.1514	http://dx.doi.org/10.1001/jama.279.19.1514			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN087	9605881				2022-12-24	WOS:000073608100008
J	Meier, CR; Jick, SS; Derby, LE; Vasilakis, C; Jick, H				Meier, CR; Jick, SS; Derby, LE; Vasilakis, C; Jick, H			Acute respiratory-tract infections and risk of first-time acute myocardial infarction	LANCET			English	Article							PHYSICAL EXERTION; CASE-CROSSOVER; ATHEROSCLEROSIS; INFLAMMATION; DISEASE; DEATH; ONSET	Background. There is growing interest in the role of infections in the aetiology of acute myocardial infarction (AMI). We undertook a large, population-based study to explore the association between risk of AMI and recent acute respiratory-tract infection Methods We used data from general practices in the UK (General Practice Research Database). Potential cases were people aged 75 years or younger, with no history of clinical risk factors, who had a first-time diagnosis of AMI between Jan 1, 1994, and Oct 31, 1996. Four controls were matched to each case on age, sex, and the practice attended. The date of the AMI in the case was defined as the index date. For both cases and controls the date of the last respiratory-tract infection before the index date was identified. We also did a case-crossover analysis of cases who had an acute respiratory-tract infection either before the index date or before an arbitrarily chosen date (1 year before AMI). Findings. In the case-control analysis of 1922 cases and 7649 matched controls, significantly more cases than controls had an acute respiratory-tract infection in the 10 days before the index date (54 [2.8%] vs 72 [0.9%]). The odds ratios, adjusted for smoking and body-mass index, for first-time AMI in association with an acute respiratory-tract infection 1-5, 6-10, 11-15, or 16-30 days before the index date (compared with participants who had no such infection during the preceding year) were 3.6 (95% CI 2.2-5.7), 2.3 (1.3-4.2), 1.8 (1.0-3.3), and 1.0 (0.7-1.6); (test for trend p < 0.01). The case-crossover analysis showed a relative risk of 2.7 (1.6-4.7) for AMI in relation to an acute respiratory-tract infection in the 10 days before the index date. Interpretation. Our findings suggest that in people without a history of clinical risk factors for AMI, acute respiratory-tract infections are associated with an increased risk of AMI for a period of about 2 weeks. We cannot, however, completely exclude the possibility of misdiagnosis bias, if prodromal symptoms of AMI were mistaken for respiratory-tract infection.	Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, Lexington, MA 02173 USA	Boston University	Meier, CR (corresponding author), Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, 11 Muzzey St, Lexington, MA 02173 USA.			Jick, Hershel/0000-0003-4270-5992; Jick, Susan/0000-0002-2215-1067				Buja LM, 1996, CIRCULATION, V94, P872, DOI 10.1161/01.CIR.94.5.872; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Gullette ECD, 1997, JAMA-J AM MED ASSOC, V277, P1521, DOI 10.1001/jama.277.19.1521; Gupta S, 1997, CIRCULATION, V96, P404; Gurfinkel E, 1997, LANCET, V350, P404, DOI 10.1016/S0140-6736(97)07201-2; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H, 1996, PHARMACOTHERAPY, V16, P321; Jick H, 1997, EPIDEMIOLOGY, V8, P446, DOI 10.1097/00001648-199707000-00017; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; MATTILA KJ, 1989, J INTERN MED, V225, P293, DOI 10.1111/j.1365-2796.1989.tb00084.x; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; MITTLEMAN MA, 1995, AM J EPIDEMIOL, V142, P91, DOI 10.1093/oxfordjournals.aje.a117550; Mittleman MA, 1997, JAMA-J AM MED ASSOC, V277, P1558; NIEMINEN MS, 1993, EUR HEART J, V14, P12; PESONEN E, 1981, AM HEART J, V101, P512, DOI 10.1016/0002-8703(81)90150-2; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Rothman K, 1986, MODERN EPIDEMIOLOGY; SPODICK DH, 1985, ANN INTERN MED, V102, P699, DOI 10.7326/0003-4819-102-5-699; SPODICK DH, 1984, AM J CARDIOL, V53, P481, DOI 10.1016/0002-9149(84)90016-X; SYRJANEN J, 1988, BRIT MED J, V296, P1156, DOI 10.1136/bmj.296.6630.1156; TILLETT HE, 1983, INT J EPIDEMIOL, V12, P344, DOI 10.1093/ije/12.3.344; Vallance P, 1997, LANCET, V349, P1391, DOI 10.1016/S0140-6736(96)09424-X; VALTONEN VV, 1991, ANN MED, V23, P539, DOI 10.3109/07853899109150515; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; WILLICH SN, 1993, NEW ENGL J MED, V329, P1684, DOI 10.1056/NEJM199312023292302; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	28	300	313	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1467	1471		10.1016/S0140-6736(97)11084-4	http://dx.doi.org/10.1016/S0140-6736(97)11084-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605802	hybrid			2022-12-24	WOS:000073707300008
J	Dyson, S; Gurdon, JB				Dyson, S; Gurdon, JB			The interpretation of position in a morphogen gradient as revealed by occupancy of activin receptors	CELL			English	Article							GROWTH-FACTOR-BETA; XENOPUS EMBRYOS; SPEMANNS ORGANIZER; MAD PROTEINS; DROSOPHILA; HEDGEHOG; MESODERM; CELLS; THRESHOLDS; OOCYTES	Xenopus blastula cells activate different mesodermal genes as a concentration-dependent response to activin, which behaves like a morphogen. To understand how cells recognize morphogen concentration, we have bound naturally labeled activin to cells and related this to choice of gene activation. We find that the increasing occupancy of a single receptor type can cause cells to switch gene expression. Cells sense ligand concentration by the absolute number of occupied receptors per cell (100 and 300 molecules of bound activin induce Xbra and Xgsc, respectively, i.e., 2% and 6% of the total receptors) and not by a ratio of occupied to unoccupied receptors. The long duration of occupancy explains a previously described ratchet effect. Our results suggest a new concept of morphogen gradient formation and interpretation that is particularly well suited to the needs of early development.	Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	University of Cambridge	Gurdon, JB (corresponding author), Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			GURDON, JOHN/0000-0002-5621-3799	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Armes NA, 1997, DEVELOPMENT, V124, P3797; Chang CB, 1997, DEVELOPMENT, V124, P827; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COLMAN A, 1979, CELL, V17, P517, DOI 10.1016/0092-8674(79)90260-5; DAWID IB, 1965, J MOL BIOL, V12, P581, DOI 10.1016/S0022-2836(65)80313-8; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; Furriols M, 1996, DEVELOPMENT, V122, P2313; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GURDON JB, 1971, NATURE, V233, P177, DOI 10.1038/233177a0; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; GURDON JB, 1995, NATURE, V376, P520, DOI 10.1038/376520a0; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HOPPLER S, 1995, EMBO J, V14, P5016, DOI 10.1002/j.1460-2075.1995.tb00184.x; HUSKENHINDI P, 1994, J BIOL CHEM, V269, P19380; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; Koenig JA, 1996, MOL PHARMACOL, V49, P351; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MASSAGUE J, 1986, J CELL PHYSIOL, V128, P216, DOI 10.1002/jcp.1041280212; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; McDowell N, 1997, CURR BIOL, V7, P671, DOI 10.1016/S0960-9822(06)00294-6; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Natsume T, 1997, J BIOL CHEM, V272, P11535; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NISHIMATSU SI, 1992, FEBS LETT, V303, P81, DOI 10.1016/0014-5793(92)80482-V; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Rothenberg EV, 1996, SCIENCE, V273, P78, DOI 10.1126/science.273.5271.78; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; ZernickaGoetz M, 1996, DEVELOPMENT, V122, P3719; Zorn AM, 1997, GENE DEV, V11, P2176, DOI 10.1101/gad.11.17.2176	50	184	192	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					557	568		10.1016/S0092-8674(00)81185-X	http://dx.doi.org/10.1016/S0092-8674(00)81185-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604931	Bronze			2022-12-24	WOS:000073722200009
J	White, RH; Zhou, H; Romano, PS				White, RH; Zhou, H; Romano, PS			Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California	ANNALS OF INTERNAL MEDICINE			English	Article							EPIDEMIOLOGY; COAGULATION	Background: Few studies have compared the incidence of deep venous thrombosis among ethnic groups. Objective: To determine the incidence of deep venous thrombosis among ethnic groups. Design: Analysis of the linked California Patient Discharge Data Set from 1991 to 1994. Setting: California. Patients: 17 991 patients with idiopathic deep venous thrombosis (thrombosis without cancer or hospitalization within preceding 6 months) and 5573 patients with secondary thromboembolism (thromboembolism occurring within 3 months of seven different events). Measurements: Ethnicity was determined by using race as documented in the data set. For idiopathic deep venous thrombosis, standardized age- and sex-adjusted incidences were calculated. For secondary thromboembolism, proportional hazards modeling was done. Results: The annual incidence of idiopathic deep venous thrombosis per 1 000 000 persons older than 18 years of age was 230 for white persons, 293 for African Americans (rate ratio, 1.27 [95% CI, 1.07 to 1.51]), 139 for Hispanic persons (rate ratio, 0.60 [CI, 0.54 to 0.67]), and 60 for Asians and Pacific Islanders (rate ratio, 0.26 [CI, 0.22 to 0.30]). Compared with white persons, Asians and Pacific Islanders who developed secondary thromboembolism had a significantly lower relative risk (range, 0.22 to 0.61) for all seven conditions analyzed. Conclusions: Compared with white persons, Asians and Pacific Islanders have a very low incidence of idiopathic deep venous thrombosis and a very low relative risk for secondary venous thromboembolism.	Univ Calif Davis, Sacramento, CA 95817 USA	University of California System; University of California Davis	White, RH (corresponding author), Primary Care Ctr, Room 3107,2221 Stockton Blvd, Sacramento, CA 95817 USA.		Romano, Patrick S/N-4225-2014	Romano, Patrick S/0000-0001-6749-3979				ATICHARTAKARN V, 1988, ARCH INTERN MED, V148, P1349, DOI 10.1001/archinte.148.6.1349; *CENS BUR, 1992, 1990 CENS POP HOUS; CUNNINGHAM IG, 1974, BRIT J SURG, V61, P482, DOI 10.1002/bjs.1800610616; DUTHIE SJ, 1989, BRIT J OBSTET GYNAEC, V96, P4, DOI 10.1111/j.1471-0528.1989.tb01568.x; INADA K, 1983, AM J SURG, V145, P775, DOI 10.1016/0002-9610(83)90138-1; KATZ MH, 1993, J GEN INTERN MED, V8, P702, DOI 10.1007/BF02598295; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861, DOI 10.1001/archinte.154.8.861; Lauderdale DS, 1996, AM J PUBLIC HEALTH, V86, P712, DOI 10.2105/AJPH.86.5.712; MEUX EF, 1990, EVALUATION RELIABILI; NANDI P, 1980, BRIT J SURG, V67, P251, DOI 10.1002/bjs.1800670407; NATHWANI AC, 1992, BAILLIERE CLIN HAEM, V5, P383, DOI 10.1016/S0950-3536(11)80025-9; Price DT, 1997, ANN INTERN MED, V127, P895, DOI 10.7326/0003-4819-127-10-199711150-00007; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; Ridker PM, 1997, JAMA-J AM MED ASSOC, V277, P1305, DOI 10.1001/jama.277.16.1305; ROTHMAN K, 1986, MODERN EPIDEMIOLOGY, P211; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P41; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; TSO SC, 1980, BRIT J HAEMATOL, V46, P603, DOI 10.1111/j.1365-2141.1980.tb06018.x	18	272	279	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					737	740		10.7326/0003-4819-128-9-199805010-00006	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK790	9556467				2022-12-24	WOS:000073363800005
J	Kumar, S; Hedges, SB				Kumar, S; Hedges, SB			A molecular timescale for vertebrate evolution	NATURE			English	Article							CLOCK; DIVERGENCE; PHYLOGENY; ORIGINS; MAMMALS	A timescale is necessary for estimating rates of molecular and morphological change in organisms and for interpreting patterns of macroevolution and biogeography(1-9). Traditionally, these times have been obtained from the fossil record, where the earliest representatives of two lineages establish a minimum time of divergence of these lineages(10). The clock-like accumulation of sequence differences in some genes provides an alternative method(11) by which the mean divergence time can be estimated. Estimates from single genes may have large statistical errors, but multiple genes can be studied to obtain a more reliable estimate of divergence time(1,12-13). However, until recently, the number of genes available for estimation of divergence time has been limited. Here we present divergence-time estimates for mammalian orders and major lineages of vertebrates, from an analysis of 658 nuclear genes. The molecular times agree with most early (Palaeozoic) and late (Cenozoic) fossil-based times, but indicate major gaps in the Mesozoic fossil record. At least five lineages of placental mammals arose more than 100 million years ago, and most of the modern orders seem to have diversified before the Cretaceous/Tertiary extinction of the dinosaurs.	Penn State Univ, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA; Penn State Univ, Inst Mol Evolutionary Genet, Mueller Lab 208, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Hedges, SB (corresponding author), Penn State Univ, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA.		Kumar, Sudhir/F-1411-2011	Kumar, Sudhir/0000-0002-9918-8212				[Anonymous], 1993, MEGA MOL EVOLUTIONAR; Archibald JD, 1996, SCIENCE, V272, P1150, DOI 10.1126/science.272.5265.1150; Avise John C., 1994, pi; Benefit BR, 1997, NATURE, V388, P368, DOI 10.1038/41078; BENTON MJ, 1990, J MOL EVOL, V30, P409, DOI 10.1007/BF02101113; Benton MJ, 1997, VERTEBRATE PALEONTOL; BENTON MJ, 1993, FOSSIL RECORD, V2; Carroll RL, 1988, VERTEBRATE PALEONTOL; Cooper A, 1997, SCIENCE, V275, P1109, DOI 10.1126/science.275.5303.1109; DURET L, 1994, NUCLEIC ACIDS RES, V22, P2360, DOI 10.1093/nar/22.12.2360; Easteal S., 1995, MAMMALIAN MOL CLOCK; Gee C. H. R., COMMUNICATION; Gerhart J, 1997, CELLS EMBRYOS EVOLUT; Gheerbrant E, 1996, NATURE, V383, P68, DOI 10.1038/383068a0; Hallam A, 1995, OUTLINE PHANEROZOIC; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; JAEGER JJ, 1986, CR ACAD SCI II, V302, P917; Kay RF, 1997, SCIENCE, V275, P797, DOI 10.1126/science.275.5301.797; Kielan-Jaworowska Z., 1992, Historical Biology, V6, P185; MARTIN RD, 1993, NATURE, V363, P223, DOI 10.1038/363223a0; Nei M, 1987, MOL EVOLUTIONARY GEN; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; PARKER PH, 1996, THESIS PENNSYLVANIA; Pilbeam D, 1996, MOL PHYLOGENET EVOL, V5, P155, DOI 10.1006/mpev.1996.0010; Springer MS, 1997, NATURE, V388, P61, DOI 10.1038/40386; TAJIMA F, 1993, GENETICS, V135, P599; TAKEZAKI N, 1995, MOL BIOL EVOL, V12, P823; Ward Steve, 1997, P269; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; ZUCKERKANDL E, 1987, J MOL EVOL, V26, P34, DOI 10.1007/BF02111280	30	1552	1595	3	375	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					917	920		10.1038/31927	http://dx.doi.org/10.1038/31927			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582070				2022-12-24	WOS:000073359900047
J	Akhter, SA; Luttrell, LM; Rockman, HA; Iaccarino, G; Lefkowitz, RJ; Koch, WJ				Akhter, SA; Luttrell, LM; Rockman, HA; Iaccarino, G; Lefkowitz, RJ; Koch, WJ			Targeting the receptor-G(q) interface to inhibit in vivo pressure overload myocardial hypertrophy	SCIENCE			English	Article							CARDIAC GENE-EXPRESSION; VENTRICULAR MYOCYTES; PATHWAYS MEDIATE; MICE; CARDIOMYOCYTES; INDUCTION; MECHANISM; KINASE	Hormones and neurotransmitters may mediate common responses through receptors that couple to the same class of heterotrimeric guanine nucleotide-binding (G) protein. For example, several receptors that couple to G(q) class proteins can induce cardiomyocyte hypertrophy. Class-specific inhibition of G(q)-mediated signaling was produced in the hearts of transgenic mice by targeted expression of a carboxyl-terminal peptide of the alpha subunit G alpha(q). When pressure overload was surgically induced, the transgenic mice developed significantly less ventricular hypertrophy than control animals. The data demonstrate the role of myocardial G(q) in the initiation of myocardial hypertrophy and indicate a possible strategy for preventing pathophysiological signaling by simultaneously blocking multiple receptors coupled to G(q).	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Univ N Carolina, Dept Med Cardiol, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Koch, WJ (corresponding author), Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.	koch0002@mc.duke.edu	Lefkowitz, Robert/AAW-2649-2021; IACCARINO, Guido/A-7702-2010; Iaccarino, Guido/D-4540-2009	IACCARINO, Guido/0000-0002-8997-835X; Iaccarino, Guido/0000-0002-8997-835X; Luttrell, Louis/0000-0003-2805-6949	NHLBI NIH HHS [HL-16037, HL-09436, HL-03041] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, K08HL003041, R37HL016037, F32HL009436] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKHTER SA, UNPUB; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; ITO H, 1994, CIRCULATION, V89, P2198, DOI 10.1161/01.CIR.89.5.2198; KNOWLTON KU, 1995, J CLIN INVEST, V96, P1311, DOI 10.1172/JCI118166; Koch WJ, 1996, CIRC RES, V78, P511, DOI 10.1161/01.RES.78.4.511; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; ROCKMAN HA, 1994, AM J PHYSIOL, V266, pH2468, DOI 10.1152/ajpheart.1994.266.6.H2468; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Sakai S, 1996, NATURE, V384, P353, DOI 10.1038/384353a0; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023	22	381	394	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1998	280	5363					574	577		10.1126/science.280.5363.574	http://dx.doi.org/10.1126/science.280.5363.574			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554846				2022-12-24	WOS:000073242100043
J	Lacey, DL; Timms, E; Tan, HL; Kelley, MJ; Dunstan, CR; Burgess, T; Elliott, R; Colombero, A; Elliott, G; Scully, S; Hsu, H; Sullivan, J; Hawkins, N; Davy, E; Capparelli, C; Eli, A; Qian, YX; Kaufman, S; Sarosi, I; Shalhoub, V; Senaldi, G; Guo, J; Delaney, J; Boyle, WJ				Lacey, DL; Timms, E; Tan, HL; Kelley, MJ; Dunstan, CR; Burgess, T; Elliott, R; Colombero, A; Elliott, G; Scully, S; Hsu, H; Sullivan, J; Hawkins, N; Davy, E; Capparelli, C; Eli, A; Qian, YX; Kaufman, S; Sarosi, I; Shalhoub, V; Senaldi, G; Guo, J; Delaney, J; Boyle, WJ			Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation	CELL			English	Article							BONE-RESORPTION; IDENTIFICATION; CULTURES; MATRIX	The ligand for osteoprotegerin has been identified, and it is a TNF-related cytokine that replaces the requirement for stromal cells, vitamin D3, and glucocorticoids in the coculture model of in vitro osteoclastogenesis. OPG ligand (OPGL) binds to a unique hematopoeitic progenitor cell that is committed to the osteoclast lineage and stimulates the rapid induction of genes that typify osteoclast development. OPGL directly activates isolated mature osteoclasts in vitro, and shortterm administration into normal adult mice results in osteoclast activation associated with systemic hypercalcemia. These data suggest that OPGL is an osteoclast differentiation and activation factor. The effects of OPGL are blocked in vitro and in vivo by OPG, suggesting that OPGL and OPG are key extracellular regulators of osteoclast development.	Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Prot Chem, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Mammalian Cell Mol Biol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Bacterial Express, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Proc Sci, Thousand Oaks, CA 91320 USA	Amgen; Amgen; Amgen; Amgen; Amgen; Amgen	Boyle, WJ (corresponding author), Amgen Inc, Dept Cell Biol, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.		Dunstan, Colin/G-6214-2013	Dunstan, Colin/0000-0001-7586-4071; Sullivan, John/0000-0001-9840-852X				ABE E, 1986, P NATL ACAD SCI USA, V83, P5958, DOI 10.1073/pnas.83.16.5958; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ARNETT TR, 1986, ENDOCRINOLOGY, V119, P119, DOI 10.1210/endo-119-1-119; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; CHEN PCH, 1995, J BIOL CHEM, V270, P2874, DOI 10.1074/jbc.270.6.2874; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; EVANS RA, 1979, MINER ELECTROL METAB, V2, P179; FULLER K, 1991, BIOCHEM BIOPH RES CO, V181, P67, DOI 10.1016/S0006-291X(05)81382-8; HENTUNEN TA, 1994, BONE MINER, V25, P183, DOI 10.1016/S0169-6009(08)80238-3; HORTON JE, 1972, SCIENCE, V177, P793, DOI 10.1126/science.177.4051.793; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; LACEY DL, 1995, ENDOCRINOLOGY, V136, P2367, DOI 10.1210/en.136.6.2367; LEE MY, 1991, P NATL ACAD SCI USA, V88, P8500, DOI 10.1073/pnas.88.19.8500; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; Udagawa N, 1996, BONE, V18, P511, DOI 10.1016/8756-3282(96)00076-2; WILCOX JN, 1993, J HISTOCHEM CYTOCHEM, V41, P1725, DOI 10.1177/41.12.8245419; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; YONEDA T, 1993, J PERIODONTAL RES, V28, P521, DOI 10.1111/j.1600-0765.1993.tb02117.x	24	4257	4559	15	207	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					165	176		10.1016/S0092-8674(00)81569-X	http://dx.doi.org/10.1016/S0092-8674(00)81569-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568710	Bronze			2022-12-24	WOS:000073174000004
J	Herrada, J; Cabanillas, F; Rice, L; Manning, J; Pugh, W				Herrada, J; Cabanillas, F; Rice, L; Manning, J; Pugh, W			The clinical behavior of localized and multicentric Castleman disease	ANNALS OF INTERNAL MEDICINE			English	Review							LYMPH-NODE HYPERPLASIA; SYSTEMIC MANIFESTATIONS; KAPOSIS SARCOMA; POEMS SYNDROME; INTERLEUKIN-6; EXPRESSION; RADIOTHERAPY	Background: Castleman disease, an unusual condition of unknown cause consisting of a massive proliferation of lymphoid tissue, remains a clinicopathologic diagnosis. Three histologic variants (hyaline vascular, plasma-cell, and mixed) and two clinical types (localized and multicentric) of Castleman disease have been described. Objective: To analyze the clinical features, management, and outcome of patients with Castleman disease. Design: Case series. Setting: University referral hospitals. Patients: All patients with Castleman disease who were seen at Texas Medical Center, Houston, Texas, between 1977 and 1995. Interventions: Surgical excision for localized disease; surgery, combination chemotherapy, or prednisone for multicentric disease. Measurements: Patients were identified according to initial presentation as having localized or multicentric Castleman disease. Patients within each group were further subdivided according to whether they had hyaline vascular, plasma-cell, or mixed disease. Results: Data from 15 patients were analyzed. All 7 patients with localized disease underwent surgical excision and remain free of disease. The 8 patients with multicentric disease were further subdivided according to initial treatment: Three patients who received combination chemotherapy are currently alive and free of disease; 2 patients treated with prednisone are alive but have needed intermittent maintenance therapy for disease reactivations; and 2 patients treated with surgery only have died, 1 of infectious complications and 1 of non-Hodgkin lymphoma. Conclusions: Localized and multicentric Castleman disease are different clinical disorders with overlapping histologic features. Localized disease can be cured with surgery, but complete remissions in patients with multicentric disease have been achieved only with chemotherapy or prednisone given at the time of diagnosis.	Univ Texas, Md Anderson Canc Ctr, Dept Hematol, Lymphoma Sect,Baylor Coll Med, Houston, TX 77030 USA; Baylor Coll Med, Methodist Hosp, Hematol Oncol Sect, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston	Cabanillas, F (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Hematol, Lymphoma Sect,Baylor Coll Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Cabanillas, Fernando/0000-0001-9234-7893				AISENBERG AC, 1991, MALIGNANT LYMPHOMA B, P11; BARDWICK PA, 1980, MEDICINE, V59, P311, DOI 10.1097/00005792-198007000-00006; BARTOLI E, 1980, AM J CLIN PATHOL, V73, P423; BECK JT, 1994, NEW ENGL J MED, V330, P602, DOI 10.1056/NEJM199403033300904; BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; CASTLEMAN B, 1956, CANCER, V9, P822, DOI 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4; CHAN TM, 1993, NEPHRON, V65, P628, DOI 10.1159/000187576; CROS D, 1990, NEW ENGL J MED, V323, P895; FEIGERT JM, 1990, ANN INTERN MED, V113, P362, DOI 10.7326/0003-4819-113-5-362; Flendrig JA, 1969, FOLIA MED NEERD, V12, P119; FRIZZERA G, 1985, J CLIN ONCOL, V3, P1202, DOI 10.1200/JCO.1985.3.9.1202; FRIZZERA G, 1988, SEMIN DIAGN PATHOL, V5, P346; FRIZZERA G, 1992, NEOPLASTIC HEMATOPAT, P454; GABA AR, 1978, AM J CLIN PATHOL, V69, P86; GILI A, 1991, J AM ACAD DERMATOL, V25, P955, DOI 10.1016/0190-9622(91)70293-B; HANCHARD B, 1987, W INDIAN MED J, V36, P104; HSU SM, 1993, HUM PATHOL, V24, P833, DOI 10.1016/0046-8177(93)90132-Z; KELLER AR, 1972, CANCER-AM CANCER SOC, V29, P670, DOI 10.1002/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO;2-#; KESSLER E, 1985, CANCER-AM CANCER SOC, V56, P2446, DOI 10.1002/1097-0142(19851115)56:10<2446::AID-CNCR2820561020>3.0.CO;2-4; LACHANT NA, 1985, AM J CLIN PATHOL, V83, P27, DOI 10.1093/ajcp/83.1.27; LEGERRAVET MB, 1991, BLOOD, V78, P2923; LOTZ M, 1993, CANCER INVEST, V11, P732, DOI 10.3109/07357909309046948; MARTI S, 1983, CANCER, V51, P808, DOI 10.1002/1097-0142(19830301)51:5<808::AID-CNCR2820510510>3.0.CO;2-5; MARTIN JME, 1985, AM J CLIN PATHOL, V84, P439, DOI 10.1093/ajcp/84.4.439; MUNOZ G, 1990, HISTOPATHOLOGY, V17, P172, DOI 10.1111/j.1365-2559.1990.tb00692.x; NAKANISHI T, 1984, NEUROLOGY, V34, P712, DOI 10.1212/WNL.34.6.712; NORDSTROM DG, 1978, INT J RADIAT ONCOL, V4, P1045, DOI 10.1016/0360-3016(78)90019-6; ORDI J, 1993, AM J CLIN PATHOL, V100, P394, DOI 10.1093/ajcp/100.4.394; PAVLIDIS NA, 1990, MED PEDIATR ONCOL, V18, P333, DOI 10.1002/mpo.2950180416; PAVLIDIS NA, 1992, ANN ONCOL, V3, P85, DOI 10.1093/oxfordjournals.annonc.a058082; PETERSON BA, 1993, SEMIN ONCOL, V20, P636; REPETTO L, 1986, HEMATOL ONCOL, V4, P213, DOI 10.1002/hon.2900040305; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; STEINBERG D, 1992, NEW ENGL J MED, V327, P1014; SUMMERFIELD GP, 1983, J CLIN PATHOL, V36, P1005, DOI 10.1136/jcp.36.9.1005; Ushio T, 1994, Nihon Kyobu Shikkan Gakkai Zasshi, V32, P1175; WEISENBURGER DD, 1985, HUM PATHOL, V16, P162, DOI 10.1016/S0046-8177(85)80065-4; WEISENBURGER DD, 1979, CANCER, V44, P457, DOI 10.1002/1097-0142(197908)44:2<457::AID-CNCR2820440212>3.0.CO;2-4; YOSHIZAKI K, 1989, BLOOD, V74, P1360	39	298	324	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					657	662		10.7326/0003-4819-128-8-199804150-00010	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537940				2022-12-24	WOS:000073052500007
J	Garvican, L; Grimsey, E; Littlejohns, P; Lowndes, S; Sacks, N				Garvican, L; Grimsey, E; Littlejohns, P; Lowndes, S; Sacks, N			Satisfaction with clinical nurse specialists in a breast care clinic: Questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									Univ London St Georges Hosp, Breast Unit, London SW17 0QT, England; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, Hlth Care Evaluat Unit, London SW17 0RE, England	St Georges University London; St Georges University London	Garvican, L (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, Hlth Care Evaluat Unit, London SW17 0RE, England.							*BRIT ASS SURG ONC, 1995, EUR J SURG ONCOL S, V21, pA13; BROWN LA, 1991, CYTOPATHOLOGY, V2, P1, DOI 10.1111/j.1365-2303.1991.tb00377.x; English T, 1997, BRIT MED J, V314, P661, DOI 10.1136/bmj.314.7081.661; HAMMOND C, 1994, THESIS U SURREY; WATSON M, 1988, COUNSEL PSYCHOL Q, V1, P25	5	28	28	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					976	+		10.1136/bmj.316.7136.976	http://dx.doi.org/10.1136/bmj.316.7136.976			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550957	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000072856100021
J	Cruickshanks, KJ; Klein, R; Klein, BEK; Wiley, TL; Nondahl, DM; Tweed, TS				Cruickshanks, KJ; Klein, R; Klein, BEK; Wiley, TL; Nondahl, DM; Tweed, TS			Cigarette smoking and hearing loss - The epidemiology of hearing loss study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BEAVER-DAM EYE; RECEPTORS	Context.-Clinical studies have suggested that cigarette smoking may be associated with hearing loss, a common condition affecting older adults. Objective.-To evaluate the association between smoking and hearing loss. Design.-Population-based, cross-sectional study. Setting.-Community of Beaver Dam, Wis. Participants.-Adults aged 48 to 92 years. Of 4541 eligible subjects, 3753 (83%) participated in the hearing study. Main Outcome Measures.-The examination included otoscopy, screening tympanometry, and pure-tone air-conduction and bone-conduction audiometry, Smoking history was ascertained by self-report. Hearing loss was defined as a pure-tone average (0.5, 1, 2, and 4 kHz) greater than 25-dB hearing level in the worse ear. Results.-After adjusting for other factors, current smokers were 1.69 times as likely to have a hearing loss as nonsmokers (95% confidence interval, 1.31-2.17), This relationship remained for those without a history of occupational noise exposure and in analyses excluding those with non-age-related hearing loss. There was weak evidence of a dose-response effect. Nonsmoking participants who lived with a smoker were more likely to have a hearing loss than those who were not exposed to a household member who smoked (odds ratio, 1.94; 95% confidence interval, 1.01-3.74). Conclusions.-These data suggest that environmental exposures may play a role in age-related hearing loss. If longitudinal studies confirm these findings, modification of smoking habits may prevent or delay age-related declines in hearing sensitivity.	Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53705 USA; Univ Wisconsin, Dept Communicat Disorders, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Cruickshanks, KJ (corresponding author), Univ Wisconsin, Dept Ophthalmol & Visual Sci, 610 N Walnut St,460 WARF, Madison, WI 53705 USA.	cruickshanks@epi.ophth.wisc.edu	Legarth, Jonas/A-9156-2012		NEI NIH HHS [EY0694] Funding Source: Medline; NIA NIH HHS [AG11099] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011099] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM NAT STAND I, 1989, ANSI PUBL; *AM NAT STAND I, 1991, ANSI PUBL; [Anonymous], 1978, ASHA, V20, P297; Blanchet C, 1996, J NEUROSCI, V16, P2574; Brant L J, 1996, J Am Acad Audiol, V7, P152; CAMPBELL JA, 1988, P SURV RES METH SECT, P549; CRUICKSHANKS KJ, IN PRESS AM J EPIDEM; GATES GA, 1993, ARCH OTOLARYNGOL, V119, P156; Guth PS, 1996, HEARING RES, V98, P1, DOI 10.1016/0378-5955(96)00031-7; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; Jarvis J F, 1967, J Laryngol Otol, V81, P63, DOI 10.1017/S0022215100066779; Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5; LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049; LYONS JA, 1992, J TRAUMA STRESS, V5, P111, DOI 10.1007/BF00976816; MAFFEL G, 1962, ARCHIV OTOLARYNGOL, V75, P386; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MCCARTNEY JS, 1994, NEUROTOXICOL TERATOL, V16, P269, DOI 10.1016/0892-0362(94)90048-5; *NAT CTR HLTH STAT, 1967, VITAL HLTH STAT 10, V34, P11; *NAT STRAT RES PLA, 1996, HEAR HEAR IMP, P33; Nondahl D M, 1996, J Am Acad Audiol, V7, P251; ROSEN S, 1962, ANN OTO RHINOL LARYN, V71, P727, DOI 10.1177/000348946207100313; SHAPIRO SL, 1965, EYE EAR NOSE THROAT, V44, P94; SIEGELAUB AB, 1974, ARCH ENVIRON HEALTH, V29, P107, DOI 10.1080/00039896.1974.10666542; Weiss W, 1970, Med Times, V98, P84; WESTON T E, 1964, J Laryngol Otol, V78, P273, DOI 10.1017/S0022215100062071; Wiley T L, 1996, J Am Acad Audiol, V7, P260; ZELMAN S, 1973, JAMA-J AM MED ASSOC, V223, P920, DOI 10.1001/jama.1973.03220080050016	27	264	278	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1715	1719		10.1001/jama.279.21.1715	http://dx.doi.org/10.1001/jama.279.21.1715			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624024	Bronze			2022-12-24	WOS:000073878700032
J	Nightingale, SL				Nightingale, SL			Web site for "year 2000" information on biomedical equipment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	10	11	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1684	1684		10.1001/jama.279.21.1684	http://dx.doi.org/10.1001/jama.279.21.1684			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624011				2022-12-24	WOS:000073878700006
J	Penninx, BWJH; Guralnik, JM; Ferrucci, L; Simonsick, EM; Deeg, DJH; Wallace, RB				Penninx, BWJH; Guralnik, JM; Ferrucci, L; Simonsick, EM; Deeg, DJH; Wallace, RB			Depressive symptoms and physical decline in community-dwelling older persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; IMMUNE-SYSTEM; DISABILITY; PERFORMANCE; ANXIETY; FALLS; CARE	Context.-Significant symptoms of depression are common in the older community-dwelling population. Although depressive symptoms and disability may commonly occur in the same person, whether depressive symptoms contribute to subsequent functional decline has not been elucidated, Objective.-To determine whether depressive symptoms in older persons increase the risk of subsequent decline in physical function as measured by objective performance-based tests. Design.-A 4-year prospective cohort study. Setting.-The communities of Iowa and Washington counties, Iowa. Participants.-A total of 1286 persons aged 71 years and older who completed a short battery of physical performance tests in 1988 and again 4 years later. Main Outcome Measures.-Baseline depressive symptoms were assessed by the Center for Epidemiological Studies Depression Scale. Physical performance tests included an assessment of standing balance, a timed 2.4-m (8-ft) walk, and a timed test of 5 repetitions of rising from a chair and sitting down. Results.-After adjustment far baseline performance score, health status, and sociodemographic factors, increasing levels of depressive symptoms were predictive of greater decline in physical performance over 4 years (odds ratio for decline in those with depressed mood vs those without, 1.55; 95% confidence interval [CI], 1.02-2.34), Even among those at the high end of the functional spectrum, who reported no disability, the severity of depressive symptoms predicted subsequent decline in physical performance (odds ratio for decline, 1.03; 95% CI, 1.00-1.08). Conclusions.-This study provides evidence that older persons who report depressive symptoms are at higher risk of subsequent physical decline, These results suggest that prevention or reduction of depressed mood could play a role in reducing functional decline in older persons.	NIA, Epidemiol Demogr & Biometry Program, Bethesda, MD 20892 USA; INRCA Florence, Dept Geriatr, Florence, Italy; Vrije Univ Amsterdam, Inst Res Extramural Med, Amsterdam, Netherlands; Vrije Univ Amsterdam, Dept Psychiat, Amsterdam, Netherlands; Univ Iowa, Dept Prevent Med & Environm Hlth, Iowa City, IA 52242 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); IRCCS INRCA; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Iowa	Guralnik, JM (corresponding author), NIA, Epidemiol Demogr & Biometry Program, Gateway Bldg,Suite 3C-309,7201 Wisconsin Ave, Bethesda, MD 20892 USA.	jg48s@nih.gov	Penninx, Brenda WJH/S-7627-2017; Simonsick, Eleanor/W-6864-2019	Penninx, Brenda WJH/0000-0001-7779-9672; 	NATIONAL INSTITUTE ON AGING [N01AG002107, N01AG002106, Z01AG000215] Funding Source: NIH RePORTER; NIA NIH HHS [N01-AG-0215, N01-AG-02107, N01-AG-02106] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barefoot JC, 1996, CIRCULATION, V93, P1976, DOI 10.1161/01.CIR.93.11.1976; BARSKY AJ, 1988, PSYCHOSOM MED, V50, P510, DOI 10.1097/00006842-198809000-00007; Beekman ATF, 1995, J AFFECT DISORDERS, V36, P65, DOI 10.1016/0165-0327(95)00061-5; Beekman ATF, 1997, PSYCHOL MED, V27, P231, DOI 10.1017/S0033291796003510; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; BRUCE ML, 1994, AM J PUBLIC HEALTH, V84, P1796, DOI 10.2105/AJPH.84.11.1796; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; CRESS ME, 1995, J AM GERIATR SOC, V43, P93, DOI 10.1111/j.1532-5415.1995.tb06372.x; CRONBACH LJ, 1970, PSYCHOL BULL, V74, P68, DOI 10.1037/h0029382; Gallo JJ, 1997, J AM GERIATR SOC, V45, P570, DOI 10.1111/j.1532-5415.1997.tb03089.x; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1989, J GERONTOL, V44, pM141, DOI 10.1093/geronj/44.5.M141; GURALNIK JM, 1994, AGING-CLIN EXP RES, V6, P303, DOI 10.1007/BF03324256; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; HUISIANI BA, 1980, J COMMUNITY PSYCHOL, V8, P20; *HYP DET FOLL UP P, 1977, JAMA-J AM MED ASSOC, V237, P2385; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kempen GIJM, 1996, J GERONTOL B-PSYCHOL, V51, pP254, DOI 10.1093/geronb/51B.5.P254; Kohout FJ, 1993, J AGING HEALTH, V5, P79; KRONFOL Z, 1984, LANCET, V1, P1026; Lyness JM, 1997, ARCH INTERN MED, V157, P449, DOI 10.1001/archinte.157.4.449; MILLER AH, 1993, ANN MED, V25, P481, DOI 10.3109/07853899309147316; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; ORMEL J, 1991, ARCH GEN PSYCHIAT, V48, P700; ORMEL J, 1993, AM J PUBLIC HEALTH, V83, P385, DOI 10.2105/AJPH.83.3.385; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; ROSOW I, 1966, J GERONTOL, V39, P686; SEEMAN TE, 1994, J GERONTOL, V49, pM97, DOI 10.1093/geronj/49.3.M97; SEEMAN TE, 1995, J GERONTOL A-BIOL, V50, pM177, DOI 10.1093/gerona/50A.4.M177; *SPSS INC, 1993, SPSS ADV STAT REF GU; STEIN M, 1991, ARCH GEN PSYCHIAT, V48, P171; STURM R, 1995, JAMA-J AM MED ASSOC, V273, P51; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1988, JAMA-J AM MED ASSOC, V259, P1190, DOI 10.1001/jama.259.8.1190; TURNER RJ, 1988, J HEALTH SOC BEHAV, V29, P23, DOI 10.2307/2137178; Unutzer J, 1997, JAMA-J AM MED ASSOC, V277, P1618, DOI 10.1001/jama.277.20.1618; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WHO (World Health Organization), 1977, MAN INT STAT CLASS D; WINOGRAD CH, 1994, J AM GERIATR SOC, V42, P743, DOI 10.1111/j.1532-5415.1994.tb06535.x	42	579	588	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1720	1726		10.1001/jama.279.21.1720	http://dx.doi.org/10.1001/jama.279.21.1720			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZQ544	9624025				2022-12-24	WOS:000073878700033
J	Zhu, JY; Shibasaki, F; Price, R; Guillemot, JC; Yano, T; Dotsch, V; Wagner, G; Ferrara, P; McKeon, F				Zhu, JY; Shibasaki, F; Price, R; Guillemot, JC; Yano, T; Dotsch, V; Wagner, G; Ferrara, P; McKeon, F			Intramolecular masking of nuclear import signal on NF-AT4 by casein kinase I and MEKK1	CELL			English	Article							NF-KAPPA-B; SUBSTRATE DETERMINANTS; MOLECULAR-CLONING; PROTEIN-KINASE; GENE FAMILY; CALCINEURIN; PHOSPHORYLATION; LOCALIZATION; EXPRESSION; ACTIVATION	T cell activation requires the import of NF-AT transcription factors to the nucleus, a process promoted by calcineurin-dependent dephosphorylation and inhibited by poorly understood protein kinases. Here, we report the identification of two protein kinases that oppose NF-AT4 nuclear import. Casein kinase I alpha directly binds and phosphorylates NF-AT4, resulting in the inhibiton of NF-AT4 nuclear translocation. MEKK1 indirectly suppresses NF-AT4 nuclear import by stabilizing the interaction between NF-AT4 and CKI alpha. CKI alpha thus acts to establish an intramolecular masking of the nuclear location signal on NF-AT4, while MEKK1 augments this mechanism, and may further provide a link to signal transduction pathways regulating NF-AT4.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Sanofi Biorech, F-31676 Labege, France	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Sanofi-Aventis; Sanofi France	McKeon, F (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Doetsch, Volker/D-5697-2011	Dotsch, Volker/0000-0001-5720-212X				Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; HO U, 1997, P NATL ACAD SCI USA, V94, P581; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Kusuda J, 1996, GENOMICS, V32, P140, DOI 10.1006/geno.1996.0091; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; YAN MH, 1994, NATURE, V372, P798; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717	34	261	266	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					851	861		10.1016/S0092-8674(00)81445-2	http://dx.doi.org/10.1016/S0092-8674(00)81445-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630228	Bronze			2022-12-24	WOS:000073956700020
J	Stenzl, A; Ninkovic, M; Kolle, D; Napp, R; Anderl, H; Bartsch, G				Stenzl, A; Ninkovic, M; Kolle, D; Napp, R; Anderl, H; Bartsch, G			Restoration of voluntary emptying of the bladder by transplantation of innervated free skeletal muscle	LANCET			English	Article							NEUROGENIC BLADDER; DETRUSOR-MYOPLASTY	Background. On the basis of studies with animals and experience with functioning muscle transfer in plastic surgery, we have developed a surgical technique to restore detrusor function for patients with bladder acontractility in whom there is no treatment alternative. Methods. Three patients (aged 26 years, 28 years, and 68 years) with bladder acontractility as a result of spinal-cord injury (two patients) and chronic overdistension (one patient), who required catheterisation for bladder emptying for 5 years, 2 years, and 2 years, respectively, took part in our study. The patients were treated with microneurovascular free transfer of autologous latissimus dorsi muscle to the bladder to restore detrusor function. Follow-up included clinical and urodynamic evaluation, colour doppler sonography, intravenous urography, and flow-mode computerised tomography. Findings. The three patients voluntarily emptied their bladders at 16 weeks, 16 weeks, and 30 weeks after surgery, respectively. There was no need for further catheterisation throughout the follow-up period. On urodynamic assessment at 12 months after the operation bladder capacity was found to be 600 mt, 600 mt, and 650 mL, residual urinary volume 0 mL, 50 mL, 90 mL, and maximum flow rate 26 mL/s, 25 mL/s, and 18 mL/s, respectively. Activity at the transplanted latissimus dorsi was confirmed by ultrasonography and flow-mode computerised tomography. Interpretation. Microneurovascular free transfer of latissimus dorsi muscle to functionally restore a deficient detrusor muscle has proved to be successful for the three patients in our study. This technique may also be an option to restore the function of other smooth-muscle organs.	Univ Innsbruck, Med Ctr, Dept Urol, A-6020 Innsbruck, Austria; Univ Innsbruck, Med Ctr, Dept Plast Surg, A-6020 Innsbruck, Austria; Univ Innsbruck, Med Ctr, Dept Gynaecol, A-6020 Innsbruck, Austria; Univ Innsbruck, Med Ctr, Dept Radiodiagnost 2, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck; University of Innsbruck; University of Innsbruck	Stenzl, A (corresponding author), Univ Innsbruck, Med Ctr, Dept Urol, Anichstr 35, A-6020 Innsbruck, Austria.	arnulf.stenzl@uibk.ac.at						BAETEN CGMI, 1991, LANCET, V338, P1163, DOI 10.1016/0140-6736(91)92030-6; BRINDLEY GS, 1990, PARAPLEGIA, V28, P469, DOI 10.1038/sc.1990.63; CARPENTIER A, 1985, LANCET, V1, P1267; CHANCELLOR MB, 1994, LANCET, V343, P669, DOI 10.1016/S0140-6736(94)92661-1; CHANCELLOR MB, 1994, NEUROUROL URODYNAM, V13, P547, DOI 10.1002/nau.1930130509; MANKTELOW R, 1985, RECENT ADV PLASTIC S, P123; MANKTELOW RT, 1989, ANN PLAS SURG, V22, P275, DOI 10.1097/00000637-198904000-00001; MESSING EM, 1985, J UROLOGY, V134, P1202, DOI 10.1016/S0022-5347(17)47687-7; Ninkovic M, 1997, PLAST RECONSTR SURG, V100, P402, DOI 10.1097/00006534-199708000-00020; NINKOVIC M, 1994, BRIT J PLAST SURG, V47, P185, DOI 10.1016/0007-1226(94)90052-3; Ninkovic M, 1998, PLAST RECONSTR SURG, V101, P971, DOI 10.1097/00006534-199804040-00013; RUSSELL RC, 1986, PLAST RECONSTR SURG, V78, P336, DOI 10.1097/00006534-198609000-00009; Stenzl A, 1997, J UROLOGY, V157, P1103, DOI 10.1016/S0022-5347(01)65150-4; TANAGHO EA, 1988, J UROLOGY, V140, P1331, DOI 10.1016/S0022-5347(17)42038-6; Wechselberger G, 1997, J RECONSTR MICROSURG, V13, P125, DOI 10.1055/s-2007-1000228; ZHANG YH, 1990, J UROLOGY, V144, P1194	16	35	38	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1483	1485		10.1016/S0140-6736(97)10005-8	http://dx.doi.org/10.1016/S0140-6736(97)10005-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605805				2022-12-24	WOS:000073707300011
J	Hankinson, SE; Willett, WC; Colditz, GA; Hunter, DJ; Michaud, DS; Deroo, B; Rosner, B; Speizer, FE; Pollak, M				Hankinson, SE; Willett, WC; Colditz, GA; Hunter, DJ; Michaud, DS; Deroo, B; Rosner, B; Speizer, FE; Pollak, M			Circulating concentrations of insulin-like growth factor-I and risk of breast cancer	LANCET			English	Article							FACTOR-BINDING PROTEIN-3; BODY-MASS INDEX; CELL-PROLIFERATION; SERUM LEVELS; IGF-II; MICE; HORMONE; STAGE; SEX; ADOLESCENTS	Background. Insulin-like growth factor (IGF)-I, a mitogenic and antiapoptotic peptide, can affect the proliferation of breast epithelial cells, and is thought to have a role in breast cancer. We hypothesised that high circulating IGF-I concentrations would be associated with an increased risk of breast cancer. Methods. We carried out a nested case-control study within the prospective Nurses' Health Study cohort. Plasma concentrations of IGF-I and IGF binding protein 3 (IGFBP-3) were measured in blood samples collected in 1989-90. We identified 397 women who had a diagnosis of breast cancer after this date and 620 age-matched controls, IGF-I concentrations were compared by logistic regression with adjustment for other breast-cancer risk factors. Findings. There was no association between IGF-I concentrations and breast-cancer risk among the whole study group. In postmenopausal women there was no association between IGF-I concentrations and breast-cancer risk (top vs bottom quintile of IGF-I, relative risk 0.85 [95% CI 0.53-1.39]). The relative risk of breast cancer among premenopausal women by IGF-I concentration (top vs bottom tertile) was 2.33 (1.06-5.16; p for trend 0.08). Among premenopausal women less than 50 years old at the time of blood collection, the relative risk was 4.58 (1.75-12.0; p for trend 0.02). After further adjustment for plasma IGFBP-3 concentrations these relative risks were 2.88 and 7.28, respectively. Interpretation. A positive relation between circulating IGF-I concentration and risk of breast cancer was found among premenopausal but not postmenopausal women. Plasma IGF-I concentrations may be useful in the identification of women at high risk of breast cancer and in the development of risk reduction strategies. Additional larger studies of this association among premenopausal women are needed to provide more precise estimates of effect.	Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Oncol,Canc Prevent Res Unit, Montreal, PQ H3T 1E2, Canada	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Hankinson, SE (corresponding author), Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009; Michaud, Dominique S/I-5231-2014; Pollak, Michael/G-9094-2011	Colditz, Graham/0000-0002-7307-0291; Pollak, Michael/0000-0003-3047-0604	NATIONAL CANCER INSTITUTE [R01CA049449, R01CA040356, R37CA040356, U01CA049449] Funding Source: NIH RePORTER; NCI NIH HHS [CA-49449, CA-40356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; BRUNING PF, 1995, INT J CANCER, V62, P266, DOI 10.1002/ijc.2910620306; CAMPAGNOLI C, 1993, GYNECOL ENDOCRINOL, V7, P251, DOI 10.3109/09513599309152509; Cats A, 1996, CANCER RES, V56, P523; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chen NY, 1997, ENDOCRINOLOGY, V138, P851, DOI 10.1210/en.138.2.851; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; GoodmanGruen D, 1997, AM J EPIDEMIOL, V145, P970, DOI 10.1093/oxfordjournals.aje.a009065; Gucev ZS, 1996, CANCER RES, V56, P1545; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; HANKINSON SE, 1995, J NATL CANCER I, V87, P1297, DOI 10.1093/jnci/87.17.1297; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; JUUL A, 1995, J CLIN ENDOCR METAB, V80, P2534, DOI 10.1210/jc.80.8.2534; JUUL A, 1994, J CLIN ENDOCR METAB, V78, P744, DOI 10.1210/jc.78.3.744; Michels KB, 1996, LANCET, V348, P1542, DOI 10.1016/S0140-6736(96)03102-9; Ng ST, 1997, NAT MED, V3, P1141, DOI 10.1038/nm1097-1141; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; Osorio M, 1996, EARLY HUM DEV, V46, P15, DOI 10.1016/0378-3782(96)01737-9; PEYRAT JP, 1993, EUR J CANCER, V29A, P492, DOI 10.1016/S0959-8049(05)80137-6; Pollak M, 1997, ADJ THER CANC, V8, P145; POLLAK M, 1990, J NATL CANCER I, V82, P1693, DOI 10.1093/jnci/82.21.1693; Pollak MN, 1998, P SOC EXP BIOL MED, V217, P143; Pollak MN, 1998, BREAST CANCER RES TR, V47, P209, DOI 10.1023/A:1005950916707; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; Rozen F, 1997, J NATL CANCER I, V89, P652, DOI 10.1093/jnci/89.9.652; RUAN W, 1997, P END SOC 79 ANN M, V79, P165; RUAN W, 1995, ENDOCRINOLOGY, V36, P1296; RUGGERI B, 1998, CANCER RES, V49, P4135; SINHA YN, 1979, INT J CANCER, V24, P40; TORNELL J, 1992, J STEROID BIOCHEM, V43, P237, DOI 10.1016/0960-0760(92)90213-3; Yang XF, 1996, CANCER RES, V56, P1509; ZARANDI M, 1994, P NATL ACAD SCI USA, V91, P12298, DOI 10.1073/pnas.91.25.12298	36	1456	1504	3	50	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 9	1998	351	9113					1393	1396		10.1016/S0140-6736(97)10384-1	http://dx.doi.org/10.1016/S0140-6736(97)10384-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM665	9593409				2022-12-24	WOS:000073563400009
J	Boddy, MN; Furnari, B; Mondesert, O; Russell, P				Boddy, MN; Furnari, B; Mondesert, O; Russell, P			Replication checkpoint enforced by kinases Cds1 and Chk1	SCIENCE			English	Article							FISSION YEAST; CDC2; PHOSPHORYLATION; MITOSIS; PATHWAY; CELLS	Cdc2, the kinase that induces mitosis, is regulated by checkpoints that couple mitosis to the completion of DNA replication and repair. The repair checkpoint kinase Chk1 regulates Cdc25, a phosphatase that activates Cdc2, Effecters of the replication checkpoint evoked by hydroxyurea (HU) are unknown. Treatment of fission yeast with HU stimulated the kinase Cds1, which appears to phosphorylate the kinase Wee1, an inhibitor of Cdc2, The protein kinase Cds1 was also required for a large HU-induced increase in the amount of Mik1, a second inhibitor of Cdc2. HU-induced arrest of cell division was abolished in cds? chk1 cells. Thus, Cds1 and Chk1 appear to jointly enforce the replication checkpoint.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Russell, P (corresponding author), Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.	prussell@scripps.edu	Boddy, Michael/A-7214-2009					Aligue R, 1997, J BIOL CHEM, V272, P13320, DOI 10.1074/jbc.272.20.13320; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; BODDY MN, UNPUB; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; RHIND N, UNPUB; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SARABIA MJF, 1993, MOL GEN GENET, V238, P241, DOI 10.1007/BF00279553; Shiozaki K, 1997, METHOD ENZYMOL, V283, P506; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0	23	287	296	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1998	280	5365					909	912		10.1126/science.280.5365.909	http://dx.doi.org/10.1126/science.280.5365.909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572736				2022-12-24	WOS:000073532900043
J	Nachtigal, MW; Hirokawa, Y; Enyeart-VanHouten, DL; Flanagan, JN; Hammer, GD; Ingraham, HA				Nachtigal, MW; Hirokawa, Y; Enyeart-VanHouten, DL; Flanagan, JN; Hammer, GD; Ingraham, HA			Wilms' tumor 1 and DAX-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression	CELL			English	Article							VENTROMEDIAL HYPOTHALAMIC NUCLEUS; ADRENAL HYPOPLASIA CONGENITA; AFFINITY DNA-BINDING; TRANSCRIPTION FACTOR; SUBNUCLEAR LOCALIZATION; STEROIDOGENIC FACTOR-1; WT1; MUTATIONS; PROTEIN; MICE	Products of steroidogenic factor 1 (SF-1) and Wilms' tumor 1 (WT1) genes are essential for mammalian gonadogenesis prior to sexual differentiation. In males, SF-1 participates in sexual development by regulating expression of the polypeptide hormone Mullerian inhibiting substance (MIS). Here, we show that WT1 -KTS isoforms associate and synergize with SF-1 to promote MIS expression. In contrast, WT1 missense mutations, associated with male pseudohermaphroditism in Denys-Drash syndrome, fail to synergize with SF-1. Additionally, the X-linked, candidate dosage-sensitive sex-reversal gene, Dax-1, antagonizes synergy between SF-1 and WT1, most likely through a direct interaction with SF-1. We propose that WT1 and Dax-1 functionally oppose each other in testis development by modulating SF-1-mediated transactivation.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ingraham, HA (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.		Flanagan, John/AAG-4857-2019	Flanagan, John/0000-0001-6957-756X; Nachtigal, Mark/0000-0003-3291-8628				Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Giuili G, 1997, DEVELOPMENT, V124, P1799; Guo WW, 1996, GENE, V178, P31, DOI 10.1016/0378-1119(96)00320-4; HATANO O, 1994, DEVELOPMENT, V120, P2787; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Kent J, 1996, DEVELOPMENT, V122, P2813; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Lalli E, 1997, MOL ENDOCRINOL, V11, P1950, DOI 10.1210/me.11.13.1950; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MOFFETT P, 1995, P NATL ACAD SCI USA, V92, P11105, DOI 10.1073/pnas.92.24.11105; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SHINODA K, 1995, DEV DYNAM, V204, P22, DOI 10.1002/aja.1002040104; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; Swain A, 1998, NATURE, V391, P761, DOI 10.1038/35799; Tamai KT, 1996, MOL ENDOCRINOL, V10, P1561, DOI 10.1210/me.10.12.1561; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899; ZHANG P, 1996, MOL ENDOCRINOL, V6, P1249	43	460	475	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 1	1998	93	3					445	454		10.1016/S0092-8674(00)81172-1	http://dx.doi.org/10.1016/S0092-8674(00)81172-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590178	Bronze			2022-12-24	WOS:000073471500019
J	Philips, AV; Timchenko, LT; Cooper, TA				Philips, AV; Timchenko, LT; Cooper, TA			Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy	SCIENCE			English	Article							CARDIAC TROPONIN-T; SKELETAL-MUSCLE; HYPERTROPHIC CARDIOMYOPATHY; ALPHA-TROPOMYOSIN; REPEAT EXPANSION; EXPRESSION; MUTATIONS; ISOFORMS; LENGTH; CELLS	Myotonic dystrophy (DM) is caused by a CTG expansion in the 3' untranslated region of the DM gene. One model of DM pathogenesis suggests that RNAs from the expanded allele create a gain-of-function mutation by the inappropriate binding of proteins to the CUG repeats. Data presented here indicate that the conserved heterogeneous nuclear ribonucleoprotein, CUG-binding protein (CUG-BP), may mediate the trans-dominant effect of the RNA. CUG-BP was found to bind to the human cardiac troponin T (cTNT) pre-messenger RNA and regulate its alternative splicing. Splicing of cTNT was disrupted in DM striated muscle and in normal cells expressing transcripts that contain CUG repeats. Altered expression of genes regulated posttranscriptionally by CUG-BP therefore may contribute to DM pathogenesis.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Cooper, TA (corresponding author), Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.	tcooper@bcm.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045565, R29HL045565] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45565] Funding Source: Medline; NIAMS NIH HHS [AR 44387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON PAW, 1991, CIRC RES, V69, P1226, DOI 10.1161/01.RES.69.5.1226; Bertrand E, 1997, RNA, V3, P75; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Caskey CT, 1996, COLD SPRING HARB SYM, V61, P607; COOPER TA, 1992, J BIOL CHEM, V267, P5330; COOPER TA, 1985, J BIOL CHEM, V260, P1140; COOPER TA, 1984, SCIENCE, V226, P979, DOI 10.1126/science.6095446; COOPER TM, UNPUB; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDOM F, 1994, DEV BIOL, V164, P219, DOI 10.1006/dbio.1994.1193; Hamshere MG, 1997, P NATL ACAD SCI USA, V94, P7394, DOI 10.1073/pnas.94.14.7394; Harper P.S., 1989, MYOTONIC DYSTROPHY; HUNTER A, 1992, J MED GENET, V29, P774, DOI 10.1136/jmg.29.11.774; Korade-Mirnics Z, 1998, NUCLEIC ACIDS RES, V26, P1363, DOI 10.1093/nar/26.6.1363; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; Phillips MF, 1997, CARDIOVASC RES, V33, P13, DOI 10.1016/S0008-6363(96)00163-0; REDMAN JB, 1993, JAMA-J AM MED ASSOC, V269, P1960, DOI 10.1001/jama.269.15.1960; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; Roeder E., 1994, American Journal of Human Genetics, V55, pA7; Ryan KJ, 1996, MOL CELL BIOL, V16, P4014; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; Timchenko LT, 1996, HUM MOL GENET, V5, P115, DOI 10.1093/hmg/5.1.115; TOKGOZOGLU LS, 1995, JAMA-J AM MED ASSOC, V274, P813, DOI 10.1001/jama.274.10.813; TOWNSEND PJ, 1995, J MOL CELL CARDIOL, V27, P2223, DOI 10.1016/S0022-2828(95)91587-7; TOYOTA N, 1983, MUSCULAR DYSTROPHY B, P89; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; WANG JZ, 1995, HUM MOL GENET, V4, P599, DOI 10.1093/hmg/4.4.599; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334	33	639	657	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					737	741		10.1126/science.280.5364.737	http://dx.doi.org/10.1126/science.280.5364.737			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563950				2022-12-24	WOS:000073415600048
J	Rao, JH; Lahiri, J; Isaacs, L; Weis, RM; Whitesides, GM				Rao, JH; Lahiri, J; Isaacs, L; Weis, RM; Whitesides, GM			A trivalent system from vancomycin center dot D-Ala-D-Ala with higher affinity than avidin center dot biotin	SCIENCE			English	Article							STRONGLY INHIBIT AGGLUTINATION; INFLUENZA-VIRUS; BINDING; ANTIBIOTICS; ERYTHROCYTES; RECOGNITION; COMPLEXES; PEPTIDES; DIMERS	Tris(vancomycin carboxamide) binds a trivalent ligand derived from D-Ala-D-Ala with very high affinity: dissociation constant (K-d) approximate to 4 x 10(-17) +/- 1 x 10(-17) M. High-affinity trivalent binding and monovalent binding are fundamentally different. In trivalent (and more generally, polyvalent) binding, dissociation occurs in stages, and its rate can be accelerated by monovalent ligand at sufficiently high concentrations. In monovalent binding, dissociation is determined solely by the rate constant for dissociation and cannot be accelerated by added monomer. Calorimetric measurements for the trivalent system indicate an approximately additive gain in enthalpy relative to the corresponding monomers. This system is one of the most stable organic receptor-ligand pairs involving small molecules that is known. It illustrates the practicality of designing very high-affinity systems based on polyvalency.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	Harvard University; University of Massachusetts System; University of Massachusetts Amherst	Whitesides, GM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.	gwhitesides@gmwgroup.harvard.edu	Isaacs, Lyle D/B-4472-2009	Isaacs, Lyle D/0000-0002-4079-332X	NIGMS NIH HHS [GM 53210, GM 30367, GM 51559] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030367, R01GM051559, R37GM030367] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Breslow R, 1996, J AM CHEM SOC, V118, P8495, DOI 10.1021/ja961567b; COOPER A, 1993, PHILOS T R SOC A, V345, P23, DOI 10.1098/rsta.1993.0114; DEFREES SA, 1995, J AM CHEM SOC, V117, P66, DOI 10.1021/ja00106a008; GERHARD U, 1993, J AM CHEM SOC, V115, P232, DOI 10.1021/ja00054a033; GREEN NM, 1963, BIOCHEM J, V89, P585, DOI 10.1042/bj0890585; GROVES P, 1995, J AM CHEM SOC, V117, P7958, DOI 10.1021/ja00135a014; HARRIS CM, 1982, J AM CHEM SOC, V104, P4293, DOI 10.1021/ja00379a062; HORNICK CL, 1972, IMMUNOCHEMISTRY, V9, P325, DOI 10.1016/0019-2791(72)90096-1; LEE YC, 1995, ACCOUNTS CHEM RES, V28, P321, DOI 10.1021/ar00056a001; Loll PJ, 1997, J AM CHEM SOC, V119, P1516, DOI 10.1021/ja963566p; MATROSOVICH MN, 1989, FEBS LETT, V252, P1, DOI 10.1016/0014-5793(89)80879-8; NIETO M, 1971, BIOCHEM J, V123, P773, DOI 10.1042/bj1230773; POPIENIEK PH, 1991, J AM CHEM SOC, V113, P2264, DOI 10.1021/ja00006a053; Rao JH, 1997, J AM CHEM SOC, V119, P10286, DOI 10.1021/ja971225l; ROY R, 1988, J CHEM SOC CHEM COMM, P1058, DOI 10.1039/c39880001058; Schafer M, 1996, STRUCTURE, V4, P1509, DOI 10.1016/S0969-2126(96)00156-6; Sigal GB, 1996, J AM CHEM SOC, V118, P3789, DOI 10.1021/ja953729u; SPALTENSTEIN A, 1991, J AM CHEM SOC, V113, P686, DOI 10.1021/ja00002a053; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; SUNDRAM UN, 1995, J ORG CHEM, V60, P1102, DOI 10.1021/jo00110a004; Sundram UN, 1996, J AM CHEM SOC, V118, P13107, DOI 10.1021/ja9621298; WILLIAMS DH, 1984, ACCOUNTS CHEM RES, V17, P364, DOI 10.1021/ar00106a004; WILLIAMSON MP, 1984, TETRAHEDRON, V40, P569, DOI 10.1016/0040-4020(84)85062-0; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	24	266	282	3	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					708	711		10.1126/science.280.5364.708	http://dx.doi.org/10.1126/science.280.5364.708			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563940				2022-12-24	WOS:000073415600038
J	Yao, TP; Oh, SP; Fuchs, M; Zhou, ND; Ch'ng, LE; Newsome, D; Bronson, RT; Li, E; Livingston, DM; Eckner, R				Yao, TP; Oh, SP; Fuchs, M; Zhou, ND; Ch'ng, LE; Newsome, D; Bronson, RT; Li, E; Livingston, DM; Eckner, R			Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300	CELL			English	Article							CREB-BINDING-PROTEIN; COACTIVATOR CBP; BHLH PROTEINS; NEURAL-TUBE; COMPLEX; ACETYLTRANSFERASE; SUPPRESSOR; ACTIVATION; EXPRESSION; LETHALITY	The transcriptional coactivator and integrator p300 and its closely related family member CBP mediate multiple, signal-dependent transcriptional events. We have generated mice lacking a functional p300 gene. Animals nullizygous for p300 died between days 9 and 11.5 of gestation, exhibiting defects in neurulation, cell proliferation, and heart development. Cells derived from p300-deficient embryos displayed specific transcriptional defects and proliferated poorly. Surprisingly, p300 heterozygotes also manifested considerable embryonic lethality. Moreover, double heterozygosity for p300 and cbp was invariably associated with embryonic death. Thus, mouse development is exquisitely sensitive to the overall gene dosage of p300 and cbp. Our results provide genetic evidence that a coactivator endowed with histone acetyltransferase activity is essential for mammalian cell proliferation and development.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Vet Med, Boston, MA 02111 USA; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Tufts University; Tufts University; University of Zurich	Livingston, DM (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.							Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NEVINS JR, 1992, SCIENCE, V258, P424; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parker D, 1996, MOL CELL BIOL, V16, P694; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VANTAGGIATI ML, 1997, CELL, V89, P1175; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WHITE P, 1989, CELL, V56, P67; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	55	787	814	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 1	1998	93	3					361	372		10.1016/S0092-8674(00)81165-4	http://dx.doi.org/10.1016/S0092-8674(00)81165-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590171	Bronze			2022-12-24	WOS:000073471500012
J	Femino, A; Fay, FS; Fogarty, K; Singer, RH				Femino, A; Fay, FS; Fogarty, K; Singer, RH			Visualization of single RNA transcripts in situ	SCIENCE			English	Article							ACTIN GENE-TRANSCRIPTION; HUMAN-COMPLEMENT GENES; INSITU HYBRIDIZATION; MESSENGER-RNA; GROWTH-FACTOR; C-MYC; CELLS; MICROFILAMENTS; LOCALIZATION; FLUORESCENCE	Fluorescence in situ hybridization (FISH) and digital imaging microscopy were modified to allow detection of single RNA molecules. Oligodeoxynucleotide probes were synthesized with five fluorochromes per molecule, and the light emitted by a single probe was calibrated. Points of light in exhaustively deconvolved images of hybridized cells gave fluorescent intensities and distances between probes consistent with single messenger RNA molecules. Analysis of beta-actin transcription sites after serum induction revealed synchronous and cyclical transcription from single genes. The rates of transcription initiation and termination and messenger RNA processing could be determined by positioning probes along the transcription unit. This approach extends the power of FISH to yield quantitative molecular information on a single cell.	Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Univ Massachusetts, Sch Med, Biomed Engn Facil, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	Yeshiva University; Albert Einstein College of Medicine; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Singer, RH (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA.				NIGMS NIH HHS [GM 54887] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; ASHFIELD R, 1991, EMBO J, V10, P4197, DOI 10.1002/j.1460-2075.1991.tb04998.x; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; DIRKS RW, 1995, J CELL SCI, V108, P2565; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; Fay F S, 1986, Soc Gen Physiol Ser, V40, P51; FAY FS, 1989, J MICROSC-OXFORD, V153, P133, DOI 10.1111/j.1365-2818.1989.tb00554.x; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; LAWRENCE JB, 1985, NUCLEIC ACIDS RES, V13, P1777; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; OSHEIM YN, 1985, CELL, V43, P143, DOI 10.1016/0092-8674(85)90019-4; SCHWARTZ RJ, 1981, BIOCHEMISTRY-US, V20, P412; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TANEJA KL, 1990, J CELL BIOCHEM, V44, P241, DOI 10.1002/jcb.240440406; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; THUMMEL CS, 1992, SCIENCE, V255, P39, DOI 10.1126/science.1553530; Xing YG, 1995, J CELL BIOL, V131, P1635, DOI 10.1083/jcb.131.6.1635; ZHANG GH, 1994, NATURE, V372, P809	24	896	950	10	146	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					585	590		10.1126/science.280.5363.585	http://dx.doi.org/10.1126/science.280.5363.585			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554849				2022-12-24	WOS:000073242100046
J	Nimmo, ER; Pidoux, AL; Perry, PE; Allshire, RC				Nimmo, ER; Pidoux, AL; Perry, PE; Allshire, RC			Defective meiosis in telomere-silencing mutants of Schizosaccharomyces pombe	NATURE			English	Article							POSITION-EFFECT VARIEGATION; FISSION YEAST CENTROMERES; CHROMOSOME MOVEMENT; MEIOTIC PROPHASE; EXPRESSION; MUTATIONS; DISRUPT; GENOME; GENE	During meiotic prophase, chromosomes frequently adopt a bouquet-like arrangement, with their telomeres clustered close to the nuclear periphery(1-3). A dramatic example of this occurs in the fission yeast, Schizosaccharomyces pombe, where all telomeres aggregate adjacent to the spindle pole body (SPB)(4-7). Nuclei then undergo rapid traverses of the cell, known as 'horsetail' movement, which is led by the SPB dragging telomeres and chromosomes behind(4,6,7). This process may initiate or facilitate chromosome pairing before recombination and meiosis. With the aim of identifying components involved in telomere structure and function, we report here the isolation of S. pombe mutants defective in the ability to impose transcriptional silencing on genes placed near telomeres(8). Two of these mutants, lot2-s17 and lot3-uv3, also display a dramatic lengthening of telomeric repeats. lot3-uv3 carries a mutation in Tazl (ref. 9), a telomere-binding protein containing a Myb-like moth similar to two human telomere-binding proteins(10,11). Meiosis is aberrant in these mutant yeast strains, and our analysis demonstrates a decreased association of telomeres with the SPB in meiotic prophase, This results in defective 'horsetail' movement, a significant reduction in recombination, low spore viability and chromosome missegregation through meiosis.	Univ Edinburgh, Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Western Gen Hosp, Canc Res Campaign Project, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Allshire, RC (corresponding author), Univ Edinburgh, Western Gen Hosp, MRC, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	robin.allshire@hgu.mrc.ac.uk		Allshire, Robin/0000-0002-8005-3625				ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bass HW, 1997, J CELL BIOL, V137, P5, DOI 10.1083/jcb.137.1.5; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Chikashige Y, 1997, EMBO J, V16, P193, DOI 10.1093/emboj/16.1.193; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; DERNBURG AF, 1995, TELOMERES, P295; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; Ekwall K, 1996, J CELL SCI, V109, P2637; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; HELM R, 1995, NATURE, V373, P663; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KOHLI J, 1994, CURR BIOL, V4, P724, DOI 10.1016/S0960-9822(00)00160-3; Lamb NE, 1997, HUM MOL GENET, V6, P1391, DOI 10.1093/hmg/6.9.1391; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MOLNAR M, 1995, GENETICS, V141, P61; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MUNZ P, 1994, GENETICS, V137, P701; NIMMO ER, 1994, EMBO J, V13, P3801, DOI 10.1002/j.1460-2075.1994.tb06691.x; NIWA O, 1985, CURR GENET, V9, P463, DOI 10.1007/BF00434051; PARVINEN M, 1976, NATURE, V260, P534, DOI 10.1038/260534a0; SCHERTHAN H, 1994, J CELL BIOL, V127, P273, DOI 10.1083/jcb.127.2.273; Scherthan H, 1996, J CELL BIOL, V134, P1109, DOI 10.1083/jcb.134.5.1109; Shimanuki M, 1997, MOL GEN GENET, V254, P238, DOI 10.1007/s004380050412; SVOBODA A, 1995, CHROMOSOMA, V104, P203, DOI 10.1007/s004120050109; THON G, 1992, GENETICS, V131, P287	30	218	221	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1998	392	6678					825	828		10.1038/33941	http://dx.doi.org/10.1038/33941			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572142				2022-12-24	WOS:000073241200056
J	Sorensen, HT; Mellemkjaer, L; Steffensen, FH; Olsen, JH; Nielsen, GL				Sorensen, HT; Mellemkjaer, L; Steffensen, FH; Olsen, JH; Nielsen, GL			The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Several small studies have indicated an association between deep venous thrombosis or pulmonary embolism and a subsequent diagnosis of cancer, but the subject is controversial. Methods We conducted a nationwide study of a cohort of patients with deep venous thrombosis or pulmonary embolism that was drawn from the Danish National Registry of Patients for the years 1977 th rough 1992. The occurrence of cancer in the cohort was determined by linkage to the Danish Cancer Registry. The expected number of cancer cases was estimated on the basis of national age-, sex-, and site-specific incidence rates. Results A total of 15,348 patients with deep venous thrombosis and 11,305 patients with pulmonary embolism were identified. We observed 1737 cases of cancer in the cohort with deep venous thrombosis, as compared with 1372 expected cases (standardized incidence ratio, 1.3; 95 percent confidence interval, 1.21 to 1.33). Among the patients with pulmonary embolism, the standardized incidence ratio was 1.3, with a 95 percent confidence interval of 1.22 to 1.41. The risk was substantially elevated only during the first six months of follow-up and declined rapidly thereafter to a constant level slightly above 1.0 one year after the thrombotic event. Forty percent of the patients given a diagnosis of cancer within one year after hospitalization for thromboembolism had distant metastases at the time of the diagnosis of cancer. There were strong associations with several cancers, most pronounced for those of the pancreas, ovary, liver (primary hepatic cancer), and brain. Conclusions An aggressive search for a hidden cancer in a patient with a primary deep venous thrombosis or pulmonary embolism is not warranted. (C)1998, Massachusetts Medical Society.	Aarhus Univ, Danish Epidemiol Sci Ctr, Dept Epidemiol & Social Med, DK-8000 Aarhus, Denmark; Aarhus Univ, Dept Internal Med, DK-8000 Aarhus, Denmark; Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark; Aalborg Hosp, Dept Internal Med M, Aalborg, Denmark	Aarhus University; Aarhus University; Danish Cancer Society; Aalborg University; Aalborg University Hospital	Sorensen, HT (corresponding author), Aarhus Univ, Danish Epidemiol Sci Ctr, Dept Epidemiol & Social Med, Hoegh Guldbergs Gade 10, DK-8000 Aarhus, Denmark.		Sorensen, Henrik Toft/Z-6181-2019; Steffensen, Flemming Hald/AAH-8742-2020	Sorensen, Henrik Toft/0000-0003-4299-7040; Steffensen, Flemming Hald/0000-0003-0252-6631; Olsen, Jorgen Helge/0000-0001-9633-5662				Cornuz J, 1996, ANN INTERN MED, V125, P785, DOI 10.7326/0003-4819-125-10-199611150-00001; GOLDBERG RJ, 1987, ARCH INTERN MED, V147, P251, DOI 10.1001/archinte.147.2.251; GRIFFIN MR, 1987, ARCH INTERN MED, V147, P1907, DOI 10.1001/archinte.147.11.1907; LEVINE M, 1990, SEMIN ONCOL, V17, P160; MONREAL M, 1991, CANCER, V67, P541, DOI 10.1002/1097-0142(19910115)67:2<541::AID-CNCR2820670237>3.0.CO;2-J; Naschitz JE, 1996, CANCER-AM CANCER SOC, V77, P1759; NORDSTROM M, 1994, BRIT MED J, V308, P891, DOI 10.1136/bmj.308.6933.891; OCONNOR NTJ, 1984, POSTGRAD MED J, V60, P275, DOI 10.1136/pgmj.60.702.275; Piccioli A, 1996, AM HEART J, V132, P850, DOI 10.1016/S0002-8703(96)90321-X; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; PRINS MH, 1994, ARCH INTERN MED, V154, P1310, DOI 10.1001/archinte.154.12.1310; ROTHMAN KJ, 1979, DHHS PUBLICATION; Sorensen H T, 1997, Int J Risk Saf Med, V10, P1, DOI 10.3233/JRS-1997-10101; Storm HH, 1997, DAN MED BULL, V44, P535; STORM HH, 1996, CANC INCIDENCE DENMA; *SUNDH, 1981, AKT SYG 1979; *SUNDH, 1976, KLASS SYGD; Trousseau A., 1872, LECT CLIN MED DELIVE, P281	18	471	491	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1998	338	17					1169	1173		10.1056/NEJM199804233381701	http://dx.doi.org/10.1056/NEJM199804233381701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ376	9554856				2022-12-24	WOS:000073208400001
J	Wolters-Arts, M; Lush, WM; Mariani, C				Wolters-Arts, M; Lush, WM; Mariani, C			Lipids are required for directional pollen-tube growth	NATURE			English	Article							DRY STIGMAS; ARABIDOPSIS; POLLINATION; PLANTS; COMPONENTS; NICOTIANA; RESPONSES; GRADIENTS; BRASSICA; FIELDS	Successful pollination and fertilization are absolute requirements for sexual reproduction in higher plants. Pollen hydration, germination and penetration of the stigma by pollen tubes are influenced by the exudate on wet stigmas(1) and by the pollen coat in species with dry stigmas(2-5). The exudate allows pollen tubes to grow directly into the stigma, whereas the pollen coat establishes the contact with the stigma. Pollen tubes then grow into the papillae, which are covered by a cuticle. The components of the exudate or pollen coat that are responsible for pollen tube penetration are not known. To discover the role of the exudate, we tested selected compounds for their ability to act as functional substitutes for exudate in the initial stages of pollen-tube growth on transgenic stigmaless tobacco plants' that did not produce exudate. Here we show that lipids are the essential factor needed for pollen tubes to penetrate the stigma, and that, in the presence of these lipids, pollen tubes will also penetrate leaves. We propose that lipids direct pollen-tube growth by controlling the flow of water to pollen in species with dry and wet stigmas.	Catholic Univ Nijmegen, Dept Expt Bot, Grad Sch Expt Plant Sci, NL-6525 ED Nijmegen, Netherlands; Univ Melbourne, Sch Bot, Plant Cell Biol Res Ctr, Parkville, Vic 3052, Australia	Radboud University Nijmegen; University of Melbourne	Wolters-Arts, M (corresponding author), Catholic Univ Nijmegen, Dept Expt Bot, Grad Sch Expt Plant Sci, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	mwolters@sci.kun.nl	Mariani, Celestina/C-6920-2013					BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; Boden N., 1994, MICELLES MEMBRANES M, P153; Cheung AY, 1996, P NATL ACAD SCI USA, V93, P3853, DOI 10.1073/pnas.93.9.3853; CRESTI M, 1986, AM J BOT, V73, P1713, DOI 10.2307/2444237; DICKINSON H, 1995, SEX PLANT REPROD, V8, P1, DOI 10.1007/BF00228756; DICKINSON H, 1993, NATURE, V364, P573, DOI 10.1038/364573a0; DICKINSON H, 1994, NATURE, V367, P517, DOI 10.1038/367517a0; DUMAS C, 1977, PLANTA, V137, P177, DOI 10.1007/BF00387556; Elleman CJ, 1996, NEW PHYTOL, V133, P197, DOI 10.1111/j.1469-8137.1996.tb01886.x; ELLEMAN CJ, 1992, NEW PHYTOL, V121, P413, DOI 10.1111/j.1469-8137.1992.tb02941.x; EVANS DE, 1990, PLANT PHYSIOL, V92, P418; GOLDMAN MHS, 1994, EMBO J, V13, P2976, DOI 10.1002/j.1460-2075.1994.tb06596.x; HULSKAMP M, 1995, PLANT J, V8, P703, DOI 10.1046/j.1365-313X.1995.08050703.x; HYDE GJ, 1995, EUR J CELL BIOL, V67, P356; Ikeda S, 1997, SCIENCE, V276, P1564, DOI 10.1126/science.276.5318.1564; KANDASAMY MK, 1994, DEVELOPMENT, V120, P3405; KONAR RN, 1966, PLANTA, V71, P378; LABARCA C, 1970, PLANT PHYSIOL, V46, P150, DOI 10.1104/pp.46.1.150; LOLLE SJ, 1993, DEV BIOL, V155, P250, DOI 10.1006/dbio.1993.1022; Lolle SJ, 1997, DEV BIOL, V189, P311, DOI 10.1006/dbio.1997.8671; MALHO R, 1992, SEX PLANT REPROD, V5, P57, DOI 10.1007/BF00714558; MARET G, 1985, TOP APPL PHYS, V57, P143; MARIANI C, 1990, NATURE, V347, P737, DOI 10.1038/347737a0; Piffanelli P, 1997, PLANT J, V11, P549, DOI 10.1046/j.1365-313X.1997.11030549.x; PREUSS D, 1993, GENE DEV, V7, P974, DOI 10.1101/gad.7.6.974; Pruitt RE, 1997, TRENDS PLANT SCI, V2, P328, DOI 10.1016/S1360-1385(97)84615-8; REGER BJ, 1992, SEX PLANT REPROD, V5, P47, DOI 10.1007/BF00714557; ROBBERTSE PJ, 1990, S AFR J BOT, V56, P487, DOI 10.1016/S0254-6299(16)31046-8; Taylor LP, 1997, ANNU REV PLANT PHYS, V48, P461, DOI 10.1146/annurev.arplant.48.1.461; WoltersArts M, 1996, SEX PLANT REPROD, V9, P243, DOI 10.1007/BF02152698	30	278	289	2	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1998	392	6678					818	821		10.1038/33929	http://dx.doi.org/10.1038/33929			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572141				2022-12-24	WOS:000073241200054
J	Eccles, M; Freemantle, N; Mason, J				Eccles, M; Freemantle, N; Mason, J			North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; METAANALYSIS		Univ Newcastle Upon Tyne, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Univ York, Ctr Hlth Econ, York YP1 5DD, N Yorkshire, England	Newcastle University - UK; University of York - UK	Eccles, M (corresponding author), Univ Newcastle Upon Tyne, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.	Martin.Eccles@nd.ac.uk	Mason, James M/D-9904-2011; Eccles, Martin P/AAD-4029-2020	Mason, James M/0000-0001-9210-4082; Freemantle, Nick/0000-0001-5807-5740				Adams P, 1996, BMJ-BRIT MED J, V312, P827; Anderson J, 1996, BMJ-BRIT MED J, V312, P762; [Anonymous], 1994, EFF HLTH CAR B; Cook T.C., 1979, QUASIEXPERIMENTATION; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Eccles M, 1996, QUAL HEALTH CARE, V5, P44, DOI 10.1136/qshc.5.1.44; Eccles M, 1996, BMJ-BRIT MED J, V312, P760; ECCLES M, IN PRESS BMJ; Field MJ., 1992, GUIDELINES CLIN PRAC; Freemantle N, 1997, ANN INTERN MED, V126, P81, DOI 10.7326/0003-4819-126-1-199701010-00011; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GRIMSHAW JM, 1994, QUAL HEALTH CARE, V3, P552; Hedges L.V., 1985, STAT METHODS META AN; HEDGES LV, 1992, J EDUC STAT, V17, P279, DOI 10.2307/1165125; IOANNIDIS JPA, 1995, ANN INTERN MED, V122, P856, DOI 10.7326/0003-4819-122-11-199506010-00009; *N ENGL ASTHM GUID, 1997, EV BAS CLIN PRACT GU; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; US Department of Health and Human Services Public Health Services Agency for Health Care Policy and Research, 1992, AC PAIN MAN OP MED P; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	21	88	93	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1232	1235		10.1136/bmj.316.7139.1232	http://dx.doi.org/10.1136/bmj.316.7139.1232			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9553004	Green Published			2022-12-24	WOS:000073224100032
J	Feneley, MR				Feneley, MR			Electrovaporisation of the prostate	LANCET			English	Editorial Material							HYPERPLASIA		Royal Hosp NHS Trust, Dept Urol, London, England	University of London; Queen Mary University London	Feneley, MR (corresponding author), Royal Hosp NHS Trust, Dept Urol, London, England.							Cetinkaya M, 1996, BRIT J UROL, V78, P901, DOI 10.1046/j.1464-410X.1996.23616.x; Chen SS, 1997, UROLOGY, V50, P235, DOI 10.1016/S0090-4295(97)00214-8; Kaplan SA, 1996, UROLOGY, V48, P876, DOI 10.1016/S0090-4295(96)00487-6; Lim LM, 1997, UROLOGY, V49, P851, DOI 10.1016/S0090-4295(97)00092-7; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; NARAYAN P, 1995, J UROLOGY, V154, P2083, DOI 10.1016/S0022-5347(01)66701-6; Schatzl G, 1997, J UROLOGY, V158, P105, DOI 10.1097/00005392-199707000-00029; Shokeir AA, 1997, BRIT J UROL, V80, P570, DOI 10.1046/j.1464-410X.1997.00428.x; TE AE, 1997, CURR OPIN UROL, V7, P25; Tewari A, 1996, BRIT J UROL, V78, P667, DOI 10.1046/j.1464-410X.1996.01771.x; Thomas KJ, 1997, BRIT J UROL, V79, P186, DOI 10.1046/j.1464-410X.1997.03098.x; WASSON JH, 1995, NEW ENGL J MED, V332, P75, DOI 10.1056/NEJM199501123320202	12	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					999	1001		10.1016/S0140-6736(05)78989-3	http://dx.doi.org/10.1016/S0140-6736(05)78989-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546499				2022-12-24	WOS:000072927200003
J	Rosendorff, C				Rosendorff, C			Statins for prevention of stroke	LANCET			English	Editorial Material							DISEASE		CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Rosendorff, C (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.							Bucher HC, 1998, ANN INTERN MED, V128, P89, DOI 10.7326/0003-4819-128-2-199801150-00002; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001	7	11	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 4	1998	351	9108					1002	1003		10.1016/S0140-6736(05)78991-1	http://dx.doi.org/10.1016/S0140-6736(05)78991-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546501				2022-12-24	WOS:000072927200005
J	Zheng, WJ; Johnston, SA; Joshua-Tor, L				Zheng, WJ; Johnston, SA; Joshua-Tor, L			The unusual active site of Gal6/bleomycin hydrolase can act as a carboxypeptidase, aminopeptidase, and peptide ligase	CELL			English	Article							BINDING CYSTEINE PROTEASE; HUMAN BLEOMYCIN HYDROLASE; 20S PROTEASOME; CRYSTAL-STRUCTURE; CLONING; PROTEINASE; DNA; EXPRESSION; RESOLUTION; PROGRAM	The Gal6 protease is in a class of cysteine peptidases identified by their ability to inactivate the anti-cancer drug bleomycin. The protein forms a barrel structure with the active sites embedded in a channel as in the proteasome. In Gal6 the C termini lie in the active site clefts. We show that Gal6 acts as a carboxypeptidase on its C terminus to convert itself to an aminopeptidase and peptide ligase. The substrate specificity of the peptidase activity is determined by the position of the C terminus of Gal6 rather than the sequence of the substrate. We propose a model to explain these diverse activities and Gal6's singular ability to inactivate bleomycin.	Cold Spring Harbor Lab, WM Keck Struct Biol Lab, Cold Spring Harbor, NY 11724 USA; Univ Texas, SW Med Ctr, Dept Med, Ctr Biomed Invent, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Cold Spring Harbor Laboratory; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Joshua-Tor, L (corresponding author), Cold Spring Harbor Lab, WM Keck Struct Biol Lab, POB 100, Cold Spring Harbor, NY 11724 USA.			Joshua-Tor, Leemor/0000-0001-8185-8049	NATIONAL CANCER INSTITUTE [R01CA067982, R01CA071746] Funding Source: NIH RePORTER; NCI NIH HHS [CA67982, R01-CA71746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi H, 1997, EUR J BIOCHEM, V245, P283, DOI 10.1111/j.1432-1033.1997.t01-1-00283.x; AKIYAMA S, 1981, BIOCHEM BIOPH RES CO, V101, P55, DOI 10.1016/S0006-291X(81)80009-5; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bromme D, 1996, BIOCHEMISTRY-US, V35, P6706, DOI 10.1021/bi960092y; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHAPOTCHARTIER MP, 1993, APPL ENVIRON MICROB, V59, P330, DOI 10.1128/AEM.59.1.330-333.1993; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; ENENKEL C, 1993, J BIOL CHEM, V268, P7036; Ferrando AA, 1996, CANCER RES, V56, P1746; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KAMBOURIS NG, 1992, J BIOL CHEM, V267, P21570; Klein JR, 1997, MICROBIOL-SGM, V143, P527, DOI 10.1099/00221287-143-2-527; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAZO JS, 1983, P NATL ACAD SCI-BIOL, V80, P3064, DOI 10.1073/pnas.80.10.3064; Lazo JS, 1996, CANC CHEMOTHERAPY BI; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; MAGDOLEN U, 1993, BIOCHIM BIOPHYS ACTA, V1171, P299, DOI 10.1016/0167-4781(93)90069-P; Mata L, 1997, BIOCHEM J, V328, P343, DOI 10.1042/bj3280343; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; OTWINSOWSKI Z, 1993, DATA COLLECTION PROC; SCHECTER I, 1968, BIOCHEM BIOPH RES CO, V32, P888; SCHRODER E, 1993, FEBS LETT, V315, P38, DOI 10.1016/0014-5793(93)81128-M; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; Takeda A, 1996, J BIOCHEM-TOKYO, V120, P353; TONG L, 1993, J MOL BIOL, V230, P228, DOI 10.1006/jmbi.1993.1139; XU HE, 1994, J BIOL CHEM, V269, P21177; ZHENG W, 1997, IN PRESS MOL CELL BI; Zheng WJ, 1997, J BIOL CHEM, V272, P30350, DOI 10.1074/jbc.272.48.30350	32	45	46	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					103	109		10.1016/S0092-8674(00)81150-2	http://dx.doi.org/10.1016/S0092-8674(00)81150-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546396	Bronze			2022-12-24	WOS:000072910800014
J	Bennett, SRM; Carbone, FR; Karamalis, F; Flavell, RA; Miller, JFAP; Heath, WR				Bennett, SRM; Carbone, FR; Karamalis, F; Flavell, RA; Miller, JFAP; Heath, WR			Help for cytotoxic-T-cell responses is mediated by CD40 signalling	NATURE			English	Article							CD40-CD40 LIGAND INTERACTION; ANTIBODY-RESPONSES; HUMAN MONOCYTES; CD8(+) CTL; MICE; ACTIVATION; INDUCTION; INVIVO; LYMPHOCYTES; REQUIREMENT	Cytotoxic T lymphocytes (CTLs) which carry the CD8 antigen recognize antigens that are presented on target cells by the class I major histocompatibility complex. CTLs are responsible for the killing of antigen-bearing target cells, such as virus-infected cells. Although CTL effecters can act alone when killing target cells, their differentiation from naive CD8-positive T cells is often dependent on 'help' from CD4-positive helper T (T-H) cells(1-4).Furthermore, for effective CTL priming, this help must be provided in a cognate manner, such that both the T-H cell and the CTL recognize antigen on the same antigen-presenting cell(2,4). One explanation for this requirement is that T-H cells are needed to convert the antigen-presenting cell into a cell that is fully competent to prime CTL5. Here we show that signalling through CD40 on the antigen-presenting cells can replace the requirement for T-H cells, indicating that T-cell 'help', at least for generation of CTLs by cross-priming, is mediated by signalling through CD40 on the antigen-presenting cell.	PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia; PO Royal Brisbane Hosp, Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Herston, Qld 4029, Australia; Monash Med Sch, Prahran, Vic 3181, Australia; Yale Univ, Immunol Sect, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Monash University; Yale University; Howard Hughes Medical Institute; Yale University	Carbone, FR (corresponding author), PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia.		Carbone, Francis/ABF-2141-2020	Heath, William/0000-0001-9670-259X				AHMED R, 1988, J VIROL, V62, P2102, DOI 10.1128/JVI.62.6.2102-2106.1988; ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ARMITAGE RJ, 1993, EUR J IMMUNOL, V23, P2326, DOI 10.1002/eji.1830230941; Bennett SRM, 1997, J EXP MED, V186, P65, DOI 10.1084/jem.186.1.65; Borrow P, 1996, J EXP MED, V183, P2129, DOI 10.1084/jem.183.5.2129; BUTLER RM, 1987, NATURE, V328, P77; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; Cardin RD, 1996, J EXP MED, V184, P863, DOI 10.1084/jem.184.3.863; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; Grewal IS, 1996, SCIENCE, V273, P1864, DOI 10.1126/science.273.5283.1864; Grewal IS, 1996, IMMUNOL TODAY, V17, P410, DOI 10.1016/0167-5699(96)10030-X; GUERDER S, 1992, J EXP MED, V176, P553, DOI 10.1084/jem.176.2.553; Guo Y, 1996, J EXP MED, V184, P955, DOI 10.1084/jem.184.3.955; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Ke Y, 1996, J IMMUNOL, V156, P916; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; KIENER PA, 1995, J IMMUNOL, V155, P4917; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; ROY M, 1993, J IMMUNOL, V151, P2497; Sad S, 1997, EUR J IMMUNOL, V27, P914, DOI 10.1002/eji.1830270417; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Shinde S, 1996, J IMMUNOL, V157, P2764; SHU U, 1995, EUR J IMMUNOL, V25, P1125, DOI 10.1002/eji.1830250442; Stout RD, 1996, IMMUNOL TODAY, V17, P487, DOI 10.1016/0167-5699(96)10060-I; vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996; WAGNER DH, 1994, EUR J IMMUNOL, V24, P3148, DOI 10.1002/eji.1830241235; Whitmire JK, 1996, J VIROL, V70, P8375, DOI 10.1128/JVI.70.12.8375-8381.1996; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; Yang YP, 1996, J VIROL, V70, P6370, DOI 10.1128/JVI.70.9.6370-6377.1996; Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862	30	1701	1783	0	51	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					478	480		10.1038/30996	http://dx.doi.org/10.1038/30996			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624004				2022-12-24	WOS:000074020000047
J	Tsujii, M; Kawano, S; Tsuji, S; Sawaoka, H; Hori, M; DuBois, RN				Tsujii, M; Kawano, S; Tsuji, S; Sawaoka, H; Hori, M; DuBois, RN			Cyclooxygenase regulates angiogenesis induced by colon cancer cells	CELL			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1; MICROVASCULAR ENDOTHELIAL-CELLS; GROWTH-FACTOR; EXPRESSION; DIFFERENTIATION; MODULATION; MIGRATION; MATRIX; MODEL	To explore the role of cyclooxygenase (COX) in endothelial cell migration and angiogenesis, we have used two in vitro model systems involving coculture of endothelial cells with colon carcinoma cells. COX-2-overexpressing cells produce prostaglandins, proangiogenic factors, and stimulate both endothelial migration and tube formation, while control cells have little activity. The effect is inhibited by antibodies to combinations of angiogenic factors, by NS-398 (a selective COX-2 inhibitor), and by aspirin. NS-398 does not inhibit production of angiogenic factors or angiogenesis induced by COX-2-negative cells. Treatment of endothelial cells with aspirin or a COX-1 antisense oligonucleotide inhibits COX-1 activity/expression and suppresses tube formation. Cyclooxygenase regulates colon carcinoma-induced angiogenesis by two mechanisms: COX-2 can modulate production of angiogenic factors by colon cancer cells, while COX-1 regulates angiogenesis in endothelial cells.	Vanderbilt Univ, Med Ctr, Dept Med, VA Med Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Osaka Univ, Sch Med, Dept Med 1, Osaka 5650871, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Osaka University	Tsujii, M (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, VA Med Ctr, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047297, R37DK047297] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47297] Funding Source: Medline; NCEH CDC HHS [NIEHS-00267] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCEH CDC HHS		ABE T, 1993, J CLIN INVEST, V92, P54, DOI 10.1172/JCI116599; BRANNON TS, 1994, J CLIN INVEST, V93, P2230, DOI 10.1172/JCI117220; Breyer MD, 1996, J AM SOC NEPHROL, V7, P8; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; DuBois RN, 1996, CANCER RES, V56, P733; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; GIARDIELLO FM, 1995, EUR J CANCER, V31A, P1071, DOI 10.1016/0959-8049(95)00137-8; HOFF T, 1993, FEBS LETT, V320, P38, DOI 10.1016/0014-5793(93)81653-H; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Kawamori T, 1998, CANCER RES, V58, P409; Koolwijk P, 1996, J CELL BIOL, V132, P1177, DOI 10.1083/jcb.132.6.1177; MASUDA E, 1992, AM J PHYSIOL, V262, pG785, DOI 10.1152/ajpgi.1992.262.5.G785; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; Narko K, 1997, J BIOL CHEM, V272, P21455, DOI 10.1074/jbc.272.34.21455; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Papapetropoulos A, 1997, AM J PATHOL, V150, P1835; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; Seed MP, 1997, CANCER RES, V57, P1625; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Shiff SJ, 1997, GASTROENTEROLOGY, V113, P1992, DOI 10.1016/S0016-5085(97)99999-6; SKOBE M, 1997, NAT MED, V3, P122; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006/bbrc.1993.1483; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Ueda N, 1997, BBA-LIPID LIPID MET, V1344, P103, DOI 10.1016/S0005-2760(96)00131-2; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WILLIAMS CS, 1997, J CLIN INVEST, V100, P1; Yamazaki K, 1996, IN VIVO, V10, P459; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731	35	2030	2226	0	91	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					705	716		10.1016/S0092-8674(00)81433-6	http://dx.doi.org/10.1016/S0092-8674(00)81433-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630216	Bronze			2022-12-24	WOS:000073956700008
J	Kemp, M				Kemp, M			Hyde's horrors	NATURE			English	Editorial Material									Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.							Darwin C., 1872, EXPRESS EMOT MAN, DOI [10.1037/h0076058, DOI 10.1037/10001-000]; Stevenson RL., 1886, STRANGE CASE DR JEKY	2	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					219	219		10.1038/30370	http://dx.doi.org/10.1038/30370			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607757	Bronze			2022-12-24	WOS:000073761000032
J	Diaz, E; Pfeffer, SR				Diaz, E; Pfeffer, SR			TIP47: A cargo selection device for mannose 6-phosphate receptor trafficking	CELL			English	Article							TRANS-GOLGI NETWORK; FACTOR-II RECEPTOR; HIGH-AFFINITY INTERACTION; CYTOPLASMIC DOMAIN; RAPID INTERNALIZATION; ASSEMBLY PROTEINS; CYTOSOLIC PROTEIN; PLASMA-MEMBRANE; SIGNALS; TAIL	Mannose B-phosphate receptors (MPRs) transport newly synthesized lysosomal hydrolases from the Golgi to prelysosomes and then return to the Golgi for another round of transport. We have identified a 47 kDa protein (TIP47) that binds selectively to the cytoplasmic domains of cation-independent and cation-dependent MPRs. TIP47 is present in cytosol and on endosomes and is required for MPR transport from endosomes to the trans-Golgi network in vitro and in vivo. TIP47 recognizes a phenylalanine/tryptophan signal in the tail of the cation-dependent MPR that is essential for its proper sorting within the endosomal pathway. These data suggest that TIP47 binds MPR cytoplasmic domains and facilitates their collection into transport vesicles destined for the Golgi.	Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA	Stanford University	Pfeffer, SR (corresponding author), Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK037332, R56DK037332, R01DK037332] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37332] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brodsky FM, 1997, TRENDS CELL BIOL, V7, P175, DOI 10.1016/S0962-8924(97)01038-6; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Diaz E, 1997, J CELL BIOL, V138, P283, DOI 10.1083/jcb.138.2.283; DINTZIS SM, 1994, J BIOL CHEM, V269, P12159; DRAPER RK, 1990, SCIENCE, V248, P1539, DOI 10.1126/science.2163108; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HUBER LA, 1993, J CELL BIOL, V123, P47, DOI 10.1083/jcb.123.1.47; Itin C, 1997, J BIOL CHEM, V272, P27737, DOI 10.1074/jbc.272.44.27737; JADOT M, 1992, J BIOL CHEM, V267, P11069; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; ROSORIUS O, 1993, J BIOL CHEM, V268, P21470; Schimmoller F, 1997, CURR BIOL, V7, pR235, DOI 10.1016/S0960-9822(06)00109-6; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOSA MA, 1993, J BIOL CHEM, V268, P12537; Wang XL, 1997, FEBS LETT, V402, P57, DOI 10.1016/S0014-5793(96)01500-1; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	42	320	330	1	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 1	1998	93	3					433	443		10.1016/S0092-8674(00)81171-X	http://dx.doi.org/10.1016/S0092-8674(00)81171-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590177	Bronze			2022-12-24	WOS:000073471500018
J	Kreusch, A; Pfaffinger, PJ; Stevens, CF; Choe, S				Kreusch, A; Pfaffinger, PJ; Stevens, CF; Choe, S			Crystal structure of the tetramerization domain of the Shaker potassium channel	NATURE			English	Article							K+ CHANNEL; INACTIVATION; DROSOPHILA; STOICHIOMETRY; DIVERSITY; RECEPTOR; PEPTIDE; GENE	Voltage-dependent, ion-selective channels such as Na+, Ca2+ and K+ channel proteins function as tetrameric assemblies of identical or similar subunits(1-4). The clustering of four subunits is thought to create an aqueous pore(5,6) centred at the four-fold symmetry axis. The highly conserved, amino-terminal cytoplasmic domain (similar to 130 amino acids) immediately preceding the first putative transmembrane helix S1 is designated T1 It is known to confer specificity for tetramer formation(7,8), so the heteromeric assembly of K+-channel subunits is an important mechanism for the observed channel diversity(9-11). We have determined the crystal structure of the T1 domain of a Shaker potassium channel at 1.55 Angstrom resolution. The structure reveals that four identical subunits are arranged in a four-fold symmetry surrounding a centrally located pore about 20 Angstrom in length. Subfamily-specific assembly is provided primarily by polar interactions encoded in a conserved set of amino acids at its tetramerization interface. Most highly conserved amino acids in the T1 domain of all known potassium channels are found in the core of the protein, indicating a common structural framework for the tetramer assembly.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA; Baylor Coll Med, Houston, TX 77030 USA	Salk Institute; Salk Institute; Baylor College of Medicine	Choe, S (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Antz C, 1997, NATURE, V385, P272, DOI 10.1038/385272a0; BRUNGER AT, 1996, XPLOR VERSION 3 8; *COLL COMP PROJ, 1994, ACTA CRYSTALLOGR D, V50, P670; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FOSTER CD, 1992, NEURON, V9, P229, DOI 10.1016/0896-6273(92)90162-7; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOL WG, 1978, NATURE, V2734, P43; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIU T, 1997, NEURON, V19, P175; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SHEN NV, 1993, NEURON, V11, P67; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TORO L, 1992, NEURON, V9, P237, DOI 10.1016/0896-6273(92)90163-8; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511	30	263	266	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					945	948		10.1038/31978	http://dx.doi.org/10.1038/31978			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582078				2022-12-24	WOS:000073359900055
J	Auer, M; Scarborough, GA; Kuhlbrandt, W				Auer, M; Scarborough, GA; Kuhlbrandt, W			Three-dimensional map of the plasma membrane H+-ATPase in the open conformation	NATURE			English	Article							ELECTRON-MICROSCOPY; CYTOPLASMIC LOCATION; PROTEIN; MODEL; IDENTIFICATION; CRYOMICROSCOPY; VISUALIZATION; REGIONS; AMINO	The H+-ATPase from the plasma membrane of Neurospora crassa is an integral membrane protein of relative molecular mass 100K, which belongs to the P-type ATPase family that includes the plasma membrane Na+/K+-ATPase and the sarcoplasmic reticulum Ca2+-ATPase. The H+-ATPase pumps protons across the cell's plasma membrane using ATP as an energy source, generating a membrane potential in excess of 200 mV (refs 1-3). Despite the importance of P-type ATPases in controlling membrane potential and intracellular ion concentrations, little is known about the molecular mechanism they use for ion transport. This is largely due to the difficulty in growing well ordered crystals and the resulting lack of detail in the three-dimensional structure of these large membrane proteins. We have now obtained a three-dimensional map of the H+-ATPase by electron crystallography of two-dimensional crystals grown directly on electron microscope grids. At an in-plane resolution of 8 Angstrom, this map reveals ten membrane-spanning alpha-helices in the membrane domain, and four major cytoplasmic domains in the open conformation of the enzyme without bound ligands.	Max Planck Inst Biophys, Abt Strukturbiol, D-60528 Frankfurt, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	Max Planck Society; European Molecular Biology Laboratory (EMBL); University of North Carolina; University of North Carolina Chapel Hill	Kuhlbrandt, W (corresponding author), Max Planck Inst Biophys, Abt Strukturbiol, Heinrich Hoffman Str 7, D-60528 Frankfurt, Germany.	kuehlbrandt@biophys.mpg.de		Kuhlbrandt, Werner/0000-0002-2013-4810; Auer, Manfred/0000-0001-8920-3522				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; CHADWICK CC, 1987, ARCH BIOCHEM BIOPHYS, V252, P348, DOI 10.1016/0003-9861(87)90041-5; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; CYRKLAFF M, 1995, EMBO J, V14, P1854, DOI 10.1002/j.1460-2075.1995.tb07177.x; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GOORMAGHTIGH E, 1994, J BIOL CHEM, V269, P27409; GOORMAGHTIGH E, 1986, J BIOL CHEM, V261, P7466; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KUHLBRANDT W, 1982, ULTRAMICROSCOPY, V7, P221, DOI 10.1016/0304-3991(82)90169-3; Li HL, 1997, NAT STRUCT BIOL, V4, P263, DOI 10.1038/nsb0497-263; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; NAKAMOTO RK, 1989, ANN NY ACAD SCI, V574, P165; NAKAMOTO RK, 1989, J BIOENERG BIOMEMBR, V21, P621, DOI 10.1007/BF00808117; RAO US, 1991, J BIOL CHEM, V266, P14740; RAO US, 1992, BIOCHIM BIOPHYS ACTA, V1108, P153, DOI 10.1016/0005-2736(92)90020-M; SCARBOROUGH GA, 1994, ACTA CRYSTALLOGR D, V50, P643, DOI 10.1107/S0907444993014283; SCARBOROUGH GA, 1990, J BIOL CHEM, V265, P16145; SCARBOROUGH GA, 1996, HDB BIOL PHYS, V2, P75; SCARBOROUGH GA, 1992, MOL ASPECTS MEMBRANE, P117; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; Sheehan B, 1996, J STRUCT BIOL, V116, P99, DOI 10.1006/jsbi.1996.0017; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512	30	184	191	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1998	392	6678					840	843		10.1038/33967	http://dx.doi.org/10.1038/33967			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572146				2022-12-24	WOS:000073241200060
J	Cooper, JP; Watanabe, Y; Nurse, P				Cooper, JP; Watanabe, Y; Nurse, P			Fission yeast Taz1 protein is required for meiotic telomere clustering and recombination	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; MEIOSIS; CENTROMERES; INTEGRATION; GENES; DNA	The alignment of homologous chromosomes during meiosis is essential for their recombination and segregation. Telomeres form and protect the ends of eukaryotic linear chromosomes, and are composed of tandem repeats of a simple DNA sequence and the proteins that bind to these repeats(1-3). A role for telomeres in meiosis was suspected from observations of telomere clustering in meiotic cells(4-7), and has now been supported experimentally by the dramatic rearrangement of telomere locations during premeiotic stages in fission yeast(8,9). Here we show that the fission yeast telomere protein, Tazl (ref. 10), is required for stable association between telomeres and spindle pole bodies during meiotic prophase. In the absence of Tazl, telomere clustering at the spindle pole bodies is disrupted, meiotic recombination is reduced, and both spore viability and the ability of zygotes to re-enter mitosis are impaired to a level that would be expected if chromosome segregation were occurring randomly. Such telomeric association mediated by telomere-specific proteins may also be important for proper chromosome alignment and recombination during meiosis in humans.	Imperial Canc Res Fund, Cell Cycle Lab, London WC2A 3PX, England	Cancer Research UK	Cooper, JP (corresponding author), Imperial Canc Res Fund, Cell Cycle Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	cooperj@essex.uchsc.edu		Watanabe, Yoshinori/0000-0002-5488-4812; cooper, julia promisel/0000-0003-2171-2587				BAHLER J, 1991, CURR GENET, V19, P445, DOI 10.1007/BF00312735; Blackburn EH, 1995, TELOMERES; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Chikashige Y, 1997, EMBO J, V16, P193, DOI 10.1093/emboj/16.1.193; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; DERNBURG AF, 1995, TELOMERES, P295; EGEL R, 1973, MOL GEN GENET, V121, P277, DOI 10.1007/BF00267055; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUTZ H, 1971, GENETICS, V69, P331; GUTZ H, 1974, HDB GENETICS, P211; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; LOIDL J, 1990, GENOME, V33, P759, DOI 10.1139/g90-115; MELOSIS JB, 1990, DEV CELL BIOL SER, V22; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NIMMO ER, 1994, EMBO J, V13, P3801, DOI 10.1002/j.1460-2075.1994.tb06691.x; SCHERTHAN H, 1994, J CELL BIOL, V127, P273, DOI 10.1083/jcb.127.2.273; Shimanuki M, 1997, MOL GEN GENET, V254, P238, DOI 10.1007/s004380050412; TODA T, 1984, CURR GENET, V8, P93, DOI 10.1007/BF00420224; UZAWA S, 1992, J CELL SCI, V101, P267; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; WATANABE Y, 1994, CELL, V78, P487, DOI 10.1016/0092-8674(94)90426-X; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	26	238	242	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1998	392	6678					828	831		10.1038/33947	http://dx.doi.org/10.1038/33947			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572143				2022-12-24	WOS:000073241200057
J	Tollefson, AE; Hermiston, TW; Lichtenstein, DL; Colle, CF; Tripp, RA; Dimitrov, T; Toth, K; Wells, CE; Doherty, PC; Wold, WSM				Tollefson, AE; Hermiston, TW; Lichtenstein, DL; Colle, CF; Tripp, RA; Dimitrov, T; Toth, K; Wells, CE; Doherty, PC; Wold, WSM			Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR RECEPTOR; REGION E3; MEDIATED CYTOTOXICITY; PLASMA-MEMBRANE; MW PROTEIN; CYTOLYSIS; ACTIVATION; TRANSFORMATION; 10,400-DALTON	DNA viruses have evolved elaborate mechanisms To overcome host antiviral defences. In adenovirus-infected cells, programmed cell death (apoptosis) induced by the cytokine tumour necrosis factor (TNF) is inhibited by several adenovirus-encoded proteins(1-3). Occupation of the cell-surface receptor Fas, a member of the TNF-receptor superfamily that is expressed on most cell types, triggers apoptosis of that cell(4-6). Here we show that the adenovirus RID (for receptor internalization and degradation) protein complex, which is an inhibitor of TNF-induced apoptosis(2), mediates internalization of cell-surface Fas and its destruction inside lysosomes within the cell. Fas has not previously been shown to be internalized and then degraded. RID also mediates internalization of the receptor for epidermal growth factor(7,8), but it does not affect the transferrin receptor or class I antigens of the major histocompatibility complex. Removal of Fas from the surface of adenovirus-infected cells expressing RID may allow infected cells to resist Fas-mediated cell death and thus promote their survival.	St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA	Saint Louis University; St Jude Children's Research Hospital	Wold, WSM (corresponding author), St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	woldws@slu.edu	Tripp, Ralph/F-5218-2011; Doherty, Peter Charles/C-4185-2013	Tripp, Ralph/0000-0002-2924-9956; Doherty, Peter Charles/0000-0002-5028-3489; Toth, Karoly/0000-0001-6624-9683				AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; BABISS LE, 1984, J VIROL, V52, P389, DOI 10.1128/JVI.52.2.389-395.1984; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CARLIN CR, 1989, CELL, V57, P135, DOI 10.1016/0092-8674(89)90179-7; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CLARK WR, 1995, IMMUNOL REV, V146, P33, DOI 10.1111/j.1600-065X.1995.tb00682.x; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; GOODING LR, 1991, J VIROL, V65, P4114, DOI 10.1128/JVI.65.8.4114-4123.1991; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; GOODING LR, 1988, CELL, V53, P341, DOI 10.1016/0092-8674(88)90154-7; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HOFFMAN P, 1992, J BIOL CHEM, V267, P13480; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAATTELA M, 1995, ONCOGENE, V10, P2297; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OHEM A, 1992, J BIOL CHEM, V267, P10709; RANHEIM TS, 1993, J VIROL, V67, P2159, DOI 10.1128/JVI.67.4.2159-2167.1993; STEWART AR, 1995, J VIROL, V69, P172, DOI 10.1128/JVI.69.1.172-181.1995; SUBRAMANIAN T, 1984, J VIROL, V52, P336, DOI 10.1128/JVI.52.2.336-343.1984; TOLLEFSON AE, 1991, J VIROL, V65, P3095, DOI 10.1128/JVI.65.6.3095-3105.1991; TOLLEFSON AE, 1990, VIROLOGY, V175, P19, DOI 10.1016/0042-6822(90)90182-Q; TOLLEFSON AE, 1990, J VIROL, V64, P794, DOI 10.1128/JVI.64.2.794-801.1990; TRIPP RA, 1995, J IMMUNOL, V154, P6013; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	30	172	176	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1998	392	6677					726	730		10.1038/33712	http://dx.doi.org/10.1038/33712			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565035				2022-12-24	WOS:000073129000062
J	Blitzer, RD; Conner, JH; Brown, GP; Wong, T; Shenolikar, S; Iyengar, R; Landau, EM				Blitzer, RD; Conner, JH; Brown, GP; Wong, T; Shenolikar, S; Iyengar, R; Landau, EM			Gating of CaMKII by cAMP-regulated protein phosphatase activity during LTP	SCIENCE			English	Article							LONG-TERM POTENTIATION; DEPENDENT KINASE-II; PHOSPHORYLATION; INHIBITOR-1; MEMORY; TRANSMISSION; LOCALIZATION; HIPPOCAMPUS; ACTIVATION; NEURONS	Long-term potentiation (LTP) at the Schaffer collateral-CA1 synapse involves interacting signaling components, including calcium (Ca2+)/calmodulin-dependent protein kinase II (CaMKII) and cyclic adenosine monophosphate (cAMP) pathways. Postsynaptic injection of thiophosphorylated inhibitor-1 protein, a specific inhibitor of protein phosphatase-1 (PP1), substituted for cAMP pathway activation in LTP. Stimulation that induced LTP triggered cAMP-dependent phosphorylation of endogenous inhibitor-1 and a decrease in PP1 activity. This stimulation also increased phosphorylation of CaMKII at Thr(286) and Ca2+-independent CaMKII activity in a cAMP-dependent man ner. The blockade of LTP by a CaMKII inhibitor was not overcome by thiophosphorylated inhibitor-1. Thus, the cAMP pathway uses PP1 to gate CaMKII signaling in LTP.	Bronx VA Med Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27712 USA; CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Duke University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Blitzer, RD (corresponding author), Bronx VA Med Ctr, New York, NY 10029 USA.			Connor, John/0000-0002-8867-7256	NIDDK NIH HHS [DK52054] Funding Source: Medline; NIGMS NIH HHS [GM54508] Funding Source: Medline; NINDS NIH HHS [NS33646] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033646] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLITCH JG, 1995, AI EXCHANGE, V9, P15; BRAUN AP, 1995, J PHYSIOL-LONDON, V488, P37, DOI 10.1113/jphysiol.1995.sp020944; CAHILL L, 1994, NATURE, V371, P702, DOI 10.1038/371702a0; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Huang Y Y, 1994, Learn Mem, V1, P74; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; PATTON BL, 1993, MOL BIOL CELL, V4, P159, DOI 10.1091/mbc.4.2.159; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; SAKAGAMI H, 1994, MOL BRAIN RES, V25, P7, DOI 10.1016/0169-328X(94)90273-9; SHARP GWG, 1973, ANNU REV MED, V24, P19, DOI 10.1146/annurev.me.24.020173.000315; SHIELDS SM, 1985, J NEUROSCI, V5, P3414; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8	27	336	343	2	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1940	1943		10.1126/science.280.5371.1940	http://dx.doi.org/10.1126/science.280.5371.1940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632393				2022-12-24	WOS:000074323800065
J	Luecke, H; Richter, HT; Lanyi, JK				Luecke, H; Richter, HT; Lanyi, JK			Proton transfer pathways in bacteriorhodopsin at 2.3 Angstrom resolution	SCIENCE			English	Article							RELEASE; RESIDUES; CYCLE; PUMP	Photoisomerization of the retinal of bacteriorhodopsin initiates a cyclic reaction in which a proton is translocated across the membrane. Studies of this protein promise a better understanding of how ion pumps function. Together with a large amount of spectroscopic and mutational data, the atomic structure of bacteriorhodopsin, determined in the last decade at increasing resolutions, has suggested plausible but often contradictory mechanisms. X-ray diffraction of bacteriorhodopsin crystals grown in cubic lipid phase revealed unexpected two-fold symmetries that indicate merohedral twinning along the crystallographic c axis. The structure, refined to 2.3 angstroms taking this twinning into account, is different from earlier models, including that most recently reported. One of the carboxyl oxygen atoms of the proton acceptor Asp(85) is connected to the proton donor, the retinal Schiff base, through a hydrogen-bonded water and forms a second hydrogen bond with another water. The other carboxyl oxygen atom of Asp(85) accepts a hydrogen bond from Thr(89). This structure forms the active site. The nearby Arg(82) is the center of a network of numerous hydrogen-bonded residues and an ordered water molecule. This network defines the pathway of the proton from the buried Schiff base to the extracellular surface.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Luecke, H (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.		Luecke, Hartmut/F-4712-2012; Lanyi, Janos/C-3808-2011	Luecke, Hartmut/0000-0002-4938-0775; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029498, R01GM056445] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM56445, R01-GM29498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balashov SP, 1996, BIOPHYS J, V70, P473, DOI 10.1016/S0006-3495(96)79591-7; BALASHOV SP, 1993, BIOCHEMISTRY-US, V32, P10331, DOI 10.1021/bi00090a008; Balashov SP, 1997, BIOCHEMISTRY-US, V36, P8671, DOI 10.1021/bi970744y; BROWN LO, UNPUB; BROWN LS, 1994, J MOL BIOL, V239, P401, DOI 10.1006/jmbi.1994.1381; BROWN LS, 1995, J BIOL CHEM, V270, P27122, DOI 10.1074/jbc.270.45.27122; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; DEGROOT HJM, 1989, BIOCHEMISTRY-US, V28, P3346, DOI 10.1021/bi00434a033; Dioumaev AK, 1998, BIOCHEMISTRY-US, V37, P2496, DOI 10.1021/bi971842m; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; Kimura Y, 1997, PHOTOCHEM PHOTOBIOL, V66, P764, DOI 10.1111/j.1751-1097.1997.tb03221.x; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; MARTI T, 1991, J BIOL CHEM, V266, P6919; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; REDINBO MR, 1993, ACTA CRYSTALLOGR D, V49, P375, DOI 10.1107/S090744499300294X; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SZARAZ S, 1994, BIOPHYS J, V67, P1706, DOI 10.1016/S0006-3495(94)80644-7; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; YAMAZAKI Y, 1995, BIOCHEMISTRY-US, V34, P577; ZHOU F, 1993, BIOCHEMISTRY-US, V32, P2291, DOI 10.1021/bi00060a022	25	529	537	0	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1934	1937		10.1126/science.280.5371.1934	http://dx.doi.org/10.1126/science.280.5371.1934			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632391				2022-12-24	WOS:000074323800063
J	Hippisley-Cox, J; Fielding, K; Pringle, M				Hippisley-Cox, J; Fielding, K; Pringle, M			Depression as a risk factor for ischaemic heart disease in men: population based case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SERUM-CHOLESTEROL CONCENTRATION; ACUTE MYOCARDIAL-INFARCTION; GENERAL-PRACTICE; MORTALITY; SYMPTOMS; EVENTS; TRIALS	Objective: To determine the relation between depression, anxiety, and use of antidepressants and the onset of ischaemic heart disease. Design: Population based case-control study. Setting: All 5623 patients registered with one general practice. Subjects: 188 male cases with ischaemic heart disease matched by age to 485 male controls without ischaemic heart disease; 139 female cases with ischaemic heart disease matched by age to 412 female controls. Main outcome measure: Adjusted odds ratios calculated by conditional logistic regression. Results: The risk of ischaemic heart disease was three times higher among men with a recorded diagnosis of depression than among controls of the sane age (odds ratio 3.09; 95% confidence interval 1.33 to 7.21; P = 0.009). This association persisted when smoking status, diabetes, hypertension, and underprivileged area (UPA(8)) score were included in a multivariate model (adjusted 2.75; 1.13 to 6.69; P = 0.03). Men with depression within the preceding 10 years were three times more likely to develop ischaemic heart disease than were the controls (3.13; 1.27 to 7.70; P = 0.01). Men with ischaemic heart disease had a higher risk of subsequent ischaemic heart disease than men without ischaemic heart disease (adjusted 2.34; 1.34 to 4.10; P = 0.003). Depression was not a risk factor for ischaemic heart disease in women on multivariate analysis (adjusted 1.34; 0.70 to 2.56; P = 0.38). Anxiety and subsequent ischaemic heart disease were not significantly associated in men or women. Conclusion: Depression may be an independent risk factor for ischaemic heart disease in men, but not in women.	Queens Med Ctr, Sch Med, Dept Gen Practice, Nottingham NG7 2UH, England; Queens Med Ctr, Sch Med, Trent Inst Hlth Serv Res, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Hippisley-Cox, J (corresponding author), Queens Med Ctr, Sch Med, Dept Gen Practice, Nottingham NG7 2UH, England.	julia.h-cox@nottingham.ac.uk	Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283				APPELS A, 1990, BRIT J PSYCHIAT, V156, P465, DOI 10.1192/bjp.156.4.465; BROWN SL, 1994, BRIT MED J, V308, P1328, DOI 10.1136/bmj.308.6940.1328; CARNEY RM, 1990, PSYCHOSOM MED, V52, P603, DOI 10.1097/00006842-199011000-00001; CARNEY RM, 1988, PSYCHOSOM MED, V50, P627, DOI 10.1097/00006842-198811000-00009; FIELDING R, 1991, SOC SCI MED, V32, P1017, DOI 10.1016/0277-9536(91)90159-A; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; KEECH A, 1994, EUR HEART J, V15, P255, DOI 10.1093/oxfordjournals.eurheartj.a060485; LADWIG KH, 1994, LANCET, V343, P20, DOI 10.1016/S0140-6736(94)90877-X; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; Lesperance F, 1996, PSYCHOSOM MED, V58, P99, DOI 10.1097/00006842-199603000-00001; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; MORGAN RE, 1993, LANCET, V341, P75, DOI 10.1016/0140-6736(93)92556-9; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; OCONNOR NJ, 1995, CIRCULATION, V92, P1458, DOI 10.1161/01.CIR.92.6.1458; PRINGLE M, 1995, BRIT J GEN PRACT, V45, P537; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; SIEGLER IC, 1992, AM J EPIDEMIOL, V136, P146, DOI 10.1093/oxfordjournals.aje.a116481; SIRELING LI, 1985, BRIT J PSYCHIAT, V147, P113, DOI 10.1192/bjp.147.2.113; SIRELING LI, 1985, BRIT J PSYCHIAT, V147, P119, DOI 10.1192/bjp.147.2.119; THOMAS C, 1992, J GERONTOL, V47, pS80, DOI 10.1093/geronj/47.2.S80; TILYARD MW, 1995, NEW ZEAL MED J, V108, P118; Wardle J, 1996, BRIT MED J, V313, P75, DOI 10.1136/bmj.313.7049.75; WassertheilSmoller S, 1996, ARCH INTERN MED, V156, P553, DOI 10.1001/archinte.156.5.553; WYSOWSKI DK, 1990, ARCH INTERN MED, V150, P2169, DOI 10.1001/archinte.150.10.2169; Zureik M, 1996, BMJ-BRIT MED J, V313, P649, DOI 10.1136/bmj.313.7058.649	26	136	140	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 6	1998	316	7146					1714	1719		10.1136/bmj.316.7146.1714	http://dx.doi.org/10.1136/bmj.316.7146.1714			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZT806	9614024	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000074129500024
J	Farquhar, J; Thiemens, MH; Jackson, T				Farquhar, J; Thiemens, MH; Jackson, T			Atmosphere-surface interactions on Mars: Delta O-17 measurements of carbonate from ALH 84001	SCIENCE			English	Article							SNC METEORITES; MARTIAN ATMOSPHERE; ISOTOPIC COMPOSITION; OXYGEN-ISOTOPE; VOLATILE EVOLUTION; CHAOTIC OBLIQUITY; STRATOSPHERIC CO2; WATER; ORIGIN; FRACTIONATION	Oxygen isotope measurements of carbonate from martian meteorite ALH 84001 (delta(18)O = 18.3 +/- 0.4 per mil, delta(17)O = 10.3 +/- 0.2 per mil, and Delta(17)O = 0.8 +/- 0.05 per mil) are fractionated with respect to those of silicate minerals. These measurements support the existence of two oxygen isotope reservoirs (the atmosphere and the silicate planet) on Mars at the time of carbonate growth. The cause of the atmospheric oxygen isotope anomaly may be exchange between CO2 and O(D-1) produced by the photodecomposition of ozone. Atmospheric oxygen isotope compositions may be transferred to carbonate minerals by CO2-H2O exchange and mineral growth. A sink of O-17-depleted oxygen, as required by mass balance, may exist in the planetary regolith.	Univ Calif San Diego, Dept Chem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Farquhar, J (corresponding author), Univ Calif San Diego, Dept Chem, La Jolla, CA 92093 USA.	jfarquha@ucsd.edu; mht@ucsd.edu; tjackson@ucsd.edu						BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; BARTH CA, 1986, PHOTOCHEMISTRY ATMOS, P337; BECKER RH, 1984, EARTH PLANET SC LETT, V69, P225, DOI 10.1016/0012-821X(84)90183-3; BHATTACHARYA SK, 1989, Z NATURFORSCH A, V44, P435; BJORAAKER GL, 1989, B AM ASTRON SOC, V29, P991; BOGARD DD, 1983, SCIENCE, V221, P651, DOI 10.1126/science.221.4611.651; CARR MH, 1986, ICARUS, V68, P187, DOI 10.1016/0019-1035(86)90019-9; CARR MH, 1990, ICARUS, V87, P210, DOI 10.1016/0019-1035(90)90031-4; CARR RH, 1985, NATURE, V314, P248, DOI 10.1038/314248a0; Clayton RN, 1996, GEOCHIM COSMOCHIM AC, V60, P1999, DOI 10.1016/0016-7037(96)00074-9; CLAYTON RN, 1963, GEOCHIM COSMOCHIM AC, V27, P43, DOI 10.1016/0016-7037(63)90071-1; CLAYTON RN, 1983, EARTH PLANET SC LETT, V62, P1, DOI 10.1016/0012-821X(83)90066-3; Cliff SS, 1997, SCIENCE, V278, P1774, DOI 10.1126/science.278.5344.1774; COPLEN TB, 1983, NATURE, V302, P236, DOI 10.1038/302236a0; CRISS RE, 1986, REV MINERAL, V16, P373; DONAHUE TM, 1995, NATURE, V374, P432, DOI 10.1038/374432a0; FANALE FP, 1971, NATURE, V230, P502, DOI 10.1038/230502a0; FANALE FP, 1974, J GEOPHYS RES, V79, P3397, DOI 10.1029/JC079i024p03397; Farmer C. B., 1977, Journal of Geophysical Research, V82, P4225, DOI 10.1029/JS082i028p04225; Forget F, 1997, SCIENCE, V278, P1273, DOI 10.1126/science.278.5341.1273; FORSYTHE RD, 1998, LUNAR PLANET SCI C, V29, P1410; GEISSLER PE, 1993, ICARUS, V106, P380, DOI 10.1006/icar.1993.1179; Gregory R. T., 1991, GEOCHEM SOC SPEC PUB, V3, P65; Gulick VC, 1997, ICARUS, V130, P68, DOI 10.1006/icar.1997.5802; GULICK VC, 1990, J GEOPHYS RES-SOLID, V95, P14325, DOI 10.1029/JB095iB09p14325; HABERLE RM, 1994, ICARUS, V109, P102, DOI 10.1006/icar.1994.1079; Harvey RP, 1996, NATURE, V382, P49, DOI 10.1038/382049a0; Holland H.D., 1984, CHEM EVOLUTION ATMOS; Hutchins KS, 1996, J GEOPHYS RES-PLANET, V101, P14933, DOI 10.1029/96JE00860; JAKOSKY BM, 1993, ICARUS, V102, P286, DOI 10.1006/icar.1993.1049; Jakosky BM, 1997, REV GEOPHYS, V35, P1, DOI 10.1029/96RG02903; Jakosky BM, 1997, ICARUS, V130, P87, DOI 10.1006/icar.1997.5799; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; JAKOSKY BM, 1993, GEOPHYS RES LETT, V20, P1591, DOI 10.1029/93GL01598; JAKOSKY BM, 1991, ICARUS, V94, P14, DOI 10.1016/0019-1035(91)90138-J; JAKOSKY BM, 1994, NATURE, V370, P328, DOI 10.1038/370328a0; JAKOSKY BM, 1982, J GEOPHYS RES, V87, P2999, DOI 10.1029/JB087iB04p02999; JAKOSKY BM, 1990, J GEOPHYS RES-SOLID, V95, P1475, DOI 10.1029/JB095iB02p01475; JAKOSKY BM, 1995, J GEOPHYS RES-PLANET, V100, P1579, DOI 10.1029/94JE02801; Johnston JC, 1997, J GEOPHYS RES-ATMOS, V102, P25395, DOI 10.1029/97JD02075; JULL AJT, 1995, METEORITICS, V30, P311, DOI 10.1111/j.1945-5100.1995.tb01129.x; KARRISON HR, 1992, SCIENCE, V255, P1409; KASS DM, 1995, SCIENCE, V268, P697, DOI 10.1126/science.7732377; KERRIDGE JF, 1988, LUNAR PLANET SCI, V19, P599; KRASNOPOLSKY VA, 1996, ICARUS, V553, P124; LASKAR J, 1993, NATURE, V361, P608, DOI 10.1038/361608a0; Leshin LA, 1996, GEOCHIM COSMOCHIM AC, V60, P2635, DOI 10.1016/0016-7037(96)00122-6; LESHIN LA, 1997, LUNAR PLANET SCI, V28, P805; LESHIN LA, 1998, LUNAR PLANET SCI C, V29, P1468; MARTI K, 1995, SCIENCE, V267, P1981, DOI 10.1126/science.7701319; MAUERSBERGER K, 1987, GEOPHYS RES LETT, V14, P80, DOI 10.1029/GL014i001p00080; MCCREA JM, 1950, J CHEM PHYS, V18, P849, DOI 10.1063/1.1747785; MCELROY MB, 1976, SCIENCE, V194, P70, DOI 10.1126/science.194.4260.70; MCSWEEN HY, 1984, GEOLOGY, V12, P3, DOI 10.1130/0091-7613(1984)12<3:SMATMR>2.0.CO;2; MELLON MT, 1995, J GEOPHYS RES-PLANET, V100, P11781, DOI 10.1029/95JE01027; MUEHLENBACHS K, 1976, J GEOPHYS RES, V81, P4365, DOI 10.1029/JB081i023p04365; NAIR H, 1994, ICARUS, V111, P124, DOI 10.1006/icar.1994.1137; Nier A. O., 1977, Journal of Geophysical Research, V82, P4341, DOI 10.1126/science.194.4271.1298; NIER AO, 1976, SCIENCE, V194, P68, DOI 10.1126/science.194.4260.68; OWEN T, 1988, SCIENCE, V240, P1767, DOI 10.1126/science.240.4860.1767; PEPIN RO, 1994, ICARUS, V111, P289, DOI 10.1006/icar.1994.1146; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; ROSENBAUM J, 1986, GEOCHIM COSMOCHIM AC, V50, P1147, DOI 10.1016/0016-7037(86)90396-0; Sagan C, 1997, SCIENCE, V276, P1217, DOI 10.1126/science.276.5316.1217; SCAMBOS TA, 1990, J GEOPHYS RES-SOLID, V95, P14779, DOI 10.1029/JB095iB09p14779; THIEMENS MH, 1991, GEOPHYS RES LETT, V18, P669, DOI 10.1029/91GL00121; THIEMENS MH, 1995, SCIENCE, V270, P969, DOI 10.1126/science.270.5238.969; THIEMENS MH, 1995, GEOPHYS RES LETT, V22, P255, DOI 10.1029/94GL02996; TOUMA J, 1993, SCIENCE, V259, P1294, DOI 10.1126/science.259.5099.1294; Valley JW, 1997, SCIENCE, V275, P1633, DOI 10.1126/science.275.5306.1633; WALLIS MK, 1978, PLANET SPACE SCI, V26, P949, DOI 10.1016/0032-0633(78)90077-6; WALLIS MK, 1989, EARTH PLANET SC LETT, V93, P321, DOI 10.1016/0012-821X(89)90031-9; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; WIENS RC, 1986, EARTH PLANET SC LETT, V77, P149, DOI 10.1016/0012-821X(86)90156-1; Wood C.A., 1981, P LUNAR PLANET SCI C, V12B, P1359; WRIGHT IP, 1990, J GEOPHYS RES-SOLID, V95, P14789, DOI 10.1029/JB095iB09p14789; YUNG YL, 1988, ICARUS, V76, P146, DOI 10.1016/0019-1035(88)90147-9; [No title captured]	79	108	113	5	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1580	1582		10.1126/science.280.5369.1580	http://dx.doi.org/10.1126/science.280.5369.1580			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616116				2022-12-24	WOS:000074061200034
J	Wannamethee, SG; Shaper, AG; Walker, M				Wannamethee, SG; Shaper, AG; Walker, M			Changes in physical activity, mortality, and incidence of coronary heart disease in older men	LANCET			English	Article							AGED BRITISH MEN; LEISURE-TIME; RISK-FACTORS; ACTIVITY LEVEL; FOLLOW-UP; DEATH; EXERCISE; ATTACK; RATES	Background We studied the relations between physical activity and changes in physical activity, all-cause mortality, and incidence of major coronary-heart-disease events in older men. Methods In 1978-80 (Q1), 7735 men aged 40-59 were selected from general practices in 24 British towns, and enrolled in a prospective study of cardiovascular disease, which included physical activity data. In 1992 (Q92), 12-14 years later, 5934 of the men (91% of available survivors, mean age 63 years) gave further information on physical activity and,were then followed up for a further 4 years. The main endpoints were all-cause mortality during 4 years of follow-up from Q92, and major fatal and non-fatal coronary-heart-disease events during 3 years of follow-up from Q92. Findings Among 4311 men with no history of coronary heart disease, stroke, or "other heart trouble" by Q92 and who did not report "poor health", there were 219 deaths. In the inactive/occasionally active, light, moderate, and moderately vigorous/vigorous activity groups there were 101 (18.5/1000 person-years) 48 (11.4), 23 (7.3), and 47 (9.1) deaths, respectively (adjusted risk ratios 1.00, 0.61 [95% CI 0.48-0.86], 0.50 [0.31-0.79], 0.65 [0.45-0.94]). Men who were sedentary at Q1 and who began at least light activity by Q92 had significantly lower all-cause mortality than those who remained sedentary, even after adjustment for potential confounders (risk ratio=0.55 [0.36-0.84]). Physical activity improved both cardiovascular mortality (0.66 [0.35-1.23]) and noncardiovascular mortality (0.48 [0.27-0.85]). The relation between physical activity at Q92, changes in physical activity, and mortality were similar for men with pre-existing cardiovascular disease. Interpretation Maintaining or taking up light or moderate physical activity reduces mortality and heart attacks in older men with and without diagnosed cardiovascular disease. Our results support public-health recommendations for older sedentary people to increase physical activity, and for active middle-aged people to continue their activity into old age.	Royal Free Hosp, Sch Med, Dept Publ Hlth & Primary Care, London NW3 2PF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Wannamethee, SG (corresponding author), Royal Free Hosp, Sch Med, Dept Publ Hlth & Primary Care, London NW3 2PF, England.		Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351				[Anonymous], 1996, JAMA, V276, P241; ASTRAND PO, 1986, ACTA MED SCAND, P241; Bennett N, 1995, HLTH SURVEY ENGLAND; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; CHAVE SPW, 1978, J EPIDEMIOL COMMUN H, V32, P239, DOI 10.1136/jech.32.4.239; *DEP HLTH PHYS ACT, 1995, MOR PEOPL MOR ACT MO; EDWARDS KE, 1992, CLIN GERIATR MED, V1, P35; HAGBERG JM, 1994, PHYSICAL ACTIVITY FI, P993; Hakim AA, 1998, NEW ENGL J MED, V338, P94, DOI 10.1056/NEJM199801083380204; Hein H. O., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P57; *HLTH ED AUTH, 1995, HLTH UPD PHYS ACT; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; Kujala UM, 1998, JAMA-J AM MED ASSOC, V279, P440, DOI 10.1001/jama.279.6.440; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; Lissner L, 1996, AM J EPIDEMIOL, V143, P54; MORRIS JN, 1990, BRIT HEART J, V63, P325; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHAPER AG, 1994, J HUM HYPERTENS, V8, P3; SHERMAN SE, 1994, AM HEART J, V128, P965, DOI 10.1016/0002-8703(94)90596-7; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365; WANNAMETHEE G, 1992, BRIT MED J, V304, P597, DOI 10.1136/bmj.304.6827.597; WANNAMETHEE G, 1991, INT J EPIDEMIOL, V20, P239, DOI 10.1093/ije/20.1.239; WANNAMETHEE G, 1993, AM J EPIDEMIOL, V137, P735, DOI 10.1093/oxfordjournals.aje.a116734; WILSON PWF, 1986, AM HEART J, V111, P1177, DOI 10.1016/0002-8703(86)90022-0	30	350	358	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	1998	351	9116					1603	1608		10.1016/S0140-6736(97)12355-8	http://dx.doi.org/10.1016/S0140-6736(97)12355-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620713				2022-12-24	WOS:000074026600006
J	Hardt, WD; Chen, LM; Schuebel, KE; Bustelo, XR; Galan, JE				Hardt, WD; Chen, LM; Schuebel, KE; Bustelo, XR; Galan, JE			S-typhimurium encodes an activator of Rho GTPases that induces membrane ruffling and nuclear responses in host cells	CELL			English	Article							CULTURED EPITHELIAL-CELLS; SALMONELLA-TYPHIMURIUM; PROTEIN SECRETION; INVASION GENES; FAMILY; ENTRY; IDENTIFICATION; GROWTH; RAS; CYTOSKELETAL	S. typhimurium stimulates signaling pathways leading to membrane ruffling, actin cytoskeleton rearrangements, and nuclear responses. The stimulation requires a protein secretion system (type III) that translocates bacterial proteins into the host cell. We show that SopE, a substrate of this secretion system, stimulates cytoskeletal reorganization and JNK activation in a CDC42- and Rac-1-dependent manner. A lambda gt11 cDNA library screen for proteins that interact with SopE identified Rac-1 and CDC42. Furthermore, purified SopE was shown to stimulate GDP/GTP nucleotide exchange in several Rho GTPases in vitro, including Rac-1 and CDC42. These findings establish a paradigm for microbial stimulation of cellular responses in which the pathogen induces signaling events by directly engaging the signaling machinery within the host cell.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Med, Dept Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Galan, JE (corresponding author), SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.		Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Hardt, Wolf-Dietrich/0000-0002-9892-6420	NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030492, R29AI030492, R37AI030492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052543] Funding Source: NIH RePORTER; NCI NIH HHS [CA7373501] Funding Source: Medline; NIAID NIH HHS [AI30492] Funding Source: Medline; NIGMS NIH HHS [GM52543] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD JW, 1993, MICROB PATHOGENESIS, V14, P217, DOI 10.1006/mpat.1993.1021; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; COLLAZO CM, 1995, MOL MICROBIOL, V15, P25, DOI 10.1111/j.1365-2958.1995.tb02218.x; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FINLAY BB, 1990, J INFECT DIS, V162, P1096, DOI 10.1093/infdis/162.5.1096; FINLAY BB, 1991, J CELL SCI, V99, P283; Fu YX, 1998, MOL MICROBIOL, V27, P359, DOI 10.1046/j.1365-2958.1998.00684.x; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GALAN JE, 1992, J BACTERIOL, V174, P4338; GALAN JE, 1996, ANNU REV CELL DEV BI, V12, P219; GARCIADELPORTILLO F, 1994, INFECT IMMUN, V62, P4641, DOI 10.1128/IAI.62.10.4641-4645.1994; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hardt WD, 1997, P NATL ACAD SCI USA, V94, P9887, DOI 10.1073/pnas.94.18.9887; Hardt WD, 1998, P NATL ACAD SCI USA, V95, P2574, DOI 10.1073/pnas.95.5.2574; Hobbie S, 1997, J IMMUNOL, V159, P5550; Hotchin NA, 1996, CANCER SURV, V27, P311; JONES BD, 1993, P NATL ACAD SCI USA, V90, P10390, DOI 10.1073/pnas.90.21.10390; KANIGA K, 1995, J BACTERIOL, V177, P3965, DOI 10.1128/jb.177.14.3965-3971.1995; KANIGA K, 1994, MOL MICROBIOL, V13, P555, DOI 10.1111/j.1365-2958.1994.tb00450.x; Kaniga K, 1996, MOL MICROBIOL, V21, P633, DOI 10.1111/j.1365-2958.1996.tb02571.x; KANIGA K, 1995, J BACTERIOL, V177, P7078, DOI 10.1128/jb.177.24.7078-7085.1995; LI J, 1995, P NATL ACAD SCI USA, V92, P7252, DOI 10.1073/pnas.92.16.7252; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PEGUES DA, 1995, MOL MICROBIOL, V17, P169, DOI 10.1111/j.1365-2958.1995.mmi_17010169.x; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; Wood MW, 1996, MOL MICROBIOL, V22, P327, DOI 10.1046/j.1365-2958.1996.00116.x; XU X, 1997, BIOCHEMISTRY-US, V36, P826	40	640	658	2	33	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					815	826		10.1016/S0092-8674(00)81442-7	http://dx.doi.org/10.1016/S0092-8674(00)81442-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630225	Bronze			2022-12-24	WOS:000073956700017
J	Kaufer, D; Friedman, A; Seidman, S; Soreq, H				Kaufer, D; Friedman, A; Seidman, S; Soreq, H			Acute stress facilitates long-lasting changes in cholinergic gene expression	NATURE			English	Article							HUMAN ACETYLCHOLINESTERASE; ALZHEIMERS-DISEASE; GULF-WAR; PROMOTER; BRAIN; PYRIDOSTIGMINE; NEURONS; CALCIUM; TACRINE; CELLS	Acute traumatic stress may lead to post-traumatic stress disorder (PTSD)(1), which is characterized by delayed neuropsychiatric symptoms including depression, irritability, and impaired cognitive performance(2). Curiously, inhibitors of the acetylcholine-hydrolysing enzyme acetylcholinesterase may induce psychopathologies that are reminiscent of PTSD3,4. It is unknown how a single stressful event mediates long-term neuronal plasticity. Moreover, no mechanism has been proposed to explain the convergent neuropsychological outcomes of stress and of acetylcholinesterase inhibition. However, acute stress elicits a transient increase in the amounts released of the neurotransmitter acetylcholine and a phase of enhanced neuronal excitability(5). Inhibitors of acetylcholinesterase also promote enhanced electrical brain activity(6), presumably by increasing the survival of acetylcholine at the synapse. Here we report that there is similar bidirectional modulation of genes that regulate acetylcholine availability after stress and blockade of acetylcholinesterase. These calcium-dependent changes in gene expression coincide with phases of rapid enhancement and delayed depression of neuronal excitability, Both of these phases are mediated by muscarinic acetylcholine receptors, Our results suggest a model in which robust cholinergic stimulation triggers rapid induction of the gene encoding the transcription factor c-Fos. This protein then mediates selective regulatory effects on the long-lasting activities of genes involved in acetylcholine metabolism.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Dept Neurosurg, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel	Hebrew University of Jerusalem; Ben Gurion University; Ben Gurion University; Ben Gurion University	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	soreq@shum.huji.ac.il		Soreq, Hermona/0000-0002-0955-526X				Andres C, 1997, P NATL ACAD SCI USA, V94, P8173, DOI 10.1073/pnas.94.15.8173; BAUSERO P, 1993, NEUROREPORT, V4, P287, DOI 10.1097/00001756-199303000-00015; Beeri R, 1997, J NEUROCHEM, V69, P2441; BEERI R, 1995, CURR BIOL, V5, P1063, DOI 10.1016/S0960-9822(95)00211-9; BENAZIZALOYA R, 1993, P NATL ACAD SCI USA, V90, P2471, DOI 10.1073/pnas.90.6.2471; CERVINI R, 1995, J BIOL CHEM, V270, P24654, DOI 10.1074/jbc.270.42.24654; COLE AE, 1983, SCIENCE, V221, P1299, DOI 10.1126/science.6612345; ENNIS M, 1992, EXP NEUROL, V118, P164, DOI 10.1016/0014-4886(92)90033-M; Friedman A, 1996, NAT MED, V2, P1382, DOI 10.1038/nm1296-1382; FRIEDMAN A, 1989, EUR J NEUROSCI, V1, P374, DOI 10.1111/j.1460-9568.1989.tb00802.x; GHOSH A, 1994, J NEUROBIOL, V25, P294, DOI 10.1002/neu.480250309; GURVITS TV, 1993, J NEUROPSYCH CLIN N, V5, P183; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; IMPERATO A, 1991, BRAIN RES, V538, P111, DOI 10.1016/0006-8993(91)90384-8; KARPEL R, 1994, EXP CELL RES, V210, P268, DOI 10.1006/excr.1994.1039; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; Koenigsberger C, 1997, J NEUROCHEM, V69, P1389; LAYER PG, 1995, PROG HISTOCHEM CYTOC, V29, P1; LI Y, 1993, J BIOL CHEM, V268, P3563; MILNER IB, 1994, JAMA-J AM MED ASSOC, V271, P661, DOI 10.1001/jama.1994.03510330039024; ROSENSTOCK L, 1991, LANCET, V338, P223, DOI 10.1016/0140-6736(91)90356-T; Sapolsky RM, 1996, SCIENCE, V273, P749, DOI 10.1126/science.273.5276.749; SEIDMAN S, 1995, MOL CELL BIOL, V15, P2993; SHARABI Y, 1991, ISRAEL J MED SCI, V27, P656; Sternfeld M, 1998, J NEUROSCI, V18, P1240; Wickelgren I, 1997, SCIENCE, V278, P1404; WINKER MA, 1994, JAMA-J AM MED ASSOC, V271, P1023, DOI 10.1001/jama.271.13.1023	27	510	528	1	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 28	1998	393	6683					373	377		10.1038/30741	http://dx.doi.org/10.1038/30741			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620801				2022-12-24	WOS:000073883600056
J	Williams, SP; Sigler, PB				Williams, SP; Sigler, PB			Atomic structure of progesterone complexed with its receptor	NATURE			English	Article							THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; CRYSTAL-STRUCTURE; RETINOIC ACID; C-TERMINUS; ACTIVATION; DIMERIZATION; RU486; MECHANISM; DNA	The physiological effects of progestins are mediated by the progesterone receptor, a member of the steroid/nuclear receptor superfamily(1). As progesterone is required for maintenance of pregnancy, its receptor has been a target for pharmaceuticals(2). Here we report the 1.8 Angstrom crystal structure of a progesterone-bound ligand-binding domain of the human progesterone receptor. The nature of this structure explains the receptor's selective affinity for progestins and establishes a common mode of recognition of 3-oxy steroids by the cognate receptors. Although the overall fold of the progesterone receptor is similar to that found in related receptors(3-6), the progesterone receptor has a quite different mode of dimerization(3,6). A hormone-induced stabilization of the carboxy-terminal secondary structure of the ligand-binding domain of the progesterone receptor accounts for the stereo-chemistry of this distinctive dimer, explains the receptor's characteristic pattern of ligand-dependent protease resistance and its loss of repression(7,8), and indicates how the anti-progestin RU486 might work in birth control. The structure also indicates that the analogous 3-keto-steroid receptors may have a similar mechanism of action.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06510 USA	Yale University; Howard Hughes Medical Institute; Yale University	Sigler, PB (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 160 Whitney Ave, New Haven, CT 06510 USA.			Williams, Shawn/0000-0001-8311-2638				ALLAN GF, 1992, J BIOL CHEM, V267, P19513; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BENHAMOU B, 1992, SCIENCE, V255, P206, DOI 10.1126/science.1372753; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; DEMARZO AM, 1992, BIOCHEMISTRY-US, V31, P10491, DOI 10.1021/bi00158a012; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EDWARDS DP, 1995, J STEROID BIOCHEM, V53, P449, DOI 10.1016/0960-0760(95)00091-D; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Jeyakumar M, 1997, MOL ENDOCRINOL, V11, P755, DOI 10.1210/me.11.6.755; Klotzbucher M, 1997, MOL ENDOCRINOL, V11, P768, DOI 10.1210/me.11.6.768; LANZ R, 1996, ENDOCRINOLOGY, V135, P2183; LeDouarin B, 1996, PHILOS T R SOC B, V351, P569, DOI 10.1098/rstb.1996.0056; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RODRIGUEZ R, 1990, MOL ENDOCRINOL, V4, P1782, DOI 10.1210/mend-4-12-1782; SKAFAR DF, 1993, J STEROID BIOCHEM, V44, P39, DOI 10.1016/0960-0760(93)90149-Q; SKAFAR DF, 1991, BIOCHEMISTRY-US, V30, P6148, DOI 10.1021/bi00239a010; TETAL MJ, 1997, MOL ENDOCRINOL, V11, P1114; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WISHART DS, 1994, COMPUT APPL BIOSCI, V10, P687; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang SM, 1996, MOL ENDOCRINOL, V10, P24, DOI 10.1210/me.10.1.24	28	542	564	3	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1998	393	6683					392	396		10.1038/30775	http://dx.doi.org/10.1038/30775			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620806				2022-12-24	WOS:000073883600061
J	Jamal, SA; Browner, WS; Bauer, DC; Cummings, SR				Jamal, SA; Browner, WS; Bauer, DC; Cummings, SR		Study Osteoporotic Fractures Res Grp	Warfarin use and risk for osteoporosis in elderly women	ANNALS OF INTERNAL MEDICINE			English	Article							SERUM UNDERCARBOXYLATED OSTEOCALCIN; BONE-MINERAL DENSITY; HIP FRACTURE; VITAMIN-K; CIRCULATING LEVELS; ANTICOAGULANT; THERAPY; NECK; MASS	Background: Vitamin K deficiency may be associated with osteoporosis. Objective: To assess the effects of warfarin on bone. Design: Prospective observational study. Setting: Four centers in the United States. Participants: 6201 elderly, postmenopausal women. Measurements: Self-reported warfarin use, bone mineral density at the hip and the heel, hip bone loss over 2 years, and fractures during 3.5 years of follow-up. Analyses were adjusted for baseline differences, age, weight, and estrogen use. Results: Compared with warfarin nonusers (n = 6052), warfarin users (n = 149) more frequently had poor health, involuntary weight loss, nonthiazide diuretic use, and frailty but had similar bone mineral density at the hip (difference, 1.6% [95% CI, -0.7% to 4.1%]) and heel (difference, 2.1% [CI, -1.6% to 5.6%]). Users and nonusers had similar rates of bone loss (1.1% and 0.8%; P = 0.18) and fractures (relative hazard, 1.0 [CI, 0.60 to 1.7]). Conclusion: In this population, warfarin use did not decrease bone mineral density or increase fracture rates.	Prevent Sci Grp, Suite 512,74 New Montgomery St, San Francisco, CA 94105 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)		sophie_jamal@quickmail.ucsf.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35582] Funding Source: Medline; NIA NIH HHS [AG05407, AG05394] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BINKLEY NC, 1995, J NUTR, V125, P1812, DOI 10.1093/jn/125.7.1812; BITENSKY L, 1988, J BONE JOINT SURG BR, V70, P663, DOI 10.1302/0301-620X.70B4.3403621; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; FIORE CE, 1990, SOUTH MED J, V83, P538, DOI 10.1097/00007611-199005000-00013; HART JP, 1984, LANCET, V2, P283, DOI 10.1016/S0140-6736(84)90321-0; HART JP, 1985, J CLIN ENDOCR METAB, V60, P1268, DOI 10.1210/jcem-60-6-1268; HODGES SJ, 1993, J BONE MINER RES, V8, P1241; HODGES SJ, 1991, BONE, V12, P387, DOI 10.1016/8756-3282(91)90027-G; HOUVENAGEL E, 1989, REV RHUM, V56, P677; MENON RK, 1987, J CLIN ENDOCR METAB, V64, P59, DOI 10.1210/jcem-64-1-59; MONREAL M, 1991, LANCET, V338, P706, DOI 10.1016/0140-6736(91)91292-3; PHILIP WJU, 1995, QJM-INT J MED, V88, P635; PIRO LD, 1982, J CLIN ENDOCR METAB, V54, P470, DOI 10.1210/jcem-54-2-470; PRICE PA, 1985, VITAM HORM, V42, P65; RESCH H, 1991, EUR HEART J, V12, P439, DOI 10.1093/oxfordjournals.eurheartj.a059914; ROSEN HN, 1993, AM J MED, V94, P62, DOI 10.1016/0002-9343(93)90121-5; Sato Y, 1997, STROKE, V28, P2390, DOI 10.1161/01.STR.28.12.2390; STEIGER P, 1992, J BONE MINER RES, V7, P625; SZULC P, 1994, J BONE MINER RES, V9, P1591; SZULC P, 1993, J CLIN INVEST, V91, P1769, DOI 10.1172/JCI116387	20	109	115	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1998	128	10					829	832		10.7326/0003-4819-128-10-199805150-00006	http://dx.doi.org/10.7326/0003-4819-128-10-199805150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM889	9599195				2022-12-24	WOS:000073586500006
J	Rocha, BA; Scearce-Levie, K; Lucas, JJ; Hiroi, N; Castanon, N; Crabbe, JC; Nestler, EJ; Hen, R				Rocha, BA; Scearce-Levie, K; Lucas, JJ; Hiroi, N; Castanon, N; Crabbe, JC; Nestler, EJ; Hen, R			Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor	NATURE			English	Article							PROGRESSIVE-RATIO SCHEDULE; 5-HT1B; ADDICTION; DOPAMINE; PROTEINS; ALCOHOL; ABUSE; BRAIN	There is increasing evidence that genetic factors can influence individual differences in vulnerability to drugs of abuse(1,2). Serotonin (5-hydroxytryptamine, 5-HT), acting through many receptors can modulate the activity of neural reward pathways and thus the effects of various drugs of abuse(3-8). Here we examine the effects of cocaine in mice lacking one of the serotonin-receptor subtypes, the 5-HT1B receptor(9). We show that mice lacking 5-HT1B display increased locomotor responses to cocaine and that they are more motivated to self-administer cocaine. We propose that even drug-naive 5-HT1B-knockout mice are in a behavioural and biochemical state that resembles that of wild-type mice sensitized to cocaine by repeated exposure to the drug. This altered state might be responsible for their increased vulnerability to cocaine.	Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA; Univ N Texas, Hlth Sci Ctr, Dept Pharmacol, Ft Worth, TX 76107 USA; Yale Univ, Sch Med, Mol Psychiat Lab, New Haven, CT 06508 USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Dept Vet Affairs Med Ctr, Portland, OR 97201 USA	Columbia University; University of North Texas System; University of North Texas Health Science Center; Yale University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System	Hen, R (corresponding author), Columbia Univ, Ctr Neurobiol & Behav, 722 W 168th St,PI Annes 731, New York, NY 10032 USA.	rh95@columbia.edu	Hiroi, Noboru/E-2215-2013; Lucas, Jose J./U-6543-2019	Hiroi, Noboru/0000-0002-6846-5969; Castanon, Nathalie/0000-0002-0079-0562; Lucas, Jose J./0000-0003-1597-3916	NIAAA NIH HHS [P60 AA010760] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA010760] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BOSCHERT U, 1994, NEUROSCIENCE, V58, P167, DOI 10.1016/0306-4522(94)90164-3; BROWNE SP, 1991, J FORENSIC SCI, V36, P1662; Brunner D, 1997, ANN NY ACAD SCI, V836, P81, DOI 10.1111/j.1749-6632.1997.tb52356.x; CALLAHAN PM, 1995, J PHARMACOL EXP THER, V274, P1414; CAMERON DL, 1994, J NEUROSCI, V14, P6763; CARROLL ME, 1990, PHARMACOL BIOCHEM BE, V35, P237, DOI 10.1016/0091-3057(90)90232-7; CASTANON N, 1996, SOC NEUR 26 ANN M WA; Chen JS, 1997, J NEUROSCI, V17, P4933; Crabbe JC, 1996, NAT GENET, V14, P98, DOI 10.1038/ng0996-98; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; DEPOORTERE RY, 1993, PHARMACOL BIOCHEM BE, V45, P539, DOI 10.1016/0091-3057(93)90503-L; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; Hiroi N, 1997, P NATL ACAD SCI USA, V94, P10397, DOI 10.1073/pnas.94.19.10397; HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2; HORGER BA, 1990, PHARMACOL BIOCHEM BE, V37, P707, DOI 10.1016/0091-3057(90)90552-S; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LOH EA, 1990, PSYCHOPHARMACOLOGY, V101, P262, DOI 10.1007/BF02244137; Lucas JJ, 1997, MOL PHARMACOL, V51, P755, DOI 10.1124/mol.51.5.755; Mandelzys A, 1997, J NEUROSCI, V17, P5407; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; Parsons LH, 1996, PSYCHOPHARMACOLOGY, V128, P150, DOI 10.1007/s002130050120; PARSONS LH, 1993, BRAIN RES, V606, P195, DOI 10.1016/0006-8993(93)90984-U; PARSONS LH, 1996, SOC NEUR 26 ANN M WA; PELTIER R, 1993, PSYCHOPHARMACOLOGY, V110, P390, DOI 10.1007/BF02244643; Rocha BA, 1997, PHARMACOL BIOCHEM BE, V57, P407, DOI 10.1016/S0091-3057(96)00444-3; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291	29	266	270	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 14	1998	393	6681					175	178		10.1038/30259	http://dx.doi.org/10.1038/30259			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN200	9603521				2022-12-24	WOS:000073619900050
J	Tucker, AW; Haddix, AC; Bresee, JS; Holman, RC; Parashar, UD; Glass, RI				Tucker, AW; Haddix, AC; Bresee, JS; Holman, RC; Parashar, UD; Glass, RI			Cost-effectiveness analysis of a rotavirus immunization program for the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ECONOMIC-ANALYSIS; YOUNG-CHILDREN; US CHILDREN; DIARRHEA; GASTROENTERITIS; INFECTION; VACCINES; INFANTS; TRIAL; MORTALITY	Context.-Rotavirus is the most common cause of severe diarrhea in children, and a live, oral vaccine may soon be licensed for prevention. Objective.-To estimate the economic impact of a national rotavirus immunization program in the United States. Design.-Cost-effectiveness was analyzed from the perspectives of the health care system and society. A decision tree used estimates of disease burden, costs, vaccine coverage, efficacy, and price obtained from published and unpublished sources. Intervention.-The proposed vaccine would be administered to infants at ages 2, 4, and 6 months as part of the routine schedule of childhood immunizations. Main Outcome Measures.-Total costs, outcomes prevented, and incremental cost-effectiveness. Results.-A routine, universal rotavirus immunization program would prevent 1.08 million cases of diarrhea, avoiding 34 000 hospitalizations, 95 000 emergency department visits, and 227 000 physician visits in the first 5 years of life. At $20 per dose, the program would cost $289 million and realize a net loss of $107 million to the health care system-$103 per case prevented. The program would provide a net savings of $296 million to society. Threshold analysis identified a break-even price per dose of $9 for the health care system and $51 for the societal perspective. Greater disease burden and greater vaccine efficacy and lower vaccine price increased cost-effectiveness. Conclusions.-A US rotavirus immunization program would be cost-effective from the perspectives of society and the health care system, although the cost of the immunization program would not be fully offset by the reduction in health care cost of rotavirus diarrhea unless the price fell to $9 per dose.	Ctr Dis Control & Prevent, Viral Gastroenteritis Sect, Resp & Enter Viruses Branch, US DHHS, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Prevent Effectiveness Branch, Div Prevent Res & Analyt Methods, Epidemiol Program Off, Atlanta, GA 30333 USA; Ctr Dis Control, Natl Ctr Infect Dis, Off Director, Div Viral & Rickettsial Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Glass, RI (corresponding author), Ctr Dis Control & Prevent, Viral Gastroenteritis Sect, Resp & Enter Viruses Branch, US DHHS, 1600 Clifton Rd NE,Mailstom G04, Atlanta, GA 30333 USA.							*ADV COMM IMM PRAC, 1997, ROT VACC PREV ROT DI, P1; AVENDANO P, 1993, PEDIATR INFECT DIS J, V12, P897, DOI 10.1097/00006454-199311000-00001; BERNSTEIN DI, 1995, JAMA-J AM MED ASSOC, V273, P1191, DOI 10.1001/jama.273.15.1191; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P57; CHALMERS TC, 1982, CONTROL CLIN TRIALS, P285; CHUNG MA, 1997, THESIS YALE U NEW HA; Clark HF, 1996, J INFECT DIS, V174, pS73, DOI 10.1093/infdis/174.Supplement_1.S73; CLEMENS JD, 1992, AM J EPIDEMIOL, V135, P865, DOI 10.1093/oxfordjournals.aje.a116382; DRUMMOND MF, 1984, CONTROL CLIN TRIALS, V5, P115, DOI 10.1016/0197-2456(84)90118-1; Glass RI, 1996, J INFECT DIS, V174, pS5, DOI 10.1093/infdis/174.Supplement_1.S5; GLASS RI, 1990, PROSPECTS PUBLIC HLT, V2, P102; GONZALEZ ML, 1996, SOCIOECONOMIC CHARAC, P77; GRIFFITHS RI, 1995, ARCH PEDIAT ADOL MED, V149, P407, DOI 10.1001/archpedi.1995.02170160061009; GURWITH M, 1981, J INFECT DIS, V144, P218, DOI 10.1093/infdis/144.3.218; GURWITH M, 1983, J INFECT DIS, V147, P685, DOI 10.1093/infdis/147.4.685; HADDIX A, 1994, PRACTICAL GUIDE PREV; *HEALTHC CONS AM, 1996, 1996 PHYS FEE COD GU, P42; HO MS, 1988, J INFECT DIS, V158, P1112, DOI 10.1093/infdis/158.5.1112; Jin SX, 1996, PEDIATR INFECT DIS J, V15, P397, DOI 10.1097/00006454-199605000-00004; Joensuu J, 1997, LANCET, V350, P1205, DOI 10.1016/S0140-6736(97)05118-0; KAPIKIAN AZ, 1993, JAMA-J AM MED ASSOC, V269, P627, DOI 10.1001/jama.269.5.627; KILGORE PE, 1995, JAMA-J AM MED ASSOC, V274, P1143, DOI 10.1001/jama.274.14.1143; KOOPMAN JS, 1984, AM J EPIDEMIOL, V119, P114, DOI 10.1093/oxfordjournals.aje.a113712; KOTLOFF KL, 1988, PEDIATR INFECT DIS J, V7, P753, DOI 10.1097/00006454-198811000-00002; LIEU TA, 1994, JAMA-J AM MED ASSOC, V271, P375, DOI 10.1001/jama.271.5.375; MARGOLIS HS, 1995, JAMA-J AM MED ASSOC, V274, P1201, DOI 10.1001/jama.274.15.1201; MATSON DO, 1990, J INFECT DIS, V162, P598, DOI 10.1093/infdis/162.3.598; *NAT CTR HLTH STAT, 1996, US DEP HLTH HUM SERV; Parashar UD, 1998, J INFECT DIS, V177, P13, DOI 10.1086/513808; PerezSchael I, 1997, NEW ENGL J MED, V337, P1181, DOI 10.1056/NEJM199710233371701; Rennels MB, 1996, PEDIATRICS, V97, P7; RODRIGUEZ WJ, 1980, AM J DIS CHILD, V134, P777, DOI 10.1001/archpedi.1980.02130200047015; RODRIGUEZ WJ, 1987, PEDIATR INFECT DIS J, V6, P170, DOI 10.1097/00006454-198702000-00006; Santosham M, 1997, J PEDIATR-US, V131, P632, DOI 10.1016/S0022-3476(97)70076-3; SMITH JC, 1995, PEDIATRICS, V96, P609; United States Census Bureau, 1996, CURR POP REP POP PRO	36	252	263	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1998	279	17					1371	1376		10.1001/jama.279.17.1371	http://dx.doi.org/10.1001/jama.279.17.1371			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK758	9582045	Bronze			2022-12-24	WOS:000073359800029
J	Chua, PR; Roeder, GS				Chua, PR; Roeder, GS			Zip2, a meiosis-specific protein required for the initiation of chromosome synapsis	CELL			English	Article							SYNAPTONEMAL COMPLEX-FORMATION; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; ESCHERICHIA-COLI; GENE-EXPRESSION; SHUTTLE VECTORS; RECA HOMOLOGS; DNA-REPAIR; YEAST	We describe the identification and characterization of the Saccharomyces cerevisiae ZIP2 gene, which encodes a novel meiosis-specific protein essential for synaptonemal complex formation. In the zip2 mutant, chromosomes are homologously paired but not synapsed. The Zip2 protein localizes to discrete foci on meiotic chromosomes; these foci correspond to sites of convergence between paired homologs that are believed to be sites of synapsis initiation. Localization of Zip2p requires the initiation of meiotic recombination. In a mutant defective in double-strand break repair, Zip2p colocalizes with proteins involved in double-strand break formation and processing. We propose that Zip2p promotes the initiation of chromosome synapsis and that localization of Zip2p to sites of interhomolog recombination ensures synapsis between homologous chromosomes.	Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Genet, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University	Chua, PR (corresponding author), Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028904] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28904] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; ALBINI SM, 1987, CHROMOSOMA, V95, P324, DOI 10.1007/BF00293179; Anderson LK, 1997, P NATL ACAD SCI USA, V94, P6868, DOI 10.1073/pnas.94.13.6868; ANDERSON LK, 1988, CHROMOSOMA, V97, P96, DOI 10.1007/BF00331799; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BUCKINGHAM LE, 1990, P NATL ACAD SCI USA, V87, P9406, DOI 10.1073/pnas.87.23.9406; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; BYERS B, 1975, P NATL ACAD SCI USA, V72, P5056, DOI 10.1073/pnas.72.12.5056; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; Chua PR, 1997, GENE DEV, V11, P1786, DOI 10.1101/gad.11.14.1786; DEMASSY B, 1994, P NATL ACAD SCI USA, V91, P11929, DOI 10.1073/pnas.91.25.11929; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; GILBERTSON LA, 1994, P NATL ACAD SCI USA, V91, P11934, DOI 10.1073/pnas.91.25.11934; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; IVANOV EL, 1992, GENETICS, V132, P651; JOHZUKA K, 1995, GENETICS, V139, P1521; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; KLECKNER N, 1991, COLD SH Q B, V56, P729; LOIDL J, 1994, J CELL BIOL, V125, P1191, DOI 10.1083/jcb.125.6.1191; LOIDL J, 1986, CHROMOSOMA, V93, P420, DOI 10.1007/BF00285824; McKee AHZ, 1997, GENETICS, V146, P797; MCKNIGHT GL, 1981, CELL, V25, P409, DOI 10.1016/0092-8674(81)90059-3; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; MOENS PB, 1969, CHROMOSOMA, V28, P1, DOI 10.1007/BF00325986; NAG DK, 1995, GENETICS, V141, P75; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; NEWLON CS, 1991, GENETICS, V129, P343; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; Prinz S, 1997, GENETICS, V146, P781; RASMUSSEN SW, 1978, CARLSBERG RES COMMUN, V43, P275, DOI 10.1007/BF02906106; ROCKMILL B, 1995, GENE DEV, V9, P2684, DOI 10.1101/gad.9.21.2684; ROCKMILL B, 1990, GENETICS, V126, P563; ROCKMILL B, 1991, GENE DEV, V5, P2392, DOI 10.1101/gad.5.12b.2392; ROEDER GS, 1995, P NATL ACAD SCI USA, V92, P10450, DOI 10.1073/pnas.92.23.10450; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; Schwacha A, 1997, CELL, V90, P1123, DOI 10.1016/S0092-8674(00)80378-5; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SEIFERT HS, 1986, GENETIC ENG PRINCIPL, P123; Sharpe PT, 1995, CONNECT TISSUE RES, V32, P17, DOI 10.3109/03008209509013701; Sherman F., 1986, METHODS YEAST GENETI; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; STACK S, 1986, CHROMOSOMA, V94, P253, DOI 10.1007/BF00290853; Storlazzi A, 1996, P NATL ACAD SCI USA, V93, P9043, DOI 10.1073/pnas.93.17.9043; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1995, J CELL BIOL, V128, P455, DOI 10.1083/jcb.128.4.455; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; Tettelin H, 1997, NATURE, V387, P81, DOI 10.1038/387s081; Tsubouchi H, 1998, MOL CELL BIOL, V18, P260, DOI 10.1128/MCB.18.1.260; TUNG KS, 1998, IN PRESS GENETICS; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; ZICKLER D, 1992, GENETICS, V132, P135	66	189	191	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1998	93	3					349	359		10.1016/S0092-8674(00)81164-2	http://dx.doi.org/10.1016/S0092-8674(00)81164-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590170	hybrid			2022-12-24	WOS:000073471500011
J	Lannin, DR; Mathews, HF; Mitchell, J; Swanson, MS; Swanson, FH; Edwards, MS				Lannin, DR; Mathews, HF; Mitchell, J; Swanson, MS; Swanson, FH; Edwards, MS			Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AFRICAN-AMERICAN WOMEN; CARE-SEEKING BEHAVIOR; CERVICAL-CANCER; UNITED-STATES; MAMMOGRAPHY UTILIZATION; WHITE WOMEN; SURVIVAL; RACE; BLACK; DIAGNOSIS	Context.-Breast cancer mortality is higher among African American women than among white women in the United States, but the reasons for the racial difference are not known. Objective.-To evaluate the influence of socioeconomic and cultural factors on the racial difference in breast cancer stage at diagnosis. Design.-Case-control study of patients diagnosed as having breast cancer at the University Medical Center of Eastern Carolina from 1985 through 1992. Setting.-The major health care facility for 2 rural counties in eastern North Carolina. Subjects.-Five hundred forty of 743 patients with newly diagnosed breast cancer and 414 control women from the community matched by age, race, and area of residence. Main Outcome Measures.-Breast cancer stage at diagnosis. Results.-Of the 540 patients, 94 (17.4%) presented with TNM stage III or IV disease. The following demographic and socioeconomic factors were significant predictors of advanced stage: being African American (odds ratio [OR], 3.0; 95% confidence interval [CI], 1.9-4.7); having low income (OR, 3.7; 95% CI, 2.1-6.5); never having been married (OR, 2.9; 95% CI, 1.4-5.9); having no private health insurance (OR, 2.5; 95% CI, 1.6-4.0);delaying seeing a physician because of money (OR, 1.6, 95% CI, 1.1-2.5); or lacking transportation (OR, 2.0; 95% CI, 1.2-3.6). Univariate analysis also revealed a large number of cultural beliefs to be significant predictors. Examples include the following beliefs: air causes a cancer to spread (OR, 2.8; 95% CI, 1.8-4.3); the devil can cause a person to get cancer (OR, 2.1, 95% CI, 1.2-3.5);women who have breast surgery are no longer attractive to men (OR, 1.9, 95% CI, 1.1-3.5); and chiropractic is an effective treatment for breast cancer (OR, 2.4; 95% CI, 1.4-4.4). When the demographic and socioeconomic variables were included in a multivariate logistic regression model, the OR for late stage among Af rican Americans decreased to 1.8 (95% CI, 1.1-3.2) compared with 3.0 (95% CI, 1.9-4.7) for race alone. However, when the belief measures were included with the demographic and socioeconomic variables, the OR for late stage among African Americans decreased further to 1.2 (95% CI, 0.6-2.5). Conclusions.-Socioeconomic factors alone were not sufficient to explain the dramatic effect of race on breast cancer stage; however, socioeconomic variables in conjunction with cultural beliefs and attitudes could largely account for the observed effect.	E Carolina Univ, Sch Med, Dept Surg, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Dept Family Med, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Dept Sociol, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Dept Anthropol, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Leo W Jenkins Canc Ctr, Greenville, NC 27858 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	Lannin, DR (corresponding author), E Carolina Univ, Sch Med, Dept Surg, PCMH 304, Greenville, NC 27858 USA.							AZTELL LM, 1978, J NATL CANCER I, V60, P1209; BAILEY EJ, 1987, J NATL MED ASSOC, V79, P389; BAIN RP, 1986, J CHRON DIS, V39, P631, DOI 10.1016/0021-9681(86)90188-8; BAQUET CR, 1986, PUBL NIH; BERG JW, 1977, CANCER, V39, P467, DOI 10.1002/1097-0142(197702)39:2<467::AID-CNCR2820390215>3.0.CO;2-B; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BUESCHER PA, 1994, CHES STUDIES SPECIAL, V82, P1; CAPLAN LS, 1992, J GERONTOL, V47, P101; CELLA DF, 1991, J CLIN ONCOL, V9, P1500, DOI 10.1200/JCO.1991.9.8.1500; CHAVEZ LR, 1995, MED ANTHROPOL Q, V9, P40, DOI 10.1525/maq.1995.9.1.02a00030; CHEN VW, 1994, CANCER EPIDEM BIOMAR, V3, P127; Chevarley F, 1997, AM J PUBLIC HEALTH, V87, P775, DOI 10.2105/AJPH.87.5.775; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; DRESSLER WW, 1993, MED ANTHROPOL Q, V7, P325, DOI 10.1525/maq.1993.7.4.02a00030; ELEY JW, 1994, JAMA-J AM MED ASSOC, V272, P947, DOI 10.1001/jama.272.12.947; FARLEY TA, 1989, AM J PUBLIC HEALTH, V79, P1508, DOI 10.2105/AJPH.79.11.1508; FISHER ER, 1993, CANCER, V71, P2507, DOI 10.1002/1097-0142(19930415)71:8<2507::AID-CNCR2820710813>3.0.CO;2-0; FLETCHER SW, 1993, JNCI-J NATL CANCER I, V85, P112, DOI 10.1093/jnci/85.2.112; FREEMAN HP, 1989, CANCER, V63, P2562, DOI 10.1002/1097-0142(19890615)63:12<2562::AID-CNCR2820631234>3.0.CO;2-0; FREEMAN HP, 1989, CA, V39, P267; GORDON NH, 1992, AM J EPIDEMIOL, V135, P609, DOI 10.1093/oxfordjournals.aje.a116340; GREGG J, 1994, SOC SCI MED, V39, P519, DOI 10.1016/0277-9536(94)90094-9; Hsu JL, 1997, J NATL CANCER I, V89, P1311, DOI 10.1093/jnci/89.17.1311; HUNTER CP, 1993, J NATL CANCER I, V85, P1129, DOI 10.1093/jnci/85.14.1129; JEPSON C, 1991, AM J PUBLIC HEALTH, V81, P501, DOI 10.2105/AJPH.81.4.501; JONES BA, 1995, CANCER, V75, P2103, DOI 10.1002/1097-0142(19950415)75:8<2103::AID-CNCR2820750813>3.0.CO;2-2; KATZ SJ, 1994, JAMA-J AM MED ASSOC, V272, P530, DOI 10.1001/jama.272.7.530; Kleinbaum DG, 1994, LOGISTIC REGRESSION; LAUVER D, 1992, NURS RES, V41, P236; LAUVER D, 1994, RES NURS HEALTH, V17, P421, DOI 10.1002/nur.4770170605; LOEHRER PJ, 1991, CANCER, V68, P1665, DOI 10.1002/1097-0142(19911001)68:7<1665::AID-CNCR2820680734>3.0.CO;2-3; MANDELBLATT J, 1991, AM J PUBLIC HEALTH, V81, P646, DOI 10.2105/AJPH.81.5.646; MATHEWS HF, 1994, SOC SCI MED, V38, P789, DOI 10.1016/0277-9536(94)90151-1; MICHIELUTTE R, 1982, SOC SCI MED, V16, P245, DOI 10.1016/0277-9536(82)90335-5; Mitchell J, 1997, RES AGING, V19, P199, DOI 10.1177/0164027597192003; NATARAJAN N, 1985, CANCER-AM CANCER SOC, V56, P1704, DOI 10.1002/1097-0142(19851001)56:7<1704::AID-CNCR2820560740>3.0.CO;2-L; OMalley MS, 1997, AM J PUBLIC HEALTH, V87, P782, DOI 10.2105/AJPH.87.5.782; OVERBY MM, 1997, ANTHR NEWSLETT, V38, P1; PACHTER LM, 1994, JAMA-J AM MED ASSOC, V271, P690, DOI 10.1001/jama.271.9.690; PEREZSTABLE EJ, 1992, JAMA-J AM MED ASSOC, V268, P3219, DOI 10.1001/jama.268.22.3219; REYNOLDS P, 1994, CANCER EPIDEM BIOMAR, V3, P253; RICHARDSON JL, 1992, BRIT J CANCER, V65, P922, DOI 10.1038/bjc.1992.193; ROACH M, 1995, J NATL MED ASSOC, V87, P214; SWANSON GM, 1990, CANCER-AM CANCER SOC, V66, P1297, DOI 10.1002/1097-0142(19900915)66:6<1297::AID-CNCR2820660633>3.0.CO;2-M; SWANSON GM, 1993, CANCER, V72, P788, DOI 10.1002/1097-0142(19930801)72:3<788::AID-CNCR2820720326>3.0.CO;2-C; TROCK B, 1993, CANCER EPIDEM BIOMAR, V2, P151; VERNON SW, 1985, CANCER-AM CANCER SOC, V55, P1563, DOI 10.1002/1097-0142(19850401)55:7<1563::AID-CNCR2820550726>3.0.CO;2-1; WELLS BL, 1992, AM J PUBLIC HEALTH, V82, P1383, DOI 10.2105/AJPH.82.10.1383; Wilson-Ford V, 1992, Health Soc Work, V17, P28; YOUNG JL, 1984, J NATL CANCER I, V73, P341, DOI 10.1093/jnci/73.2.341; [No title captured]	51	469	474	0	40	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1801	1807		10.1001/jama.279.22.1801	http://dx.doi.org/10.1001/jama.279.22.1801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZR635	9628711	Bronze			2022-12-24	WOS:000073998500032
J	Anderson, JD; Schubert, G; Jacobson, RA; Lau, EL; Moore, WB; Sjogren, WL				Anderson, JD; Schubert, G; Jacobson, RA; Lau, EL; Moore, WB; Sjogren, WL			Distribution of rock, metals, and ices in Callisto	SCIENCE			English	Article							GALILEAN SATELLITES; TIDAL DISSIPATION; ICY SATELLITES; INTERNAL STRUCTURES; GANYMEDE; MODELS; IO; EVOLUTION; MIXTURES	Radio Doppler data from a single encounter (C3) of the Galileo spacecraft with Callisto, the outermost Galilean moon of Jupiter, indicated that Callisto was probably undifferentiated. Now, similar data from a second encounter (C9) corroborate this conclusion, but more accurate data from a third encounter (C10) indicate that the rock and ice within Callisto have partially, but not completely, separated. Callisto may be differentiated into a rock-metal core less than 25 percent of Callisto's radius, an outer layer of clean ice less than 350 km thick, and a middle layer of mixed rock and ice. Models in which ice and rock are mixed all the way to the center of Callisto are also consistent with the data.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Dept Earth & Space Sci, Los Angeles, CA 90095 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of California System; University of California Los Angeles	Anderson, JD (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.							Anderson JD, 1996, NATURE, V384, P541, DOI 10.1038/384541a0; Anderson JD, 1997, NATURE, V387, P264, DOI 10.1038/387264a0; ANDERSON JD, 1974, EXPT GRAVITATION, P163; COHEN ER, 1996, PHYS TODAY, V49, pBG9; Collins GC, 1998, GEOPHYS RES LETT, V25, P233, DOI 10.1029/97GL03772; Davies ME, 1992, CELEST MECH DYN ASTR, V53, P377, DOI 10.1007/BF00051818; DERMOTT SF, 1979, ICARUS, V37, P310, DOI 10.1016/0019-1035(79)90137-4; FRIEDSON AJ, 1983, ICARUS, V56, P1, DOI 10.1016/0019-1035(83)90124-0; HOBBS PV, 1974, ICE PHYSICS; HUBBARD WB, 1978, ICARUS, V33, P336, DOI 10.1016/0019-1035(78)90153-7; Kaula W.M., 1966, THEORY SATELLITE GEO; KESZTHELYI L, IN PRESS ICARUS; Khurana KK, 1997, NATURE, V387, P262, DOI 10.1038/387262a0; KLEMASZEWSKI J, COMMUNICATION; LELIWAKOPYSTYNSKI J, 1994, PLANET SPACE SCI, V42, P545, DOI 10.1016/0032-0633(94)90076-0; LIESKE JH, 1980, ASTRON ASTROPHYS, V82, P340; LUPO MJ, 1982, ICARUS, V52, P40, DOI 10.1016/0019-1035(82)90167-1; MALHOTRA R, 1991, ICARUS, V94, P399, DOI 10.1016/0019-1035(91)90237-N; MCEWEN AB, UNPUB; McKinnon WB, 1997, ICARUS, V130, P540, DOI 10.1006/icar.1997.5826; Moyer T., 1971, JPLTR321527 CALTECH; MUELLER S, 1988, ICARUS, V76, P437, DOI 10.1016/0019-1035(88)90014-0; PAPPALARDO RR, UNPUB; PEALE SJ, 1979, SCIENCE, V203, P892, DOI 10.1126/science.203.4383.892; PROCKTER LM, UNPUB; ROSS MN, 1985, ICARUS, V64, P391, DOI 10.1016/0019-1035(85)90063-6; SCHENK PM, 1995, J GEOPHYS RES-PLANET, V100, P19023, DOI 10.1029/95JE01855; Schubert G, 1996, NATURE, V384, P544, DOI 10.1038/384544a0; SCHUBERT G, 1994, ICARUS, V111, P433, DOI 10.1006/icar.1994.1154; SCHUBERT G, 1981, ICARUS, V47, P46, DOI 10.1016/0019-1035(81)90090-7; SCHUBERT G, 1986, SATELLITES, P629; SEGATZ M, 1988, ICARUS, V75, P187, DOI 10.1016/0019-1035(88)90001-2; Showman AP, 1997, ICARUS, V127, P93, DOI 10.1006/icar.1996.5669; SHOWMAN DJ, 1997, ICARUS, V129, P367; Squyres S. W., 1986, SATELLITES, P293; TAPLEY BD, 1973, RECENT ADV DYNAMICAL, P396; WOO R, 1979, J GEOPHYS RES-SPACE, V84, P7288, DOI 10.1029/JA084iA12p07288; ZHARKOV VN, 1985, ICARUS, V61, P92, DOI 10.1016/0019-1035(85)90157-5; [No title captured]	39	67	71	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1573	1576		10.1126/science.280.5369.1573	http://dx.doi.org/10.1126/science.280.5369.1573			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616114				2022-12-24	WOS:000074061200032
J	Griffiths, I; Klugmann, M; Anderson, T; Yool, D; Thomson, C; Schwab, MH; Schneider, A; Zimmermann, F; McCulloch, M; Nadon, N; Nave, KA				Griffiths, I; Klugmann, M; Anderson, T; Yool, D; Thomson, C; Schwab, MH; Schneider, A; Zimmermann, F; McCulloch, M; Nadon, N; Nave, KA			Axonal swellings and degeneration in mice lacking the major proteolipid of myelin	SCIENCE			English	Article							PELIZAEUS-MERZBACHER DISEASE; PROTEIN GENE; TRANSPORTED ORGANELLES; JIMPY MOUSE; EXPRESSION; MUTATION; FAMILY; HYPOMYELINATION; ACCUMULATION; DISRUPTION	Glial cells produce myelin and contribute to axonal morphology in the nervous system. Two myelin membrane proteolipids, PLP and DM20, were shown to be essential for the integrity of myelinated axons. In the absence of PLP-DM20, mice assembled compact myelin sheaths but subsequently developed widespread axonal swellings and degeneration, associated predominantly with small-caliber nerve fibers. Similar swellings were absent in dysmyelinated shiverer mice, which lack myelin basic protein (MBP), but recurred in (MBPPLP)-P-star double mutants. Thus, fiber degeneration, which was probably secondary to impaired axonal transport, could indicate that myelinated axons require local oligodendroglial support.	Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; Univ Glasgow, Dept Vet Clin Sci, Appl Neurobiol Grp, Glasgow G61 1QH, Lanark, Scotland	Ruprecht Karls University Heidelberg; Oklahoma Medical Research Foundation; University of Glasgow	Nave, KA (corresponding author), Univ Heidelberg, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	nave@sun0.urz.uni-heldelberg.de	Nave, Klaus-Armin/C-8883-2011	Yool, Donald/0000-0002-3562-9111	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anzini P, 1997, J NEUROSCI, V17, P4545; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BOISON D, 1994, P NATL ACAD SCI USA, V91, P11709, DOI 10.1073/pnas.91.24.11709; BUCHHEIT TE, 1992, J NEUROBIOL, V23, P217, DOI 10.1002/neu.480230303; DENTINGER P, 1982, J NEUROCYTOL, V11, P671; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; Duncan A, 1996, GLIA, V17, P349, DOI 10.1002/(SICI)1098-1136(199608)17:4<349::AID-GLIA10>3.3.CO;2-V; DUNCAN ID, 1987, P NATL ACAD SCI USA, V84, P6287, DOI 10.1073/pnas.84.17.6287; DUNCAN ID, 1989, GLIA, V2, P148, DOI 10.1002/glia.440020303; FRIEDE RL, 1970, BRAIN RES, V19, P165, DOI 10.1016/0006-8993(70)90432-4; FRIEDE RL, 1972, ANAT RECORD, V172, P1, DOI 10.1002/ar.1091720101; Garbern JY, 1997, NEURON, V19, P205, DOI 10.1016/S0896-6273(00)80360-8; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; Gow A, 1996, NAT GENET, V13, P422, DOI 10.1038/ng0896-422; Griffiths I. M., UNPUB; GRIFFITHS IR, 1981, J NEUROL SCI, V50, P423, DOI 10.1016/0022-510X(81)90154-4; Griffiths IR, 1996, BIOESSAYS, V18, P789, DOI 10.1002/bies.950181005; HELYNCK G, 1983, EUR J BIOCHEM, V133, P689, DOI 10.1111/j.1432-1033.1983.tb07518.x; Jung M, 1996, J NEUROSCI, V16, P7920; KITAGAWA K, 1993, NEURON, V11, P433, DOI 10.1016/0896-6273(93)90148-K; Klugmann M, 1997, NEURON, V18, P59, DOI 10.1016/S0896-6273(01)80046-5; MCDONALD WI, 1994, J NEUROPATH EXP NEUR, V53, P338, DOI 10.1097/00005072-199407000-00003; NADON NL, 1994, J NEUROCHEM, V63, P822; OLDFIELD BJ, 1982, J NEUROCYTOL, V11, P627, DOI 10.1007/BF01262428; RASKIND WH, 1991, AM J HUM GENET, V49, P1355; READHEAD C, 1994, NEURON, V12, P583, DOI 10.1016/0896-6273(94)90214-3; ROACH A, 1985, CELL, V42, P149, DOI 10.1016/S0092-8674(85)80110-0; Sanchez I, 1996, J NEUROSCI, V16, P5095; SAUGIERVEBER P, 1994, NAT GENET, V6, P257, DOI 10.1038/ng0394-257; SCHNEIDER A, 1995, P NATL ACAD SCI USA, V92, P4447, DOI 10.1073/pnas.92.10.4447; SCHNEIDER A, 1992, NATURE, V358, P758, DOI 10.1038/358758a0; Seitelberger F, 1996, NEURODYSTROPHIES NEU, P559; Sistermans EA, 1996, HUM GENET, V97, P337, DOI 10.1007/s004390050046; SKOFF R, 1981, BRAIN RES, V212, P175, DOI 10.1016/0006-8993(81)90047-0; SMITH RS, 1980, J NEUROCYTOL, V9, P39, DOI 10.1007/BF01205226; SNIPES GJ, 1995, BRAIN PATHOL, V5, P233, DOI 10.1111/j.1750-3639.1995.tb00600.x; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; TSUKITA S, 1980, J CELL BIOL, V84, P513, DOI 10.1083/jcb.84.3.513; TYTELL M, 1986, BRAIN RES, V363, P161, DOI 10.1016/0006-8993(86)90671-2; WILLIAMS MA, 1977, PRACTICAL METHODS EL, V6, P5	40	637	642	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1610	1613		10.1126/science.280.5369.1610	http://dx.doi.org/10.1126/science.280.5369.1610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616125				2022-12-24	WOS:000074061200043
J	Lan, N; Howrey, RP; Lee, SW; Smith, CA; Sullenger, BA				Lan, N; Howrey, RP; Lee, SW; Smith, CA; Sullenger, BA			Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors	SCIENCE			English	Article							MESSENGER-RNA; TETRAHYMENA; HEMOGLOBIN; SEQUENCE; GENE; MORBIDITY; GELATION	Sickle cell anemia is the most common heritable hematological disease, yet no curative treatment exists for this disorder. Moreover, the intricacies of globin gene expression have made the development of treatments for hemoglobinopathies based on gene therapy difficult. An alternative genetic approach to sickle cell therapy is based on RNA repair. A trans-splicing group I ribozyme was used to alter mutant beta-globin transcripts in erythrocyte precursors derived from peripheral blood from individuals with sickle cell disease. Sickle beta-globin transcripts were converted into messenger RNAs encoding the anti-sickling protein gamma-globin. These results suggest that RNA repair may become a useful approach in the treatment of genetic disorders.	Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Genet, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Pediat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Med, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Sullenger, BA (corresponding author), Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Surg, Durham, NC 27710 USA.	sulle001@mc.duke.edu		Lee, Seong-Wook/0000-0003-1718-7601	NHLBI NIH HHS [HL57606] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057606] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRIN C, 1994, BIOCHEM CELL BIOL, V72, P377, DOI 10.1139/o94-050; ASHCROFT MT, 1976, LANCET, V2, P784; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEHE MJ, 1979, J MOL BIOL, V133, P137, DOI 10.1016/0022-2836(79)90254-7; Bertrand E, 1997, RNA, V3, P75; CAMPBELL TB, 1995, RNA, V1, P598; CAVALLESCO C, 1980, GENE, V12, P215, DOI 10.1016/0378-1119(80)90103-1; CECH T, 1995, BIO-TECHNOL, V13, P323, DOI 10.1038/nbt0495-323; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; GRASSO JA, 1977, J CELL BIOL, V73, P206, DOI 10.1083/jcb.73.1.206; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; Jones JT, 1997, NAT BIOTECHNOL, V15, P902, DOI 10.1038/nbt0997-902; Jones JT, 1996, NAT MED, V2, P643, DOI 10.1038/nm0696-643; KRAMER MS, 1978, NEW ENGL J MED, V299, P686, DOI 10.1056/NEJM197809282991303; LAN N, UNPUB; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PLATT OS, 1993, HEMATOLOGY INFANCY C, P732; POWARS DR, 1984, BLOOD, V63, P921, DOI 10.1182/blood.V63.4.921.921; RAMIREZ F, 1975, J BIOL CHEM, V250, P6054; RUCKNAGEL DL, 1987, DEV CONTROL GLOBIN G, P487; SADELAIN M, 1995, P NATL ACAD SCI USA, V92, P6728, DOI 10.1073/pnas.92.15.6728; SEARS DA, 1978, AM J MED, V64, P1021, DOI 10.1016/0002-9343(78)90458-8; SULLENGER BA, 1995, CHEM BIOL, V2, P249, DOI 10.1016/1074-5521(95)90043-8; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; SUNSHINE HR, 1978, NATURE, V275, P238, DOI 10.1038/275238a0; TELEN MJ, 1987, VOX SANG, V52, P236, DOI 10.1111/j.1423-0410.1987.tb03035.x; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	29	179	192	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	1998	280	5369					1593	1596		10.1126/science.280.5369.1593	http://dx.doi.org/10.1126/science.280.5369.1593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616120				2022-12-24	WOS:000074061200038
J	Yin, MJ; Christerson, LB; Yamamoto, Y; Kwak, YT; Xu, SC; Mercurio, F; Barbosa, M; Cobb, MH; Gaynor, RB				Yin, MJ; Christerson, LB; Yamamoto, Y; Kwak, YT; Xu, SC; Mercurio, F; Barbosa, M; Cobb, MH; Gaynor, RB			HTLV-I tax protein binds to MEKK1 to stimulate I kappa B kinase activity and NF-kappa B activation	CELL			English	Article							CELL LEUKEMIA-VIRUS; SITE-SPECIFIC PHOSPHORYLATION; ALPHA; GENE; IDENTIFICATION; TRANSFORMATION; PATHWAYS; CASCADE; REGION; CREB	NF-kappa B, a key regulator of the cellular inflammatory and immune response, is activated by the HTLV-I transforming and transactivating protein Tax. We show that Tax binds to the amino terminus of the protein kinase MEKK1, a component of an I kappa B kinase complex, and stimulates MEKK1 kinase activity. Tax expression increases the activity of I kappa B kinase 8 (IKK beta) to enhance phosphorylation of serine residues in I kappa B alpha that lead to its degradation. Dominant negative mutants of both IKK beta and MEKK1 prevent Tax activation of the NF-kappa B pathway. Furthermore, recombinant MEKK1 stimulates IKK beta phosphorylation of I kappa B alpha. Thus, Tax-mediated increases in NF-kappa B nuclear translocation result from direct interactions of Tax and MEKK1 leading to enhanced IKK beta phosphorylation of I kappa B alpha.	Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Harold Simmons Canc Ctr,Div Hematol Oncol, Dallas, TX 75235 USA; Signal Pharmaceut Inc, San Diego, CA 92121 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gaynor, RB (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, Dallas, TX 75235 USA.			Cobb, Melanie/0000-0003-0833-5473				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHOI KY, 1994, CELL, V78, P499; DEAK JC, 1997, J BIOCH, V322, P185; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FELBER BK, 1985, SCIENCE, V229, P54; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; KOEFFLER HP, 1984, BLOOD, V64, P482; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; OHTANI K, 1989, NUCLEIC ACIDS RES, V17, P1589, DOI 10.1093/nar/17.4.1589; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; POLESZ BJ, 1980, P NATL ACAD SCI USA, V77, P7415; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YAN MH, 1994, NATURE, V372, P798; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	43	229	234	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					875	884		10.1016/S0092-8674(00)81447-6	http://dx.doi.org/10.1016/S0092-8674(00)81447-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630230	Bronze			2022-12-24	WOS:000073956700022
J	Bannon, MJ; Ross, EM				Bannon, MJ; Ross, EM			Administration of medicines in school: who is responsible?	BRITISH MEDICAL JOURNAL			English	Article							TEACHERS; ASTHMA; CHILDREN; EPILEPSY; ILLNESS; SERVICE; AGE		Northwick Pk Hosp, Northwick Pk & St Marks NHS Trust, Harrow HA1 3UJ, Middx, England; Univ London Kings Coll, Mary Sheridan Ctr, London SE11 4QW, England	Imperial College London; University of London; King's College London	Bannon, MJ (corresponding author), Northwick Pk Hosp, Northwick Pk & St Marks NHS Trust, Harrow HA1 3UJ, Middx, England.							ANDERSON HR, 1994, BRIT MED J, V308, P1600, DOI 10.1136/bmj.308.6944.1600; BAGNALL P, 1996, DIFFERENT LIGHT SCH; BANNON M. J., 1995, PROG COM CH HLTH, V1, P125; BANNON MJ, 1992, ARCH DIS CHILD, V67, P1467, DOI 10.1136/adc.67.12.1467; BEVIS M, 1990, ARCH DIS CHILD, V65, P622, DOI 10.1136/adc.65.6.622; Billingham K, 1998, BRIT MED J, V316, P406, DOI 10.1136/bmj.316.7129.406; *BMA COMM HLTH DOC, 1994, MED SCH; BRADBURY AJ, 1983, ARCH DIS CHILD, V58, P692, DOI 10.1136/adc.58.9.692; CASEY FA, 1994, ARCH DIS CHILD, V70, P382, DOI 10.1136/adc.70.5.382; CELANO MP, 1993, J LEARN DISABIL-US, V26, P23, DOI 10.1177/002221949302600103; CHETCUTI P, 1993, ARCH DIS CHILD, V68, P167, DOI 10.1136/adc.68.2.167; *DEP ED EMPL DEP H, 1996, SUPP PUP MED NEEDS S; Dyer J, 1996, Prof Nurse, V11, P518; Eboh W O, 1996, Br J Nurs, V5, P30; EISER C, 1995, ARCH DIS CHILD, V72, P302, DOI 10.1136/adc.72.4.302; FILIMORE EJ, 1997, ARCH DIS CHILD, V77, P420; FOX TK, 1991, PUBLIC HEALTH, V105, P399, DOI 10.1016/S0033-3506(05)80600-6; Leffert Nancy, 1993, Current Opinion in Pediatrics, V5, P429; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; *NHS MAN EX, 1992, PAT CHART PRIM HLTH; *NHS MAN EX, 1995, CHILDR CHART; PAPOLA P, 1994, PEDIATRICS, V94, P914; Polnay L, 1995, HLTH NEEDS SCH AGE C; STURNIOLO MG, 1994, ARCH DIS CHILD, V70, P424, DOI 10.1136/adc.70.5.424; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; VERITY CM, 1985, PAEDIAT PERSPECTIVES; WHITMORE K, 1984, PROGR CHILD HLTH, V1; 1991, CONTACT FAMILY DIREC	28	11	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1998	316	7144					1591	1593		10.1136/bmj.316.7144.1591	http://dx.doi.org/10.1136/bmj.316.7144.1591			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ495	9596602	Green Published			2022-12-24	WOS:000073867800031
J	Farley, KA; Montanari, A; Shoemaker, EM; Shoemaker, CS				Farley, KA; Montanari, A; Shoemaker, EM; Shoemaker, CS			Geochemical evidence for a comet shower in the Late Eocene	SCIENCE			English	Article							INTERPLANETARY DUST; OORT CLOUD; MASS EXTINCTIONS; ORIGIN; MASSIGNANO; SEDIMENTS; IMPACTS; FLUX	Analyses of pelagic limestones indicate that the flux of extraterrestrial helium-3 to Earth was increased for a 2.5-million year (My) period in the late Eocene. The enhancement began similar to 1 My before and ended similar to 1.5 My after the major impact events that produced the large Popigai and Chesapeake Bay craters similar to 36 million years ago. The correlation between increased concentrations of helium-3, a tracer of fine-grained interplanetary dust, and large impacts indicates that the abundance of Earth-crossing objects and dustiness in the inner solar system were simultaneously but only briefly enhanced. These observations provide evidence for a comet shower triggered by an impulsive perturbation of the Oort cloud.	CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Ecole Mines, Paris, France; Osservatorio Geol Coldigioco, I-62020 Frontale Apiro, Apiro, Italy; US Geol Survey, Flagstaff, AZ 86001 USA	California Institute of Technology; UDICE-French Research Universities; PSL Research University Paris; MINES ParisTech; United States Department of the Interior; United States Geological Survey	Farley, KA (corresponding author), CALTECH, Div Geol & Planetary Sci, MS 170-25, Pasadena, CA 91125 USA.	farley@gps.caltech.edu	Farley, Kenneth/AAE-7735-2020	Farley, Kenneth/0000-0002-7846-7546				AMARI S, 1985, NATURE, V317, P520, DOI 10.1038/317520a0; Bottomley R, 1997, NATURE, V388, P365, DOI 10.1038/41073; Clymer AK, 1996, GEOLOGY, V24, P483, DOI 10.1130/0091-7613(1996)024<0483:SQFTLE>2.3.CO;2; DERMOTT SF, 1984, NATURE, V312, P505, DOI 10.1038/312505a0; Dermott SF, 1996, ASTR SOC P, V104, P143; FARLEY KA, 1995, NATURE, V376, P153, DOI 10.1038/376153a0; Farley KA, 1997, GEOCHIM COSMOCHIM AC, V61, P2309, DOI 10.1016/S0016-7037(97)00068-9; Gladman BJ, 1997, SCIENCE, V277, P197, DOI 10.1126/science.277.5323.197; Grieve RAF, 1996, EARTH MOON PLANETS, V72, P357, DOI 10.1007/BF00117541; HAZEL J, 1988, PALAIOS, V4, P318; HILLS JG, 1981, ASTRON J, V86, P1730, DOI 10.1086/113058; HUT P, 1987, NATURE, V329, P118, DOI 10.1038/329118a0; KELLER G, 1983, SCIENCE, V221, P150, DOI 10.1126/science.221.4606.150; Koeberl C, 1996, SCIENCE, V271, P1263, DOI 10.1126/science.271.5253.1263; Lanci L, 1996, EARTH PLANET SC LETT, V143, P37, DOI 10.1016/0012-821X(96)00136-7; LIOU JC, 1995, PLANET SPACE SCI, V43, P717, DOI 10.1016/0032-0633(95)00065-D; Liou JC, 1996, ICARUS, V123, P491, DOI 10.1006/icar.1996.0174; LOVE SG, 1993, SCIENCE, V262, P550, DOI 10.1126/science.262.5133.550; MARZARI F, 1995, ICARUS, V113, P168, DOI 10.1006/icar.1995.1014; MATESE JJ, 1995, ICARUS, V116, P255, DOI 10.1006/icar.1995.1124; MERRIHUE C, 1964, ANN NY ACAD SCI, V119, P351; MOLINA E, 1993, GEOL MAG, V130, P483, DOI 10.1017/S0016756800020550; MONTANARI A, 1993, PALAIOS, V8, P420, DOI 10.2307/3515017; OZIMA M, 1984, NATURE, V311, P448, DOI 10.1038/311448a0; PATTERSON DB, UNPUB; Pierrard O, 1998, GEOLOGY, V26, P307, DOI 10.1130/0091-7613(1998)026<0307:ENRSIU>2.3.CO;2; PREMOLISILVA I, 1988, EOCENE OLIGOCENE BOU; RAMPINO MR, 1984, NATURE, V308, P709, DOI 10.1038/308709a0; SHOEMAKER EM, 1990, GEOL S AM S, V247, P155; VISHNEVSKY SA, UNPUB; WEISSMAN P, COMMUNICATION; WEISSMAN PR, 1990, NATURE, V344, P825, DOI 10.1038/344825a0	32	135	141	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 22	1998	280	5367					1250	1253		10.1126/science.280.5367.1250	http://dx.doi.org/10.1126/science.280.5367.1250			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596575				2022-12-24	WOS:000073852500044
J	Ford, CE; Skiba, NP; Bae, HS; Daaka, YH; Reuveny, E; Shekter, LR; Rosal, R; Weng, GZ; Yang, CS; Iyengar, R; Miller, RJ; Jan, LY; Lefkowitz, RJ; Hamm, HE				Ford, CE; Skiba, NP; Bae, HS; Daaka, YH; Reuveny, E; Shekter, LR; Rosal, R; Weng, GZ; Yang, CS; Iyengar, R; Miller, RJ; Jan, LY; Lefkowitz, RJ; Hamm, HE			Molecular basis for interactions of G protein beta gamma subunits with effectors	SCIENCE			English	Article							HETEROTRIMERIC G-PROTEIN; PHOSPHOLIPASE-C; POTASSIUM CHANNEL; CRYSTAL-STRUCTURE; ACTIVATION; ADENYLYL-CYCLASE-2; MODULATION; BINDING	Both the alpha and beta gamma subunits of heterotrimeric guanine nucleotide-binding proteins (G proteins) communicate signals from receptors to effecters. G beta gamma subunits, can regulate a diverse array of effecters, including ion channels and enzymes. G alpha subunits bound to guanine diphosphate (G alpha-GDP) inhibit signal transduction through G beta gamma subunits, suggesting a common interface on G beta gamma subunits for G alpha binding and effector interaction. The molecular basis for interaction of G beta gamma with effecters was characterized by mutational analysis of G beta residues that make contact with G alpha-GDP. Analysis of the ability of these mutants to regulate the activity of calcium and potassium channels, adenylyl cyclase 2, phospholipase C-beta 2, and beta-adrenergic receptor kinase revealed the G beta residues required for activation of each effector and provides evidence for partially overlapping domains on G beta for regulation of these effecters. This organization of interaction regions on G beta for different effecters and G alpha explains why subunit dissociation is crucial for signal transmission through G beta gamma subunits.	Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA; Northwestern Univ, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Weizmann Inst Sci, Dept Membrane Res & Biophys, IL-76100 Rehovot, Israel; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA; Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol & Biochem, San Francisco, CA 94143 USA	Northwestern University; Northwestern University; Duke University; Duke University; Howard Hughes Medical Institute; Weizmann Institute of Science; University of Chicago; Icahn School of Medicine at Mount Sinai; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hamm, HE (corresponding author), Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA.		Bae, Hyunsu/ABH-6248-2020; Hamm, Heidi E/G-2374-2014; Lefkowitz, Robert/AAW-2649-2021	Jan, Lily/0000-0003-3938-8498; Bae, Hyunsu/0000-0002-0299-3582; YANG, CHII-SHEN/0000-0002-2792-6247	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040165, R37MH040165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002121, R01DA002575] Funding Source: NIH RePORTER; NIDA NIH HHS [DA02575, DA02121] Funding Source: Medline; NIMH NIH HHS [MH40165] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bluml K, 1997, EMBO J, V16, P4908, DOI 10.1093/emboj/16.16.4908; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHEN J, 1995, SCIENCE, V268, P1168; Chen YB, 1997, P NATL ACAD SCI USA, V94, P2711, DOI 10.1073/pnas.94.6.2711; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; DEVIVO M, 1994, METHOD ENZYMOL, V238, P131; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GRISHIN AV, 1994, MOL CELL BIOL, V14, P4571, DOI 10.1128/MCB.14.7.4571; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; KATADA T, 1994, METHOD ENZYMOL, V237, P131; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Pellegrino S, 1997, J BIOL CHEM, V272, P25360, DOI 10.1074/jbc.272.40.25360; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Romoser V, 1996, J BIOL CHEM, V271, P25071, DOI 10.1074/jbc.271.41.25071; Schneider T, 1997, TRENDS PHARMACOL SCI, V18, P8, DOI 10.1016/S0165-6147(96)01001-2; Shekter LR, 1997, MOL PHARMACOL, V52, P282, DOI 10.1124/mol.52.2.282; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Stoffel RH, 1997, J MEMBRANE BIOL, V157, P1, DOI 10.1007/s002329900210; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Weng GZ, 1996, J BIOL CHEM, V271, P26445, DOI 10.1074/jbc.271.43.26445; Yamauchi J, 1997, J BIOL CHEM, V272, P7602, DOI 10.1074/jbc.272.12.7602; Yan K, 1997, J BIOL CHEM, V272, P2056; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597; Zhang SY, 1996, J BIOL CHEM, V271, P20208, DOI 10.1074/jbc.271.33.20208	40	354	364	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 22	1998	280	5367					1271	1274		10.1126/science.280.5367.1271	http://dx.doi.org/10.1126/science.280.5367.1271			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596582				2022-12-24	WOS:000073852500051
J	Posfai, M; Buseck, PR; Bazylinski, DA; Frankel, RB				Posfai, M; Buseck, PR; Bazylinski, DA; Frankel, RB			Reaction sequence of iron sulfide minerals in bacteria and their use as biomarkers	SCIENCE			English	Article							MAGNETOTACTIC MICROORGANISM; GREIGITE FE3S4; BIOMINERALIZATION; PYRITE; LIFE; FES	Some bacteria form intracellular nanometer-scale crystals of greigite (Fe3S4) that cause the bacteria to be oriented in magnetic fields. Transmission electron microscope observations showed that ferrimagnetic greigite in these bacteria forms from nonmagnetic mackinawite (tetragonal FeS) and possibly from cubic FeS. These precursors apparently transform into greigite by rearrangement of iron atoms over a period of days to weeks. Neither pyrrhotite nor pyrite was found. These results have implications for the interpretation of the presence of pyrrhotite and greigite in the martian meteorite ALH84001.	Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; Arizona State Univ, Dept Chem Biochem, Tempe, AZ 85287 USA; Iowa State Univ, Dept Microbiol Immunol & Prevent Med, Ames, IA 50011 USA; Calif Polytech State Univ San Luis Obispo, Dept Phys, San Luis Obispo, CA 93407 USA; Univ Veszprem, Dept Earth & Environm Sci, H-8200 Veszprem, Hungary	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Iowa State University; California State University System; California Polytechnic State University San Luis Obispo; University of Pannonia	Posfai, M (corresponding author), Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA.		Pósfai, Mihály/C-1792-2012	Pósfai, Mihály/0000-0001-9355-3533				Bazylinski D. A., 1990, IRON BIOMINERALS, P239; Bazylinski DA, 1997, REV MINERAL, V35, P181; BAZYLINSKI DA, 1995, APPL ENVIRON MICROB, V61, P3232, DOI 10.1128/AEM.61.9.3232-3239.1995; BERNER RA, 1967, AM J SCI, V265, P773, DOI 10.2475/ajs.265.9.773; Bertaut EF, 1965, SOLID STATE COMMUN, V3, P335, DOI 10.1016/0038-1098(65)90090-6; DELONG EF, 1993, SCIENCE, V259, P803, DOI 10.1126/science.259.5096.803; FARINA M, 1983, BIOL CELL, V48, P85; FARINA M, 1990, NATURE, V343, P256, DOI 10.1038/343256a0; Frankel RB, 1997, BIOPHYS J, V73, P994, DOI 10.1016/S0006-3495(97)78132-3; HEYWOOD BR, 1991, MATER RES SOC SYMP P, V218, P93; KRUPP RE, 1994, EUR J MINERAL, V6, P265; Lennie AR, 1997, AM MINERAL, V82, P302; MANN S, 1990, NATURE, V343, P258, DOI 10.1038/343258a0; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MEDICIS RD, 1970, SCIENCE, V170, P1191, DOI 10.1126/science.170.3963.1191; MORSE JW, 1987, EARTH-SCI REV, V24, P1, DOI 10.1016/0012-8252(87)90046-8; MUROWCHICK JB, 1986, AM MINERAL, V71, P1243; MUROWOHICK JB, 1989, GEOL SOC AM PROGR AB, V21, pA120; Rickard D., 1969, STOCK CONTRIB GEOL, V20, P67; RICKARD DT, 1969, STOCKHOLM CONTRIB GE, V20, P55; SCHOONEN MAA, 1991, GEOCHIM COSMOCHIM AC, V55, P1505, DOI 10.1016/0016-7037(91)90123-M; SKINNER BJ, 1964, AM MINERAL, V49, P543; WACHTERSHAUSER G, 1988, SYST APPL MICROBIOL, V10, P207; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; WILLIAMS RJP, 1990, NATURE, V343, P213, DOI 10.1038/343213a0; WINTENBERGER M, 1978, J PHYS-PARIS, V39, P965, DOI 10.1051/jphys:01978003909096500	26	160	164	2	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1998	280	5365					880	883		10.1126/science.280.5365.880	http://dx.doi.org/10.1126/science.280.5365.880			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572727	Green Submitted			2022-12-24	WOS:000073532900034
J	Nightingale, SL				Nightingale, SL			Ultrasound device for evaluating bone strength approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1998	279	17					1339	1339		10.1001/jama.279.17.1339	http://dx.doi.org/10.1001/jama.279.17.1339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK758	9582030				2022-12-24	WOS:000073359800006
J	Grodstein, F; Martinez, ME; Platz, EA; Giovannucci, E; Colditz, GA; Kautzky, M; Fuchs, C; Stampfer, MJ				Grodstein, F; Martinez, ME; Platz, EA; Giovannucci, E; Colditz, GA; Kautzky, M; Fuchs, C; Stampfer, MJ			Postmenopausal hormone use and risk for colorectal cancer and adenoma	ANNALS OF INTERNAL MEDICINE			English	Article						colorectal neoplasms; estrogen replacement therapy; adenoma; colonoscopy; sigmoidoscopy	LARGE-BOWEL-CANCER; EXOGENOUS FEMALE HORMONES; COLON-CANCER; REPRODUCTIVE FACTORS; ESTROGEN-RECEPTOR; PROGESTERONE RECEPTORS; REPLACEMENT THERAPY; PROSPECTIVE COHORT; UNITED-STATES; CELL-LINES	Background: Accumulating evidence suggests that postmenopausal hormone use may decrease the risk for colorectal cancer. Objective: To examine the relation of postmenopausal hormone therapy to colorectal adenoma and cancer. Design: Prospective cohort and nested case-control studies. Setting: Nurses' Health Study, a study of registered nurses recruited from 11 U.S. states. Participants: 59 002 postmenopausal participants in the Nurses' Health Study. Measurements: Self-reported data on hormone use and cases of distal colorectal adenoma and colorectal cancer obtained from biennial questionnaires completed from 1980 to 1994. Cases of colorectal adenoma and cancer were confirmed by medical record review. Results: 470 women developed colorectal cancer, and 838 developed distal colorectal adenomas. Current use of postmenopausal hormones was associated with a decreased risk for colorectal cancer (relative risk [RR], 0.65 [95% CI, 0.50 to 0.83]). This association was attenuated in past users (RR, 0.84 [CI, 0.67 to 1.05]) and disappeared 5 years after hormone use was discontinued (RR, 0.92 [Cl, 0.70 to 1.21]). Longer duration of current use did not afford greater protection (RR with greater than or equal to 5 years of use. 0.72 [CI, 0.53 to 0.96]). Even after exclusion of women who reported having screening sigmoidoscopy, the relative risk for colorectal cancer seen with current hormone use was 0.64 (CI, 0.49 to 0.82). This suggests that the apparent protection is unlikely to be due to more intensive screening among hormone users. Current users also had a lower risk for large (greater than or equal to 1 cm) adenomas than did women who had never used hormones (RR, 0.74 [CI, 0.55 to 0.99]), although no overall material association was seen between colorectal adenoma and current hormone use (RR, 0.91 [CI, 0.77 to 1.08]). Conclusions: The risk for colorectal cancer was decreased among women currently receiving postmenopausal hormone therapy, but the apparent reduction substantially diminished upon cessation of therapy. Hormone use was inversely associated with large colorectal adenomas but not small ones.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Grodstein, F (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG013482] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356] Funding Source: Medline; NIA NIH HHS [AG13482] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BOSTICK RM, 1994, CANCER CAUSE CONTROL, V5, P38, DOI 10.1007/BF01830725; BURCH JC, 1975, ESTROGENS POST MENOP, P208; CALLE EE, 1995, J NATL CANCER I, V87, P517, DOI 10.1093/jnci/87.7.517; CHUTE CG, 1991, EPIDEMIOLOGY, V2, P395, DOI 10.1097/00001648-199109000-00019; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; CONCOLINO G, 1986, CANCER DETECT PREV, V9, P477; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS FG, 1989, INT J CANCER, V43, P587, DOI 10.1002/ijc.2910430409; DEVERDIER MG, 1992, CANCER CAUSE CONTROL, V3, P355, DOI 10.1007/BF00146889; FURNER SE, 1989, CANCER RES, V49, P4936; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; HENDRICKSE CW, 1993, BRIT J SURG, V80, P636, DOI 10.1002/bjs.1800800531; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; JACOBS EJ, 1994, CANCER CAUSE CONTROL, V5, P359, DOI 10.1007/BF01804987; JACOBSON JS, 1995, CANCER CAUSE CONTROL, V6, P513, DOI 10.1007/BF00054159; Kampman E, 1997, CANCER CAUSE CONTROL, V8, P146, DOI 10.1023/A:1018459911147; LOINTIER P, 1992, ANTICANCER RES, V12, P1327; MAMINTA MLD, 1991, MOL CELL ENDOCRINOL, V78, P61, DOI 10.1016/0303-7207(91)90186-V; MCMICHAEL AJ, 1980, J NATL CANCER I, V65, P1201; MOROTOMI M, 1990, CANCER RES, V50, P3595; NEWCOMB PA, 1995, JNCI-J NATL CANCER I, V87, P1067, DOI 10.1093/jnci/87.14.1067; Peipins LA, 1997, CANCER EPIDEM BIOMAR, V6, P671; PETERS RK, 1990, BRIT J CANCER, V61, P741, DOI 10.1038/bjc.1990.166; Potter JD, 1996, CANCER EPIDEM BIOMAR, V5, P779; POTTER JD, 1995, JNCI-J NATL CANCER I, V87, P1039, DOI 10.1093/jnci/87.14.1039; POTTER JD, 1983, J NATL CANCER I, V71, P703; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RISCH HA, 1995, CANCER EPIDEM BIOMAR, V4, P21; Rothman KJ, 1979, NIH PUBLICATION, V79-1649, P31; SICA V, 1984, CANCER RES, V44, P4670; SINGH S, 1994, ANTICANCER RES, V14, P1037; STURGEON SR, 1995, EPIDEMIOLOGY, V6, P227, DOI 10.1097/00001648-199505000-00006; THOMAS ML, 1993, ENDOCRINOLOGY, V132, P426, DOI 10.1210/en.132.1.426; Troisi R, 1997, CANCER CAUSE CONTROL, V8, P130, DOI 10.1023/A:1018455810238; WEISS NS, 1981, J NATL CANCER I, V67, P57; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WU AH, 1987, BRIT J CANCER, V55, P687, DOI 10.1038/bjc.1987.140; WUWILLIAMS AH, 1991, CANCER RES, V51, P2307; XU XM, 1994, MOL CELL ENDOCRINOL, V105, P197	43	230	236	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					705	+		10.7326/0003-4819-128-9-199805010-00001	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK790	9556463				2022-12-24	WOS:000073363800001
J	Thiadens, HA; de Bock, GH; Deker, FW; Huysman, JAN; van Houwelingen, JC; Springer, MP; Postma, DS				Thiadens, HA; de Bock, GH; Deker, FW; Huysman, JAN; van Houwelingen, JC; Springer, MP; Postma, DS			Identifying asthma and chronic obstructive pulmonary disease in patients with persistent cough presenting to general practitioners: descriptive study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WORKING PARTY STANDARDIZATION; EUROPEAN RESPIRATORY SOCIETY; BRONCHIAL HYPERRESPONSIVENESS; OFFICIAL STATEMENT; RESPONSIVENESS; BRONCHODILATOR; ASSOCIATION; COMMUNITY; SYMPTOMS; ADULTS	Objective: To determine the prevalence of asthma and chronic obstructive pulmonary disease in patients not known to have these disorders, who present in general practice with persistent cough, and to ascertain criteria to help general practitioners in diagnosis. Design: Descriptive study. Setting: Primary healthcare centre in the Netherlands. Subjects: 192 patients aged 18-75 years, not known to have asthma or chronic obstructive pulmonary disease, attending their general practitioner with cough persisting for at least 2 weeks. Methods: A diagnosis of asthma or chronic obstructive pulmonary was based on the recurrence of airway symptoms in the past year accompanied by spirometric measurements (including bronchodilator testing) and methacholine provocation tests. A scoring formula to estimate the probability of asthma or chronic obstructive pulmonary disease, based on history and physical examination, was generated by means of logistic regression. Results: 74 patients (39%) were classified as having asthma, 14 (7%) as hating chronic obstructive pulmonary disease. The best formula for predicting asthma or chronic obstructive pulmonary disease used scores for three symptoms: (reported) wheeze, (reported) dyspnoea, and allergen induced symptoms, together with prolonged expiration, pack years of smoking, and female sex variables were scored 1 when present and 0 when absent except for allergen induced symptoms (1.5) and number of pack years of smoking (n/25). With a cut off value of 3 on the scoring formula 76% of the patients could be classified correctly. Conclusions: About half of patients with persistent cough who present to a general practitioner have asthma or chronic obstructive pulmonary disease. With a simple formula based on three symptoms and prolonged expiration, pack years of smoking, and female sex most patients may be identified correctly in general practice.	Leiden Univ, Med Ctr, Dept Gen Practice, NL-2301 CB Leiden, Netherlands; Leiden Univ, Med Ctr, Med Decis Making Unit, NL-2301 CB Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Med Stat, NL-2301 CB Leiden, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands; Univ Groningen Hosp, Dept Lung Dis, NL-9700 RB Groningen, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam; University of Groningen	Thiadens, HA (corresponding author), Leiden Univ, Med Ctr, Dept Gen Practice, POB 2088, NL-2301 CB Leiden, Netherlands.		de Bock, Geertruida Hendrika/F-6529-2014; van houwelingen, hans c/C-1872-2008; Dekker, Friedo/B-6452-2011	de Bock, Geertruida Hendrika/0000-0003-3104-4471; van houwelingen, hans c/0000-0002-0494-4637; Dekker, Friedo/0000-0002-2433-2494	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOEZEN HM, 1995, THORAX, V50, P121, DOI 10.1136/thx.50.2.121; BOTTEMA BJA, 1993, THESIS U AMSTERDAM A, P64; BRAND PLP, 1992, THORAX, V47, P429, DOI 10.1136/thx.47.6.429; CERVERI I, 1993, EUR RESPIR REV, V14, P424; CORRAO WM, 1979, NEW ENGL J MED, V300, P633, DOI 10.1056/NEJM197903223001201; DALES RE, 1988, AM REV RESPIR DIS, V138, P317, DOI 10.1164/ajrccm/138.2.317; HALLETT JS, 1985, ANN ALLERGY, V55, P568; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640, DOI 10.1164/ajrccm/141.3.640; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; RIJCKEN B, 1995, AM J RESP CRIT CARE, V151, P1377, DOI 10.1164/ajrccm.151.5.7735588; RUTTEN GEHM, 1988, HUISARTS WETENSCHAP, V31, P293; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; TRIGG CJ, 1990, THORAX, V45, P866, DOI 10.1136/thx.45.11.866; VANDELENDE R, 1991, SCAND J RESPIR DIS, V4, P612; WILLIAMSON HA, 1987, J FAM PRACTICE, V24, P35; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	19	46	48	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	1998	316	7140					1286	1290		10.1136/bmj.316.7140.1286	http://dx.doi.org/10.1136/bmj.316.7140.1286			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554899	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000073335900023
J	Cheng, YK; Rossky, PJ				Cheng, YK; Rossky, PJ			Surface topography dependence of biomolecular hydrophobic hydration	NATURE			English	Article							MOLECULAR-DYNAMICS; PROTEIN; WATER; MELITTIN; SOLVENT; SOLVATION	Many biomolecules are characterized by surfaces containing extended nonpolar regions(1), and the aggregation and subsequent removal of such surfaces from water is believed to play a critical role in the biomolecular assembly in cells(2). A better understanding of the hydrophobic hydration of biomolecules may therefore yield new insights into intracellular assembly, Conventional views hold that the hydration shell of small hydrophobic solutes is clathrate-like, characterized by local cage-like hydrogen-bonding structures and a distinct loss in entropy(2). The hydration of extended nonpolar planar surfaces, however, appears to involve structures that are orientationally inverted relative to clathrate-like hydration shells(3,4), with unsatisfied hydrogen bonds that are directed towards the hydrophobic surface. Here we present computer simulations of the interaction between the polypeptide melittin and water that demonstrate that the two different hydration structures also exist near a biomolecular surface. We find that the two structures are distinguished by a substantial difference in the water-water interaction enthalpy, and that their relative contributions depend strongly on the surface topography of the melittin molecule: clathrate-like structures dominate near con-vex surface patches, whereas the hydration shell near flat surfaces fluctuates between clathrate-like and less-ordered or inverted structures. The strong influence of surface topography on the structure and free energy of hydrophobic hydration is likely to hold in general, and will be particularly important for the many biomolecules whose surfaces contain convex patches, deep or shallow concave grooves and roughly planar areas(5).	Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Rossky, PJ (corresponding author), Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA.			Cheng, Yuen-Kit/0000-0002-5643-5949				Berendsen HJC, 1981, INTERMOLECULAR FORCE, P331, DOI [DOI 10.1007/978-94-015-7658-1_21, 10.1007/978-94-015-7658-1_21]; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLOKZIJL W, 1993, ANGEW CHEM INT EDIT, V32, P1545, DOI 10.1002/anie.199315451; Clarke Anthony R., 1996, P167, DOI 10.1016/B978-012237455-5/50008-7; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DU Q, 1994, SCIENCE, V264, P826, DOI 10.1126/science.264.5160.826; FREIRE E, 1992, BIOCHEMISTRY-US, V31, P250, DOI 10.1021/bi00116a034; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; KITAO A, 1991, CHEM PHYS, V158, P447, DOI 10.1016/0301-0104(91)87082-7; KUHN LA, 1992, J MOL BIOL, V228, P13, DOI 10.1016/0022-2836(92)90487-5; LEE CY, 1984, J CHEM PHYS, V80, P4448, DOI 10.1063/1.447226; MEHROTRA PK, 1980, J AM CHEM SOC, V102, P4287, DOI 10.1021/ja00533a001; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PASCUALAHUIR JL, 1994, J COMPUT CHEM, V15, P1127, DOI 10.1002/jcc.540151009; ROSSKY PJ, 1979, J AM CHEM SOC, V101, P1913, DOI 10.1021/ja00502a001; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SanchezRuiz JM, 1996, EUR BIOPHYS J BIOPHY, V24, P261; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; TEETER MM, 1991, ANNU REV BIOPHYS BIO, V20, P577, DOI 10.1146/annurev.biophys.20.1.577; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6010; VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98; ZICHI DA, 1985, J CHEM PHYS, V83, P797, DOI 10.1063/1.449495	22	360	360	0	105	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1998	392	6677					696	699		10.1038/33653	http://dx.doi.org/10.1038/33653			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565030				2022-12-24	WOS:000073129000052
J	Simon, JB				Simon, JB			Should all people over the age of 50 have regular fecal occult-blood tests? Postpone population screening until problems are solved	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COLORECTAL-CANCER; COST-EFFECTIVENESS; MORTALITY; PROGRAM; CHANCE		Queens Univ, Kingston, ON K7L 5G2, Canada	Queens University - Canada	Simon, JB (corresponding author), Hotwl Dieu Hosp, Div Gastroenterol, 166 Brock St, Kingston, ON K7L 5G2, Canada.							AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; Hardcastle JD, 1996, LANCET, V348, P1472, DOI 10.1016/S0140-6736(96)03386-7; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; LANG CA, 1994, JAMA-J AM MED ASSOC, V271, P1011, DOI 10.1001/jama.271.13.1011; LIEBERMAN DA, 1995, GASTROENTEROLOGY, V109, P1781, DOI 10.1016/0016-5085(95)90744-0; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MANDEL JS, 1993, NEW ENGL J MED, V329, P672; MORRIS JB, 1991, AM J SURG, V161, P101, DOI 10.1016/0002-9610(91)90368-N; Simon J B, 1998, Gastroenterologist, V6, P66; SIMON JB, 1990, JAMA-J AM MED ASSOC, V264, P84, DOI 10.1001/jama.264.1.84; WAGNER JL, 1991, ANN INTERN MED, V115, P807, DOI 10.7326/0003-4819-115-10-807; Wagner JL, 1996, PREVENTION EARLY DET, P321; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; WINCHESTER DP, 1980, CANCER, V45, P2955, DOI 10.1002/1097-0142(19800615)45:12<2955::AID-CNCR2820451211>3.0.CO;2-T; WINDELER J, 1987, INT J COLORECTAL DIS, V2, P223, DOI 10.1007/BF01649510; Wolf AMD, 1996, ARCH INTERN MED, V156, P1069, DOI 10.1001/archinte.156.10.1069	16	28	28	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1998	338	16					1151	1152						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH080	9545367				2022-12-24	WOS:000073070100012
J	Vita, AJ; Terry, RB; Hubert, HB; Fries, JF				Vita, AJ; Terry, RB; Hubert, HB; Fries, JF			Aging, health risks, and cumulative disability	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; ELDERLY POPULATION; COLLEGE ALUMNI; OLDER PERSONS; LONGER LIFE; FOLLOW-UP; MEN; COMPRESSION; MORBIDITY	Background Persons with lower health risks tend to live longer than those with higher health risks, but there has been concern that greater longevity may bring with it greater disability. We performed a longitudinal study to determine whether persons with lower potentially modifiable health risks have more or less cumulative disability. Methods We studied 1741 university alumni who were surveyed first in 1962 (average age, 43 years) and then annually starting in 1986, Strata of high, moderate, and low risk were defined on the basis of smoking, body-mass index, and exercise patterns. Cumulative disability was determined with a health-assessment questionnaire and scored on a scale of 0 to 3. Cumulative disability from 1986 to 1994 (average age in 1994, 75 years) or death was the measure of lifetime disability. Results Persons with high health risks in 1962 or 1986 had twice the cumulative disability of those with low health risks (disability index, 1.02 vs. 0.49; P < 0.001). The results were consistent among survivors, subjects who died, men, and women and for both the last year and the last two years of observation. The onset of disability was postponed by more than five years in the low-risk group as compared with the high-risk group. The disability index for the low-risk subjects who died was half that for the high-risk subjects in the last one or two years of observation. Conclusions Smoking, body-mass index, and exercise patterns in midlife and late adulthood are predictors of subsequent disability. Not only do persons with better health habits survive longer, but in such persons, disability is postponed and compressed into fewer years at the end of life. (C) 1998, Massachusetts Medical Society.	Stanford Univ, Sch Med, Dept Med, Stanford, CA USA	Stanford University	Fries, JF (corresponding author), 1000 Welch Rd,Suite 203, Palo Alto, CA 94304 USA.		Fries, James F/F-6271-2011		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR043584] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43584] Funding Source: Medline; NICHD NIH HHS [R01 HD35641-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; BROWN JH, 1984, AM J PUBLIC HEALTH, V74, P159, DOI 10.2105/AJPH.74.2.159; CRIMMINS EM, 1990, J INSURANCE MED, V22, P89; *DEP HLTH HUM SERV, 1990, DHHS PUBL PHS; *DEP HLTH HUM SERV, 1996, DHHS PUBL PHS; DUFFY ME, 1990, GERONTOLOGIST, V30, P503, DOI 10.1093/geront/30.4.503; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; FRIES JF, 1994, ANN INTERN MED, V121, P502, DOI 10.7326/0003-4819-121-7-199410010-00005; FRIES JF, 1989, MILBANK Q, V67, P208, DOI 10.2307/3350138; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; FRIES JF, 1982, J RHEUMATOL, V9, P789; Fries JF, 1981, VITALITY AGING; GRUENBERG EM, 1977, MILBANK FUND Q, V55, P3, DOI 10.2307/3349592; HJERMANN I, 1981, LANCET, V2, P1303; HOUSE JS, 1990, MILBANK Q, V68, P383, DOI 10.2307/3350111; HUBERT HB, 1993, J RHEUMATOL, V20, P480; Hubert Helen B., 1994, Annals of Epidemiology, V4, P285; LEE IM, 1995, JAMA-J AM MED ASSOC, V273, P1179, DOI 10.1001/jama.273.15.1179; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; LEIGH JP, 1994, INT J AGING HUM DEV, V39, P233, DOI 10.2190/XQXR-UTGP-WA8X-9FQJ; Lewis CE, 1997, AM J PUBLIC HEALTH, V87, P635, DOI 10.2105/AJPH.87.4.635; MANTON KG, 1993, J GERONTOL, V48, pS153, DOI 10.1093/geronj/48.4.S153; MANTON KG, 1982, MILBANK FUND Q, V60, P183, DOI 10.2307/3349767; MYERS GC, 1984, GERONTOLOGIST, V24, P346, DOI 10.1093/geront/24.4.346; Nusselder WJ, 1996, GERONTOLOGIST, V36, P773, DOI 10.1093/geront/36.6.773; OCONNOR GT, 1995, AM J EPIDEMIOL, V142, P1147, DOI 10.1093/oxfordjournals.aje.a117573; OLSHANSKY SJ, 1986, MILBANK Q, V64, P355, DOI 10.2307/3350025; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1994, MED SCI SPORT EXER, V26, P857; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; Ramey D., 1996, QUALITY LIFE PHARMAC, V2nd ed, P227; Ramey D R, 1992, Arthritis Care Res, V5, P119, DOI 10.1002/art.1790050303; ROGERS A, 1990, GERONTOLOGIST, V30, P640, DOI 10.1093/geront/30.5.640; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; *SAS I, 1989, SAS STAT US GUID VER; SIMONSICK EM, 1993, AM J PUBLIC HEALTH, V83, P1443, DOI 10.2105/AJPH.83.10.1443; STEWART AL, 1993, GERONTOLOGIST, V33, P782, DOI 10.1093/geront/33.6.782; VERBRUGGE LM, 1984, MILBANK FUND Q, V62, P475, DOI 10.2307/3349861; WAIDMANN T, 1995, MILBANK Q, V73, P253, DOI 10.2307/3350259; WARNER KE, 1992, AM J PUBLIC HEALTH, V82, P126, DOI 10.2105/AJPH.82.1.126; WARNER KE, 1988, J OCCUP ENVIRON MED, V30, P106	43	435	440	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1035	1041		10.1056/NEJM199804093381506	http://dx.doi.org/10.1056/NEJM199804093381506			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZG134	9535669				2022-12-24	WOS:000072969500006
J	Nathanson, V				Nathanson, V			Cambodia - after the killing fields	BRITISH MEDICAL JOURNAL			English	Article									BMA, Profess Resources & Res Grp, London WC1H 9JP, England		Nathanson, V (corresponding author), BMA, Profess Resources & Res Grp, London WC1H 9JP, England.								0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1082	1086						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552916				2022-12-24	WOS:000072987400037
J	Lebron, JA; Bennett, MJ; Vaughn, DE; Chirino, AJ; Snow, PM; Mintier, GA; Feder, JN; Bjorkman, PJ				Lebron, JA; Bennett, MJ; Vaughn, DE; Chirino, AJ; Snow, PM; Mintier, GA; Feder, JN; Bjorkman, PJ			Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor	CELL			English	Article							NEONATAL FC RECEPTOR; CLASS-I MOLECULES; HEREDITARY HEMOCHROMATOSIS; VIRAL PEPTIDES; BINDING; ASSOCIATION; RESOLUTION; PROGRAM; HLA-A2	HFE is an MHC-related protein that is mutated in the iron-overload disease hereditary hemochromatosis. HFE binds to transferrin receptor (TfR) and reduces its affinity for iron-loaded transferrin, implicating HFE in iron metabolism. The 2.6 Angstrom crystal structure of HFE reveals the locations of hemochromatosis mutations and a patch of histidines that could be involved in pH-dependent interactions. We also demonstrate that soluble TfR and HFE bind tightly at the basic pH of the cell surface, but not at the acidic pH of intracellular vesicles. TfR:HFE stoichiometry (2:1) differs from TfR: transferrin stoichiometry (2:2), implying a different mode of binding for HFE and transferrin to TfR, consistent with our demonstration that HFE, transferrin, and TfR form a ternary complex.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Caltech Prot Express Ctr, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Progenitor Inc, Menlo Park, CA 94025 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; California Institute of Technology	Lebron, JA (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.							BACON BR, 1996, HEPATOLOGY TXB LIVER; Bebbington CRH, 1987, DNA CLONING; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; Beutler E, 1997, AM J HUM GENET, V61, P762; BORHANI DW, 1991, J MOL BIOL, V218, P685, DOI 10.1016/0022-2836(91)90255-5; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; Chapman TL, 1998, J VIROL, V72, P460, DOI 10.1128/JVI.72.1.460-466.1998; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Cuthbert JA, 1997, J INVEST MED, V45, P518; ENNS CA, 1981, J BIOL CHEM, V256, P9820; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feder JN, 1997, J BIOL CHEM, V272, P14025, DOI 10.1074/jbc.272.22.14025; Fersht A., 1985, ENZYME STRUCTURE MEC; Hashimoto K, 1997, BIOCHEM BIOPH RES CO, V230, P35, DOI 10.1006/bbrc.1996.5889; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P199; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Junghans RP, 1997, IMMUNOL RES, V16, P29, DOI 10.1007/BF02786322; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuziemko GM, 1996, BIOCHEMISTRY-US, V35, P6375, DOI 10.1021/bi952314i; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Malmqvist Magnus, 1994, Methods (Orlando), V6, P95, DOI 10.1006/meth.1994.1012; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MCLAREN GD, 1991, J LAB CLIN MED, V117, P390; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P8318; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P16309; Vaughn DE, 1997, BIOCHEMISTRY-US, V36, P9374, DOI 10.1021/bi970841r; Vaughn DE, 1998, STRUCTURE, V6, P63, DOI 10.1016/S0969-2126(98)00008-2; Waheed A, 1997, P NATL ACAD SCI USA, V94, P12384, DOI 10.1073/pnas.94.23.12384; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	50	506	520	3	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					111	123		10.1016/S0092-8674(00)81151-4	http://dx.doi.org/10.1016/S0092-8674(00)81151-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546397	Bronze			2022-12-24	WOS:000072910800015
J	DiGuiseppi, C; Li, L; Roberts, I				DiGuiseppi, C; Li, L; Roberts, I			Influence of travel patterns on mortality from injury among teenagers in England and Wales, 1985-95: trend analysis	BRITISH MEDICAL JOURNAL			English	Article									UCL, Sch Med, Inst Child Hlth, Dept Epidemiol,Child Hlth Monitoring Unit, London WC1N 1EH, England	University of London; University College London; UCL Medical School	DiGuiseppi, C (corresponding author), UCL, Sch Med, Inst Child Hlth, Dept Epidemiol,Child Hlth Monitoring Unit, London WC1N 1EH, England.		DiGuiseppi, Carolyn/AAU-1341-2020	DiGuiseppi, Carolyn/0000-0002-6440-7817				*DEP TRANSP, 1992, TRANSP STAT REP NAT; Department of Health, 1992, HLTH NAT STRAT HLTH; DiGuiseppi C, 1997, BRIT MED J, V314, P710, DOI 10.1136/bmj.314.7082.710; FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; WOODROFFE C, 1993, CHILDREN TEENAGERS H	5	8	9	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					904	905		10.1136/bmj.316.7135.904	http://dx.doi.org/10.1136/bmj.316.7135.904			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552840	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000072713300030
J	Schwan, TG; Hinnebusch, BJ				Schwan, TG; Hinnebusch, BJ			Bloodstream- versus tick-associated variants of a relapsing fever bacterium	SCIENCE			English	Article							VARIABLE MAJOR PROTEINS; OUTER SURFACE PROTEIN; BORRELIA-HERMSII; ANTIGENIC VARIATION; BURGDORFERI; GENES; OSPC; CULTIVATION; SEQUENCE; EPITOPE	The relapsing fever spirochete, Borrelia hermsii, alternates infections between a mammal and a tick vector. Whether the spirochete changes;phenotypically in the different hosts was examined by allowing the tick vector Ornithodoros hermsi to feed on mice infected with serotype 7 or serotype 8 of B. hermsii. Upon infection of ticks, the spirochetal serotype-specific variable major proteins (Vmps) 7 and 8 became undetectable and were replaced by Vmp33. This switch from a bloodstream- to tick-associated phenotype could be induced in culture by a decrease in temperature. After tick-bite transmission back to mice, the process was reversed and the spirochetes resumed expression of the same Vmp present in the previous infectious blood meal.	NIAID, Microbial Struct & Funct Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Schwan, TG (corresponding author), NIAID, Microbial Struct & Funct Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.	tom_schwan@nih.gov						Barbour A G, 1987, Contrib Microbiol Immunol, V8, P125; Barbour A.G., 1985, GENOME REARRANGEMENT, P123; BARBOUR AG, 1982, J EXP MED, V156, P1312, DOI 10.1084/jem.156.5.1312; BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; BARBOUR AG, 1986, MICROBIOL REV, V50, P381, DOI 10.1128/MMBR.50.4.381-400.1986; BARBOUR AG, 1986, INFECT IMMUN, V52, P549, DOI 10.1128/IAI.52.2.549-554.1986; BARBOUR AG, UNPUB; BARSTAD PA, 1985, J EXP MED, V161, P1302, DOI 10.1084/jem.161.6.1302; Cadavid D, 1997, INFECT IMMUN, V65, P3352, DOI 10.1128/IAI.65.8.3352-3360.1997; CARTER CJ, 1994, INFECT IMMUN, V62, P2792, DOI 10.1128/IAI.62.7.2792-2799.1994; Dworkin MS, 1998, CLIN INFECT DIS, V26, P122, DOI 10.1086/516273; Felsenfeld O., 1971, BORRELIA STRAINS VEC; HAJDUK SL, 1981, PARASITOLOGY, V83, P609, DOI 10.1017/S0031182000080574; Hinnebusch BJ, 1998, INFECT IMMUN, V66, P432, DOI 10.1128/IAI.66.2.432-440.1998; HINNEBUSCH BJ, UNPUB; KELLY R, 1971, SCIENCE, V173, P443, DOI 10.1126/science.173.3995.443; KITTEN T, 1990, P NATL ACAD SCI USA, V87, P6077, DOI 10.1073/pnas.87.16.6077; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE RS, 1991, ANNU REV ENTOMOL, V36, P587, DOI 10.1146/annurev.en.36.010191.003103; MARCONI RT, 1993, J CLIN MICROBIOL, V31, P2577, DOI 10.1128/JCM.31.10.2577-2583.1993; MARGOLIS N, 1994, GENE, V143, P105, DOI 10.1016/0378-1119(94)90613-0; MEIER JT, 1985, CELL, V41, P403, DOI 10.1016/S0092-8674(85)80013-1; PIESMAN J, 1987, J CLIN MICROBIOL, V25, P557, DOI 10.1128/JCM.25.3.557-558.1987; PLASTERK RHA, 1985, NATURE, V318, P257, DOI 10.1038/318257a0; PORCELLA SF, UNPUB; RESTREPO BI, 1994, MOL MICROBIOL, V13, P287, DOI 10.1111/j.1365-2958.1994.tb00423.x; RESTREPO BI, 1994, CELL, V78, P867, DOI 10.1016/S0092-8674(94)90642-4; SCHWAN TG, 1995, P NATL ACAD SCI USA, V92, P2909, DOI 10.1073/pnas.92.7.2909; SCHWAN TG, 1989, INFECT IMMUN, V57, P3445, DOI 10.1128/IAI.57.11.3445-3451.1989; Schwan Tom G., 1995, P626; SOUTHERN PM, 1969, MEDICINE, V48, P129, DOI 10.1097/00005792-196903000-00002; STOENNER HG, 1982, J EXP MED, V156, P1297, DOI 10.1084/jem.156.5.1297; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILSKE B, 1993, INFECT IMMUN, V61, P2182, DOI 10.1128/IAI.61.5.2182-2191.1993	34	124	127	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1938	1940		10.1126/science.280.5371.1938	http://dx.doi.org/10.1126/science.280.5371.1938			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632392				2022-12-24	WOS:000074323800064
J	Andes, GM				Andes, GM			Mark Twain's cat	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Andes, GM (corresponding author), 51 Hunthurst Circle, Worcester, MA 01602 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				1043	1044		10.7326/0003-4819-128-12_Part_1-199806150-00019	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00019			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625670				2022-12-24	WOS:000074201300014
J	Ridker, PM; Miletich, JP; Buring, JE; Ariyo, AA; Price, DT; Manson, JE; Hill, JA				Ridker, PM; Miletich, JP; Buring, JE; Ariyo, AA; Price, DT; Manson, JE; Hill, JA			Factor V Leiden mutation as a risk factor for recurrent pregnancy loss	ANNALS OF INTERNAL MEDICINE			English	Article							ACTIVATED PROTEIN-C; POOR ANTICOAGULANT RESPONSE; COAGULATION-FACTOR-V; VENOUS THROMBOSIS; RESISTANCE; THROMBOPHILIA; THROMBOEMBOLISM	Background: Recurrent pregnancy loss may result from hypercoagulability. Objective: To determine whether women with factor V Leiden mutation, a common inherited defect of coagulation, are at increased risk for recurrent pregnancy loss. Design: Case-control study. Setting: University hospital. Patients: 113 consecutive women referred for evaluation of recurrent spontaneous abortion (case-patients) and 437 postmenopausal women with at least one successful pregnancy and no history of pregnancy loss (controls). An additional survey of 387 postmenopausal women with at least one pregnancy loss was also conducted. Measurements: Prevalence of factor V Leiden mutation determined by a second-generation screening test for resistance to activated protein C with genetic confirmation of all borderline and low-value results. Results: Prevalence of the factor V Leiden mutation was greater among case-patients (8.0%) than among controls (3.7%) (odds ratio, 2.3 [95% CI, 1.0 to 5.2]; P = 0.050). In the subgroup of case-patients with three or more pregnancy losses and no successful pregnancies, prevalence of the mutation was 9.0% (odds ratio, 2.6 [CI, 1.0 to 6.7]; P = 0.048). Among the additional women surveyed, the prevalence of the mutation in those with three or more pregnancy losses (7.5%) was almost identical to that in case-patients. Thus, in all evaluated women with several pregnancy losses, the prevalence of factor V Leiden was increased 2.2-fold (P = 0.026). Conclusion: These data are compatible with the hypothesis that factor V Leiden mutation may play a role in some cases of unexplained recurrent pregnancy loss.	Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Washington Univ, Med Ctr, St Louis, MO USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Washington University (WUSTL)	Ridker, PM (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.							BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Brenner B, 1997, BRIT J HAEMATOL, V97, P551, DOI 10.1046/j.1365-2141.1997.882901.x; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; CUMMING AM, 1995, BRIT J HAEMATOL, V90, P725, DOI 10.1111/j.1365-2141.1995.tb05610.x; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DizonTownson DS, 1997, AM J OBSTET GYNECOL, V176, P883, DOI 10.1016/S0002-9378(97)70615-X; Grandone E, 1997, THROMB HAEMOSTASIS, V77, P822; Grisaru D, 1996, AM J OBSTET GYNECOL, V174, P801, DOI 10.1016/S0002-9378(96)70478-7; HELLGREN M, 1995, AM J OBSTET GYNECOL, V173, P210, DOI 10.1016/0002-9378(95)90192-2; HILL JA, 1994, CURRENT PROBLEMS OBS, V4, P116; Hirsch DR, 1996, AM HEART J, V131, P1145, DOI 10.1016/S0002-8703(96)90089-7; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; Preston FE, 1996, LANCET, V348, P913, DOI 10.1016/S0140-6736(96)04125-6; Price DT, 1997, ANN INTERN MED, V127, P895, DOI 10.7326/0003-4819-127-10-199711150-00007; Rai R, 1996, BRIT J HAEMATOL, V92, P489, DOI 10.1046/j.1365-2141.0000.d01-1465.x; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; Ridker PM, 1997, ANN INTERN MED, V126, P528, DOI 10.7326/0003-4819-126-7-199704010-00005; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; Ridker PM, 1997, JAMA-J AM MED ASSOC, V277, P1305, DOI 10.1001/jama.277.16.1305; Ridker PM, 1997, CIRCULATION, V95, P1777; SVENSSON PJ, 1998, NEW ENGL J MED, V330, P517; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8	23	165	167	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				1000	1003		10.7326/0003-4819-128-12_Part_1-199806150-00007	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625662				2022-12-24	WOS:000074201300006
J	Krasnopolsky, VA; Mumma, MJ; Gladstone, GR				Krasnopolsky, VA; Mumma, MJ; Gladstone, GR			Detection of atomic deuterium in the upper atmosphere of Mars	SCIENCE			English	Article							INNER SOLAR-SYSTEM; MARTIAN ATMOSPHERE; LYMAN-ALPHA; TERRESTRIAL PLANETS; CHARGE-TRANSFER; WATER; D/H; EVOLUTION; IONS; ABUNDANCE	High-resolution spectroscopy of Mars' atmosphere with the Hubble Space Telescope revealed the deuterium Lyman alpha line at an intensity of 23 +/- 6 rayleighs. This measured intensity corresponds to HD/H-2 = 1.5 +/- 0.6 x 10(-4), which is smaller by a factor of 11 than HDO/H2O. This indicates that fractionation of HD/H-2 relative to that of HDO/H2O is not kinetically controlled by the rates of formation and destruction of H-2 and HD but is thermodynamically controlled by the isotope exchange HD + H2O <-> HDO + H-2. Molecular hydrogen is strongly depleted in deuterium relative to water on Mars because of the very long lifetime of H-2 (1200 years). The derived isotope fractionation corresponds to an estimate of a planetwide reservoir of water ice about 5 meters thick that is exchangeable with the atmosphere.	NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Catholic Univ Amer, Dept Phys, Washington, DC 20064 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Catholic University of America	Krasnopolsky, VA (corresponding author), NASA, Goddard Space Flight Ctr, Code 6902, Greenbelt, MD 20771 USA.		mumma, michael j/I-2764-2013; Krasnopolsky, Vladimir/L-5085-2013	mumma, michael j/0000-0003-4627-750X; 				Acuna MH, 1998, SCIENCE, V279, P1676, DOI 10.1126/science.279.5357.1676; AJELLO JM, 1987, ASTROPHYS J, V317, P964, DOI 10.1086/165345; ANDERSON DE, 1974, J GEOPHYS RES, V79, P1513, DOI 10.1029/JA079i010p01513; ANICICH VG, 1993, J PHYS CHEM REF DATA, V22, P1469, DOI 10.1063/1.555940; Atreya S. K., 1986, ATMOSPHERES IONOSPHE; Bertaux J. L., 1992, SCI HUBBLE SPACE TEL, P459; Bjoraker G. L., 1989, B AM ASTRON SOC, V21, P991; CARR MH, 1990, ICARUS, V87, P210, DOI 10.1016/0019-1035(90)90031-4; CLARKE JT, 1995, ASTROPHYS J, V448, P893, DOI 10.1086/176018; DEMORE WB, 1994, JPL PUBL, V9426; DONAHUE TM, 1995, NATURE, V374, P432, DOI 10.1038/374432a0; EBERHARDT P, 1995, ASTRON ASTROPHYS, V302, P301; Gurvich L.V., 1989, THERMODYNAMIC PROPER; HAGEMANN R, 1970, TELLUS, V22, P712, DOI 10.1111/j.2153-3490.1970.tb00540.x; Hanson W. B., 1977, Journal of Geophysical Research, V82, P4351, DOI 10.1029/JS082i028p04351; HUNTEN DM, 1993, SCIENCE, V259, P915, DOI 10.1126/science.259.5097.915; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; JAKOSKY BM, 1994, NATURE, V370, P328, DOI 10.1038/370328a0; JAKOSKY BM, 1990, J GEOPHYS RES-SOLID, V95, P1475, DOI 10.1029/JB095iB02p01475; Kieffer L. J., 1969, Atomic Data, V1, P19, DOI 10.1016/S0092-640X(69)80020-3; Krasnopolsky V. A., 1986, PHOTOCHEMISTRY ATMOS; KRASNOPOLSKY VA, 1995, J GEOPHYS RES-PLANET, V100, P3263, DOI 10.1029/94JE03283; Krasnopolsky VA, 1997, J GEOPHYS RES-PLANET, V102, P6525, DOI 10.1029/96JE03766; KRASNOPOLSKY VA, 1993, ICARUS, V101, P313, DOI 10.1006/icar.1993.1027; KRASNOPOLSKY VA, 1994, ICARUS, V109, P337, DOI 10.1006/icar.1994.1098; KRASNOPOLSKY VA, 1993, ICARUS, V101, P33, DOI 10.1006/icar.1993.1003; Krasnopolsky VA, 1996, J GEOPHYS RES-SPACE, V101, P15765, DOI 10.1029/96JA01080; LECLUSE C, 1994, GEOCHIM COSMOCHIM AC, V58, P2927, DOI 10.1016/0016-7037(94)90126-0; LEMAIRE P, 1978, ASTROPHYS J, V223, pL55, DOI 10.1086/182727; LUHMANN JG, 1992, GEOPHYS RES LETT, V19, P2151, DOI 10.1029/92GL02485; MELOSH HJ, 1989, NATURE, V338, P487, DOI 10.1038/338487a0; MERLIVAT L, 1967, TELLUS, V19, P122, DOI 10.1111/j.2153-3490.1967.tb01465.x; NAIR H, 1994, ICARUS, V111, P124, DOI 10.1006/icar.1994.1137; NAKAI Y, 1987, ATOM DATA NUCL DATA, V37, P69, DOI 10.1016/0092-640X(87)90005-2; NEWMAN JH, 1982, PHYS REV A, V25, P2976, DOI 10.1103/PhysRevA.25.2976; Nier A. O., 1977, Journal of Geophysical Research, V82, P4341, DOI 10.1126/science.194.4271.1298; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; OWEN T, 1988, SCIENCE, V240, P1767, DOI 10.1126/science.240.4860.1767; RICHARDS PG, 1994, J GEOPHYS RES-SPACE, V99, P8981, DOI 10.1029/94JA00518; STUMPNER W, 1998, ANN GEOPHYS S111, V16, pC1002; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; WU FM, 1980, ASTROPHYS J, V239, P389, DOI 10.1086/158119; YUNG YL, 1988, ICARUS, V76, P146, DOI 10.1016/0019-1035(88)90147-9; Yung YL, 1998, SCIENCE, V280, P1545, DOI 10.1126/science.280.5369.1545; ZHANG MHG, 1993, J GEOPHYS RES-PLANET, V98, P3311, DOI 10.1029/92JE02229	45	95	94	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1576	1580		10.1126/science.280.5369.1576	http://dx.doi.org/10.1126/science.280.5369.1576			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616115				2022-12-24	WOS:000074061200033
J	Brown, RH; Cruikshank, DP; Pendleton, Y; Veeder, GJ				Brown, RH; Cruikshank, DP; Pendleton, Y; Veeder, GJ			Identification of water ice on the Centaur 1997 CU26	SCIENCE			English	Article							SHORT-PERIOD COMETS; OUTER SOLAR-SYSTEM; OPTICAL-CONSTANTS; KUIPER BELT; OBJECTS	Spectra of the Centaur 1997 CU26 were obtained at the Keck Observatory on 27 October 1997 (universal time). The data show strong absorptions at 1.52 and 2.03 micrometers attributable to water ice on the surface of 1997 CU26. The reflectance spectrum of 1997 CU26 is matched by the spectrum of a mixture of low-temperature particulate water ice and spectrally featureless but otherwise red-colored material. Water ice dominates the Spectrum of 1997 CU26, whereas methane or methane-like hydrocarbons apparently dominate the spectrum of the Kuiper belt object 1993 SC, perhaps indicating different origins, thermal histories, or both for these two objects.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Univ Arizona, Steward Observ, Tucson, AZ 85721 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	University of Arizona; University of Arizona; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Brown, RH (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.							BELL JF, 1988, LUNAR PLANET SCI, V19, P57; Brown RH, 1997, SCIENCE, V276, P937, DOI 10.1126/science.276.5314.937; CRUIKSHANK DP, 1997, STARDUST PLANETESIMA; CRUIKSHANK DP, UNPUB; DUNCAN M, 1988, ASTROPHYS J, V328, pL69, DOI 10.1086/185162; EDGEWORTH KE, 1949, MON NOT R ASTRON SOC, V109, P600, DOI 10.1093/mnras/109.5.600; GLADMAN B, 1990, ASTRON J, V100, P1680, DOI 10.1086/115628; Hapke B, 1993, REMOTE GEOCHEMICAL A, P31; HOLMAN MJ, 1993, ASTRON J, V105, P1987, DOI 10.1086/116574; Irwin M, 1995, ASTRON J, V110, P3082, DOI 10.1086/117749; Jewitt D, 1996, ASTRON J, V112, P1225, DOI 10.1086/118093; JEWITT DC, UNPUB; Kuiper G.P., 1951, ASTROPHYSICS TOPICAL, P357; LUU J, 1994, ICARUS, V109, P133, DOI 10.1006/icar.1994.1081; Luu JX, 1998, ASTROPHYS J, V494, pL117, DOI 10.1086/311172; Matthews M. S., 1989, ASTEROIDS, VII; SAGAN C, 1984, SATURN, P788; TOON OB, 1994, J GEOPHYS RES-ATMOS, V99, P25631, DOI 10.1029/94JD02388; WARREN SG, 1984, APPL OPTICS, V23, P1206, DOI 10.1364/AO.23.001206; [No title captured]; 1997, 31010 MIN PLAN	21	44	44	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 29	1998	280	5368					1430	1432		10.1126/science.280.5368.1430	http://dx.doi.org/10.1126/science.280.5368.1430			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9603731				2022-12-24	WOS:000073883400054
J	Villa, A; Santagata, S; Bozzi, F; Giliani, S; Frattini, A; Imberti, L; Gatta, LB; Ochs, HD; Schwarz, K; Notarangelo, LD; Vezzoni, P; Spanopoulou, E				Villa, A; Santagata, S; Bozzi, F; Giliani, S; Frattini, A; Imberti, L; Gatta, LB; Ochs, HD; Schwarz, K; Notarangelo, LD; Vezzoni, P; Spanopoulou, E			Partial V(D)J recombination activity leads to Omenn syndrome	CELL			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; IMMUNOGLOBULIN-E PRODUCTION; COMBINED IMMUNE-DEFICIENCY; T-CELLS; LYMPHOCYTES-T; SCID MICE; DNA; RAG-1; SEQUENCE; GENES	Genomic rearrangement of the antigen receptor loci is initiated by the two lymphoid-specific proteins Rag-1 and Rag-2. Null mutations in either of the two proteins abrogate initiation of V(D)J recombination and cause severe combined immunodeficiency with complete absence of mature B and T rymphocytes. We report here that patients with Omenn syndrome, a severe immunodeficiency characterized by the presence of activated, anergic, oligoclonal T cells, hypereosinophilia, and high IgE levels, bear missense mutations in either the Rag-1 or Rag-2 genes that result in partial activity of the two proteins. Two of the amino acid substitutions map within the Rag-1 homeodomain and decrease DNA binding activity, while three others lower the efficiency of Rag-1/Rag-2 interaction. These findings provide evidence to indicate that the immunodeficiency manifested in patients with Omenn syndrome arises from mutations that decrease the efficiency of V(D)J recombination.	CNR, Ist Tecnol Biomed Avanzate, Dept Human Genome & Multifactorial Dis, I-20090 Segrate, Milano, Italy; Mt Sinai Sch Med, Ruttenberg Canc Ctr, Howard Hughes Med Inst, New York, NY 10029 USA; Spedali Civili, Dept Paediat, I-25123 Brescia, Italy; Univ Brescia, I-25123 Brescia, Italy; Spedali Civili, Terzo Lab Anal, I-25123 Brescia, Italy; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Univ Ulm, Dept Transfus Med, D-89070 Ulm, Germany	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Howard Hughes Medical Institute; Icahn School of Medicine at Mount Sinai; Hospital Spedali Civili Brescia; University of Brescia; Hospital Spedali Civili Brescia; University of Washington; University of Washington Seattle; Ulm University	Vezzoni, P (corresponding author), CNR, Ist Tecnol Biomed Avanzate, Dept Human Genome & Multifactorial Dis, Via Fratelli Cervi 93, I-20090 Segrate, Milano, Italy.		Vezzoni, Paolo/K-3197-2018; Frattini, Annalisa/B-7684-2015; Santagata, Sandro/A-7714-2009; Vezzoni, Paolo/R-3416-2019; Bozzi, Fabio Luigi/H-6091-2017; Giliani, Silvia/AAX-8843-2020; Notarangelo, Luigi D/F-9718-2016	Frattini, Annalisa/0000-0002-1166-3091; Bozzi, Fabio Luigi/0000-0003-0729-1288; Giliani, Silvia/0000-0001-8137-4642; Notarangelo, Luigi D/0000-0002-8335-0262; Santagata, Sandro/0000-0002-7528-9668; Villa, Anna/0000-0003-4428-9013; Vezzoni, Paolo/0000-0002-6382-3923; Imberti, Luisa/0000-0002-2075-8391	NIAID NIH HHS [AI40191] Funding Source: Medline; NICHD NIH HHS [HD17427] Funding Source: Medline; Telethon [E.0495, E.0668] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017427, R37HD017427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040191] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Telethon(Fondazione Telethon); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Arden Bernhard, 1995, Immunogenetics, V42, P455; Bendelac A, 1996, J EXP MED, V184, P1285, DOI 10.1084/jem.184.4.1285; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Bernstein RM, 1996, P NATL ACAD SCI USA, V93, P9454, DOI 10.1073/pnas.93.18.9454; BETTINARDI A, 1992, J IMMUNOL METHODS, V146, P71, DOI 10.1016/0022-1759(92)90050-4; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; Bogue MA, 1997, IMMUNITY, V7, P37, DOI 10.1016/S1074-7613(00)80508-7; Brugnoni D, 1997, EUR J IMMUNOL, V27, P2765, DOI 10.1002/eji.1830271104; CAVAZZANACALVO M, 1993, J CLIN INVEST, V91, P1214, DOI 10.1172/JCI116282; Chilosi M, 1996, EUR J IMMUNOL, V26, P329, DOI 10.1002/eji.1830260209; Cortes P, 1996, P NATL ACAD SCI USA, V93, P14008, DOI 10.1073/pnas.93.24.14008; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DESAINTBASILE G, 1991, J CLIN INVEST, V87, P1352, DOI 10.1172/JCI115139; Difilippantonio MJ, 1996, CELL, V87, P253, DOI 10.1016/S0092-8674(00)81343-4; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; GOMEZ L, 1995, J PEDIATR-US, V127, P76, DOI 10.1016/S0022-3476(95)70260-1; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; GU Y, 1997, IMMUNITY, V7, P853; GUIDOS CJ, 1995, J EXP MED, V181, P1187, DOI 10.1084/jem.181.3.1187; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Harville TO, 1997, J CLIN IMMUNOL, V17, P322, DOI 10.1023/A:1027330800085; Hiom K, 1997, CELL, V88, P65, DOI 10.1016/S0092-8674(00)81859-0; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Imberti L, 1997, BLOOD, V89, P2822, DOI 10.1182/blood.V89.8.2822; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Leu TMJ, 1997, IMMUNITY, V7, P303, DOI 10.1016/S1074-7613(00)80532-4; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; Livak F, 1996, J EXP MED, V184, P419, DOI 10.1084/jem.184.2.419; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MACHE CJ, 1994, ANN HEMATOL, V69, P85, DOI 10.1007/BF01698488; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McMahan CJ, 1997, J IMMUNOL, V158, P2202; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Nagawa F, 1998, MOL CELL BIOL, V18, P655, DOI 10.1128/MCB.18.1.655; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OMENN GS, 1965, NEW ENGL J MED, V273, P427, DOI 10.1056/NEJM196508192730806; RAMSDEN DA, 1994, NUCLEIC ACIDS RES, V22, P1785, DOI 10.1093/nar/22.10.1785; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; ROLDAN EQ, 1995, IMMUNOGENETICS, V41, P91; Roman CAJ, 1996, P NATL ACAD SCI USA, V93, P2333, DOI 10.1073/pnas.93.6.2333; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; SANTAGATA S, 1998, IN PRESS J BIOL CHEM; SCHANDENE L, 1993, EUR J IMMUNOL, V23, P56, DOI 10.1002/eji.1830230110; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; SILVER DP, 1994, THESIS MIT CAMBRIDGE; Sottini A, 1996, HUM IMMUNOL, V48, P12, DOI 10.1016/0198-8859(96)00087-0; Spanopoulou E, 1995, IMMUNITY, V3, P715, DOI 10.1016/1074-7613(95)90061-6; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; WeisGarcia F, 1997, MOL CELL BIOL, V17, P6379, DOI 10.1128/MCB.17.11.6379; WEN L, 1994, NATURE, V369, P654, DOI 10.1038/369654a0; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	67	325	338	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					885	896		10.1016/S0092-8674(00)81448-8	http://dx.doi.org/10.1016/S0092-8674(00)81448-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630231	Bronze			2022-12-24	WOS:000073956700023
J	Hinuma, S; Habata, Y; Fujii, R; Kawamata, Y; Hosoya, N; Fukusumi, S; Kitada, C; Masuo, Y; Asano, T; Matsumoto, H; Sekiguchi, M; Kurokawa, T; Nishimura, O; Onda, H; Fujino, M				Hinuma, S; Habata, Y; Fujii, R; Kawamata, Y; Hosoya, N; Fukusumi, S; Kitada, C; Masuo, Y; Asano, T; Matsumoto, H; Sekiguchi, M; Kurokawa, T; Nishimura, O; Onda, H; Fujino, M			A prolactin-releasing peptide in the brain	NATURE			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; COUPLED RECEPTOR; PITUITARY-GLAND; GROWTH-HORMONE; CELL-LINE; RAT; SECRETION; CLONING; EXPRESSION; INVITRO	Hypothalamic peptide hormones regulate the secretion of most of the anterior pituitary hormones, that is, growth hormone, follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone and adrenocorticotropin(1,2). These peptides do not regulate the secretion of prolactin(1,2), at least in a specific manner, however. The peptides act through specific receptors, which are referred to as seven-transmembrane-domain receptors or G-protein-coupled receptors(3-7). Although prolactin is important in pregnancy and lactation in mammals, and is involved in the development of the mammary glands and the promotion of milk synthesis(8,9), a specific prolactin-releasing hormone has remained unknown. Here we identify a potent candidate for such a hormone. We first proposed that there may still be unknown peptide hormone factors that control pituitary function through seven-transmembrane-domain receptors. We isolated the complementary DNA encoding an 'orphan' receptor (that is, one for which the ligand is unknown). This receptor, hGR3, is specifically expressed in the human pituitary. We then searched for the hGR3 Ligand in the hypothalamus and identified a new peptide. which shares no sequence similarity with known peptides and proteins, as an endogenous ligand. We show that this ligand is a potent prolactin-releasing factor for rat anterior pituitary cells; we have therefore named this peptide prolactin-releasing peptide.	Takeda Chem Ind Ltd, Pharmaceut Discovery Res Div, Discovery Res Labs 1, Ibaraki, Osaka 3004293, Japan; Takeda Chem Ind Ltd, Div Pharmaceut Res, Ibaraki, Osaka 3004293, Japan; Takeda Chem Ind Ltd, Pharmaceut Dev Div, Ibaraki, Osaka 3004293, Japan	Takeda Chemical Industries; Takeda Chemical Industries; Takeda Chemical Industries	Hinuma, S (corresponding author), Takeda Chem Ind Ltd, Pharmaceut Discovery Res Div, Discovery Res Labs 1, 10 Wadai, Ibaraki, Osaka 3004293, Japan.	Hinuma_Shuji@takeda.co.jp		Kawamata, Yuji/0000-0001-5652-4899				CANONICO PL, 1983, NEUROENDOCRINOLOGY, V37, P212, DOI 10.1159/000123545; Chalmers DT, 1996, TRENDS PHARMACOL SCI, V17, P166, DOI 10.1016/0165-6147(96)81594-X; Cox KJA, 1997, J NEUROSCI, V17, P1197; DROUHAULT R, 1994, NEUROENDOCRINOLOGY, V60, P179, DOI 10.1159/000126749; Erfurth EM, 1996, HORM METAB RES, V28, P599, DOI 10.1055/s-2007-979861; FRANTZ AG, 1978, NEW ENGL J MED, V298, P201, DOI 10.1056/NEJM197801262980408; Hammond PJ, 1996, J NEUROENDOCRINOL, V8, P457, DOI 10.1046/j.1365-2826.1996.04747.x; HINUMA S, 1994, BBA-GENE STRUCT EXPR, V1219, P251, DOI 10.1016/0167-4781(94)90046-9; HURBAINKOSMATH I, 1990, IN VITRO CELL DEV B, V26, P431; HYDE JF, 1987, ENDOCRINOLOGY, V121, P1531, DOI 10.1210/endo-121-4-1531; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V189, P289, DOI 10.1016/0006-291X(92)91556-6; KOENIG JI, 1989, TOXICOL PATHOL, V17, P256, DOI 10.1177/019262338901700204; KOYAMA N, 1994, J BIOTECHNOL, V32, P273, DOI 10.1016/0168-1656(94)90213-5; LAMBERTS SWJ, 1990, PHYSIOL REV, V70, P279, DOI 10.1152/physrev.1990.70.2.279; MARCHESE A, 1995, GENOMICS, V29, P335, DOI 10.1006/geno.1995.9996; Mayo KE, 1996, ANN NY ACAD SCI, V805, P184, DOI 10.1111/j.1749-6632.1996.tb17483.x; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MIYAMOTO Y, 1994, BBA-GENE STRUCT EXPR, V1218, P297, DOI 10.1016/0167-4781(94)90181-3; NAKAGAWA S, 1994, J AM CHEM SOC, V116, P5513, DOI 10.1021/ja00091a083; PATEL YC, 1995, LIFE SCI, V57, P1249, DOI 10.1016/0024-3205(95)02082-T; REICHLIN S, 1989, TOXICOL PATHOL, V17, P250, DOI 10.1177/019262338901700203; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; RIVIER C, 1977, ENDOCRINOLOGY, V100, P751, DOI 10.1210/endo-100-3-751; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SAMSON WK, 1986, ENDOCRINOLOGY, V119, P554, DOI 10.1210/endo-119-2-554; SAMSON WK, 1980, PEPTIDES, V1, P325, DOI 10.1016/0196-9781(80)90010-8; SHIOTA K, 1984, ACTA ENDOCRINOL-COP, V106, P71, DOI 10.1530/acta.0.1060071; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WELCH SK, 1995, BIOCHEM BIOPH RES CO, V209, P606, DOI 10.1006/bbrc.1995.1543	29	482	525	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 21	1998	393	6682					272	276		10.1038/30515	http://dx.doi.org/10.1038/30515			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607765				2022-12-24	WOS:000073761000055
J	Reichardt, HM; Kaestner, KH; Tuckermann, J; Kretz, O; Wessely, O; Bock, R; Gass, P; Schmid, W; Herrlich, P; Angel, P; Schutz, G				Reichardt, HM; Kaestner, KH; Tuckermann, J; Kretz, O; Wessely, O; Bock, R; Gass, P; Schmid, W; Herrlich, P; Angel, P; Schutz, G			DNA binding of the glucocorticoid receptor is not essential for survival	CELL			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTORS; RESPONSE ELEMENT; FUNCTIONAL ANTAGONISM; THYMOCYTE APOPTOSIS; PROTEIN-INTERACTION; POSSIBLE MECHANISM; GENE-EXPRESSION; MESSENGER-RNA; C-JUN	Transcriptional regulation by the glucocorticoid receptor (GR) is essential for survival. Since the GR can influence transcription both through DNA-binding-dependent and -independent mechanisms, we attempted to assess their relative importance in vivo. In order to separate these modes of action, we introduced the point mutation A458T into the GR by gene targeting using the Cre/loxP system. This mutation impairs dimerization and therefore GRE-dependent transactivation while functions that require cross-talk with other transcription factors, such as transrepression of AP-1-driven genes, remain intact. In contrast to GR(-/-) mice, these mutants termed GR(dim) are viable, revealing the in vivo relevance of DNA-binding-independent activities of the GR.	German Canc Res Ctr, Div Mol Biol Cell 1, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany; Univ Saarland, Inst Anat, D-66421 Homburg, Germany; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Saarland University; Helmholtz Association; Karlsruhe Institute of Technology	Schutz, G (corresponding author), German Canc Res Ctr, Div Mol Biol Cell 1, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Piris, Miguel A/AAP-1445-2020; Reichardt, Holger/AAF-3048-2020	Piris, Miguel A/0000-0001-5839-3634; Reichardt, Holger/0000-0003-4647-057X; Kretz, Oliver/0000-0003-1152-5956				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BIRNBERG NC, 1983, P NATL ACAD SCI-BIOL, V80, P6982, DOI 10.1073/pnas.80.22.6982; BOCK R, 1991, ACTA HISTOCHEM, V91, P201, DOI 10.1016/S0065-1281(11)80277-1; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; GACK S, 1994, J BIOL CHEM, V269, P10363; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; IMAI E, 1993, J BIOL CHEM, V268, P5353; JIANG W, 1989, INT J DEV NEUROSCI, V7, P513, DOI 10.1016/0736-5748(89)90010-5; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Murphy EP, 1997, MOL ENDOCRINOL, V11, P39, DOI 10.1210/me.11.1.39; NAZARETH LV, 1991, J BIOL CHEM, V266, P12976; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NITSCH D, 1990, MOL CELL BIOL, V10, P3334, DOI 10.1128/MCB.10.7.3334; OEHLER T, 1992, MOL CELL BIOL, V12, P5508, DOI 10.1128/MCB.12.12.5508; Phillips A, 1997, MOL CELL BIOL, V17, P5952, DOI 10.1128/MCB.17.10.5952; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reichardt HM, 1996, MOL MED, V2, P735, DOI 10.1007/BF03401657; ROSS ME, 1990, J NEUROSCI, V10, P520; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEASHOLTZ AF, 1988, MOL ENDOCRINOL, V2, P1311, DOI 10.1210/mend-2-12-1311; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; Wilkinson DG, 1992, SITU HYBRIDIZATION P; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	48	870	919	1	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1998	93	4					531	541		10.1016/S0092-8674(00)81183-6	http://dx.doi.org/10.1016/S0092-8674(00)81183-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604929	hybrid			2022-12-24	WOS:000073722200007
J	Thomas, MJ; Platas, AA; Hawley, DK				Thomas, MJ; Platas, AA; Hawley, DK			Transcriptional fidelity and proofreading by RNA polymerase II	CELL			English	Article							DNA-REPLICATION FIDELITY; ELONGATION-FACTOR TFIIS; SACCHAROMYCES-CEREVISIAE; KINETIC MECHANISM; FACTOR-SII; CLEAVAGE; COMPLEXES; SITES; TERMINATION; EXONUCLEASE	We have addressed whether the intrinsic 3'-->15' nuclease activity of human RNA polymerase II (pol II) can proofread during transcription in vitro. In the presence of SII, a protein that stimulates the nuclease activity, pol II quantitatively removed misincorporated nucleotides from the nascent transcript during rapid chain extension. The basis of discrimination between the correct and incorrect base was the slow addition of the next nucleotide to the mismatched terminus. Incorporation of inosine monophosphate inhibited next nucleotide addition by a similar magnitude as a mismatched base. We used this finding to demonstrate that addition of SII to a transcription reaction dramatically altered the RNA base content, reflecting the stable incorporation of more "correct" (GMP) and fewer "incorrect" (IMP) nucleotides.	Univ Oregon, Inst Mol Biol, Dept Chem, Eugene, OR 97403 USA; Univ Oregon, Inst Mol Biol, Dept Biol, Eugene, OR 97403 USA	University of Oregon; University of Oregon	Hawley, DK (corresponding author), Univ Oregon, Inst Mol Biol, Dept Chem, Eugene, OR 97403 USA.							ABBOTTS J, 1988, J BIOL CHEM, V263, P15094; ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; CHAMBERLIN M, 1974, ENZYMES, P333; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; Jeon C, 1996, P NATL ACAD SCI USA, V93, P13677, DOI 10.1073/pnas.93.24.13677; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; KAHN JD, 1989, J MOL BIOL, V205, P291, DOI 10.1016/0022-2836(89)90342-2; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KIRKWOOD TBL, 1986, ACCURACY MOL PROCESS; KOHALMI SE, 1991, J MOL BIOL, V220, P933, DOI 10.1016/0022-2836(91)90364-C; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; LIBBY RT, 1991, MOL MICROBIOL, V5, P999, DOI 10.1111/j.1365-2958.1991.tb01872.x; LO KY, 1976, J BIOL CHEM, V251, P2480; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; NAKANISHI Y, 1981, FEBS LETT, V130, P69, DOI 10.1016/0014-5793(81)80667-9; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; Shilatifard A, 1997, CURR OPIN GENET DEV, V7, P199, DOI 10.1016/S0959-437X(97)80129-3; TAMURA H, 1980, J BIOCHEM-TOKYO, V88, P1475, DOI 10.1093/oxfordjournals.jbchem.a133117; Umehara T, 1997, J BIOCHEM-TOKYO, V121, P598, DOI 10.1093/oxfordjournals.jbchem.a021627; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WIEST DK, 1992, J BIOL CHEM, V267, P7733; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	45	199	202	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					627	637		10.1016/S0092-8674(00)81191-5	http://dx.doi.org/10.1016/S0092-8674(00)81191-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604937	Bronze			2022-12-24	WOS:000073722200015
J	Gho, M; Schweisguth, F				Gho, M; Schweisguth, F			Frizzled signalling controls orientation of asymmetric sense organ precursor cell divisions in Drosophila	NATURE			English	Article							NUMB PROTEIN; NOTCH; MECHANISMS; ENCODES; DOMAINS; FATES; GENE	During metazoan development, cell-fate diversity is brought about, in part, by asymmetric cell divisions(1). In Drosophila, bristle mechanosensory organs are composed of four different cells that originate from a single precursor cell, pI, after two rounds of asymmetric division(2). At each division, distinct fates are conferred on sister cells by the asymmetric segregation ofNumb, a negative regulator of Notch signalling(3-6). Here we show that the orientation of the mitotic spindles and the localization of the Numb crescent follow a stereotyped pattern. Mitosis of pI is orientated parallel eo the anteroposterior axis of the fly. We show that signalling mediated by the Frizzled receptor polarizes pi along this axis, thereby specifying the orientation of the mitotic spindle and positioning the Numb crescent. The mitoses of the two cells produced by mitosis of pI are orientated parallel and orthogonal, respectively, to the division axis of pI. This difference in cell-division orientation is largely independent of the identity of the secondary precursor cells, and is regulated by Frizzled-independent mechanisms.	Ecole Normale Super, Lab Genet Dev Drosophile, URA 1857,46 Rue Ulm, F-75005 Paris, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Gho, M (corresponding author), Ecole Normale Super, Lab Genet Dev Drosophile, URA 1857,46 Rue Ulm, F-75005 Paris, France.	mgho@wotan.ens.fr						ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; BATE CM, 1978, HDB SENSORY PHYSL, P1; EMERY JF, 1995, DEVELOPMENT, V121, P3549; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Gho M, 1996, DEVELOPMENT, V122, P1673; Gonczy P, 1996, TRENDS CELL BIOL, V6, P382, DOI 10.1016/0962-8924(96)10035-0; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P398; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; Jones KH, 1996, GENETICS, V142, P205; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; LAWRENCE PA, 1966, J EXP BIOL, V44, P607; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; PARK WJ, 1994, MECH DEVELOP, V45, P127, DOI 10.1016/0925-4773(94)90026-4; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; USUI K, 1993, ROUX ARCH DEV BIOL, V203, P151, DOI 10.1007/BF00365054; Wang SW, 1997, DEVELOPMENT, V124, P4435	22	188	190	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1998	393	6681					178	181		10.1038/30265	http://dx.doi.org/10.1038/30265			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN200	9603522				2022-12-24	WOS:000073619900051
J	Behrens, J; Jerchow, BA; Wurtele, M; Grimm, J; Asbrand, C; Wirtz, R; Kuhl, M; Wedlich, D; Birchmeier, W				Behrens, J; Jerchow, BA; Wurtele, M; Grimm, J; Asbrand, C; Wirtz, R; Kuhl, M; Wedlich, D; Birchmeier, W			Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3 beta	SCIENCE			English	Article							TUMOR-SUPPRESSOR PROTEIN; E-CADHERIN; XENOPUS; ASSOCIATION; EXPRESSION; MIGRATION; MESODERM; COMPLEX	Control of stability of beta-catenin is central in the wnt signaling pathway. Here, the protein conductin was found to form a complex with both beta-catenin and the tumor suppressor gene product adenomatous polyposis coli (APC), Conductin induced beta-catenin degradation, whereas mutants of conductin that were deficient in complex formation stabilized beta-catenin. Fragments of APC that contained a conductin-binding domain also blocked beta-catenin degradation. Thus, conductin is a component of the multiprotein complex that directs beta-catenin to degradation and is located downstream of APC. In Xenopus embryos, conductin interfered with wnt-induced axis formation.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Univ Ulm, D-89081 Ulm, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Ulm University	Birchmeier, W (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.	wbirch@mdc-berlin.de	Würtele, Martin/D-2686-2012	Jerchow, Boris-Alexander/0000-0002-7031-8730				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ABERLE H, 1994, J CELL SCI, V107, P3655; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BLADT D, 1996, NATURE, V376, P768; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; GUGER KA, 1995, DEV BIOL, V172, P115, DOI 10.1006/dbio.1995.0009; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhl M, 1996, MECH DEVELOP, V54, P71, DOI 10.1016/0925-4773(95)00462-9; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Morrison EE, 1997, NEUROSCIENCE, V81, P553, DOI 10.1016/S0306-4522(97)00099-7; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	35	1072	1103	2	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1998	280	5363					596	599		10.1126/science.280.5363.596	http://dx.doi.org/10.1126/science.280.5363.596			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554852				2022-12-24	WOS:000073242100049
J	Nelms, BE; Maser, RS; MacKay, JF; Lagally, MG; Petrini, JHJ				Nelms, BE; Maser, RS; MacKay, JF; Lagally, MG; Petrini, JHJ			In situ visualization of DNA double-strand break repair in human fibroblasts	SCIENCE			English	Article							CULTURED MAMMALIAN-CELLS; ULTRASOFT X-RAYS; ESCHERICHIA-COLI; RAD51 GENE; RECOMBINATION; DAMAGE; PROTEIN; INACTIVATION; RADIATIONS; EXPRESSION	A method was developed to examine DNA repair within the intact cell. Ultrasoft x-rays were used to induce DNA double-strand breaks (DSBs) in defined subnuclear volumes of human fibroblasts and DNA repair was visualized at those sites. The DSBs remained in a fixed position during the initial stages of DNA repair, and the DSB repair protein hMre11 migrated to the sites of damage within 30 minutes. In contrast, hRad51, a human RecA homolog, did not localize at sites of DNA damage, a finding consistent with the distinct roles of these proteins in DNA repair.	Univ Wisconsin, Sch Med, Genet Lab, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Med Phys, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Mat Sci & Engn, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Petrini, JHJ (corresponding author), Univ Wisconsin, Sch Med, Genet Lab, Madison, WI 53706 USA.		Maser, Richard/B-2970-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008349, T32GM007133] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM08349, 5T32GM07133] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADIE C, 1995, CANCER RES, V55, P1232; BADIE C, 1995, RADIAT RES, V144, P26, DOI 10.2307/3579232; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Botchway SW, 1997, RADIAT RES, V148, P317, DOI 10.2307/3579516; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; CORNFORTH MN, 1983, SCIENCE, V222, P1141, DOI 10.1126/science.6648528; COX R, 1977, INT J RADIAT BIOL, V31, P561, DOI 10.1080/09553007714550661; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Flygare J, 1996, BBA-MOL CELL RES, V1312, P231, DOI 10.1016/0167-4889(96)00040-7; GOODHEAD DT, 1993, INT J RADIAT BIOL, V63, P543, DOI 10.1080/09553009314450721; GOODHEAD DT, 1979, INT J RADIAT BIOL, V36, P101, DOI 10.1080/09553007914550861; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; Jackson SP, 1996, CANCER SURV, V28, P261; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Kanaar Roland, 1997, Genes and Function, V1, P165; KODYM R, 1995, INT J RADIAT BIOL, V68, P133, DOI 10.1080/09553009514551031; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; Li X, 1995, CELL PROLIFERAT, V28, P571, DOI 10.1111/j.1365-2184.1995.tb00045.x; Lobrich M, 1995, P NATL ACAD SCI USA, V92, P12050, DOI 10.1073/pnas.92.26.12050; MACKAY JF, IN PRESS MED PHYS; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; NELMS BE, IN PRESS RAD RES; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEVALDINE B, 1993, RADIAT RES, V133, P370, DOI 10.2307/3578224; Park MS, 1996, P NATL ACAD SCI USA, V93, P8368, DOI 10.1073/pnas.93.16.8368; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Singer RH, 1997, CELL, V91, P291, DOI 10.1016/S0092-8674(00)80411-0; Strouboulis J, 1996, J CELL SCI, V109, P1991; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; VIRSIKPEUCKERT RP, 1983, RAD INDUCED CHROMOSO, V4, P51; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; Yamamoto A, 1996, MOL GEN GENET, V251, P1	42	411	419	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					590	592		10.1126/science.280.5363.590	http://dx.doi.org/10.1126/science.280.5363.590			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554850				2022-12-24	WOS:000073242100047
J	Nureki, O; Vassylyev, DG; Tateno, M; Shimada, A; Nakama, T; Fukai, S; Konno, M; Hendrickson, TL; Schimmel, P; Yokoyama, S				Nureki, O; Vassylyev, DG; Tateno, M; Shimada, A; Nakama, T; Fukai, S; Konno, M; Hendrickson, TL; Schimmel, P; Yokoyama, S			Enzyme structure with two catalytic sites for double-sieve selection of substrate	SCIENCE			English	Article							TRANSFER-RNA-SYNTHETASES; PROTEIN-SYNTHESIS; VALINE; ISOLEUCINE; DISCRIMINATION; RECOGNITION; MECHANISMS; RESIDUES; ERRORS	High-fidelity transfers of genetic information in the central dogma can be achieved by a reaction called editing. The crystal structure of an enzyme with editing activity in translation is presented here at 2.5 angstroms resolution. The enzyme, isoleucyl-transfer RNA synthetase, activates not only the cognate substrate L-isoleucine but also the minimally distinct L-valine in the first, aminoacylation step. Then, in a second, "editing" step, the synthetase itself rapidly hydrolyzes only the valylated products. For this two-step substrate selection, a "double-sieve" mechanism has already been proposed. The present crystal structures of the synthetase in complexes with L-isoleucine and L-valine demonstrate that the first sieve is on the aminoacylation domain containing the Rossmann fold, whereas the second, editing sieve exists on a globular beta-barrel domain that protrudes from the aminoacylation domain.	Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 113, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 35101, Japan; Matsushita Elect Ind Co Ltd, Int Inst Adv Res, Cent Res Labs, Kyoto 61902, Japan; Ochanomizu Univ, Fac Sci, Dept Chem, Bunkyo Ku, Tokyo 112, Japan; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	University of Tokyo; RIKEN; Panasonic; Ochanomizu University; Scripps Research Institute	Yokoyama, S (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.	yokoyama@y-sun.biochem.s.u-tokyo.ac.jp	Vassylyev, Dmitry/A-9005-2008; Fukai, Shuya/X-4838-2018; Yokoyama, Shigeyuki/N-6911-2015	Fukai, Shuya/0000-0002-1241-1443; Yokoyama, Shigeyuki/0000-0003-3133-7338; Shimada, Atsushi/0000-0002-4108-770X	NIGMS NIH HHS [GM15539] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015539, R37GM015539] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; BURGESS SM, 1993, TRENDS BIOCHEM SCI, V18, P381, DOI 10.1016/0968-0004(93)90094-4; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FARRASH MA, 1994, J VIROL, V68, P233; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FREIST W, 1985, BIOCHEMISTRY-US, V24, P7014, DOI 10.1021/bi00345a040; FREIST W, 1989, BIOCHEMISTRY-US, V28, P6787, DOI 10.1021/bi00443a001; FUKAI S, UNPUB; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; MILLER M, 1993, FEBS LETT, V328, P275, DOI 10.1016/0014-5793(93)80943-O; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; NUREKI O, UNPUB; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pauling L., 1957, FESTSCHRIFT ARTHUR S, P597; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; SCHMIDT EG, UNPUB; SNEDDON SF, 1992, BIOCHEMISTRY-US, V31, P2842, DOI 10.1021/bi00125a028; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; TAKANO K, 1995, J MOL BIOL, V254, P62, DOI 10.1006/jmbi.1995.0599; Zhang ZY, 1996, CANCER RES, V56, P3926	34	310	324	3	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1998	280	5363					578	582		10.1126/science.280.5363.578	http://dx.doi.org/10.1126/science.280.5363.578			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554847				2022-12-24	WOS:000073242100044
J	Fletcher, RH				Fletcher, RH			Should all people over the age of 50 have regular fecal occult-blood tests? If it works, why not do it?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COLORECTAL-CANCER; PREVENTION		Harvard Univ, Sch Med, Dep Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care	Fletcher, RH (corresponding author), Harvard Univ, Sch Med, Dep Ambulatory Care & Prevent, 126 Brookline Ave, Boston, MA 02215 USA.							Allison JE, 1996, NEW ENGL J MED, V334, P155, DOI 10.1056/NEJM199601183340304; Byers T, 1997, CA-CANCER J CLIN, V47, P154, DOI 10.3322/canjclin.47.3.154; Church TR, 1997, JNCI-J NATL CANCER I, V89, P1440, DOI 10.1093/jnci/89.19.1440; Ederer F, 1997, J NATL CANCER I, V89, P1423, DOI 10.1093/jnci/89.19.1423; FLEISHER M, 1991, ANN INTERN MED, V114, P875, DOI 10.7326/0003-4819-114-10-875; Hardcastle JD, 1996, LANCET, V348, P1472, DOI 10.1016/S0140-6736(96)03386-7; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; MANDEL JS, 1993, NEW ENGL J MED, V329, P672; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV; Wagner JL, 1996, PREVENTION EARLY DET, P321; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; WINAWER SJ, 1995, B WORLD HEALTH ORGAN, V73, P7; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P1060; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; 1995, MMWR MORB MORTAL WKL, V45, P57	16	9	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1998	338	16					1153	1154						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH080	9547141				2022-12-24	WOS:000073070100013
J	Reynolds, T				Reynolds, T			Epilepsy treatment enters a new era	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					702	704		10.7326/0003-4819-128-8-199804150-00039	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00039			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537959				2022-12-24	WOS:000073052500032
J	Zatonski, WA; McMichael, AJ; Powles, JW				Zatonski, WA; McMichael, AJ; Powles, JW			Ecological study of reasons for sharp decline in mortality from ischaemic heart disease in Poland since 1991	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIET; ACID	Objective: To investigate the reasons for the decline in deaths attributed to ischaemic heart disease in Poland since 1991 after two decades of rising rates. Design: Recent changes in mortality were measured as percentage deviations in 1994 from rates predicted by extrapolation of sex and age specific death rates for 1980-91 for diseases of the circulatory system and selected other categories, Available data on national and household food availability, alcohol consumption, cigarette smoking, socioeconomic indices, and medical services over time were reviewed. Main outcome measures: Age specific and age standardised rates of death attributed to ischaemic heart disease and related causes. Results: The change in trend in mortality attributed to diseases of the circulatory system was similar in men and women and most marked (> 20%) in early middle age, For ages 45 to 64 the decrease was greatest for deaths attributed to ischaemic heart disease and atherosclerosis (around 25%) and less for stroke (< 10%), For most of the potentially explanatory variables considered, there were no corresponding changes in trend. However, between 1986-90 and 1994 there was a marked switch from animal fats (estimated availability down 23%) to vegetable fats (up 48%) and increased imports of fruit. Conclusion: Reporting biases are unlikely to have exaggerated the true fall in ischaemic heart disease; neither is it likely to be mainly due to changes in smoking, drinking, stress, or medical care, Changes in type of dietary fat and increased supplies of fresh fruit and vegetables seem to be the best candidates.	Maria Sklodowska Curie Mem Canc Ctr, Dept Epidemiol & Canc Prevent, PL-02781 Warsaw, Poland; Inst Oncol, PL-02781 Warsaw, Poland; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, London WC1E 7HT, England; Inst Publ Hlth, Cambridge CB2 2SR, England	Maria Sklodowska-Curie National Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology; University of London; London School of Hygiene & Tropical Medicine; University of Cambridge	Zatonski, WA (corresponding author), Maria Sklodowska Curie Mem Canc Ctr, Dept Epidemiol & Canc Prevent, PL-02781 Warsaw, Poland.	zatonskiw@coi.waw.pl		Powles, John/0000-0002-0766-7989				Bobak M, 1996, BRIT MED J, V312, P421; BRUTHANS J, 1997, CAN J CARDIOL SB, V13; BURR ML, 1989, LANCET, V2, P757; *CENTR STAT OFF, 1995, ROCZN STAT DEM; *CENTR STAT OFF, 1995, ROCZN STAT; *CENTR STAT OFF, 1970, ROCZN STAT; CHALLARAJ G, 1996, TRENDS HLTH STATUS S, V2, P44; CHARNOCK JS, 1994, PROG LIPID RES, V33, P355, DOI 10.1016/0163-7827(94)90023-X; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; *DEP STAT INF AN, 1995, HLTH CAR NUMB; DESPAIGNET ET, 1991, AUSTR I HLTH MORTALI, V1, P94; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; HEINEMANN L, 1994, ACTA CARDIOL, V44, P338; KHAW KT, 1995, BRIT MED J, V310, P1559, DOI 10.1136/bmj.310.6994.1559; KOZAK LJ, 1988, COMP INT VITAL HLTH, V5; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Leon DA, 1997, LANCET, V350, P383, DOI 10.1016/S0140-6736(97)03360-6; McLennan P, 1996, EUR J PHARMACOL, V300, P83, DOI 10.1016/0014-2999(95)00861-6; Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1; OKOLSKI M, 1994, STUD DEMOGR, V17, P3; OLES P, 1983, WORLD SMOKING HLTH, V8, P38; Pajak A, 1996, Przegl Lek, V53, P707; Powles JW, 1996, LANCET, V348, P898, DOI 10.1016/S0140-6736(05)64777-0; SCHWARTZ S, 1994, AM J PUBLIC HEALTH, V84, P819, DOI 10.2105/AJPH.84.5.819; Sekula W, 1996, FOOD CONSUMPTION POL; SEKULA W, 1970, BUDZETY GOSPONDARSTW; SIEROSLAWSKI J, 1995, ALKOHOLIZM NARKOMANI, V3, P57; STEWART AW, 1994, INT J EPIDEMIOL, V23, P505; STROM A, 1948, ACTA MED SCAND, V214, P22; STROM A, LANCET, V1, P126; Thiel Christine, 1996, Reviews on Environmental Health, V11, P35; THOM TJ, 1992, NIH PUBL; Waterhouse J., 1976, CANCER INCIDENCE 5 C, V3, P456; WATSON P, 1996, E W LIFE EXP GAP EUR, P152; *WHO, 1997, HLTH DATA BAS COMP P; *WHO, 1960, WORLD HLTH STAT ANN; *WHO, 1988, WORLD HLTH STAT ANN, pR17; *WORLD BANK, 1996, PLAN MARK WORLD DEV, P173; Zatonski W, 1995, Public Health Rev, V23, P139; ZATONSKI W, 1996, EVOLUTION HLTH POLAN, P27	40	146	149	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 4	1998	316	7137					1047	1051						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552904				2022-12-24	WOS:000072987400022
J	An, WG; Kanekal, M; Simon, MC; Maltepe, E; Blagosklonny, MV; Neckers, LM				An, WG; Kanekal, M; Simon, MC; Maltepe, E; Blagosklonny, MV; Neckers, LM			Stabilization of wild-type p53 by hypoxia-inducible factor 1 alpha	NATURE			English	Article							DNA-BINDING ACTIVITY; GROWTH-FACTOR GENE; FACTOR-I; TRANSCRIPTION FACTOR; ERYTHROPOIETIN GENE; SIGNAL-TRANSDUCTION; ACTIVATION; EXPRESSION; RECEPTOR; PROTEIN	Although hypoxia (lack of oxygen in body tissues) is perhaps the most physiological inducer of the wild-type p53 gene(1), the mechanism of this induction is unknown. Cells may detect low oxygen levels through a haem-containing sensor protein(2), The hypoxic state can be mimicked by using cobalt chloride and the iron chelator desferrioxamine(2-5): like hypoxia, cobalt chloride and desferrioxamine activate hypoxia-inducible factor 1 alpha (HIF-1 alpha) (ref. 6), which stimulates the transcription of several genes that are associated with hypoxia(6-9). Here we show that these treatments induce accumulation of wild-type p53 through HIF-1 alpha-dependent stabilization of p53 protein. Induction of p53 does not occur in either a mutant hepatoma cell line that is unable to induce HIF-1 alpha (ref. 10) or embryonic stem cells derived from mice lacking HIF-1 beta (ref. 11). HIF-1 alpha is found in p53 immunoprecipitates from II MCF7 cells that express wild-type p53 and are either hypoxic or have been exposed to desferrioxamine. Similarly, anti-haemagglutinin immunoprecipitates from lysates of normoxic PC3M cells that had been co-transfected with haemagglutinin-tagged HIF-1 alpha and wild-type p53 also contain p53. Transfection of normoxic MCF7 cells with HIF-1 alpha. stimulates a co-transfected p53-dependent reporter plasmid and increases the amount of endogenous p53. Our results suggest that hypoxic induction of transcriptionally active wild-type p53 is achieved as a result of the stabilization of p53 by its association with HIF-1 alpha.	NCI, Med Branch, NIH, Rockville, MD 20850 USA; NCI, Dept Cell & Canc Biol, Med Branch, NIH, Bethesda, MD 20892 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Dept Pathol, Chicago, IL 60637 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago	Neckers, LM (corresponding author), NCI, Med Branch, NIH, Key W Facil,9610 Med Ctr Dr,Room 300, Rockville, MD 20850 USA.	len@helix.nih.gov	Simon, Celeste/AAG-3941-2021					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Gradin K, 1996, MOL CELL BIOL, V16, P5221; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Maki CG, 1996, CANCER RES, V56, P2649; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117	23	727	762	3	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 26	1998	392	6674					405	408		10.1038/32925	http://dx.doi.org/10.1038/32925			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537326				2022-12-24	WOS:000072713600056
J	McWhinney, IR				McWhinney, IR			Primary care: core values - Core values in a changing world	BRITISH MEDICAL JOURNAL			English	Article							ORIENTED PRIMARY CARE; GENERAL-PRACTITIONERS; COMMUNITY		Univ Western Ontario, Ctr Studies Family Med, Dept Family Med, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	McWhinney, IR (corresponding author), Univ Western Ontario, Ctr Studies Family Med, Dept Family Med, London, ON N6A 5C1, Canada.							Brown JB, 1997, CAN FAM PHYSICIAN, V43, P901; Carmichael LP, 1997, AM FAM PHYSICIAN, V56, P713; Dostoevsky Fyodor, 1958, BROTHERS KARAMAZOV; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; HART JT, 1970, LANCET, V2, P223; HJORTDAHL P, 1992, FAM PRACT, V9, P3, DOI 10.1093/fampra/9.1.3; *I MED, 1978, IOM PUBL, V7302; MacIntyre A., 2007, VIRTUE STUDY MORAL T; MAY WF, 1983, PHYSICIANS COVENANT; MCCORMICK J, 1994, LANCET, V344, P390; Nutting P A, 1986, Am J Prev Med, V2, P140; NUTTING PA, 1986, AM J PUBLIC HEALTH, V76, P279, DOI 10.2105/AJPH.76.3.279; SALTMAN DC, 1995, MED J AUSTRALIA, V162, P3, DOI 10.5694/j.1326-5377.1995.tb138397.x; SMITH LFP, 1994, J MED ETHICS, V20, P175, DOI 10.1136/jme.20.3.175; Stewart M., 1995, PATIENT CTR MED PATIENT CTR MED; VEALE BM, 1996, THESIS AUSTR NATL U; WHITE KL, 1987, INT CLASSIFICATION P; Wilber K., 1995, SEX ECOLOGY SPIRITUA; World Health Organisation, 1978, ALM 1978 PRIM HLTH C; WRIGHT RA, 1993, JAMA-J AM MED ASSOC, V269, P2544, DOI 10.1001/jama.269.19.2544	21	89	89	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1807	1809		10.1136/bmj.316.7147.1807	http://dx.doi.org/10.1136/bmj.316.7147.1807			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624075	Green Published			2022-12-24	WOS:000074286300032
J	Chalmers, R; Guhathakurta, A; Benjamin, H; Kleckner, N				Chalmers, R; Guhathakurta, A; Benjamin, H; Kleckner, N			IHF modulation of Tn10 transposition: Sensory transduction of supercoiling status via a proposed protein/DNA molecular spring	CELL			English	Article							SITE-SPECIFIC RECOMBINATION; DNA; INVIVO; FAVOR	Architectural protein IHF modulates Tn10 transposition in vitro. IHF stimulates transposon excision. Also, separately, IHF forces transposon end/target DNA interactions into a constrained pathway, "channeling," that yields only unknotted intratransposon inversion circles. Negative supercoiling influences both effects, differently. We infer that IHF is an architectural catalyst: it promotes initial transpososome assembly and is then ejected from the transpososome. IHF then rebinds, altering transpososome conformation to promote channeling. We also infer that the developing transpososome is a molecular spring: DNA provides basic elasticity; a conformational change in transposase provides force; and IHF and/or supercoiling provide conformational inputs. In vivo, IHF is a sensory transducer of chromosomal supercoiling status: with supercoiling absent, IHF is "supercoiling relief factor"; with supercoiling present, stimulation and channeling comprise a homeostatic pair such that modest changes in chromosome condition strongly influence transpositional outcome.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Chalmers, R (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.			chalmers, ronald/0000-0002-1395-7173	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025326] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37-GM25326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; Benjamin KR, 1996, J MOL BIOL, V256, P50, DOI 10.1006/jmbi.1996.0067; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; Carmona M, 1997, P NATL ACAD SCI USA, V94, P9568, DOI 10.1073/pnas.94.18.9568; CASSLER MR, 1995, EMBO J, V14, P5833, DOI 10.1002/j.1460-2075.1995.tb00271.x; Chalmers RM, 1996, EMBO J, V15, P5112, DOI 10.1002/j.1460-2075.1996.tb00892.x; HUISMAN O, 1989, EMBO J, V8, P211; Johnson RC, 1991, CURR OPIN GENET DEV, V1, P404, DOI 10.1016/S0959-437X(05)80307-7; KLECKNER N, 1990, GENETICS, V124, P449; Kleckner N, 1996, CURR TOP MICROBIOL, V204, P49; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; LEE MS, 1997, P ANTL ACAD SCI US, V91, P9823; MIZUUCHI M, 1995, CELL, V83, P375, DOI 10.1016/0092-8674(95)90115-9; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; MOSKOWITZ IPG, 1991, GENE DEV, V5, P1635, DOI 10.1101/gad.5.9.1635; Nash Howard A., 1996, P149; PETTIJOHN DE, 1980, P NATL ACAD SCI-BIOL, V77, P1331, DOI 10.1073/pnas.77.3.1331; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; Sakai J, 1997, CELL, V89, P205, DOI 10.1016/S0092-8674(00)80200-7; SAKAI J, 1995, EMBO J, V14, P4374, DOI 10.1002/j.1460-2075.1995.tb00112.x; SAKAI J, 1996, THESIS HARVARD U CAM; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SIGNON L, 1995, GENE DEV, V9, P1123, DOI 10.1101/gad.9.9.1123; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; WANG ZG, 1994, P NATL ACAD SCI USA, V91, P699, DOI 10.1073/pnas.91.2.699; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x	28	94	94	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					897	908		10.1016/S0092-8674(00)81449-X	http://dx.doi.org/10.1016/S0092-8674(00)81449-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630232	Bronze			2022-12-24	WOS:000073956700024
J	Grindstaff, KK; Yeaman, C; Anandasabapathy, N; Hsu, SC; Rodriguez-Boulan, E; Scheller, RH; Nelson, WJ				Grindstaff, KK; Yeaman, C; Anandasabapathy, N; Hsu, SC; Rodriguez-Boulan, E; Scheller, RH; Nelson, WJ			Sec6/8 complex is recruited to cell-cell contacts and specifies transport vesicle delivery to the basal-lateral membrane in epithelial cells	CELL			English	Article							CANINE KIDNEY-CELLS; GTP-BINDING-PROTEIN; PLASMA-MEMBRANE; NONPOLARIZED CELLS; TIGHT JUNCTION; SEC15 PROTEIN; MDCK CELLS; POLARITY; YEAST; SURFACE	In budding yeast, the Sec6/8p complex is essential for generating cell polarity by specifying vesicle delivery to the bud tip. We show that Sec6/8 homologs are components of a cytosolic, similar to 17S complex in nonpolarized MDCK epithelial cells. Upon initiation of calcium-dependent cell-cell adhesion, similar to 70% of Sec6/8 is rapidly (t(1/2) = 3-6 hr) recruited to sites of cell-cell contact. In streptolysin-O-permeabilized MDCK cells, Sec8 antibodies inhibit delivery of LDL receptor to the basal-lateral membrane, but not p75(NTR) to the apical membrane. These results indicate that lateral membrane recruitment of the Sec6/8 complex is a consequence of cell-cell adhesion and is essential for the biogenesis of epithelial cell surface polarity.	Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Cornell Univ, Coll Med, Dyson Vis Res Inst, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Cell Biol & Anat, New York, NY 10021 USA	Stanford University; Howard Hughes Medical Institute; Stanford University; Cornell University; Dyson; Cornell University	Nelson, WJ (corresponding author), Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA.		Yeaman, Charles A/A-1624-2009	Yeaman, Charles/0000-0001-6149-628X; Anandasabapathy, Niroshana/0000-0002-0473-8358	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035527, R37GM035527, R01GM034107] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09368] Funding Source: Medline; NIGMS NIH HHS [GM34107, R01 GM034107, GM35527] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Finger FP, 1997, MOL BIOL CELL, V8, P647, DOI 10.1091/mbc.8.4.647; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; Grindstaff KK, 1998, MOL BIOL CELL, V9, P685, DOI 10.1091/mbc.9.3.685; Hazuka CD, 1997, GENE, V187, P67, DOI 10.1016/S0378-1119(96)00720-2; Herskowitz I, 1995, COLD SPRING HARB SYM, V60, P717, DOI 10.1101/SQB.1995.060.01.078; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LOUVARD D, 1980, P NATL ACAD SCI-BIOL, V77, P4132, DOI 10.1073/pnas.77.7.4132; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; PASDAR M, 1989, J CELL BIOL, V109, P163, DOI 10.1083/jcb.109.1.163; Pringle JR, 1995, COLD SPRING HARB SYM, V60, P729, DOI 10.1101/SQB.1995.060.01.079; SALMINEN A, 1989, J CELL BIOL, V109, P1023, DOI 10.1083/jcb.109.3.1023; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHELLER RH, 1995, NEURON, V14, P893; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; TING AE, 1995, P NATL ACAD SCI USA, V92, P9613, DOI 10.1073/pnas.92.21.9613; VEGASALAS DE, 1987, J CELL BIOL, V104, P905, DOI 10.1083/jcb.104.4.905; VESTWEBER D, 1984, EXP CELL RES, V152, P169, DOI 10.1016/0014-4827(84)90241-6; WANG AZ, 1990, J CELL SCI, V95, P137; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; WOLLNER DA, 1992, J CELL BIOL, V116, P889, DOI 10.1083/jcb.116.4.889; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101	39	424	430	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					731	740		10.1016/S0092-8674(00)81435-X	http://dx.doi.org/10.1016/S0092-8674(00)81435-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630218	hybrid			2022-12-24	WOS:000073956700010
J	Anthony, RG; Waldin, TR; Ray, JA; Bright, SWJ; Hussey, PJ				Anthony, RG; Waldin, TR; Ray, JA; Bright, SWJ; Hussey, PJ			Herbicide resistance caused by spontaneous mutation of the cytoskeletal protein tubulin	NATURE			English	Article							DINITROANILINE HERBICIDES; ELEUSINE-INDICA; GENE FAMILY; ZEA-MAYS; PLANTS; INVITRO; CELLS	The dinitroaniline herbicides (such as trifluralin and oryzalin) have been developed for the selective control of weeds in arable crops. However, prolonged use of these chemicals has resulted in the selection of resistant biotypes of goosegrass, a major weed. These herbicides bind to the plant tubulin protein but not to mammalian tubulin(1). Here we show that the major alpha-tubulin gene of the resistant biotype has three base changes within the coding sequence. These base changes swap cytosine and thymine, most likely as the result of the spontaneous deamination of methylated cytosine. One of these base changes causes an amino-acid change in the protein: normal threonine at position 239 is changed to isoleucine. This position is dose to the site of interaction between tubulin dimers in the microtubule protofilament. We show that the mutated gene is the cause of the herbicide resistance by using it to transform maize and confer resistance to dinitroaniline herbicides. Our results provide a molecular explanation for the resistance of goosegrass to dinitroanaline herbicides, a phenomenon that has arisen, and been selected for, as a result of repeated exposure to this class of herbicide.	Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England; Zeneca Agrochem, Jeolotts Hill Res Stn, Bracknell RG42 6ET, Berks, England	University of London; Royal Holloway University London	Hussey, PJ (corresponding author), Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham Hill, Egham TW20 0EX, Surrey, England.			Hussey, Patrick/0000-0002-7349-8722				AKASHI T, 1988, PLANT CELL PHYSIOL, V29, P1053; APPLEBY AP, 1989, WEED TECHNOL, V3, P198, DOI 10.1017/S0890037X00031626; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Burns Roy G., 1994, V13, P3; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRAME BR, 1994, PLANT J, V6, P941, DOI 10.1046/j.1365-313X.1994.6060941.x; HUSSEY PJ, 1990, PLANT MOL BIOL, V15, P957, DOI 10.1007/BF00039438; JIANG CJ, 1993, J CELL SCI, V105, P891; LAST DI, 1991, THEOR APPL GENET, V81, P581, DOI 10.1007/BF00226722; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; MOREJOHN LC, 1987, PLANTA, V172, P252, DOI 10.1007/BF00394595; MOREJOHN LC, 1991, PHARMACOL THERAPEUT, V51, P217, DOI 10.1016/0163-7258(91)90078-Z; MUDGE LC, 1984, WEED SCI, V32, P591, DOI 10.1017/S0043174500059610; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; PARKA SJ, 1977, WEED SCI, V25, P79, DOI 10.1017/S0043174500032975; THOMPSON C, 1995, EUPHYTICA, V85, P169, DOI 10.1007/BF00023945; VAUGHN KC, 1987, PLANT PHYSIOL, V83, P956, DOI 10.1104/pp.83.4.956; VILLEMUR R, 1992, J MOL BIOL, V227, P81, DOI 10.1016/0022-2836(92)90683-B; WALDIN TR, 1992, PLANTA, V188, P258, DOI 10.1007/BF00216822	19	113	117	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					260	263		10.1038/30484	http://dx.doi.org/10.1038/30484			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607761				2022-12-24	WOS:000073761000051
J	Kawasaki, H; Eckner, R; Yao, TP; Taira, K; Chiu, R; Livingston, DM; Yokoyama, KK				Kawasaki, H; Eckner, R; Yao, TP; Taira, K; Chiu, R; Livingston, DM; Yokoyama, KK			Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation	NATURE			English	Article							300 KDA PROTEIN; TRANSCRIPTIONAL ADAPTER; COACTIVATOR; CELLS; APOPTOSIS; ANTIGEN; TARGET; E1A	The related proteins p300 and CBP (cAMP-response-element-binding protein (CREB)-binding protein)) are transcriptional co-activators that act with other factors to regulate gene expression(1-5) and play roles in many cell-differentiation add signal transduction pathways(6-10). Both proteins have intrinsic histone-acetyltransferase activity(11,12) and may act directly on chromatin, of which histone is a component, to facilitate transcription. They are also involved in growth control pathways, as shown by their interaction with the tumour-suppressor p53 (refs 13-15) and the viral oncogenes E1A (refs 1, 2, 16) and SV40 T antigen(5). Here we report functional differences of p300 and CBP in vivo. We examined their roles during retinoic-acid-induced differentiation, cell-cycle exit and programmed cell death (apoptosis) of embryonal carcinoma F9 cells(17,20), using hammerhead ribozymes capable of cleaving either p300 or CBP messenger RNAs. F9 cells expressing a p300-specific ribozyme became resistant to retinoic-acid-induced differentiation, whereas cells expressing a CBP-specific ribozyme were unaffected. Similarly, retinoic-acid-induced transcriptional upregulation of the cell-cycle inhibitor p21(Cip1) required normal levels of p300, but not CBP, whereas the reverse was true for p27(Kip1). In contrast, both ribozymes blocked retinoic-acid-induced apoptosis, indicating that both co-activators are required for this process. Thus, despite their similarities, p300 and CBP have distinct functions during retinoic-acid-induced differentiation of F9 cells.	Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba Sci City 3050074, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba Sci City 3050006, Japan; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Calif Los Angeles, Sch Med, Dept Surg Oncol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA	RIKEN; University of Tsukuba; University of Zurich; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Yokoyama, KK (corresponding author), Inst Phys & Chem Res, Tsukuba Life Sci Ctr, 3-1-1 Koyadai, Tsukuba Sci City 3050074, Japan.							ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ATENCIA R, 1994, EXP CELL RES, V214, P663, DOI 10.1006/excr.1994.1304; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHAMBON P, 1996, FASEB J, V10, P1187; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1996, NUCLEIC ACIDS RES, V24, P3010, DOI 10.1093/nar/24.15.3010; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUND J, 1995, MG PESH INST LEIDEN, V8, P85; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; TANAKA Y, 1995, P NATL ACAD SCI USA, V94, P10125; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	28	292	302	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					284	289		10.1038/30538	http://dx.doi.org/10.1038/30538			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607768				2022-12-24	WOS:000073761000058
J	Koepp, MJ; Gunn, RN; Lawrence, AD; Cunningham, VJ; Dagher, A; Jones, T; Brooks, DJ; Bench, CJ; Grasby, PM				Koepp, MJ; Gunn, RN; Lawrence, AD; Cunningham, VJ; Dagher, A; Jones, T; Brooks, DJ; Bench, CJ; Grasby, PM			Evidence for striatal dopamine release during a video game	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; C-11 RACLOPRIDE; BASAL GANGLIA; MOTOR CONTROL; HUMAN BRAIN; PET; ACTIVATION; RESPONSES; NEURONS; BINDING	Dopaminergic neurotransmission may be involved in learning, reinforcement of behaviour, attention, and sensorimotor integration(1,2). Binding of the radioligand C-11-labelled raclopride to dopamine D-2 receptors is sensitive to levels of endogenous dopamine, which can be released by pharmacological challenge(3-8). Here we use C-11-labelled raclopride and positron emission tomography scans to provide evidence that endogenous dopamine is released in the human striatum during a goal-directed motor task, namely a video game. Binding of raclopride to dopamine receptors in the striatum was significantly reduced during the video game compared with baseline levels of binding, consistent with increased release and binding of dopamine to its receptors. The reduction in binding of raclopride in the striatum positively correlated with the performance level during the task and was greatest in the ventral striatum. These results show, to our knowledge for the first time, behavioural conditions under which dopamine is released in humans, and illustrate the ability of positron emission tomography to detect neurotransmitter fluxes in vivo during manipulations of behaviour.	Hammersmith Hosp, MRC, Cyclotron Unit, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Div Neurosci & Psychol Med, London W6 8RP, England	Imperial College London; Imperial College London	Grasby, PM (corresponding author), Hammersmith Hosp, MRC, Cyclotron Unit, DuCane Rd, London W12 0NN, England.	grasby@cu.rpms.ac.uk	Gunn, Roger/H-1666-2012; Lawrence, Andrew/A-1673-2010	Gunn, Roger/0000-0003-1181-5769; Law, Ian/0000-0001-9644-7496				ASHBURNER J, 1996, QUANTIFICATION BRAIN, P301; Breier A, 1997, P NATL ACAD SCI USA, V94, P2569, DOI 10.1073/pnas.94.6.2569; BROOKS DJ, 1995, J NEUROL SCI, V128, P1, DOI 10.1016/0022-510X(94)00206-4; DEWEY SL, 1993, P NATL ACAD SCI USA, V90, P11816, DOI 10.1073/pnas.90.24.11816; Endres CJ, 1997, J CEREBR BLOOD F MET, V17, P932, DOI 10.1097/00004647-199709000-00002; FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538; Fisher RE, 1995, HUM BRAIN MAPP, V3, P24, DOI 10.1002/hbm.460030104; Friston K.J., 1994, HUMAN BRAIN MAPPING, V2, P211, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; HUME SP, 1992, SYNAPSE, V12, P47, DOI 10.1002/syn.890120106; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Laruelle M, 1997, SYNAPSE, V25, P1, DOI 10.1002/(SICI)1098-2396(199701)25:1<1::AID-SYN1>3.0.CO;2-H; LJUNGBERG T, 1992, J NEUROPHYSIOL, V67, P145, DOI 10.1152/jn.1992.67.1.145; LOGAN J, 1994, J CEREBR BLOOD F MET, V14, P995, DOI 10.1038/jcbfm.1994.132; Morris ED, 1995, HUM BRAIN MAPP, V3, P35, DOI 10.1002/hbm.460030105; Richardson NR, 1996, J NEUROSCI, V16, P8160; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; SALAMONE JD, 1994, PHARM BIOCH BEHAV, V49, P651; Schultz W, 1997, CURR OPIN NEUROBIOL, V7, P191, DOI 10.1016/S0959-4388(97)80007-4; SCHULTZ W, 1993, J NEUROSCI, V13, P900; THIERRY AM, 1976, NATURE, V263, P242, DOI 10.1038/263242a0; VOLKOW ND, 1993, J NUCL MED, V34, P609; VOLKOW ND, 1994, SYNAPSE, V16, P255, DOI 10.1002/syn.890160402; WISE R, 1980, TRENDS NEUROSCI, V3, P91, DOI 10.1016/0166-2236(80)90035-1; YAMAMURO Y, 1994, NEUROSCI LETT, V177, P83, DOI 10.1016/0304-3940(94)90050-7	26	795	814	4	111	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					266	268		10.1038/30498	http://dx.doi.org/10.1038/30498			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607763				2022-12-24	WOS:000073761000053
J	Paul, AV; van Boom, JH; Filippov, D; Wimmer, E				Paul, AV; van Boom, JH; Filippov, D; Wimmer, E			Protein-primed RNA synthesis by purified poliovirus RNA polymerase	NATURE			English	Article							GENOME-LINKED PROTEIN; DNA-REPLICATION; INITIATION; 3AB; TRANSLATION; SEQUENCE; VIRUSES; LINKAGE; POLY(A); ENTRY	A small protein, VPg, is covalently linked to the 5' end of the plus-stranded poliovirus genomic RNA(1-3). Poliovirus messenger RNA, identical in nucleotide sequence to genomic RNA,is not capped at its 5' end by the methylated structure that is common to most eukaryotic mRNAs, These discoveries presented two problems. First, as cap structures are usually required for transition of mRNA into protein, how does this uncapped viral RNA act as a template for translation? Second, what is the function of VPg? The identification of the internal ribosomal-entry site, which allows the entry of ribosomes into viral mRNA independently of the 5' mRNA end, has solved the first conundrum(4-6). Here we describe the resolution of the second problem. VPg is linked to the genomic RNA through the 5'-terminal uridylic acid of the RNA. We show that VPg can be uridylylated by the poliovirus RNA polymerase 3D(pol). Uridylylated VPg can then prime the transcription of polyadenylate RNA by 3D(pol) to produce VPg-linked poly(U). Initiation of transcription of the poliovirus genome from the polyadenylated 3' end therefore depends on VPg.	SUNY Stony Brook, Hlth Sci Ctr, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; Leiden Univ, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Leiden University; Leiden University - Excl LUMC	Paul, AV (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	apaul@asterix.bio.sunysb.edu	Filippov, Dmitri/J-7612-2017	Filippov, Dmitri/0000-0002-6978-7425				AMBROS V, 1978, J BIOL CHEM, V253, P5263; Barton DJ, 1996, VIROLOGY, V217, P459, DOI 10.1006/viro.1996.0140; CAO XM, 1995, VIROLOGY, V209, P315, DOI 10.1006/viro.1995.1263; DORSCHHASLER K, 1975, J VIROL, V16, P1512; DREEFTROMP CM, 1992, NUCLEIC ACIDS RES, V20, P2435, DOI 10.1093/nar/20.10.2435; ESTEBAN JA, 1992, BIOCHEMISTRY-US, V31, P350, DOI 10.1021/bi00117a006; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P961, DOI 10.1073/pnas.74.3.961; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P3677, DOI 10.1073/pnas.74.9.3677; HSIEH JC, 1990, P NATL ACAD SCI USA, V87, P8665, DOI 10.1073/pnas.87.21.8665; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; KUHN RJ, 1988, P NATL ACAD SCI USA, V85, P519, DOI 10.1073/pnas.85.2.519; LEE YF, 1977, P NATL ACAD SCI USA, V74, P59, DOI 10.1073/pnas.74.1.59; LEE YF, 1976, PROGR NUCL ACID RES, P89; MOLLA A, 1992, NATURE, V356, P255, DOI 10.1038/356255a0; NOMOTO A, 1977, NATURE, V268, P208, DOI 10.1038/268208a0; PATA JD, 1995, RNA, V1, P466; PAUL AV, 1994, J BIOL CHEM, V269, P29173; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; RICHARDS OC, 1990, CURR TOP MICROBIOL, V161, P89; RODRIGUEZ PL, 1992, J VIROL, V66, P1971, DOI 10.1128/JVI.66.4.1971-1976.1992; ROTHBERG PG, 1978, P NATL ACAD SCI USA, V75, P4868, DOI 10.1073/pnas.75.10.4868; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; TAKEDA N, 1986, J VIROL, V60, P43, DOI 10.1128/JVI.60.1.43-53.1986; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; TOYODA H, 1987, J VIROL, V61, P2816, DOI 10.1128/JVI.61.9.2816-2822.1987; WIMMER E, 1982, CELL, V28, P199, DOI 10.1016/0092-8674(82)90335-X; Xiang WK, 1995, RNA, V1, P892; YOGO Y, 1972, P NATL ACAD SCI USA, V69, P1877, DOI 10.1073/pnas.69.7.1877; YOGO Y, 1975, J MOL BIOL, V92, P467, DOI 10.1016/0022-2836(75)90292-2	30	286	296	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 21	1998	393	6682					280	284		10.1038/30529	http://dx.doi.org/10.1038/30529			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607767				2022-12-24	WOS:000073761000057
J	Winberg, ML; Mitchell, KJ; Goodman, GS				Winberg, ML; Mitchell, KJ; Goodman, GS			Genetic analysis of the mechanisms controlling target selection: Complementary and combinatorial functions of netrins, semaphorins, and IgCAMs	CELL			English	Article							GROWTH CONE GUIDANCE; C-ELEGANS; MOTOR AXON; NEUROMUSCULAR SPECIFICITY; COLORECTAL-CANCER; COMMISSURAL AXONS; SYNAPSE FORMATION; DROSOPHILA; UNC-6; MOTONEURON	The molecular mechanisms controlling the ability of motor axons to recognize their appropriate muscle targets were dissected using Drosophila genetics to add or subtract Netrin A, Netrin B, Semaphorin II, and Fasciclin II alone or in combination, Fas II and Sema II are expressed by all muscles where they promote (Fas II) or inhibit (Sema II) promiscuous synaptogenesis, NetB is expressed by a subset of muscles where it attracts some axons and repels others, However, growth cones in this system apparently do not rely solely on single molecular labels on individual targets, Rather, these growth cones assess the relative balance of attractive and repulsive forces and select their targets based on the combinatorial and simultaneous input of multiple cues.	Univ Calif Berkeley, Dept Mol & Cell Biol, Howard Hughes Med Inst, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Goodman, GS (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Howard Hughes Med Inst, 229 Stanley Hall, Berkeley, CA 94720 USA.			Mitchell, Kevin/0000-0002-3433-4530	NICHD NIH HHS [HD21294] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021294, R37HD021294] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BALL EE, 1985, J NEUROSCI, V5, P1808; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BRAND AH, 1993, DEVELOPMENT, V118, P401; CASH S, 1992, J NEUROSCI, V12, P2051; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHIANG C, 1994, DEVELOPMENT, V120, P3581; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; CHIBA A, 1993, J NEUROSCI, V13, P714; Davis GW, 1997, NEURON, V19, P561, DOI 10.1016/S0896-6273(00)80372-4; Fambrough D, 1996, CELL, V87, P1049, DOI 10.1016/S0092-8674(00)81799-7; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; GORCZYCA MG, 1994, DEVELOPMENT, V120, P2143; HALFON MS, 1995, DEV BIOL, V169, P151, DOI 10.1006/dbio.1995.1134; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KESHISHIAN H, 1993, J NEUROBIOL, V24, P757, DOI 10.1002/neu.480240606; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; Kose H, 1997, DEVELOPMENT, V124, P4143; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; Schuster CM, 1996, NEURON, V17, P641, DOI 10.1016/S0896-6273(00)80197-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Sink H., 1994, Society for Neuroscience Abstracts, V20, P1283; SINK H, 1991, DEVELOPMENT, V113, P701; Stewart B., 1973, DROS INFORM SERV, V50, P167; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Thor S, 1997, NEURON, V18, P397, DOI 10.1016/S0896-6273(00)81241-6; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	37	212	215	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					581	591		10.1016/S0092-8674(00)81187-3	http://dx.doi.org/10.1016/S0092-8674(00)81187-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604933	Green Published, Bronze			2022-12-24	WOS:000073722200011
J	Duesbery, NS; Webb, CP; Leppla, SH; Gordon, VM; Klimpel, KR; Copeland, TD; Ahn, NG; Oskarsson, MK; Fukasawa, K; Paull, KD; Vande Woude, GF				Duesbery, NS; Webb, CP; Leppla, SH; Gordon, VM; Klimpel, KR; Copeland, TD; Ahn, NG; Oskarsson, MK; Fukasawa, K; Paull, KD; Vande Woude, GF			Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor	SCIENCE			English	Article							BACILLUS-ANTHRACIS; PROTECTIVE ANTIGEN; ADENYLATE-CYCLASE; MAMMALIAN-CELLS; TOXIN; PROTEIN; INHIBITORS; TRANSFORMATION; COMPONENTS; INVITRO	Anthrax lethal toxin, produced by the bacterium Bacillus anthracis, is the major cause of death in animals infected with anthrax. One component of this toxin, lethal factor (LF), is suspected to be a metalloprotease, but no physiological substrates have been identified. Here it is shown that LF is a protease that cleaves the amino terminus of mitogen-activated protein kinase kinases 1 and 2 (MAPKK1 and MAPKK2) and that this cleavage inactivates MAPKK1 and inhibits the MAPK signal transduction pathway. The identification of a cleavage site for LF may facilitate the development of LF inhibitors.	NCI, Adv Biosci Lab, Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; NIDR, NIH, Bethesda, MD 20892 USA; Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, Boulder, CO 80309 USA; Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; NCI, Div Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Vande Woude, GF (corresponding author), NCI, Adv Biosci Lab, Basic Res Program, Frederick Canc Res & Dev Ctr, POB B, Frederick, MD 21702 USA.		Webb, Craig/I-8123-2012	Duesbery, Nicholas/0000-0002-5708-4984; DUESBERY, NICK/0000-0002-4258-5655				DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Duesbery NS, 1997, P NATL ACAD SCI USA, V94, P9165, DOI 10.1073/pnas.94.17.9165; DUESBERY NS, UNPUB; EZZELL JW, 1984, INFECT IMMUN, V45, P761, DOI 10.1128/IAI.45.3.761-767.1984; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; HAMMOND SE, 1997, 97 GEN M AM SOC MICR; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; KOCHI SK, 1994, FEMS MICROBIOL LETT, V124, P343, DOI 10.1111/j.1574-6968.1994.tb07306.x; Koo HM, 1996, CANCER RES, V56, P5211; Leppla S. H., 1995, Bacterial toxins and virulence factors in disease., P543; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LEPPLA SH, 1988, METHOD ENZYMOL, V165, P103; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Matten Wayne T., 1994, Seminars in Developmental Biology, V5, P173, DOI 10.1006/sedb.1994.1023; Menard A, 1996, BIOCHEM J, V320, P687, DOI 10.1042/bj3200687; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Moriguchi T, 1996, Adv Pharmacol, V36, P121, DOI 10.1016/S1054-3589(08)60579-7; Murakami MS, 1997, METHOD ENZYMOL, V283, P584; PEZARD C, 1991, INFECT IMMUN, V59, P3472, DOI 10.1128/IAI.59.10.3472-3477.1991; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SINGH Y, 1994, J BIOL CHEM, V269, P29039; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	31	852	908	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1998	280	5364					734	737		10.1126/science.280.5364.734	http://dx.doi.org/10.1126/science.280.5364.734			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563949				2022-12-24	WOS:000073415600047
J	Juvonen, J; Juvonen, T; Laurila, A; Kuusisto, J; Alarakkola, E; Sarkioja, T; Bodian, CA; Kairaluoma, MI; Saikku, P				Juvonen, J; Juvonen, T; Laurila, A; Kuusisto, J; Alarakkola, E; Sarkioja, T; Bodian, CA; Kairaluoma, MI; Saikku, P			Can degenerative aortic valve stenosis be related to persistent Chlamydia pneumoniae infection?	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERIES; DISEASE; TWAR; HEART	Background: The cause of age-related degenerative (tricuspid) aortic valve calcification is largely unknown, but one typical characteristic is an active inflammatory process. The presence of Chlamydia pneumoniae in aortic valve stenosis was recently shown. Objective: To test the hypothesis that if persistent C. pneumoniae infection plays an active role in the development of aortic stenosis, the organism can be detected in the healthy aortic valves of young persons. Design: A cadaver study. Setting: Oulu University Hospital, Oulu, Finland. Subjects: 46 consecutive cadavers undergoing autopsy. Measurements: Macroscopic and histologic pathology of aortic valves was determined. The presence of C, pneumoniae was determined by immunohistochemistry. Results: 34 of 46 valves were macroscopically normal. Early lesions of aortic valve disease were found in 12 valves (no lesions in valves from persons 20 to 40 years of age [n = 15], 4 lesions in valves from persons 41 to 60 years of age [n = 16], and 8 lesions in valves from persons older than 60 years of age [n = 15]; P = 0.004). Fifteen of 34 normal valves (44%) and 10 of 12 valves with early lesions (83%) had positive results on staining for C. pneumoniae (P = 0.02). In persons older than 60 years of age, the chance of an early lesion was higher if the valve tested positive for C. pneumoniae (7 of 8 valves with C. pneumoniae infection compared with 1 of 7 valves without C. pneumoniae infection; P = 0.01). Conclusions: Chlamydia pneumoniae is frequently present in aortic valves and is associated with early lesions of aortic valve stenosis in elderly persons.	Oulu Univ Hosp, Dept Surg, Natl Publ Hlth Inst, FIN-90220 Oulu, Finland; Univ Oulu, Dept Forens Med, FIN-90220 Oulu, Finland; Kuopio Univ Hosp, Dept Internal Med, FIN-70211 Kuopio, Finland; Univ Kuopio, FIN-70211 Kuopio, Finland; Mt Sinai Sch Med, Dept Biomath, New York, NY 10029 USA	Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; Kuopio University Hospital; University of Eastern Finland; Icahn School of Medicine at Mount Sinai	Juvonen, T (corresponding author), Oulu Univ Hosp, Dept Surg, Natl Publ Hlth Inst, FIN-90220 Oulu, Finland.							DARE AJ, 1993, HUM PATHOL, V24, P1330, DOI 10.1016/0046-8177(93)90267-K; Davies MJ, 1996, HEART, V75, P174, DOI 10.1136/hrt.75.2.174; GRAYSTON JT, 1995, CIRCULATION, V92, P3397, DOI 10.1161/01.CIR.92.12.3397; HAMMERSCHLAG MR, 1992, CLIN INFECT DIS, V14, P178, DOI 10.1093/clinids/14.1.178; HSU SM, 1981, AM J CLIN PATHOL, V75, P734, DOI 10.1093/ajcp/75.5.734; Juvonen J, 1997, J AM COLL CARDIOL, V29, P1054, DOI 10.1016/S0735-1097(97)00003-X; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; KUO CC, 1995, CLIN MICROBIOL REV, V8, P451, DOI 10.1128/CMR.8.4.451; LEINONEN M, 1990, MICROB PATHOGENESIS, V9, P67, DOI 10.1016/0882-4010(90)90042-O; LINDROOS M, 1993, J AM COLL CARDIOL, V21, P1220, DOI 10.1016/0735-1097(93)90249-Z; Mabey D. C. W., 1992, Reviews in Medical Microbiology, V3, P112; Muhlestein JB, 1996, J AM COLL CARDIOL, V27, P1555, DOI 10.1016/0735-1097(96)00055-1; ODEH M, 1992, EUR J CLIN MICROBIOL, V11, P885, DOI 10.1007/BF01962368; OLSSON M, 1994, J AM COLL CARDIOL, V23, P1162, DOI 10.1016/0735-1097(94)90606-8; OTTO CM, 1994, CIRCULATION, V90, P844, DOI 10.1161/01.CIR.90.2.844; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SAIKKU P, 1985, J INFECT DIS, V151, P832, DOI 10.1093/infdis/151.5.832; WALLER BF, 1994, CLIN CARDIOL, V17, P150, DOI 10.1002/clc.4960170308; WARD C, 1974, LANCET, V2, P734; Ward ME, 1995, APMIS, V103, P769, DOI 10.1111/j.1699-0463.1995.tb01436.x	20	48	50	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					741	744		10.7326/0003-4819-128-9-199805010-00007	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK790	9556468				2022-12-24	WOS:000073363800006
J	McCarthy, EP; Burns, RB; Coughlin, SS; Freund, KM; Rice, J; Marwill, SL; Ash, A; Shwartz, M; Moskowitz, MA				McCarthy, EP; Burns, RB; Coughlin, SS; Freund, KM; Rice, J; Marwill, SL; Ash, A; Shwartz, M; Moskowitz, MA			Mammography use helps to explain differences in breast cancer stage at diagnosis between older black and white women	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	19th Annual National Meeting of the Society-of-General-Internal-Medicine	MAY 02-04, 1996	WASHINGTON, D.C.	Soc Gen Internal Med		mammography; breast neoplasms; neoplasm staging; racial stocks	SOCIOECONOMIC-STATUS; HEALTH-SERVICES; RACE; AGE; SURVIVAL; INSURANCE; COVERAGE; DISEASE; EXTENT; CARE	Background: Older black women are less likely to undergo mammography and are more often given a diagnosis of advanced-stage breast cancer than older white women. Objective: To investigate the extent to which previous mammography explains observed differences in cancer stage at diagnosis between older black and white women with breast cancer. Design: Retrospective cohort study using the Linked Medicare-Tumor Registry Database. Setting: Population-based data from three geographic areas of the United States included in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program (Connecticut; metropolitan Atlanta, Georgia; and Seattle-Puget Sound, Washington). Participants: Black and white women 67 years of age and older in whom breast cancer was diagnosed between 1987 and 1989. Measurements: Medicare claims were used to classify women according to mammography use in the 2 years before diagnosis as nonusers (no previous mammography), regular users (greater than or equal to 2 mammographies done at least 10 months apart), or peri-diagnosis users (mammography done only within 3 months before diagnosis). Information on mammography use was linked with SEER data to determine cancer stage at diagnosis. Stage was classified as early (in situ or local) or late (regional or distant). Results: Black women were more likely to not undergo mammography (odds ratio [OR], 3.00 [95% Cl, 2.41 to 3.75]) and to be given a diagnosis of late-stage disease (OR, 2.49 [CI, 1.59 to 3.92]) than white women. When women were stratified by previous mammography use, the black-white difference in cancer stage occurred only among nonusers (adjusted OR, 2.54 [CI, 1.37 to 4.71]). Among regular users, cancer was diagnosed in black and white women at similar stages (adjusted OR, 1.34 [CI, 0.40 to 4.51]). In logistic modeling, previous mammography alone explained about 30% of the excess late-stage disease in black women. In a separate model, previous mammography explained 12% of the excess late-stage disease among black women after adjustment for sociodemographic and comorbidity information. Conclusion: Differences in breast cancer stage at diagnosis between older black and white women are related to previous mammography use. Increased regular use of mammography may result in a shift toward earlier-stage disease at diagnosis and narrow the observed differences in stage at diagnosis between older black and white women.	Boston Med Ctr, Evans Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA; Tulane Univ, Sch Publ Hlth & Trop Med, Dept Biostat, New Orleans, LA 70112 USA; Boston Univ, Sch Management, Boston, MA 02215 USA	Boston Medical Center; Tulane University; Boston University	McCarthy, EP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, 330 Brookline Ave,Libby 326, Boston, MA 02215 USA.		Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253; Freund, Karen/0000-0002-9049-5574	PHS HHS [30-P-90665/6] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; BLUSTEIN J, 1995, NEW ENGL J MED, V332, P1138, DOI 10.1056/NEJM199504273321706; *BUR DAT MAN STRAT, 1997, US DEP HLTH HUM SERV; BURACK RC, 1989, AM J PUBLIC HEALTH, V79, P721, DOI 10.2105/AJPH.79.6.721; Burns RB, 1996, ANN INTERN MED, V125, P173, DOI 10.7326/0003-4819-125-3-199608010-00002; Burns RB, 1996, J AM GERIATR SOC, V44, P922, DOI 10.1111/j.1532-5415.1996.tb01861.x; CAPLAN LS, 1992, J GERONTOL, V47, P101; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; FARLEY TA, 1989, AM J PUBLIC HEALTH, V79, P1508, DOI 10.2105/AJPH.79.11.1508; GOODWIN JS, 1986, J AM GERIATR SOC, V34, P20, DOI 10.1111/j.1532-5415.1986.tb06335.x; GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340; HAYWARD RA, 1991, AM J PUBLIC HEALTH, V81, P434, DOI 10.2105/AJPH.81.4.434; HOLMES FF, 1981, J AM GERIATR SOC, V29, P55, DOI 10.1111/j.1532-5415.1981.tb01227.x; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; HUNTER CP, 1993, J NATL CANCER I, V85, P1129, DOI 10.1093/jnci/85.14.1129; JONES BA, 1995, CANCER, V75, P2103, DOI 10.1002/1097-0142(19950415)75:8<2103::AID-CNCR2820750813>3.0.CO;2-2; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; MANDELBLATT J, 1991, AM J PUBLIC HEALTH, V81, P646, DOI 10.2105/AJPH.81.5.646; MCWHORTER WP, 1989, CANCER, V63, P982, DOI 10.1002/1097-0142(19890301)63:5<982::AID-CNCR2820630533>3.0.CO;2-I; OMalley MS, 1997, AM J PUBLIC HEALTH, V87, P782, DOI 10.2105/AJPH.87.5.782; POTOSKY AL, 1993, MED CARE, V31, P732; Preston JA, 1997, J AM GERIATR SOC, V45, P1310, DOI 10.1111/j.1532-5415.1997.tb02929.x; *SAS I, 1992, SAS STAT US GUID VER, V2; *SAS I, 1992, SAS STAT US GUID VER, V1; SATARIANO WA, 1986, AM J PUBLIC HEALTH, V76, P779, DOI 10.2105/AJPH.76.7.779; *SEER PROGR, 1994, NIH PUBL; SONDIK EJ, 1994, CANCER, V74, P995, DOI 10.1002/1097-0142(19940801)74:3+<995::AID-CNCR2820741504>3.0.CO;2-M; SWANSON GM, 1993, CANCER, V72, P788, DOI 10.1002/1097-0142(19930801)72:3<788::AID-CNCR2820720326>3.0.CO;2-C; SWANSON GM, 1990, CANCER, V66, P1267; WELLS BL, 1992, AM J PUBLIC HEALTH, V82, P1383, DOI 10.2105/AJPH.82.10.1383; YANCIK R, 1989, CANCER, V63, P976, DOI 10.1002/1097-0142(19890301)63:5<976::AID-CNCR2820630532>3.0.CO;2-A; ZAPKA JG, 1989, AM J PUBLIC HEALTH, V79, P1499, DOI 10.2105/AJPH.79.11.1499; 1995, MMWR MORB MORTAL WKL, V45, P57; 1995, MMWR MORB MORTAL WKL, V44, P777	35	148	148	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					729	+		10.7326/0003-4819-128-9-199805010-00005	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZK790	9556466				2022-12-24	WOS:000073363800004
J	Holland, NB; Qiu, YX; Ruegsegger, M; Marchant, RE				Holland, NB; Qiu, YX; Ruegsegger, M; Marchant, RE			Biomimetic engineering of non-adhesive glycocalyx-like surfaces using oligosaccharide surfactant polymers	NATURE			English	Article							FORCE MICROSCOPY; LIQUID; ADSORPTION; INTERFACES; GRAPHITE	The external region of a cell membrane, known as the glycocalyx, is dominated by glycosylated molecules(1-3), which direct specific interactions such as cell-cell recognition and contribute to the steric repulsion that prevents undesirable non-specific adhesion of other molecules and cells. Mimicking the non-adhesive properties of a glycocalyx provides a potential solution to the clinical problems, such as thrombosis(4), that are associated with implantable devices owing to non-specific adsorption of plasma proteins. Here we describe a biomimetic surface modification of graphite using oligosaccharide surfactant polymers, which, like a glycocalyx, provides a dense and confluent layer of oligosaccharides. The surfactant polymers consist of a flexible poly(vinyl amine) with dextran and alkanoyl side chains. We show that alkanoyl side chains assemble on graphite through hydrophobic interaction and epitaxial adsorption. This constrains the polymer backbone to lie parallel to the substrate, with solvated dextran side chains protruding into the aqueous phase, creating a glycocalyx-like coating. The resulting biomimetic surface is effective in suppressing protein adsorption from human plasma protein solution.	Case Western Reserve Univ, Dept Macromol Sci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Marchant, RE (corresponding author), Case Western Reserve Univ, Dept Macromol Sci, Cleveland, OH 44106 USA.	rxm4@po.cwru.edu	Holland, Nolan B./F-6933-2011	Holland, Nolan B./0000-0002-0752-6887				Badesso R. J., 1993, P AM CHEM SOC DIV PO, V69, P251; BONGRAND P, 1987, PHYSICAL BASIS CELL, P1; EVANS WH, 1991, MEMBRANE STRUCTURE F, P1; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; Golander C. G., 1992, POLYETHYLENE GLYCOL, P221, DOI DOI 10.1007/978-1-4899-0703-5_15.; GROSZEK AJ, 1970, PROC R SOC LON SER-A, V314, P473, DOI 10.1098/rspa.1970.0019; HELMUS MN, 1993, CARDIOVASC PATHOL, V2, pS53; MANNE S, 1994, LANGMUIR, V10, P4409, DOI 10.1021/la00024a003; MANNE S, 1995, SCIENCE, V270, P1480, DOI 10.1126/science.270.5241.1480; MCGONIGAL GC, 1990, APPL PHYS LETT, V57, P28, DOI 10.1063/1.104234; MILNER ST, 1991, SCIENCE, V251, P905, DOI 10.1126/science.251.4996.905; NEMANICH RJ, 1977, SOLID STATE COMMUN, V23, P117, DOI 10.1016/0038-1098(77)90663-9; OSTERBERG E, 1995, J BIOMED MATER RES, V29, P741, DOI 10.1002/jbm.820290610; PUTMAN CAJ, 1994, APPL PHYS LETT, V64, P2454, DOI 10.1063/1.111597; Qiu Y., 1997, T SOC BIOMATER, V20, P224; Qiu YX, 1998, MACROMOLECULES, V31, P165, DOI 10.1021/ma9707401; RABE JP, 1991, SCIENCE, V253, P424, DOI 10.1126/science.253.5018.424; Salzman E. W., 1994, HEMOSTASIS THROMBOSI, P1469; Sharma R, 1995, ACS SYM SER, V615, P1; WELLINGHOFF S, 1974, J MACROMOL SCI PHYS, VB 10, P1, DOI 10.1080/00222347408219394; WHITTMANN JC, 1990, PROG POLYM SCI, V15, P909; Zhang TH, 1996, J COLLOID INTERF SCI, V177, P419, DOI 10.1006/jcis.1996.0054	22	271	297	3	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1998	392	6678					799	801		10.1038/33894	http://dx.doi.org/10.1038/33894			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572137				2022-12-24	WOS:000073241200048
J	Grossniklaus, U; Vielle-Calzada, JP; Hoeppner, MA; Gagliano, WB				Grossniklaus, U; Vielle-Calzada, JP; Hoeppner, MA; Gagliano, WB			Maternal control of embryogenesis by medea, a Polycomb group gene in Arabidopsis	SCIENCE			English	Article							DROSOPHILA; EXPRESSION; ENDOSPERM; TRITHORAX; TRANSFORMATION; REGULATOR; EVOLUTION; MUTATION; ENHANCER; THALIANA	The gametophytic maternal effect mutant medea (mea) shows aberrant growth regulation during embryogenesis in Arabidopsis thaliana. Embryos derived from mea eggs grow excessively and die during seed desiccation. Embryo lethality is independent of the paternal contribution and gene dosage. The mea phenotype is consistent with the parental conflict theory for the evolution of parent-of-origin-specific effects. MEA encodes a SET domain protein similar to Enhancer of zeste, a member of the Polycomb group. In animals, Polycomb group proteins ensure the stable inheritance of expression patterns through cell division and regulate the control of cell proliferation.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Grossniklaus, U (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd,POB 100, Cold Spring Harbor, NY 11724 USA.	grossnik@cshl.org	Grossniklaus, Ueli/E-9995-2016; Grossniklaus, Ueli/A-2736-2012; Vielle-Calzada, Jean-Philippe/AAG-4036-2019	Grossniklaus, Ueli/0000-0002-0522-8974; Vielle-Calzada, Jean-Philippe/0000-0002-3017-2490				ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; BERLETH T, 1993, DEVELOPMENT, V118, P575; BOUHARMONT J, 1972, J GENET CYTOL, V14, P257; CAPOWSKI EE, 1991, GENETICS, V129, P1061; Carrington EA, 1996, DEVELOPMENT, V122, P4073; CASTLE LA, 1993, MOL GEN GENET, V241, P504, DOI 10.1007/BF00279892; Chaudhury AM, 1997, P NATL ACAD SCI USA, V94, P4223, DOI 10.1073/pnas.94.8.4223; Colombo L, 1997, PLANT CELL, V9, P703, DOI 10.1105/tpc.9.5.703; EDWARDS K, 1991, NUCLEIC ACIDS RES, V19, P1349, DOI 10.1093/nar/19.6.1349; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GUERCHE P, 1990, PLANT CELL, V2, P469, DOI 10.1105/tpc.2.5.469; HAIG D, 1991, PHILOS T ROY SOC B, V333, P1, DOI 10.1098/rstb.1991.0057; HAIG D, 1991, CELL, V64, P1045; HAIG D, 1989, AM NAT, V134, P147, DOI 10.1086/284971; Hobert O, 1996, MOL CELL BIOL, V16, P3066; HOLDERMAN R, COMMUNICATION; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; KERMICLE J, 1990, DEVELOPMENT S, V1, P9; LIN BY, 1982, GENETICS, V100, P475; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; MALUSZYNSKA J, 1993, ANN BOT-LONDON, V71, P479, DOI 10.1006/anbo.1993.1063; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; McDowell JM, 1996, GENETICS, V142, P587; Ohad N, 1996, P NATL ACAD SCI USA, V93, P5319, DOI 10.1073/pnas.93.11.5319; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; PHILLIPS MD, 1990, GENETICS, V125, P91; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Ray S, 1996, DEV BIOL, V180, P365, DOI 10.1006/dbio.1996.0309; Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6; ROBBELEN G, 1966, ARABID INF SERV, V3, P16; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; SPRINGER PS, 1995, SCIENCE, V268, P877, DOI 10.1126/science.7754372; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; TKACHUK DC, 1992, CELL, V71, P869; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; VANDERVEEN JH, 1973, ARABID INF SERV, V10, P11; VIELLECALZADA JP, UNPUB; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YU BD, 1995, NATURE, V378, P595	43	662	713	5	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					446	450		10.1126/science.280.5362.446	http://dx.doi.org/10.1126/science.280.5362.446			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545225				2022-12-24	WOS:000073159600051
J	Legault, P; Li, J; Mogridge, J; Kay, LE; Greenblatt, J				Legault, P; Li, J; Mogridge, J; Kay, LE; Greenblatt, J			NMR structure of the bacteriophage lambda N peptide/boxB RNA complex: Recognition of a GNRA fold by an arginine-rich motif	CELL			English	Article							NUSA GENE PROTEIN; ESCHERICHIA-COLI; RIBOSOMAL-RNA; TRANSCRIPTION ANTITERMINATION; HAMMERHEAD RIBOZYME; CRYSTAL-STRUCTURE; ANTI-TERMINATION; GAAA TETRALOOP; PHAGE-LAMBDA; LOOP	The structure of the complex formed by the arginine-rich motif of the transcriptional antitermination protein N of phage lambda and boxB RNA was determined by heteronuclear magnetic resonance spectroscopy. A bent alpha helix in N recognizes primarily the shape and negatively charged surface of the boxB hairpin through multiple hydrophobic and ionic interactions. The GAAGA boxB loop forms a GNRA fold, previously described for tetraloops, which is essential for N binding. The fourth nucleotide of the loop extrudes from the GNRA fold to enable the E. coli elongation factor NusA to recognize the N protein/RNA complex. This structure reveals a new mode of RNA-protein recognition and shows how a small RNA element can facilitate a protein-protein interaction and thereby nucleate formation of a large ribonucleoprotein complex.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Prot Engn Network Ctr Excellence, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Chem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Legault, P (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 100 Coll St, Toronto, ON M5S 1A8, Canada.			Legault, Pascale/0000-0003-1782-5204				Abramovitz DL, 1997, J MOL BIOL, V266, P493, DOI 10.1006/jmbi.1996.0810; Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0; ALLEN P, 1995, VIROLOGY, V209, P327, DOI 10.1006/viro.1995.1264; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARAFA YD, 1990, J MOL BIOL, V216, P835, DOI 10.1016/S0022-2836(99)80005-9; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CHATTOPADHYAY S, 1995, P NATL ACAD SCI USA, V92, P4061, DOI 10.1073/pnas.92.9.4061; Chattopadhyay S, 1995, P NATL ACAD SCI USA, V92, P12131, DOI 10.1073/pnas.92.26.12131; Cilley CD, 1997, RNA, V3, P57; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; deQuinto SL, 1997, J VIROL, V71, P4171; DOELLING JH, 1989, NUCLEIC ACIDS RES, V17, P5565, DOI 10.1093/nar/17.14.5565; FRANKLIN NC, 1993, J MOL BIOL, V231, P343, DOI 10.1006/jmbi.1993.1287; FRANKLIN NC, 1985, J MOL BIOL, V181, P75, DOI 10.1016/0022-2836(85)90325-0; FRIEDMAN DI, 1995, MOL MICROBIOL, V18, P191, DOI 10.1111/j.1365-2958.1995.mmi_18020191.x; GLUCK A, 1992, J MOL BIOL, V226, P411, DOI 10.1016/0022-2836(92)90956-K; GREENBLATT J, 1981, J MOL BIOL, V147, P11, DOI 10.1016/0022-2836(81)90076-0; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; GUTELL RR, 1994, MICROBIOL REV, V58, P10, DOI 10.1128/MMBR.58.1.10-26.1994; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jucker FM, 1996, J MOL BIOL, V264, P968, DOI 10.1006/jmbi.1996.0690; JUCKER FM, 1995, RNA, V1, P219; Konrat R, 1997, J BIOMOL NMR, V9, P409, DOI 10.1023/A:1018354712430; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LeCuyer KA, 1996, EMBO J, V15, P6847, DOI 10.1002/j.1460-2075.1996.tb01076.x; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOGRIDGE J, 1995, GENE DEV, V9, P2831, DOI 10.1101/gad.9.22.2831; Mogridge J, 1998, MOL CELL, V1, P265, DOI 10.1016/S1097-2765(00)80027-1; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; MUNOZ V, 1995, NAT STRUCT BIOL, V2, P380, DOI 10.1038/nsb0595-380; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; OLSON ER, 1984, J MOL BIOL, V180, P1053, DOI 10.1016/0022-2836(84)90270-5; ORITA M, 1993, NUCLEIC ACIDS RES, V21, P5670, DOI 10.1093/nar/21.24.5670; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; Saenger W., 1984, PRINCIPLES NUCL ACID; SALSTROM JS, 1978, J MOL BIOL, V124, P195, DOI 10.1016/0022-2836(78)90156-0; Schultze P, 1997, NATURE, V387, P668, DOI 10.1038/42632; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; Su LL, 1997, GENE DEV, V11, P2214, DOI 10.1101/gad.11.17.2214; Su LL, 1997, BIOCHEMISTRY-US, V36, P12722, DOI 10.1021/bi971408k; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; VanGilst MR, 1997, BIOCHEMISTRY-US, V36, P1514, DOI 10.1021/bi961920q; Varani G, 1997, ACCOUNTS CHEM RES, V30, P189, DOI 10.1021/ar960035x; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wijmenga S. S., 1993, NMR MACROMOLECULES P, P217; Ye XM, 1995, CHEM BIOL, V2, P827, DOI 10.1016/1074-5521(95)90089-6; Ye XM, 1996, NAT STRUCT BIOL, V3, P1026, DOI 10.1038/nsb1296-1026; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	58	223	226	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					289	299		10.1016/S0092-8674(00)81579-2	http://dx.doi.org/10.1016/S0092-8674(00)81579-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568720	Bronze			2022-12-24	WOS:000073174000014
J	Anand, SS; Wells, PS; Hunt, D; Brill-Edwards, P; Cook, D; Ginsberg, JS				Anand, SS; Wells, PS; Hunt, D; Brill-Edwards, P; Cook, D; Ginsberg, JS			Does this patient have deep vein thrombosis?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUSPECTED VENOUS THROMBOSIS; SERIAL IMPEDANCE PLETHYSMOGRAPHY; TIME COMPRESSION ULTRASONOGRAPHY; B-MODE ULTRASONOGRAPHY; SYMPTOMATIC OUTPATIENTS; DIAGNOSTIC MANAGEMENT; CLINICAL EXAMINATION; PULMONARY-EMBOLISM; D-DIMER; VENOGRAPHY	Objective.-To review the validity of the clinical assessment and diagnostic tests in patients with suspected deep vein thrombosis (DVT). Methods.-A comprehensive review of the literature was conducted by searching MEDLINE from 1966 to April 1997. Results.-Individual symptoms and signs alone do nor reliably predict which patients have DVT, Overall, the diagnostic properties of the clinical examination are poor; the sensitivity of the clinical examination ranges from 60% to 96%, and the specificity ranges from 20% to 72%, However, using specific combinations of risk factors, symptoms, and physical signs for DVT, clinicians can reliably stratify patients with suspected DVT into low, moderate, or high pretest probability categories of actually suffering from DVT, This stratification process in combination with noninvasive testing, such as compression ultrasonography, simplifies the management strategies for patients with suspected DVT. Conclusions.-Use of a clinical prediction guide that includes specific factors from both the history and physical examination in combination with noninvasive tests simplifies management strategies for patients with suspected DVT.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol, Hamilton, ON L8S 4L8, Canada; Ottawa Civic Hosp, Dept Med, Ottawa, ON K1Y 4E9, Canada	McMaster University; McMaster University; University of Ottawa; Ottawa Hospital Research Institute	Anand, SS (corresponding author), Hamilton Gen Hosp, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	anands@ths.momaster.ca	ginsberg, jeffrey s/ABC-1065-2020					ANDERSON DR, 1993, ANN INTERN MED, V118, P25, DOI 10.7326/0003-4819-118-1-199301010-00005; BARNES RW, 1975, JAMA-J AM MED ASSOC, V234, P605, DOI 10.1001/jama.234.6.605; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; BROWSE N, 1969, BRIT MED J, V684, P676; COGO A, 1994, ARCH INTERN MED, V154, P164, DOI 10.1001/archinte.154.2.164; COGO A, 1994, ANGIOLOGY, V45, P377, DOI 10.1177/000331979404500507; COGO A, 1993, ARCH INTERN MED, V153, P2777, DOI 10.1001/archinte.153.24.2777; COGO A, 1995, THROMB HAEMOSTASIS, V73, P1098; COGO A, 1993, THROMB HAEMOSTASIS, V70, P404; GINSBERG JS, 1991, RADIOLOGY, V181, P651, DOI 10.1148/radiology.181.3.1947076; GINSBERG JS, 1994, ARCH INTERN MED, V154, P1930, DOI 10.1001/archinte.154.17.1930; Ginsberg JS, 1996, NEW ENGL J MED, V335, P1816, DOI 10.1056/NEJM199612123352407; GUNINTINI C, 1995, CHEST, V107, pS3; HAEGER K, 1969, ANGIOLOGY, V20, P219, DOI 10.1177/000331976902000406; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HEIJBOER H, 1992, ARCH INTERN MED, V152, P1901, DOI 10.1001/archinte.152.9.1901; HIRSH J, 1995, CHEST, V108, pS258, DOI 10.1378/chest.108.4_Supplement.258S; Hirsh J, 1996, CIRCULATION, V93, P2212, DOI 10.1161/01.CIR.93.12.2212; HIRSH J, 1986, J AM COLL CARDIOL, V8, pB114, DOI 10.1016/S0735-1097(86)80013-4; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1989, ARCH INTERN MED, V149, P511, DOI 10.1001/archinte.149.3.511; HULL R, 1977, NEW ENGL J MED, V296, P1497, DOI 10.1056/NEJM197706302962604; HULL R, 1976, CIRCULATION, V53, P696, DOI 10.1161/01.CIR.53.4.696; HULL R, 1981, ANN INTERN MED, V94, P12, DOI 10.7326/0003-4819-94-1-12; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; HULL RD, 1984, CLIN CHEST MED, V5, P439; HYERS TM, 1995, CHEST, V108, pS335, DOI 10.1378/chest.108.4_Supplement.335S; LANDEFELD CS, 1990, AM J MED, V88, P388; LENSING AWA, 1990, RADIOLOGY, V177, P503, DOI 10.1148/radiology.177.2.2217792; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LENSING AWA, 1994, HEMOSTASIS THROMBOSI, P1297; MATTOS MA, 1992, J VASC SURG, V15, P366, DOI 10.1016/0741-5214(92)90258-A; MCLACHLIN J, 1962, ARCH SURG-CHICAGO, V85, P738; MOLLOY W, 1982, IRISH MED J, V75, P119; ODONNELL TF, 1980, SURG GYNECOL OBSTET, V150, P69; PRANDONI P, 1991, THROMB HAEMOSTASIS, V65, P229; PRANDONI P, 1991, THROMB HAEMOSTASIS, V65, P233; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SALE S, 1994, THROMB HEMOST, V71, P270; SALZMAN EW, 1994, HEMOSTASIS THROMBOSI, P1275; SIMPSON FG, 1980, LANCET, V1, P331; VINE HS, 1981, AM J ROENTGENOL, V136, P167, DOI 10.2214/ajr.136.1.167; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WELLS P, 1997, LANCET, V356, P1795; Wells PS, 1995, THROMB HAEMOSTASIS, V74, P1423; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; WELLS PS, 1995, CIRCULATION, V91, P2184, DOI 10.1161/01.CIR.91.8.2184; WHITE RH, 1989, ANN INTERN MED, V111, P297, DOI 10.7326/0003-4819-111-4-297	51	133	136	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1998	279	14					1094	1099		10.1001/jama.279.14.1094	http://dx.doi.org/10.1001/jama.279.14.1094			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF216	9546569				2022-12-24	WOS:000072875300034
J	Owsley, C; Ball, K; McGwin, G; Sloane, ME; Roenker, DL; White, MF; Overley, ET				Owsley, C; Ball, K; McGwin, G; Sloane, ME; Roenker, DL; White, MF; Overley, ET			Visual processing impairment and risk of motor vehicle crash among older adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELDERLY DRIVERS; ACCIDENTS; FIELD; SENSITIVITY; ATTENTION; AGE	Context.-Motor vehicle crash risk in older drivers has been associated with visual acuity loss, but only weakly so, suggesting other factors contribute. The useful field of view is a measure that reflects decline in visual sensory function, slowed visual processing speed, and impaired visual attention skills. Objective.-To identify whether measures of visual processing ability, including the useful field of view test, are associated with crash involvement by older drivers. Design.-Prospective cohort study with 3 years of follow-up, 1990-1993. Setting.-Ophthalmology clinic assessment of community-based sample. Patients.-A total of 294 drivers aged 55 to 87 years at enrollment. Main Outcome Measure.-Motor vehicle crash occurrence. Results.-Older drivers with a 40% or greater impairment in the useful field of view were 2.2 times (95% confidence interval, 1.2-4.1) more likely to incur a crash during 3 years of follow-up, after adjusting for age, sex, race, chronic medical conditions, mental status, and days driven per week, This association was primarily mediated by difficulty in dividing attention under brief target durations. Conclusion.-Reduction in the useful field of view increases crash risk in older drivers, Given the relatively high prevalence of visual processing impairment among the elderly, visual dysfunction and eye disease deserve further examination as causes of motor vehicle crashes and injury.	Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA; Univ Alabama Birmingham, Sch Med, Dept Psychol, Birmingham, AL USA; Univ Alabama Birmingham, Sch Med, Dept Epidemiol, Birmingham, AL USA; Univ Alabama Birmingham, Sch Med, Dept Physiol Opt, Birmingham, AL USA; Western Kentucky Univ, Dept Psychol, Bowling Green, KY 42101 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Western Kentucky University	Owsley, C (corresponding author), Univ Alabama Birmingham, Sch Med, Eye Fdn Hosp, Dept Ophthalmol,Clin Res Unit, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.	owsley@eyes.uab.edu		Ball, Karlene/0000-0003-1811-9870	NATIONAL INSTITUTE ON AGING [P50AG011684, R01AG005739, R01AG004212, R37AG005739] Funding Source: NIH RePORTER; NIA NIH HHS [AG04212, AG05739, AG11684] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allison P. D., 1995, SURVIVAL ANAL USING; BALL K, 1993, INVEST OPHTH VIS SCI, V34, P3110; Ball K, 1993, J Am Optom Assoc, V64, P71; Ball K., 1990, DEV ATTENTION RES TH, V69, P489, DOI DOI 10.1016/S0166-4115(08)60472-0; BALL K, IN PRESS ACCID ANAL; BALL KK, 1988, J OPT SOC AM A, V5, P2210, DOI 10.1364/JOSAA.5.002210; BRENTON RS, 1986, OPHTHALMOLOGICA, V193, P56, DOI 10.1159/000309679; Collett D, 1994, MODELLING SURVIVAL D; COOPER PJ, 1993, J SAFETY RES, V24, P9, DOI 10.1016/0022-4375(93)90047-Q; DECINA LE, 1993, ACCIDENT ANAL PREV, V25, P267, DOI 10.1016/0001-4575(93)90021-N; DRACHMAN DA, 1988, ANN NEUROL, V24, P787, DOI 10.1002/ana.410240614; EVANS L, 1988, J TRAUMA, V28, P368, DOI 10.1097/00005373-198803000-00013; Evans L., 1991, TRAFFIC SAFETY DRIVE; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0; FLAHERTY JH, 1995, CLIN GERIATR MED, V3, P44; FOLEY DJ, 1995, J AM GERIATR SOC, V43, P776, DOI 10.1111/j.1532-5415.1995.tb07049.x; Haapanen N, 1997, AM J EPIDEMIOL, V145, P762, DOI 10.1093/aje/145.8.762; HANSOTIA P, 1991, NEW ENGL J MED, V324, P22, DOI 10.1056/NEJM199101033240105; Janke M., 1994, TRANSPORT RES REC, V1438, P77; Johansson K, 1996, J AM GERIATR SOC, V44, P1198, DOI 10.1111/j.1532-5415.1996.tb01369.x; JOHNSON CA, 1983, ARCH OPHTHALMOL-CHIC, V101, P371; KAHNEMAN D, 1973, J APPL PSYCHOL, V58, P113, DOI 10.1037/h0035426; Karusu T.B., 1976, GERIATRIC PSYCHIAT, P77; KELTNER JL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1697, DOI 10.1001/archopht.1992.01080240037023; Kleinbaum DG, 1996, SURVIVAL ANAL SELF L; KOEPSEL TD, 1994, J AM GERIATR SOC, V42, P695, DOI 10.1111/j.1532-5415.1994.tb06526.x; LEVEILLE SG, 1994, EPIDEMIOLOGY, V5, P591, DOI 10.1097/00001648-199411000-00006; MAROTTOLI RA, 1994, ANN INTERN MED, V121, P842, DOI 10.7326/0003-4819-121-11-199412010-00003; MARTINEZ R, 1995, JAMA-J AM MED ASSOC, V274, P1060, DOI 10.1001/jama.274.13.1060; MCKNIGHT AJ, 1982, HS806336 DOT; Murakami E, 1997, COMP COMPUTER ASSIST; *NAT HIGHW TRAFF S, 1989, C RES DEV NEED IMPR; OWSLEY C, 1995, VISION RES, V35, P579, DOI 10.1016/0042-6989(94)00166-J; OWSLEY C, 1991, PSYCHOL AGING, V6, P403, DOI 10.1037/0882-7974.6.3.403; OWSLEY C, IN PRESS OPHTHALMIC; PELLI DG, 1988, CLIN VISION SCI, V2, P187; RAY WA, 1992, AM J EPIDEMIOL, V136, P873, DOI 10.1093/aje/136.7.873; REUBEN DB, 1988, J AM GERIATR SOC, V36, P1135, DOI 10.1111/j.1532-5415.1988.tb04403.x; ROENKER DL, 1997, INVEST OPHTHALMOL  S, V38, P871; Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557; SANDERS A F, 1970, Ergonomics, V13, P101, DOI 10.1080/00140137008931124; SIMONS K, 1981, ARCH OPHTHALMOL-CHIC, V99, P446; Transportation Research Board, 1988, TRANSP AG SOC, V1; WALLER JA, 1967, J CHRON DIS, V20, P615, DOI 10.1016/0021-9681(67)90038-0	44	569	574	1	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1998	279	14					1083	1088		10.1001/jama.279.14.1083	http://dx.doi.org/10.1001/jama.279.14.1083			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZF216	9546567	Bronze			2022-12-24	WOS:000072875300032
J	Montgomery, SM; Morris, DL; Thompson, NP; Subhani, J; Pounder, RE; Wakefield, AJ				Montgomery, SM; Morris, DL; Thompson, NP; Subhani, J; Pounder, RE; Wakefield, AJ			Prevalence of inflammatory bowel disease in British 26 year olds: national longitudinal birth cohort	BRITISH MEDICAL JOURNAL			English	Article									Univ London, Royal Free Hosp, Sch Med, Dept Med, London NW3 2PF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Montgomery, SM (corresponding author), Univ London, Royal Free Hosp, Sch Med, Dept Med, London NW3 2PF, England.		Montgomery, Scott/AAN-2546-2020	Montgomery, Scott/0000-0001-6328-5494				EKINSMYTH C, 1993, INTEGRATED APPROACH; EVANS JG, 1965, GUT, V6, P311, DOI 10.1136/gut.6.4.311; KEIGHLEY A, 1976, SCAND J GASTROENTERO, V2, P293; MAYBERRY J, 1979, GUT, V20, P602, DOI 10.1136/gut.20.7.602; Montgomery SM, 1997, LANCET, V349, P472, DOI 10.1016/S0140-6736(05)61183-X	5	38	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1058	1059						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552907				2022-12-24	WOS:000072987400025
J	Greenhalgh, T; Helman, C; Chowdhury, AM				Greenhalgh, T; Helman, C; Chowdhury, AM			Health beliefs and folk models of diabetes in British Bangladeshis: A qualitative study	BRITISH MEDICAL JOURNAL			English	Article							OJIBWAY	Objective: To explore the experience of diabetes in British Bangladeshis, since successful management of diabetes requires attention not just to observable behaviour but to the underlying attitudes and belief systems which drive that behaviour. Design: Qualitative study of subjects' experience of diabetes using narratives, semi-structured interviews, focus groups, and pile sorting exercises. A new qualitative method, the structured vignette, was developed for validating researchers' understanding of primary level culture. Subjects: 40 British Bangladeshi patients with diabetes, and 10 non-Bangladeshi controls, recruited from primary care. Result: Several constructs were detected in relation to body image, cause and nature of diabetes, food classification, and knowledge of complications. In some areas, the similarities between Bangladeshi and non-Bangladeshi subjects were as striking as their differences. There was little evidence of a fatalistic or deterministic attitude to prognosis, and most informants seemed highly motivated to alter their diet and comply with treatment Structural and material barriers to behaviour change were at least as important as "cultural" ones. Conclusion: Bangladeshi culture is neither seamless nor static, but some widely held beliefs and behaviours have been identified. Some of these have a potentially beneficial effect on health and should be used as the starting point for culturally sensitive diabetes education.	UCL, Royal Free Hosp,Sch Med,Whittington Hosp, Joint Dept Primary Care & Populat, Qualitat Res Unit, London N19 5NF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Greenhalgh, T (corresponding author), UCL, Royal Free Hosp,Sch Med,Whittington Hosp, Joint Dept Primary Care & Populat, Qualitat Res Unit, London N19 5NF, England.	p.greenhalgh@ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIRHIHENBUWA CO, 1992, AIDS EDUC PREV, V4, P267; AIRHIHENBUWA CO, 1995, HLTH CULTURE W PARAD, P25; ANDERSON JM, 1995, SOC SCI MED, V41, P181, DOI 10.1016/0277-9536(94)00324-M; Becker M H, 1986, Public Health Rev, V14, P15; BRADLEY C, 1994, DIABETIC MED, V11, P510, DOI 10.1111/j.1464-5491.1994.tb00316.x; Calman KC, 1997, BRIT MED J, V314, P1187, DOI 10.1136/bmj.314.7088.1187a; CHOWDHURY AM, 1986, THESIS U EXETER EXET; Clandinin DJ., 1994, HDB QUALITATIVE RES, P413; Crawford Robert, 1984, ISSUES POLITICAL EC, P60; Daniel M, 1995, DIABET SPECTRUM, V8, P80; Garro L C, 1995, Soc Sci Med, V40, P37, DOI 10.1016/0277-9536(94)00125-D; Gittelsohn J, 1996, HEALTH EDUC QUART, V23, P365, DOI 10.1177/109019819602300307; Grams GD, 1996, CAN MED ASSOC J, V155, P1563; Greenhalgh PM, 1997, DIABETIC MED, V14, P10; HALL ET, 1977, BEYOND CULTURE; HAYES BE, 1994, QUALITY PROGR    FEB, P41; HELMAN C, 1994, CULTURE HLTH ILLNESS, P21; HELMAN CG, 1991, PRIMARY CARE RES TRA, P105; Helman CG, 1994, CULTURE HLTH ILLNESS; Hiller, 1996, RES CULTURAL DIFFERE, P220; *HLTH ED AUTH, 1994, HLTH LIF SURV BLACK; KITZINGER J, 1994, SOCIOLOGY HLTH ILLNE, V16, P104; LAMBERT H, 1992, SOC SCI MED, V34, P1069, DOI 10.1016/0277-9536(92)90280-4; LAMBERT H, 1996, MISUNDERSTANDING SCI, P65, DOI DOI 10.1017/CBO9780511563737.004; PIERCE M, 1997, THESIS U LONDON LOND; [No title captured]	26	196	197	0	14	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					978	983		10.1136/bmj.316.7136.978	http://dx.doi.org/10.1136/bmj.316.7136.978			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550958	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000072856100022
J	Fontana, W; Schuster, P				Fontana, W; Schuster, P			Continuity in evolution: On the nature of transitions	SCIENCE			English	Article							RNA SECONDARY STRUCTURES; SEQUENCES; SELECTION	To distinguish continuous from discontinuous evolutionary change, a relation of nearness between phenotypes is needed. Such a relation is based on the probability of one phenotype being accessible from another through changes in the genotype. This nearness relation is exemplified by calculating the shape neighborhood of a transfer RNA secondary structure and provides a characterization of discontinuous shape transformations in RNA. The simulation of replicating and mutating RNA populations under selection shows that sudden adaptive progress coincides mostly, but not always, with discontinuous shape transformations. The nature of these transformations illuminates the key role of neutral genetic drift in their realization.	Univ Vienna, Inst Theoret Chem, A-1090 Vienna, Austria; Santa Fe Inst, Santa Fe, NM 87501 USA	University of Vienna; The Santa Fe Institute	Fontana, W (corresponding author), Univ Vienna, Inst Theoret Chem, Wahringerstr 17, A-1090 Vienna, Austria.							BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; CRUTCHFIELD JP, 1995, P NATL ACAD SCI USA, V92, P10742, DOI 10.1073/pnas.92.23.10742; Eldredge N., 1972, P82; Elena SF, 1996, SCIENCE, V272, P1802, DOI 10.1126/science.272.5269.1802; ELINGTON AD, 1990, NATURE, V346, P818; FONTANA W, 1987, BIOPHYS CHEM, V26, P123, DOI 10.1016/0301-4622(87)80017-0; FONTANA W, 1997, 9711081 SANT FE I; GOULD SJ, 1993, NATURE, V366, P223, DOI 10.1038/366223a0; Gruner W, 1996, MONATSH CHEM, V127, P355, DOI 10.1007/BF00810881; HOFACKER IL, 1994, MONATSH CHEM, V125, P167, DOI 10.1007/BF00818163; Huynen MA, 1996, J MOL EVOL, V43, P165; Huynen MA, 1996, P NATL ACAD SCI USA, V93, P397, DOI 10.1073/pnas.93.1.397; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; KOMIYAMA NH, 1995, NATURE, V373, P244, DOI 10.1038/373244a0; NUSSINOV R, 1978, SIAM J APPL MATH, V35, P68, DOI 10.1137/0135006; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; SCHUSTER P, 1994, P ROY SOC B-BIOL SCI, V255, P279, DOI 10.1098/rspb.1994.0040; Schuster P, 1997, BIOPHYS CHEM, V66, P75, DOI 10.1016/S0301-4622(97)00058-6; SPIEGELMAN S, 1971, Quarterly Reviews of Biophysics, V4, P213; TUREK C, 1990, SCIENCE, V249, P505; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; WALTER AE, 1994, P NATL ACAD SCI USA, V91, P9218, DOI 10.1073/pnas.91.20.9218; Waterman M.S., 1978, ADV MATH SUPPLEMENTA, V1, P167; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	26	322	334	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 29	1998	280	5368					1451	1455		10.1126/science.280.5368.1451	http://dx.doi.org/10.1126/science.280.5368.1451			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9603737	Green Submitted			2022-12-24	WOS:000073883400060
J	Kogan, MD; Martin, JA; Alexander, GR; Kotelchuck, M; Ventura, SJ; Frigoletto, FD				Kogan, MD; Martin, JA; Alexander, GR; Kotelchuck, M; Ventura, SJ; Frigoletto, FD			The changing pattern of prenatal care utilization in the United States, 1981-1995, using different prenatal care indices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BIRTH-WEIGHT; GESTATIONAL-AGE; PREGNANCY; MEDICAID; HEALTH; ADEQUACY; INDEXES; ULTRASOUND; LITIGATION; EXPANSION	Context.-Two measures traditionally used to examine adequacy of prenatal care indicate that prenatal care utilization remained unchanged through the 1980s and only began to rise slightly in the 1990s. In recent years, new measures have been developed that include a category for women who receive more than the recommended amount of care (intensive utilization). Objective.-To compare the older and newer indices in the monitoring of prenatal care trends in the United States from 1981 to 1995, for the overall population and for selected subpopulations. Second, to examine factors associated with receiving intensive utilization. Design.-Cross-sectional and trend analysis of national birth records. Setting.-The United States. Subjects.-All live births between 1981 and 1995 (N=54 million). Main Outcome Measures.-Trends in prenatal care utilization, according to 4 indices (the older indices: the Institute of Medicine Index and the trimester that care began, and the newer indices: the R-GINDEX and the Adequacy of Prenatal Care Utilization Index). Multiple logistic regression was used to assess the risk of intensive prenatal care use in 1981 and 1995. Results.-The newer indices showed a steadily increasing trend toward more prenatal care use throughout the study period (R-GINDEX, intensive or adequate use, 32.7% in 1981 to 47.1% in 1995; the Adequacy of Prenatal Care Utilization Index, intensive use, 18.4% in 1981 to 28.8% in 1995), especially for intensive utilization. Women having a multiple birth were much more likely to have had intensive utilization in 1995 compared with 1981 (R-GINDEX, 22.8% vs 8.5%). Teenagers were more likely to begin care later than adults, but similar proportions of teens and adults had intensive utilization. Intensive use among low-risk women also increased steadily each year. Factors associated with a greater likelihood of receiving intensive use in 1981 and 1995 were having a multiple birth, primiparity, being married, and maternal age of 35 years or older. Conclusions.-The proportion of women who began care early and received at least the recommended number of visits increased between 1981 and 1995. This change was undetected by more traditional prenatal care indices. These increases have cost and practice implications and suggest a paradox since previous studies have shown that rates of preterm delivery and low birth weight did not improve during this time.	Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; Univ Alabama, Dept Maternal & Child Hlth, Birmingham, AL USA; Univ N Carolina, Dept Maternal & Child Hlth, Chapel Hill, NC USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Obstet, Boston, MA USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); University of Alabama System; University of Alabama Birmingham; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Harvard Medical School; Massachusetts General Hospital	Kogan, MD (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 6525 Belcrest Rd,Room 820, Hyattsville, MD 20782 USA.							Alexander GR, 1996, PUBLIC HEALTH REP, V111, P408; ALEXANDER GR, 1987, AM J PREV MED, V3, P243; ALEXANDER GR, 1995, PUBLIC HEALTH REP, V110, P395; ALEXANDER GR, 1995, FUTURE CHILD, V5, P103, DOI 10.2307/1602510; Alexander GR, 1997, AM J PREV MED, V13, P290, DOI 10.1016/S0749-3797(18)30177-6; ALEXANDER GR, 1991, AM J PUBLIC HEALTH, V81, P1013, DOI 10.2105/AJPH.81.8.1013; *AM COLL OBST GYN, 1985, PROF LIAB INS ITS EF; *AM COLL OBST GYN, 1974, STAND OBST GYN SERV; [Anonymous], CAR OUR FUT CONT PRE; BALDWIN LM, 1995, JAMA-J AM MED ASSOC, V274, P1606, DOI 10.1001/jama.274.20.1606; BUESCHER PA, 1993, AM J PUBLIC HEALTH, V83, P1163, DOI 10.2105/AJPH.83.8.1163; DelgadoRodriguez M, 1996, EPIDEMIOLOGY, V7, P648, DOI 10.1097/00001648-199611000-00016; ENNIS M, 1991, LANCET, V338, P616, DOI 10.1016/0140-6736(91)90616-W; EWIGMAN B, 1993, BIRTH-ISS PERINAT C, V20, P212, DOI 10.1111/j.1523-536X.1993.tb00229.x; Farrow DC, 1997, MED CARE, V35, P297, DOI 10.1097/00005650-199703000-00010; FISCELLA K, 1995, OBSTET GYNECOL, V85, P468, DOI 10.1016/0029-7844(94)00408-6; Floyd L, 1981, J Med Assoc Ga, V70, P871; GORSKY RD, 1989, HLTH SERV RES, V24, P580; GORTMAKER SL, 1979, AM J PUBLIC HEALTH, V69, P653, DOI 10.2105/AJPH.69.7.653; GUYER B, 1990, JAMA-J AM MED ASSOC, V264, P2264, DOI 10.1001/jama.264.17.2264; HUNTINGTON J, 1994, NEW ENGL J MED, V331, P1303, DOI 10.1056/NEJM199411103311910; *I MED, 1993, ACC HLTH CAR AM; *I MED, 1985, PREV LOW BIRTH WEIGH; JEWELL SE, 1995, OBSTET GYNECOL, V85, P229, DOI 10.1016/0029-7844(94)00354-G; JOYCE T, 1988, MED CARE, V26, P348, DOI 10.1097/00005650-198804000-00004; KESSNER DM, 1973, CONTRASTS HLTH STATU, V1, P50; Kirby RS, 1997, PAEDIATR PERINAT EP, V11, P122, DOI 10.1046/j.1365-3016.1997.d01-6.x; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V271, P1340, DOI 10.1001/jama.271.17.1340; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1486, DOI 10.2105/AJPH.84.9.1486; Kotelchuck M, 1994, AM J PUBLIC HEALTH, V84, P1314; KRAMER MS, 1988, JAMA-J AM MED ASSOC, V260, P3306, DOI 10.1001/jama.260.22.3306; LEWIS CT, 1996, VITAL HLTH STAT, V21; McDermott J, 1997, PAEDIATR PERINAT EP, V11, P105, DOI 10.1046/j.1365-3016.1997.d01-4.x; MOR JM, 1995, AM J PREV MED, V11, P79, DOI 10.1016/S0749-3797(18)30481-1; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; MUSTARD CA, 1994, AM J PUBLIC HEALTH, V84, P1450, DOI 10.2105/AJPH.84.9.1450; *NAT CTR HLTH STAT, 1995, 1992 VIT STAT US, V1; *NAT CTR HLTH STAT, 1982, VIT HLTH STAT, V2; National Center for Health Statistics, 1987, HOSP PHYS HDB BIRTH; OREILLY MP, 1991, P 1991 PUBL HLTH C R, P57; Petersen D J, 1994, Minn Med, V77, P41; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; QUICK JD, 1981, AM J PUBLIC HEALTH, V71, P381, DOI 10.2105/AJPH.71.4.381; RICCIOTTI HA, 1995, FUTURE CHILD, V5, P71, DOI 10.2307/1602508; SAARIKEMPPAINEN A, 1995, ACTA OBSTET GYN SCAN, V74, P12, DOI 10.3109/00016349509009935; Schappert SM, 1997, VITAL HLTH STAT, V13; SCHRAMM WF, 1992, PUBLIC HEALTH REP, V107, P647; SHIONO PH, 1986, JAMA-J AM MED ASSOC, V255, P48, DOI 10.1001/jama.255.1.48; SHOWSTACK JA, 1984, AM J PUBLIC HEALTH, V74, P1003, DOI 10.2105/AJPH.74.9.1003; *US DEP HHS, 1991, HLTH PEOPL 2000 NAT; *US DEP HHS, 1996, TRENDS WELL BEING AM; *US GEN ACC OFF, 1993, PUBL GAO; VENTURA SJ, 1997, MON VITAL STAT RE S2, V11; WEISMAN CS, 1989, MED CARE, V27, P16, DOI 10.1097/00005650-198901000-00002; Wells S, 1991, J Fla Med Assoc, V78, P31; Wilcox LS, 1996, FERTIL STERIL, V65, P361, DOI 10.1016/S0015-0282(16)58100-X	56	154	157	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1998	279	20					1623	1628		10.1001/jama.279.20.1623	http://dx.doi.org/10.1001/jama.279.20.1623			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZP489	9613911	Bronze			2022-12-24	WOS:000073758600031
J	Ando, Y; Anan, I; Suhr, O; Holmgren, G; Costa, PMP				Ando, Y; Anan, I; Suhr, O; Holmgren, G; Costa, PMP			Detection of a variant protein in hair: new diagnostic method in Portuguese type familial amyloid polyneuropathy	BRITISH MEDICAL JOURNAL			English	Article							TRANSTHYRETIN		Umea Univ Hosp, Dept Med, S-90185 Umea, Sweden; Umea Univ Hosp, Dept Clin Genet, S-90185 Umea, Sweden; Hosp St Antonio, Ctr Estudos Paramiloidose, P-4000 Porto, Portugal	Umea University; Umea University	Ando, Y (corresponding author), Umea Univ Hosp, Dept Med, S-90185 Umea, Sweden.		Costa, Paulo Pinho/B-4392-2008	Costa, Paulo Pinho/0000-0001-6125-7000; Ando, Yukio/0000-0001-7115-9105; Suhr, Ole/0000-0002-1175-2369				ANDO Y, 1993, INTERNAL MED, V32, P920, DOI 10.2169/internalmedicine.32.920; Benson MD, 1996, AMYLOID, V3, P44, DOI 10.3109/13506129609014354; COSTA PMP, 1993, SCAND J IMMUNOL, V38, P177, DOI 10.1111/j.1365-3083.1993.tb01710.x; HOLMGREN G, 1994, J MED GENET, V31, P351, DOI 10.1136/jmg.31.5.351; Petersen RB, 1997, ANN NEUROL, V41, P307, DOI 10.1002/ana.410410305	5	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1998	316	7143					1500	1501		10.1136/bmj.316.7143.1500	http://dx.doi.org/10.1136/bmj.316.7143.1500			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP020	9582138	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000073707700028
J	Pisetsky, DS				Pisetsky, DS			Doing everything	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Vet Adm Med Ctr, Durham, NC 27705 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Pisetsky, DS (corresponding author), Vet Adm Med Ctr, Box 151G,Room E-1008,508 Fulton St, Durham, NC 27705 USA.								0	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1998	128	10					869	870		10.7326/0003-4819-128-10-199805150-00013	http://dx.doi.org/10.7326/0003-4819-128-10-199805150-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM889	9599202				2022-12-24	WOS:000073586500013
J	Tan, PB; Lackner, MR; Kim, SK				Tan, PB; Lackner, MR; Kim, SK			MAP kinase signaling specificity mediated by the LIN-1 Ets/LIN31 WH transcription factor complex during C-elegans vulval induction	CELL			English	Article							CAENORHABDITIS-ELEGANS; REGULATED KINASE; CELL LINEAGE; LET-60 RAS; PROTEIN; PATHWAY; GENES; ACTIVATION; DEFINES; FATES	The let-23 receptor/mpk-1 MAP kinase signaling pathway induces the vulva in C. elegans. We show that MPK-1 directly regulates both the LIN-31 winged-helix and the LIN-1 Ets transcription factors to specify the vulval cell fate, lin-31 and lin-1 act genetically downstream of mpk-1, and both proteins can be directly phosphorylated by MAP kinase. LIN-31 binds to LIN-1, and the LIN-1/LIN-31 complex inhibits vulval induction. Phosphorylation of LIN-31 by MPK-1 disrupts the LIN-1/LIN-31 complex, relieving vulval inhibition. Phosphorylated LIN-31 may also act as a transcriptional activator, promoting vulval cell fates. LIN-31 is a vulval-specific effector of MPK-1, while LIN-1 acts as a general effector. The partnership of tissue-specific and general effecters may confer specificity onto commonly used signaling pathways, creating distinct tissue-specific outcomes.	Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA	Stanford University	Kim, SK (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.		Lackner, Mark/G-4597-2012	Lackner, Mark/0000-0002-6375-2037				AROIAN RV, 1991, GENETICS, V128, P251; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; CHAMBERLIN HM, 1994, DEVELOPMENT, V120, P2713; CHURCH DL, 1995, DEVELOPMENT, V121, P2525; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Euling S, 1996, CELL, V84, P667, DOI 10.1016/S0092-8674(00)81045-4; FERGUSON EL, 1985, GENETICS, V110, P17; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Hajnal A, 1997, GENE DEV, V11, P2715, DOI 10.1101/gad.11.20.2715; HAN M, 1990, GENETICS, V126, P899; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KOGA M, 1995, DEVELOPMENT, V121, P2655; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Maloof JN, 1998, DEVELOPMENT, V125, P181; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; PTASHNE M, 1980, CELL, V19, P1, DOI 10.1016/0092-8674(80)90383-9; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Sundaram M, 1996, DEVELOPMENT, V122, P2823; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wood WB, 1988, NEMATODE CAENORHABDI; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147; Yochem J, 1997, MOL CELL BIOL, V17, P2716, DOI 10.1128/MCB.17.5.2716	33	161	173	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					569	580		10.1016/S0092-8674(00)81186-1	http://dx.doi.org/10.1016/S0092-8674(00)81186-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604932	Bronze			2022-12-24	WOS:000073722200010
J	Liebowitz, D				Liebowitz, D			Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KAPPA-B ACTIVATION; LATENT MEMBRANE PROTEIN-1; TRANSFORMING PROTEIN; CELLS; EXPRESSION; LMP1; INDUCTION; DELETION; BCL-2; GENE	Background. Epstein-Barr virus (EBV) is associated with various malignant and benign lymphoproliferative disorders. It also efficiently transforms human B lymphocytes in vitro. The latent membrane protein 1 (LMP1) of EBV-infected cells plays a central part in this process by mimicking members of the family of tumor necrosis factor (TNF) receptors, thereby transmitting growth signals from the cell membrane to the nucleus through cytoplasmic TNF-receptor-associated factors (TRAFs). I sought evidence of LMP1-mediated signal transduction through TRAFs in tumor tissue from patients with post-transplantation lymphoproliferative disease and non-Hodgkin's lymphomas related to the acquired immunodeficiency syndrome (AIDS). Methods. The association of LMP1 with TRAF-1 or TRAF-3 in tumor tissue was studied with double-immunofluorescence microscopy and immunoprecipitation assays. Evidence of LMP1-TRAF signaling was sought with an electrophoretic mobility shift assay for the nuclear factor-kappa B (NF-kappa B) transcription factor. Results. Tumors from eight patients with post-transplantation lymphoproliferative disease, two patients with AIDS-associated non-Hodgkin's lymphoma, and three patients with endemic Burkitt's lymphoma were analyzed. Tumors from six of the patients with post-transplantation lymphoproliferative disease were positive for EBV and expressed LMP1; two samples were EBV-negative. Tumors from both patients with AIDS-associated non-Hodgkin's lymphoma were EBV-positive and expressed LMP1, whereas tumors from all three patients with Burkitt's tumors were positive for EBV but negative for LMP1. Double-immunofluorescence microscopy showed that LMP1 localized with and immunoprecipitated with TRAF-1 and TRAF-3 in all eight of the EBV-positive, LMP1-positive samples. An electrophoretic mobility shift assay revealed activated NF-kappa B in all eight EBV-positive, LMP1-positive samples as well, but not in either of the EBV-negative, LMP1-negative samples or in the three EBV-positive, LMP1-negative samples. Conclusions. LMP1-mediated signaling through the TRAF system has a role in the pathogenesis of the EBV-positive lymphomas that arise in immunosuppressed patients. (C) 1998, Massachusetts Medical Society.	Univ Chicago, Dept Med, Viral Oncol Labs, Sect Hematol Oncol & Virol, Chicago, IL 60637 USA	University of Chicago	Liebowitz, D (corresponding author), Univ Chicago, Med Ctr, Dept Med, Hematol Oncol Sect, 5841 S Maryland Ave,MC2115, Chicago, IL 60637 USA.				NCI NIH HHS [CA 73545] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA073545] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAICHWAL VR, 1988, ONCOGENE, V2, P461; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; Devergne O, 1996, MOL CELL BIOL, V16, P7098; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HATZUBAI A, 1987, INT J CANCER, V40, P358, DOI 10.1002/ijc.2910400313; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1996, FIELDS VIROLOGY, V2, P2343; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; Liebowitz D., 1997, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, V14, pA51; Liebowitz David, 1993, P107; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B	22	165	171	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 14	1998	338	20					1413	1421		10.1056/NEJM199805143382003	http://dx.doi.org/10.1056/NEJM199805143382003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM667	9580648				2022-12-24	WOS:000073563700003
J	Oberhauser, AF; Marszalek, PE; Erickson, HP; Fernandez, JM				Oberhauser, AF; Marszalek, PE; Erickson, HP; Fernandez, JM			The molecular elasticity of the extracellular matrix protein tenascin	NATURE			English	Article							ATOMIC-FORCE MICROSCOPE; ADHESION; MODULES; DOMAIN; FLOW	Extracellular matrix proteins are thought to provide a rigid mechanical anchor that supports and guides migrating and rolling cells(1-4). Here we examine the mechanical properties of the extracellular matrix protein tenascin by using atomic-force-microscopy techniques. Our results indicate that tenascin is an elastic protein. Single molecules of tenascin could be stretched to several times their resting length. Force-extension curves showed a saw-tooth pattern, with peaks of force at 137 pN. These peaks were similar to 25 nm apart. Similar results have been obtained by study of titin(5). We also found similar results by studying recombinant tenascin fragments encompassing the 15 fibronectin type III domains of tenascin. This indicates that the extensibility of tenascin map be due to the stretch-induced unfolding of its fibronectin type III domains. Refolding of tenascin after stretching, observed when the force was reduced to near zero, showed a double-exponential recovery with time constants of 42 domains refolded per second and 0.5 domains per second. The former speed of refolding is more than twice as fast as any previously reported speed of refolding of a fibronectin type III domain(6,7). We suggest that the extensibility of the modular fibronectin type III region may be important in allowing tenascin-ligand bonds to persist over long extensions. These properties of fibronectin type III modules may be of widespread use in extracellular proteins containing such domain(8,9).	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Mayo Clinic; Duke University	Fernandez, JM (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA.							Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; CAMPBELL ID, 1994, STRUCTURE, V2, P333, DOI 10.1016/S0969-2126(00)00034-4; CHIQUETEHRISMANN R, 1995, EXPERIENTIA, V51, P853, DOI 10.1007/BF01921736; Clark RA, 1997, J CELL BIOL, V137, P755, DOI 10.1083/jcb.137.3.755; Clarke J, 1997, J MOL BIOL, V270, P771, DOI 10.1006/jmbi.1997.1147; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FLORIN EL, 1995, BIOSENS BIOELECTRON, V10, P895, DOI 10.1016/0956-5663(95)99227-C; HAMMER DA, 1992, BIOPHYS J, V63, P35, DOI 10.1016/S0006-3495(92)81577-1; Keller TCS, 1997, NATURE, V387, P233, DOI 10.1038/387233a0; KELLERMAYER SB, 1997, SCIENCE, V276, P1112; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Plaxco KW, 1997, J MOL BIOL, V270, P763, DOI 10.1006/jmbi.1997.1148; Plaxco KW, 1996, P NATL ACAD SCI USA, V93, P10703, DOI 10.1073/pnas.93.20.10703; Potts JR, 1996, MATRIX BIOL, V15, P313, DOI 10.1016/S0945-053X(96)90133-X; RADMACHER M, 1994, SCIENCE, V265, P1577, DOI 10.1126/science.8079171; REIF M, 1997, SCIENCE, V276, P1109; Rief M, 1997, SCIENCE, V275, P1295, DOI 10.1126/science.275.5304.1295; Tskhovrebova L, 1997, NATURE, V387, P308, DOI 10.1038/387308a0	27	707	721	1	85	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1998	393	6681					181	185		10.1038/30270	http://dx.doi.org/10.1038/30270			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN200	9603523				2022-12-24	WOS:000073619900052
J	Levine, MM; Dougan, G				Levine, MM; Dougan, G			Optimism over vaccines administered via mucosal surfaces	LANCET			English	Editorial Material							ADP-RIBOSYLTRANSFERASE ACTIVITY		Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA; WHO, Global Programme Vaccines & Immunizat, Geneva, Switzerland; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London, England	University System of Maryland; University of Maryland Baltimore; World Health Organization; Imperial College London	Levine, MM (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.							Aggerbeck H, 1997, VACCINE, V15, P307, DOI 10.1016/S0264-410X(96)00175-2; Agren LC, 1997, J IMMUNOL, V158, P3936; BELSHE RB, IN PRESS N ENGL J ME; Darji A, 1997, CELL, V91, P765, DOI 10.1016/S0092-8674(00)80465-1; DICKINSON BL, 1995, INFECT IMMUN, V63, P1617, DOI 10.1128/IAI.63.5.1617-1623.1995; DOUCE G, 1995, P NATL ACAD SCI USA, V92, P1644, DOI 10.1073/pnas.92.5.1644; Galen JE, 1997, VACCINE, V15, P700, DOI 10.1016/S0264-410X(96)00227-7; Giuliani MM, 1998, J EXP MED, V187, P1123, DOI 10.1084/jem.187.7.1123; Glenn GM, 1998, NATURE, V391, P851, DOI 10.1038/36014; GONZALEZ C, 1994, J INFECT DIS, V169, P927, DOI 10.1093/infdis/169.4.927; Hohmann EL, 1996, J INFECT DIS, V173, P1408, DOI 10.1093/infdis/173.6.1408; JOHN TJ, 1972, AM J EPIDEMIOL, V96, P263, DOI 10.1093/oxfordjournals.aje.a121457; Levine MM, 1995, B I PASTEUR, V93, P243, DOI 10.1016/0020-2452(96)85758-7; LOWELL GH, 1997, NEW GENERATION VACCI, P193; PerezSchael I, 1997, NEW ENGL J MED, V337, P1181, DOI 10.1056/NEJM199710233371701; Snapper CM, 1996, J IMMUNOL, V157, P2229; Tacket CO, 1998, NAT MED, V4, P607, DOI 10.1038/nm0598-607; Tacket CO, 1997, INFECT IMMUN, V65, P452, DOI 10.1128/IAI.65.2.452-456.1997	18	78	80	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 9	1998	351	9113					1375	1376		10.1016/S0140-6736(05)79439-3	http://dx.doi.org/10.1016/S0140-6736(05)79439-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM665	9593404				2022-12-24	WOS:000073563400004
J	Ferrell, JE; Machleder, EM				Ferrell, JE; Machleder, EM			The biochemical basis of an all-or-none cell fate switch in Xenopus oocytes	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; MOS; MATURATION; CASCADE; SYSTEMS; AMPLIFICATION; SENSITIVITY; INITIATION; EXTRACTS	Xenopus oocytes convert a continuously variable stimulus, the concentration of the maturation-inducing hormone progesterone, into an all-or-none biological response-oocyte maturation, Here evidence is presented that the all-or-none character of the response is generated by the mitogen-activated protein kinase (MAPK) cascade. Analysis of individual oocytes showed that the response of MAPK to progesterone or Mos was equivalent to that of a cooperative enzyme with a Hill coefficient of at least 35, more than 10 times the Hill coefficient for the binding of oxygen to hemoglobin. The response can be accounted for by the intrinsic ultrasensitivity of the oocyte's MAPK cascade and a positive feedback loop in which the cascade is embedded. These findings provide a biochemical rationale for the all-or-none character of this cell fate switch.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Ferrell, JE (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.	ferrell@cmgm.stanford.edu			NCI NIH HHS [CA09302] Funding Source: Medline; NIGMS NIH HHS [GM56383] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brown GC, 1997, TRENDS BIOCHEM SCI, V22, P288, DOI 10.1016/S0968-0004(97)82216-5; Burack WR, 1997, BIOCHEMISTRY-US, V36, P5929, DOI 10.1021/bi970535d; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; Ferrell JE, 1997, TRENDS BIOCHEM SCI, V22, P288, DOI 10.1016/S0968-0004(97)82217-7; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Gerhart J.C., 1980, Biological Regulation and Development, V2, P133; GOLDBETER A, 1982, Q REV BIOPHYS, V15, P555, DOI 10.1017/S0033583500003449; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Kholodenko BN, 1997, FEBS LETT, V414, P430, DOI 10.1016/S0014-5793(97)01018-1; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; MASUI Y, 1967, J EXP ZOOL, V166, P365, DOI 10.1002/jez.1401660309; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NEBREDA AR, 1995, EMBO J, V14, P5597, DOI 10.1002/j.1460-2075.1995.tb00247.x; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; NOVAK B, 1993, J CELL SCI, V106, P1153; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Roy LM, 1996, ONCOGENE, V12, P2203; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SMITH LD, 1991, METHOD CELL BIOL, V36, P45; STRYER L, 1995, BIOCHEMISTRY-US, P168; Thron CD, 1996, BIOPHYS CHEM, V57, P239, DOI 10.1016/0301-4622(95)00075-5; Tyson JJ, 1996, TRENDS BIOCHEM SCI, V21, P89; WALLACE RA, 1973, J EXP ZOOL, V184, P321, DOI 10.1002/jez.1401840305; WASSERMAN WJ, 1974, BIOL REPROD, V11, P133, DOI 10.1095/biolreprod11.2.133; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	35	815	828	7	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 8	1998	280	5365					895	898		10.1126/science.280.5365.895	http://dx.doi.org/10.1126/science.280.5365.895			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572732				2022-12-24	WOS:000073532900039
J	Gupta, S; Ferguson, N; Anderson, R				Gupta, S; Ferguson, N; Anderson, R			Chaos, persistence, and evolution of strain structure in antigenically diverse infectious agents	SCIENCE			English	Article							OUTER-MEMBRANE PROTEIN; PLASMODIUM-FALCIPARUM; ERYTHROCYTES; DYNAMICS; CHILDREN	The effects of selection by host immune responses on transmission dynamics was analyzed in a broad class of antigenically diverse pathogens. Strong selection can cause pathogen populations to stably segregate into discrete strains with nonoverlapping antigenic repertoires. However, over a wide range of intermediate levels of selection, strain structure is unstable, varying in a manner that is either cyclical or chaotic. These results have implications for the interpretation of longitudinal epidemiological data on strain or serotype abundance, design of surveillance strategies, and the assessment of multivalent vaccine trials.	Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, England	University of Oxford	Gupta, S (corresponding author), Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, S Parks Rd, Oxford OX1 3PS, England.	sunetra.gupta@zoology.ox.ac.uk	Ferguson, Neil/B-8578-2008	Ferguson, Neil/0000-0002-1154-8093	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R M, 1991; Andreasen V, 1997, J MATH BIOL, V35, P825, DOI 10.1007/s002850050079; ANTHONY BF, 1976, AM J EPIDEMIOL, V104, P652, DOI 10.1093/oxfordjournals.aje.a112344; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BOLKER B, 1995, PHILOS T R SOC B, V348, P309, DOI 10.1098/rstb.1995.0070; CAUGANT DA, 1990, J INFECT DIS, V162, P867, DOI 10.1093/infdis/162.4.867; *CDC, 1997, MMWR-MORBID MORTAL W, P1; CLIFF A, 1986, SPATIAL ASPECTS INFL; Contamin H, 1996, AM J TROP MED HYG, V54, P632, DOI 10.4269/ajtmh.1996.54.632; Feavers IM, 1996, CLIN DIAGN LAB IMMUN, V3, P444, DOI 10.1128/CDLI.3.4.444-450.1996; FERGUSON NM, 1997, SPATIAL ECOLOGY ROLE; GUPTA S, 1994, SCIENCE, V263, P961, DOI 10.1126/science.8310293; Gupta S, 1996, NAT MED, V2, P437, DOI 10.1038/nm0496-437; GUPTA S, IN PRESSS P R SOC B; MAIDEN MCJ, 1995, SYMP SOC GEN MICROBI, V52, P269; RAKONJAC JV, 1995, INFECT IMMUN, V63, P622, DOI 10.1128/IAI.63.2.622-631.1995; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; VANDERLEY P, 1992, INFECT IMMUN, V60, P3156, DOI 10.1128/IAI.60.8.3156-3161.1992; WATSON DA, 1995, EUR J CLIN MICROBIOL, V14, P479, DOI 10.1007/BF02113425; 1993, MORB MORTAL WKLY REP, V42, P1; 1992, MORB MORTAL WKLY REP, V41, P3; 1992, MORB MORTAL WKLY REP, V41, P5	23	212	215	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1998	280	5365					912	915		10.1126/science.280.5365.912	http://dx.doi.org/10.1126/science.280.5365.912			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572737				2022-12-24	WOS:000073532900044
J	Qiu, Y; Ravi, L; Kung, HJ				Qiu, Y; Ravi, L; Kung, HJ			Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells	NATURE			English	Article							GROWTH-FACTOR; RECEPTOR; EXPRESSION; TRANSFORMATION; TRANSDUCTION; ACTIVATION	Interleukin-6 (IL-6) is a cytokine that was initially recognized as a regulator of immune and inflammatory responses(1), but it also regulates the growth of many tumour cells, including prostrate carcinoma(2-4). Overexpression of the growth-factor receptors ErbB2/neu and ErbB3 has been implicated in the neoplastic transformation of prostate carcinoma(5-7). Here we show that treatment of the prostate cancer cell line LNCaP with IL-6 induces tyrosine phosphorylation of ErbB2 and ErbB3, but not ErbB1/ EGFR. We also show that ErbB2 forms a complex with the gp130 subunit of the IL-6 receptor in an IL-6-dependent manner. This association is important because the inhibition of ErbB2 activity results in abrogation of IL-6-induced MAPK activation. Thus ErbB2 is a critical component of IL-6 signalling through the MAP kinase pathway. These data show how a cytokine receptor can diversify its signalling pathways by engaging with a growth-factor receptor kinase.	Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; Natl Hlth Res Inst, Mol & Genom Med Div, Taipei, Taiwan	Case Western Reserve University; National Health Research Institutes - Taiwan	Kung, HJ (corresponding author), Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	hxk5@po.cwru.edu	Kung, Hsing-Jien/C-7651-2013					BEERLI RR, 1994, J BIOL CHEM, V269, P23931; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chen-Kiang S, 1995, Curr Top Microbiol Immunol, V194, P189; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DOUGALL WC, 1994, ONCOGENE, V9, P2109; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HIRANO T, 1992, CHEM IMMUNOL, V51, P153; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUTCHINS D, 1994, INT J CANCER, V58, P80, DOI 10.1002/ijc.2910580114; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; Okamoto M, 1997, CANCER RES, V57, P141; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUI H, 1994, J BIOL CHEM, V269, P5364; SIEGALL CB, 1990, CANCER RES, V50, P7786; SIEGSMUND MJ, 1994, J UROLOGY, V151, P1396, DOI 10.1016/S0022-5347(17)35267-9; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; ZHAU HE, 1994, J CELL BIOCHEM, P208	24	242	251	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 7	1998	393	6680					83	85		10.1038/30012	http://dx.doi.org/10.1038/30012			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590694				2022-12-24	WOS:000073497500052
J	van Turennout, M; Hagoort, P; Brown, CM				van Turennout, M; Hagoort, P; Brown, CM			Brain activity during speaking: From syntax to phonology in 40 milliseconds	SCIENCE			English	Article							PARTIAL INFORMATION; LEXICAL ACCESS; POTENTIALS	In normal conversation, speakers translate thoughts into words at high speed. To enable this speed, the retrieval of distinct types of linguistic knowledge has to be orchestrated with millisecond precision. The nature of this orchestration is still largely unknown. This report presents dynamic measures of the real-time activation of two basic types of linguistic knowledge, syntax and phonology. Electrophysiological data demonstrate that during noun-phrase production speakers retrieve the syntactic gender of a noun before its abstract phonological properties. This two-step process operates at high speed: the data show that phonological information is already available 40 milliseconds after syntactic properties have been retrieved.	Max Planck Inst Psycholinguist, NL-6525 XD Nijmegen, Netherlands	Max Planck Society	van Turennout, M (corresponding author), NIMH, Lab Brain & Cognit, Bldg 10,Room 4C104,10 Ctr Dr,MSC 1366, Bethesda, MD 20892 USA.		Hagoort, Peter/B-7417-2012					Butterworth B., 1989, LEXICAL REPRESENTATI, P108; COLES MGH, 1989, PSYCHOPHYSIOLOGY, V26, P251, DOI 10.1111/j.1469-8986.1989.tb01916.x; COLES MGH, 1995, OX PSYCH S, P86; DEJONG R, 1988, J EXP PSYCHOL HUMAN, V14, P682, DOI 10.1037/0096-1523.14.4.682; DELL GS, 1992, COGNITION, V42, P287, DOI 10.1016/0010-0277(92)90046-K; GARRETT M, 1992, COGNITION, V42, P143, DOI 10.1016/0010-0277(92)90042-G; KUTAS M, 1980, BRAIN RES, V202, P95, DOI 10.1016/S0006-8993(80)80037-0; LEVELT WJM, 1991, PSYCHOL REV, V98, P122, DOI 10.1037/0033-295X.98.1.122; LEVELT WJM, 1989, SPEAKING INTENTION A; MILLER J, 1992, J EXP PSYCHOL GEN, V121, P195, DOI 10.1037/0096-3445.121.2.195; Miozzo M, 1997, J COGNITIVE NEUROSCI, V9, P160, DOI 10.1162/jocn.1997.9.1.160; OSMAN A, 1992, J EXP PSYCHOL HUMAN, V18, P217, DOI 10.1037/0096-1523.18.1.217; SMID HGOM, 1992, J EXP PSYCHOL HUMAN, V18, P1101, DOI 10.1037/0096-1523.18.4.1101	13	177	179	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					572	574		10.1126/science.280.5363.572	http://dx.doi.org/10.1126/science.280.5363.572			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZJ684	9554845	Green Submitted			2022-12-24	WOS:000073242100042
J	Chicurel, ME; Singer, RH; Meyer, CJ; Ingber, DE				Chicurel, ME; Singer, RH; Meyer, CJ; Ingber, DE			Integrin binding and mechanical tension induce movement of mRNA and ribosomes to focal adhesions	NATURE			English	Article							ANCHORAGE-DEPENDENT FIBROBLASTS; SIGNAL-TRANSDUCTION MECHANISMS; PROTEIN-KINASE-C; MESSENGER-RNA; ENDOTHELIAL-CELLS; GROWTH; FIBRONECTIN; EIF-4E; HYBRIDIZATION; CYTOSKELETON	The extracellular matrix (ECM) activates signalling pathways that control cell behaviour by binding to cell-surface integrin receptors and inducing the formation of focal adhesion complexes (FACs)(1,2). In addition to clustered integrins, FACs contain proteins that mechanically couple the integrins to the cytoskeleton(3) and to immobilized signal-transducing molecules(1,2). Cell adhesion to the ECM also induces a rapid increase in the translation of preexisting messenger RNAs4,5. Gene expression can be controlled locally by targeting mRNAs to specialized cytoskeletal domains(6). Here we investigate whether cell binding to the ECM promotes formation of a cytoskeletal microcompartment specialized for translational control at the site of integrin binding. High-resolution in situ hybridization revealed that mRNA and ribosomes rapidly and specifically localized to FACs that form when cells bind to ECM-coated microbeads, Relocation of these protein synthesis components to the FAC depended on the ability of integrins to mechanically couple the ECM to the contractile cytoskeleton and on associated tension-moulding of the actin lattice. Our results suggest a new type of gene regulation by integrins and by mechanical stress which may involve translation of mRNAs into proteins near the sites of signal reception.	Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine	Ingber, DE (corresponding author), Childrens Hosp, Dept Surg, 300 Longwood Ave, Boston, MA 02115 USA.		Ingber, Donald E/AAC-5894-2019					Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; BASSELL GJ, 1994, J CELL BIOL, V126, P863, DOI 10.1083/jcb.126.4.863; BENECKE BJ, 1978, CELL, V14, P931, DOI 10.1016/0092-8674(78)90347-1; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; EDMONDS BT, 1995, J BIOL CHEM, V270, P15222, DOI 10.1074/jbc.270.25.15222; FARMER SR, 1978, CELL, V15, P627, DOI 10.1016/0092-8674(78)90031-4; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; INGBER DE, 1993, J CELL SCI, V104, P613; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; LATHAM VM, 1994, J CELL BIOL, V126, P1211, DOI 10.1083/jcb.126.5.1211; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; LUCAS JJ, 1976, CELL, V7, P115, DOI 10.1016/0092-8674(76)90261-0; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Schmeichel KL, 1997, MOL BIOL CELL, V8, P219, DOI 10.1091/mbc.8.2.219; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SINGH NK, 1994, P NATL ACAD SCI USA, V91, P12770, DOI 10.1073/pnas.91.26.12770; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; VANMANTEUFFEL S, 1996, P NATL ACAD SCI USA, V93, P4076; VUORI K, 1993, J BIOL CHEM, V268, P21459; Wada H, 1996, J BIOL CHEM, V271, P8359, DOI 10.1074/jbc.271.14.8359; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wang N, 1995, BIOCHEM CELL BIOL, V73, P327, DOI 10.1139/o95-041; Whalen SG, 1996, J BIOL CHEM, V271, P11831, DOI 10.1074/jbc.271.20.11831; ZHANG GH, 1994, NATURE, V372, P809	30	305	313	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1998	392	6677					730	733		10.1038/33719	http://dx.doi.org/10.1038/33719			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565036				2022-12-24	WOS:000073129000063
J	Elmore, G; Barton, MB; Moceri, VM; Polk, S; Arena, PJ; Fletcher, SW				Elmore, G; Barton, MB; Moceri, VM; Polk, S; Arena, PJ; Fletcher, SW			Ten-year risk of false positive screening mammograms and clinical breast examinations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	National Meeting of the Society-of-General-Internal-Medicine	MAY 01-03, 1997	WASHINGTON, D.C.	Soc Gen Internal Med			PREDICTIVE VALUE; CANCER; AUDIT; ANXIETY	Background The cumulative risk of a false positive result of a breast-cancer screening test is unknown. Methods We performed a 10-year retrospective cohort study of breast-cancer screening and diagnostic evaluations among 2400 women who were 40 to 69 years old at study entry. Mammograms or clinical breast examinations that were interpreted as indeterminate, aroused a suspicion of cancer, or prompted recommendations for additional workup in women in whom breast cancer was not diagnosed within the next year were considered to be false positive tests. Results A total of 9762 screening mammograms and 10,905 screening clinical breast examinations were performed, for a median of 4 mammograms and 5 clinical breast examinations per woman over the 10-year period. Of the women who were screened, 23.8 percent had at least one false positive mammogram, 13.4 percent had at least one false positive breast examination, and 31.7 percent had at least one false positive result for either test. The estimated cumulative risk of a false positive result was 49.1 percent (95 percent confidence interval, 40.3 to 64.1 percent) after 10 mammograms and 22.3 percent (95 percent confidence interval, 19.2 to 27.5 percent) after 10 clinical breast examinations. The false positive tests led to 870 outpatient appointments, 539 diagnostic mammograms, 186 ultrasound examinations, 188 biopsies, and 1 hospitalization. We estimate that among women who do not have breast cancer, 18.6 percent (95 percent confidence interval, 9.8 to 41.2 percent) will undergo a biopsy after 10 mammograms, and 6.2 percent (95 percent confidence interval, 3.7 to 11.2 percent) after 10 clinical breast examinations. For every $100 spent for screening, an additional $33 was spent to evaluate the false positive results. Conclusions Over 10 years, one third of the women screened had abnormal test results requiring additional evaluation, even though no breast cancer was present. Techniques are needed to decrease false positive results while maintaining high sensitivity. Physicians should educate women about the risk of a false positive result of a screening test for breast cancer. (C) 1998, Massachusetts Medical Society.	Univ Washington, Sch Med, Div Gen Internal Med, Dept Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Epidemiol, Seattle, WA 98195 USA; Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Pilgrim Hlth Care, Dept Diagnost Radiol, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harvard Pilgrim Health Care; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School	Elmore, G (corresponding author), Univ Washington, Sch Med, Div Gen Internal Med, Dept Med, 1959 NE Pacific,Rm BB527E,Box 356429, Seattle, WA 98195 USA.		SALAZAR, ANTONIO/A-5806-2013	SALAZAR, ANTONIO/0000-0003-2639-2340				BARNETT GO, 1984, NEW ENGL J MED, V310, P1643, DOI 10.1056/NEJM198406213102506; BARNETT GO, 1979, P IEEE, V67, P1226, DOI 10.1109/PROC.1979.11438; Bassett LW, 1994, AHCPR PUBLICATION; BIRD RE, 1989, RADIOLOGY, V171, P87, DOI 10.1148/radiology.171.1.2494683; BROWN ML, 1995, AM J ROENTGENOL, V165, P1373, DOI 10.2214/ajr.165.6.7484568; BULL AR, 1991, BRIT J RADIOL, V64, P510, DOI 10.1259/0007-1285-64-762-510; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; ELLMAN R, 1989, BRIT J CANCER, V60, P781, DOI 10.1038/bjc.1989.359; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; GRAM IT, 1990, BRIT J CANCER, V62, P1018, DOI 10.1038/bjc.1990.430; GRAM IT, 1992, AM J PUBLIC HEALTH, V82, P249, DOI 10.2105/AJPH.82.2.249; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P39, DOI 10.1001/jama.276.1.39; KIRSCHNER CG, 1994, PHYSICIANS CURRENT P; KOPANS DB, 1992, AM J ROENTGENOL, V158, P521, DOI 10.2214/ajr.158.3.1310825; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; LERMAN C, 1991, HEALTH PSYCHOL, V10, P259, DOI 10.1037/0278-6133.10.4.259; LERMAN C, 1991, J CLIN ONCOL, V9, P1275, DOI 10.1200/JCO.1991.9.7.1275; Lidbrink E, 1996, BRIT MED J, V312, P273; LINVER MN, 1995, AM J ROENTGENOL, V165, P19, DOI 10.2214/ajr.165.1.7785586; Paskett ED, 1995, J WOMENS HEALTH, V4, P73; ROBERTSON CL, 1993, RADIOLOGY, V187, P75, DOI 10.1148/radiology.187.1.8451440; *SAS I, 1996, SAS VERS 6 11; SICKLES EA, 1992, RADIOL CLIN N AM, V30, P265; SUTTON S, 1995, J EPIDEMIOL COMMUN H, V49, P413, DOI 10.1136/jech.49.4.413; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; 1995, MMWR MORB MORTAL WKL, V45, P57; 1996, FED REG, V61, P59490	27	761	777	1	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1998	338	16					1089	1096		10.1056/NEJM199804163381601	http://dx.doi.org/10.1056/NEJM199804163381601			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH080	9545356	Bronze			2022-12-24	WOS:000073070100001
J	Devitt, A; Moffatt, OD; Raykundalia, C; Capra, JD; Simmons, DL; Gregory, CD				Devitt, A; Moffatt, OD; Raykundalia, C; Capra, JD; Simmons, DL; Gregory, CD			Human CD14 mediates recognition and phagocytosis of apoptotic cells	NATURE			English	Article							MACROPHAGE RECOGNITION; VITRONECTIN RECEPTOR; BINDING-PROTEIN; HUMAN-MONOCYTES; ANTIGEN; STIMULATION; ENDOTOXIN; ANTIBODY; POLYMERS; DEATH	Cells undergoing programmed cell death (apoptosis) are cleared rapidly in vivo by phagocytes without inducing inflammation(1), Here we show that the glycosylphosphatidylinositol-linked plasma-membrane glycoprotein CD14 (refs 2, 3) on the surface of human macrophages is important for the recognition and clearance of apoptotic cells, CD14 can also act as a receptor that binds bacterial lipopolysaccharide (LPS), triggering inflammatory responses(4), Overstimulation of CD14 by LPS can cause the often fatal toxic-shock syndrome(5,6). Here we show that apoptotic cells interact with CD14, triggering phagocytosis of the apoptotic cells, This interaction depends on a region of CD14 that is identical to, or at least closely associated with, a region known to bind LPS, However, apoptotic cells, unlike LPS, do not provoke the release of pro-inflammatory cytokines from macrophages, These results indicate that clearance of apoptotic cells is mediated by a receptor whose interactions with 'non-self' components (LPS) and 'self' components (apoptotic cells) produce distinct macrophage responses.	Univ Birmingham, Sch Med, Dept Immunol, Birmingham B15 2TT, W Midlands, England; Univ Nottingham, Sch Med, Queens Med Ctr, Inst Cell Signalling, Nottingham NG7 2UH, England; Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; SmithKline Beecham Pharmaceut, Harlow CM19 5AW, Essex, England	University of Birmingham; University of Nottingham; University of Nottingham; Oklahoma Medical Research Foundation; GlaxoSmithKline	Gregory, CD (corresponding author), Univ Birmingham, Sch Med, Dept Immunol, Birmingham B15 2TT, W Midlands, England.		Gregory, Chris/C-6927-2019	Gregory, Chris/0000-0002-7553-0132; Devitt, Andrew/0000-0002-4651-6761				Cavaillon JM, 1996, J ENDOTOXIN RES, V3, P471, DOI 10.1177/096805199600300605; DELUDE RL, 1995, P NATL ACAD SCI USA, V92, P9288, DOI 10.1073/pnas.92.20.9288; DINI L, 1992, FEBS LETT, V296, P174, DOI 10.1016/0014-5793(92)80373-O; DUVALL E, 1985, IMMUNOLOGY, V56, P351; ESPEVIK T, 1993, EUR J IMMUNOL, V23, P255, DOI 10.1002/eji.1830230140; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; FERRERO E, 1993, P NATL ACAD SCI USA, V90, P380; FLORA PK, 1994, EUR J IMMUNOL, V24, P2625, DOI 10.1002/eji.1830241109; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; HARIOT A, 1996, IMMUNITY, V4, P407; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; NEWMAN SL, 1995, J IMMUNOL, V154, P753; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Petty HR, 1996, IMMUNOL TODAY, V17, P209, DOI 10.1016/0167-5699(96)30013-3; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; Pradhan D, 1997, MOL BIOL CELL, V8, P767, DOI 10.1091/mbc.8.5.767; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SIMMONS DL, 1989, BLOOD, V73, P284; SOELL M, 1995, J IMMUNOL, V154, P851; UGOLINI V, 1980, P NATL ACAD SCI-BIOL, V77, P6764, DOI 10.1073/pnas.77.11.6764; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Weidemann B, 1997, INFECT IMMUN, V65, P858, DOI 10.1128/IAI.65.3.858-864.1997; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yu B, 1997, J CLIN INVEST, V99, P315, DOI 10.1172/JCI119160	30	547	561	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					505	509		10.1038/33169	http://dx.doi.org/10.1038/33169			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548256				2022-12-24	WOS:000072875200061
J	Boyle, JS; Brady, JL; Lew, AM				Boyle, JS; Brady, JL; Lew, AM			Enhanced response to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction	NATURE			English	Article							PROTEIN; MICE; IMMUNIZATION; CTLA4IG; INVIVO	Viral infection and vaccination with DNA both induce similar immune responses to encoded antigens that are produced by the host(1,2). The availability of antigens in lymphoid organs is important in generating an immune response to viral challenge(3). Antigen availability may also be important in the response to DNA vaccines, because immune responses are stronger when antigen is secreted from DNA-transfected cells(4,5). We directed antigen to lymphoid organs by vaccination,vith DNA encoding antigen-ligand fusion proteins, The two ligands examined bind to receptors that are present on high endothelial venule cells of lymph nodes or on antigen-presenting cells. Here we show that both the humoral and the cellular immune responses to a model DNA vaccine were enhanced using either antigen-targeting strategy. Moreover, directing antigen to antigen-presenting cells speeded up, and altered the form of, the immune response, Directing antigen to sites of immune-response induction may represent a generic means of tailoring a potent and effective immune response to a DNA vaccine.	Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Brisbane, Qld 4029, Australia; Walter & Eliza Hall Inst Med Res, Autoimmun & Transplantat Div, Melbourne, Vic 3050, Australia	QIMR Berghofer Medical Research Institute; Walter & Eliza Hall Institute	Lew, AM (corresponding author), Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Brisbane, Qld 4029, Australia.	lew@wehi.edu.au	Lew, Andrew M/C-7248-2013	Lew, Andrew M/0000-0002-2198-8164				AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; Boyle JS, 1997, P NATL ACAD SCI USA, V94, P14626, DOI 10.1073/pnas.94.26.14626; Boyle JS, 1997, INT IMMUNOL, V9, P1897, DOI 10.1093/intimm/9.12.1897; Catalina MD, 1996, J EXP MED, V184, P2341, DOI 10.1084/jem.184.6.2341; Inchauspe G, 1997, DNA CELL BIOL, V16, P185, DOI 10.1089/dna.1997.16.185; JOHNSON KS, 1989, NATURE, V338, P585, DOI 10.1038/338585a0; Karrer U, 1997, J EXP MED, V185, P2157, DOI 10.1084/jem.185.12.2157; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; Lew AM, 1996, TRANSPLANTATION, V62, P83, DOI 10.1097/00007890-199607150-00017; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; MICHEL ML, 1995, P NATL ACAD SCI USA, V92, P5307, DOI 10.1073/pnas.92.12.5307; MOR G, 1995, J IMMUNOL, V155, P2039; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; SNAPPER CM, 1993, IMMUNOL TODAY, V14, P15, DOI 10.1016/0167-5699(93)90318-F; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8	19	215	255	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					408	411		10.1038/32932	http://dx.doi.org/10.1038/32932			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537327				2022-12-24	WOS:000072713600057
J	Malone, KE; Daling, JR; Thompson, JD; O'Brien, CA; Francisco, LV; Ostrander, EA				Malone, KE; Daling, JR; Thompson, JD; O'Brien, CA; Francisco, LV; Ostrander, EA			BRCA1 mutations and breast cancer in the general population - Analyses in women before age 35 years and in women before age 45 years with first-degree family history	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EARLY-ONSET BREAST; OVARIAN-CANCER; YOUNG-WOMEN; JEWISH WOMEN; SURVIVAL; LINKAGE; ORIGINS; RISK	Context.-Studies of high-risk families with multiple early-onset cases of breast cancer have been useful for assessing the type and spectrum of germline mutations on the BRCA1 gene, but do not provide guidance to women with modest family history profiles. Thus, studies of women from the general population are needed to determine the BRCA1 mutation frequency in women perceived to be at high risk, and to develop profiles of those most likely to be carriers. Objective.-To characterize frequency and spectrum of germline BRCA1 mutations in 2 categories of women identified via population-based studies hypothesized to be at increased risk of carrying such mutations: those diagnosed as having breast cancer before age 35 years and those diagnosed before age 35 years who have first-degree breast cancer family history, Design.-Study subjects were drawn from 2 population-based case-control studies of breast cancer in young women on the basis of their family history or their age of diagnosis. Cases were younger than 35 years or were younger than 45 years with first-degree family history at the time of breast cancer diagnosis and were ascertained via a population-based cancer registry, and controls (women without breast cancer) were identified via random-digit dialing. Setting.-Three counties in western Washington State, Main Outcome Measure.-BRCA1 germline mutations in study subjects identified in DNA from peripheral blood lymphocytes by single-strand conformation polymorphism analysis using primer pairs that span the BRCA1 coding region and intron-exon boundaries. Results.-Of 193 women diagnosed as having breast cancer before age 35 years, none of whom were selected on the basis of family history status, 12 (6.2%, 95% confidence interval [CI], 3.2%-10.6%) had germline BRCA1 mutations. in 208 women diagnosed before age 45 years who had first-degree breast cancer family history, 15 (7.2%, 95% CI, 4.1%-11.6%) had germline mutations in BRCA1. In both groups, there were variations in mutation frequency noted by age and by family history. Mutation frequency decreased with increasing age of diagnosis. Higher proportions of mutations were seen in cases with at least 1 relative diagnosed as having breast cancer before age 45 years, in cases with greater numbers of affected relatives, and those with ovarian cancer family history. Mutation frequency did not vary by bilateral breast cancer family history. No frameshift or nonsense mutations were observed in 71 control women with a first-degree family history, although missense changes of unknown significance were seen in cases and controls. Conclusions.-Women with BRCA1 germline mutations lacked a common family history profile. Also, a large proportion of the women with a first-degree breast cancer family history and women diagnosed as having breast cancer before age 35 years did not carry germline BRCA1 mutations. Hence, while early-onset disease and a strong breast cancer family history may be useful guidelines for checking BRCA1 status, these findings on women drawn from the general population suggest that it may be difficult to develop BRCA1 mutation screening criteria among women with modest family history profiles.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Malone, KE (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,POB 19024,MP-381, Seattle, WA 98109 USA.			Ostrander, Elaine/0000-0001-6075-9738	NCI NIH HHS [N01-CP-95671, R01-CA-41416, R01-CA-63705] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP095671] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA063705, R01CA041416] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berman DB, 1996, AM J HUM GENET, V58, P1166; BRINTON LA, 1995, J NATL CANCER I, V87, P827, DOI 10.1093/jnci/87.11.827; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; COUCH FJ, 1995, J NCI MONOGR, V17, P9; DALING JR, 1994, JNCI-J NATL CANCER I, V86, P1584, DOI 10.1093/jnci/86.21.1584; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1995, AM J HUM GENET, V57, P1547; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Hakansson S, 1997, AM J HUM GENET, V60, P1068; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; JACQUEMIER J, 1995, LANCET, V345, P1503, DOI 10.1016/S0140-6736(95)91060-3; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Jordanova A, 1997, HUM MUTAT, V10, P65, DOI 10.1002/(SICI)1098-1004(1997)10:1<65::AID-HUMU9>3.3.CO;2-9; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; Malone KE, 1996, CANCER, V78, P1417, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1417::AID-CNCR7>3.3.CO;2-Q; Mathew CG, 1996, NEW ENGL J MED, V334, P1198; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1995, AM J HUM GENET, V56, P254; NAROD SA, 1991, LANCET, V338, P82; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P1; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; Serova O, 1996, AM J HUM GENET, V58, P42; ShattuckEidens D, 1997, JAMA-J AM MED ASSOC, V278, P1242, DOI 10.1001/jama.278.15.1242; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; StoppaLyonnet D, 1997, AM J HUM GENET, V60, P1021; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Szabo CI, 1997, AM J HUM GENET, V60, P1013; TONIN P, 1995, AM J HUM GENET, V57, P189; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; Whittemore AS, 1997, AM J HUM GENET, V60, P496	37	182	188	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1998	279	12					922	929		10.1001/jama.279.12.922	http://dx.doi.org/10.1001/jama.279.12.922			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC304	9544766				2022-12-24	WOS:000072563600032
J	Sillanpaa, M; Jalava, M; Kaleva, O; Shinnar, S				Sillanpaa, M; Jalava, M; Kaleva, O; Shinnar, S			Long-term prognosis of seizures with onset in childhood	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUDDEN UNEXPLAINED DEATH; ANTIEPILEPTIC DRUGS; EPILEPSY; PREDICTORS; ADJUSTMENT; REMISSION; CHILDREN; THERAPY; COHORT	Background The long-term prognosis of seizures that begin in childhood is uncertain. Methods We prospectively studied 245 children from the catchment area of Turku University Hospital in Turku, Finland, who had active epilepsy diagnosed between 1961 and 1964. Sixty-eight patients (28 percent) had idiopathic seizures (presumed to have a genetic origin), 54 (22 percent) had cryptogenic seizures (occurring in otherwise normal persons with no clear cause), and 123 (50 percent) had remote symptomatic seizures (with no immediate cause but occurring in persons with a prior brain injury or a static encephalopathy). Results At the final follow-up in 1992, we had sufficient data on 220 patients (90 percent), 176 of whom were alive and 44 of whom had died; the remaining 25 had emigrated, could not be traced, or declined to participate. Thirty-nine patients who died were not free of seizures at the time of death, and 33 had remote symptomatic seizures. Among the surviving patients, 112 (64 percent) had been seizure-free for at least five years, including 83 (47 percent) who were not taking antiepileptic medications. The most important predictors of being seizure-free for at least five years were a rapid response to therapy (defined as a reduction in the frequency of seizures of 75 to 100 percent within three months of beginning treatment) and a diagnosis of idiopathic seizures. As compared with a matched control group, 99 patients with epilepsy but no other initial neurologic impairment were of similar socioeconomic status and had similar rates of passing an examination given after 12 years of school. Significantly more patients, however, had completed only six years of school (relative risk, 2.13), were unemployed (relative risk, 3.76), were not married (relative risk, 3.50), and did not have children (relative risk, 3.00). Conclusions Although the majority of patients with epilepsy in childhood are free of seizures by the time they become adults, they are at increased risk for social and educational problems. Patients whose epilepsy does not remit also have an increased risk of death. (C) 1998, Massachusetts Medical Society.	Univ Turku, Dept Pediat Neurol, Turku, Finland; Univ Turku, Dept Biostat, Turku, Finland; Montefiore Med Ctr, Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA; Montefiore Med Ctr, Albert Einstein Coll Med, Comprehens Epilepsy Management Ctr, Bronx, NY 10467 USA	University of Turku; University of Turku; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Sillanpaa, M (corresponding author), Turku Univ Hosp TYKS, Dept Child Neurol, FIN-20520 Turku, Finland.		Sillanpaa, Matti L/G-4708-2015	Sillanpaa, Matti L/0000-0003-4190-3698	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026151] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26151] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1993, EPILEPSIA, V34, P592; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BAX M C, 1964, Dev Med Child Neurol, V6, P295; BEGHI E, 1988, EPILEPSIA, V29, P236, DOI 10.1111/j.1528-1157.1988.tb03712.x; Berg A T, 1995, CHILDHOOD SEIZURES, P1; Berg AT, 1996, EPILEPSIA, V37, P24, DOI 10.1111/j.1528-1157.1996.tb00507.x; BERG AT, 1995, EPILEPSIA, V36, P3; BERG AT, 1995, CHILDHOOD SEIZURES, P93; BRORSON LO, 1987, EPILEPSIA, V28, P324, DOI 10.1111/j.1528-1157.1987.tb03651.x; CALLAGHAN N, 1992, IRISH MED J, V85, P17; CAMFIELD C, 1993, J PEDIATR-US, V122, P861, DOI 10.1016/S0022-3476(09)90008-7; CAMFIELD C, 1993, J PEDIATR-US, V122, P869, DOI 10.1016/S0022-3476(09)90009-9; Camfield CS, 1996, EPILEPSIA, V37, P19, DOI 10.1111/j.1528-1157.1996.tb00506.x; CARLTONFORD S, 1995, J HEALTH SOC BEHAV, V36, P285, DOI 10.2307/2137344; *CENTR STAT OFF, 1989, CLASS SOC GROUPS; COCKERELL OC, 1995, LANCET, V346, P140, DOI 10.1016/S0140-6736(95)91208-8; COX DR, 1972, J R STAT SOC B, V34, P187; Derby LE, 1996, EPILEPSIA, V37, P931, DOI 10.1111/j.1528-1157.1996.tb00529.x; Dichter MA, 1996, NEW ENGL J MED, V334, P1583, DOI 10.1056/NEJM199606133342407; Dixon W.J, 1990, BMDP STAT SOFTWARE; Elandt-Johnson RC, 1980, SURVIVAL MODELS DATA, P150; ELWES RDC, 1984, NEW ENGL J MED, V311, P944, DOI 10.1056/NEJM198410113111503; Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; Hauser W, 1990, EPILEPSY FREQUENCY C; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1980, EPILEPSIA, V21, P399, DOI 10.1111/j.1528-1157.1980.tb04088.x; HUTTENLOCHER PR, 1990, ANN NEUROL, V28, P699, DOI 10.1002/ana.410280516; Jacoby A, 1996, EPILEPSIA, V37, P148, DOI 10.1111/j.1528-1157.1996.tb00006.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELSEY JL, 1986, METHODS OBSERVATIONA; LATHERS CM, 1990, EPILEPSY SUDDEN DEAT; LEESTMA JE, 1989, ANN NEUROL, V26, P195, DOI 10.1002/ana.410260203; MITCHELL WG, 1991, J CHILD NEUROL, V6, P65, DOI 10.1177/088307389100600114; NASHEF L, 1995, EPILEPSIA, V36, P1187, DOI 10.1111/j.1528-1157.1995.tb01061.x; OLSSON I, 1993, EPILEPSIA, V34, P846, DOI 10.1111/j.1528-1157.1993.tb02101.x; OUNSTED C, 1987, 103 CLIN DEV MED; SCHUPF N, 1994, EPILEPSIA, V35, P750, DOI 10.1111/j.1528-1157.1994.tb02506.x; Shinnar S, 1996, EPILEPSIA, V37, P701, DOI 10.1111/j.1528-1157.1996.tb00639.x; Sillanpaa M., 1973, ACTA PAEDIATR SC   S, V237, P1; SOFIJANOV NG, 1982, EPILEPSIA, V23, P61, DOI 10.1111/j.1528-1157.1982.tb05053.x; TENNIS P, 1995, EPILEPSIA, V36, P29, DOI 10.1111/j.1528-1157.1995.tb01661.x; WESTBROOK LE, 1991, J EPILEPSY, V4, P87, DOI 10.1016/S0896-6974(05)80066-0; World Health Organization, 1980, INT CLASS IMP DIS HA	45	497	503	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1998	338	24					1715	1722		10.1056/NEJM199806113382402	http://dx.doi.org/10.1056/NEJM199806113382402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT654	9624191	Bronze			2022-12-24	WOS:000074109800002
J	Agmon-Snir, H; Carr, CE; Rinzel, J				Agmon-Snir, H; Carr, CE; Rinzel, J			The role of dendrites in auditory coincidence detection	NATURE			English	Article							INTERAURAL TIME DIFFERENCES; MEDIAL SUPERIOR OLIVE; COCHLEAR NUCLEUS; BRAIN-STEM; NEURONS; CELLS; INFORMATION; MODEL; INTERNEURONS; INTEGRATION	Coincidence-detector neurons in the auditory brainstem of mammals and birds use interaural time differences to localize sounds(1,2). Each neuron receives many narrow-band inputs from both ears and compares the time of arrival of the inputs with an accuracy of 10-100 mu s (refs 3-6). Neurons that receive low-frequency auditory inputs (up to about 2 kHz) have bipolar dendrites, and each dendrite receives inputs from only one ear(7,8). Using a simple model that mimics the essence of the known electrophysiology and geometry of these cells, we show here that dendrites improve the coincidence-detection properties of the cells. The biophysical mechanism for this improvement is based on the nonlinear summation of excitatory inputs in each of the dendrites and the use of each dendrite as a current sink for inputs to the other dendrite. This is a rare casein which the contribution of dendrites to the known computation of a neuron may be understood. Our results show that, in these neurons, the cell morphology and the spatial distribution of the inputs enrich the computational power of these neurons beyond that expected from 'point neurons' (model neurons lacking dendrites).	Univ Maryland, Dept Zool, College Pk, MD 20742 USA; NIDDK, Math Res Branch, NIH, Bethesda, MD 20892 USA	University System of Maryland; University of Maryland College Park; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Carr, CE (corresponding author), Univ Maryland, Dept Zool, College Pk, MD 20742 USA.	carr@zool.umd.edu						Agmon-Snir H., 1996, Society for Neuroscience Abstracts, V22, P402; BORST A, 1994, TRENDS NEUROSCI, V17, P257, DOI 10.1016/0166-2236(94)90009-4; Borst A, 1996, ACTA PHYSIOL SCAND, V157, P403, DOI 10.1046/j.1365-201X.1996.30250000.x; Brughera AR, 1996, AUDIT NEUROSCI, V2, P219; CARR CE, 1993, ANNU REV NEUROSCI, V16, P223, DOI 10.1146/annurev.ne.16.030193.001255; CARR CE, 1990, J NEUROSCI, V10, P3227; COLBURN HS, 1990, HEARING RES, V49, P335, DOI 10.1016/0378-5955(90)90112-3; Gerstner W, 1996, NATURE, V383, P76, DOI 10.1038/383076a0; GOLDBERG JM, 1969, J NEUROPHYSIOL, V32, P613, DOI 10.1152/jn.1969.32.4.613; Haag J, 1996, NATURE, V379, P639, DOI 10.1038/379639a0; JEFFRESS LA, 1948, J COMP PHYSIOL PSYCH, V41, P35, DOI 10.1037/h0061495; Mainen ZF, 1996, NATURE, V382, P363, DOI 10.1038/382363a0; MANIS PB, 1991, J NEUROSCI, V11, P2865; MEL BW, 1994, NEURAL COMPUT, V6, P1031, DOI 10.1162/neco.1994.6.6.1031; MORRIS C, 1981, BIOPHYS J, V35, P193, DOI 10.1016/S0006-3495(81)84782-0; OVERHOLT EM, 1992, J NEUROSCI, V12, P1698; PARKS TN, 1978, J COMP NEUROL, V180, P439, DOI 10.1002/cne.901800303; Pinsky P F, 1994, J Comput Neurosci, V1, P39, DOI 10.1007/BF00962717; REYES AD, 1994, J NEUROSCI, V14, P5352; Reyes AD, 1996, J NEUROSCI, V16, P993; Rinzel J., 1989, METHODS NEURONAL MOD, P135; SEGEV I, 1995, HDB BRAIN THEORY NEU, P282; Shepherd G.M., 1995, THEORETICAL FDN DEND; SMITH DJ, 1979, J COMP NEUROL, V186, P213, DOI 10.1002/cne.901860207; SMITH PH, 1995, J NEUROPHYSIOL, V73, P1653, DOI 10.1152/jn.1995.73.4.1653; SOFTKY WR, 1993, J NEUROSCI, V13, P334; STOTLER WA, 1953, J COMP NEUROL, V98, P401, DOI 10.1002/cne.900980303; WARCHOL ME, 1990, J COMP PHYSIOL A, V166, P721; YIN TCT, 1990, J NEUROPHYSIOL, V64, P465, DOI 10.1152/jn.1990.64.2.465; ZHANG S, 1994, J NEUROPHYSIOL, V72, P705, DOI 10.1152/jn.1994.72.2.705	30	268	271	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					268	272		10.1038/30505	http://dx.doi.org/10.1038/30505			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607764				2022-12-24	WOS:000073761000054
J	Pellegrino, ED				Pellegrino, ED			Emerging ethical issues in palliative care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Georgetown Univ, Med Ctr, Ctr Clin Bioeth, Washington, DC 20007 USA	Georgetown University	Pellegrino, ED (corresponding author), Georgetown Univ, Med Ctr, Ctr Clin Bioeth, 4000 Reservior Rd NW,Room D-238, Washington, DC 20007 USA.							ASHLEY BM, 1989, HLTH CARE ETHICS, P184; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Canadian Palliative Care Association, 1995, PALL CAR CONS STAND; CLARK D, 1993, FUTURE PALLIATIVE CA; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FOLEY KM, 1993, OPIOIDS, V2, P697; Glick SM, 1997, NEW ENGL J MED, V336, P954, DOI 10.1056/NEJM199703273361312; GREGORY J, 1772, DUTIES OFFICES PHYSI; HIGGINSON I, 1993, J PUBLIC HEALTH MED, V15, P3, DOI 10.1093/oxfordjournals.pubmed.a042817; HIPPOCRATES, 1972, JOINTS 8, V2, P299; Hippocrates, 1923, ART HIPPOCRATES, V2, P193; Kaldjian LC, 1998, AIDS, V12, P103, DOI 10.1097/00002030-199801000-00012; Limbird, 1996, GOODMAN GILMANS PHAR, P557; Lynn J, 1997, New Horiz, V5, P56; Nash A, 1989, Prof Nurse, V4, P443; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; PELLEGRINO ED, 1981, PHILOS BASIS MED PRA, P223; PIUS XII, 1957, ALLOCUTIO ACTA APOST, V49, P129; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; RANDALL F, 1996, PALLIATIVE CARE ETHI; Sulmasy DP, 1996, CLIN PULM MED, V3, P86; SURBONE A, 1997, COMMUNICATION CANC P; WOODRUFF R, 1993, PALLIATIVE MED SYMPT	23	34	36	2	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1521	1522		10.1001/jama.279.19.1521	http://dx.doi.org/10.1001/jama.279.19.1521			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN087	9605885				2022-12-24	WOS:000073608100013
J	Dodwell, DJ				Dodwell, DJ			Adjuvant cytotoxic chemotherapy for early breast cancer: doubts and decisions	LANCET			English	Editorial Material							BENEFIT		Cookridge Hosp, York Ctr Clin Oncol, Leeds LS16 6QB, W Yorkshire, England; Leeds Gen Infirm, Breast Unit, Leeds, W Yorkshire, England	Cookridge Hospital; Leeds General Infirmary; University of Leeds	Dodwell, DJ (corresponding author), Cookridge Hosp, York Ctr Clin Oncol, Leeds LS16 6QB, W Yorkshire, England.							ABE O, 1992, LANCET, V339, P71; COATES AS, 1992, INTRO NEW TREATMENTS, P448; *EARL BREAST CANC, 1992, LANCET, V339, P1; FETTING JH, 1990, J CLIN ONCOL, V8, P1476, DOI 10.1200/JCO.1990.8.9.1476; Fisher B, 1997, JNCI-J NATL CANCER I, V89, P1673, DOI 10.1093/jnci/89.22.1673; Gelber RD, 1996, LANCET, V347, P1066, DOI 10.1016/S0140-6736(96)90277-9; Hurny C, 1996, LANCET, V347, P1279; LINDLEY CM, 1995, P AN M AM SOC CLIN, V14, P149; MACKILLOP WJ, 1988, BRIT J CANCER, V58, P355, DOI 10.1038/bjc.1988.218; McNeil C, 1997, J NATL CANCER I, V89, P838; RAJAGOPAL S, 1994, J CLIN ONCOL, V12, P1296, DOI 10.1200/JCO.1994.12.6.1296; RICHARDS MA, 1995, EUR J CANCER, V31A, P112, DOI 10.1016/0959-8049(94)00478-N; SAINSBURY R, 1995, BRIT J CANCER, V71, P1275, DOI 10.1038/bjc.1995.246; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458	14	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1506	1507		10.1016/S0140-6736(97)11247-8	http://dx.doi.org/10.1016/S0140-6736(97)11247-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605820				2022-12-24	WOS:000073707300043
J	Veit, B; Briggs, SP; Schmidt, RJ; Yanofsky, MF; Hake, S				Veit, B; Briggs, SP; Schmidt, RJ; Yanofsky, MF; Hake, S			Regulation of leaf initiation by the terminal ear 1 gene of maize	NATURE			English	Article							CELL-LINEAGE PATTERNS; SHOOT APICAL MERISTEM; EXPRESSION; PROTEINS; MEIOSIS	Higher plants elaborate much of their architecture post-embryonically through development initiated at the tips of shoots(1,2) During vegetative growth, leaf primordia arise at predictable sires to give characteristic leaf arrangements, or phyllotaxies(3,4). How these sites are determined is a long-standing question(5,6) that bears on the nature of pattern-formation mechanisms in plants, Fate-mapping studies in several species indicate that each leaf primordium becomes organized from a group of 100-200 cells on the flank of the shoot apes'. Although molecular studies indicate that the regulated expression of specific homeobox genes plays some part in this determination process(8-11), mechanisms that regulate the timing and position of leaf initiation are less well understood. Here we describe a gene from maize, terminal ear 1. Patterns of expression of this gene in the shoot and phenotypes of mutants indicate a role for terminal ear 1 in regulating leaf initiation. The te1 gene product contains conserved RNA-binding motifs, indicating that it may function through an RNA-binding activity.	Massey Univ, Inst Mol Biosci, Palmerston North, New Zealand; Univ Calif Berkeley, USDA, Ctr Plant Gene Express, Albany, CA 94710 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Pioneer Hi Bred Int Inc, Johnston, IA 50131 USA	Massey University; United States Department of Agriculture (USDA); University of California System; University of California Berkeley; University of California System; University of California San Diego; DuPont; Pioneer Hi-Bred International, Inc.	Veit, B (corresponding author), Massey Univ, Inst Mol Biosci, Palmerston North, New Zealand.							BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHANDLER VL, 1992, ADV GENET, V30, P77, DOI 10.1016/S0065-2660(08)60319-3; CHURCH AH, 1904, RELATION PHYLLOTAXY; Doebley J, 1997, NATURE, V386, P485, DOI 10.1038/386485a0; ITIS H, 1983, SCIENCE, V222, P886; JACKSON D, 1994, DEVELOPMENT, V120, P405; KIESSELBACH TA, 1949, STRUCTURE REPRODUCTI; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; MATTHEWS DL, 1974, J AGR SCI-CAMBRIDGE, V82, P433, DOI 10.1017/S0021859600051327; MCDANIEL CN, 1988, PLANTA, V175, P13, DOI 10.1007/BF00402877; POETHIG RS, 1987, AM J BOT, V74, P581, DOI 10.2307/2443838; RICHARDS FJ, 1951, PHILOS T ROY SOC B, V235, P509, DOI 10.1098/rstb.1951.0007; Scanlon MJ, 1996, DEVELOPMENT, V122, P1683; SMITH LG, 1992, PLANT CELL, V4, P1017, DOI 10.1105/tpc.4.9.1017; SMITH LG, 1992, DEVELOPMENT, V116, P21; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; SUSSEX IM, 1989, CELL, V56, P225, DOI 10.1016/0092-8674(89)90895-7; WALBOT V, 1985, TRENDS GENET, V1, P165, DOI 10.1016/0168-9525(85)90071-X; WATANABE Y, 1994, CELL, V78, P487, DOI 10.1016/0092-8674(94)90426-X; WATANABE Y, 1988, EMBO J, V7, P761, DOI 10.1002/j.1460-2075.1988.tb02873.x; Watanabe Y, 1997, NATURE, V386, P187, DOI 10.1038/386187a0	23	105	118	2	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1998	393	6681					166	168		10.1038/30239	http://dx.doi.org/10.1038/30239			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN200	9603518				2022-12-24	WOS:000073619900047
J	Stanley, CA; Lieu, YK; Hsu, BYL; Burlina, AB; Greenberg, CR; Hopwood, NJ; Perlman, K; Rich, BH; Zammarchi, E; Poncz, M				Stanley, CA; Lieu, YK; Hsu, BYL; Burlina, AB; Greenberg, CR; Hopwood, NJ; Perlman, K; Rich, BH; Zammarchi, E; Poncz, M			Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SULFONYLUREA RECEPTOR GENE; INSULIN RELEASE; AMINO-ACID; HYPOGLYCEMIA; LEUCINE; ORGANIZATION; SITE	Background A new form of congenital hyperinsulinism characterized by hypoglycemia and hyperammonemia was described recently. We hypothesized that this syndrome of hyperinsulinism and hyperammonemia was caused by excessive activity of glutamate dehydrogenase, which oxidizes glutamate to alpha-ketoglutarate and which is a potential regulator of insulin secretion in pancreatic beta cells and of ureagenesis in the liver. Methods We measured glutamate dehydrogenase activity in lymphoblasts from eight unrelated children with the hyperinsulinism-hyperammonemia syndrome: six with sporadic cases and two with familial cases. We identified mutations in the glutamate dehydrogenase gene by sequencing glutamate dehydrogenase complementary DNA prepared from lymphoblast messenger RNA. Site-directed mutagenesis was used to express the mutations in COS-7 cells. Results The sensitivity of glutamate dehydrogenase to inhibition by guanosine 5'-triphosphate was a quarter of the normal level in the patients with sporadic hyperinsulinism-hyperammonemia syndrome and half the normal level in patients with familiar cases and their affected relatives, findings consistent with overactivity of the enzyme. These differences in enzyme insensitivity correlated with differences in the severity of hypoglycemia in the two groups. All eight children were heterozygous for the wild-type allele and had a mutation in the proposed allosteric domain of the enzyme. Four different mutations were identified in the six patients with sporadic cases; the two patients with familiar cases shared a fifth mutation. In two clones of COS-7 cells transfected with the mutant sequence from one patient, the sensitivity of the enzyme to guanosine 5'-triphosphate was reduced, findings similar to those in the child's lymphoblasts. Conclusions The hyperinsulinism-hyperammonemia syndrome is caused by mutations in the glutamate dehydrogenase gene that impair the control of enzyme activity. (C)1998, Massachusetts Medical Society.	Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Endocrinol, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Hematol, Philadelphia, PA 19104 USA; Univ Padua, Dept Pediat, Padua, Italy; Univ Manitoba, Dept Pediat & Child Hlth, Sect Genet & Metab, Winnipeg, MB R3T 2N2, Canada; Univ Michigan, CS Mott Childrens Hosp, Sch Med, Div Endocrinol, Ann Arbor, MI USA; Univ Toronto, Hosp Sick Children, Sch Med, Div Endocrinol, Toronto, ON M5G 1X8, Canada; Univ Chicago, Chicago Childrens Hosp, Pritzker Sch Med, Endocrinol Sect, Chicago, IL 60637 USA; Univ Florence, Dept Pediat, Florence, Italy	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Padua; University of Manitoba; University of Michigan System; University of Michigan; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Chicago; University of Florence	Stanley, CA (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Endocrinol, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.		burlina, alberto/AHE-6095-2022	STANLEY, CHARLES/0000-0003-4881-9392	NCRR NIH HHS [RR-00240] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000240] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BRUNHUBER NMW, 1994, CRIT REV BIOCHEM MOL, V29, P415, DOI 10.3109/10409239409083486; BRUSILOW SW, 1995, METABOLIC BASIS INHE, V1, P1187; BRYLA J, 1994, METABOLISM, V43, P1187, DOI 10.1016/0026-0495(94)90064-7; Cho SW, 1996, BIOCHEMISTRY-US, V35, P13907, DOI 10.1021/bi9618575; COLMAN RF, 1991, STUDY ENZYMES, V2, P173; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; FAHIEN LA, 1981, ARCH BIOCHEM BIOPHYS, V212, P247, DOI 10.1016/0003-9861(81)90364-7; Glaser B, 1998, NEW ENGL J MED, V338, P226, DOI 10.1056/NEJM199801223380404; GYLFE E, 1976, ACTA DIABETOL LAT, V13, P20, DOI 10.1007/BF02591577; Kukuvitis A, 1997, J CLIN ENDOCR METAB, V82, P1192, DOI 10.1210/jc.82.4.1192; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSCHINSKY FM, 1996, DIABETES REV, V4, P130; MICHAELIDIS TM, 1993, GENOMICS, V16, P150, DOI 10.1006/geno.1993.1152; NAKATANI Y, 1988, NUCLEIC ACIDS RES, V16, P6237, DOI 10.1093/nar/16.13.6237; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; PERMUTT MA, 1996, DIABETES REV, V4, P347; Plaitakis A, 1993, Can J Neurol Sci, V20 Suppl 3, pS109; SENER A, 1980, NATURE, V288, P187, DOI 10.1038/288187a0; SENER A, 1981, P NATL ACAD SCI-BIOL, V78, P5460, DOI 10.1073/pnas.78.9.5460; Stanley CA, 1997, PEDIATR CLIN N AM, V44, P363, DOI 10.1016/S0031-3955(05)70481-8; STEWART PM, 1980, J BIOL CHEM, V255, P5270; TELLER JK, 1995, BBA-PROTEIN STRUCT M, V1247, P231, DOI 10.1016/0167-4838(94)00240-H; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; THORNTON PS, 1991, J PEDIATR-US, V119, P721, DOI 10.1016/S0022-3476(05)80286-0; Thornton PS, 1998, J PEDIATR-US, V132, P9, DOI 10.1016/S0022-3476(98)70477-9; Weinzimer SA, 1997, J PEDIATR-US, V130, P661, DOI 10.1016/S0022-3476(97)70256-7; WRZESZCZYNSKI KO, 1994, BIOCHEMISTRY-US, V33, P11544, DOI 10.1021/bi00204a017; Zammarchi E, 1996, METABOLISM, V45, P957, DOI 10.1016/S0026-0495(96)90262-0	30	517	543	1	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1998	338	19					1352	1357		10.1056/NEJM199805073381904	http://dx.doi.org/10.1056/NEJM199805073381904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL720	9571255				2022-12-24	WOS:000073463700004
J	Alroy, J				Alroy, J			Cope's rule and the dynamics of body mass evolution in North American fossil mammals	SCIENCE			English	Article							ISLAND RULE; SIZE; PHYLOGENY; TRENDS; RECORD	Body mass estimates for 1534 North American fossil mammal species show that new species are on average 9.1% larger than older species in the same genera. This within-lineage effect is not a sampling bias. It persists throughout the Cenozoic; accounting for the gradual overall increase in average mass (Cope's rule). The effect is stronger for larger mammals, being near zero for small mammals. This variation partially explains the unwavering lower size limit and the gradually expanding mid-sized gap, but not the sudden large increase in the upper size limit, at the Cretaceous-Tertiary boundary.	Smithsonian Inst, Dept Paleobiol, Washington, DC 20560 USA	Smithsonian Institution; Smithsonian National Museum of Natural History	Alroy, J (corresponding author), Smithsonian Inst, Dept Paleobiol, MRC 121, Washington, DC 20560 USA.		Alroy, John/B-4585-2009	Alroy, John/0000-0002-9882-2111				ALROY J, 1994, PALEOBIOLOGY, V20, P191, DOI 10.1017/S0094837300012677; Alroy J, 1996, PALAEOGEOGR PALAEOCL, V127, P285, DOI 10.1016/S0031-0182(96)00100-9; ALROY J, 1992, PALEOBIOLOGY, V18, P326, DOI 10.1017/S0094837300010873; ARNOLD AJ, 1995, J PALEONTOL, V69, P203, DOI 10.1017/S0022336000034557; BROWN JH, 1991, AM NAT, V138, P1478, DOI 10.1086/285297; BROWN JH, 1986, NATURE, V324, P248, DOI 10.1038/324248a0; Brown JH, 1995, MACROECOLOGY; BROWN JH, 1993, AM NAT, V142, P574; Cope ED., 1887, ORIGIN FITTEST; DAMUTH J, 1993, NATURE, V365, P748, DOI 10.1038/365748a0; Damuth J., 1990, P229; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FISHER DC, 1994, INTERPRETING HIERARC, P133; Foote M, 1996, PALEOBIOLOGY, V22, P121, DOI 10.1017/S0094837300016134; Foote M, 1996, PALEOBIOLOGY, V22, P141, DOI 10.1017/S0094837300016146; GAUTHIER J, 1988, CLADISTICS, V4, P105, DOI 10.1111/j.1096-0031.1988.tb00514.x; Gingerich P.D., 1979, P41; GINGERICH PD, 1980, ANNU REV EARTH PL SC, V8, P407, DOI 10.1146/annurev.ea.08.050180.002203; GOULD SJ, 1988, J PALEONTOL, V62, P319, DOI 10.1017/S0022336000059126; Gunnell GF., 1989, U MICH PAP PALEONT, V27, P1; Gunnell Gregg F., 1996, Contributions from the Museum of Paleontology University of Michigan, V29, P413; Harvey P.H., 1991, COMP METHOD EVOLUTIO; Hitchin R, 1997, PALEOBIOLOGY, V23, P20, DOI 10.1017/S0094837300016626; Huelsenbeck JP, 1997, PALEOBIOLOGY, V23, P174, DOI 10.1017/S0094837300016778; HUELSENBECK JP, 1994, PALEOBIOLOGY, V20, P470, DOI 10.1017/S009483730001294X; Jablonski D, 1997, NATURE, V385, P250, DOI 10.1038/385250a0; Jablonski David, 1996, P256; KURTEN BJORN, 1953, ACTA ZOOL FENNICA, V76, P1; Legendre S., 1986, Palaeovertebrata (Montpellier), V16, P191; Legendre S., 1988, Historical Biology, V1, P85; LOMOLINO MV, 1985, AM NAT, V125, P310, DOI 10.1086/284343; MacFadden B.J., 1990, P337; MACFADDEN BJ, 1986, PALEOBIOLOGY, V12, P355, DOI 10.1017/S0094837300003109; Martins E.P., 1996, PHYLOGENIES COMP MET; MAURER BA, 1992, EVOLUTION, V46, P939, DOI 10.1111/j.1558-5646.1992.tb00611.x; McKinney M.L., 1990, P75; MCKINNEY ML, 1986, PALEOBIOLOGY, V12, P282, DOI 10.1017/S0094837300013786; McNamara K.J., 1990, P205; MCSHEA DW, 1994, EVOLUTION, V48, P1747, DOI 10.1111/j.1558-5646.1994.tb02211.x; Miles DB, 1996, EVOLUTION, V50, P594, DOI 10.1111/j.1558-5646.1996.tb03871.x; NEWELL ND, 1949, EVOLUTION, V3, P103, DOI 10.2307/2405545; NORRIS RD, 1991, PALEOBIOLOGY, V17, P388, DOI 10.1017/S0094837300010721; RUMMEL JD, 1985, EVOLUTION, V39, P1009, DOI 10.1111/j.1558-5646.1985.tb00444.x; STANLEY SM, 1973, EVOLUTION, V27, P1, DOI 10.1111/j.1558-5646.1973.tb05912.x; Trammer J, 1997, ACTA PALAEONTOL POL, V42, P1; WAGNER PJ, 1995, PALEOBIOLOGY, V21, P153, DOI 10.1017/S009483730001318X; WILSON EO, 1959, EVOLUTION, V13, P122, DOI 10.2307/2405948; WING SL, 1995, PALAEOGEOGR PALAEOCL, V115, P117, DOI 10.1016/0031-0182(94)00109-L	48	339	346	0	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					731	734		10.1126/science.280.5364.731	http://dx.doi.org/10.1126/science.280.5364.731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563948	Green Submitted			2022-12-24	WOS:000073415600046
J	Doll, JJ				Doll, JJ			The patenting of DNA	SCIENCE			English	Editorial Material									US Patent & Trademark Off, Technol Ctr 1600, Washington, DC 20231 USA		Doll, JJ (corresponding author), US Patent & Trademark Off, Technol Ctr 1600, Washington, DC 20231 USA.							COLLINS FS, 1997, SCIENCE, V278, P180	1	61	65	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					689	690		10.1126/science.280.5364.689	http://dx.doi.org/10.1126/science.280.5364.689			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9599146				2022-12-24	WOS:000073415600030
J	Faundez, V; Horng, JT; Kelly, RB				Faundez, V; Horng, JT; Kelly, RB			A function for the AP3 coat complex in synaptic vesicle formation from endosomes	CELL			English	Article							GUINEA-PIG MEGAKARYOCYTE; ADP-RIBOSYLATION FACTOR; TRANSPORT VESICLES; GOLGI MEMBRANES; ENDOPLASMIC-RETICULUM; BREFELDIN-A; DEPENDENT FORMATION; GUANINE-NUCLEOTIDE; ARF PROTEIN; CLATHRIN	Synaptic vesicles can be coated in vitro in a reaction that is ARF-, ATP-, and temperature-dependent and requires synaptic vesicle membrane proteins. The coat is largely made up of the heterotetrameric complex, adaptor protein 3, recently implicated in Golgi-to-vacuole traffic in yeast. Depletion of AP3 from brain cytosol inhibits small vesicle formation from PC12 endosomes in vitro. Budding from washed membranes can be reconstituted with purified AP3 and recombinant ARF1. We conclude that AP3 coating is involved in at least one pathway of small vesicle formation from endosomes.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kelly, RB (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.		Faundez, Victor/H-5539-2012	Faundez, Victor/0000-0002-2114-5271	NIDA NIH HHS [DA10154] Funding Source: Medline; NINDS NIH HHS [NS09878, NS15927] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015927, R01NS009878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010154] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; DELLANGELICA EC, 1998, IN PRESS SCIENCE; DESNOS C, 1995, J CELL BIOL, V130, P1041, DOI 10.1083/jcb.130.5.1041; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Erickson RP, 1997, P NATL ACAD SCI USA, V94, P8924, DOI 10.1073/pnas.94.17.8924; Estes PS, 1996, J NEUROSCI, V16, P5443; FAUNDEZ V, 1992, J BIOL CHEM, V267, P20363; Faundez V, 1997, J CELL BIOL, V138, P505, DOI 10.1083/jcb.138.3.505; FRANCO M, 1993, J BIOL CHEM, V268, P24531; GonzalezGaitan M, 1997, CELL, V88, P767, DOI 10.1016/S0092-8674(00)81923-6; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; HANDAGAMA P, 1993, J CLIN INVEST, V91, P193, DOI 10.1172/JCI116170; HANDAGAMA PJ, 1989, J CLIN INVEST, V84, P73, DOI 10.1172/JCI114173; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Koenig JH, 1996, J CELL BIOL, V135, P797, DOI 10.1083/jcb.135.3.797; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LEPOOLE IC, 1993, EXP CELL RES, V205, P388, DOI 10.1006/excr.1993.1102; LERNER AB, 1979, COLD SPRING HARBOR C, V6, P187; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; NOEBELS JL, 1989, J NEUROGENET, V6, P53, DOI 10.3109/01677068909107100; OKA T, 1994, J CELL BIOL, V124, P25; Ooi CE, 1997, EMBO J, V16, P4508; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PEVSNER J, 1994, GENE, V146, P279, DOI 10.1016/0378-1119(94)90306-9; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHRAERMEYER U, 1994, CELL TISSUE RES, V276, P273, DOI 10.1007/BF00306113; Seymour A. B., 1997, Molecular Biology of the Cell, V8, p227A; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; VANDEGOOR J, 1995, P NATL ACAD SCI USA, V92, P5739, DOI 10.1073/pnas.92.12.5739; WAGNER JA, 1978, BIOCHEMISTRY-US, V17, P1199, DOI 10.1021/bi00600a010; WHITNEY JA, 1995, CELL, V83, P703; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	60	239	244	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 1	1998	93	3					423	432		10.1016/S0092-8674(00)81170-8	http://dx.doi.org/10.1016/S0092-8674(00)81170-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590176	Bronze			2022-12-24	WOS:000073471500017
J	Rodig, SJ; Meraz, MA; White, JM; Lampe, PA; Riley, JK; Arthur, CD; King, KL; Sheehan, KCF; Yin, L; Pennica, D; Johnson, EM; Schreiber, RD				Rodig, SJ; Meraz, MA; White, JM; Lampe, PA; Riley, JK; Arthur, CD; King, KL; Sheehan, KCF; Yin, L; Pennica, D; Johnson, EM; Schreiber, RD			Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the jaks in cytokine-lnduced biologic responses	CELL			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION PATHWAY; LEUKEMIA INHIBITORY FACTOR; MICE LACKING JAK3; TARGETED DISRUPTION; INTERFERON-GAMMA; LYMPHOID DEVELOPMENT; INTERLEUKIN-6 FAMILY; CYTOPLASMIC DOMAIN; FACTOR-RECEPTOR	Herein we report the generation of mice lacking the ubiquitously expressed Janus kinase, Jak1. Jak1(-/-) mice are runted at birth, fail to nurse, and die perinatally. Although Jak1(-/-) cells are responsive to many cytokines, they fail to manifest biologic responses to cytokines that bind to three distinct families of cytokine receptors. These include all class II cytokine receptors, cytokine receptors that utilize the gamma(c) subunit for signaling, and the family of cytokine receptors that depend on the gp130 subunit for signaling. Our results thus demonstrate that Jak1 plays an essential and nonredundant role in promoting biologic responses induced by a select subset of cytokine receptors, including those in which Jak utilization was thought to be nonspecific.	Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Chem, S San Francisco, CA 94080 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Roche Holding; Genentech; Roche Holding; Genentech	Schreiber, RD (corresponding author), Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA.		Schreiber, Robert D/A-1276-2013; MERAZ RIOS, MARCO ANTONIO/F-4194-2016; Lampe, Patricia/AAH-9545-2020; Rodig, Scott/Y-3889-2019; Schreiber, Robert/Q-7550-2019	Schreiber, Robert D/0000-0001-6311-0432; MERAZ RIOS, MARCO ANTONIO/0000-0001-6748-8117; White, James Michael/0000-0001-5110-6567; Schreiber, Robert/0000-0003-1590-2341	NATIONAL CANCER INSTITUTE [R37CA043059, R01CA043059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG012947] Funding Source: NIH RePORTER; NCI NIH HHS [CA43059] Funding Source: Medline; NIA NIH HHS [AG12947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DIGHE AS, 1995, IMMUNITY, V3, P657, DOI 10.1016/1074-7613(95)90136-1; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRIBAUDO G, 1985, J BIOL CHEM, V260, P9936; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HO ASY, 1995, MOL CELL BIOL, V15, P5043; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; King KL, 1996, ENDOCRINE, V5, P85, DOI 10.1007/BF02738660; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kouro T, 1996, INT IMMUNOL, V8, P237, DOI 10.1093/intimm/8.2.237; Leonard WJ, 1995, IMMUNOL REV, V148, P97, DOI 10.1111/j.1600-065X.1995.tb00095.x; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SUDA T, 1989, BLOOD, V74, P1936; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WARE CB, 1995, DEVELOPMENT, V121, P1283; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	37	630	737	1	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 1	1998	93	3					373	383		10.1016/S0092-8674(00)81166-6	http://dx.doi.org/10.1016/S0092-8674(00)81166-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590172	Bronze			2022-12-24	WOS:000073471500013
J	Eberstadt, M; Huang, BH; Chen, ZH; Meadows, RP; Ng, SC; Zheng, LX; Lenardo, MJ; Fesik, SW				Eberstadt, M; Huang, BH; Chen, ZH; Meadows, RP; Ng, SC; Zheng, LX; Lenardo, MJ; Fesik, SW			NMR structure and mutagenesis of the FADD (Mort1) death-effector domain	NATURE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CELL-DEATH; PROTEINS; PROTEASE; FAS; INTERACTS; C-13	When activated, membrane-bound receptors for Fas and tumour-necrosis factor initiate programmed cell death by recruiting the death domain of the adaptor protein FADD(1) (Mort1; ref, 2) to the membrane. FADD then activates caspase 8 (ref. 3) (also known as FLICE4 or MACH(5)) through an interaction between the death-effector domains of FADD and caspase 8. This ultimately leads to the apoptotic response. Death-effector domains and homologous protein modules known as caspase-recruitment domains(6) have been found in several proteins(1-14) and are important regulators of caspase (FLICE) activity and of apoptosis. Here we describe the solution structure of a soluble, biologically active mutant of the FADD death-effector domain. The structure consists of six antiparallel, amphipathic alpha-helices and resembles the overall fold of the death domains of Fas(15) and p75 (ref. 16). Despite this structural similarity, mutations that inhibit protein-protein interactions involving the Fas death domain have no effect when introduced into the FADD death-effector domain. Instead, a hydrophobic region of the FADD death-effector domain that is not present in the death domains is vital for binding to FLICE and for apoptotic activity.	Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA; NIH, Immunol Lab, Bethesda, MD 20892 USA	Abbott Laboratories; National Institutes of Health (NIH) - USA	Fesik, SW (corresponding author), Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRUNGER AT, 1992, XPLOR 3 2 MANUAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Eberstadt M, 1997, NAT STRUCT BIOL, V4, P983, DOI 10.1038/nsb1297-983; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Keane MM, 1996, CANCER RES, V56, P4791; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; LOGAN TM, 1993, J BIOMOL NMR, V3, P225; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005	28	195	203	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					941	945		10.1038/31972	http://dx.doi.org/10.1038/31972			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582077				2022-12-24	WOS:000073359900054
J	Cebul, RD; Snow, RJ; Pine, R; Hertzer, NR; Norris, DG				Cebul, RD; Snow, RJ; Pine, R; Hertzer, NR; Norris, DG			Indications, outcomes, and provider volumes for carotid endarterectomy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AD-HOC-COMMITTEE; VASCULAR-SURGERY; OPERATIONS; EXPERIENCE; GUIDELINES; MORTALITY; SPECIALTY; STENOSIS; PERFECT; STROKE	Context.-While trials have demonstrated that carotid endarterectomy is superior to best medical therapy, most recently among asymptomatic patients, uses and outcomes of the procedure in more representative settings have not been established. Objectives.-To profile the use and outcomes of carotid endarterectomy in a representative sample of Ohio's Medicare beneficiaries and to examine the relationships between provider-specific procedural volumes and patient outcomes. Design.-Retrospective cohort using Medicare Provider Analysis and Review files supplemented by detailed reviews of medical records on a random sample of patients. Setting.-Ohio hospitals performing carotid endarterectomy. Patients.-A random sample of 678 charts of the 4120 non-health maintenance organization Medicare beneficiaries who underwent carotid endarterectomy between July 1, 1993, and June 30, 1994. Main Outcome Measures.-Nonfatal stroke or death within 30 days of surgery. Results.-The reviewed patients were similar to all eligible patients in sociodemographic characteristics and 30-day mortality rates. Among the 678 patients, indications for surgery were asymptomatic carotid stenosis in 167 (24.6%), transient ischemic attack in 294 (43.4%), completed stroke in 62 (9.1%), and nonspecific symptoms in 155 (22.9%), Thirty-two patients (4.7%) died or suffered nonfatal strokes by 30 days postoperatively. In univariate analyses, rates varied by hospital volume (P=.004) but not surgeons' volume (P=.47), although power to detect this difference was limited. Patients at higher- and lower-volume hospitals had similar indications and distributions of comorbidities. In analyses controlling for indications, comorbid conditions, and surgeon's volume, being operated on in a higher-volume hospital conferred a 71% reduction in risk for 30-day stroke or death (odds ratio, 0.29; 95% confidence interval, 0.12-0.69; P=.006). Conclusions.-Almost half (47.5%) of the carotid endarterectomies among Ohio's Medicare population are performed on persons who are asymptomatic or who have nonspecific symptoms. These results highlight the importance of identifying patients and providers having the most favorable outcome profiles. The higher rate of adverse outcomes observed in lower-volume hospitals deserves further investigation, as it does not appear to be due to differences in patient selection.	Case Western Reserve Univ, Metrohlth Med Ctr, Inst Publ Hlth Sci, Dept Epidemiol & Biostat, Cleveland, OH 44109 USA; Case Western Reserve Univ, Metrohlth Med Ctr, Inst Publ Hlth Sci, Dept Med, Cleveland, OH 44109 USA; Cleveland Clin Fdn, Dept Vasc Surg, Cleveland, OH 44106 USA; Peer Review Syst Inc, Westerville, OH USA	Case Western Reserve University; MetroHealth System; Case Western Reserve University; MetroHealth System; Cleveland Clinic Foundation	Cebul, RD (corresponding author), Case Western Reserve Univ, Metrohlth Med Ctr, Inst Publ Hlth Sci, Dept Epidemiol & Biostat, 2500 MetroHlth Dr,Room 220A, Cleveland, OH 44109 USA.	rdc@po.cwru.edu		Hertzer, Norman/0000-0002-9698-1776	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG010418] Funding Source: NIH RePORTER; AHRQ HHS [HS-00059-03] Funding Source: Medline; NIA NIH HHS [AG-10418-03] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARNETT HJM, 1991, STROKE, V22, P711, DOI 10.1161/01.STR.22.6.711; BARNETT HJM, 1995, NEW ENGL J MED, V332, P238, DOI 10.1056/NEJM199501263320408; Barnett HJM, 1996, NEUROLOGY, V46, P603, DOI 10.1212/WNL.46.3.603; BROTT T, 1984, STROKE, V15, P950, DOI 10.1161/01.STR.15.6.950; CEBUL RD, 1989, ANN INTERN MED, V111, P660, DOI 10.7326/0003-4819-111-8-660; CEBUL RD, 1993, QUAL REV B, P150; EASTON JD, 1977, STROKE, V8, P565, DOI 10.1161/01.STR.8.5.565; FISHER ES, 1989, AM J PUBLIC HEALTH, V79, P1617, DOI 10.2105/AJPH.79.12.1617; FLOOD AB, 1984, MED CARE, V22, P115, DOI 10.1097/00005650-198402000-00003; FLOOD AB, 1984, MED CARE, V22, P98, DOI 10.1097/00005650-198402000-00002; FRIEDMANN P, 1988, STROKE, V19, P1323, DOI 10.1161/01.STR.19.11.1323; HERTZER NR, 1995, J VASC SURG, V21, P6, DOI 10.1016/S0741-5214(95)70239-3; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; KEMPCZINSKI RF, 1986, J VASC SURG, V3, P911, DOI 10.1067/mva.1986.avs0030911; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; MATTOS MA, 1995, J VASC SURG, V21, P719, DOI 10.1016/S0741-5214(05)80003-5; MOORE WS, 1995, CIRCULATION, V91, P566, DOI 10.1161/01.CIR.91.2.566; MOORE WS, 1992, J VASC SURG, V15, P469, DOI 10.1016/0741-5214(92)90185-B; Moore WS, 1996, J VASC SURG, V23, P323, DOI 10.1016/S0741-5214(96)70277-X; RICHARDSON JD, 1989, J VASC SURG, V9, P65, DOI 10.1067/mva.1989.vs0090065; Ruby ST, 1996, ANN VASC SURG, V10, P22, DOI 10.1007/BF02002337; Sarasin FP, 1995, NEUROLOGY, V45, P2147, DOI 10.1212/WNL.45.12.2147; *SAS I INC, 1996, SAS COMP PROGR VERS; Segal H E, 1993, QRB Qual Rev Bull, V19, P152; SLAKENBORG GJ, 1997, ARCH NEUROL-CHICAGO, V54, P826; SLAVISH LG, 1984, STROKE, V15, P956, DOI 10.1161/01.STR.15.6.956; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TOOLE JF, 1989, STROKE, V20, P844; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WHITE LJ, 1989, ANN INTERN MED, V111, P675, DOI 10.7326/0003-4819-111-8-675	32	168	169	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 29	1998	279	16					1282	1287		10.1001/jama.279.16.1282	http://dx.doi.org/10.1001/jama.279.16.1282			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH270	9565009	Bronze			2022-12-24	WOS:000073090300034
J	Shmerling, D; Hegyi, I; Fischer, M; Blattler, T; Brandner, S; Gotz, J; Rulicke, T; Flechsig, E; Cozzio, A; von Mering, C; Hangartner, C; Aguzzi, A; Weissmann, C				Shmerling, D; Hegyi, I; Fischer, M; Blattler, T; Brandner, S; Gotz, J; Rulicke, T; Flechsig, E; Cozzio, A; von Mering, C; Hangartner, C; Aguzzi, A; Weissmann, C			Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions	CELL			English	Article							HUMAN PRION PROTEIN; TRANSGENIC MICE; SYNAPTIC TRANSMISSION; PURKINJE-CELLS; KNOCKOUT MICE; NULL MICE; WILD-TYPE; SCRAPIE; GENE; NEURODEGENERATION	The physiological role of prion protein (PrP) remains unknown. Mice devoid of PrP develop normally but are resistant to scrapie; introduction of a PrP transgene restores susceptibility to the disease. To identify the regions of PrP necessary for this activity, we prepared PrP knockout mice expressing PrPs with amino-proximal deletions. Surprisingly, PrP lacking residues 32-121 or 32-134, but not with shorter deletions, caused severe ataxia and neuronal death limited to the granular layer of the cerebellum as early as 1-3 months after birth. The defect was completely abolished by introducing one copy of a wild-type PrP gene. We speculate that these truncated PrPs may be nonfunctional and compete with some other molecule with a PrP-like function for a common ligand.	Univ Zurich, Inst Mol Biol, Abt 1, CH-8093 Zurich, Switzerland; Universitatsspital Zurich, Inst Neuropathol, CH-8091 Zurich, Switzerland; Universitatsspital Zurich, Biol Zent Lab, CH-8091 Zurich, Switzerland	University of Zurich	Weissmann, C (corresponding author), Univ Zurich, Inst Mol Biol, Abt 1, CH-8093 Zurich, Switzerland.		Götz, Jürgen/C-2448-2014; Aguzzi, Adriano/A-3351-2008; von Mering, Christian/B-3300-2008; Brandner, Sebastian/J-4562-2014	Götz, Jürgen/0000-0001-8501-7896; von Mering, Christian/0000-0001-7734-9102; Brandner, Sebastian/0000-0002-9821-0342; Aguzzi, Adriano/0000-0002-0344-6708				BARRY RA, 1988, J IMMUNOL, V140, P1188; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colling SB, 1996, NEUROSCI LETT, V209, P49, DOI 10.1016/0304-3940(96)12596-9; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; FISCHER M, 1995, RESTORATION SUSCEPTI; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HALTIA M, 1993, ACTA NEUROPATHOL, V85, P241; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; Herms JW, 1995, EUR J NEUROSCI, V7, P2508, DOI 10.1111/j.1460-9568.1995.tb01049.x; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; Lledo PM, 1996, P NATL ACAD SCI USA, V93, P2403, DOI 10.1073/pnas.93.6.2403; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; Martins VR, 1997, NAT MED, V3, P1376, DOI 10.1038/nm1297-1376; MCANDREW J, 1995, ENDOCRINOLOGY, V136, P4479, DOI 10.1210/en.136.10.4479; MCKUSICK VA, 1988, MENDELIAN INHERITANC; Muramoto T, 1997, NAT MED, V3, P750, DOI 10.1038/nm0797-750; Norman RM, 1940, BRAIN, V63, P365, DOI 10.1093/brain/63.4.365; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PASCUALCASTROVIEJO I, 1994, NEUROPEDIATRICS, V25, P183, DOI 10.1055/s-2008-1073020; PETTY KJ, 1996, CURRENT PROTOCOLS PR; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; SAKAGUCHI S, 1995, J VIROL, V69, P7586, DOI 10.1128/JVI.69.12.7586-7592.1995; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMSON JAV, 1994, LAB INVEST, V71, P680; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; Weissmann C, 1996, CURR BIOL, V6, P1359, DOI 10.1016/S0960-9822(96)00729-4; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; WHITTINGTON MA, 1995, NAT GENET, V9, P197, DOI 10.1038/ng0295-197; WILMUT I, 1991, J REPROD FERTIL, V92, P245, DOI 10.1530/jrf.0.0920245; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Yehiely F, 1997, NEUROBIOL DIS, V3, P339, DOI 10.1006/nbdi.1997.0130	45	424	430	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					203	214		10.1016/S0092-8674(00)81572-X	http://dx.doi.org/10.1016/S0092-8674(00)81572-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568713	Green Accepted, Bronze			2022-12-24	WOS:000073174000007
J	Xie, JY; McCobb, DP				Xie, JY; McCobb, DP			Control of alternative splicing of potassium channels by stress hormones	SCIENCE			English	Article							PITUITARY-ADRENOCORTICAL AXIS; ADRENAL CHROMAFFIN CELLS; EXPRESSION; GENE; IDENTIFICATION; DEXAMETHASONE; CLONING	Many molecular mechanisms for neural adaptation to stress remain unknown. Expression of alternative splice variants of Slo, a gene encoding calcium-and voltage-activated potassium channels, was measured in rat adrenal chromaffin tissue from normal and hypophysectomized animals. Hypophysectomy triggered an abrupt decrease in the proportion of Slo transcripts containing a "STREX" exon. The decrease was prevented by adrenocorticotropic hormone injections. In Xenopus oocytes, STREX variants produced channels with functional properties associated with enhanced repetitive firing Thus, the hormonal stress axis is likely to control the excitable properties of epinephrine-secreting cells by regulating alternative splicing of Slo messenger RNA.	Cornell Univ, Neurobiol & Behav Sect, Ithaca, NY 14853 USA	Cornell University	McCobb, DP (corresponding author), Cornell Univ, Neurobiol & Behav Sect, Seeley G Mudd Hall, Ithaca, NY 14853 USA.	dpm9@cornell.edu	Xie, Jiuyong/D-2899-2013	Xie, Jiuyong/0000-0003-2909-1033				ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; ATTARDI B, 1993, RECEPTOR CHANNEL, V1, P287; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CECCATELLI S, 1989, ACTA PHYSIOL SCAND, V137, P559, DOI 10.1111/j.1748-1716.1989.tb08800.x; Coupland RE., 1965, NATURAL HIST CHROMAF; DIVIACCO S, 1992, GENE, V122, P313, DOI 10.1016/0378-1119(92)90220-J; EBERT SN, 1994, J BIOL CHEM, V269, P20885; Ferrer J, 1996, DIABETOLOGIA, V39, P891, DOI 10.1007/BF00403907; Kraus JE, 1996, MOL BRAIN RES, V41, P97, DOI 10.1016/0169-328X(96)00072-1; LAKE RC, 1985, CATECHOLAMINES PSYCH; Levitan ES, 1996, NEUROPHARMACOLOGY, V35, P1001, DOI 10.1016/0028-3908(96)00095-0; Lingle C J, 1996, Ion Channels, V4, P261; McCobb D. P., 1997, Society for Neuroscience Abstracts, V23, P1477; MCCOBB DP, 1995, AM J PHYSIOL-HEART C, V269, pH767, DOI 10.1152/ajpheart.1995.269.3.H767; Nussdorfer GG, 1996, PHARMACOL REV, V48, P495; ROSS ME, 1990, J NEUROSCI, V10, P520; Saito M, 1997, J BIOL CHEM, V272, P11710, DOI 10.1074/jbc.272.18.11710; SOLARO CR, 1995, J NEUROSCI, V15, P6110; STACHOWIAK MK, 1988, MOL BRAIN RES, V3, P275, DOI 10.1016/0169-328X(88)90050-2; TAKIMOTO K, 1993, NEURON, V11, P359, DOI 10.1016/0896-6273(93)90191-S; TAKIMOTO K, 1994, CIRC RES, V75, P1; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; VISKUPIC E, 1994, J NEUROCHEM, V63, P808; WONG DL, 1992, FASEB J, V6, P3310, DOI 10.1096/fasebj.6.14.1426768; WONG DL, 1985, BRAIN RES, V330, P209, DOI 10.1016/0006-8993(85)90679-1; WURTMAN RJ, 1966, J BIOL CHEM, V241, P2301; Xie J., 1997, Society for Neuroscience Abstracts, V23, P309; XIE J, 1996, SOC NEUR ABSTR, V22, P402	29	247	250	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					443	446		10.1126/science.280.5362.443	http://dx.doi.org/10.1126/science.280.5362.443			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545224				2022-12-24	WOS:000073159600050
J	Manian, FA				Manian, FA			Should we accept mediocrity?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Infect Dis Consultants, St Louis, MO 63141 USA		Manian, FA (corresponding author), Infect Dis Consultants, St Louis, MO 63141 USA.								0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1067	1069		10.1056/NEJM199804093381513	http://dx.doi.org/10.1056/NEJM199804093381513			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG134	9535676				2022-12-24	WOS:000072969500013
J	Zambrowicz, BP; Friedrich, GA; Buxton, EC; Lilleberg, SL; Person, C; Sands, AT				Zambrowicz, BP; Friedrich, GA; Buxton, EC; Lilleberg, SL; Person, C; Sands, AT			Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells	NATURE			English	Article							GENOME PROJECT; PROMOTER TRAPS; MICE; VECTORS	The dramatic increase in sequence information in the form of expressed sequence tags (ESTs)(1) and genomic sequence has created a 'gene function gap', with the identification of new genes far outpacing the rate at which their function can be identified. The ability to create mutations in embryonic stem (ES) cells on a large scale by tagged random mutagenesis provides a powerful approach for determining gene function in a mammalian system; this approach is well established in lower organisms(2,3). Here we describe a high-throughput mutagenesis method based on gene trapping that allows the automated identification of sequence tags from the mutated genes, This method traps and mutates genes regardless of their expression status in ES cells, To facilitate the study of gene function on a large scale, we are using these techniques to create a library of ES cells called Omnibank, from which sequence-tagged mutations in 2,000 genes are described.	Lexicon Genet, The Woodlands, TX 77381 USA	Lexicon Pharmaceuticals	Zambrowicz, BP (corresponding author), Lexicon Genet, 4000 Res Forest Dr, The Woodlands, TX 77381 USA.							ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CHANG W, 1993, VIROLOGY, V193, P737, DOI 10.1006/viro.1993.1182; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CRAIGIE R, 1992, TRENDS GENET, V8, P187, DOI 10.1016/0168-9525(92)90223-Q; DEWEERS M, 1993, EUR J IMMUNOL, V23, P319; FRIEDRICH G, 1993, METHOD ENZYMOL, V225, P681; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GOSSLER A, 1993, GENE TARGETING PRACT, P181; HASTY P, 1991, MOL CELL BIOL, V11, P4509, DOI 10.1128/MCB.11.9.4509; Hicks GG, 1997, NAT GENET, V16, P338, DOI 10.1038/ng0897-338; Oeltjen JC, 1997, GENOME RES, V7, P315, DOI 10.1101/gr.7.4.315; PLASTERK RHA, 1992, BIOESSAYS, V14, P629, DOI 10.1002/bies.950140911; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; SORIANO P, 1991, J VIROL, V65, P2314, DOI 10.1128/JVI.65.5.2314-2319.1991; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Townley DJ, 1997, GENOME RES, V7, P293, DOI 10.1101/gr.7.3.293; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; ZAMBROWICZ P, 1997, P NATL ACAD SCI USA, V94, P3789; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	20	394	425	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					608	611		10.1038/33423	http://dx.doi.org/10.1038/33423			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560157				2022-12-24	WOS:000072987200061
J	Climo, MW; Israel, DS; Wong, ES; Williams, D; Coudron, P; Markowitz, SM				Climo, MW; Israel, DS; Wong, ES; Williams, D; Coudron, P; Markowitz, SM			Hospital-wide restriction of clindamycin: Effect on the incidence of Clostridium difficile-associated diarrhea and cost	ANNALS OF INTERNAL MEDICINE			English	Article						clindamycin; Clostridium difficile; diarrhea; drug resistance, microbial; cost savings	TOXIN-ASSOCIATED DIARRHEA; AMINOGLYCOSIDE USAGE; RISK-FACTORS; SURVEILLANCE; RESISTANCE; COLITIS	Background: Widespread antibiotic use has been associated with increases in both bacterial resistance and nosocomial infection. Objective: To characterize the impact of hospital-wide clindamycin restriction on the incidence of Clostridium difficile-associated diarrhea and on antimicrobial prescribing practices. Design: Prospective, observational cohort study. Setting: University-affiliated Veterans Affairs Medical Center. Patients: Hospitalized patients with symptomatic diarrhea. Measurements: Clinical data on individual patients and data on antibiotic use were obtained from hospital pharmacy records. Hospital-wide use of antimicrobial agents was monitored. Isolates of C. difficile underwent antimicrobial susceptibility testing and molecular typing. Results: An outbreak of C. difficile-associated diarrhea was ca used by a clonal isolate of clindamycin-resistant C. difficile and was associated with increased use of clindamycin. Hospital-wide requirement of approval by an infectious disease consultant of clindamycin use led to an overall reduction in clindamycin use, a sustained reduction in the mean number of cases of C. difficile-associated diarrhea (11.5 cases/month compared with 3.33 cases/month; P < 0.001), and an increase in clindamycin susceptibility among C. difficile isolates (9% compared with 61%, P < 0.001). A parallel increase was noted in the use of and costs associated with other antibiotics with antianaerobic activity, including cefotetan, ticarcillin-clavulanate, and imipenem-cilastin. The hospital realized overall cost savings as a result of the decreased incidence of C. difficile-associated diarrhea. Conclusions: Hospital formulary restriction of clindamycin is an effective way to decrease the number of infections due to C. difficile. It can also lead to a return in clindamycin susceptibility among isolates and can effect cost savings to the hospital.	Virginia Commonwealth Univ Med Coll Virginia, Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA 23249 USA	Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University	Climo, MW (corresponding author), Virginia Commonwealth Univ Med Coll Virginia, Hunter Holmes McGuire Vet Affairs Med Ctr, 1201 Broad Rock Blvd,Sect 111C, Richmond, VA 23249 USA.							BALLOW CH, 1992, DIAGN MICR INFEC DIS, V15, pS37; BAMBERGER DM, 1992, ARCH INTERN MED, V152, P554, DOI 10.1001/archinte.152.3.554; BARTLETT JG, 1990, REV INFECT DIS, V12, pS243, DOI 10.1093/clinids/12.Supplement_2.S243; BARTLETT JG, 1981, JOHNS HOPKINS MED J, V149, P6; BARTLETT JG, 1992, CLIN INFECT DIS, V15, P573, DOI 10.1093/clind/15.4.573; BETTS RF, 1984, ANN INTERN MED, V100, P219, DOI 10.7326/0003-4819-100-2-219; BROWN E, 1990, INFECT CONT HOSP EP, V11, P283; DONTA ST, 1980, J INFECT DIS, V141, P218, DOI 10.1093/infdis/141.2.218; FEKETY R, 1993, JAMA-J AM MED ASSOC, V1, P71; GEORGE WL, 1979, J CLIN MICROBIOL, V9, P214; GERDING DN, 1989, ANN INTERN MED, V110, P255, DOI 10.7326/0003-4819-110-4-255; GERDING DN, 1991, ANTIMICROB AGENTS CH, V35, P1284, DOI 10.1128/AAC.35.7.1284; JOHNSON S, 1990, AM J MED, V88, P137, DOI 10.1016/0002-9343(90)90462-M; JONES RN, 1992, DIAGN MICR INFEC DIS, V15, pS3; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; KING JW, 1992, CLIN INFECT DIS, V14, P908, DOI 10.1093/clinids/14.4.908; KOFSKY P, 1991, DIS COLON RECTUM, V34, P244, DOI 10.1007/BF02090164; Maslow Joel N., 1993, P563; MCFARLAND LV, 1990, J INFECT DIS, V162, P678, DOI 10.1093/infdis/162.3.678; MULLANY P, 1995, J ANTIMICROB CHEMOTH, V35, P305, DOI 10.1093/jac/35.2.305; OLSON MM, 1994, INFECT CONT HOSP EP, V15, P371; PEAR SM, 1994, ANN INTERN MED, V120, P272, DOI 10.7326/0003-4819-120-4-199402150-00003; REINKE CM, 1994, AM J HOSP PHARM, V51, P1771, DOI 10.1093/ajhp/51.14.1771; RILEY TV, 1995, LANCET, V345, P455, DOI 10.1016/S0140-6736(95)90439-5; STRATTON CW, 1993, CLIN THER, V15, P12; THIBAULT A, 1991, INFECT CONT HOSP EP, V12, P345, DOI 10.2307/30145209; YOUNG EJ, 1985, AM J MED SCI, V290, P223, DOI 10.1097/00000441-198512000-00001	27	185	189	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				989	+		10.7326/0003-4819-128-12_Part_1-199806150-00005	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625685				2022-12-24	WOS:000074201300004
J	Camps, M; Nichols, A; Gillieron, C; Antonsson, B; Muda, M; Chabert, C; Boschert, U; Arkinstall, S				Camps, M; Nichols, A; Gillieron, C; Antonsson, B; Muda, M; Chabert, C; Boschert, U; Arkinstall, S			Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase	SCIENCE			English	Article							DUAL-SPECIFICITY PHOSPHATASE; SIGNAL-REGULATED KINASE; OF-FUNCTION MUTATION; MAP KINASE; TYROSINE-PHOSPHATASE; GENE-PRODUCT; TRANSFORMATION; EXPRESSION; CELLS	MAP kinase phosphatase-3 (MKP-3) dephosphorylates phosphotyrosine and phosphothreonine and inactivates selectively ERK family mitogen-activated protein (MAP) kinases. MKP-3 was activated by direct binding to purified ERK2. Activation was independent of protein kinase activity and required binding of ERK2 to the noncatalytic amino-terminus of MKP-3. Neither the gain-of-function Sevenmaker ERK2 mutant D319N nor c-Jun amino-terminal kinase-stress-activated protein kinase (JNK/SAPK) or p38 MAP kinases bound MKP-3 or caused its catalytic activation. These kinases were also resistant to enzymatic inactivation by MKP-3. Another homologous but nonselective phosphatase, MKP-4, bound and was activated by ERK2, JNK/SAPK, and p38 MAP kinases. Catalytic activation of MAP kinase phosphatases through substrate binding may regulate MAP kinase activation by a large number of receptor systems.	Glaxo Wellcome Res & Dev SA, Geneva Biomed Res Inst, CH-1228 Geneva, Switzerland	GlaxoSmithKline	Arkinstall, S (corresponding author), Glaxo Wellcome Res & Dev SA, Geneva Biomed Res Inst, CH-1228 Geneva, Switzerland.			Camps, Montserrat/0000-0002-9849-8657				BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CAMPS M, UNPUB; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Kornhauser JM, 1997, NEURON, V18, P839, DOI 10.1016/S0896-6273(00)80322-0; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; MUDA M, 1998, EMBO J, V273, P9323; Reszka AA, 1997, MOL BIOL CELL, V8, P1219, DOI 10.1091/mbc.8.7.1219; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	28	421	430	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 22	1998	280	5367					1262	1265		10.1126/science.280.5367.1262	http://dx.doi.org/10.1126/science.280.5367.1262			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596579				2022-12-24	WOS:000073852500048
J	Baker, EH; Dong, YB; Sagnella, GA; Rothwell, M; Onipinla, AK; Markandu, ND; Cappuccio, FP; Cook, DG; Persu, A; Corvol, P; Jeunemaitre, X; Carter, ND; MacGregor, GA				Baker, EH; Dong, YB; Sagnella, GA; Rothwell, M; Onipinla, AK; Markandu, ND; Cappuccio, FP; Cook, DG; Persu, A; Corvol, P; Jeunemaitre, X; Carter, ND; MacGregor, GA			Association of hypertension with T594M mutation in beta subunit of epithelial sodium channels in black people resident in London	LANCET			English	Article							LIDDLES SYNDROME; GAMMA-SUBUNIT	Background. Liddle's syndrome is a rare inherited form of hypertension in which mutations of the epithelial sodium channel result in increased renal sodium reabsorption. Essential hypertension in black patients also shows clinical features of sodium retention so we screened black people for the T594M mutation, the most commonly identified sodium-channel mutation. Methods. In a case-control study, 206 hypertensive (mean age 48.0 [SD 11.8] years, men:women 80:126) and 142 normotensive (48.7 [7.4] years; 61:81) black people who lived in London, UK, were screened for T594M. Part of the last exon of the epithelial sodium-channel beta subunit from genomic DNA was amplified by PCR. The T594M variant was detected by single-strand conformational polymorphism analysis of PCR products and confirmed by DNA sequencing. Findings. 17 (8.3%) of 206 hypertensive participants compared with three (2.1%) of 142 normotensive partcipants possessed the T594M variant (odds ratio [OR]=4.17 [95% CI 1.12-18.25], p = 0.029). A high proportion of participants with the T594M variant were women (15 of 17 hypertensive participants and all three normotensive participants), whereas women comprised a lower proportion of the individuals screened (61.2% hypertensive, 57.7% normotensive). However, the association between the T594M variant and hypertension persisted after adjustment for sex and body-mass index (Mantel-Haenszel OR=5.52 [1.40-30.61], p = 0.012). Plasma renin activity was significantly lower in 13 hypertensive participants with the T594M variant (median=0.19 ng mL(-1) h(-1)) than in 39 untreated hypertensive individuals without the variant (median=0.45 ng mL(-1) h(-1), p=0.009). Interpretation. Among black London people the T594M sodium-channel beta subunit mutation occurs more frequently in people with hypertension than those without. The T594M variant may increase sodium-channel activity and could raise blood pressure in affected people by increasing renal tubular sodium reabsorption. These findings suggest that the T594M mutation could be the most common secondary cause of essential hypertension in black people identified to date.	St George Hosp, Sch Med, Dept Pharmacol, London SW17 0RE, England; St George Hosp, Sch Med, Blood Pressure Unit, London SW17 0RE, England; St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; St George Hosp, Sch Med, Med Genet Unit, London SW17 0RE, England; Coll France, INSERM, U36, F-75231 Paris, France	St Georges University London; St Georges University London; St Georges University London; St Georges University London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Baker, EH (corresponding author), St George Hosp, Sch Med, Dept Pharmacol, London SW17 0RE, England.	ebaker@sghms.ac.uk	Cappuccio, Francesco/D-3028-2009; Cappuccio, Francesco Paolo/ABF-1094-2020; JEUNEMAITRE, Xavier/AAQ-4853-2021	Cappuccio, Francesco Paolo/0000-0002-7842-5493; JEUNEMAITRE, Xavier/0000-0001-5925-381X; Persu, Alexandre/0000-0002-4007-9695; Baker, Emma/0000-0002-0871-3721; Cook, Derek/0000-0002-9723-5759				[Anonymous], 1985, J HYPERTENS, V3, P293; BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; Cappuccio FP, 1997, HEART, V78, P555, DOI 10.1136/hrt.78.6.555; Chang HG, 1996, J HYPERTENS, V14, P1417, DOI 10.1097/00004872-199612000-00005; CURTIS JJ, 1983, NEW ENGL J MED, V309, P1009, DOI 10.1056/NEJM198310273091702; DEWARDENER HE, 1982, LANCET, V1, P1450; GEORGE CF, 1975, BRIT HEART J, V37, P804; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; JAMES VHT, 1976, METHODOLOGICAL DEV B, V5, P149; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; MUNROE PB, 1997, AM J HYPERTENS, V10, pA5; PERSU A, 1998, IN PRESS HYPERTENSIO; ROULSTON JE, 1978, CLIN CHIM ACTA, V88, P45, DOI 10.1016/0009-8981(78)90147-X; SAMMONS DW, 1981, ELECTROPHORESIS, V2, P135, DOI 10.1002/elps.1150020303; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Su YR, 1996, J AM SOC NEPHROL, V7, P2543; VOILLEY N, 1995, GENOMICS, V28, P560, DOI 10.1006/geno.1995.1188	19	198	204	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 9	1998	351	9113					1388	1392		10.1016/S0140-6736(97)07306-6	http://dx.doi.org/10.1016/S0140-6736(97)07306-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM665	9593408				2022-12-24	WOS:000073563400008
J	Cullen, MR				Cullen, MR			Chrysotile asbestos: enough is enough	LANCET			English	Editorial Material							MORTALITY; MESOTHELIOMA; TREMOLITE; EXPOSURE; CANCER		Yale Univ, Sch Med, Yale Occupat & Environm Med Program, New Haven, CT 06510 USA	Yale University	Cullen, MR (corresponding author), Yale Univ, Sch Med, Yale Occupat & Environm Med Program, 333 Cedar St, New Haven, CT 06510 USA.							AMANDUS HE, 1987, AM J IND MED, V11, P15, DOI 10.1002/ajim.4700110103; CULLEN MR, 1987, OCCUP MED, V2, P259; DEMENT JM, 1983, AM J IND MED, V4, P421, DOI 10.1002/ajim.4700040304; Liddell FDK, 1997, ANN OCCUP HYG, V41, P13, DOI 10.1016/S0003-4878(96)00044-0; Liddell FDK, 1998, ANN OCCUP HYG, V42, P7, DOI 10.1016/S0003-4878(97)00053-7; MCDONALD AD, 1983, BRIT J IND MED, V40, P361; McDonald AD, 1997, ANN OCCUP HYG, V41, P707, DOI 10.1016/S0003-4878(97)00020-3; MCDONALD JC, 1989, CANCER, V63, P1544, DOI 10.1002/1097-0142(19890415)63:8<1544::AID-CNCR2820630815>3.0.CO;2-G; McDonald JC, 1997, ANN OCCUP HYG, V41, P699, DOI 10.1093/annhyg/41.6.699; MCDONALD JC, 1998, ANN OCCUP HYG, V42, P1; Smith AH, 1996, AM J IND MED, V30, P252, DOI 10.1002/(SICI)1097-0274(199609)30:3<252::AID-AJIM2>3.0.CO;2-0; Stayner LT, 1996, AM J PUBLIC HEALTH, V86, P179, DOI 10.2105/AJPH.86.2.179; WAGNER JC, 1982, BRIT J CANCER, V45, P352, DOI 10.1038/bjc.1982.61	13	27	27	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 9	1998	351	9113					1377	1378		10.1016/S0140-6736(05)79440-X	http://dx.doi.org/10.1016/S0140-6736(05)79440-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM665	9593405				2022-12-24	WOS:000073563400005
J	Fryer, CJ; Archer, TK				Fryer, CJ; Archer, TK			Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex	NATURE			English	Article							MMTV PROMOTER; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; STEROID-RECEPTORS; NUCLEAR RECEPTORS; BINDING; COACTIVATOR; NUCLEOSOME; PROTEIN; CBP	The assembly of transcriptional regulatory DNA sequences into chromatin plays a fundamental role in modulating gene expression(1,2). The promoter of the mouse mammary-tumour virus (MMTV) is packaged into a regular array of nucleosomes when it becomes stably integrated into mammalian chromosomes, and has been used to investigate the relationship between chromatin architecture and transcriptional activation by the hormone-bound glucocorticoid and progesterone receptors(3,4). In mammalian cells that express both of these receptors, the progesterone receptor activates transcription from transiently transfected MMTV DNA(5,6) but not from organized chromatin templates(7). Moreover, the activated progesterone receptor inhibits the chromatin remodelling and consequent transcriptional stimulation that is mediated by the glucocorticoid receptor. Here we investigate the mechanism of this inhibition by characterizing the interaction of the glucocorticoid receptor with transcriptional co-activator and chromatin remodelling protein complexes(2,8). We show that when this receptor is prevented from interacting with the hBRG1/BAF chromatin remodelling complex, it can activate transcription from transiently transfected DNA but not from organized chromatin templates. Our results indicate that it may be possible to separate the transcriptional activation and chromatin remodelling activities of proteins that interact with hormone receptors.	Univ Western Ontario, London Reg Canc Ctr, Dept Obstet & Gynaecol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Biochem, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Oncol, London, ON N6A 4L6, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Archer, TK (corresponding author), Univ Western Ontario, London Reg Canc Ctr, Dept Obstet & Gynaecol, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.		Archer, Trevor K/E-5191-2019	Archer, Trevor K/0000-0001-7651-3644				ARCHER TK, 1995, J STEROID BIOCHEM, V53, P421, DOI 10.1016/0960-0760(95)00088-H; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P1154, DOI 10.1210/me.8.9.1154; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; MCKNIGHT GS, 1980, CELL, V22, P469; MCKNIGHT GS, 1997, NATURE, V387, P677; MIZUTANI T, 1992, J STEROID BIOCHEM, V42, P695, DOI 10.1016/0960-0760(92)90110-5; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	30	404	413	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1998	393	6680					88	91		10.1038/30032	http://dx.doi.org/10.1038/30032			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590696				2022-12-24	WOS:000073497500054
J	Varon, R; Vissinga, C; Platzer, M; Cerosaletti, KM; Chrzanowska, KH; Saar, K; Beckmann, G; Seemanova, E; Cooper, PR; Nowak, NJ; Stumm, M; Weemaes, CMR; Gatti, RA; Wilson, RK; Digweed, M; Rosenthal, A; Sperling, K; Concannon, P; Reis, A				Varon, R; Vissinga, C; Platzer, M; Cerosaletti, KM; Chrzanowska, KH; Saar, K; Beckmann, G; Seemanova, E; Cooper, PR; Nowak, NJ; Stumm, M; Weemaes, CMR; Gatti, RA; Wilson, RK; Digweed, M; Rosenthal, A; Sperling, K; Concannon, P; Reis, A			Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome	CELL			English	Article							CHROMOSOMAL INSTABILITY DISORDER; ATAXIA-TELANGIECTASIA; HUMAN GENOME; HUMAN MRE11; GENE; IMMUNODEFICIENCY; COMPLEMENTATION; MAP	Nijmegen breakage syndrome (NBS) Is an autosomal recessive chromosomal instability syndrome characterized by microcephaly, growth retardation, immunodeficiency, and cancer predisposition. Cells from NBS patients are hypersensitive to ionizing radiation with cytogenetic features indistinguishable from ataxia telangiectasia. We describe the positional cloning of a gene encoding a novel protein, nibrin. It contains two modules found in cell cycle checkpoint proteins, a forkhead-associated domain adjacent to a breast cancer carboxy-terminal domain. A truncating 5 bp deletion was identified in the majority of NBS patients, carrying a conserved marker haplotype. Five further truncating mutations were identified in patients with other distinct haplotypes. The domains found in nibrin and the NBS phenotype suggest that this disorder is caused by defective responses to DNA double-strand breaks.	Humboldt Univ, Charite, Inst Human Genet, D-13353 Berlin, Germany; Univ Washington, Sch Med, Virginia Mason Res Ctr, Seattle, WA 98101 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98101 USA; Inst Mol Biol, Dept Genome Anal, D-07745 Jena, Germany; Childrens Mem Hlth Inst, Dept Med Genet, PL-04736 Warsaw, Poland; Max Delbruck Ctr Mol Med, Mikrosatellitenzentrum, D-14059 Berlin, Germany; Max Delbruck Ctr Mol Med, Dept Bioinformat, D-13125 Berlin, Germany; Charles Univ Prague, Dept Med Genet, CR-15018 Prague, Czech Republic; Roswell Pk Canc Inst, Dept Human Genet, Buffalo, NY 14263 USA; Univ Magdeburg, Inst Human Genet, D-39112 Magdeburg, Germany; Univ Nijmegen Hosp, NL-6500 HB Nijmegen, Netherlands; Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90095 USA; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Washington; University of Washington Seattle; Virginia Mason Medical Center; University of Washington; University of Washington Seattle; Children's Memorial Health Institute; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Charles University Prague; Roswell Park Cancer Institute; Otto von Guericke University; Radboud University Nijmegen; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Washington University (WUSTL)	Reis, A (corresponding author), Humboldt Univ, Charite, Inst Human Genet, Augustenburger Pl 1, D-13353 Berlin, Germany.		Weemaes, C.M.R./L-4747-2015; Reis, André/D-2309-2009; Wilson, Richard K./AAF-4139-2019	Reis, André/0000-0002-6301-6363; Wilson, Richard K./0000-0002-1992-1358; Cooper, Paul/0000-0003-1305-7287; Chrzanowska, Krystyna/0000-0003-3888-0624; Saar, Kathrin/0000-0002-4483-1557; Concannon, Patrick/0000-0002-5801-1859	NATIONAL CANCER INSTITUTE [R01CA057569, R01CA063333] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000333] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA057569, CA63333, CA57569] Funding Source: Medline; NHGRI NIH HHS [HG00333] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Beckmann G, 1998, J MOL BIOL, V275, P725, DOI 10.1006/jmbi.1997.1510; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CHRZANOWSKA KH, 1995, AM J MED GENET, V57, P462, DOI 10.1002/ajmg.1320570321; Concannon P, 1997, HUM MUTAT, V10, P100, DOI 10.1002/(SICI)1098-1004(1997)10:2<100::AID-HUMU2>3.0.CO;2-O; DIGWEED M, 1993, TOXICOL LETT, V67, P259, DOI 10.1016/0378-4274(93)90061-2; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; HANAWALT P, 1985, ATAXIA TELANGIECTASI, P67; Hendrickson EA, 1997, AM J HUM GENET, V61, P795, DOI 10.1086/514895; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JASPERS NGJ, 1988, AM J HUM GENET, V42, P66; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; Komatsu K, 1996, AM J HUM GENET, V58, P885; LICHTER P, 1992, HUMAN CYTOGENETICS P, P157; Matsuura K, 1998, BIOCHEM BIOPH RES CO, V242, P602, DOI 10.1006/bbrc.1997.7924; MEYN MS, 1995, CANCER RES, V55, P5991; MORRAL N, 1994, NAT GENET, V7, P169, DOI 10.1038/ng0694-169; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; Platzer M, 1997, GENOME RES, V7, P592, DOI 10.1101/gr.7.6.592; Saar K, 1997, AM J HUM GENET, V60, P605; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVOV A, 1992, NUCLEIC ACIDS RES, V20, P6741, DOI 10.1093/nar/20.24.6741; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SEYSCHAB H, 1992, EUR J PEDIATR, V151, P756, DOI 10.1007/BF01959085; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stumm M, 1997, AM J HUM GENET, V60, P1246; TAALMAN RDFM, 1983, MUTAT RES, V112, P23, DOI 10.1016/0167-8817(83)90021-4; TROELSTRA C, 1994, CURR BIOL, V4, P1149, DOI 10.1016/S0960-9822(00)00260-8; vanderBurgt I, 1996, J MED GENET, V33, P153, DOI 10.1136/jmg.33.2.153; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; WEEMAES CMR, 1981, ACTA PAEDIATR SCAND, V70, P557, DOI 10.1111/j.1651-2227.1981.tb05740.x; WEGNER RD, 1988, CLIN GENET, V33, P20; WEGNER RD, 1998, IN PRESS PRIMARY IMM; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016	40	799	823	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1998	93	3					467	476		10.1016/S0092-8674(00)81174-5	http://dx.doi.org/10.1016/S0092-8674(00)81174-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590180	Green Submitted, Bronze			2022-12-24	WOS:000073471500021
J	Tontonoz, P; Nagy, L; Alvarez, JGA; Thomazy, VA; Evans, RM				Tontonoz, P; Nagy, L; Alvarez, JGA; Thomazy, VA; Evans, RM			PPAR gamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL	CELL			English	Article							LOW-DENSITY-LIPOPROTEIN; ACTIVATED RECEPTOR-GAMMA; RETINOIC ACID; ADIPOCYTE DIFFERENTIATION; CHOLESTEROL DEPOSITION; GENE-EXPRESSION; THYROID-HORMONE; HUMAN CD36; MACROPHAGE; BINDING	The formation of foam cells from macrophages in the arterial wall is characterized by dramatic changes in lipid metabolism, including increased expression of scavenger receptors and the uptake of oxidized low-density lipoprotein (oxLDL). We demonstrate here that the nuclear receptor PPAR gamma is induced in human monocytes following exposure to oxLDL and is expressed at high levels in the foam cells of atherosclerotic lesions. Ligand activation of the PPBR gamma:RXR alpha heterodimer in myelomonocytic cell lines induces changes characteristic of monocytic differentiation and promotes uptake of oxLDL through transcriptional induction of the scavenger receptor CD36. These results reveal a novel signaling pathway controlling differentiation and lipid metabolism in monocytic cells, and suggest that endogenous PPAR gamma ligands may be important regulators of gene expression during atherogenesis.	Howard Hughes Med Inst, La Jolla, CA 92037 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Univ Texas, Sch Med, Dept Pathol, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Integrat Biol, Houston, TX 77225 USA	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego; University of Texas System; University of Texas System	Evans, RM (corresponding author), Howard Hughes Med Inst, La Jolla, CA 92037 USA.		Nagy, Laszlo/A-3814-2008; Evans, Ronald/AAF-4001-2019	Nagy, Laszlo/0000-0001-6653-2155; Evans, Ronald/0000-0002-9986-5965				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ARMESILLA AL, 1994, J BIOL CHEM, V269, P18985; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUJA LM, 1983, ARTERIOSCLEROSIS, V3, P87, DOI 10.1161/01.ATV.3.1.87; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GRAVES RA, 1992, MOL CELL BIOL, V12, P1202, DOI 10.1128/MCB.12.3.1202; Greene M. E., 1995, Gene Expression, V4, P281; GREENWALT DE, 1995, J CLIN INVEST, V96, P1382, DOI 10.1172/JCI118173; HAMILTON TA, 1995, J CLIN INVEST, V95, P2020, DOI 10.1172/JCI117887; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUBBERT M, 1991, BLOOD, V77, P909; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; MOULTON KS, 1992, P NATL ACAD SCI USA, V89, P8102, DOI 10.1073/pnas.89.17.8102; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; NAGELKERKE JF, 1984, ARTERIOSCLEROSIS, V4, P256, DOI 10.1161/01.ATV.4.3.256; NAGY L, 1995, MOL CELL BIOL, V15, P3540; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROSS TK, 1994, VITAM HORM, V49, P281; SANAN DA, 1998, IN PRESS P ACAD NATL; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SFEIR Z, 1997, ESSENT FATTY ACIDS, V57, P17; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STARY HC, 1994, ARTERIOSCLER THROMB, V14, P840, DOI 10.1161/01.ATV.14.5.840; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837; Yesner LM, 1996, ARTERIOSCL THROM VAS, V16, P1019, DOI 10.1161/01.ATV.16.8.1019; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	55	1517	1573	1	93	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					241	252		10.1016/S0092-8674(00)81575-5	http://dx.doi.org/10.1016/S0092-8674(00)81575-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568716	Bronze			2022-12-24	WOS:000073174000010
J	Stollberger, C; Chnupa, P; Kronik, G; Brainin, M; Finsterer, J; Schneider, B; Slany, J				Stollberger, C; Chnupa, P; Kronik, G; Brainin, M; Finsterer, J; Schneider, B; Slany, J		ELAT Study Grp	Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation	ANNALS OF INTERNAL MEDICINE			English	Article						echocardiography, transesophageal; atrial fibrillation; embolism and thrombosis; cerebrovascular disorders; atrial function, left	SPONTANEOUS ECHO CONTRAST; MITRAL-VALVE DISEASE; APPENDAGE THROMBUS; ANATOMIC CORRELATIONS; CLINICAL-APPLICATIONS; THROMBOEMBOLIC RISK; STROKE	Background: Transesophageal echocardiography visualizes the left atrium and its appendage, thrombi, and spontaneous echocardiographic contrast. Objective: To assess the association of transesophageal echocardiographic characteristics with stroke or embolism in atrial fibrillation. Design: Multicenter observational follow-up study. Setting: Hospitals in Austria and Slovakia. Patients: 409 outpatients with nonrheumatic atrial fibrillation and without recent stroke. Intervention: Patients with thrombi received anticoagulation, and patients without thrombi received aspirin. Measurements: Primary events were stroke or embolism. Secondary events were death not caused by stroke or embolism and need for anticoagulation. Results: In the left atrium or left atrial appendage, 10 patients (2.5%) had thrombi and 47 (12%) had spontaneous echocardiographic contrast. The appendage had a mean (+/- SD) length of 44 +/- 10 mm, a mean width of 23 +/- 6 mm, and a mean area of 5.8 +/- 2.5 cm(2). Follow-up ranged from 1 to 74 months (mean, 58 months). Fifty patients had stroke or embolism, 53 died of a cause other than stroke or embolism, and 38 required anticoagulation. On univariate analysis, thrombi (risk ratio, 3.9 [95% CI, 1.4 to 10.1]; P = 0.009), length of the left atrial appendage (risk ratio, 1.6 [CI, 1.05 to 2.5]; P = 0.03), and width of the left atrial appendage (risk ratio, 2.4 [CI, 1.2 to 4.8]; P = 0.01) were associated with stroke or embolism. Multivariate analysis identified hypertension (risk ratio, 3.6 [CI, 1.8 to 8.4]; P = 0.001), previous stroke (risk ratio, 3.7 [CI, 1.5 to 7.5]; P = 0.002), and age (risk ratio, 1.1 [CI, 1.0 to 1.1]; P < 0.001) as risk factors for stroke or embolism and provided evidence of an association between thrombi and stroke or embolism (risk ratio, 2.4 [CI, 0.9 to 6.9]; P = 0.09). Conclusions: In outpatients with atrial fibrillation and without recent stroke, thrombi of the left atrium or left atrial appendage and length and width of the left atrial appendage were associated with stroke or embolism in univariate analysis. In a multivariate analysis, age, hypertension, and previous stroke were risk factors for stroke or embolism, and thrombi of the left atrium or left atrial appendage were possible risk factors. In these patients, history may be more useful than transesophageal echocardiography for the assessment of embolic risk.	Ustav Kardiovaskularnych Chorob, SK-81105 Bratislava, Slovakia; Krankenhaus Krems, A-3500 Krems, Austria; Neurol Krankenhaus, A-3400 Maria Gugging, Austria; Neurol Krankenhaus Rosenhugel, Inst Med Stat, A-1130 Vienna, Austria; Krankenanstalt Rudolfstiftung Wien, Vienna, Austria	Rudolfstiftung Hospital	Stollberger, C (corresponding author), Steingasse 31-18, A-1030 Vienna, Austria.		Finsterer, J/AAE-5733-2020					ABERG H, 1969, ACTA MED SCAND, V185, P373; ARCHER SL, 1995, AM HEART J, V130, P287, DOI 10.1016/0002-8703(95)90442-5; ASCHENBERG W, 1986, J AM COLL CARDIOL, V7, P163, DOI 10.1016/S0735-1097(86)80275-3; BEPPU S, 1985, J AM COLL CARDIOL, V6, P744, DOI 10.1016/S0735-1097(85)80476-9; BLACK IW, 1993, J AM COLL CARDIOL, V21, P451, DOI 10.1016/0735-1097(93)90688-W; BRAININ M, 1992, NEUROEPIDEMIOLOGY, V11, P190, DOI 10.1159/000110931; CHAN SK, 1995, AM J CARDIOL, V76, P528, DOI 10.1016/S0002-9149(99)80147-7; DANIEL WG, 1988, J AM COLL CARDIOL, V11, P1204, DOI 10.1016/0735-1097(88)90283-5; DUNN M, 1989, CHEST, V95, pS118, DOI 10.1378/chest.95.2_Supplement.118S; ERNST G, 1995, ANAT REC, V242, P553, DOI 10.1002/ar.1092420411; FATKIN D, 1994, J AM COLL CARDIOL, V23, P961, DOI 10.1016/0735-1097(94)90644-0; KRONIK G, 1995, BRIT HEART J, V74, P80; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LEUNG DYC, 1994, J AM COLL CARDIOL, V24, P755, DOI 10.1016/0735-1097(94)90025-6; MANNING WJ, 1995, J AM COLL CARDIOL, V25, P1354, DOI 10.1016/0735-1097(94)00560-D; MANNING WJ, 1995, ANN INTERN MED, V123, P817, DOI 10.7326/0003-4819-123-11-199512010-00001; MCBRIDE R, 1990, NEW ENGL J MED, V322, P863; MUGGE A, 1990, American Journal of Cardiac Imaging, V4, P173; MUGGE A, 1994, J AM COLL CARDIOL, V23, P599; Orsinelli DA, 1996, AM HEART J, V131, P622, DOI 10.1016/S0002-8703(96)90553-0; POLLICK C, 1991, CIRCULATION, V84, P223, DOI 10.1161/01.CIR.84.1.223; Pozzoli M, 1991, J Am Soc Echocardiogr, V4, P435; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SEWARD JB, 1990, MAYO CLIN PROC, V65, P1193, DOI 10.1016/S0025-6196(12)62744-X; SEWARD JB, 1988, MAYO CLIN PROC, V63, P649, DOI 10.1016/S0025-6196(12)65529-3; SHERMAN DG, 1986, ARCH NEUROL-CHICAGO, V43, P68, DOI 10.1001/archneur.1986.00520010062024; STODDARD MF, 1995, J AM COLL CARDIOL, V25, P452, DOI 10.1016/0735-1097(94)00396-8; STOLLBERGER C, 1995, CARDIOLOGY, V86, P457, DOI 10.1159/000176923	28	145	151	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					630	+		10.7326/0003-4819-128-8-199804150-00004	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537936				2022-12-24	WOS:000073052500003
J	Maison, P; Balkau, B; Simon, D; Chanson, P; Rosselin, G; Eschwege, E				Maison, P; Balkau, B; Simon, D; Chanson, P; Rosselin, G; Eschwege, E			Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study	BRITISH MEDICAL JOURNAL			English	Article									Fac Med Paris Sud, INSERM, U21, F-94807 Villejuif, France; Hop St Antoine, INSERM, U55, F-75571 Paris, France; Hop Bicetre, Serv Endocrinol, Le Kremlin Bicetre, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Maison, P (corresponding author), Fac Med Paris Sud, INSERM, U21, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.		Chanson, Philippe/F-8511-2013	Chanson, Philippe/0000-0001-5096-5722				BALKAU B, 1993, BRIT MED J, V307, P295, DOI 10.1136/bmj.307.6899.295; BENGTSSON BA, 1988, ACTA MED SCAND, V223, P327; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; ROSSELIN G, 1966, NATURE, V212, P355, DOI 10.1038/212355a0; SACCA L, 1994, ENDOCR REV, V15, P555, DOI 10.1210/er.15.5.555	5	61	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1998	316	7138					1132	1133		10.1136/bmj.316.7138.1132	http://dx.doi.org/10.1136/bmj.316.7138.1132			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH054	9552951	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000073067500024
J	Goldring, O				Goldring, O			Therapeutics: a glimpse of the future	NATURE			English	Editorial Material																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					420	420		10.1038/32957	http://dx.doi.org/10.1038/32957			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537332				2022-12-24	WOS:000072713600063
J	Berenson, GS; Srinivasan, SR; Bao, WH; Newman, WP; Tracy, RE; Wattigney, WA				Berenson, GS; Srinivasan, SR; Bao, WH; Newman, WP; Tracy, RE; Wattigney, WA		Bogaulas Heart Study	Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; INSULIN-RESISTANCE; SYNDROME-X; HYPERTENSION; NECROPSY; OBESITY; YOUTH	Background In adults, cardiovascular risk factors reinforce each other in their effect on cardiovascular events. However, information is scant on the relation of multiple risk factors to the extent of asymptomatic atherosclerosis in young people. Methods We performed autopsies on 204 young persons 2 to 39 years of age, who had died from various causes, principally trauma. Data on antemortem risk factors were available for 93 of these persons, who were the focus of this study. We correlated risk factors with the extent of atherosclerosis in the aorta and coronary arteries. Results The extent of fatty streaks and fibrous plaques in the aorta and coronary arteries increased with age. The association between fatty streaks and fibrous plaques was much stronger in the coronary arteries (r=0.60, P<0.001) than in the aorta (r=0.23, P=0.03). Among the cardiovascular risk factors, body-mass index, systolic and diastolic blood pressure, and serum concentrations of total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol, as a group, were strongly associated with the extent of lesions in the aorta and coronary arteries (canonical correlation [a measure of the association between groups of variables]: r=0.70; P<0.001). In addition, cigarette smoking increased the percentage of the intimal surface involved with fibrous plaques in the aorta (1.22 percent in smokers vs. 0.12 percent in nonsmokers, P=0.02) and fatty streaks in the coronary vessels (8.27 percent vs. 2.89 percent, P=0.04). The effect of multiple risk factors on the extent of atherosclerosis was quite evident. Subjects with 0, 1, 2, and 3 or 4 risk factors had, respectively, 19.1 percent, 30.3 percent, 37.9 percent, and 35.0 percent of the intimal surface covered with fatty streaks in the aorta (P for trend=0.01). The comparable figures for the coronary arteries were 1.3 percent, 2.5 percent, 7.9 percent, and 11.0 percent, respectively, for fatty streaks (P for trend=0.01) and 0.6 percent, 0.7 percent, 2.4 percent, and 7.2 percent for collagenous fibrous plaques (P for trend=0.003). Conclusions These findings indicate that as the number of cardiovascular risk factors increases, so does the severity of asymptomatic coronary and aortic atherosclerosis in young people. (C) 1998, Massachusetts Medical Society.	Tulane Univ, Sch Publ Hlth & Trop Med, Tulane Ctr Cardiovasc Hlth, New Orleans, LA 70112 USA; Louisiana State Univ, Med Ctr, Dept Pathol, New Orleans, LA 70112 USA	Tulane University; Louisiana State University System	Berenson, GS (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Tulane Ctr Cardiovasc Hlth, 1501 Canal St,14th Fl, New Orleans, LA 70112 USA.		tracy, richard/L-6072-2019; Robles-Sardin, Alma E/M-7714-2015; Hrafnkelsson, Hannes/C-8490-2011	Robles-Sardin, Alma E/0000-0003-2044-7793; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032194] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038844, U01HL038844] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38844] Funding Source: Medline; NICHD NIH HHS [HD-32194] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAO WH, 1994, ARCH INTERN MED, V154, P1842; Bao WH, 1996, CIRCULATION, V93, P54, DOI 10.1161/01.CIR.93.1.54; Berenson G.S., 1986, CAUSATION CARDIOVASC; BERENSON GS, 1992, AM J CARDIOL, V70, P851, DOI 10.1016/0002-9149(92)90726-F; Berenson GS, 1980, CARDIOVASCULAR RISK; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; GUZMAN MA, 1968, LAB INVEST, V18, P479; HAFFNER SM, 1992, DIABETES, V41, P715, DOI 10.2337/diabetes.41.6.715; HUNTER SMD, 1980, PREV MED, V9, P701; KANNEL WB, 1988, AM J CARDIOL, V62, P1109, DOI 10.1016/0002-9149(88)90558-9; KANNEL WB, 1987, NIH PUBL; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; KHOURY P, 1980, AM J EPIDEMIOL, V112, P524, DOI 10.1093/oxfordjournals.aje.a113022; MCGILL HC, 1984, ARTERIOSCLEROSIS, V4, P443, DOI 10.1161/01.ATV.4.5.443; MCGILL HC, 1995, ARTERIOSCL THROM VAS, V15, P2222, DOI 10.1161/01.ATV.15.12.2222; McGill HC, 1997, ARTERIOSCL THROM VAS, V17, P95, DOI 10.1161/01.ATV.17.1.95; MCGILL HC, 1995, ARTERIOSCL THROM VAS, V15, P431, DOI 10.1161/01.ATV.15.4.431; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROBERTS WC, 1990, AM J CARDIOL, V66, P121, DOI 10.1016/0002-9149(90)90751-L; ROBERTS WC, 1989, AM J CARDIOL, V64, P324, DOI 10.1016/0002-9149(89)90528-6; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAS Institute, 1990, SAS US GUID STAT VER; SMOAK CG, 1987, AM J EPIDEMIOL, V125, P364, DOI 10.1093/oxfordjournals.aje.a114543; SOLBERG LA, 1983, ARTERIOSCLEROSIS, V3, P187, DOI 10.1161/01.ATV.3.3.187; Srinivasan SR., 1983, CRC HDB ELECTROPHORE, P185; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; TEJADA C, 1968, LAB INVEST, V18, P509; WEBBER LS, 1979, PREV MED, V8, P407, DOI 10.1016/0091-7435(79)90018-5	30	2672	2790	1	136	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1998	338	23					1650	1656		10.1056/NEJM199806043382302	http://dx.doi.org/10.1056/NEJM199806043382302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR451	9614255				2022-12-24	WOS:000073978000002
J	Watts, DJ; Strogatz, SH				Watts, DJ; Strogatz, SH			Collective dynamics of 'small-world' networks	NATURE			English	Article							PULSE-COUPLED OSCILLATORS; SYNCHRONIZATION; DISEASE; SPREAD; CHAOS	Networks of coupled dynamical systems have been used to model biological oscillators(1-4), Josephson junction arrays(5,6), excitable media(7), neural networks(8-10), spatial games(11), genetic control networks(12) and many other self-organizing systems. Ordinarily, the connection topology is assumed to be either completely regular or completely random. But many biological, technological and social networks lie somewhere between these two extremes. Here we explore simple models of networks that can be tuned through this middle ground: regular networks 'rewired' to introduce increasing amounts of disorder. We find that these systems can be highly clustered, like regular lattices, yet have small characteristic path lengths, like random graphs. We call them 'small-world' networks, by analogy with the small-world phenomenon(13,14) (popularly known as six degrees of separation(15)). The neural network of the worm Caenorhabditis elegans, the power grid of the western United States, and the collaboration graph of film actors are shown to be small-world networks. Models of dynamical systems with small-world coupling display enhanced signal-propagation speed, computational power, and synchronizability. In particular, infectious diseases spread more easily in small-world networks than in regular lattices.	Cornell Univ, Dept Theoret & Appl Mech, Ithaca, NY 14853 USA	Cornell University	Watts, DJ (corresponding author), Columbia Univ, Paul F Lazarsfeld Ctr Social Sci, 812 SIPA Bldg,420 W118 St, New York, NY 10027 USA.		Xie, Jianjun/D-9838-2012; Strogatz, Steven H/A-1641-2014; Watts, Duncan J/J-6483-2012	Strogatz, Steven H/0000-0003-2923-3118; 				ABBOTT LF, 1993, PHYS REV E, V48, P1483, DOI 10.1103/PhysRevE.48.1483; [Anonymous], 1990, 6 DEGREES SEPARATION; [Anonymous], 1992, AYS NEUROANATOMY C E; Axelrod R., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; BLYTHE SP, 1991, MATH BIOSCI, V107, P379, DOI 10.1016/0025-5564(91)90015-B; BOLLABAS B, 1985, RANDOM GRAPHS; BRAIMAN Y, 1995, NATURE, V378, P465, DOI 10.1038/378465a0; Bressloff PC, 1997, PHYS REV LETT, V79, P2791, DOI 10.1103/PhysRevLett.79.2791; COLLINS JJ, 1995, NATURE, V376, P236, DOI 10.1038/376236a0; Das R, 1994, LECT NOTES COMPUT SC, V866, P344; GERHARDT M, 1990, SCIENCE, V247, P1563, DOI 10.1126/science.2321017; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; Hess G, 1996, ECOLOGY, V77, P1617, DOI 10.2307/2265556; HOPFIELD JJ, 1995, P NATL ACAD SCI USA, V92, P6655, DOI 10.1073/pnas.92.15.6655; KAUFFMAN SA, 1969, J THEOR BIOL, V22, P437, DOI 10.1016/0022-5193(69)90015-0; Kochen Manfred, 1989, SMALL WORLD; Kretzschmar M, 1996, MATH BIOSCI, V133, P165, DOI 10.1016/0025-5564(95)00093-3; Kuramoto Y, 1984, CHEM OSCILLATIONS WA; LONGINI IM, 1988, MATH BIOSCI, V90, P367, DOI 10.1016/0025-5564(88)90075-2; MILGRAM S, 1967, PSYCHOL TODAY, V1, P61; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; PHADKE AG, 1988, COMPUTER RELAYING PO; SATTENSPIEL L, 1988, MATH BIOSCI, V90, P341, DOI 10.1016/0025-5564(88)90074-0; STROGATZ SH, 1993, SCI AM, V269, P102, DOI 10.1038/scientificamerican1293-102; Wasserman S., 1994, SOCIAL NETWORK ANAL; Wiesenfeld K, 1996, PHYSICA B, V222, P315, DOI 10.1016/0921-4526(96)85057-5; Winfree A. T., 1980, GEOMETRY BIOL TIME, DOI 10.1007/978-1-4757-3484-3	27	25936	28025	241	4399	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					440	442		10.1038/30918	http://dx.doi.org/10.1038/30918			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9623998				2022-12-24	WOS:000074020000035
J	Westphal, RS; Anderson, KA; Means, AR; Wadzinski, BE				Westphal, RS; Anderson, KA; Means, AR; Wadzinski, BE			A signaling complex of Ca2+-calmodulin-dependent protein kinase IV and protein phosphatase 2A	SCIENCE			English	Article							TRANSCRIPTION FACTOR NFAT1; T-LYMPHOCYTES; CREB; PHOSPHORYLATION; ACTIVATION; AUTOPHOSPHORYLATION; DEPHOSPHORYLATION; PROLIFERATION; EXPRESSION; ANTIGENS	Stimulation of T lymphocytes results in a rapid increase in intracellular calcium concentration ([Ca2+](i)) that parallels the activation of Ca2+-calmodulin-dependent protein kinase IV (CaMKIV), a nuclear enzyme that can phosphorylate and activate the cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB). However, inactivation of CaMKIV occurs despite the sustained increase in [Ca2+](i) that is required for T cell activation. A stable and stoichiometric complex of CaM KIV with protein serine-threonine phosphatase 2A (PP2A) was identified in wh ich PP2A dephosphorylates CaMKIV and functions as a negative regulator of CaMKIV signaling. In Jurkat T cells, inhibition of PP2A activity by small t antigen enhanced activation of CREB-mediated transcription by CaMKIV. These findings reveal an intracellular signaling mechanism whereby a protein serine-threonine kinase (CaMKIV) is regulated by a tightly associated protein serine-threonine phosphatase (PP2A).	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Vanderbilt University; Duke University	Wadzinski, BE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA.				NICHD NIH HHS [HD07503] Funding Source: Medline; NIGMS NIH HHS [GM51366, GM33976] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051366, R56GM051366, R01GM033976] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON K, UNPUB; Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; KAMESHITA I, 1993, J BIOCHEM-TOKYO, V113, P583, DOI 10.1093/oxfordjournals.jbchem.a124087; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WESTPHAL R, UNPUB	32	219	226	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 22	1998	280	5367					1258	1261		10.1126/science.280.5367.1258	http://dx.doi.org/10.1126/science.280.5367.1258			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596578				2022-12-24	WOS:000073852500047
J	Zuany-Amorim, C; Ruffie, C; Haile, S; Vargaftig, BB; Pereira, P; Pretolani, M				Zuany-Amorim, C; Ruffie, C; Haile, S; Vargaftig, BB; Pereira, P; Pretolani, M			Requirement for gamma delta T cells in allergic airway inflammation	SCIENCE			English	Article							EOSINOPHILIC INFLAMMATION; IMMUNE-RESPONSES; TRANSGENIC MICE; IN-VIVO; ASTHMA; INTERLEUKIN-4; IGE; RECRUITMENT; LYMPHOCYTE; THYMOCYTES	The factors that contribute to allergic asthma are unclear but the resulting condition is considered a consequence of a type-2 T helper (T(H)2) cell response. In a model of pulmonary allergic inflammation, mice that lacked gamma delta T cells had decreases in specific immunoglobulin E (IgE) and IgG1 and pulmonary interleukin-5 (IL-5) release as well as in eosinophil and T cell infiltration compared with wild-type mice. These responses were restored by administration of IL-4 to gamma delta T cell-deficient mice during the primary immunization. Thus, gamma delta T cells are essential for inducing IL-4-dependent IgE and IgG1 responses and for T(H)2-mediated airway inflammation to peptidic antigens.	Inst Pasteur, Unite Pharmacol Cellulaire, U485, Paris, France; Inst Pasteur, Immunol Unit, CNRS, URA 1961, Paris, France; Inst Pasteur, Hepatol Unit, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Pretolani, M (corresponding author), Inst Pasteur, Unite Pharmacol Cellulaire, U485, Paris, France.		Pereira, Pablo/M-7224-2014; Pretolani, Marina/G-6643-2017; Vargaftig, Bernardo Boris B.B.J./C-3323-2013	Pereira, Pablo/0000-0003-1784-2776				ARASE H, 1993, EUR J IMMUNOL, V23, P307, DOI 10.1002/eji.1830230151; Azuara V, 1997, EUR J IMMUNOL, V27, P544, DOI 10.1002/eji.1830270228; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425, DOI 10.1165/ajrcmb.14.5.8624247; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Brown DR, 1996, J EXP MED, V184, P1295, DOI 10.1084/jem.184.4.1295; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Chvatchko Y, 1996, J EXP MED, V184, P2353, DOI 10.1084/jem.184.6.2353; CORRY DB, 1996, J EXP MED, V183, P1; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54, DOI 10.1165/ajrcmb.13.1.7598937; ERARD F, 1993, SCIENCE, V260, P1802, DOI 10.1126/science.8511588; Eum SY, 1995, P NATL ACAD SCI USA, V92, P12290, DOI 10.1073/pnas.92.26.12290; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUNG TT, 1995, AM J RESP CELL MOL, V12, P404, DOI 10.1165/ajrcmb.12.4.7695919; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; VAJDY M, 1995, J EXP MED, V181, P41, DOI 10.1084/jem.181.1.41; Vicari AP, 1996, EUR J IMMUNOL, V26, P1424, DOI 10.1002/eji.1830260704; Wen L, 1996, J EXP MED, V183, P2271, DOI 10.1084/jem.183.5.2271; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; Zhang Y, 1996, J EXP MED, V184, P1507, DOI 10.1084/jem.184.4.1507; ZuanyAmorim C, 1996, J IMMUNOL, V157, P377; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	28	227	236	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 22	1998	280	5367					1265	1267		10.1126/science.280.5367.1265	http://dx.doi.org/10.1126/science.280.5367.1265			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596580				2022-12-24	WOS:000073852500049
J	Li, DY; Brooke, B; Davis, EC; Mecham, RP; Sorensen, LK; Boak, BB; Eichwald, E; Keating, MT				Li, DY; Brooke, B; Davis, EC; Mecham, RP; Sorensen, LK; Boak, BB; Eichwald, E; Keating, MT			Elastin is an essential determinant of arterial morphogenesis	NATURE			English	Article							ATHEROSCLEROSIS; DISRUPTION; CELLS; GENE	Elastin, the main component of the extracellular matrix of arteries, was thought to have a purely structural role(1). Disruption of elastin was believed to lead to dissection of arteries(2,3), but we showed that mutations in one allele encoding elastin cause a human disease in which arteries are blocked, namely, supravalvular aortic stenosis(4,5). Here we define the role of elastin in arterial development and disease by generating mice that lack elastin. These mice die of an obstructive arterial disease, which results from subendothelial cell proliferation and reorganization of smooth muscle. These cellular changes are similar to those seen in atherosclerosis. However, lack of elastin is not associated with endothelial damage, thrombosis or inflammation, which occur in models of atherosclerosis. Haemodynamic stress is not associated with arterial obstruction in these mice either, as the disease still occurred in arteries that were isolated in organ culture and therefore not subject to haemodynamic stress. Disruption of elastin is enough to induce subendothelial proliferation of smooth muscle and may contribute to obstructive arterial disease. Thus, elastin has an unanticipated regulatory function during arterial development, controlling proliferation of smooth muscle and stabilizing arterial structure.	Univ Utah, Hlth Sci Ctr, Div Cardiol, Salt Lake City, UT 84112 USA; Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84112 USA; Eccles Inst Human Genet, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Washington University (WUSTL); Washington University (WUSTL)	Li, DY (corresponding author), Univ Utah, Hlth Sci Ctr, Div Cardiol, Salt Lake City, UT 84112 USA.		Davis, Elaine/F-3449-2012					Bittar, 1993, ADV MOL CELL BIOL, P133, DOI [10.1016/S1569-2558(08)60201-5, DOI 10.1016/S1569-2558(08)60201-5]; CURRAN ME, 1993, CELL, V73, P159, DOI 10.1016/0092-8674(93)90168-P; DENG CX, 1993, MOL CELL BIOL, V13, P2134, DOI 10.1128/MCB.13.4.2134; EWART AK, 1993, NAT GENET, V5, P11, DOI 10.1038/ng0993-11; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Gibbons GH, 1996, SCIENCE, V272, P689, DOI 10.1126/science.272.5262.689; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Langille BL, 1997, TRENDS CARDIOVAS MED, V7, P111, DOI 10.1016/S1050-1738(97)00005-4; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; OWENS GK, 1995, PHYSIOL REV, V75, P487; PROSSER IW, 1989, AM J PATHOL, V135, P1073; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; TERPIN T, 1987, CAN J PHYSIOL PHARM, V65, P395, DOI 10.1139/y87-066; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; Thompson RW, 1996, CURR OPIN CARDIOL, V11, P504, DOI 10.1097/00001573-199609000-00010	18	561	587	0	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					276	280		10.1038/30522	http://dx.doi.org/10.1038/30522			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607766				2022-12-24	WOS:000073761000056
J	Kanopka, A; Muhlemann, O; Petersen-Mahrt, S; Estmer, C; Ohrmalm, C; Akusjarvi, G				Kanopka, A; Muhlemann, O; Petersen-Mahrt, S; Estmer, C; Ohrmalm, C; Akusjarvi, G			Regulation of adenovirus alternative RNA splicing by dephosphorylation of SR proteins	NATURE			English	Article							PRE-MESSENGER-RNA; PHOSPHORYLATION; TRANSCRIPTION; INFECTION; SITES; LEVEL	SR proteins are a family of essential splicing factors required for early recognition of splice sites during spliceosome assembly(1,2). They also function as alternative RNA splicing factors when overexpressed in vivo or added in excess to extracts in vitro(1,2). SR proteins are highly phosphorylated in vivo, a modification that is required for their function in spliceosome assembly(3,4) and splicing catalysis(5,6). Here we show that SR proteins purified from late adenovirus-infected cells are inactivated as splicing enhancer or splicing repressor proteins by virus-induced dephosphorylation. We further show that the virus-encoded protein E4-ORF4 activates dephosphorylation by protein phosphatase 2A of HeLa SR proteins and converts their splicing properties into that of SR proteins purified from late adenovirus-infected cells. Taken together, our results suggest that E4-ORF4 is an important factor controlling the temporal shift in adenovirus alternative RNA splicing,We conclude that alternative pre-mRNA splicing, like many other biological processes, is regulated by reversible protein phosphorylation.	Univ Uppsala, BMC, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	Uppsala University	Akusjarvi, G (corresponding author), Univ Uppsala, BMC, Dept Med Biochem & Microbiol, Box 582, S-75123 Uppsala, Sweden.			Ohrmalm, Christina/0000-0002-3287-3549				Bondesson M, 1996, J VIROL, V70, P3844, DOI 10.1128/JVI.70.6.3844-3851.1996; CAO W, 1997, RNA, V3, P1; FU XD, 1995, RNA, V1, P663; HIMMELSPACH M, 1995, RNA, V1, P794; IMPERIALE M, 1995, CURR TOP MICROBIOL, P139; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; KREIVI JP, 1994, NUCLEIC ACIDS RES, V22, P332, DOI 10.1093/nar/22.3.332; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Moore DD, 1995, GLOB MOB SURV; MUHLEMANN O, 1995, J VIROL, V69, P7324; MULLER U, 1992, J VIROL, V66, P5867; OHMAN K, 1993, VIROLOGY, V194, P50, DOI 10.1006/viro.1993.1234; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	19	165	169	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1998	393	6681					185	187		10.1038/30277	http://dx.doi.org/10.1038/30277			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN200	9603524				2022-12-24	WOS:000073619900053
J	Hemingway, H; Shipley, M; Christie, D; Marmot, M				Hemingway, H; Shipley, M; Christie, D; Marmot, M			Is cardiothoracic ratio in healthy middle aged men an independent predictor of coronary heart disease mortality? Whitehall study 25 year follow up	BRITISH MEDICAL JOURNAL			English	Article									Univ Newcastle, Dept Environm & Occupat Hlth, Newcastle, NSW 2308, Australia; Kensington Chelsea & Westminster Hlth Author, Dept Res & Dev, London W2 6LX, England; UCL, Sch Med, Dept Epidemiol & Publ Hlth, Int Ctr Hlth & Soc, London WC1E 6BT, England	University of Newcastle; University of London; University College London; UCL Medical School	Hemingway, H (corresponding author), UCL, Sch Med, Dept Epidemiol & Publ Hlth, Int Ctr Hlth & Soc, Mortimer St, London WC1E 6BT, England.	h.hemingway@public-health.ucl.ac.uk	Hemingway, Harry/C-1219-2009; Marmot, M G/Y-3920-2019	Hemingway, Harry/0000-0003-2279-0624; Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		CHAMBERS J, 1995, BRIT MED J, V311, P273, DOI 10.1136/bmj.311.7000.273; CHRISTIE D, 1978, ACTA RADIOL DIAGN, V19, P732, DOI 10.1177/028418517801900503; DAVIS JL, 1986, AM J CARDIOL, V58, P658, DOI 10.1016/0002-9149(86)90300-0; RAUTAHARJU PM, 1988, AM J CARDIOL, V62, P59, DOI 10.1016/0002-9149(88)91365-3; REID DD, 1974, LANCET, V1, P469	5	13	13	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 2	1998	316	7141					1353	1354		10.1136/bmj.316.7141.1353	http://dx.doi.org/10.1136/bmj.316.7141.1353			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL882	9563985	Green Published, Green Submitted			2022-12-24	WOS:000073483000018
J	Brooke, NM; Garcia-Fernandez, J; Holland, PWH				Brooke, NM; Garcia-Fernandez, J; Holland, PWH			The ParaHox gene cluster is an evolutionary sister of the Hox gene cluster	NATURE			English	Article							HOMEOBOX GENES; MOUSE CHROMOSOME-5; DROSOPHILA; EXPRESSION; INSIGHTS; ZOOTYPE; EMBRYOS; IPF1	Genes of the Hox cluster are restricted to the animal kingdom and play a central role in axial patterning in divergent animal phyla(1). Despite its evolutionary and developmental significance, the origin of the Hox gene cluster is obscure. The consensus is that a primordial Hox cluster arose by tandem gene duplication close to animal origins(2-5). Several homeobox genes with high sequence identity to Hox genes are found outside the Hox cluster and are known as 'dispersed' Hox-like genes; these genes may have been transposed away from an expanding clusters. Here we show that three of these dispersed homeobox genes form a novel gene cluster in the cephalochordate amphioxus, We argue that this 'ParaHox' gene cluster is an ancient paralogue (evolutionary sister) of the Hox gene cluster; the two gene clusters arose by duplication of a ProtoHox gene cluster. Furthermore, we show that amphioxus ParaHox genes have co-linear developmental expression patterns in anterior, middle and posterior tissues. We propose that the origin of distinct Hox and ParaHox genes by gene-duster duplication facilitated an increase in body complexity during the Cambrian explosion.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England; Univ Barcelona, Fac Biol, Dept Genet, E-08028 Barcelona, Spain	University of Reading; University of Barcelona	Holland, PWH (corresponding author), Univ Reading, Sch Anim & Microbial Sci, POB 228, Reading RG6 6AJ, Berks, England.		Garcia-Fernandez, Jordi/B-3839-2013	Garcia-Fernandez, Jordi/0000-0001-5677-5970; Holland, Peter/0000-0003-1533-9376				Averof M, 1996, SEMIN CELL DEV BIOL, V7, P539, DOI 10.1006/scdb.1996.0068; Burglin Thomas R., 1994, P25; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; FELSENSTEIN J, 1993, PHYLIP VERSION 3 5C; FIEDOREK FT, 1995, GENOMICS, V28, P581, DOI 10.1006/geno.1995.1193; GARCIAFERNANDEZ J, 1994, NATURE, V370, P563, DOI 10.1038/370563a0; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.bi.63.070194.002415; GORBMAN A, 1983, AM ZOOL, V23, P639; HOLLAND PWH, 1992, DEVELOPMENT, V116, P653; Irvine SQ, 1997, MOL PHYLOGENET EVOL, V7, P331, DOI 10.1006/mpev.1997.0407; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KAPPEN C, 1989, P NATL ACAD SCI USA, V86, P5458; KOZAK CA, 1994, MAMM GENOME, V5, pS65; LEHRACH H, 1990, GENOME ANAL, V1, P38; Li H, 1996, EMBO J, V15, P714, DOI 10.1002/j.1460-2075.1996.tb00407.x; MILLER DJ, 1993, NATURE, V365, P215, DOI 10.1038/365215b0; MORRIS SC, 1994, DEVELOPMENT, P1; Offield MF, 1996, DEVELOPMENT, V122, P983; Popodi E, 1996, MOL BIOL EVOL, V13, P1078, DOI 10.1093/oxfordjournals.molbev.a025670; SCHUBERT FR, 1993, P NATL ACAD SCI USA, V90, P143, DOI 10.1073/pnas.90.1.143; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; STOFFEL M, 1995, GENOMICS, V28, P125, DOI 10.1006/geno.1995.1120; Szucsik JC, 1997, DEV BIOL, V191, P230, DOI 10.1006/dbio.1997.8733; Williams NA, 1996, NATURE, V383, P490, DOI 10.1038/383490a0; WRIGHT CVE, 1988, DEVELOPMENT, V104, P787; WYSOCKADILLER J, 1995, DEV BIOL, V171, P439, DOI 10.1006/dbio.1995.1294; Zhang JZ, 1996, GENETICS, V142, P295	30	341	354	6	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					920	922		10.1038/31933	http://dx.doi.org/10.1038/31933			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582071				2022-12-24	WOS:000073359900048
J	Schriger, DL; Kalafut, M; Starkman, S; Krueger, M; Saver, JL				Schriger, DL; Kalafut, M; Starkman, S; Krueger, M; Saver, JL			Cranial computed tomography interpretation in acute stroke - Physician accuracy in determining eligibility for thrombolytic therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Intracranial hemorrhage must be excluded prior to administration of thrombolytic agents in acute stroke. Objective.-To evaluate physician accuracy in cranial computed tomography scan interpretation for determining eligibility for thrombolytic therapy in acute stroke. Design.-Administration of randomly selected, randomly ordered series of 15 computed tomography scans from a pool of 54 scans that demonstrated intracerebral hemorrhage, acute infarction, intracerebral calcifications (impostor for hemorrhage), old cerebral infarction (impostor for acute infarction), and normal findings. Participants.-A convenience sample of 38 emergency physicians, 29 neurologists, and 36 general radiologists. Main Outcome Measures.-Physician determination of eligibility for thrombolytic therapy based on computed tomography scan interpretation. Results.-Average correct score by all physicians on all computed tomography scans was 77% (95% confidence interval, 74%-80%), Of 569 computed tomography readings by emergency physicians, 67% were correct; of 435 readings by neurologists, 83% were correct; and of 540 readings by radiologists, 83% were correct. Overall sensitivity for detecting hemorrhage was 82% (95% confidence interval, 78%-85%); 17% of emergency physicians, 40% of neurologists, and 52% of radiologists achieved 100% sensitivity for identification of hemorrhage. Conclusion.-Physicians in this study did not uniformly achieve a level of sensitivity for identification of intracerebral hemorrhage sufficient to permit safe selection of candidates for thrombolytic therapy.	Univ Calif Los Angeles, Sch Med, Ctr Emergency Med, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Stroke Ctr, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Schriger, DL (corresponding author), 924 Westwood Blvd,Suite 300, Los Angeles, CA 90024 USA.	schriger@ucla.edu		Schriger, David/0000-0003-0242-1127; Saver, Jeffrey/0000-0001-9141-2251				Adams HP, 1996, STROKE, V27, P1711; Adams HP, 1996, NEUROLOGY, V47, P835; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; CANDELISE L, 1995, LANCET, V346, P1509; Chavot D, 1996, CEREBROVASC DIS, V6, P182; Donnan GA, 1996, JAMA-J AM MED ASSOC, V276, P961, DOI 10.1001/jama.276.12.961; EBEL RL, 1986, ESSENTIALS ED MEASUR, P335; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hommel M, 1996, NEW ENGL J MED, V335, P145; Larrue V, 1997, STROKE, V28, P957, DOI 10.1161/01.STR.28.5.957; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; *NAT STROK ASS, 1997, STROK CLIN UPD; Nightingale SL, 1996, JAMA-J AM MED ASSOC, V276, P443; SACCO RL, 1994, CLIN ATLAS CEREBROVA; *STAT CORP, 1997, STAT STAT SOFTW REL, P235; vonKummer R, 1997, RADIOLOGY, V205, P327, DOI 10.1148/radiology.205.2.9356611; Wainer H.W., 1990, COMPUTERIZED ADAPTIV	18	160	163	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 29	1998	279	16					1293	1297		10.1001/jama.279.16.1293	http://dx.doi.org/10.1001/jama.279.16.1293			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH270	9565011	Bronze			2022-12-24	WOS:000073090300036
J	Wennberg, DE; Lucas, FL; Birkmeyer, JD; Bredenberg, CE; Fisher, ES				Wennberg, DE; Lucas, FL; Birkmeyer, JD; Bredenberg, CE; Fisher, ES			Variation in carotid endarterectomy mortality in the Medicare population - Trial hospitals, volume, and patient characteristics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STENOSIS; ATHEROSCLEROSIS; COMPLICATIONS	Context.-The North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the Asymptomatic Carotid Atherosclerosis Study (ACAS) demonstrated the efficacy of carotid endarterectomy (CEA) in reducing the risk of stroke and death in selected patients when surgery was performed in institutions whose participation depended on demonstrated excellence. Thirty-day mortality rates in the trials were very low: 0.6% in NASCET and 0.1% in ACAS. Objective.-To assess perioperative mortality among Medicare patients undergoing CEA in all nonfederal institutional settings. Design.-Retrospective national cohort study. Setting and Patients.-All 113 300 Medicare patients undergoing CEA during 1992 and 1993 in "trial hospitals" (those participating in NASCET and ACAS, n=86) and "nontrial hospitals" tall other nonfederal institutions performing CEAs, n=2613). Nontrial hospitals were stratified into terciles based on volume of CEAs performed. Main Outcome Measures.-Crude and adjusted perioperative (30 day) mortality rates. Results.-The perioperative mortality rate was 1.4% (95% confidence interval [CI], 1.2%-1.7%) at trial hospitals; mortality in nontrial hospitals was higher: 1.7% (95% CI, 1.6%-1.8%) thigh volume); 1.9% (95% CI, 1.7%-2.1%) (average volume); 2.5% (95% CI, 2.0%-2.9%) (low volume); (P for trend, <.001). In multivariate modeling, patients undergoing their procedures at trial hospitals had a mortality risk reduction of 15% (95% CI, 0%-31%) compared with high-volume nontrial hospitals, 25% (95% CI, 7%-40%) compared with average-volume hospitals, and 43% (95% CI, 25%-56%) compared with low-volume hospitals (P for trend, <.001). Conclusion.-Medicare patients' perioperative mortality following CEA is substantially higher than that reported in the trials, even in those institutions that participated in the randomized studies. Caution is advised in translating the efficacy of carefully controlled studies of CEA to effectiveness in everyday practice.	Maine Med Ctr, Div Hlth Serv Res, Portland, ME 04102 USA; Maine Med Ctr, Dept Surg, Portland, ME 04102 USA; Maine Med Assessment Fdn, Augusta, ME USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Ctr Evaluat Clin Sci, Hanover, NH 03756 USA; Dept Vet Affairs Med Ctr, White River Jct, VT USA	Maine Medical Center; Maine Medical Center; Dartmouth College	Wennberg, DE (corresponding author), Maine Med Ctr, Div Hlth Serv Res, Portland, ME 04102 USA.	wennbd@mail.mmc.org						BARNETT HJM, 1995, ANN INTERN MED, V123, P723, DOI 10.7326/0003-4819-123-9-199511010-00012; BARNETT HJM, 1991, STROKE, V22, P711, DOI 10.1161/01.STR.22.6.711; Barnett HJM, 1996, NEUROLOGY, V46, P603, DOI 10.1212/WNL.46.3.603; BROOK RH, 1990, ANN INTERN MED, V113, P747, DOI 10.7326/0003-4819-113-10-747; BROTT T, 1995, ANN INTERN MED, V123, P720, DOI 10.7326/0003-4819-123-9-199511010-00011; DAVIDOFF F, 1995, ANN INTERN MED, V123, P729, DOI 10.7326/0003-4819-123-9-199511010-00015; DIENER HC, 1991, STROKE, V22, P1229; *EUR CAR SURG TRIA, 1996, LANCET, V347, P1592; FISHER ES, 1989, AM J PUBLIC HEALTH, V79, P1617, DOI 10.2105/AJPH.79.12.1617; Fleiss J. L., 1981, STAT METHODS RATES P, V2; GRAVES EJ, 1997, VITAL HLTH STAT 13, V130, P124; Hertzer NR, 1996, J VASC SURG, V23, P167, DOI 10.1016/S0741-5214(05)80049-7; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; HSIA DC, 1992, J VASC SURG, V16, P201, DOI 10.1016/0741-5214(92)90108-K; KISTLER JP, 1991, NEW ENGL J MED, V325, P505, DOI 10.1056/NEJM199108153250709; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; Mitchell JB, 1996, HEALTH SERV RES, V31, P141; MOORE WS, 1991, STROKE, V22, P1353, DOI 10.1161/01.STR.22.11.1353; *N AM SYMPT CAR EN, 1991, STROKE, V22, P816; *NAT I NEUR DIS ST, 1994, CLIN AL CLIN ADV CAR; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Sarasin FP, 1995, NEUROLOGY, V45, P2147, DOI 10.1212/WNL.45.12.2147; Stukenborg GJ, 1997, ARCH NEUROL-CHICAGO, V54, P826, DOI 10.1001/archneur.1997.00550190018009; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WENNBERG J, 1997, DARTMOUTH ATLAS HLTH; WIEBERS DO, 1992, MAYO CLIN PROC, V67, P513; World Health Organisation, 1977, INT CLASS DIS 9 REV	31	364	381	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 29	1998	279	16					1278	1281		10.1001/jama.279.16.1278	http://dx.doi.org/10.1001/jama.279.16.1278			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH270	9565008	Bronze			2022-12-24	WOS:000073090300033
J	Artlett, CM; Smith, JB; Jimenez, SA				Artlett, CM; Smith, JB; Jimenez, SA			Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VERSUS-HOST DISEASE; BONE-MARROW TRANSPLANTATION; CHRONIC GRAFT; AUTOIMMUNE-DISEASE; SCLERODERMA; EPIDEMIOLOGY; BLOOD; CHIMERISM	Background Systemic sclerosis is a disease of unknown origin which often occurs in women after their childbearing years. It has many clinical and histopathological similarities to chronic graft-versus-host disease. Recent studies indicate that fetal stem cells can survive in the maternal circulation for many years post partum. This finding suggests that fetal cells persisting in the maternal circulation or tissues could be involved in the pathogenesis of systemic sclerosis by initiating a graft-versus-host reaction. Methods We used the polymerase chain reaction (PCR) to identify Y-chromosome sequences in DNA extracted from peripheral-blood cells and skin lesions from women with systemic sclerosis of recent onset. To confirm the PCR findings, we used fluorescence in situ hybridization of peripheral-blood cells and cells within chronic inflammatory-cell infiltrates in biopsy specimens of affected skin. Results Y-chromosome sequences were found in DNA from peripheral-blood cells in 32 of 69 women with systemic sclerosis (46 percent), as compared with 1 of 25 normal women (4 percent, P<0.001), and in T lymphocytes from 3 women with systemic sclerosis who had male offspring. Furthermore, Y-chromosome sequences were identified in skin-biopsy specimens from 11 of 19 women with systemic sclerosis (58 percent); 9 of the 11 were known to have carried male fetuses. Nucleated cells containing Y chromosomes were detected by fluorescence in situ hybridization in paraffin-embedded sections of skin lesions from all seven women we tested whose skin-biopsy specimens contained Y-chromosome sequences. Conclusions Fetal antimaternal graft-versus-host reactions may be involved in the pathogenesis of systemic sclerosis in some women. (C)1998, Massachusetts Medical Society.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Rheumatol, Philadelphia, PA 19107 USA	Jefferson University	Jimenez, SA (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Rheumatol, Rm 509,Bluemle Life Sci Bldg,233 S 10th St, Philadelphia, PA 19107 USA.			Jimenez, Sergio/0000-0001-5213-1203	NIADDK NIH HHS [AM19616] Funding Source: Medline; PHS HHS [CRMC-92-15] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM019616] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; APPLETON AL, 1994, BONE MARROW TRANSPL, V14, P157; Artlett CM, 1997, IMMUNOGENETICS, V47, P17, DOI 10.1007/s002510050321; BASSUKAS ID, 1992, MED HYPOTHESES, V38, P334, DOI 10.1016/0306-9877(92)90028-B; Bell SA, 1996, BRIT J DERMATOL, V134, P848; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; BLACK CM, 1989, RHEUM DIS CLIN N AM, V15, P193; BOS GMJ, 1989, TRANSPLANT P, V21, P3262; BRUBAKER DB, 1993, P SOC EXP BIOL MED, V202, P122; CHOSIDOW O, 1992, J AM ACAD DERMATOL, V26, P49, DOI 10.1016/0190-9622(92)70005-Z; CLEMENTS PJ, 1985, CURRENT TOPICS RHEUM, P376; FAGUNDUS DM, 1994, CLIN DERMATOL, V12, P407, DOI 10.1016/0738-081X(94)90293-3; FLEISCHMAJER R, 1977, ARTHRITIS RHEUM, V20, P975, DOI 10.1002/art.1780200410; GILL TJ, 1977, TRANSPLANT P, V9, P1423; GRAHAMBROWN RAC, 1983, CLIN EXP DERMATOL, V8, P531, DOI 10.1111/j.1365-2230.1983.tb01820.x; HERZOG P, 1980, J RHEUMATOL, V7, P56; JANINMERCIER A, 1984, AM J PATHOL, V115, P296; JIMENEZ SA, 1983, SEMIN ARTHRITIS RHEU, V13, P104, DOI 10.1016/0049-0172(83)90029-X; JUJI T, 1989, NEW ENGL J MED, V321, P56; KAHALEH MB, 1989, ANN INTERN MED, V110, P446, DOI 10.7326/0003-4819-110-6-446; LAMPERT IA, 1981, LANCET, V2, P1352; LAWLEY TJ, 1977, ANN INTERN MED, V87, P707, DOI 10.7326/0003-4819-87-6-707; MEDSGER TA, 1994, CLIN DERMATOL, V12, P207, DOI 10.1016/S0738-081X(94)90323-9; MEDSGER TA, 1971, ANN INTERN MED, V74, P714, DOI 10.7326/0003-4819-74-5-714; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nelson JL, 1996, ARTHRITIS RHEUM, V39, P191, DOI 10.1002/art.1780390203; OREILLY RJ, 1973, TRANSPLANTATION, V15, P505; PATRI S, 1994, PCR METH APPL, V3, P361; Postlethwaite Arnold E., 1993, Current Opinion in Rheumatology, V5, P766; SCHRODER J, 1975, J MED GENET, V12, P230, DOI 10.1136/jmg.12.3.230; SILMAN A, 1988, BRIT J RHEUMATOL, V27, P286; SILMAN AJ, 1988, ANN RHEUM DIS, V47, P441, DOI 10.1136/ard.47.6.441; SILMAN AJ, 1996, EPIDEMIOLOGY DEMOGRA, P23; Steele CD, 1996, CLIN OBSTET GYNECOL, V39, P801, DOI 10.1097/00003081-199612000-00009; STEEN VD, 1990, RHEUM DIS CLIN N AM, V16, P1; VALENTA LJ, 1987, ARCH DERMATOL, V123, P1438, DOI 10.1001/archderm.123.11.1438	36	364	371	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 23	1998	338	17					1186	1191		10.1056/NEJM199804233381704	http://dx.doi.org/10.1056/NEJM199804233381704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ376	9554859	Green Published			2022-12-24	WOS:000073208400004
J	Bushdid, PB; Brantley, DM; Yull, FE; Blaeuer, GL; Hoffman, LH; Niswander, L; Kerr, LD				Bushdid, PB; Brantley, DM; Yull, FE; Blaeuer, GL; Hoffman, LH; Niswander, L; Kerr, LD			Inhibition of NF-kappa B activity results in disruption of the apical ectodermal ridge and aberrant limb morphogenesis	NATURE			English	Article							CHICK LIMB; SONIC-HEDGEHOG; VERTEBRATE LIMB; FEEDBACK LOOP; GROWTH; TRANSCRIPTION; DROSOPHILA; EXPRESSION; PROMOTER; INITIATION	In Drosophila, the Dorsal protein establishes the embryonic dorso-ventral axis during development(1), Here we show that the vertebrate homologue of Dorsal, nuclear factor-kappa B (NF-kappa B), is vital for the formation of the proximo-distal organizer of the developing limb bud, the apical ectodermal ridge (AER). Transcription of the NF-kappa B proto-oncogene c-rel is regulated, in part, during morphogenesis of the limb bud by AER-derived signals such as fibroblast growth factors. Interruption of NF-kappa B activity using viral-mediated delivery of an inhibitor results in a highly dysmorphic AER, reduction in overall limb size, loss of distal elements and reversal in the direction of limb outgrowth. Furthermore, inhibition of NF-kappa B activity in limb mesenchyme leads to a reduction in expression of Sonic hedgehog and Twist but derepresses expression of the bone morphogenetic protein-4 gene. These results are the first evidence that vertebrate NF-kappa B proteins act to transmit growth factor signals between the ectoderm and the underlying mesenchyme during embryonic limb formation.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Canc Ctr, Nashville, TN 37232 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Memorial Sloan Kettering Cancer Center	Kerr, LD (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA.		Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594				BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; Gitelman I, 1997, DEV BIOL, V189, P205, DOI 10.1006/dbio.1997.8614; GRUMONT RJ, 1993, CELL GROWTH DIFFER, V4, P731; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NUSSLEINVOLHARD C, 1980, NATURE, V283, P474, DOI 10.1038/283474a0; PAN DJ, 1991, GENE DEV, V5, P1892, DOI 10.1101/gad.5.10.1892; ROS MA, 1993, PROG CLIN BIOL RES, V383, P79; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SCHWYTER DH, 1995, MOL CELL BIOL, V15, P3960; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; TRANCKNER EB, 1995, EMBO J, V14, P2876; Vogel A, 1996, DEVELOPMENT, V122, P1737; WALL NA, 1995, MECH DEVELOP, V53, P383, DOI 10.1016/0925-4773(95)00453-X; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Winnier GE, 1997, GENE DEV, V11, P926, DOI 10.1101/gad.11.7.926; Yokouchi Y, 1996, DEVELOPMENT, V122, P3725	29	148	151	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					615	618		10.1038/33435	http://dx.doi.org/10.1038/33435			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560159				2022-12-24	WOS:000072987200063
J	Stansby, G				Stansby, G			Vein quality in vascular surgery	LANCET			English	Editorial Material							SAPHENOUS-VEIN; GRAFT; FAILURE; DISEASE		Imperial Coll Sch Med, Div Surg Anaesthet & Intens Care, London W2 1NY, England	Imperial College London	Stansby, G (corresponding author), Imperial Coll Sch Med, Div Surg Anaesthet & Intens Care, London W2 1NY, England.			Stansby, Gerard/0000-0001-5539-3049				ADCOCK OT, 1984, SURGERY, V96, P886; DAVIES MG, 1995, EUR J VASC ENDOVASC, V9, P7, DOI 10.1016/S1078-5884(05)80218-7; Giannoukas AD, 1997, EUR J VASC ENDOVASC, V14, P37, DOI 10.1016/S1078-5884(97)80223-7; HARRIS PL, 1993, BRIT J SURG, V80, P173, DOI 10.1002/bjs.1800800213; Hedin U, 1997, EUR J VASC ENDOVASC, V13, P101, DOI 10.1016/S1078-5884(97)80004-4; MOODY AP, 1992, EUR J VASCULAR SURG, V6, P509, DOI 10.1016/S0950-821X(05)80625-5; PANETTA TF, 1992, J VASC SURG, V15, P102, DOI 10.1016/0741-5214(92)70018-G; SALES CM, 1993, J VASC SURG, V18, P198, DOI 10.1016/0741-5214(93)90599-H; THIENE G, 1980, THORAX, V35, P519, DOI 10.1136/thx.35.7.519; Wilson YG, 1998, ANN ROY COLL SURG, V80, P3	10	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1001	1002		10.1016/S0140-6736(05)78990-X	http://dx.doi.org/10.1016/S0140-6736(05)78990-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546500				2022-12-24	WOS:000072927200004
J	Welch, AM; Semlitsch, RD; Gerhardt, HC				Welch, AM; Semlitsch, RD; Gerhardt, HC			Call duration as an indicator of genetic quality in male gray tree frogs	SCIENCE			English	Article							ACOUSTIC CRITERIA; HYLA-VERSICOLOR; FEMALE CHOICE; LIFE-HISTORY; MATE CHOICE; SELECTION; VARIABILITY; BEHAVIOR; GROWTH; BUFO	The "good genes" hypothesis predicts that mating preferences enable females to select mates of superior genetic quality. The genetic consequences of the preference shown by female gray tree frogs for long-duration calls were evaluated by comparing the performance of maternal half-siblings sired by males with different call durations. Offspring of male gray tree frogs that produced long calls showed better performance during larval and juvenile stages than did offspring of males that produced short calls. These data suggest that call duration can function as a reliable indicator of heritable genetic quality.	Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Welch, AM (corresponding author), Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.			Semlitsch, Raymond/0000-0002-7999-5762				BERVEN KA, 1983, AM ZOOL, V23, P85; Falconer D. S., 1996, INTRO QUANTITATIVE G; FELLERS GM, 1979, COPEIA, P286, DOI 10.2307/1443416; Gerhardt HC, 1996, BEHAV ECOL, V7, P7, DOI 10.1093/beheco/7.1.7; GERHARDT HC, 1991, ANIM BEHAV, V42, P615, DOI 10.1016/S0003-3472(05)80245-3; GERHARDT HC, 1995, ANIM BEHAV, V50, P1187; Gosner K. L., 1960, Herpetologica, V16, P183; Grafe U, 1997, COPEIA, P356, DOI 10.2307/1447755; HOWARD RD, 1994, EVOLUTION, V48, P1286, DOI 10.1111/j.1558-5646.1994.tb05313.x; Kirkpatrick M, 1997, P NATL ACAD SCI USA, V94, P1282, DOI 10.1073/pnas.94.4.1282; KLUMP GM, 1987, NATURE, V326, P286, DOI 10.1038/326286a0; KRENZ JD, UNPUB; MITCHELL SL, 1990, EVOLUTION, V44, P502, DOI 10.1111/j.1558-5646.1990.tb05935.x; NORRIS K, 1993, NATURE, V362, P537, DOI 10.1038/362537a0; PETRIE M, 1994, NATURE, V371, P598, DOI 10.1038/371598a0; RITKE ME, 1990, J HERPETOL, V24, P135, DOI 10.2307/1564220; RUNKLE LS, 1994, BEHAV ECOL, V5, P318, DOI 10.1093/beheco/5.3.318; Semlitsch RD, 1996, EVOL ECOL, V10, P531, DOI 10.1007/BF01237883; Semlitsch RD, 1997, EVOLUTION, V51, P1249, DOI 10.1111/j.1558-5646.1997.tb03972.x; SEMLITSCH RD, 1994, BEHAV ECOL SOCIOBIOL, V34, P19; Sokal R. R, 1981, BIOMETRY; SULLIVAN BK, 1992, ANIM BEHAV, V44, P733, DOI 10.1016/S0003-3472(05)80299-4; WELLS KD, 1986, BEHAV ECOL SOCIOBIOL, V19, P9, DOI 10.1007/BF00303837; WILBUR HM, 1973, SCIENCE, V182, P1305, DOI 10.1126/science.182.4119.1305; WOODWARD BD, 1986, AM NAT, V128, P58, DOI 10.1086/284539; ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3	26	347	355	2	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1928	1930		10.1126/science.280.5371.1928	http://dx.doi.org/10.1126/science.280.5371.1928			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632389				2022-12-24	WOS:000074323800061
J	Eudy, JD; Weston, MD; Yao, SF; Hoover, DM; Rehm, HL; Ma-Edmonds, M; Yan, D; Ahmad, I; Cheng, JJ; Ayuso, C; Cremers, C; Davenport, S; Moller, C; Talmadge, CB; Beisel, KW; Tamayo, M; Morton, CC; Swaroop, A; Kimberling, WJ; Sumegi, J				Eudy, JD; Weston, MD; Yao, SF; Hoover, DM; Rehm, HL; Ma-Edmonds, M; Yan, D; Ahmad, I; Cheng, JJ; Ayuso, C; Cremers, C; Davenport, S; Moller, C; Talmadge, CB; Beisel, KW; Tamayo, M; Morton, CC; Swaroop, A; Kimberling, WJ; Sumegi, J			Mutation of a gene encoding a protein with extracellular matrix motifs in usher syndrome type IIa	SCIENCE			English	Article							SYNDROME TYPE-I; ALPORT SYNDROME; LOCALIZATION; IDENTIFICATION; CHROMOSOME-11	Usher syndrome type IIa (OMIM 276901), an autosomal recessive disorder characterized by moderate to severe sensorineural hearing loss and progressive retinitis pigmentosa, maps to the long arm of human chromosome 1q41 between markers AFM268ZD1 and AFM144XF2. Three biologically important mutations in Usher syndrome type IIa patients were identified in a gene (USH2A) isolated from this critical region. The USH2A gene encodes a protein with a predicted size of 171.5 kilodaltons that has laminin epidermal growth factor and fibronectin type III motifs; these motifs are most commonly observed in proteins comprising components of the basal lamina and extracellular matrixes and in cell adhesion molecules.	Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Boys Town Natl Res Hosp, Dept Genet, Omaha, NE 68131 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol, Ann Arbor, MI 48105 USA; Univ Nebraska, Med Ctr, Dept Cell Biol & Anat, Omaha, NE 68198 USA; Fdn Jimenez Diaz, E-28003 Madrid, Spain; Univ Nijmegen, Sint Radboudziekenhuis, NL-6500 NB Nijmegen, Netherlands; Univ Hosp RIL, Ear Nose & Throat Clin, S-58180 Linkoping, Sweden; Univ Javeriana, Unidad Genet Clin, Bogota, Colombia; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet Gynecol & Reprod Biol & Pathol, Boston, MA 02115 USA	University of Nebraska System; University of Nebraska Medical Center; Boys Town National Research Hospital; Harvard University; Harvard Medical School; University of Michigan System; University of Michigan; University of Nebraska System; University of Nebraska Medical Center; Radboud University Nijmegen; Pontificia Universidad Javeriana; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Sumegi, J (corresponding author), Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA.	jsumegi@mail.unmc.edu	Cremers, C.W.R.J./L-4254-2015	Rehm, Heidi L./0000-0002-6025-0015; Tamayo, Martha Lucia/0000-0001-8297-3970; Ayuso, Carmen/0000-0002-9242-7065; Swaroop, Anand/0000-0002-1975-1141	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P01DC001813, R01DC003402] Funding Source: NIH RePORTER; NEI NIH HHS [EY07003] Funding Source: Medline; NIDCD NIH HHS [DC03402, 5PO1 DC01813-05] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BARTSCH U, 1990, J NEUROCYTOL, V19, P550, DOI 10.1007/BF01257243; BOUGHMAN JA, 1983, BRIT J OPHTHALMOL, V67, P449, DOI 10.1136/bjo.67.7.449; Chaib H, 1997, HUM MOL GENET, V6, P27, DOI 10.1093/hmg/6.1.27; DAHL SP, 1993, J MED GENET, V30, P843, DOI 10.1136/jmg.30.10.843; ElAmraoui A, 1996, HUM MOL GENET, V5, P1171, DOI 10.1093/hmg/5.8.1171; EUDY JD, UNPUB; HALLGREN B, 1959, ACTA PSYCHIAT SCAN S, V138; KAPLAN J, 1992, GENOMICS, V14, P979, DOI 10.1016/S0888-7543(05)80120-X; Kimberling W J, 1995, J Am Acad Audiol, V6, P63; KIMBERLING WJ, 1992, GENOMICS, V14, P988, DOI 10.1016/S0888-7543(05)80121-1; KIMBERLING WJ, 1990, GENOMICS, V7, P245, DOI 10.1016/0888-7543(90)90546-7; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; MOCHIZUKI T, 1994, NAT GENET, V8, P77, DOI 10.1038/ng0994-77; OGDEN TE, 1994, RETINA, P58; PIASSA L, 1986, ARCH OPHTHALMOL-CHIC, V1041, P1336; ROBERTSON NG, 1994, GENOMICS, V23, P42, DOI 10.1006/geno.1994.1457; Rosenberg T, 1997, CLIN GENET, V51, P314; SANKILA EM, 1995, HUM MOL GENET, V4, P93, DOI 10.1093/hmg/4.1.93; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; SoussiYanicostas N, 1996, J CELL SCI, V109, P1749; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; Sumegi J, 1996, GENOMICS, V35, P79, DOI 10.1006/geno.1996.0325; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Vielmetter J, 1997, GENOMICS, V41, P414, DOI 10.1006/geno.1997.4688; Wayne S, 1996, HUM MOL GENET, V5, P1689, DOI 10.1093/hmg/5.10.1689; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0	27	291	301	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	1998	280	5370					1753	1757		10.1126/science.280.5370.1753	http://dx.doi.org/10.1126/science.280.5370.1753			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624053				2022-12-24	WOS:000074197800042
J	Shann, F				Shann, F			Pneumococcal vaccine: time for another controlled trial	LANCET			English	Editorial Material							RESPIRATORY-TRACT INFECTIONS; PAPUA-NEW-GUINEA; CHILDREN		Royal Childrens Hosp, Intens Care Unit, Melbourne, Vic 3052, Australia	Royal Children's Hospital Melbourne	Shann, F (corresponding author), Royal Childrens Hosp, Intens Care Unit, Flemington Rd, Melbourne, Vic 3052, Australia.		Shann, Frank/C-9510-2011					AABY P, 1995, SOC SCI MED, V41, P673, DOI 10.1016/0277-9536(95)00038-9; Dullforce P, 1998, NAT MED, V4, P88, DOI 10.1038/nm0198-088; Goldblatt D, 1993, Immunodeficiency, V4, P47; Kayhty H, 1996, EMERG INFECT DIS, V2, P289, DOI 10.3201/eid0204.9604; LEHMANN D, 1991, ANN TROP PAEDIATR, V11, P247, DOI 10.1080/02724936.1991.11747510; POMAT WS, 1994, INFECT IMMUN, V62, P1848, DOI 10.1128/IAI.62.5.1848-1853.1994; RILEY ID, 1986, LANCET, V2, P877; TEMPLE K, 1991, PEDIATR INFECT DIS J, V10, P386, DOI 10.1097/00006454-199105000-00008; Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006; *WHO, 1997, TECHN REV GROUP M JU, P32; *WHO, 1995, WORLD HLTH REP 1995, P9; WITT CS, 1991, CLIN EXP IMMUNOL, V83, P219, DOI 10.1111/j.1365-2249.1991.tb05618.x; Woolfson A, 1997, B WORLD HEALTH ORGAN, V75, P453; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	14	19	20	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1600	1601		10.1016/S0140-6736(05)77683-2	http://dx.doi.org/10.1016/S0140-6736(05)77683-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620711				2022-12-24	WOS:000074026600004
J	McCord, TB; Hansen, GB; Fanale, FP; Carlson, RW; Matson, DL; Johnson, TV; Smythe, WD; Crowley, JK; Martin, PD; Ocampo, A; Hibbitts, CA; Granahan, JC				McCord, TB; Hansen, GB; Fanale, FP; Carlson, RW; Matson, DL; Johnson, TV; Smythe, WD; Crowley, JK; Martin, PD; Ocampo, A; Hibbitts, CA; Granahan, JC		NIMS Team	Salts an Europa's surface detected by Galileo's Near Infrared Mapping Spectrometer	SCIENCE			English	Article							MAGNETOSPHERIC ION-BOMBARDMENT; PLAYA EVAPORITE MINERALS; AMORPHOUS SOLID WATER; MU-M; DEATH-VALLEY; SATELLITES; REFLECTANCE; SPECTRA; ICE; SPECTROSCOPY	Reflectance spectra in the 1- to 2.5-micrometer wavelength region of the surface of Europa obtained by Galileo's Near Infrared Mapping Spectrometer exhibit distorted water absorption bands that indicate the presence of hydrated minerals, The laboratory spectra of hydrated salt minerals such as magnesium sulfates and sodium carbonates and mixtures of these minerals provide a close match to the Europa spectra. The distorted bands are only observed in the optically darker areas of Europa, including the lineaments, and may represent evaporite deposits formed by water, rich in dissolved salts, reaching the surface from a water-rich layer underlying an ice crust.	Univ Hawaii, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; US Geol Survey, Reston, VA 22091 USA; STI Inc, Honolulu, HI 96813 USA	University of Hawaii System; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); United States Department of the Interior; United States Geological Survey	McCord, TB (corresponding author), Univ Hawaii, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA.		Hibbitts, Charles/B-7787-2016	Hibbitts, Charles/0000-0001-9089-4391				Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; CALVIN WM, 1995, J GEOPHYS RES-PLANET, V100, P19041, DOI 10.1029/94JE03349; Carlson R, 1996, SCIENCE, V274, P385, DOI 10.1126/science.274.5286.385; CARLSON RW, 1992, SPACE SCI REV, V60, P457, DOI 10.1007/BF00216865; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CARR MH, 1997, LUNAR PLANET SCI, V28, P207; CASSEN P, 1980, GEOPHYS RES LETT, V7, P987, DOI 10.1029/GL007i011p00987; CASSEN P, 1979, GEOPHYS RES LETT, V6, P731, DOI 10.1029/GL006i009p00731; CLARK RN, 1980, ICARUS, V44, P388, DOI 10.1016/0019-1035(80)90033-0; CLARK RN, 1981, J GEOPHYS RES, V86, P3087, DOI 10.1029/JB086iB04p03087; CLARK RN, 1982, ICARUS, V49, P244, DOI 10.1016/0019-1035(82)90075-6; Crowley JK, 1996, ECON GEOL BULL SOC, V91, P622, DOI 10.2113/gsecongeo.91.3.622; CROWLEY JK, 1991, J GEOPHYS RES-SOL EA, V96, P16231, DOI 10.1029/91JB01714; CROWLEY JK, 1993, REMOTE SENS ENVIRON, V44, P337, DOI 10.1016/0034-4257(93)90025-S; FANALE FP, 1998, LUNAR PLANET SCI, V29, P1248; FANALE FP, UNPUB; FANALE FP, 1977, PLANETARY SATELLITES, P379; FINK UWE, 1975, ICARUS, V24, P411, DOI 10.1016/0019-1035(75)90058-5; Gaines R.V., 1998, DANAS NEW MINERALOGY, V120, P2693; GRANAHAN JC, 1997, B AM ASTRON SOC, V29, P982; GRANAHAN JC, 1997, EOS S, V78, pF417; GRUNDY WM, IN PRESS J GEOPHYS R; HAGEN W, 1981, CHEM PHYS, V56, P367, DOI 10.1016/0301-0104(81)80158-9; HAGEN W, 1982, SPECTROCHIM ACTA A, V38, P1089, DOI 10.1016/0584-8539(82)80040-8; HANSEN GB, 1997, LUNAR PLANET SCI, V28, P505; HARDIE LA, 1968, GEOCHIM COSMOCHIM AC, V32, P1279, DOI 10.1016/0016-7037(68)90029-X; HOBBS PV, 1974, ICE PHYSICS; Hunt G. R., 1973, Modern Geology, V4, P85; Hunten D. M., 1971, Comments on Astrophysics and Space Physics, V3, P1; IRVINE WM, 1968, ICARUS, V8, P324, DOI 10.1016/0019-1035(68)90083-3; JOHNSON RE, 1988, ICARUS, V75, P423, DOI 10.1016/0019-1035(88)90155-8; JOHNSON TV, 1983, J GEOPHYS RES, V88, P5789, DOI 10.1029/JB088iB07p05789; JOHNSON TV, 1971, ASTROPHYS J, V169, P589, DOI 10.1086/151177; KARGEL JS, 1991, ICARUS, V94, P368, DOI 10.1016/0019-1035(91)90235-L; Kempe S, 1989, ORIGIN EVOLUTION MOD, P29; KIEFFER HH, 1974, ICARUS, V21, P506, DOI 10.1016/0019-1035(74)90153-5; KUIPER GP, 1961, SOLAR SYSTEM, V3, P305; LANE AL, 1981, NATURE, V292, P38, DOI 10.1038/292038a0; Luchitta B. K., 1982, SATELLITES JUPITER, P521; MALIN MC, 1986, SATELLITES, P689; McCord TB, 1998, J GEOPHYS RES-PLANET, V103, P8603, DOI 10.1029/98JE00788; McCord TB, 1997, SCIENCE, V278, P271, DOI 10.1126/science.278.5336.271; MCCORD TB, 1997, EOS T AGU S, V78, pF407; MCCORD TB, 1998, LUNAR PLANET SCI, V29, P1560; MCCORD TB, 1997, EOS S, V78, pS202; MOROZ VI, 1965, T SOVIET ASTRON A J, V9, P999; NELSON RM, 1987, ICARUS, V72, P358, DOI 10.1016/0019-1035(87)90180-1; NOLL KS, 1995, J GEOPHYS RES-PLANET, V100, P19057, DOI 10.1029/94JE03294; OCKMAN N, 1958, ADV PHYS, V7, P199, DOI 10.1080/00018735800101227; PITCHER CB, 1972, SCIENCE, V178, P1087; POLLACK JB, 1978, ICARUS, V36, P271, DOI 10.1016/0019-1035(78)90110-0; POSPIESZALSKA MK, 1989, ICARUS, V78, P1, DOI 10.1016/0019-1035(89)90065-1; REYNOLDS RT, 1983, ICARUS, V56, P246, DOI 10.1016/0019-1035(83)90037-4; SACK NJ, 1992, ICARUS, V100, P534, DOI 10.1016/0019-1035(92)90116-O; SMITH BA, 1979, SCIENCE, V206, P927, DOI 10.1126/science.206.4421.927; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; STANIER RY, 1986, MICROBIAL WORLD, P22; Swayze G., 1993, B AM ASTRON SOC, V25, P1033; WARREN SG, 1984, APPL OPTICS, V23, P1206, DOI 10.1364/AO.23.001206; WISCOMBE WJ, 1980, J ATMOS SCI, V37, P2712, DOI 10.1175/1520-0469(1980)037<2712:AMFTSA>2.0.CO;2	60	299	306	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 22	1998	280	5367					1242	1245		10.1126/science.280.5367.1242	http://dx.doi.org/10.1126/science.280.5367.1242			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596573				2022-12-24	WOS:000073852500042
J	Herzog, KH; Chong, MJ; Kapsetaki, M; Morgan, JI; McKinnon, PJ				Herzog, KH; Chong, MJ; Kapsetaki, M; Morgan, JI; McKinnon, PJ			Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system	SCIENCE			English	Article							ATAXIA-TELANGIECTASIA; DEFICIENT MICE; P53; APOPTOSIS; CYCLE	Ataxia telangiectasia (AT) is characterized by progressive neurodegeneration that results from mutation of the ATM gene. However, neither the normal function of ATM in the nervous system nor the biological basis of the degeneration in AT is known. Resistance to apoptosis in the developing central nervous system (CNS) of Atm(-/-) mice was observed after ionizing radiation, This lack of death occurred in diverse regions of the CNS, including the cerebellum, which is markedly affected in AT. In wild-type, but not Atm(-/-) mice, up-regulation of p53 coincided with cell death, suggesting that Atm-dependent apoptosis in the CNS is mediated by p53, Further, p53 null mice showed a similar lack of radiation-induced cell death in the developing nervous system, Atm may function at a developmental survival checkpoint that serves to eliminate neurons with excessive DNA damage.	St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38101 USA; St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38101 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	McKinnon, PJ (corresponding author), St Jude Childrens Res Hosp, Dept Genet, 332 N Lauderdale, Memphis, TN 38101 USA.	peter.mckinnon@stjude.org	Morgan, James/N-8104-2018; Morgan, James/GRO-2905-2022	Morgan, James/0000-0002-8920-1065	NCI NIH HHS [CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Cowan W M, 1980, Curr Top Dev Biol, V15 Pt 1, P103; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; Heintz N, 1996, CURR OPIN NEUROL, V9, P137, DOI 10.1097/00019052-199604000-00014; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kuljis RO, 1997, P NATL ACAD SCI USA, V94, P12688, DOI 10.1073/pnas.94.23.12688; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MIDGLEY CA, 1992, J CELL SCI, V101, P183; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SOARES HA, IN PRESS NEUROSCIENC; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; WOOD KA, 1995, J NEUROSCI, V15, P5851; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437	29	359	372	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1089	1091		10.1126/science.280.5366.1089	http://dx.doi.org/10.1126/science.280.5366.1089			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9582124				2022-12-24	WOS:000073663600050
J	Struhl, G; Adachi, A				Struhl, G; Adachi, A			Nuclear access and action of notch in vivo	CELL			English	Article							DEVELOPING DROSOPHILA EYE; EPIDERMAL GROWTH-FACTOR; OF-FUNCTION MUTATIONS; SPLIT COMPLEX GENES; ACTIVATES TRANSCRIPTION; SIGNAL-TRANSDUCTION; RECEPTOR; PROTEIN; EXPRESSION; SUPPRESSOR	The Drosophila Notch (N) gene encodes a conserved single-pass transmembrane receptor that transduces extracellular signals controlling cell fate. Here, we present evidence that the intracellular domain of Notch gains access to the nucleus in response to ligand, possibly through a mechanism involving proteolytic cleavage and release from the remainder of the protein. In addition, our results suggest that signal transduction by Notch depends on the ability of the intracellular domain, particularly the portion containing the CDC10 repeats, to reach the nucleus and to participate in the transcriptional activation of downstream target genes.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Struhl, G (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, Howard Hughes Med Inst, 701 W 168th St, New York, NY 10032 USA.							ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Eastman DS, 1997, MOL CELL BIOL, V17, P5620, DOI 10.1128/MCB.17.9.5620; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FISHER AL, 1998, IN PRESS GENES DEV; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD I, 1998, IN PRESS GENES DEV; HEITZLER P, 1993, DEVELOPMENT, V117, P1113; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KODOYIANNI V, 1992, MOL BIOL CELL, V3, P1199, DOI 10.1091/mbc.3.11.1199; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Roehl H, 1996, EMBO J, V15, P7002, DOI 10.1002/j.1460-2075.1996.tb01092.x; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Wang SW, 1997, DEVELOPMENT, V124, P4435; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	40	630	651	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1998	93	4					649	660		10.1016/S0092-8674(00)81193-9	http://dx.doi.org/10.1016/S0092-8674(00)81193-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604939	hybrid			2022-12-24	WOS:000073722200017
J	Weil, MD; Lamborn, K; Edwards, MSB; Wara, WM				Weil, MD; Lamborn, K; Edwards, MSB; Wara, WM			Influence of a child's sex on medulloblastoma outcome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADIATION-THERAPY; ADJUVANT CHEMOTHERAPY; PEDIATRIC-PATIENTS; SURVIVAL; TUMORS; VINCRISTINE; IRRADIATION; PATTERNS; GROWTH; TRIAL	Context.-Aggressive treatment of medulloblastoma, the most common pediatric brain tumor, has not improved survival. Identifying better prognostic indicators may warrant less morbid therapy. Objective.-To investigate the role of sex on outcome of medulloblastoma. Design.-Retrospective study of significant factors for survival with a median follow-up of 82 months. Setting.-University medical center. Patients.-A total of 109 consecutive, pediatric patients treated for primary medulloblastoma from 1970 to 1995 with surgery and postoperative radiotherapy and, after 1979, chemotherapy. Main Outcome Measures.-Factors independently associated with survival. Results.-The final multivariate model predicting improved survival included sex (hazard ratio, 0.52; 95% confidence interval [CI], 0.29-0.92; P=.03; favoring female), metastases at presentation (hazard ratio, 2.01,95% CI, 1.14-3.52; P=.02), and extent of surgical resection (hazard ratio, 0.60; 95% CI, 0.34-1.04; P=.07; favoring greater resection). The overall, 5-year freedom from progression was 40% and survival was 49%. Radiotherapy dose (P=.72), and chemotherapy (P=.90) did not significantly affect a disease outcome. Conclusions.-The sex of the child was an important predictor for survival of medulloblastoma; girls had a much better outcome. The difference in survival between sexes should be evaluated in prospective, clinical trials.	Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weil, MD (corresponding author), Univ Colorado, Ctr Canc, Dept Radiat Oncol, Box A031, Denver, CO 80262 USA.							AGARD ET, 1985, HEALTH PHYS, V48, P447, DOI 10.1097/00004032-198504000-00007; BLOOM HJG, 1969, AMER J ROENTGENOL RA, V105, P43, DOI 10.2214/ajr.105.1.43; BOURNE JP, 1992, J NEURO-ONCOL, V14, P263; BROWN IH, 1983, ARCH DIS CHILD, V58, P722, DOI 10.1136/adc.58.9.722; COX DR, 1972, J R STAT SOC B, V34, P187; Danjoux CE, 1996, MED PEDIATR ONCOL, V26, P1, DOI 10.1002/(SICI)1096-911X(199601)26:1<1::AID-MPO1>3.0.CO;2-Q; DIDCOCK E, 1995, J CLIN ONCOL, V13, P2503, DOI 10.1200/JCO.1995.13.10.2503; DUFFNER PK, 1985, CANCER-AM CANCER SOC, V56, P1841, DOI 10.1002/1097-0142(19851001)56:7+<1841::AID-CNCR2820561325>3.0.CO;2-C; EVANS AE, 1990, J NEUROSURG, V72, P572, DOI 10.3171/jns.1990.72.4.0572; FARWELL JR, 1984, J NEUROSURG, V61, P657, DOI 10.3171/jns.1984.61.4.0657; GARTON GR, 1990, MAYO CLIN PROC, V65, P1077, DOI 10.1016/S0025-6196(12)62720-7; HUGHES EN, 1988, CANCER, V61, P1992, DOI 10.1002/1097-0142(19880515)61:10<1992::AID-CNCR2820611011>3.0.CO;2-J; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KHALID H, 1995, CANCER, V75, P2571, DOI 10.1002/1097-0142(19950515)75:10<2571::AID-CNCR2820751026>3.0.CO;2-U; MOSS SD, 1988, NEUROSURGERY, V22, P758; NOVAKOVIC B, 1994, MED PEDIATR ONCOL, V23, P480, DOI 10.1002/mpo.2950230606; PACKER RJ, 1994, J NEUROSURG, V81, P690, DOI 10.3171/jns.1994.81.5.0690; PACKER RJ, 1991, J NEUROSURG, V74, P433, DOI 10.3171/jns.1991.74.3.0433; PRADOS MD, 1994, INT J RADIAT ONCOL, V28, P431, DOI 10.1016/0360-3016(94)90067-1; PRESTONMARTIN S, 1993, NEUROEPIDEMIOLOGY, V12, P270, DOI 10.1159/000110328; SILBER JH, 1992, J CLIN ONCOL, V10, P1390, DOI 10.1200/JCO.1992.10.9.1390; TAIT DM, 1990, EUR J CANCER, V26, P464; WARA WM, 1994, INT J RADIAT ONCOL, V30, P551, DOI 10.1016/0360-3016(92)90940-J	23	60	60	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1998	279	18					1474	1476		10.1001/jama.279.18.1474	http://dx.doi.org/10.1001/jama.279.18.1474			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL718	9600483	Bronze			2022-12-24	WOS:000073463500038
J	Epping-Jordan, MP; Watkins, SS; Koob, GF; Markou, A				Epping-Jordan, MP; Watkins, SS; Koob, GF; Markou, A			Dramatic decreases in brain reward function during nicotine withdrawal	NATURE			English	Article							ABSTINENCE SYNDROME; NUCLEUS-ACCUMBENS; SMOKING CESSATION; RAT; STIMULATION; DEPENDENCE; ANTAGONIST; TOLERANCE; THRESHOLD; INFUSION	Tobacco smoking is a worldwide public health problem. In the United States alone, over 400,000 deaths and $50 billion in medical costs annually are directly attributed to smoking(1). Accumulated evidence indicates that nicotine is the component of tobacco smoke that leads to addiction(2), but the means by which nicotine produces addiction remain unclear. Nicotine is less effective as a positive reinforcer than other drugs of abuse in non-dependent animals(3). Nevertheless, nicotine-withdrawal symptoms, including depressed mood, anxiety, irritability and craving(4,5) in dependent subjects may contribute to the addictive liability of nicotine(6,7). We show here that spontaneous nicotine withdrawal in rats resulted in a significant decrease in brain reward function, as measured by elevations in brain reward thresholds, which persisted for four days. Further, systemic injections of a competitive nicotinic-receptor antagonists led to a dose-dependent increase in brain reward thresholds in chronic nicotine-treated rats. The decreased function in brain reward systems during nicotine withdrawal is comparable in magnitude and duration to that of other major drugs of abuse(9-13), and may constitute an important motivational factor that contributes to craving, relapse and continued tobacco consumption in humans(7).	Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA	Scripps Research Institute	Markou, A (corresponding author), Scripps Res Inst, Dept Neuropharmacol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552				BAUCO P, 1994, J PHARMACOL EXP THER, V271, P294; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; DAMAJ MI, 1995, PSYCHOPHARMACOLOGY, V117, P67, DOI 10.1007/BF02245100; DOHERTY K, 1995, PSYCHOPHARMACOLOGY, V119, P171, DOI 10.1007/BF02246158; GELLERT VF, 1978, J PHARMACOL EXP THER, V205, P536; Hildebrand BE, 1997, PSYCHOPHARMACOLOGY, V129, P348, DOI 10.1007/s002130050200; HUGHES JR, 1992, HEALTH PSYCHOL, V11, P331, DOI 10.1037/0278-6133.11.5.331; HUGHES JR, 1991, ARCH GEN PSYCHIAT, V48, P52; HUSTONLYONS D, 1992, PHARMACOL BIOCHEM BE, V41, P755, DOI 10.1016/0091-3057(92)90223-3; KILLEN JD, 1991, PSYCHOPHARMACOLOGY, V105, P191, DOI 10.1007/BF02244308; KORNETSKY C, 1979, FED PROC, V38, P2473; LEITH NJ, 1976, PSYCHOPHARMACOLOGIA, V46, P19, DOI 10.1007/BF00421544; MALARCHER AM, 1997, MMWR-MORBID MORTAL W, V46, P444; MALIN DH, 1993, PSYCHOPHARMACOLOGY, V112, P339, DOI 10.1007/BF02244930; MALIN DH, 1994, PSYCHOPHARMACOLOGY, V115, P180, DOI 10.1007/BF02244770; MALIN DH, 1992, PHARMACOL BIOCHEM BE, V43, P779, DOI 10.1016/0091-3057(92)90408-8; MARKOU A, 1992, PHYSIOL BEHAV, V51, P111, DOI 10.1016/0031-9384(92)90211-J; MARKOU A, 1991, NEUROPSYCHOPHARMACOL, V4, P17; Markou A, 1998, NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-133X(97)00113-9; MENDELSON JH, 1979, NEW ENGL J MED, V301, P912, DOI 10.1056/NEJM197910253011704; MURRIN LC, 1987, LIFE SCI, V40, P1699, DOI 10.1016/0024-3205(87)90020-8; NISELL M, 1994, PHARMACOL TOXICOL, V75, P348, DOI 10.1111/j.1600-0773.1994.tb00373.x; OKAMOTO M, 1976, EUR J PHARMACOL, V40, P107, DOI 10.1016/0014-2999(76)90360-5; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; RISNER ME, 1983, J PHARMACOL EXP THER, V224, P319; SCHULTEIS G, 1995, P NATL ACAD SCI USA, V92, P5880, DOI 10.1073/pnas.92.13.5880; SCHULTEIS G, 1994, J PHARMACOL EXP THER, V271, P1391; Shiffman S, 1996, J CONSULT CLIN PSYCH, V64, P993, DOI 10.1037//0022-006X.64.5.993; STOLERMAN IP, 1995, PSYCHOPHARMACOLOGY, V117, P2, DOI 10.1007/BF02245088; *US DEP HHS, 1988, HLTH CONS SMOK NIC A	30	524	536	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1998	393	6680					76	79		10.1038/30001	http://dx.doi.org/10.1038/30001			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590692				2022-12-24	WOS:000073497500050
J	Taylor, S; Lever, JH; Harvey, RP				Taylor, S; Lever, JH; Harvey, RP			Accretion rate of cosmic spherules measured at the South Pole	NATURE			English	Article							DEEP-SEA SEDIMENTS; NATURAL-CONVECTION; MASS-DISTRIBUTION; BLUE ICE; DUST; ANTARCTICA; GREENLAND; INFLUX; WATER	Micrometeorites are terrestrially collected, extraterrestrial particles smaller than about 1 mm, which account for most of the mass being accreted to the Earth(1,2). Compared with meteorites, micrometeorites more completely represent the Earth-crossing meteoroid complex(3,4) and should include fragments of asteroids, comets, Mars and our Moon, as well as pre-solar and interstellar grains(3,6). Previous measurements of the flux of micrometeoroids that survive to the Earth's surface have large uncertainties owing to the destruction of particles by weathering(7-9), inefficiencies in magnetic collection or separation techniques(7-9), low particle counts(10,11), poor age constraint(7-9,12,13) or highly variable concentrating processes(12,13), Here we describe an attempt to circumvent these problems through the collection of thousands of well preserved and dated micrometeorites from the bottom of the South Pole water well, which supplies drinking water for the Scott-Amundsen station. Using this collection, we have determined precise estimates of the flu and mass distribution for 50-700-mu m cosmic spherules (melted micrometeorites). Allowing for the expected abundance of unmelted micrometeorites(1)4 in the samples, our results indicate that about 90% of the incoming mass of submillimetre particles evaporates during atmospheric entry. Our data indicate the loss of glass-rich and small stony spherules from deep-sea deposits(7,8), and they provide constraints for models describing the survival probability of micrometeoroids(15,16).	USA, Cold Reg Res & Engn Lab, Hanover, NH 03755 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA	United States Department of Defense; United States Army; U.S. Army Corps of Engineers; U.S. Army Engineer Research & Development Center (ERDC); Cold Regions Research & Engineering Laboratory (CRREL); Case Western Reserve University	Lever, JH (corresponding author), USA, Cold Reg Res & Engn Lab, 72 Lyme Rd, Hanover, NH 03755 USA.	jlever@crrel.usace.army.mil						BLANCHARD MB, 1980, EARTH PLANET SC LETT, V46, P178, DOI 10.1016/0012-821X(80)90004-7; Bradley J. P., 1988, METEORITES EARLY SOL, P861; Brownlee D. E., 1993, 24 LUN PLAN SCI C, P205; Brownlee DE, 1997, METEORIT PLANET SCI, V32, P157, DOI 10.1111/j.1945-5100.1997.tb01257.x; BROWNLEE DE, 1981, SEA, pCH19; FIREMAN EL, 1965, GEOCHIM COSMOCHIM AC, V29, P21, DOI 10.1016/0016-7037(65)90074-8; *FLUENT INC, 1995, FLUENT VERS 4 3; FLYNN GJ, 1989, ICARUS, V77, P287, DOI 10.1016/0019-1035(89)90091-2; GRUN E, 1985, ICARUS, V62, P244, DOI 10.1016/0019-1035(85)90121-6; HARVEY RP, 1991, P LUNAR PLANET SCI, V21, P569; KOEBERL C, 1989, GEOCHIM COSMOCHIM AC, V53, P937, DOI 10.1016/0016-7037(89)90039-2; Kuivinen K.C., 1982, ANTARCT J US, V17, P89; KYTE FT, 1983, THESIS U CALIFORNIA; LANKFORD KE, 1986, J HEAT TRANS-T ASME, V108, P755, DOI 10.1115/1.3247009; LEVER JH, 1996, LUNAR PLANET SCI, V27, P747; LIN DS, 1987, J HEAT TRANS-T ASME, V109, P899, DOI 10.1115/1.3248201; LOVE SG, 1991, ICARUS, V89, P26, DOI 10.1016/0019-1035(91)90085-8; LOVE SG, 1993, SCIENCE, V262, P550, DOI 10.1126/science.262.5133.550; MAURETTE M, 1991, NATURE, V351, P44, DOI 10.1038/351044a0; MAURETTE M, 1986, SCIENCE, V233, P869, DOI 10.1126/science.233.4766.869; MAURETTE M, 1987, NATURE, V328, P699, DOI 10.1038/328699a0; MAURETTE M, 1990, MANTLE METEORITES, P87; MCCORKELL RH, 1970, INT ASS SCI HYDROL, V86, P25; MURRELL MT, 1980, GEOCHIM COSMOCHIM AC, V44, P2067, DOI 10.1016/0016-7037(80)90204-5; PENG HC, 1989, METEORITICS, V24, P315; PeuckerEhrenbrink B, 1996, GEOCHIM COSMOCHIM AC, V60, P3187, DOI 10.1016/0016-7037(96)00161-5; TAYLOR S, 1997, 971 COLD REG RES ENG; VANONI VA, 1975, ASCE MANUALS REPORTS, V54, P91; YIOU F, 1987, METEORITICS, V22, P539; YIOU F, 1989, METEORITICS, V24, P344	30	157	159	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					899	903		10.1038/31894	http://dx.doi.org/10.1038/31894			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582069				2022-12-24	WOS:000073359900041
J	Balaban, N; Goldkorn, T; Nhan, RT; Dang, LB; Scott, S; Ridgley, RM; Rasooly, A; Wright, SC; Larrick, JW; Rasooly, R; Carlson, JR				Balaban, N; Goldkorn, T; Nhan, RT; Dang, LB; Scott, S; Ridgley, RM; Rasooly, A; Wright, SC; Larrick, JW; Rasooly, R; Carlson, JR			Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus	SCIENCE			English	Article							REGULATORY RNA MOLECULE; PSEUDOMONAS-AERUGINOSA; RESISTANCE	Staphylococcus aureus causes pathologies ranging from minor skin infections to life-threatening diseases. Pathogenic effects are largely due to production of bacterial toxin, which is regulated by an RNA molecule, RNAIII. The S. aureus protein called RAP (RNAIII activating protein) activates RNAIII, and a peptide called RIP (RNAIII inhibiting peptide), produced by a nonpathogenic bacteria, inhibits RNAIII. Mice vaccinated with RAP or treated with purified or synthetic RIP were protected from S. aureus pathology. Thus, these two molecules may provide useful approaches for the prevention and treatment of diseases caused by S. aureus.	Univ Calif Davis, Dept Med Pathol, Davis, CA 95616 USA; Univ Calif Davis, Davis Med Ctr, Dept Internal Med, Davis, CA 95616 USA; Univ Maryland, Dept Microbiol, College Pk, MD 20742 USA; Palo Alto Inst Mol Med, Mt View, CA 94043 USA	University of California System; University of California Davis; University of California System; University of California Davis; University System of Maryland; University of Maryland College Park	Balaban, N (corresponding author), Univ Calif Davis, Dept Med Pathol, Davis, CA 95616 USA.	nbalaban@ucdavis.edu	Rasooly, Avraham/AAH-4518-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI040830] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40830] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTHUR M, 1993, ANTIMICROB AGENTS CH, V37, P1563, DOI 10.1128/AAC.37.8.1563; BALABAN N, 1995, FEMS MICROBIOL LETT, V133, P155, DOI 10.1016/0378-1097(95)00356-A; BALABAN N, 1995, P NATL ACAD SCI USA, V92, P1619, DOI 10.1073/pnas.92.5.1619; BUNCE C, 1992, INFECT IMMUN, V60, P2636, DOI 10.1128/IAI.60.7.2636-2640.1992; GUANGYONG J, 1995, P NATL ACAD SCI USA, V92, P12055; Lee JC, 1996, TRENDS MICROBIOL, V4, P162, DOI 10.1016/0966-842X(96)10021-4; MAGNUSON R, 1994, CELL, V77, P207, DOI 10.1016/0092-8674(94)90313-1; MOERFELDT E, 1995, EMBO J, V14, P4569; NASO R, 1996, NOVEL STRATEGIES DES, P133; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; PANLILIO AL, 1992, INFECT CONT HOSP EP, V13, P582; PEARSON JP, 1995, P NATL ACAD SCI USA, V92, P1490, DOI 10.1073/pnas.92.5.1490; RAPPUOLI R, 1995, SIGNAL TRANSDUCTION, P1; ROYCHOUDHURY S, 1993, P NATL ACAD SCI USA, V90, P965, DOI 10.1073/pnas.90.3.965; SILVERSTEIN SC, 1990, MICROBIOLOGY, P485; Swift Simon, 1994, Trends in Microbiology, V2, P193, DOI 10.1016/0966-842X(94)90110-Q; WEST TE, 1985, J CLIN MICROBIOL, V21, P490, DOI 10.1128/JCM.21.4.490-492.1985	18	177	210	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					438	440		10.1126/science.280.5362.438	http://dx.doi.org/10.1126/science.280.5362.438			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545222				2022-12-24	WOS:000073159600048
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Beauty in simplicity	SCIENCE			English	Article									Harvard Univ, Sch Med, Boston, MA 02115 USA; NCI, Bethesda, MD 20892 USA	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Peters, R (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							Arras M, 1998, NAT BIOTECHNOL, V16, P159, DOI 10.1038/nbt0298-159; BATTLER A, 1993, J AM COLL CARDIOL, V22, P2001, DOI 10.1016/0735-1097(93)90790-8; ITO W, COMMUNICATION	3	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					456	457						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9575088				2022-12-24	WOS:000073159600055
J	Veazey, RS; DeMaria, M; Chalifoux, LV; Shvetz, DE; Pauley, DR; Knight, HL; Rosenzweig, M; Johnson, RP; Desrosiers, RC; Lackner, AA				Veazey, RS; DeMaria, M; Chalifoux, LV; Shvetz, DE; Pauley, DR; Knight, HL; Rosenzweig, M; Johnson, RP; Desrosiers, RC; Lackner, AA			Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; INTESTINAL LAMINA PROPRIA; RHESUS-MONKEYS; HIV-INFECTION; NEF GENE; LYMPHOCYTES; MACAQUES; ANTIGEN; AIDS; EXPRESSION	Human and simian immunodeficiency virus (HIV and SIV) replicate optimally in activated memory CD4(+) T cells, a cell type that is abundant in the intestine. SIV infection of rhesus monkeys resulted in profound and selective depletion of CD4(+) T cells in the intestine within days of infection, before any such changes in peripheral lymphoid tissues. The loss of CD4(+) T cells in the intestine occurred coincident with productive infection of large numbers of mononuclear cells at this site. The intestine appears to be a major target for SIV replication and the major site of CD4(+) T cell loss in early SIV infection.	Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Southborough, MA 01772 USA	Harvard University	Lackner, AA (corresponding author), Harvard Univ, New England Reg Primate Res Ctr, Sch Med, 1 Pine Hill Dr,POB 9102, Southborough, MA 01772 USA.	alackner@warren.med.harvard.edu	Abrams, William R/A-5782-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038559, R01AI025328, R37AI025328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050550] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25328, AI38559] Funding Source: Medline; NIDDK NIH HHS [DK50550] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amadori A, 1996, IMMUNOL TODAY, V17, P414, DOI 10.1016/0167-5699(96)10049-9; CERFBENSUSSAN N, 1991, GASTROENTEROL CLIN N, V20, P549; Clayton F, 1997, CLIN EXP IMMUNOL, V107, P288, DOI 10.1111/j.1365-2249.1997.236-ce1111.x; CLAYTON F, 1992, GASTROENTEROLOGY, V103, P919, DOI 10.1016/0016-5085(92)90026-U; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; DESROSIERS RC, 1989, INTERVIROLOGY, V30, P301, DOI 10.1159/000150108; HEISE C, 1993, AM J PATHOL, V142, P1759; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HORVATH CJ, 1993, J LEUKOCYTE BIOL, V53, P532, DOI 10.1002/jlb.53.5.532; ILYINSKII PO, 1994, J VIROL, V68, P5933, DOI 10.1128/JVI.68.9.5933-5944.1994; KAWAI T, 1994, TRANSPLANT P, V26, P1845; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KRAEHENBUHL JP, 1992, PHYSIOL REV, V72, P853, DOI 10.1152/physrev.1992.72.4.853; Lackner A A, 1994, Curr Top Microbiol Immunol, V188, P35; Lane JH, 1996, AM J PATHOL, V149, P1097; LIM SG, 1993, CLIN EXP IMMUNOL, V92, P448, DOI 10.1111/j.1365-2249.1993.tb03419.x; MacDonald TT, 1994, GASTROINTESTINAL HEP, P1; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MORI K, 1992, J VIROL, V66, P2067, DOI 10.1128/JVI.66.4.2067-2075.1992; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; REIMANN KA, 1994, J VIROL, V68, P2362, DOI 10.1128/JVI.68.4.2362-2370.1994; RODGERS VD, 1986, GASTROENTEROLOGY, V90, P552, DOI 10.1016/0016-5085(86)91108-X; ROSENBERG ZF, 1991, FASEB J, V5, P2382, DOI 10.1096/fasebj.5.10.1676689; Sasseville VG, 1996, AM J PATHOL, V149, P163; SCHIEFERDECKER HL, 1992, J IMMUNOL, V149, P2816; SCHNEIDER T, 1994, CLIN EXP IMMUNOL, V95, P430, DOI 10.1111/j.1365-2249.1994.tb07014.x; SCHNEIDER T, 1995, GUT, V37, P524, DOI 10.1136/gut.37.4.524; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SCHRAPPEBACHER M, 1990, J ACQ IMMUN DEF SYND, V3, P238; VANNOESEL CJ, 1990, J CLIN INVEST, V86; Veazey RS, 1997, CLIN IMMUNOL IMMUNOP, V82, P230, DOI 10.1006/clin.1996.4318; VEAZEY RS, UNPUB; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZEITZ M, 1988, GASTROENTEROLOGY, V94, P647, DOI 10.1016/0016-5085(88)90235-1	35	1138	1170	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					427	431		10.1126/science.280.5362.427	http://dx.doi.org/10.1126/science.280.5362.427			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545219				2022-12-24	WOS:000073159600045
J	Nelson, K; Brown, ME; Lurie, N				Nelson, K; Brown, ME; Lurie, N			Hunger in an adult patient population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITALIZED-PATIENTS; FOOD INSECURITY; MALNUTRITION	Context.-Although clinical observations suggest that some patients experience hunger and food insecurity, there are limited data on the prevalence of hunger in adult patients. Objective.-To determine the prevalence of hunger and food insecurity in adult patients at an urban county hospital. Design.-Cross-sectional survey conducted in 1997. Patients.-The primary survey included all patients aged 18 years or older who were admitted to the medicine, surgery, and neurology services during a 2-week period, and all patients who attended the hospital's general medicine clinic during 1 week. A second survey included primary care patients who received insulin from the hospital pharmacy during a 1-month period. Main Outcome Measures.-Rates of hunger and food insecurity. Results.-Of 709 eligible patients, 567 (participation rate, 80%) were interviewed in either the clinic (n=281) or hospital (n=286). An additional 170 patients who received insulin were interviewed by telephone (response rate, 75%). Of the primary sample, 68 (12%) respondents reported not having enough food, 75 (13%) reported not eating for an entire day, acid 77 (14%) reported going hungry but not eating because they could not afford food. A total of 222 (40%) had received food stamps in the previous year and of those, 113 (50%) had their food stamps reduced or eliminated. Recipients whose food stamps had been eliminated or reduced were more likely to report not having enough food (18% vs 13%, P=.006), not eating for a whole day (20% vs 16%, P=.01), going hungry but not eating (20% vs 16%, P=.08), and cutting down on the size of meals or skipping meals (33% vs 27%, P=.01). In multivariate analysis, independent predictors of hunger included an annual income of less than $10 000 (odds ratio [OR], 7.55; 95% CI, 3.01-18.92), drug use (OR, 3.56; 95% CI, 1.46-8.66), and a reduction in food stamp benefits (OR, 1.73; 95% CI, 1.01-2.96). Predictors of food insecurity included an annual income of less than $10 000 (OR, 4.12; 95% confidence interval [CI], 1.98-8.58), drug use (OR, 2.11; 95% CI, 1.66-5.08), and a reduction in food stamps (OR, 2.02; 95% CI, 1.23-3.32). In addition, 103 (61%) patients in the sample of diabetics reported hypoglycemic reactions; 32 (31%) of these were attributed to inability to afford food. Conclusion.-Hunger and food insecurity are common among patients seeking care at an urban county hospital.	Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA; Univ Minnesota, Sch Publ Hlth, Inst Hlth Serv Res, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Twin Cities; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities	Lurie, N (corresponding author), Univ Minnesota, Sch Med, Dept Med, 420 Delaware St SE,Box 741, Minneapolis, MN 55455 USA.							BROWN JL, 1988, ANNU REV PUBL HEALTH, V9, P503; CAMPBELL CC, 1991, J NUTR, V121, P408, DOI 10.1093/jn/121.3.408; Cohen B. E., 1990, NUTR TODAY, V25, P23, DOI DOI 10.1097/00017285-199007000-00004; EDMUND EJ, 1994, ADV DATA VITAL HLTH, V278; EPSTEIN AM, 1988, NEW ENGL J MED, V318, P1579, DOI 10.1056/NEJM198806163182405; GURALNIK JM, 1993, NEW ENGL J MED, V329, P110, DOI 10.1056/NEJM199307083290208; HAMILTON WL, 1997, MEASURING FOOD SECUR; KENDALL A, 1995, J NUTR, V125, P2793; KINSEY JD, 1994, J NUTR, V124, pS1878, DOI 10.1093/jn/124.suppl_9.1878S; Maslow A. H., 1970, MOTIVATION PERSONALI; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; *PHYS TASK FOR HUN, 1985, HUNG AM GROW EP; PINCUS T, 1994, J CLIN EPIDEMIOL, V47, P355, DOI 10.1016/0895-4356(94)90156-2; ROSENBERG E, 1992, SOC WORK HEALTH CARE, V16, P83, DOI 10.1300/J010v16n03_08; ROUBENOFF R, 1987, ARCH INTERN MED, V147, P1462, DOI 10.1001/archinte.147.8.1462; SMITH AD, 1997, BRIT MED J, V314, P547; STEFFEE WP, 1980, JAMA-J AM MED ASSOC, V244, P2630, DOI 10.1001/jama.244.23.2630; UVIN P, 1994, NUTR REV, V52, P151, DOI 10.1111/j.1753-4887.1994.tb01411.x; WILLIAMS MV, 1995, JAMA-J AM MED ASSOC, V274, P1677	19	82	85	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1998	279	15					1211	1214		10.1001/jama.279.15.1211	http://dx.doi.org/10.1001/jama.279.15.1211			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG133	9555762	Bronze			2022-12-24	WOS:000072969400036
J	Golbe, LI				Golbe, LI			Pallidotomy for Parkinson's disease: hitting the target?	LANCET			English	Editorial Material									Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Golbe, LI (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ 08901 USA.							Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; Fazzini E, 1997, NEUROLOGY, V48, P1273, DOI 10.1212/WNL.48.5.1273; Kishore A, 1997, BRAIN, V120, P729, DOI 10.1093/brain/120.5.729; Lang AE, 1997, NEW ENGL J MED, V337, P1036, DOI 10.1056/NEJM199710093371503; Ondo WG, 1998, NEUROLOGY, V50, P266, DOI 10.1212/WNL.50.1.266; Samuel M, 1998, BRAIN, V121, P59, DOI 10.1093/brain/121.1.59; Shannon KM, 1998, NEUROLOGY, V50, P434, DOI 10.1212/WNL.50.2.434	7	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					998	999		10.1016/S0140-6736(98)22014-9	http://dx.doi.org/10.1016/S0140-6736(98)22014-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546498				2022-12-24	WOS:000072927200002
J	Cao, YQ; Mantyh, PW; Carlson, EJ; Gillespie, AM; Epstein, CJH; Basbaum, AI				Cao, YQ; Mantyh, PW; Carlson, EJ; Gillespie, AM; Epstein, CJH; Basbaum, AI			Primary afferent tachykinins are required to experience moderate to intense pain	NATURE			English	Article							DORSAL HORN NEURONS; SUBSTANCE-P; RECEPTOR; RAT; HYPERALGESIA; INFLAMMATION; INHIBITION; ACTIVATION; GLUTAMATE; FORMALIN	The excitatory neurotransmitter glutamate coexists,vith the peptide known as substance P in primary afferents that respond to painful stimulation(1). Because blockers of glutamate receptors reliably reduce pain behaviour(2-4), it is assumed that 'pain' messages are mediated by glutamate action on dorsal horn neurons, The contribution of substance P, however, is still unclear, We have now disrupted the mouse preprotachykinin A gene (PPT-A), which encodes substance P and a related tachykinin, neurokinin A (ref. 5). We find that although the behavioural response to mildly painful stimuli is intact in these mice, the response to moderate to intense pain is significantly reduced. Neurogenic inflammation, which results from peripheral release of substance P and neurokinin A (ref. 6), is almost absent in the mutant mice. We conclude that the release of tachykinins from primary afferent pain-sensing receptors (nociceptors) is required to produce moderate to intense pain.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, WM Keck Fdn, Ctr Integrat Neurosci, Dept Pediat, San Francisco, CA 94143 USA; Vet Adm Med Ctr, Mol Neurobiol Lab, Minneapolis, MN 55417 USA; Univ Minnesota, Dept Psychiat, Minneapolis, MN 55417 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities	Basbaum, AI (corresponding author), Univ Calif San Francisco, Dept Anat, UCSF Box 0452, San Francisco, CA 94143 USA.	aib@phy.ucsf.edu						Abbadie C, 1997, J NEUROSCI, V17, P8049; AMANN R, 1995, N-S ARCH PHARMACOL, V352, P201; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; DEBIASI S, 1988, P NATL ACAD SCI USA, V85, P7820; DEFELIPE C, 1997, NEUR ABSTR, V23, P2354; DUGGAN AW, 1995, NEUROSCIENCE, V65, P849, DOI 10.1016/0306-4522(94)00541-C; GYIRES K, 1984, ARCH INT PHARMACOD T, V267, P131; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HERRERO JF, 1997, NEUR ABSTR, V23, P2354; HUNTER JC, 1994, NEUROSCI LETT, V174, P217, DOI 10.1016/0304-3940(94)90025-6; HYLDEN JLK, 1992, J NEUROSCI, V12, P1716; KAKO K, 1993, BIOMED RES-TOKYO, V14, P253, DOI 10.2220/biomedres.14.253; LANEUVILLE O, 1988, LIFE SCI, V42, P1295, DOI 10.1016/0024-3205(88)90223-8; Lawson SN, 1997, J PHYSIOL-LONDON, V505, P177, DOI 10.1111/j.1469-7793.1997.00177.x; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; MAGGI CA, 1995, GEN PHARMACOL-VASC S, V26, P911, DOI 10.1016/0306-3623(94)00292-U; Malmberg AB, 1997, SCIENCE, V278, P279, DOI 10.1126/science.278.5336.279; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; MANTYH PW, 1989, J NEUROSCI, V9, P258; Marvizon JCG, 1997, J NEUROSCI, V17, P8129; MELLER ST, 1993, NEUROREPORT, V4, P879, DOI 10.1097/00001756-199307000-00010; MUNRO FE, 1993, NEUROPEPTIDES, V25, P299, DOI 10.1016/0143-4179(93)90047-E; NAWA H, 1984, NATURE, V312, P729, DOI 10.1038/312729a0; Rupniak NMJ, 1996, PAIN, V67, P189, DOI 10.1016/0304-3959(96)03109-0; RUSIN KI, 1992, J NEUROPHYSIOL, V68, P265, DOI 10.1152/jn.1992.68.1.265; SAFIEHGARABEDIAN B, 1995, BRIT J PHARMACOL, V115, P1265, DOI 10.1111/j.1476-5381.1995.tb15035.x; VIGNA SR, 1994, J NEUROSCI, V14, P834; WILCOX GL, 1991, PAIN RES CL, V4, P97; Zimmer A, 1998, P NATL ACAD SCI USA, V95, P2630, DOI 10.1073/pnas.95.5.2630	29	473	498	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					390	394		10.1038/32897	http://dx.doi.org/10.1038/32897			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537322				2022-12-24	WOS:000072713600052
J	McKinstry, RC; Feinberg, DA				McKinstry, RC; Feinberg, DA			A new window on brain research	SCIENCE			English	Article							SENSORY STIMULATION; MR; STROKE; MOTION		Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Neuroradiol Sect, St Louis, MO 63110 USA	Washington University (WUSTL)	McKinstry, RC (corresponding author), Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Neuroradiol Sect, St Louis, MO 63110 USA.	mckinstry@mirlink.wustl.edu						Binder J, 1997, NEUROSURG CLIN N AM, V8, P383; BLEIER AR, 1991, MAGNET RESON MED, V21, P132, DOI 10.1002/mrm.1910210116; Chen YCI, 1997, MAGNET RESON MED, V38, P389, DOI 10.1002/mrm.1910380306; Davis TL, 1998, P NATL ACAD SCI USA, V95, P1834, DOI 10.1073/pnas.95.4.1834; EHMAN RL, 1997, RADIOLOGY P, V205, P487; ENZMANN DR, 1992, RADIOLOGY, V185, P653, DOI 10.1148/radiology.185.3.1438741; ERNST T, 1994, MAGN RESON MED, V32, P146, DOI 10.1002/mrm.1910320122; FEINBERG D, 1986, RADIOLOGY, V161, P571; FEINBERG DA, 1987, RADIOLOGY, V163, P793, DOI 10.1148/radiology.163.3.3575734; FEINBERG DA, 1995, MAGNET RESON MED, V33, P529, DOI 10.1002/mrm.1910330411; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Hennig J., 1993, MAGMA, V1, P39, DOI 10.1007/BF02660372; Hu XP, 1997, MAGNET RESON MED, V37, P877, DOI 10.1002/mrm.1910370612; Kim SG, 1997, MAGN RESON MED, V38, P59, DOI 10.1002/mrm.1910380110; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; Malonek D, 1996, SCIENCE, V272, P551, DOI 10.1126/science.272.5261.551; MANSFIELD P, 1977, J PHYS C SOLID STATE, V10, pL55, DOI 10.1088/0022-3719/10/3/004; MARGOS P, 1986, HLTH CARE INSTR, V1, P295; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; Mueller WM, 1997, NEUROSURG CLIN N AM, V8, P373; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; Ojemann JG, 1997, NEUROIMAGE, V6, P156, DOI 10.1006/nimg.1997.0289; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; PONCELET BP, 1992, RADIOLOGY, V185, P645, DOI 10.1148/radiology.185.3.1438740; ROBERTS DA, 1994, P NATL ACAD SCI USA, V91, P33, DOI 10.1073/pnas.91.1.33; ROSEN BR, 1991, MAGNET RESON MED, V19, P285, DOI 10.1002/mrm.1910190216; SILVERMAN SG, 1995, RADIOLOGY, V197, P175, DOI 10.1148/radiology.197.1.7568819; Sorensen AG, 1996, RADIOLOGY, V199, P391, DOI 10.1148/radiology.199.2.8668784; TURNER R, 1990, J MAGN RESON, V86, P445, DOI 10.1016/0022-2364(90)90023-3; VanEssen DC, 1997, J NEUROSCI, V17, P7079; WARACH S, 1992, NEUROLOGY, V42, P1717, DOI 10.1212/WNL.42.9.1717; Yang YH, 1998, MAGNET RESON MED, V39, P61, DOI 10.1002/mrm.1910390111	33	8	8	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1965	1966		10.1126/science.279.5358.1965	http://dx.doi.org/10.1126/science.279.5358.1965			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9537906				2022-12-24	WOS:000072613300054
J	Shen, HM; Peters, A; Baron, B; Zhu, XD; Storb, U				Shen, HM; Peters, A; Baron, B; Zhu, XD; Storb, U			Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes	SCIENCE			English	Article							IMMUNOGLOBULIN GENES; NUCLEOTIDE-SEQUENCE; INTRON ENHANCER; ELEMENTS; LYMPHOMA; REGION; LOCUS	Immunoglobulin (Ig) genes are hypermutated in B lymphocytes that are the precursors to memory B cells. The mutations are linked to transcription initiation, but non-Ig promoters are permissible for the mutation process; thus, other genes expressed in mutating B cells may also be subject to somatic hypermutation. Significant mutations were not observed in c-MYC, S14, or alpha-fetoprotein (AFP) genes, but BCL-6 was highly mutated in a large proportion of memory B cells of normal individuals. The mutation pattern was similar to that of Ig genes.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60617 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60617 USA; Univ Chicago, Dept Pathol, Chicago, IL 60617 USA; Univ Chicago, Dept Med, Chicago, IL 60617 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	Storb, U (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60617 USA.			zhu, xiangdong/0000-0002-5627-8082	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038649] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38649, GM07183] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; Cline J, 1996, NUCLEIC ACIDS RES, V24, P3546, DOI 10.1093/nar/24.18.3546; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GIBBS PEM, 1987, BIOCHEMISTRY-US, V26, P1332, DOI 10.1021/bi00379a020; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; KLEIN U, 1994, J EXP MED, V180, P1383, DOI 10.1084/jem.180.4.1383; Klotz EL, 1996, J IMMUNOL, V157, P4458; Migliazza A., 1997, Blood, V90, p177A; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MUELLER J, 1995, P NATL ACAD SCI USA, V92, P6577; Newton JS, 1996, EUR J IMMUNOL, V26, P811, DOI 10.1002/eji.1830260413; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; Storb U, 1996, CURR OPIN IMMUNOL, V8, P206, DOI 10.1016/S0952-7915(96)80059-8; Storb U, 1998, CURR TOP MICROBIOL, V229, P11; STORB U, IN PRESS BIOL GERMIN; STORB U, UNPUB; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; TumasBrundage K, 1997, J EXP MED, V185, P239, DOI 10.1084/jem.185.2.239	22	439	444	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1750	1752		10.1126/science.280.5370.1750	http://dx.doi.org/10.1126/science.280.5370.1750			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624052				2022-12-24	WOS:000074197800041
J	Glover, DW; Maron, BJ				Glover, DW; Maron, BJ			Profile of preparticipation cardiovascular screening for high school athletes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUDDEN-DEATH; YOUNG-ADULTS; DISEASE; ECHOCARDIOGRAPHY; CARDIOMYOPATHY	Context.-Sudden death in young competitive athletes due to unsuspected cardiovascular disease has heightened concern and interest in the preparticipation screening available to high school athletes in the United States. Objective.-To assess the potential adequacy of the preparticipation screening process for detecting or increasing the suspicion of cardiovascular abnormalities. Design.-Current guidelines and requirements for implementation of preparticipation screening from each of the high school jurisdictions in the 50 states and the District of Columbia were analyzed and compared with the 1996 American Heart Association (AHA) consensus panel guidelines on screening. Outcome Measures.-Items contained on preparticipation screening questionnaires; the examiners designated to perform screening. Results.-Eight states (16%) have no approved history and physical examination questionnaires to guide examiners, including 1 state without a formal screening requirement. Of the remaining 43 states, several items relevant to cardiac-related problems were frequently omitted from the questionnaires, Exertional dyspnea or chest pain, prior limitation from sports, family history of heart disease, or Marian syndrome were included in 0% to 56% of the state forms. Specific cardiovascular items on physical examination were included in forms from only 5% to 37% of states, including documentation of a heart murmur, irregular heart rhythm, peripheral pulses, or stigmata of Marfan syndrome. Seventeen (40%) of 43 states had history and physical questionnaires judged to be most adequate with at least 9 of the 13 AHA recommendations, whereas 12 states (28%) were least adequate with 4 or less of these recommended items. Therefore, a total of 20 (40%) of the 51 states have no approved history and physical examination questionnaires, or formal screening requirement, or forms that were judged to be inadequate. In addition to physicians, 21 states also permit nurses or physician assistants to administer examinations, and 11 states specifically provide for practitioners with limited cardiovascular training (such as chiropractors). Conclusions.-Preparticipation athletic screening for cardiovascular disease with standard history and physical examination, as presently employed in US high schools, is highly dependent on the state-approved questionnaires, which frequently are abbreviated and may be inadequate; is implemented by a variety of health care workers with varying levels of expertise; and may be severely limited in its power to detect potentially lethal cardiovascular abnormalities. These observations should represent an impetus for change and improvement in the preparticipation cardiovascular screening process for high school athletes.	St Lukes Hosp, Ambulatory Care Div, Kansas City, MO USA; Minneapolis Heart Inst Fdn, Minneapolis, MN USA	Saint Luke's Hospital - Missouri; Minneapolis Heart Institute Foundation	Maron, BJ (corresponding author), 920 E 28th St,Suite 40, Minneapolis, MN 55407 USA.							BHARATI S, 1986, J AM COLL CARDIOL, V8, P1096, DOI 10.1016/S0735-1097(86)80387-4; BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; CORRADO D, 1990, AM J MED, V89, P588, DOI 10.1016/0002-9343(90)90176-E; CORRADO D, 1997, CIRCULATION S1, V96, P152; Feinstein RA, 1994, CLIN J SPORT MED, V3, P149; Fuller CM, 1997, MED SCI SPORT EXER, V29, P1131, DOI 10.1097/00005768-199709000-00003; LACORTE MA, 1989, CLIN CARDIOL, V12, P41; LEWIS JF, 1989, AM J CARDIOL, V64, P1029, DOI 10.1016/0002-9149(89)90802-3; Liberthson RR, 1996, NEW ENGL J MED, V334, P1039, DOI 10.1056/NEJM199604183341607; MARON BJ, 1987, J AM COLL CARDIOL, V10, P1214, DOI 10.1016/S0735-1097(87)80121-3; MARON BJ, 1993, NEW ENGL J MED, V329, P55, DOI 10.1056/NEJM199307013290113; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; Maron BJ, 1996, CIRCULATION, V94, P850, DOI 10.1161/01.CIR.94.4.850; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; Maron BJ, 1997, LANCET, V350, P127, DOI 10.1016/S0140-6736(97)01282-8; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; MARON BJ, 1996, CIRCULATION, V94, P388; Maron BJ, 1994, J AM COLL CARDIOL, V24, P845; MARSALESE DL, 1989, J AM COLL CARDIOL, V14, P422, DOI 10.1016/0735-1097(89)90197-6; MURRY PM, 1995, AM J CARDIOL, V76, P849, DOI 10.1016/S0002-9149(99)80244-6; SMITH DM, 1997, PREPARTICIPATION PHY, P1; THIENE G, 1988, NEW ENGL J MED, V318, P129, DOI 10.1056/NEJM198801213180301; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641; WEIDENBENER EJ, 1995, CLIN J SPORT MED, V5, P86, DOI 10.1097/00042752-199504000-00003; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6	25	119	119	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1817	1819		10.1001/jama.279.22.1817	http://dx.doi.org/10.1001/jama.279.22.1817			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR635	9628714	Bronze			2022-12-24	WOS:000073998500035
J	Mdluli, K; Slayden, RA; Zhu, YQ; Ramaswamy, S; Pan, X; Mead, D; Crane, DD; Musser, JM; Barry, CE				Mdluli, K; Slayden, RA; Zhu, YQ; Ramaswamy, S; Pan, X; Mead, D; Crane, DD; Musser, JM; Barry, CE			Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid	SCIENCE			English	Article							CATALASE-PEROXIDASE GENE; ACYL CARRIER PROTEIN; DRUG-RESISTANCE; CELL-GROWTH; FATTY-ACID; TARGET; INHA; MUTATIONS; KATG; BIOSYNTHESIS	Although isoniazid (isonicotinic acid hydrazide, INH) is widely used for the treatment of tuberculosis, its molecular target has remained elusive. In response to INH treatment, saturated hexacasanoic acid (C26:0) accumulated on a 12-kilodalton acyl carrier protein (AcpM) that normally carried mycolic acid precursors as long as C50. A protein species purified from INH-treated Mycobacterium tuberculosis was shown to consist of a covalent complex of INH, AcpM, and a beta-ketoacyl acyl carrier protein synthase, KasA. Amino acid-altering mutations in the KasA protein were identified in INH-resistant patient isolates that lacked other mutations associated with resistance to this drug.	NIAID, Rocky Mt Labs, Intracellular Parasites Lab, TB Res Unit,NIH, Hamilton, MT 59840 USA; Baylor Coll Med, Dept Pathol, Inst Study Bacterial Pathogenesis, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Baylor College of Medicine	Barry, CE (corresponding author), NIAID, Rocky Mt Labs, Intracellular Parasites Lab, TB Res Unit,NIH, Hamilton, MT 59840 USA.		Barry, Clifton E/ABE-7992-2020; Barry, III, Clifton/H-3839-2012; Slayden, Richard/O-8626-2016; Slayden, Richard/AAV-2582-2021	Barry, Clifton E/0000-0002-2927-270X; Barry, III, Clifton/0000-0002-2927-270X; Slayden, Richard/0000-0001-6857-7277; Slayden, Richard/0000-0001-6857-7277	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000783, R01AI037004] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline; NIAID NIH HHS [AI37004] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; DAVIDSON LA, 1979, ANTIMICROB AGENTS CH, V16, P104, DOI 10.1128/AAC.16.1.104; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HEYM B, 1994, LANCET, V344, P293, DOI 10.1016/S0140-6736(94)91338-2; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; KEATING DH, 1995, J BIOL CHEM, V270, P22229, DOI 10.1074/jbc.270.38.22229; Marttila HJ, 1996, ANTIMICROB AGENTS CH, V40, P2187, DOI 10.1128/AAC.40.9.2187; Mdluli K, 1996, J INFECT DIS, V174, P1085, DOI 10.1093/infdis/174.5.1085; MDLULI K, UNPUB; MIDDLEBROOK G, 1952, AM REV TUBERC PULM, V65, P765; MORRIS S, 1995, J INFECT DIS, V171, P954, DOI 10.1093/infdis/171.4.954; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; OBrien KL, 1996, MOL CELL PROBE, V10, P1, DOI 10.1006/mcpr.1996.0001; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; PRESCOTT DJ, 1972, ADV ENZYMOL RAMB, V36, P269; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; Sacchettini JC, 1996, RES MICROBIOL, V147, P36, DOI 10.1016/0923-2508(96)80201-4; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; SUMMERS RG, 1995, BIOCHEMISTRY-US, V34, P9389, DOI 10.1021/bi00029a015; TAKAYAMA K, 1975, J LIPID RES, V16, P308; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; TAKAYAMA K, 1974, AM REV RESPIR DIS, V110, P43; TAKAYAMA K, 1979, ANTIBIOTICS, V1, P98; Winder F. G., 1982, The biology of the mycobacteria. Volume 1, P353; WINDER F G, 1970, Journal of General Microbiology, V63, P41; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	28	345	364	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1607	1610		10.1126/science.280.5369.1607	http://dx.doi.org/10.1126/science.280.5369.1607			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616124				2022-12-24	WOS:000074061200042
J	Morris, JS; Ohman, A; Dolan, RJ				Morris, JS; Ohman, A; Dolan, RJ			Conscious and unconscious emotional learning in the human amygdala	NATURE			English	Article							BLOOD-FLOW; DISCRIMINATION; RECOGNITION; MECHANISMS; ACTIVATION; EXPRESSION; RESPONSES; IMAGES; FACES	If subjects are shown an angry face as a target visual stimulus for less than forty milliseconds and are then immediately shown an expressionless mask, these subjects report seeing the mask but not the target. However, an aversively conditioned masked target can elicit an emotional response from subjects without being consciously perceived(1,2). Here we study the mechanism of this unconsciously mediated emotional learning. We measured neural activity in volunteer subjects who were presented with two angry faces, one of which, through previous classical conditioning, was associated with a burst of white noise. In half of the trials, the subjects' awareness of the angry faces was prevented by backward masking with a neutral face. A significant neural response was elicited in the right, but not left, amygdala to masked presentations of the conditioned angry face. Unmasked presentations of the same face produced enhanced neural activity in the left, but not right, amygdala. Our results indicate that, first, the human amygdala can discriminate between stimuli solely on the basis of their acquired behavioural significance, and second, this response is lateralized according to the subjects' level of awareness of the stimuli.	Wellcome Dept Cognit Neurol, London WC1N 3BG, England; Karolinska Hosp, Dept Clin Neurosci, Psychiat & Psychol Sect, S-17176 Stockholm, Sweden; Royal Free Hosp, London NW3 2DF, England; UCL Hosp, Sch Med, London NW3 2DF, England	University of London; University College London; Karolinska Institutet; Karolinska University Hospital; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; UCL Medical School	Dolan, RJ (corresponding author), Wellcome Dept Cognit Neurol, Queen Sq, London WC1N 3BG, England.		anand, amit/A-7222-2009	Dolan, Ray/0000-0001-9356-761X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adolphs R, 1997, LEARN MEMORY, V4, P291, DOI 10.1101/lm.4.3.291; Babinsky R, 1993, Behav Neurol, V6, P167, DOI 10.3233/BEN-1993-6310; BECHARA A, 1995, SCIENCE, V269, P1115, DOI 10.1126/science.7652558; Breiter HC, 1996, NEURON, V17, P875, DOI 10.1016/S0896-6273(00)80219-6; Cahill L, 1996, P NATL ACAD SCI USA, V93, P8016, DOI 10.1073/pnas.93.15.8016; DAVIS M, 1992, P255; DEKOSKY ST, 1980, BRAIN LANG, V9, P206, DOI 10.1016/0093-934X(80)90141-8; Ekman P., 1976, PICTURES FACIAL AFFE; Esteves F., 1994, COGNITION EMOTION, V9, P99; Fried I, 1997, NEURON, V18, P753, DOI 10.1016/S0896-6273(00)80315-3; Friston K.J., 1994, HUMAN BRAIN MAPPING, V2, P211, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; GAZZANIGA MS, 1983, ANN NEUROL, V13, P536, DOI 10.1002/ana.410130511; GAZZANIGA MS, 1995, COGNITIVE NEUROSCIEN, P1049; GUR RC, 1994, BRAIN COGNITION, V25, P271, DOI 10.1006/brcg.1994.1036; HUGDAHL K, 1995, NEUROREPORT, V6, P1723, DOI 10.1097/00001756-199509000-00005; Kapp BS, 1984, NEUROPSYCHOLOGY MEMO, P473; KLINGER MR, 1995, J EXP PSYCHOL LEARN, V21, P569, DOI 10.1037/0278-7393.21.3.569; LABAR KS, 1995, J NEUROSCI, V15, P6846; LADAVAS E, 1993, COGNITION EMOTION, V7, P95, DOI 10.1080/02699939308409179; LeDoux J. E., 1996, EMOTIONAL BRAIN; LEONARD CM, 1985, BEHAV BRAIN RES, V15, P159, DOI 10.1016/0166-4328(85)90062-2; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; Morris JS, 1997, P ROY SOC B-BIOL SCI, V264, P769, DOI 10.1098/rspb.1997.0109; OHMAN A, 1994, J ABNORM PSYCHOL, V103, P231, DOI 10.1037/0021-843X.103.2.231; STONE VS, 1995, NEUROPSYCHOLOGIA, V34, P23; WEISKRANTZ L, 1956, J COMP PHYSIOL PSYCH, V49, P381, DOI 10.1037/h0088009; Whalen PJ, 1998, J NEUROSCI, V18, P411; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O; YOUNG AW, 1993, BRAIN, V116, P941, DOI 10.1093/brain/116.4.941	30	1243	1280	2	150	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 4	1998	393	6684					467	470		10.1038/30976	http://dx.doi.org/10.1038/30976			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZR842	9624001	Green Submitted			2022-12-24	WOS:000074020000044
J	Harris, AL				Harris, AL			Are angiostatin and endostatin cures for cancer?	LANCET			English	Editorial Material							SUPPRESSION; DORMANCY		Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund, Oxford OX3 9DS, England	University of Oxford	Harris, AL (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund, Oxford OX3 9DS, England.		Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409				Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Brem S, 1998, Angiogenesis, V2, P9, DOI 10.1023/A:1009068807898; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; Harris Adrian L., 1997, Lancet (North American Edition), V349, P13; Hohenester E, 1998, EMBO J, V17, P1656, DOI 10.1093/emboj/17.6.1656; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; OREILLY MS, 1997, INVEST NEW DRUGS, V1, P5; Pezzella F, 1997, AM J PATHOL, V151, P1417; Sage EH, 1997, TRENDS CELL BIOL, V7, P182; Sim BKL, 1997, CANCER RES, V57, P1329	16	36	42	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1598	1599		10.1016/S0140-6736(98)22022-8	http://dx.doi.org/10.1016/S0140-6736(98)22022-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620709				2022-12-24	WOS:000074026600002
J	Xie, DX; Feys, BF; James, S; Nieto-Rostro, M; Turner, JG				Xie, DX; Feys, BF; James, S; Nieto-Rostro, M; Turner, JG			COI1: An Arabidopsis gene required for jasmonate-regulated defense and fertility	SCIENCE			English	Article							LEUCINE-RICH REPEATS; METHYL JASMONATE; YAC LIBRARY; THALIANA; RESISTANCE; PROTEIN; PLANTS; TRANSFORMATION; CONSTRUCTION; ENCODES	The coi1 mutation defines an Arabidopsis gene required for response to jasmonates, which regulate defense against insects and pathogens, wound healing, and pollen fertility. The wild-type allele, COI1, was mapped to a 90-kilobase genomic fragment and located by complementation of coi1-1 mutants. The predicted amino acid sequence of the COI1 protein contains 16 leucine-rich repeats and an F-box motif. It has similarity to the F-box proteins Arabidopsis TIR1, human Skp2, and yeast Grr1, which appear to function by targeting repressor proteins for removal by ubiquitination.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Turner, JG (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.		xie, daoxin d/C-8646-2017; Nieto-Rostro, Manuela/C-1621-2008					Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; CHRISTOU P, 1990, TRENDS BIOTECHNOL, V8, P145, DOI 10.1016/0167-7799(90)90160-Y; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; CREUSOT F, 1995, PLANT J, V8, P763, DOI 10.1046/j.1365-313X.1995.08050763.x; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; EPPEL CE, 1995, PLANT PHYSIOL, V109, P1813; FEYS BJF, 1994, PLANT CELL, V6, P751, DOI 10.1105/tpc.6.5.751; FLICK JS, 1991, MOL CELL BIOL, V11, P5101, DOI 10.1128/MCB.11.10.5101; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; JEFFERSON RA, 1987, EMBO J, V6, P3901; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; McConn M, 1997, P NATL ACAD SCI USA, V94, P5473, DOI 10.1073/pnas.94.10.5473; McConn M, 1996, PLANT CELL, V8, P403, DOI 10.1105/tpc.8.3.403; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; ODonnell PJ, 1996, SCIENCE, V274, P1914, DOI 10.1126/science.274.5294.1914; PENACORTES H, 1993, PLANTA, V191, P123, DOI 10.1007/BF00240903; Penninckx IAMA, 1996, PLANT CELL, V8, P2309, DOI 10.1105/tpc.8.12.2309; Rojo E, 1998, PLANT J, V13, P153, DOI 10.1046/j.1365-313X.1998.00020.x; Ruegger M, 1998, GENE DEV, V12, P198, DOI 10.1101/gad.12.2.198; RYAN CA, 1992, PLANT MOL BIOL, V19, P123, DOI 10.1007/BF00015610; SCHMIDT R, 1992, AUST J PLANT PHYSIOL, V19, P341, DOI 10.1071/PP9920341; SEMBDNER G, 1993, ANNU REV PLANT PHYS, V44, P569, DOI 10.1146/annurev.pp.44.060193.003033; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; STASWICK PE, 1992, P NATL ACAD SCI USA, V89, P6837, DOI 10.1073/pnas.89.15.6837; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; XIE DX, UNPUB; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	34	1204	1319	16	252	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 15	1998	280	5366					1091	1094		10.1126/science.280.5366.1091	http://dx.doi.org/10.1126/science.280.5366.1091			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9582125				2022-12-24	WOS:000073663600051
J	Carney, JP; Maser, RS; Olivares, H; Davis, EM; Le Beau, M; Yates, JR; Hays, L; Morgan, WF; Petrini, JHJ				Carney, JP; Maser, RS; Olivares, H; Davis, EM; Le Beau, M; Yates, JR; Hays, L; Morgan, WF; Petrini, JHJ			The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: Linkage of double-strand break repair to the cellular DNA damage response	CELL			English	Article							ATAXIA-TELANGIECTASIA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; BLOOMS SYNDROME; MEIOTIC RECOMBINATION; GENETIC-RECOMBINATION; HUMAN MRE11; IDENTIFICATION; RAD50; FIBROBLASTS	Nijmegen breakage syndrome (NBS) is an autosomal recessive disorder characterized by increased cancer incidence, cell cycle checkpoint defects, and ionizing radiation sensitivity. We have isolated the gene encoding p95, a member of the hMre11/hRad50 double-strand break repair complex. The p95 gene mapped to 8q21.3, the region that contains the NBS locus, and p95 was absent from NBS cells established from NBS patients, p95 deficiency in these cells completely abrogates the formation of hMre11/hRad50 ionizing radiation-induced foci. Comparison of the p95 cDNA to the NBS1 cDNA indicated that the p95 gene and NBS1 are identical. The implication of hMre11/hRad50/p95 protein complex in NBS reveals a direct molecular link between DSB repair and cell cycle checkpoint functions.	Univ Wisconsin, Sch Med, Genet Lab, Madison, WI 53706 USA; Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Washington; University of Washington Seattle; University of Chicago	Petrini, JHJ (corresponding author), Univ Wisconsin, Sch Med, Genet Lab, Madison, WI 53706 USA.		Maser, Richard/B-2970-2012		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052095, R01GM056888] Funding Source: NIH RePORTER; NCRR NIH HHS [5P41RR11823-02] Funding Source: Medline; NIGMS NIH HHS [GM 52095, GM56888] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJIMURA M, 1993, GENETICS, V133, P51; BIGBEE WL, 1989, AM J HUM GENET, V44, P402; BLOCHER D, 1991, INT J RADIAT BIOL, V60, P791, DOI 10.1080/09553009114552601; BUBLEY GJ, 1987, SOMAT CELL MOLEC GEN, V13, P111, DOI 10.1007/BF01534691; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; Cleaver J E, 1989, Birth Defects Orig Artic Ser, V25, P61; Connelly JC, 1997, J BIOL CHEM, V272, P19819, DOI 10.1074/jbc.272.32.19819; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; GERMAN J, 1983, CHROMOSOME MUTATION, P11; GIBSON FP, 1992, J BACTERIOL, V174, P1222, DOI 10.1128/jb.174.4.1222-1228.1992; Harlow E, 1988, ANTIBODIES LAB MANUA; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HOJO ETS, 1995, MUTAT RES-ENVIR MUTA, V334, P59; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; Ivanov EL, 1996, GENETICS, V142, P693; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; James P, 1996, GENETICS, V144, P1425; Jayakumar A, 1996, P NATL ACAD SCI USA, V93, P14509, DOI 10.1073/pnas.93.25.14509; JOHZUKA K, 1995, GENETICS, V139, P1521; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; Link AJ, 1997, ELECTROPHORESIS, V18, P1314, DOI 10.1002/elps.1150180808; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuura S, 1997, AM J HUM GENET, V60, P1487, DOI 10.1086/515461; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MEYN MS, 1995, CANCER RES, V55, P5991; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; NELMS BE, 1998, IN PRESS SCIENCE; NISHIDA C, 1988, J BIOL CHEM, V263, P501; OGAWA H, 1995, ADV BIOPHYS, V31, P67, DOI 10.1016/0065-227X(95)99383-Z; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; PerezVera P, 1997, AM J MED GENET, V70, P24, DOI 10.1002/(SICI)1096-8628(19970502)70:1<24::AID-AJMG5>3.0.CO;2-R; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; PETRINI JHJ, 1994, J IMMUNOL, V152, P176; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; ROWLEY JD, 1994, LEUKEMIA, V8, pS1; Saar K, 1997, AM J HUM GENET, V60, P605; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stavnezer J, 1996, ADV IMMUNOL, V61, P79, DOI 10.1016/S0065-2776(08)60866-4; Stumm M, 1997, AM J HUM GENET, V60, P1246; Sullivan KE, 1997, CLIN IMMUNOL IMMUNOP, V82, P43, DOI 10.1006/clin.1996.4275; TAALMAN RDFM, 1983, MUTAT RES, V112, P23, DOI 10.1016/0167-8817(83)90021-4; TIMME TL, 1988, AM J MED SCI, V295, P40, DOI 10.1097/00000441-198801000-00009; Tsubouchi H, 1998, MOL CELL BIOL, V18, P260, DOI 10.1128/MCB.18.1.260; vanderBurgt I, 1996, J MED GENET, V33, P153, DOI 10.1136/jmg.33.2.153; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; WEEMAES CMR, 1994, INT J RADIAT BIOL, V66, pS185; WEEMAES CMR, 1981, ACTA PAEDIATR SCAND, V70, P557, DOI 10.1111/j.1651-2227.1981.tb05740.x; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; YATES JR, 1995, ANAL CHEM, V67, P3202, DOI 10.1021/ac00114a016; YOUNG BR, 1989, HUM GENET, V82, P113, DOI 10.1007/BF00284040	67	958	983	0	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1998	93	3					477	486		10.1016/S0092-8674(00)81175-7	http://dx.doi.org/10.1016/S0092-8674(00)81175-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590181	Bronze			2022-12-24	WOS:000073471500022
J	Gravel, S; Larrivee, M; Labrecque, P; Wellinger, RJ				Gravel, S; Larrivee, M; Labrecque, P; Wellinger, RJ			Yeast Ku as a regulator of chromosomal DNA end structure	SCIENCE			English	Article							STRAND-BREAK REPAIR; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; TELOMERE MAINTENANCE; BINDING PROTEIN; INVOLVEMENT; MECHANISM; ABSENCE; HDF1; GENE	During telomere replication in yeast, chromosome ends acquire an S-phase-specific overhang of the guanosine-rich strand. Here it is shown that in cells lacking Ku, a heterodimeric protein involved in nonhomologous DNA end joining, these overhangs are present throughout the cell cycle. In vivo cross-linking experiments demonstrated that Ku is bound to telomeric DNA, These results show that Ku plays a direct role in establishing a normal DNA end structure on yeast chromosomes, conceivably by functioning as a terminus-binding factor. Because Ku-mediated DNA end joining involving telomeres would result in chromosome instability, our data also suggest that Ku;has a distinct function when bound to telomeres.	Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Wellinger, RJ (corresponding author), Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, 3001 12th Ave N, Sherbrooke, PQ J1H 5N4, Canada.		Wellinger, Raymund/K-3207-2019	Wellinger, Raymund/0000-0001-6670-2759				Barnes G, 1997, P NATL ACAD SCI USA, V94, P867, DOI 10.1073/pnas.94.3.867; Blackburn EH, 1995, TELOMERES; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; Feldmann H, 1996, J BIOL CHEM, V271, P27765, DOI 10.1074/jbc.271.44.27765; GRAVEL S, UNPUB; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; Lieber MR, 1997, CURR OPIN GENET DEV, V7, P99, DOI 10.1016/S0959-437X(97)80116-5; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; Mages GJ, 1996, J BIOL CHEM, V271, P7910, DOI 10.1074/jbc.271.14.7910; Milne GT, 1996, MOL CELL BIOL, V16, P4189; MIMORI T, 1986, J BIOL CHEM, V261, P375; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; Siede W, 1996, GENETICS, V142, P91; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Tsukamoto Y, 1996, NUCLEIC ACIDS RES, V24, P2067, DOI 10.1093/nar/24.11.2067; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; Wellinger RJ, 1997, EUR J CANCER, V33, P735, DOI 10.1016/S0959-8049(97)00067-1; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141	35	366	371	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					741	744		10.1126/science.280.5364.741	http://dx.doi.org/10.1126/science.280.5364.741			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563951				2022-12-24	WOS:000073415600049
J	Bush, TG; Savidge, TC; Freeman, TC; Cox, HJ; Campbell, EA; Mucke, L; Johnson, MH; Sofroniew, MV				Bush, TG; Savidge, TC; Freeman, TC; Cox, HJ; Campbell, EA; Mucke, L; Johnson, MH; Sofroniew, MV			Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice	CELL			English	Article							INFLAMMATORY BOWEL-DISEASE; FIBRILLARY ACIDIC PROTEIN; RECEPTOR MUTANT MICE; NERVOUS-SYSTEM; LACKING GDNF; INTESTINAL INFLAMMATION; REACTIVE ASTROCYTES; NEURONS; CELLS; EXPRESSION	To investigate the roles of astroglial cells, we targeted their ablation genetically. Transgenic mice were generated expressing herpes simplex virus thymidine kinase from the mouse glial fibrillary acidic protein (GFAP) promoter. In adult transgenic mice, 2 weeks of subcutaneous treatment with the antiviral agent ganciclovir preferentially ablated transgene-expressing, GFAP-positive glia from the jejunum and ileum, causing a fulminating and fatal jejuno-ileitis. This pathology was independent of bacterial overgrowth and was characterized by increased myeloperoxidase activity, moderate degeneration of myenteric neurons, and intraluminal hemorrhage. These findings demonstrate that enteric glia play an essential role in maintaining the integrity of the bowel and suggest that their loss or dysfunction may contribute to the cellular mechanisms of inflammatory bowel disease.	MRC, Cambridge Ctr Brain Repair, Cambridge CB2 2PY, England; Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Univ Birmingham, Inst Child Hlth, Birmingham B16 8ET, W Midlands, England; Sanger Ctr, Hinxton CB10 1SA, England; Univ Calif San Francisco, Gladstone Mol Neurobiol Program, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94141 USA	University of Cambridge; University of Cambridge; University of Birmingham; Wellcome Trust Sanger Institute; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Sofroniew, MV (corresponding author), MRC, Cambridge Ctr Brain Repair, Forvie Site,Robinson Way, Cambridge CB2 2PY, England.			Mucke, Lennart/0000-0001-6256-9559; Freeman, Thomas/0000-0001-5235-8483; johnson, martin/0000-0002-5906-5883	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALSHAWI R, 1988, MOL CELL BIOL, V8, P4821, DOI 10.1128/MCB.8.11.4821; Bar KJ, 1997, GASTROENTEROLOGY, V112, P1381, DOI 10.1016/S0016-5085(97)70154-9; BORRELLI E, 1989, NATURE, V339, P538, DOI 10.1038/339538a0; BUCHANAN RL, 1993, NEURON, V10, P839, DOI 10.1016/0896-6273(93)90200-B; Canfield V, 1996, P NATL ACAD SCI USA, V93, P2431, DOI 10.1073/pnas.93.6.2431; DAHL JL, 1987, GASTROENTEROLOGY, V92, P338, DOI 10.1016/0016-5085(87)90126-0; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; FRANK KB, 1984, J BIOL CHEM, V259, P1566; GERSHON MD, 1991, GLIA, V4, P195, DOI 10.1002/glia.440040211; Goyal RK, 1996, NEW ENGL J MED, V334, P1106, DOI 10.1056/NEJM199604253341707; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; HEYMAN RA, 1989, P NATL ACAD SCI USA, V86, P2698, DOI 10.1073/pnas.86.8.2698; Hogan B., 1986, MANIPULATING MOUSE E; Holst MC, 1995, J NEUROSCI METH, V62, P121, DOI 10.1016/0165-0270(95)00064-X; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; JESSEN KR, 1980, NATURE, V286, P736, DOI 10.1038/286736a0; JOHNSON WB, 1995, GLIA, V13, P174, DOI 10.1002/glia.440130304; Karaosmanoglu T, 1996, ANAT RECORD, V244, P470, DOI 10.1002/(SICI)1097-0185(199604)244:4<470::AID-AR5>3.0.CO;2-Z; KAWAJA MD, 1991, NEURON, V7, P1019, DOI 10.1016/0896-6273(91)90346-2; Kirchgessner AL, 1997, J NEUROSCI, V17, P8804; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; McCafferty DM, 1997, AM J PHYSIOL-GASTR L, V272, pG272, DOI 10.1152/ajpgi.1997.272.2.G272; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MILLER MJS, 1993, J PHARMACOL EXP THER, V264, P11; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sharkey KA, 1996, CAN J GASTROENTEROL, V10, P335, DOI 10.1155/1996/502865; SHARKEY KA, 1990, NEUROSCIENCE, V38, P13, DOI 10.1016/0306-4522(90)90370-J; STROBER W, 1993, CELL, V75, P203, DOI 10.1016/0092-8674(93)80062-J; Theodosis DT, 1996, TRENDS NEUROSCI, V19, P363, DOI 10.1016/0166-2236(96)10055-2; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; WALLACE H, 1991, ENDOCRINOLOGY, V129, P3217, DOI 10.1210/endo-129-6-3217	38	438	447	2	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1998	93	2					189	201		10.1016/S0092-8674(00)81571-8	http://dx.doi.org/10.1016/S0092-8674(00)81571-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568712	Bronze			2022-12-24	WOS:000073174000006
J	Lee, HW; Blasco, MA; Gottlieb, GJ; Horner, JW; Greider, CW; DePinho, RA				Lee, HW; Blasco, MA; Gottlieb, GJ; Horner, JW; Greider, CW; DePinho, RA			Essential role of mouse telomerase in highly proliferative organs	NATURE			English	Article							IMMORTAL CELLS; RNA; CHROMOSOMES; ACTIVATION; GROWTH; YEAST; DNA	We have investigated the role of the enzyme telomerase in highly proliferative organs in successive generations of mice lacking telomerase RNA. Late-generation animals exhibited defective spermatogenesis, with increased programmed cell death (apoptosis) and decreased proliferation in the testis. The proliferative capacity of haematopoietic cells In the bone marrow and spleen was also compromised. These progressively adverse effects coincided with substantial erosion of telomeres (the termini of eukaryotic chromosomes) and fusion and loss of chromosomes. These findings indicate an essential role for telomerase, and hence telomeres, in the maintenance of genomic integrity and in the long-term viability of high-renewal organ systems.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Quest Diagnost Inc, Teterboro, NJ 07608 USA	Yeshiva University; Albert Einstein College of Medicine; Cold Spring Harbor Laboratory; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Greider, CW (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X; DePinho, Ronald/0000-0002-5625-577X				Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; Cannizzaro L A, 1997, Methods Mol Biol, V75, P313; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DROST JB, 1995, ENVIRON MOL MUTAGEN, V25, P48, DOI 10.1002/em.2850250609; ERSLEV AJ, 1993, HEMATOLOGY, P37; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GARAGNA S, 1995, CHROMOSOMA, V103, P685, DOI 10.1007/BF00344229; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HABER JE, 1984, GENETICS, V106, P207; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; McClintock B, 1941, GENETICS, V26, P234; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Muller H., 1938, COLLECT NET, V13, P182; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; NANDA I, 1995, CHROMOSOME RES, V3, P399, DOI 10.1007/BF00713889; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SHIMA H, 1990, ENDOCRINOLOGY, V127, P3222, DOI 10.1210/endo-127-6-3222; SINGER MS, 1994, SCIENCE, V266, P403; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WATT SM, 1992, CELL PROLIFERAT, V25, P263, DOI 10.1111/j.1365-2184.1992.tb01440.x; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; Wright S, 1921, GENETICS, V6, P111; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	41	1048	1100	0	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					569	574		10.1038/33345	http://dx.doi.org/10.1038/33345			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560153				2022-12-24	WOS:000072987200049
J	Prescott, E; Hippe, M; Schnohr, P; Hein, HO; Vestbo, J				Prescott, E; Hippe, M; Schnohr, P; Hein, HO; Vestbo, J			Smoking and risk of myocardial infarction in women and men: longitudinal population study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP; CIGARETTE-SMOKING; CARDIOVASCULAR-DISEASE; BRITISH DOCTORS; OLDER MEN; MORTALITY; ESTROGEN; HEALTH	Objective: To compare risk of myocardial infarction associated with smoking in men and women, taking into consideration differences in smoking behaviour and a number of potential confounding variables. Design: Prospective cohort study with follow up of myocardial infarction. Setting: Pooled data from three population studies conducted in Copenhagen. Subjects: 11 472 women and 13 191 men followed for a mean of 12.3 years. Main outcome measures: First admission to hospital or death caused by myocardial infarction. Results: 1251 men and 512 women had a myocardial infarction during follow up. Compared with non-smokers, female current smokers had a relative risk of myocardial infarction of 2.24 (range 1.85-2.71) and male smokers 1.43 (1.26-1.62); ratio 1.57 (1.25-1.97). Relative risk of myocardial infarction increased with tobacco consumption in both men and women and was higher in inhalers than in non-inhalers. The risks associated with smoking, measured by both current and accumulated tobacco exposure, were consistently higher in women than in men and did not depend on age. This sex difference was not affected by adjustment for arterial blood pressure, total and high density lipoprotein cholesterol concentrations, triglyceride concentrations, diabetes, body mass index, height, alcohol intake, physical activity, and level of education. Conclusion: Women may be more sensitive than men to some of the harmful effects of smoking. Interactions between components of smoke and hormonal factors that may be involved in development of ischaemic heart disease should be examined further.	Univ Copenhagen, Inst Prevent Med, Copenhagen Ctr Prespect Populat Studies, Danish Epidemiol Sci Ctr, DK-1168 Copenhagen, Denmark; Univ Copenhagen, Bispebjerg Hosp, Copenhagen City Heart Study, DK-1168 Copenhagen, Denmark; Univ Copenhagen, Bispebjerg Hosp, Epidemiol Res Unit, DK-1168 Copenhagen, Denmark	Aarhus University; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Bispebjerg Hospital	Prescott, E (corresponding author), Kommune Hosp Copenhagen, Inst Prevent Med, DK-1399 Copenhagen K, Denmark.	eva.prescott@ipm.hosp.dk	Prescott, Eva/AAJ-7441-2020; Vestbo, Jorgen/Y-2912-2019	Vestbo, Jorgen/0000-0001-6355-6362; Prescott, Eva/0000-0002-4134-0349				BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; DAVIS MA, 1994, PREV MED, V23, P369, DOI 10.1006/pmed.1994.1051; Department of Health and Human Services. Epidemiology In National Heart Lung and Blood Institute, 1994, REP TASK FORC RES EP, P19; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1980, BRIT MED J, V280, P967, DOI 10.1136/bmj.280.6219.967; FLODERUS B, 1988, INT J EPIDEMIOL, V17, P332, DOI 10.1093/ije/17.2.332; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; JANGHORBANI M, 1993, INT J EPIDEMIOL, V22, P1056, DOI 10.1093/ije/22.6.1056; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; LINDENSTROM E, 1993, STROKE, V24, P1468, DOI 10.1161/01.STR.24.10.1468; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; MICHNOVICZ JJ, 1989, METABOLISM, V38, P537, DOI 10.1016/0026-0495(89)90213-8; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; MILLER VT, 1991, OBSTET GYNECOL, V77, P235, DOI 10.1097/00006250-199102000-00014; Njolstad I, 1996, CIRCULATION, V93, P450; NYBOE J, 1991, AM HEART J, V122, P438, DOI 10.1016/0002-8703(91)90997-V; Peto R, 1994, MORTALITY SMOKING DE; PRESCOTT E, IN PRESS INT J EPIDE; SELTZER CC, 1989, J CLIN EPIDEMIOL, V42, P743, DOI 10.1016/0895-4356(89)90070-X; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; *STAT, 1997, STAT STAT SOFTW REL; THUN MJ, 1995, AM J PUBLIC HEALTH, V85, P1223, DOI 10.2105/AJPH.85.9.1223; TVERDAL A, 1993, J CLIN EPIDEMIOL, V46, P475, DOI 10.1016/0895-4356(93)90025-V; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680	25	378	393	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 4	1998	316	7137					1043	1047						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552903				2022-12-24	WOS:000072987400021
J	Hyatt, BA; Yost, HJ				Hyatt, BA; Yost, HJ			The left-right coordinator: The role of Vg1 in organizing left-right axis formation	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-4; LEFT-RIGHT ASYMMETRY; XENOPUS EMBRYOS; MESODERM INDUCTION; TRUNCATED ACTIVIN; NODAL EXPRESSION; SITUS-INVERSUS; NOGGIN; BMP-4; SPECIFICATION	The asymmetries of internal organs are consistently oriented along the left-right axis in all vertebrates, and perturbations of left-right orientation lead to significant congenital disease. We propose a model in which a "left-right coordinator" interacts with the Spemann organizer to coordinate the evolutionarily conserved three-dimensional asymmetries in the embryo. The Vg1 cell-signaling pathway plays a central role in left-right coordinator function. Antagonists of Vg1 alter left-right development; antagonists of other members of the TGF beta family do not. Cell-lineage directed expression of Vg1 protein can fully invert the left-right axis (situs inversus), can randomize left-right asymmetries, or can "rescue" a perturbed left-right axis in conjoined twins to normal orientation (situs solitus), indicating that Vg1 can mimic left-right coordinator activity. These are the first molecular manipulations in any vertebrate by which the left-right axis can be reliably controlled.	Univ Minnesota, Grad Program Mol Cell Dev Biol & Genet, Minneapolis, MN 55455 USA; Univ Utah, Huntsman Canc Inst, Ctr Children, Dept Oncol Sci, Salt Lake City, UT 84103 USA; Univ Utah, Huntsman Canc Inst, Ctr Children, Dept Pediat, Salt Lake City, UT 84103 USA	University of Minnesota System; University of Minnesota Twin Cities; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Yost, HJ (corresponding author), Univ Minnesota, Grad Program Mol Cell Dev Biol & Genet, Minneapolis, MN 55455 USA.							Bowers PN, 1996, PROG PEDIATR CARDIOL, V6, P53, DOI 10.1016/1058-9813(96)00171-3; Chang CB, 1997, DEVELOPMENT, V124, P827; Chen JN, 1997, DEVELOPMENT, V124, P4373; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1992, DEVELOPMENT, V115, P573; DANOS MC, 1995, DEVELOPMENT, V121, P1467; Danos MC, 1996, DEV BIOL, V177, P96, DOI 10.1006/dbio.1996.0148; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Frisch A, 1998, DEVELOPMENT, V125, P431; FUKUI A, 1993, DEV BIOL, V159, P131, DOI 10.1006/dbio.1993.1227; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HIROSE G, 1979, DEV BIOL, V71, P191, DOI 10.1016/0012-1606(79)90163-5; Hyatt BA, 1996, NATURE, V384, P62, DOI 10.1038/384062a0; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; JOHNSON AD, 1994, GENE, V147, P223, DOI 10.1016/0378-1119(94)90070-1; Jones CM, 1996, DEVELOPMENT, V122, P1545; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; KLAR AJS, 1994, TRENDS GENET, V10, P392, DOI 10.1016/0168-9525(94)90055-8; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; Levin M, 1996, NATURE, V384, P321, DOI 10.1038/384321a0; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Lustig KD, 1996, DEVELOPMENT, V122, P3275; MOODY SA, 1987, DEV BIOL, V119, P560, DOI 10.1016/0012-1606(87)90059-5; NAKAMURA O, 1971, P JPN ACAD, V47, P407, DOI 10.2183/pjab1945.47.407; Nascone N, 1997, DEV BIOL, V189, P68, DOI 10.1006/dbio.1997.8635; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Psychoyos D, 1996, DEVELOPMENT, V122, P3263; ReemKalma Y, 1995, P NATL ACAD SCI USA, V92, P12141, DOI 10.1073/pnas.92.26.12141; Sampath K, 1997, DEVELOPMENT, V124, P3293; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; Sasai Y, 1996, EMBO J, V15, P4547, DOI 10.1002/j.1460-2075.1996.tb00832.x; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; Spemann H, 1919, ARCH ENTWICKLUNG ORG, V45, P371, DOI 10.1007/BF02554405; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; Wilson PA, 1997, DEVELOPMENT, V124, P3177; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YOSH HJ, 1995, CELL, V82, P689; YOST HJ, 1992, NATURE, V357, P158, DOI 10.1038/357158a0; YOST HJ, 1991, CIBA F SYMP, V162, P165; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	49	135	138	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					37	46		10.1016/S0092-8674(00)81144-7	http://dx.doi.org/10.1016/S0092-8674(00)81144-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546390	Bronze			2022-12-24	WOS:000072910800008
J	Nichols, WC; Seligsohn, U; Zivelin, A; Terry, VH; Hertel, CE; Wheatley, MA; Moussalli, MJ; Hauri, HP; Ciavarella, N; Kaufman, RJ; Ginsburg, D				Nichols, WC; Seligsohn, U; Zivelin, A; Terry, VH; Hertel, CE; Wheatley, MA; Moussalli, MJ; Hauri, HP; Ciavarella, N; Kaufman, RJ; Ginsburg, D			Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII	CELL			English	Article							EFFICIENT THROMBIN CLEAVAGE; FACTOR-BASED VECTOR; ENDOPLASMIC-RETICULUM; C INHIBITOR; MEMBRANE-PROTEIN; PROCOAGULANT ACTIVITY; LEGUMINOUS LECTINS; RECYCLING PATHWAY; MAMMALIAN-CELLS; CIS-GOLGI	Combined deficiency of factors V and VIII is an autosomal recessive bleeding disorder resulting from alterations in an unknown gene on chromosome 18q, distinct from the factor V and factor VIII genes. ERGIC-53, a component of the ER-Golgi intermediate compartment, was mapped to a YAC and BAC contig containing the critical region for the combined factors V and VIII deficiency gene. DNA sequence analysis identified two different mutations, accounting for all affected individuals in nine families studied. Immunofluorescence and Western analysis of immortalized lymphocytes from patients homozygous for either of the two mutations demonstrate complete lack of expression of the mutated gene in these cells. These findings suggest that ERGIC-53 may function as a molecular chaperone for the transport from ER to Golgi of a specific subset of secreted proteins, including coagulation factors V and VIII.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Chaim Sheba Med Ctr, Inst Thrombosis & Hemostasis, IL-52621 Tel Hashomer, Israel; Univ Basel, Biozentrum, Basel, Switzerland; Policlin Bari, Univ Hosp, Dept Blood Coagulat, I-70124 Bari, Italy; Policlin Bari, Univ Hosp, Hemophilia Ctr, I-70124 Bari, Italy	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; University of Basel; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Ginsburg, D (corresponding author), Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.			Wheatley, Matthew/0000-0002-4816-9548	NHLBI NIH HHS [HL39693, HL57346] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL039693, P01HL057346, R01HL039693] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM KAR, 1985, SCAND J HAEMATOL, V34, P401; ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BONTEMPO FA, 1987, BLOOD, V69, P1721; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; CANFIELD WM, 1982, J CLIN INVEST, V70, P1260, DOI 10.1172/JCI110725; CHANDRASEKHARAP.SC, 1992, ELECTROPHORESIS PROT, P235; CHIU HC, 1985, J CLIN INVEST, V75, P339, DOI 10.1172/JCI111706; COONEY KA, 1991, J CLIN INVEST, V87, P1227, DOI 10.1172/JCI115123; CRIPE LD, 1992, BIOCHEMISTRY-US, V31, P3777, DOI 10.1021/bi00130a007; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; GARDINER JE, 1984, THROMB RES, V36, P197, DOI 10.1016/0049-3848(84)90219-6; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GINSBURG D, 1997, EMERY RIMOINS PRINCI, P1651; GIROLAMI A, 1976, BLUT, V32, P415, DOI 10.1007/BF01013881; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; KAUFMAN RJ, 1998, IN PRESS THROMB HAEM; KIM UJ, 1992, NUCLEIC ACIDS RES, V20, P1083, DOI 10.1093/nar/20.5.1083; Kim UJ, 1996, P NATL ACAD SCI USA, V93, P6297, DOI 10.1073/pnas.93.13.6297; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; Lahtinen U, 1996, J BIOL CHEM, V271, P4031; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MANN KG, 1984, J BIOL CHEM, V259, P2949; MARLAR RA, 1980, J CLIN INVEST, V66, P1186, DOI 10.1172/JCI109952; MAZZONE D, 1982, ACTA HAEMATOL-BASEL, V68, P337, DOI 10.1159/000207005; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; NeermanArbez M, 1997, AM J HUM GENET, V61, P143, DOI 10.1086/513897; Nichols WC, 1997, J CLIN INVEST, V99, P596, DOI 10.1172/JCI119201; Nichols WC, 1996, BLOOD, V88, P4429, DOI 10.1182/blood.V88.12.4429.bloodjournal88124429; OERI J, 1954, MED PROBL PAEDIAT, V1, P575; ORTEL TL, 1984, P NATL ACAD SCI-BIOL, V81, P4761, DOI 10.1073/pnas.81.15.4761; OZSOYLU S, 1983, ACTA HAEMATOL-BASEL, V70, P207, DOI 10.1159/000206726; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PITTMAN DD, 1994, BLOOD, V84, P4214, DOI 10.1182/blood.V84.12.4214.bloodjournal84124214; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Schekman R, 1997, CELL, V90, P197, DOI 10.1016/S0092-8674(00)80326-8; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SELIGSOHN U, 1982, NEW ENGL J MED, V307, P1191, DOI 10.1056/NEJM198211043071907; Seligsohn U, 1989, FACTOR 8 VON WILLEBR, P89; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; SUGDEN B, 1977, J VIROL, V23, P503, DOI 10.1128/JVI.23.3.503-508.1977; SUZUKI K, 1983, BLOOD, V62, P1266; Tagliavacca L, 1997, J BIOL CHEM, V272, P27428, DOI 10.1074/jbc.272.43.27428; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; WION KL, 1985, NATURE, V317, P726, DOI 10.1038/317726a0	61	330	338	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1998	93	1					61	70		10.1016/S0092-8674(00)81146-0	http://dx.doi.org/10.1016/S0092-8674(00)81146-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546392	Bronze			2022-12-24	WOS:000072910800010
J	Singson, A; Mercer, KB; L'Hernault, SW				Singson, A; Mercer, KB; L'Hernault, SW			The C-elegans spe-9 gene encodes a sperm transmembrane protein that contains EGF-like repeats and is required for fertilization	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; EPIDERMAL GROWTH-FACTOR; MEMBRANE-PROTEIN; DROSOPHILA; DELTA; NOTCH; SERRATE; CELL; RECEPTOR; GENOME	In the nematode worm C. elegans, individuals with mutations in the spe-g gene produce spermatozoa with wild-type morphology and motility that cannot fertilize oocytes even after contact between gametes. Therefore, disruption of spe9 function affects either gamete recognition, adhesion, signaling, and/or fusion; The spe-g gene encodes a sperm transmembrane protein with an extracellular domain that contains ten epidermal growth factor-like repeats. A common feature of proteins that include epidermal growth factor-like motifs is their involvement in extracellular functions such as adhesive and ligand-receptor interactions. Additionally, the overall structure of the predicted SPE-9 protein is similar to that of ligands for the Notch/LIN-12/GLP-1 family of transmembrane receptors. These results suggest that SPE-9 functions in the specialized cell-cell interactions required for fertilization.	Emory Univ, Dept Biol, Atlanta, GA 30322 USA	Emory University	Singson, A (corresponding author), Emory Univ, Dept Biol, Atlanta, GA 30322 USA.				NIGMS NIH HHS [GM40697] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040697, R29GM040697] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achanzar WE, 1997, J CELL SCI, V110, P1073; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BRENNER S, 1974, GENETICS, V77, P71; Browning H, 1996, DEVELOPMENT, V122, P391; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; DAVIS C G, 1990, New Biologist, V2, P410; DONIACH T, 1984, DEV BIOL, V106, P223, DOI 10.1016/0012-1606(84)90077-0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; Fleming RJ, 1997, TRENDS CELL BIOL, V7, P437, DOI 10.1016/S0962-8924(97)01161-6; FOLTZ KR, 1993, DEV BIOL, V158, P46, DOI 10.1006/dbio.1993.1167; GREENSPAN R J, 1990, New Biologist, V2, P595; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; Herman RK, 1995, METHOD CELL BIOL, V48, P123; HIRSH D, 1976, DEV BIOL, V49, P200, DOI 10.1016/0012-1606(76)90267-0; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; Krause M, 1995, METHOD CELL BIOL, V48, P483; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; L'Hernault SW, 1997, C ELEGANS, P271; LHERNAULT SW, 1988, GENETICS, V120, P435; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; LHernault SW, 1995, METHOD CELL BIOL, V48, P273; LIEBER T, 1992, NEURON, V9, P847, DOI 10.1016/0896-6273(92)90238-9; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; LIU KS, 1995, NEURON, V14, P79, DOI 10.1016/0896-6273(95)90242-2; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PRIMAKOFF P, 1983, DEV BIOL, V98, P417, DOI 10.1016/0012-1606(83)90371-8; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Riddle DL, 1997, C ELEGANS; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHEDL T, 1997, C ELEGANS, V2, P241; SHAKES DC, 1989, DEV BIOL, V134, P189, DOI 10.1016/0012-1606(89)90088-2; Snell WJ, 1996, CELL, V85, P629, DOI 10.1016/S0092-8674(00)81230-1; Sun X, 1996, DEVELOPMENT, V122, P2465; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; WARD S, 1979, DEV BIOL, V73, P304, DOI 10.1016/0012-1606(79)90069-1; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Yanagimachi R., 1994, P189	53	101	108	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					71	79		10.1016/S0092-8674(00)81147-2	http://dx.doi.org/10.1016/S0092-8674(00)81147-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546393	Bronze			2022-12-24	WOS:000072910800011
J	Tacke, R; Tohyama, M; Ogawa, S; Manley, JL				Tacke, R; Tohyama, M; Ogawa, S; Manley, JL			Human Tra2 proteins are sequence-specific activators of pre-mRNA splicing	CELL			English	Article							T ALTERNATIVE EXON; RNA-BINDING PROTEINS; SR-PROTEINS; MESSENGER-RNA; PREMESSENGER RNA; SEX DETERMINATION; DROSOPHILA-MELANOGASTER; REGULATORY ELEMENTS; CONSERVED FAMILY; ENHANCER COMPLEX	The RNA-binding protein Tra2 is an important regulator of sex determination in Drosophila. Recently, two mammalian Tra2 homologs of unknown function have been described. Here, we show that human Tra2 proteins are present in HeLa cell nuclear extracts and that they bind efficiently and specifically to a previously characterized pre-mRNA splicing enhancer element. Indeed, both purified proteins bound preferentially to RNA sequences containing GAA repeats, characteristic of many enhancer elements. Neither Tra2 protein functioned in constitutive splicing in vitro, but both activated enhancer-dependent splicing in a sequence-specific manner and restored it after inhibition with competitor RNA. Our findings indicate that mammalian Tra2 proteins are sequence-specific splicing activators that likely participate in the control of cell-specific splicing patterns.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Osaka Univ, Sch Med, Dept Anat & Neurosci, Suita, Osaka 565, Japan	Columbia University; Osaka University	Manley, JL (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.			Manley, James/0000-0002-8341-1459	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048259, R01GM048259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48259] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BAKER BS, 1980, GENETICS, V94, P383; Beil B, 1997, DNA CELL BIOL, V16, P679, DOI 10.1089/dna.1997.16.679; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Burtis KC, 1993, CURR OPIN CELL BIOL, V5, P1006, DOI 10.1016/0955-0674(93)90085-5; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Chandler SD, 1997, P NATL ACAD SCI USA, V94, P3596, DOI 10.1073/pnas.94.8.3596; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; CRISPINO JD, 1994, SCIENCE, V265, P1866, DOI 10.1126/science.8091213; Dauwalder B, 1996, P NATL ACAD SCI USA, V93, P9004, DOI 10.1073/pnas.93.17.9004; Elrick LL, 1998, MOL CELL BIOL, V18, P343, DOI 10.1128/MCB.18.1.343; FU XD, 1995, RNA, V1, P663; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HAZELRIGG T, 1994, P NATL ACAD SCI USA, V91, P10752, DOI 10.1073/pnas.91.22.10752; HEINRICHS V, 1995, EMBO J, V14, P3987, DOI 10.1002/j.1460-2075.1995.tb00070.x; Heinrichs V, 1998, MOL CELL BIOL, V18, P450, DOI 10.1128/MCB.18.1.450; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; INOUE K, 1992, P NATL ACAD SCI USA, V89, P8092, DOI 10.1073/pnas.89.17.8092; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; LYNCH KW, 1995, GENE DEV, V9, P284, DOI 10.1101/gad.9.3.284; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; Madigan SJ, 1996, MOL CELL BIOL, V16, P4222; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MATSUO N, 1995, J BIOL CHEM, V270, P28216, DOI 10.1074/jbc.270.47.28216; Mattox W, 1996, GENETICS, V143, P303; MATTOX W, 1991, GENE DEV, V5, P786, DOI 10.1101/gad.5.5.786; PENG XB, 1995, MOL CELL BIOL, V15, P6273; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; RING HJ, 1994, MOL CELL BIOL, V14, P7499, DOI 10.1128/MCB.14.11.7499; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; Ryan KJ, 1996, MOL CELL BIOL, V16, P4014; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Segade F, 1996, FEBS LETT, V387, P152, DOI 10.1016/0014-5793(96)00496-6; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TARN WY, 1994, GENE DEV, V8, P2704, DOI 10.1101/gad.8.22.2704; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TIAN M, 1994, GENE DEV, V8, P1703, DOI 10.1101/gad.8.14.1703; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; Tronchere H, 1997, NATURE, V388, P397, DOI 10.1038/41137; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; WANG J, 1995, RNA, V1, P335; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; YEAKLEY JM, 1993, MOL CELL BIOL, V13, P5999, DOI 10.1128/MCB.13.10.5999; Yeakley JM, 1996, P NATL ACAD SCI USA, V93, P7582, DOI 10.1073/pnas.93.15.7582; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	64	173	180	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1998	93	1					139	148		10.1016/S0092-8674(00)81153-8	http://dx.doi.org/10.1016/S0092-8674(00)81153-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546399	hybrid			2022-12-24	WOS:000072910800017
J	Wray, GA				Wray, GA			Transcription - Promoter logic	SCIENCE			English	Article							EMBRYO		SUNY Stony Brook, Dept Ecol & Evolut, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wray, GA (corresponding author), SUNY Stony Brook, Dept Ecol & Evolut, Stony Brook, NY 11794 USA.							Arnone MI, 1997, DEVELOPMENT, V124, P1851; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; Yuh CH, 1998, SCIENCE, V279, P1896, DOI 10.1126/science.279.5358.1896; YUH CH, 1994, MECH DEVELOP, V47, P165, DOI 10.1016/0925-4773(94)90088-4	4	15	16	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1871	1872		10.1126/science.279.5358.1871	http://dx.doi.org/10.1126/science.279.5358.1871			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9537905				2022-12-24	WOS:000072613300028
J	Choi, SK; Lee, JH; Zoll, WL; Merrick, WC; Dever, TE				Choi, SK; Lee, JH; Zoll, WL; Merrick, WC; Dever, TE			Promotion of Met-tRNA(i)(Met) binding to ribosomes by yIF2, a bacterial IF2 homolog in yeast	SCIENCE			English	Article							INITIATION FACTOR-II; SACCHAROMYCES-CEREVISIAE; TRANSLATIONAL-INITIATION; SHUTTLE VECTORS; CHROMOSOME-I; START-SITE; GENE; SEQUENCE; IDENTIFICATION; SELECTION	Delivery of the initiator methionine transfer RNA (Met-tRNA(i)(Met)) to the ribosome is a key step in the initiation of protein synthesis. Previous results have indicated that this step is catalyzed by the structurally dissimilar translation factors in prokaryotes and eukaryotes-initiation factor 2 (IF2) and eukaryotic initiation factor 2 (eIF2), respectively. A bacterial IF2 homolog has been identified in both eukaryotes and archaea. By using a combination of molecular genetic and biochemical studies, the Saccharomyces cerevisiae IF2 homolog is shown to function in general translation initiation by promoting Met-tRNA(i)(Met) binding to ribosomes. Thus, the mechanism of protein synthesis in eukaryotes and prokaryotes is more similar than was previously realized.	NICHHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Case Western Reserve University	Dever, TE (corresponding author), NICHHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA.		Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678	NIGMS NIH HHS [GM08056] Funding Source: Medline; PHS HHS [26796] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS SL, 1975, J BIOL CHEM, V250, P9083; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ASTROM SU, 1993, J MOL BIOL, V233, P43, DOI 10.1006/jmbi.1993.1483; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CIGAN AM, 1988, SCIENCE, V242, P93, DOI 10.1126/science.3051379; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; Dennis PP, 1997, CELL, V89, P1007, DOI 10.1016/S0092-8674(00)80288-3; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; DIEHL BE, 1991, GENETICS, V127, P287; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; HERSHEY JWB, 1991, TRANSLATION EUKARYOT, P353; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Huang HK, 1997, GENE DEV, V11, P2396, DOI 10.1101/gad.11.18.2396; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P224, DOI 10.1073/pnas.95.1.224; LAALAMI S, 1991, J MOL BIOL, V220, P335, DOI 10.1016/0022-2836(91)90017-Z; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; MARTIN TE, 1973, EXP CELL RES, V80, P496, DOI 10.1016/0014-4827(73)90333-9; MARTIN TE, 1970, J BIOL CHEM, V245, P1504; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; Merrick W.C., 1975, J BIOL CHEM, V250, P1107; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; MOEHLE CM, 1991, MOL CELL BIOL, V11, P2723, DOI 10.1128/MCB.11.5.2723; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; SIKORSKI RS, 1989, GENETICS, V122, P19; SUTRAVE P, 1994, GENE, V146, P209, DOI 10.1016/0378-1119(94)90294-1; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; VAMBUTAS A, 1991, EUR J BIOCHEM, V201, P643, DOI 10.1111/j.1432-1033.1991.tb16325.x; WICKNER RB, 1994, METH MOL G, V3, P141; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248	33	112	114	2	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1757	1760		10.1126/science.280.5370.1757	http://dx.doi.org/10.1126/science.280.5370.1757			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624054				2022-12-24	WOS:000074197800043
J	Moore, LR; Rocap, G; Chisholm, SW				Moore, LR; Rocap, G; Chisholm, SW			Physiology and molecular phylogeny of coexisting Prochlorococcus ecotypes	NATURE			English	Article							SKELETONEMA-COSTATUM BACILLARIOPHYCEAE; DIVINYL CHLOROPHYLL-A; NORTH-ATLANTIC OCEAN; COMMUNITY STRUCTURE; GENETIC DIVERSITY; SEQUENCE-ANALYSIS; SEA; SYNECHOCOCCUS; PICOPLANKTON; DISTRIBUTIONS	The cyanobacterium Prochlorococcus(1,2) is the dominant oxygenic phototroph in the tropical and subtropical regions of the world's (1,3,4). It can grow at a range of depths over which light oceans intensities can vary by up to 4 orders of magnitude. This broad depth distribution has been hypothesized to stem from the coexistence of genetically different populations adapted for growth at high-and low-light intensities(4-6). Here we report direct evidence supporting this hypothesis, which has been generated by isolating and analysing distinct co-occurring populations of Prochlorococcus at two locations in the North Atlantic. Go-isolates from the same water sample have very different light-dependent physiologies, one growing maximally at light intensities at which the other is completely photoinhibited. Despite this ecotypic differentiation, the co-isolates have 97% similarity in their 16S ribosomal RNA sequences, demonstrating that molecular microdiversity, commonly observed in microbial systems(7-12), can be due to the coexistence of closely related, physiologically distinct populations. The coexistence and distribution of multiple ecotypes permits the survival of the population as a whole over a broader range of environmental conditions than would be possible for a homogeneous population.	MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT Woods Hole Oceanog Inst Joint Program Oceanog, Woods Hole, MA 02543 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Chisholm, SW (corresponding author), MIT, Dept Civil & Environm Engn, 48-425,77 Massachusetts Ave, Cambridge, MA 02139 USA.	chisholm@mit.edu		Chisholm, Sallie/0000-0003-1480-2445; Moore, Lisa/0000-0002-4114-1518; Rocap, Gabrielle/0000-0001-7253-611X				Amann R, 1996, J BACTERIOL, V178, P3496, DOI 10.1128/jb.178.12.3496-3500.1996; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; CAMPBELL L, 1993, DEEP-SEA RES PT I, V40, P2043, DOI 10.1016/0967-0637(93)90044-4; CHISHOLM SW, 1988, NATURE, V334, P340, DOI 10.1038/334340a0; CHISHOLM SW, 1992, ARCH MICROBIOL, V157, P297, DOI 10.1007/BF00245165; DELONG EF, 1994, NATURE, V371, P695, DOI 10.1038/371695a0; FUHRMAN JA, 1993, APPL ENVIRON MICROB, V59, P1294, DOI 10.1128/AEM.59.5.1294-1302.1993; GALLAGHER JC, 1982, J PHYCOL, V18, P148, DOI 10.1111/j.0022-3646.1982.00148.x; GALLAGHER JC, 1980, J PHYCOL, V16, P464; GIOVANNONI SJ, 1990, NATURE, V345, P60, DOI 10.1038/345060a0; GOERICKE R, 1993, MAR ECOL PROG SER, V101, P307, DOI 10.3354/meps101307; JEFFREY SW, 1975, BIOCHEM PHYSIOL PFL, V167, P191, DOI 10.1016/s0015-3796(17)30778-3; Maidak BL, 1997, NUCLEIC ACIDS RES, V25, P109, DOI 10.1093/nar/25.1.109; MOORE LR, 1995, MAR ECOL PROG SER, V116, P259, DOI 10.3354/meps116259; MOORE LR, UNPUB LIMNOL OCEANOG; OLSON RJ, 1988, DEEP-SEA RES, V35, P425, DOI 10.1016/0198-0149(88)90019-2; OLSON RJ, 1990, DEEP-SEA RES, V37, P1033, DOI 10.1016/0198-0149(90)90109-9; PALENIK B, 1994, APPL ENVIRON MICROB, V60, P3212, DOI 10.1128/AEM.60.9.3212-3219.1994; Partensky F, 1996, DEEP-SEA RES PT I, V43, P1191, DOI 10.1016/0967-0637(96)00056-8; PARTENSKY F, 1993, PLANT PHYSIOL, V101, P285, DOI 10.1104/pp.101.1.285; PLATT T, 1980, J MAR RES, V38, P687; Scanlan DJ, 1996, EUR J PHYCOL, V31, P1, DOI 10.1080/09670269600651131; Shimada A, 1996, MAR BIOL, V127, P15, DOI 10.1007/BF00993639; SMITH SW, 1994, COMPUT APPL BIOSCI, V10, P671; Toledo G, 1997, APPL ENVIRON MICROB, V63, P4298, DOI 10.1128/AEM.63.11.4298-4303.1997; Urbach E, 1998, J MOL EVOL, V46, P188, DOI 10.1007/PL00006294; VELDHUIS MJW, 1993, NETH J SEA RES, V31, P135, DOI 10.1016/0077-7579(93)90003-B; WARD DM, 1990, NATURE, V345, P63, DOI 10.1038/345063a0; Waterbury JB, 1986, CAN B FISH AQUAT SCI, V214, P71	29	562	577	3	86	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					464	467		10.1038/30965	http://dx.doi.org/10.1038/30965			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624000				2022-12-24	WOS:000074020000043
J	Schoenberger, SP; Toes, REM; van der Voort, EIH; Offringa, R; Melief, CJM				Schoenberger, SP; Toes, REM; van der Voort, EIH; Offringa, R; Melief, CJM			T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions	NATURE			English	Article							CD40 LIGAND; DENDRITIC CELLS; ANTITUMOR IMMUNITY; DEFICIENT MICE; CLASS-II; ACTIVATION; DISRUPTION; INDUCTION; ANTIGENS; MOLECULE	Although in vivo priming of CD8(+) cytotoxic T lymphocytes (CTLs) generally requires the participation of CD4(+) T-helper lymphocytes(1,2), the nature of the 'help' provided to CTLs is unknown(3). One widely held view is that help for CTLs is mediated by cytokines produced by T-helper cells activated in proximity to the CTL precursor at the surface of an antigen-presenting cell (APC)(4). An alternative theory is that, rather than being directly supplied to the CTL by the helper cell, help is delivered through activation of the APC, which can then prime the CTL directly(5). CD40 and its ligand, CD40L, may activate the APC to allow CTL priming. CD40L is expressed on the surface of activated CD4(+) T-helper cells and is involved in their activation and in the development of their effector functions(6,7). Ligation of CD40 on the surface of APCs such as dendritic cells, macrophages and B cells greatly increases their antigen-presentation and co-stimulatory capacity(8-11). Here we report that signalling through CD40 can replace CD4(+) T-helper cells in priming of helper-dependent CD8(+) CTL responses. Blockade of CD40L inhibits CTL priming; this inhibition is overcome by signalling through CD40. CD40-CD40L interactions are therefore vital in the delivery of T-cell help for CTL priming.	Univ Leiden Hosp, Dept Immunohematol, NL-2333 AZ Leiden, Netherlands; Univ Leiden Hosp, Blood Bank, NL-2333 AZ Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	Schoenberger, SP (corresponding author), Univ Leiden Hosp, Dept Immunohematol, POB 9600, NL-2333 AZ Leiden, Netherlands.	sps@liai.org		Toes, Rene/0000-0002-9618-6414				Bennett SRM, 1997, J EXP MED, V186, P65, DOI 10.1084/jem.186.1.65; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; Grewal IS, 1996, IMMUNOL TODAY, V17, P410, DOI 10.1016/0167-5699(96)10030-X; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; GUERDER S, 1992, J EXP MED, V176, P553, DOI 10.1084/jem.176.2.553; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; HUSMANN LA, 1988, ANN NY ACAD SCI, V532, P158, DOI 10.1111/j.1749-6632.1988.tb36335.x; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; KENNEDY MK, 1994, EUR J IMMUNOL, V24, P116, DOI 10.1002/eji.1830240118; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; Kurts C, 1997, J EXP MED, V186, P239, DOI 10.1084/jem.186.2.239; Mackey MF, 1997, CANCER RES, V57, P2569; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; Noelle RJ, 1996, IMMUNITY, V4, P415, DOI 10.1016/S1074-7613(00)80408-2; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Shinde S, 1996, J IMMUNOL, V157, P2764; SIMPSON E, 1977, IMMUNOL REV, V35, P59, DOI 10.1111/j.1600-065X.1977.tb00235.x; Soong L, 1996, IMMUNITY, V4, P263, DOI 10.1016/S1074-7613(00)80434-3; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Stout RD, 1996, J IMMUNOL, V156, P8; Toes REM, 1996, CANCER RES, V56, P3782; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862	29	1916	2015	2	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 4	1998	393	6684					480	483		10.1038/31002	http://dx.doi.org/10.1038/31002			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624005				2022-12-24	WOS:000074020000048
J	Das, S; Sasaki, YF; Rothe, T; Premkumar, LS; Takasu, M; Crandall, JE; Dikkes, P; Conner, DA; Rayudu, PV; Cheung, W; Chen, HSV; Lipton, SA; Nakanishi, N				Das, S; Sasaki, YF; Rothe, T; Premkumar, LS; Takasu, M; Crandall, JE; Dikkes, P; Conner, DA; Rayudu, PV; Cheung, W; Chen, HSV; Lipton, SA; Nakanishi, N			Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A	NATURE			English	Article							LONG-TERM POTENTIATION; DENDRITIC SPINES; REGIONAL EXPRESSION; RAT-BRAIN; CHANNEL; PLASTICITY; CLONING	The NMDA (N-methyl-D-aspartate) subclass of glutamate receptor(1) is essential for the synaptic plasticity thought to underlie learning and memory(2-4) and for synaptic refinement during development(5,6). It is currently believed that the NMDA receptor (NMDAR) is a heteromultimeric channel comprising the ubiquitous NR1 subunit and at least one regionally localized NR2 subunit(7-11). Here we report the characterization of a regulatory NMDAR subunit, NR3A (formerly termed NMDAR-L or chi-1), which is expressed primarily during brain development(12,13) NR3A co-immunoprecipitates with receptor subunits NR1 and NR2 in cerebrocortical extracts. In single-channel recordings from Xenopus oocytes, addition of NR3A to NR1 and NR2 leads to the appearance of a smaller unitary conductance, Genetic knockout of NR3A in mice results in enhanced NMDA responses and increased dendritic spines in early postnatal cerebrocortical neurons. These data suggest that NR3A is involved in the development of synaptic elements by modulating NMDAR activity.	Brigham & Womens Hosp, Cerebrovasc & Neurosci Res Inst, Neurosurg Serv, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA; Eunice Kennedy Shriver Ctr Mental Retardat Inc, Dev Neurosci Div, Waltham, MA 02254 USA; Childrens Hosp, Div Neurosci, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Harvard University; Boston Children's Hospital	Nakanishi, N (corresponding author), Brigham & Womens Hosp, Cerebrovasc & Neurosci Res Inst, Neurosurg Serv, 75 Francis St, Boston, MA 02115 USA.	slipton@rics.bwh.harvard.edu; nnakanis@warren.med.harvard.edu	Sasaki, Yasnory/L-7065-2018; Das, Saumya/R-7644-2019	Sasaki, Yasnory/0000-0003-2614-7038; Posina, Venkata Rayudu/0000-0002-3040-9224; Das, Saumya/0000-0002-4521-4606; Lipton, Stuart/0000-0002-3490-1259				BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Chen HSV, 1997, J PHYSIOL-LONDON, V499, P27, DOI 10.1113/jphysiol.1997.sp021909; CIABARRA AM, 1995, J NEUROSCI, V15, P6498; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; GUSTAFSSON B, 1988, TRENDS NEUROSCI, V11, P156, DOI 10.1016/0166-2236(88)90142-7; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Kossel AH, 1997, J NEUROSCI, V17, P9634; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; McAllister AK, 1996, NEURON, V17, P1057, DOI 10.1016/S0896-6273(00)80239-1; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Papa M, 1996, NEUROSCIENCE, V71, P1005, DOI 10.1016/0306-4522(95)00490-4; Premkumar LS, 1997, J GEN PHYSIOL, V110, P485, DOI 10.1085/jgp.110.5.485; ROGERS SW, 1991, J NEUROSCI, V11, P2713; SEGAL M, 1995, TRENDS NEUROSCI, V18, P468, DOI 10.1016/0166-2236(95)92765-I; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/science.270.5237.758; STERN P, 1994, J PHYSIOL-LONDON, V476, P391, DOI 10.1113/jphysiol.1994.sp020140; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; SUCHER NJ, 1995, J NEUROSCI, V15, P6509; Woolley CS, 1997, J NEUROSCI, V17, P1848; WOOLLEY CS, 1994, J NEUROSCI, V14, P7680	29	473	501	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 28	1998	393	6683					377	381		10.1038/30748	http://dx.doi.org/10.1038/30748			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620802				2022-12-24	WOS:000073883600057
J	Avorn, J; Monette, J; Lacour, A; Bohn, RL; Monane, M; Mogun, H; LeLorier, J				Avorn, J; Monette, J; Lacour, A; Bohn, RL; Monane, M; Mogun, H; LeLorier, J			Persistence of use of lipid-lowering medications - A cross-national study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHOLESTEROL-REDUCTION; CLINICAL-TRIALS; MEDICAID DATA; DRUG-THERAPY; PATIENT; PRAVASTATIN; COSTS	Context.-Although clinical trials have demonstrated the benefits of lipid-lowering therapy, little is known about how these drugs are prescribed or used in the general population. Objective.-To estimate predictors of persistence with therapy for lipid-lowering drug regimens in typical populations of patients in the United States and Canada. Design.-A cohort study defining all prescriptions filled for lipid-lowering drugs during 1 year, as well as patients' demographic and clinical characteristics. Setting.-New Jersey's Medicaid and Pharmacy Assistance for the Aged and Disabled programs and Quebec's provincial medical care program. Patients.-All continuously enrolled patients older than 65 years who filled 1 or more prescriptions for lipid-lowering drugs (N = 5611 in the US programs, and N = 1676 drawn from a 10% sample in Quebec). Main Outcome Measures.-Proportion of days during the study year for which patients had filled prescriptions for lipid-lowering drugs; predictors of good vs poor persistence with therapy. Results.-In both populations, patients failed to fill prescriptions for lipid-lowering drugs for about 40% of the study year. Persistence rates with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors were significantly higher than those seen with cholestyramine (64.3% vs 36.6% of days with drug available, respectively). Patients with hypertension, diabetes, or coronary artery disease had significantly higher rates of persistence with lipid-lowering regimens. In New Jersey, multivariable analysis indicated that the poorest patients (those enrolled in Medicaid) had lower rates of drug use than less indigent patients (those enrolled in Pharmacy Assistance for the Aged and Disabled) after adjusting for possible confounders, despite virtually complete drug coverage in both programs. When rates of use were measured in the US population for the 5 years following the study year, only 52% of surviving patients who were initially prescribed lipid-lowering drugs were still filling prescriptions for this drug class. Conclusion.-In all populations studied, patients who were prescribed lipid-lowering drug regimens remained without filled prescriptions for over a third of the study year on average. Rates of persistence varied substantially with choice of agent prescribed, comorbidity, and socioeconomic status, despite universal coverage of prescription drug costs. After 5 years, about half of the surviving original cohort in the United States had stopped using lipid-lowering therapy altogether.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA; Univ Montreal, Hotel Dieu, Ctr Rech, Montreal, PQ, Canada	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Laval University; Universite de Montreal	Avorn, J (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 221 Londwood Ave, Boston, MA 02115 USA.							ANDRADE SE, 1995, NEW ENGL J MED, V332, P1125, DOI 10.1056/NEJM199504273321703; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BRIGHT RA, 1989, J CLIN EPIDEMIOL, V42, P937, DOI 10.1016/0895-4356(89)90158-3; CARON HS, 1968, J AMER MED ASSOC, V203, P922, DOI 10.1001/jama.203.11.922; COX DR, 1990, ANAL BINARY DATA; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; DONOVAN JL, 1995, INT J TECHNOL ASSESS, V11, P443, DOI 10.1017/S0266462300008667; EFRON B, 1991, J AM STAT ASSOC, V86, P9, DOI 10.2307/2289707; EVANS L, 1983, DRUGS, V25, P63, DOI 10.2165/00003495-198325010-00004; Garber AM, 1996, ANN INTERN MED, V124, P515, DOI 10.7326/0003-4819-124-5-199603010-00013; GLICKMAN L, 1994, J AM GERIATR SOC, V42, P992, DOI 10.1111/j.1532-5415.1994.tb06594.x; HERSHEY JC, 1980, AM J PUBLIC HEALTH, V70, P1081, DOI 10.2105/AJPH.70.10.1081; HULLEY SB, 1994, JAMA-J AM MED ASSOC, V272, P1372, DOI 10.1001/jama.272.17.1372; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; LAROSA JC, 1994, ARCH INTERN MED, V154, P529, DOI 10.1001/archinte.154.5.529; MELLIES MJ, 1993, ATHEROSCLEROSIS, V101, P97, DOI 10.1016/0021-9150(93)90105-4; Monane M, 1996, AM J PUBLIC HEALTH, V86, P1805, DOI 10.2105/AJPH.86.12.1805; MONANE M, 1994, ARCH INTERN MED, V154, P433, DOI 10.1001/archinte.154.4.433; National Council on Patient Information and Education, 1990, TALK INF ED; Oster G, 1996, ARCH INTERN MED, V156, P731, DOI 10.1001/archinte.156.7.731; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; ROSENSTOCK IM, 1988, AM J PREV MED, V4, P349, DOI 10.1016/S0749-3797(18)31145-0; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P302; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SALZMAN C, 1995, J CLIN PSYCHIAT, V56, P18; *SAS I INC, 1988, SAS STAT US GUID REL, P405; SPAETH GL, 1970, INVEST OPHTH VISUAL, V9, P73; STEPHENSON BJ, 1993, JAMA-J AM MED ASSOC, V269, P2779, DOI 10.1001/jama.269.21.2779; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H	30	510	515	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1998	279	18					1458	1462		10.1001/jama.279.18.1458	http://dx.doi.org/10.1001/jama.279.18.1458			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL718	9600480	Bronze			2022-12-24	WOS:000073463500035
J	Williams, DH; Maguire, AJ; Tsuzuki, W; Westwell, MS				Williams, DH; Maguire, AJ; Tsuzuki, W; Westwell, MS			An analysis of the origins of a cooperative binding energy of dimerization	SCIENCE			English	Article								The cooperativity between binding of cell wall precursor analogs (ligands)to and antibiotic dimerization of the clinically important vancomycin group antibiotics was investigated by nuclear magnetic resonance. When dimerization was weak in the absence of a ligand, the increase in the dimerization constant in the presence of a ligand derived largely from changes associated with tightening of the dimer interface. When dimerization was strong in the absence of a ligand,, the increase in the dimerization constant in the presence of a ligand derived largely from changes associated with tightening of the ligand-antibiotic interface. These results illustrate how, when a protein has a loose structure, the binding energy of another molecule to the protein can derive in part from changes occurring within the protein.	Univ Cambridge, Dept Chem, Cambridge Ctr Mol Recognit, Cambridge CB2 1EW, England; Addenbrookes Hosp, Clin Microbiol & Publ Hlth Lab, Cambridge CB2 2QW, England; Minist Agr Forestry & Fisheries, Natl Food Res Inst, Tsukuba, Ibaraki 305, Japan; Univ Oxford, Dyson Perrins Lab, Oxford OX1 3QY, England	University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Ministry of Agriculture Forestry & Fisheries - Japan; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan; University of Oxford	Williams, DH (corresponding author), Univ Cambridge, Dept Chem, Cambridge Ctr Mol Recognit, Lensfield Rd, Cambridge CB2 1EW, England.							BEAUREGARD DA, 1995, ANTIMICROB AGENTS CH, V39, P781, DOI 10.1128/AAC.39.3.781; BOHM HJ, 1994, J COMPUT AID MOL DES, V8, P243, DOI 10.1007/BF00126743; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4501; Loll PJ, 1997, J AM CHEM SOC, V119, P1516, DOI 10.1021/ja963566p; MACKAY JP, 1994, J AM CHEM SOC, V116, P4581, DOI 10.1021/ja00090a006; Schafer M, 1996, STRUCTURE, V4, P1509, DOI 10.1016/S0969-2126(96)00156-6; SEARLE MS, 1996, J CHEM SOC P1, V10, P2781; SHELDRICK GM, 1995, ACTA CRYSTALLOGR B, V51, P89, DOI 10.1107/S0108768194010190; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; STRYER L, 1988, BIOCHEMISTRY-US, P82; Williams DH, 1997, CHEM BIOL, V4, P507, DOI 10.1016/S1074-5521(97)90322-7; WILLIAMS DH, 1991, J AM CHEM SOC, V113, P7020, DOI 10.1021/ja00018a047; WILLIAMS DH, 1996, CHEM BIOL, V3, P6953	13	152	154	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					711	714		10.1126/science.280.5364.711	http://dx.doi.org/10.1126/science.280.5364.711			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563941				2022-12-24	WOS:000073415600039
J	Takenaka, K; Moriguchi, T; Nishida, E				Takenaka, K; Moriguchi, T; Nishida, E			Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest	SCIENCE			English	Article							XENOPUS-OOCYTE MATURATION; MAP KINASE; CELL-CYCLE; TYROSINE PHOSPHORYLATION; MEIOTIC MATURATION; MAMMALIAN-CELLS; CASCADE; INDUCTION; METAPHASE; HOMOLOG	The mitogen-activated protein kinase (MAPK) superfamily comprises classical MAPK (also called ERK), c-Jun amino-terminal or stress-activated protein kinase (JNK or SAPK), and p38. Although MAPK is essential for meiotic processes in Xenopus oocytes and the spindle assembly checkpoint in Xenopus egg extracts, the role of members of the MAPK superfamily in M phase or the spindle assembly checkpoint during somatic cell cycles has not been elucidated. The kinase p38, but not MAPK or JNK, was activated in mammalian cultured cells when the cells were arrested in M phase by disruption of the spindle with nocodazole, Addition of activated recombinant p38 to Xenopus cell-free extracts caused arrest of the extracts in M phase, and injection of activated p38 into cleaving embryos induced mitotic arrest. Treatment of NIH 3T3 cells with a specific inhibitor of p38 suppressed activation of the checkpoint by nocodazole, Thus, p38 functions as a component of the spindle assembly checkpoint in somatic cell cycles.	Kyoto Univ, Grad Sch Sci, Sakyo Ku, Kyoto 60601, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Sci, Sakyo Ku, Kyoto 60601, Japan.		Moriguchi, Tetsuo/D-7061-2012	Moriguchi, Tetsuo/0000-0002-9598-4991				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MASUYAMA N, UNPUB; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P573; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; TAKENAKA K, UNPUB; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738	40	231	240	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					599	602		10.1126/science.280.5363.599	http://dx.doi.org/10.1126/science.280.5363.599			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554853				2022-12-24	WOS:000073242100050
J	Neumayr, G; Schratzberger, P; Friedrich, G; Ganzer, H; Wiedermann, CJ				Neumayr, G; Schratzberger, P; Friedrich, G; Ganzer, H; Wiedermann, CJ			Effect of electrical cardioversion on myocardial cells in patients in intensive care	BRITISH MEDICAL JOURNAL			English	Article									Univ Innsbruck, Dept Internal Med, Med & Intens Care Unit, A-6020 Innsbruck, Austria	University of Innsbruck	Neumayr, G (corresponding author), Univ Innsbruck, Dept Internal Med, Med & Intens Care Unit, Anichstr 35, A-6020 Innsbruck, Austria.		Wiedermann, Christian J./ABG-9521-2020					DOHERTY PW, 1979, AM J CARDIOL, V43, P225, DOI 10.1016/S0002-9149(79)80008-9; EHSANI A, 1976, AM J CARDIOL, V37, P12, DOI 10.1016/0002-9149(76)90492-6; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; LOWN B, 1962, JAMA-J AM MED ASSOC, V182, P548; METCALFE MJ, 1988, BRIT MED J, V296, P1364, DOI 10.1136/bmj.296.6633.1364	5	8	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1207	1207		10.1136/bmj.316.7139.1207	http://dx.doi.org/10.1136/bmj.316.7139.1207			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9552995	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000073224100023
J	Hartman, JJ; Mahr, J; McNally, K; Okawa, K; Iwamatsu, A; Thomas, S; Cheesman, S; Heuser, J; Vale, RD; McNally, FJ				Hartman, JJ; Mahr, J; McNally, K; Okawa, K; Iwamatsu, A; Thomas, S; Cheesman, S; Heuser, J; Vale, RD; McNally, FJ			Katanin, a microtubule-severing protein, is a novel AAA ATPase that targets to the centrosome using a WD40-containing subunit	CELL			English	Article							SENSITIVE FUSION PROTEIN; DYNAMIC INSTABILITY; GAMMA-TUBULIN; CAENORHABDITIS-ELEGANS; STABLE MICROTUBULES; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MITOTIC SPINDLE; BETA-GAMMA; COMPLEX	Microtubule disassembly at centrosomes is involved in mitotic spindle function. The microtubule-severing protein katanin, a heterodimer of 60 and 80 kDa subunits, was previously purified and shown to localize to centrosomes in vivo. Here we report the sequences and activities of the katanin subunits, p60 is a new member of the AAA family of ATPases, and we show that expressed p60 has microtubule-stimulated ATPase and microtubule-severing activities in the absence of p80. p80 is a novel protein containing WD40 repeats, which are frequently involved in protein-protein interactions. The p80 WD40 domain does not participate in p60 dimerization, but localizes to centrosomes in transfected mammalian cells. These results indicate katanin's activities are segregated into a subunit (p60) that possesses enzymatic activity and a subunit (p80) that targets the enzyme to the centrosome.	Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Kanagawa, Japan; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California Davis; Kirin Brewery Company Limited; Washington University (WUSTL)	McNally, FJ (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.				NIGMS NIH HHS [GM53060, GM49752] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049752, R01GM053060] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APTE AN, 1993, BIOTECHNIQUES, V15, P890; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Caplow M, 1996, MOL BIOL CELL, V7, P663, DOI 10.1091/mbc.7.4.663; CLARKMAGUIRE S, 1994, GENETICS, V136, P533; CLARKMAGUIRE S, 1994, J CELL BIOL, V126, P199, DOI 10.1083/jcb.126.1.199; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DESAI A, 1995, J CELL BIOL, V28, P1; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Harlow E, 1988, ANTIBODIES LAB MANUA; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HEUSELE C, 1987, EUR J BIOCHEM, V165, P613, DOI 10.1111/j.1432-1033.1987.tb11484.x; HEUSER J, 1989, J ELECTRON MICR TECH, V13, P244, DOI 10.1002/jemt.1060130310; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; HYMAN A, 1990, METHOD ENZYMOL, V196, P303; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; KITANISHIYUMURA T, 1987, CELL MOTIL CYTOSKEL, V8, P106, DOI 10.1002/cm.970080203; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Komachi K, 1997, MOL CELL BIOL, V17, P6023, DOI 10.1128/MCB.17.10.6023; KOWALSKI RJ, 1993, J BIOL CHEM, V268, P9847; LIN CC, 1995, INT J CANCER, V63, P140, DOI 10.1002/ijc.2910630125; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; LYNCH TJ, 1986, J BIOL CHEM, V261, P7156; MCNALLY FJ, 1993, CELL, V75, P419, DOI 10.1016/0092-8674(93)90377-3; McNally FJ, 1996, J CELL SCI, V109, P561; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MORGAN A, 1994, J BIOL CHEM, V269, P29347; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; OEGEMA K, 1995, J CELL BIOL, V131, P1261, DOI 10.1083/jcb.131.5.1261; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; SHIINA N, 1992, EMBO J, V11, P4723, DOI 10.1002/j.1460-2075.1992.tb05577.x; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; TUMA PL, 1994, J BIOL CHEM, V269, P30842; VALE RD, 1991, CELL, V64, P827, DOI 10.1016/0092-8674(91)90511-V; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Waters JC, 1996, MOL BIOL CELL, V7, P1547, DOI 10.1091/mbc.7.10.1547; WEISS SA, 1995, BACULOVIRUS EXPRESSI, P79; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	58	262	272	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					277	287		10.1016/S0092-8674(00)81578-0	http://dx.doi.org/10.1016/S0092-8674(00)81578-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568719	Bronze			2022-12-24	WOS:000073174000013
J	Gostin, LO; Webber, DW				Gostin, LO; Webber, DW			HIV infection and AIDS in the public health and health care systems - The role of law and litigation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RIGHTS COMMISSION DECISIONS; TRANSMISSION; PROJECT; COURT	The AIDS Litigation Project has reviewed nearly 600 reported cases involving individuals with human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) in the federal and state courts in the United States between 1991 and 1997. Cases were identified through a federal and 50-state computer and library search. An important subset of litigation relates to HIV/AIDS in the public health and health care systems, since the law affects health care institutions and professionals, patients, and public health policy in America. This subset of HIV/AIDS litigation includes testing and reporting; privacy, the duty to warn, and the right to know; physician standards of care in prevention and treatment; and discrimination and access to health care. In broad terms, the review demonstrates a reliance on voluntary testing and protection of patient privacy through HIV-specific statutes and the common law. Negligence with potential civil and criminal liability has been alleged in cases of erroneous or missed diagnosis of HIV infection. In the first AIDS case to be considered by the Supreme Court, the Court will decide whether patients with asymptomatic HIV infection are protected under the Americans with Disabilities Act. Considerable progress has been made, both socially and legally, during the first 2 decades of the epidemic, but much still needs to be accomplished to protect privacy, prevent discrimination, and promote tolerance.	Georgetown Johns Hopkins Program Law & Publ Hlth, Washington, DC USA; Georgetown Johns Hopkins Program Law & Publ Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.							[Anonymous], 1991, MMWR Recomm Rep, V40, P1; BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; Burris S, 1996, AM J PUBLIC HEALTH, V86, P1161, DOI 10.2105/AJPH.86.8_Pt_1.1161; Burris Scott, 1992, Univ Miami Law Rev, V47, P291; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CDC, 1985, MMWR-MORBID MORTAL W, V34, P1; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P861; Centers for Disease Control and Prevention, 1997, HIV PREV B MED ADV P; *EEOC, 1993, EEOC INT GUID APPL A; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; GOSTIN L, 1998, AM DISABILITIES ACT; Gostin L O, 1997, Emory Law J, V46, P587; Gostin LO, 1997, NEW ENGL J MED, V337, P1162, DOI 10.1056/NEJM199710163371611; GOSTIN LO, 1994, JAMA-J AM MED ASSOC, V271, P1436, DOI 10.1001/jama.271.18.1436; Gostin LO, 1997, JAMA-J AM MED ASSOC, V277, P53, DOI 10.1001/jama.277.1.53; GOSTIN LO, 1990, NEW ENGL J MED, V322, P1743, DOI 10.1056/NEJM199006143222411; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P1961, DOI 10.1001/jama.263.14.1961; Gostin LO, 1996, JAMA-J AM MED ASSOC, V275, P1921, DOI 10.1001/jama.275.24.1921; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P2086, DOI 10.1001/jama.263.15.2086; GOSTIN LO, IN PRESS DUKE J GEND; GOSTIN LO, 1990, AIDS HLTH CARE SYSTE; MILLER P, 1997, AM J PUBLIC HEALTH, V87, P1558; NORMAND J, 1995, PREVENTING HIV TRANS; *NY DEP HLTH, 1997, 972 NEW YORK DEP HLT; Parmet WE, 1997, AM J LAW MED, V23, P7; *PC, 1988, REP PRES COMM HUM IM; PECKHAM C, 1995, NEW ENGL J MED, V333, P298, DOI 10.1056/NEJM199508033330507; WEBBER DW, 1997, AIDS LAW	28	23	24	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1998	279	14					1108	1113		10.1001/jama.279.14.1108	http://dx.doi.org/10.1001/jama.279.14.1108			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZF216	9546571				2022-12-24	WOS:000072875300036
J	Feig, DS; Naylor, CD				Feig, DS; Naylor, CD			Eating for two: are guidelines for weight gain during pregnancy too liberal?	LANCET			English	Editorial Material							3RD-TRIMESTER; DELIVERY; GROWTH; BIRTH; RISK		Univ Toronto, Dept Med, Toronto, ON, Canada; Mt Sinai Hosp, Div Endocrinol & Metab, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Naylor, CD (corresponding author), Sunnybrook Hlth Sci Ctr, Inst Clin Evaluat Sci, G-106,2075 Bayview Ave, N York, ON M4N 3M5, Canada.		Feig, Denice/C-4606-2015					*AM COLL OBST GYN, 1993, ACOG TECHN B, V179, P1; Barker DJP, 1996, NUTR REV, V54, pS1; Churchill D, 1997, LANCET, V349, P7, DOI 10.1016/S0140-6736(96)06297-6; *I MED, 1990, NUTR PREGN WEIGHT GA; JOHNSON JWC, 1992, AM J OBSTET GYNECOL, V167, P353, DOI 10.1016/S0002-9378(11)91414-8; Johnson JWC, 1996, AM J OBSTET GYNECOL, V174, P254, DOI 10.1016/S0002-9378(96)70403-9; KEPPEL KG, 1993, AM J PUBLIC HEALTH, V83, P1100, DOI 10.2105/AJPH.83.8.1100; KRAMER M, 1995, COCHRANE PREGNANCY C, P1; KRAMER MS, 1992, AM J EPIDEMIOL, V136, P574, DOI 10.1093/oxfordjournals.aje.a116535; KRAMER MS, 1995, COCHRANE PREGNANCY C; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; *REP PAN DIET REF, 1991, DIET REF VAL FOOD EN, P30; Sanderson M, 1996, EPIDEMIOLOGY, V7, P34, DOI 10.1097/00001648-199601000-00007; SCHOLL TO, 1995, OBSTET GYNECOL, V86, P423, DOI 10.1016/0029-7844(95)00190-3; SHEPARD MJ, 1986, AM J OBSTET GYNECOL, V155, P947, DOI 10.1016/0002-9378(86)90323-6; SiegaRiz AM, 1996, J NUTR, V126, P146, DOI 10.1093/jn/126.1.146; SMITH DE, 1994, JAMA-J AM MED ASSOC, V271, P1747, DOI 10.1001/jama.271.22.1747; STEIN AD, 1995, HUM BIOL, V67, P135; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665	19	52	55	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 4	1998	351	9108					1054	1055		10.1016/S0140-6736(97)06261-2	http://dx.doi.org/10.1016/S0140-6736(97)06261-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546528				2022-12-24	WOS:000072927200045
J	Guilford, P; Hopkins, J; Harraway, J; McLeod, M; McLeod, N; Harawira, P; Taite, H; Scoular, R; Miller, A; Reeve, AE				Guilford, P; Hopkins, J; Harraway, J; McLeod, M; McLeod, N; Harawira, P; Taite, H; Scoular, R; Miller, A; Reeve, AE			E-cadherin germline mutations in familial gastric cancer	NATURE			English	Article							INVASION-SUPPRESSOR GENE; LOBULAR BREAST CANCERS; CARCINOMA CELL-LINES; EXPRESSION; EXTRACTION; STOMACH	The identification of genes predisposing to familial cancer is an essential step towards understanding the molecular events underlying tumorigenesis and is critical for the clinical management of affected families. Despite a declining incidence, gastric cancer remains a major cause of cancer death worldwide(1), and about 10% of cases show familial clustering(2,3), The relative contributions of inherited susceptibility and environmental effects to familial gastric cancer are poorly understood because little is known of the genetic events that predispose to gastric cancer. Here we describe the identification of the gene responsible for early-onset, histologically poorly differentiated, high grade, diffuse gastric cancer(4) in a large kindred from New Zealand (Aotearoa), Genetic linkage analysis demonstrated significant Linkage to markers flanking the gene for the calcium-dependent cell-adhesion protein E-cadherin. Sequencing of the E-cadherin gene revealed a G-->T nucleotide substitution in the donor splice consensus sequence of exon 7, leading to a truncated gene product, Diminished E-cadherin expression is associated with aggressive, poorly differentiated carcinomas(5). Underexpression of E-cadherin is a prognostic marker of poor clinical outcome in many tumour types(6), and restored expression of E-cadherin in tumour models can suppress the invasiveness of epithelial tumour cells(7,8). The role of E-cadherin in gastric cancer susceptibility was confirmed by identifying inactivating mutations in other gastric cancer families, In one family a frameshift mutation,vas identified in exon 15, and in a second family a premature stop codon interrupted exon 13, These results describe, to our knowledge for the first time, a molecular basis for familial gastric cancer, and confirm the important role of E-cadherin mutations in cancer.	Univ Otago, Dept Biochem, Canc Genet Lab, Dunedin, Aotearoa, New Zealand; Kimi Hauora Hlth Clin, Mt Maunganui S, Aotearoa, New Zealand; Tauranga Publ Hosp, Tauranga, Aotearoa, New Zealand; Univ Otago, Dept Pathol, Dunedin, Aotearoa, New Zealand	University of Otago; University of Otago	Guilford, P (corresponding author), Univ Otago, Dept Biochem, Canc Genet Lab, POB 56, Dunedin, Aotearoa, New Zealand.	parry.guilford@stonebow.otago.ac.nz		Guilford, Parry/0000-0002-7256-9576				BANERJEE SK, 1995, BIOTECHNIQUES, V18, P768; BECKER KF, 1994, CANCER RES, V54, P3845; BERX G, 1995, GENOMICS, V26, P281, DOI 10.1016/0888-7543(95)80212-5; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GRAFF JR, 1995, CANCER RES, V55, P5195; Grunwald GB, 1993, CURR OPIN CELL BIOL, V5, P797, DOI 10.1016/0955-0674(93)90028-O; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; JONES E. G., 1964, NEW ZEAL MED J, V63, P287; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LAVECCHIA C, 1992, CANCER, V70, P50, DOI 10.1002/1097-0142(19920701)70:1<50::AID-CNCR2820700109>3.0.CO;2-I; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muta H, 1996, JPN J CANCER RES, V87, P843, DOI 10.1111/j.1349-7006.1996.tb02109.x; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Tamura G, 1996, JPN J CANCER RES, V87, P1153, DOI 10.1111/j.1349-7006.1996.tb03125.x; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; ZANGHIERI G, 1990, CANCER, V66, P2047, DOI 10.1002/1097-0142(19901101)66:9<2047::AID-CNCR2820660934>3.0.CO;2-G	29	1206	1268	4	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					402	405		10.1038/32918	http://dx.doi.org/10.1038/32918			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537325				2022-12-24	WOS:000072713600055
J	Collins, S; Woodman, CBJ; Threlfall, A; Prior, P				Collins, S; Woodman, CBJ; Threlfall, A; Prior, P			Survival rates from interval cancer in NHS breast screening programme	BRITISH MEDICAL JOURNAL			English	Article									Univ Manchester, Christie Hosp NHS Trust, Ctr Canc Epidemiol, Manchester M20 4QL, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Collins, S (corresponding author), Univ Manchester, Christie Hosp NHS Trust, Ctr Canc Epidemiol, Manchester M20 4QL, Lancs, England.							ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; Day N, 1995, J Med Screen, V2, P180; HAKULINEN T, 1985, COMPUT PROG BIOMED, V19, P197, DOI 10.1016/0010-468X(85)90011-X; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; WOODMAN CBJ, 1995, BRIT MED J, V310, P224, DOI 10.1136/bmj.310.6974.224	5	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					832	833		10.1136/bmj.316.7134.832	http://dx.doi.org/10.1136/bmj.316.7134.832			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549455	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000072584300032
J	Chen, CY; Del Gatto-Konczak, F; Wu, ZG; Karin, M				Chen, CY; Del Gatto-Konczak, F; Wu, ZG; Karin, M			Stabilization of interleukin-2 mRNA by the c-Jun NH2-terminal kinase pathway	SCIENCE			English	Article							MESSENGER-RNA DEGRADATION; TUMOR-NECROSIS-FACTOR; AU-RICH ELEMENTS; PROTEIN-KINASE; 3'-UNTRANSLATED REGION; MAP KINASE; GENE-EXPRESSION; ACTIVATION; CELLS; IDENTIFICATION	Signaling pathways that stabilize interleukin-2 (IL-2) messenger RNA (mRNA) in activated T cells were examined. IL-2 mRNA contains at least two cis elements that mediated its stabilization in response to different signals, including activation of c-Jun amino-terminal kinase (JNK). This response was mediated through a cis element encompassing the 5' untranslated region (UTR) and the beginning of the coding region. IL-2 transcripts lacking this 5' element no longer responded to JNK activation but were still responsive to other signals generated during T cell activation, which were probably sensed through the 3' UTR. Thus, multiple elements within IL-2 mRNA modulate its stability in a combinatorial manner, and the JNK pathway controls turnover as well as synthesis of IL-2 mRNA.	Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA.		Del Gatto-Konczak, Fabienne/L-1506-2015					AKAHANE K, 1991, J IMMUNOL, V146, P4190; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chen C., UNPUB; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1028; ELIAS JA, 1990, J IMMUNOL, V145, P161; GUBA SC, 1989, J CLIN INVEST, V84, P1701, DOI 10.1172/JCI114352; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IWAI Y, 1993, J IMMUNOL, V150, P4386; IWAI Y, 1991, J BIOL CHEM, V266, P17959; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KOEFFLER HP, 1988, MOL CELL BIOL, V8, P3432, DOI 10.1128/MCB.8.8.3432; KRAMNIK I, 1993, J IMMUNOL METHODS, V162, P143, DOI 10.1016/0022-1759(93)90379-L; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; McKnight S.L., 1992, TRANSCRIPTIONAL REGU; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHAW J, 1988, J IMMUNOL, V140, P2243; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	41	318	325	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1945	1949		10.1126/science.280.5371.1945	http://dx.doi.org/10.1126/science.280.5371.1945			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632395				2022-12-24	WOS:000074323800067
J	Blanch, G; Quenby, S; Ballantyne, ES; Gosden, CM; Neilson, JP; Holland, K				Blanch, G; Quenby, S; Ballantyne, ES; Gosden, CM; Neilson, JP; Holland, K			Embryonic abnormalities at medical termination of pregnancy with mifepristone and misoprostol during first trimester: observational study	BRITISH MEDICAL JOURNAL			English	Article									Univ Liverpool, Dept Obstet & Gynaecol, Liverpool L69 3BX, Merseyside, England; Liverpool Womens Hosp, Day Care Abort Unit, Liverpool, Merseyside, England	University of Liverpool; University of Liverpool	Blanch, G (corresponding author), Univ Liverpool, Dept Obstet & Gynaecol, Liverpool L69 3BX, Merseyside, England.			Quenby, Siobhan/0000-0003-3221-5471				Everett C, 1997, BRIT MED J, V315, P32, DOI 10.1136/bmj.315.7099.32; HUME RF, 1994, FETAL DIAGN THER, V9, P239; KLINE J, 1990, EARLY PREGNANCY FAIL, P240; LELAIDIER C, 1993, HUM REPROD, V8, P492, DOI 10.1093/oxfordjournals.humrep.a138078; WALD NJ, 1994, CIBA F SYMP, V181, P192	5	15	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1712	1713		10.1136/bmj.316.7146.1712	http://dx.doi.org/10.1136/bmj.316.7146.1712			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614021	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000074129500023
J	Atkins, C				Atkins, C			God save the child	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1677	1677		10.1001/jama.279.21.1677	http://dx.doi.org/10.1001/jama.279.21.1677			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624008				2022-12-24	WOS:000073878700001
J	Lee, D; Lis, JT				Lee, D; Lis, JT			Transcriptional activation independent of TFIIH kinase and the RNA polymerase II mediator in vivo	NATURE			English	Article							C-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; HSP70 GENE; PHOSPHORYLATION; CTD; HOLOENZYME; YEAST; REQUIREMENT; PROMOTER; ENHANCER	The carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II becomes multiply phosphorylated by protein kinases during early steps in the gene transcription cycle both in vivo(1) and in vitro(2). In yeast, the major CTD kinase is a subunit of the general transcription factor TFIIH, and is encoded by an essential gene, KIN28 (ref. 3). Although the CTD and its phosphorylation are important for transcription(4-6), in vitro studies(7,8) have challenged whether CTD phosphorylation is an absolutely required step. The general importance of CTD phosphorylation by Kin28 for transcription in yeast has been suggested because, for all genes tested, transcription is inhibited at the non-permissive temperature in temperature-sensitive kin28 mutants(9,10). However, using such a mutant and a copper-inducible targeted destruction method, we show here that transcription of certain genes can be highly induced even when cells lack Kin28. We also show that transcription of these Kin28-independent genes is independent of Srb4 and Srb6, critical components of the CTD-associated transcriptional mediator complex(11). These results indicate that there are at least two distinct pathways for transcriptional activation: one is dependent on Kin28 and the mediator complex, and the other is not.	Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	Cornell University	Lis, JT (corresponding author), Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA.							AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BOORSTEIN WR, 1990, J BIOL CHEM, V265, P18912; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Dubois MF, 1997, NUCLEIC ACIDS RES, V25, P694, DOI 10.1093/nar/25.4.694; ELION EA, 1986, MOL CELL BIOL, V6, P2089, DOI 10.1128/MCB.6.6.2089; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; GERBER HP, 1995, NATURE, V374, P60; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316	30	88	88	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1998	393	6683					389	392		10.1038/30770	http://dx.doi.org/10.1038/30770			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620805				2022-12-24	WOS:000073883600060
J	Schroeter, EH; Kisslinger, JA; Kopan, R				Schroeter, EH; Kisslinger, JA; Kopan, R			Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain	NATURE			English	Article							GOLGI-COMPLEX; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTOR; PROTEINS; CELLS; VIRUS; RBP-J-KAPPA/SU(H); TRANSDUCTION; SUPPRESSOR; EXPRESSION	Notch proteins are ligand-activated transmembrane receptors involved in cell-fate selection throughout development(1-3). No known enzymatic activity is contained within Notch and the molecular mechanism by which it transduces signals across the cell membrane is poorly understood. In many instances, Notch activation results in transcriptional changes in the nucleus through an association with members of the CSL family of DNA-binding proteins (where CSL stands for CBF1, Su(H), Lag-1)(1-4). As Notch is located in the plasma membrane and CSL is a nuclear protein, two models have been proposed to explain how they interact (Fig. I). The first suggests that the two interact transiently at the membrane(1,5-7). The second postulates that Notch is cleaved by a protease, enabling the cleaved fragment to enter the GRAPHICS nucleus(6,8-14). Here we show that signalling by a constitutively active membrane-bound Notch-1 protein requires the proteolytic release of the Notch inh acellular domain (NICD), which interacts preferentially with CSL, Very small amounts of NICD are active, explaining why it is hard to detect in the nucleus in vivo, We also show that it is ligand binding that induces release of NICD.	Washington Univ, Div Dermatol, St Louis, MO 63110 USA; Washington Univ, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Kopan, R (corresponding author), Washington Univ, Div Dermatol, Box 8123,4940 Parkview Pl, St Louis, MO 63110 USA.	kopan@pharmdec.wustl.edu	Kopan, Raphael/AFG-3275-2022; Kopan, Raphael/AAF-1357-2022	Kopan, Raphael/0000-0002-0350-2730				ArtavanisTsakonas S, 1997, NAT GENET, V16, P212, DOI 10.1038/ng0797-212; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Aster JC, 1997, J BIOL CHEM, V272, P11336; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BREDENBEEK PJ, 1993, J VIROL, V67, P6439, DOI 10.1128/JVI.67.11.6439-6446.1993; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Gho M, 1996, DEVELOPMENT, V122, P1673; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kopan R, 1996, CURR OPIN NEUROBIOL, V6, P594, DOI 10.1016/S0959-4388(96)80090-0; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; QUINN P, 1983, J CELL BIOL, V96, P851, DOI 10.1083/jcb.96.3.851; Roehl H, 1996, EMBO J, V15, P7002, DOI 10.1002/j.1460-2075.1996.tb01092.x; Sotillos S, 1997, DEVELOPMENT, V124, P4769; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WEINTRAUB H, 1988, P NATL ACAD SCI USA, V85, P5819, DOI 10.1073/pnas.85.16.5819; Wen CH, 1997, DEVELOPMENT, V124, P4759; Wettstein DA, 1997, DEVELOPMENT, V124, P693	30	1339	1396	1	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 28	1998	393	6683					382	386		10.1038/30756	http://dx.doi.org/10.1038/30756			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620803				2022-12-24	WOS:000073883600058
J	Pounder, D; Carson, D; Davison, M; Orihara, Y				Pounder, D; Carson, D; Davison, M; Orihara, Y			Evaluation of indices of obesity in men: descriptive study	BRITISH MEDICAL JOURNAL			English	Article							WAIST CIRCUMFERENCE		Dundee Royal Infirm, Dept Forens Med, Dundee DD1 9ND, Scotland		Pounder, D (corresponding author), Dundee Royal Infirm, Dept Forens Med, Dundee DD1 9ND, Scotland.							BJORNTORP P, 1992, ANN MED, V24, P15, DOI 10.3109/07853899209164140; LEAN MEJ, 1995, BRIT MED J, V311, P158, DOI 10.1136/bmj.311.6998.158; POULIOT MC, 1994, AM J CARDIOL, V73, P460, DOI 10.1016/0002-9149(94)90676-9; Shaper AG, 1997, BRIT MED J, V314, P1311, DOI 10.1136/bmj.314.7090.1311; TunstallPedoe H, 1997, BMJ-BRIT MED J, V314, P1291, DOI 10.1136/bmj.314.7090.1291	5	14	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1998	316	7142					1428	1429		10.1136/bmj.316.7142.1428	http://dx.doi.org/10.1136/bmj.316.7142.1428			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN495	9572754	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000073651600030
J	Nightingale, SL				Nightingale, SL			New rule proposed for home drug abuse test kits	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1998	279	17					1339	1339		10.1001/jama.279.17.1339	http://dx.doi.org/10.1001/jama.279.17.1339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK758	9582030				2022-12-24	WOS:000073359800005
J	Lewin, RJP; Ingleton, R; Newens, AJ; Thompson, DR				Lewin, RJP; Ingleton, R; Newens, AJ; Thompson, DR			Adherence to cardiac rehabilitation guidelines: a survey of rehabilitation programmes in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article									Univ Hull, Fac Hlth, Inst Rehabil, Hull HU3 2PG, N Humberside, England	University of Hull	Lewin, RJP (corresponding author), Univ York, Dept Hlth Studies, British Heart Fdn Rehabil Res Unit, York YO10 5DQ, N Yorkshire, England.		Thompson, David R/E-2431-2018; Thompson, David R/C-6320-2009	Thompson, David R/0000-0001-8518-6307; 				*AUD COMM, 1995, DEAR OUR HEARTS COMM; LEWIN R, 1997, CARDIAC REHABILITATI, P21; Thompson DR, 1996, HEART, V75, P89, DOI 10.1136/hrt.75.1.89; Thompson DR, 1997, INT J CARDIOL, V59, P299, DOI 10.1016/S0167-5273(97)02951-3; World Health Organization [WHO], 1993, NEEDS ACT PRIOR CARD	5	47	47	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1998	316	7141					1354	1355		10.1136/bmj.316.7141.1354	http://dx.doi.org/10.1136/bmj.316.7141.1354			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL882	9563986	Green Submitted, Bronze, Green Published, Green Accepted			2022-12-24	WOS:000073483000019
J	Kelso, JAS; Fuchs, A; Lancaster, R; Holroyd, T; Cheyne, D; Weinberg, H				Kelso, JAS; Fuchs, A; Lancaster, R; Holroyd, T; Cheyne, D; Weinberg, H			Dynamic cortical activity in the human brain reveals motor equivalence	NATURE			English	Article							CELL DISCHARGE; ARM MOVEMENTS; CORTEX; DIRECTION; FIELDS	That animals and humans can accomplish the same goal using different effecters and different goals using the same effecters attests to the remarkable flexibility of the central nervous system. This phenomenon has been termed 'motor equivalence'(1,2), an example being the writing of a name with a pencil held between the toes or teeth. The idea of motor equivalence has reappeared because single-cell studies in monkeys have shown that parameters of voluntary movement (such as direction) may be specified in the brain, relegating muscle activation to spinal interneuronal systems(3,4). Using a novel experimental paradigm(5) and a full-head SQUID (for superconducting quantum interference device) array to record magnetic fields corresponding to ongoing brain activity, we demonstrate: (1), a robust relationship between time-dependent activity in sensorimotor cortex and movement velocity, independent of explicit task requirements; and (2) neural activations that are specific to task demands alone. It appears, therefore, that signatures of motor equivalence in humans may be found in dynamic patterns of cortical activity.	Florida Atlantic Univ, Ctr Complex Syst, Program Complex Syst & Brain Sci, Boca Raton, FL 33431 USA; Simon Fraser Univ, Brain Behav Lab, Burnaby, BC V5A 1S6, Canada	State University System of Florida; Florida Atlantic University; Simon Fraser University	Kelso, JAS (corresponding author), Florida Atlantic Univ, Ctr Complex Syst, Program Complex Syst & Brain Sci, Boca Raton, FL 33431 USA.			Cheyne, Douglas/0000-0002-2663-498X				BARTLETT NR, 1959, PSYCHOL REV, V66, P203, DOI 10.1037/h0046490; BIZZI E, 1991, SCIENCE, V253, P287, DOI 10.1126/science.1857964; CHEYNE D, 1989, EXP BRAIN RES, V78, P604; Dunlap K, 1910, PSYCHOL REV, V17, P399, DOI 10.1037/h0074736; Fuchs A, 1992, INT J BIFURCAT CHAOS, V2, P917, DOI 10.1142/S0218127492000537; Georgopoulos AP, 1997, NEUROSCIENTIST, V3, P52, DOI 10.1177/107385849700300115; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; KELSO JAS, 1992, PHYS LETT A, V169, P134, DOI 10.1016/0375-9601(92)90583-8; KRISTEVA R, 1991, ELECTROEN CLIN NEURO, V81, P284, DOI 10.1016/0168-5597(91)90015-P; Lashley KS, 1930, PSYCHOL REV, V37, P1, DOI 10.1037/h0074134; MORAN DW, IN PRESS J NEUROPHYS; Romani G L, 1989, ADV BIOMAGNETISM, P33; SCHWARTZ AB, 1988, J NEUROSCI, V8, P2913; UHL C, 1995, PHYS REV E, V51, P3890, DOI 10.1103/PhysRevE.51.3890; WIESENDANGER M, 1982, PHYSIOL REV, V62, P1234, DOI 10.1152/physrev.1982.62.4.1234; WING AM, 1973, PERCEPT PSYCHOPHYS, V13, P455, DOI 10.3758/BF03205802; [No title captured]	18	135	137	2	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1998	392	6678					814	818		10.1038/33922	http://dx.doi.org/10.1038/33922			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572140				2022-12-24	WOS:000073241200053
J	Hotopf, M; Carr, S; Mayou, R; Wadsworth, M; Wessely, S				Hotopf, M; Carr, S; Mayou, R; Wadsworth, M; Wessely, S			Why do children have chronic abdominal pain, and what happens to them when they grow up? Population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC-DISORDERS; BIRTH COHORT; LIFE EVENTS; FOLLOW-UP; FAMILIES; SOMATIZATION; ADOLESCENTS; SYMPTOMS	Objective: To test the hypotheses that children with abdominal pain have anxious parents and come from families with high rates of physical illness and that they grow up to suffer from high rates of medically unexplained symptoms and psychiatric disorders. Design: Population based birth cohort study. Setting: General population. Subjects: Participants in the Medical Research Council (MRC) national survey of health and development, a population based bir th cohort study established in 1946. Main outcome measures: Abdominal pain present throughout childhood in the absence of defined organic disease, and measures of physical symptoms and psychiatric disorder at age 36 years. Results: There were high rates of complaints about physical health among the parents of children with persistent abdominal pain, and the mothers had higher neuroticism scores. Children with persistent abdominal pain were more likely to suffer from psychiatric disorders in adulthood (odds ratio 2.72 (95% confidence interval 1.65 to 4.49)) but were not especially prone to physical symptoms once psychiatric disorder was controlled for (odds ratio 1.39 (0.83 to 2.36)). Conclusions: Persistent abdominal pain is associated with poor health and emotional disorder in the parents. Children with abdominal pain do not necessarily continue to experience physical symptoms into adulthood but are at increased risk of adult psychiatric disorders.	Kings Coll London, Sch Med & Dent, Dept Psychol Med, London SE5 8AZ, England; Inst Psychiat, London SE5 8AZ, England; Royal Free Hosp, Dept Paediat, London NW3 2QG, England; Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; UCL, Univ Coll & Middlesex Sch Med, Dept Epidemiol & Publ Hlth, MRC,Natl Survey Hlth & Dev, London WC1E 6BT, England	University of London; King's College London; University of London; King's College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Oxford; University of London; University College London	Hotopf, M (corresponding author), Kings Coll London, Sch Med & Dent, Dept Psychol Med, London SE5 8AZ, England.	m.hotopf@iop.bpmf.ac.uk	Wessely, Simon C/A-8713-2008; Hotopf, Matthew/E-4971-2010	Hotopf, Matthew/0000-0002-3980-4466; Wessely, Simon Charles/0000-0002-6743-9929				APLEY J, 1973, BRIT MED J, V3, P7, DOI 10.1136/bmj.3.5870.7; APLEY J, 1957, ARCH DIS CHILD, P165; CAMPO JV, 1994, J AM ACAD CHILD PSY, V33, P1223, DOI 10.1097/00004583-199411000-00003; Caspi A, 1996, ARCH GEN PSYCHIAT, V53, P1033; CHRISTENSEN MF, 1975, ARCH DIS CHILD, V50, P110, DOI 10.1136/adc.50.2.110; EYSENCK HJ, 1958, J APPL PSYCHOL, V42, P14, DOI 10.1037/h0041738; GARBER J, 1990, J AM ACAD CHILD PSY, V29, P648, DOI 10.1097/00004583-199007000-00021; GOODMAN JE, 1991, PAIN, V46, P247, DOI 10.1016/0304-3959(91)90108-A; HODGES K, 1984, J PSYCHOSOM RES, V28, P185, DOI 10.1016/0022-3999(84)90018-7; HODGES K, 1985, J PEDIATR-US, V107, P622, DOI 10.1016/S0022-3476(85)80037-8; MAGNI G, 1987, EUR J PEDIATR, V146, P72, DOI 10.1007/BF00647291; Pintner R, 1938, J EDUC PSYCHOL, V29, P93, DOI 10.1037/h0059933; ROBINSON JO, 1990, J PSYCHOSOM RES, V34, P171, DOI 10.1016/0022-3999(90)90051-5; SANDERS MR, 1994, J CONSULT CLIN PSYCH, V62, P306, DOI 10.1037/0022-006X.62.2.306; Scharff L, 1997, CLIN PSYCHOL REV, V17, P145, DOI 10.1016/S0272-7358(96)00001-3; Scott SC, 1997, J CLIN EPIDEMIOL, V50, P45, DOI 10.1016/S0895-4356(96)00312-5; WADSWORTH MEJ, 1992, J EPIDEMIOL COMMUN H, V46, P300, DOI 10.1136/jech.46.3.300; WALKER LS, 1993, J ABNORM PSYCHOL, V102, P248, DOI 10.1037/0021-843X.102.2.248; WALKER LS, 1989, J PEDIATR PSYCHOL, V14, P231, DOI 10.1093/jpepsy/14.2.231; WALKER LS, 1991, J ABNORM CHILD PSYCH, V19, P379, DOI 10.1007/BF00919084; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; WOODBURY MM, 1993, PSYCHOSOMATICS, V34, P485, DOI 10.1016/S0033-3182(93)71822-8	22	224	224	0	14	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1196	1200		10.1136/bmj.316.7139.1196	http://dx.doi.org/10.1136/bmj.316.7139.1196			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZJ518	9552994	Green Submitted, Green Published			2022-12-24	WOS:000073224100019
J	Wilmoth, JR				Wilmoth, JR			The future of human longevity: A demographer's perspective	SCIENCE			English	Article							MORTALITY; LIMITS		Univ Calif Berkeley, Dept Demog, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Wilmoth, JR (corresponding author), Univ Calif Berkeley, Dept Demog, Berkeley, CA 94720 USA.	jrw@demog.berkeley.edu						AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bourgeois-pichat J, 1978, Popul Bull UN, P12; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; KANNISTO V, 1994, POPUL DEV REV, V20, P793, DOI 10.2307/2137662; LEE RD, 1992, J AM STAT ASSOC, V87, P659, DOI 10.2307/2290201; MANTON KG, 1991, POPUL DEV REV, V17, P603, DOI 10.2307/1973599; OLSHANSKY SJ, 1990, SCIENCE, V250, P634, DOI 10.1126/science.2237414; PARTRIDGE L, 1997, ZEUS SALMON BIODEMOG, P78; Preston SH, 1995, STATE HUMANITY, P30; *SOC SEC ADM, 1997, 112 SOC SEC ADM OFF; *UN, 1977, WORLD POP PROSP ASS; United Nations. Dept. for Economic and Social Information and Policy Analysis. Population Division, 1995, WORLD POP PROSP 1994; Wilmoth J., 1997, ZEUS SALMON BIODEMOG, P38; Wilmoth J. R., 1996, HLTH MORTALITY ELDER, P266	15	87	89	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1998	280	5362					395	397		10.1126/science.280.5362.395	http://dx.doi.org/10.1126/science.280.5362.395			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9575086				2022-12-24	WOS:000073159600033
J	Taylor, A				Taylor, A			Violations of the international code of marketing of breast milk substitutes: prevalence in four countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DURATION; SAMPLES	Objective: To estimate the prevalence of violations of the international code of marketing of substitutes for breast milk in one city in each of Bangladesh, Poland, South Africa, and Thailand. Design: Multistage random sampling was used to select pregnant women and mothers of infants less than or equal to 6 months old to interview at health facilities. Women were asked whether they had received free samples of substitutes for breast milk (including infant formula designed to meet the nutritional needs of infants from birth to 4 to 6 months of age, follow on formula designed to replace infant formula at the age of 4 to 6 months, and complementary foods for infants aged less than or equal to 6 months), bottles, or teats. The source of the free -sample and when it had been given to the women was also determined. 3 health workers were interviewed at each facility to assess whether the facility had received free samples, to determine how they had been used, and to determine whether gifts had been given to health workers by companies that manufactured or distributed breast milk substitutes. Compliance with the marketing code for information given to health workers was evaluated using a checklist. Setting: Health facilities in Dhaka, Bangladesh; Warsaw, Poland; Durban, South Africa; and Bangkok, Thailand. Subjects: 1468 pregnant women, 1582 mothers of infants aged less than or equal to 6 months, and 466 health workers at 165 health facilities. Main outcome measures: Number of fi-ee samples received by pregnant women, mothers, and health workers; number of gifts given to health workers; and availability of information that violated the code in health facilities. Results: 97 out of 370 (26%) mothers in Bangkok reported receiving free samples of breast milk substitutes, infant formula, bottles, or teats compared with only 1 out of 385 mothers in Dhaka. Across the four cities from 3 out of 40 (8%) to 20 out of 40 (50%) health facilities had received free samples which were not being used for research or professional evaluation; from 2 out of 123 (2%) to 21 out of 119 (18%) health workers had received gifts from companies involved in the manufacturing or distribution of breast mill; substitutes. From 6 out of 40 (15%) to 22 out of 39 (56%) health facilities information that violated the code had been provided by companies and was available to staff. Conclusion: Violations of the code were detected with a simple survey instrument in all Of the four countries studied. Governmental and non-governmental agencies should monitor the prevalence of code violations using the simple methodology developed for this study.	Unicef United Kingdom Comm, Interagcy Grp Breastfeeding Monitoring, London WC2A 3NB, England		Taylor, A (corresponding author), Unicef United Kingdom Comm, Interagcy Grp Breastfeeding Monitoring, London WC2A 3NB, England.							*BAB MILK ACT, 1994, BREAK RUL; BERGEVIN Y, 1983, LANCET, V1, P1148; Collett D., 1991, MODELLING BINARY DAT; DUNGY CI, 1992, PEDIATRICS, V90, P233; Evans C J, 1986, J Obstet Gynecol Neonatal Nurs, V15, P401, DOI 10.1111/j.1552-6909.1986.tb01414.x; FEINSTEIN JM, 1986, PEDIATRICS, V78, P210; FRANK DA, 1987, PEDIATRICS, V80, P845; INCH S, 1988, EFFECTIVE CARE PREGN; PEREZESCAMILLA R, 1994, AM J PUBLIC HEALTH, V84, P89, DOI 10.2105/AJPH.84.1.89; SOKOL E, 1997, CODE HANDBOOK; World Health Organization, 1981, INT COD MARK BREASTM; World Health Organization, 1993, INF YOUNG CHILD NUTR; 1995, INFANT FORMULA FOLOW	13	56	56	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 11	1998	316	7138					1117	1122		10.1136/bmj.316.7138.1117	http://dx.doi.org/10.1136/bmj.316.7138.1117			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH054	9552947	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000073067500019
J	Murthy, VN; Stevens, CF				Murthy, VN; Stevens, CF			Synaptic vesicles retain their identity through the endocytic cycle	NATURE			English	Article							FROG NEUROMUSCULAR-JUNCTION; HIPPOCAMPAL SYNAPSES; NERVE-TERMINALS; DYNAMIN; POOL; TRANSMITTER; MEMBRANE; RINGS	After fusion of synaptic vesicles with presynaptic membrane and secretion of the contents of the vesicles into the synaptic cleft (a process known as exocytosis), the vesicular membrane is retrieved by endocytosis (internalization) for re-use(1,2). Several issues regarding endocytosis at central synapses are unresolved, including the location of membrane retrieval (relative to the active zone, where exocytosis occurs), the time course of various endocytic steps, and the recycling path taken by newly endocytosed membranes. The classical model of synaptic-vesicle recycling, proposed by analogy to other cellular endocytic pathways, involves retrieval of the membrane, fusion of the membrane with endosome-like compartments and, finally, budding of new synaptic vesicles from endosomes(1), although the endosomal station may not be obligatory(3). Here we test the classical model by using the fluorescent membrane dye FM1-43 (refs 4-6) with quantitative fluorescence microscopy. We find that the amount of dye per vesicle taken up by endocytosis equals the amount of dye a vesicle releases on exocytosis; therefore, we conclude that the internalized vesicles do not, as the classical picture suggests, communicate with intermediate endosome-like compartments during the recycling process.	Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; Salk Institute; Salk Institute	Stevens, CF (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	cfs@salk.edu		Murthy, Venkatesh/0000-0003-2443-4252				BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Ryan TA, 1997, NATURE, V388, P478, DOI 10.1038/41335; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; Schikorski T, 1997, J NEUROSCI, V17, P5858; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237	17	207	212	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					497	501		10.1038/33152	http://dx.doi.org/10.1038/33152			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548254				2022-12-24	WOS:000072875200059
J	Parkins, KJ; Poets, CF; O'Brien, LM; Stebbens, VA; Southall, DP				Parkins, KJ; Poets, CF; O'Brien, LM; Stebbens, VA; Southall, DP			Effect of exposure to 15% oxygen on breathing patterns and oxygen saturation in infants: interventional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LIFE-THREATENING EVENTS; FULL-TERM INFANTS; 1ST 6 MONTHS; SLEEP; SIDS; HYPOXEMIA; ALTITUDE; SIBLINGS; TIBET; BORN	Objective: To assess the response of healthy infants to airway hypoxia (15% oxygen in nitrogen). Design: Interventional study. Settings: Infants' homes and paediatric ward. Subjects: 34 healthy infants (20 boys) born at term; mean age at study 3.1 months. 13 of the infants had siblings whose deaths had been ascribed to the sudden infant death syndrome. Intervention: Respiratory variables were measured in room air (pre-challenge), while infants were exposed to 15% oxygen (challenge), and after infants were returned to room air (post-challenge). Main outcome measures: Baseline oxygen saturation as measured by pulse oximetry, frequency of isolated and periodic apnoea, and frequency of desaturation (oxygen saturation less than or equal to 80% for greater than or equal to 4 s), Exposure to 15% oxygen was terminated if oxygen saturation fell to less than or equal to 80% for greater than or equal to 1 min. Results: Mean duration of exposure to 15% oxygen was 6.3 (SD 2.9) hours. Baseline oxygen saturation fell from a median of 97.6% (range 94.0% to 100%) in room air to 92.8% (84.7% to 100%) in 15% oxygen. There was no correlation between baseline oxygen saturation in room air and the extent of the fall in baseline oxygen saturation on exposure to 15% oxygen. During exposure to 15% oxygen there was a reduction in the proportion of time spent in regular breathing pattern and a 3.5-fold increasein the proportion of time spent in periodic apnoea (P < 0.001). There was an increase in the frequency of desaturation from 0 episodes per hour (range 0 to 0.2) to 0.4 episodes per hour (0 to 35) (P < 0.001). In 4 infants exposure to hypoxic conditions was ended early because of prolonged and severe falls in oxygen saturation. Conclusions: A proportion of infants had episodes of prolonged (less than or equal to 80% for greater than or equal to 1 min) or recurrent shorter (less than or equal to 80% for greater than or equal to 4 s) desaturation, or both, when exposed to airway hypoxia. The quality and quantity of this response was unpredictable. These findings may explain why some infants with airway hypoxia caused by respiratory infection develop more severe hypoxaemia than others. Exposure to airway hypoxia similar to that experienced during air travel or on holiday at high altitude may be harmful to some infants.	N Staffordshire Hosp, Acad Dept Paediat, Stoke On Trent ST4 6QG, Staffs, England; Sch Med, Dept Paediat, D-30623 Hannover, Germany	Keele University; University Hospital of North Staffordshire NHS Trust	Southall, DP (corresponding author), N Staffordshire Hosp, Acad Dept Paediat, Stoke On Trent ST4 6QG, Staffs, England.	cai.uk@compuserve.com						ANAS N, 1982, J PEDIATR-US, V101, P65, DOI 10.1016/S0022-3476(82)80184-4; COTTRELL JJ, 1988, CHEST, V93, P81, DOI 10.1378/chest.93.1.81; GETTS AG, 1982, DEV MED CHILD NEUROL, V24, P61; HEATH D, 1989, THORAX, V44, P981, DOI 10.1136/thx.44.12.981; HEWERTSON J, 1994, PEDIATRICS, V94, P148; HOFFMAN HJ, 1988, ANN NY ACAD SCI, V533, P13, DOI 10.1111/j.1749-6632.1988.tb37230.x; HOPPENBROUWERS T, 1989, SLEEP, V12, P265; HULTGREN HN, 1968, ANNU REV MED, V19, P119, DOI 10.1146/annurev.me.19.020168.001003; LOZANO JM, 1992, ARCH DIS CHILD, V67, P299, DOI 10.1136/adc.67.3.299; NIERMEYER S, 1995, NEW ENGL J MED, V333, P1248, DOI 10.1056/NEJM199511093331903; POETS CF, 1991, J DEV PHYSIOL, V15, P341; POETS CF, 1992, ACTA PAEDIATR, V81, P536, DOI 10.1111/j.1651-2227.1992.tb12290.x; RICHARDS JM, 1984, PEDIATRICS, V74, P763; RIGATTO H, 1972, PEDIATRICS, V50, P219; SAMUELS MP, 1994, J PEDIATR-US, V125, P441, DOI 10.1016/S0022-3476(05)83292-5; SAMUELS MP, 1992, ARCH DIS CHILD, V67, P162, DOI 10.1136/adc.67.2.162; SCHAFER T, 1993, J APPL PHYSIOL, V74, P88, DOI 10.1152/jappl.1993.74.1.88; STEBBENS VA, 1991, ARCH DIS CHILD, V66, P569, DOI 10.1136/adc.66.5.569; Tappin DM, 1996, ARCH DIS CHILD, V74, P427, DOI 10.1136/adc.74.5.427; Weil JV, 1978, SLEEP APNEA SYNDROME, P119; Zinman R, 1985, Pediatr Pulmonol, V1, P325, DOI 10.1002/ppul.1950010610	21	60	61	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 21	1998	316	7135					887	891		10.1136/bmj.316.7135.887	http://dx.doi.org/10.1136/bmj.316.7135.887			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552835	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000072713300022
J	Hewson, MG				Hewson, MG			Traditional healers in southern Africa	ANNALS OF INTERNAL MEDICINE			English	Article							CARE	One task of medical anthropologists is to search for similarities and differences among cultural conceptions of illness and healing. This search may identify common, if not universal, characteristics of healing and effective patient care. This paper describes traditional healing practices in southern Africa as related by six traditional healers. Despite the seemingly exotic nature of their practice, the traditional healers' underlying strategies (probing deeply into the psychological, spiritual, and social contexts of illness and using healing ceremonies and natural medicinal preparations) seem to be effective in certain circumstances. Perhaps more important, these strategies can leave both patient and practitioner with a sense of connection and satisfaction. A study of these strategies reveals some general qualities of the healing process that are more apparent in the absence of sophisticated technology.	Cleveland Clin Fdn, Div Educ, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hewson, MG (corresponding author), Cleveland Clin Fdn, Div Educ, 9500 Euclid Ave, Cleveland, OH 44195 USA.							Cassel, 1991, NATURE SUFFERING GOA; Damasio A. R., 1994, DESCARTES ERROR EMOT; Fadiman J. A., 1977, AFR STUD REV, V20, P87, DOI [10.2307/523864, DOI 10.2307/523864]; Frank J. D., 1973, PERSUASION HEALING C; Hewson MG, 1996, J GEN INTERN MED, V11, P481, DOI 10.1007/BF02599044; HEWSON MGA, 1985, ANTHROPOL EDUC QUART, V16, P31, DOI 10.1525/aeq.1985.16.1.05x0849q; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; Kuhn T.S., 2012, STRUCTURE SCI REVOLU, V4th Edn, DOI [10.7208/chicago/9780226458144.001.0001, DOI 10.7208/CHICAGO/9780226458144.001.0001]; Levenstein J, 1989, COMMUNICATING MED PA; Levin J S, 1997, JAMA, V278, P792, DOI 10.1001/jama.278.9.792; Lincoln Y.S., 1985, NATURALISTIC ENQUIRY; LIPKING M, 1995, MED INTERVIEW CLIN; MBITI JS, 1969, AFRICAN REL PHILOS; MCCALLUM TG, 1992, WHITE WOMAN WITCHDOC; NGUBANE H, 1992, SOCIAL BASIS HLTH HE; NOVACK DH, 1995, MED INTERVIEW CLIN C; OSLER W, 1910, BMJ-BRIT MED J, V2, P1470; RANTALA E, 1992, BASELINE STUDY HLTH; Sandelowski M, 1991, Image J Nurs Sch, V23, P161, DOI 10.1111/j.1547-5069.1991.tb00662.x; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001; Sharma H.M., 1996, FUNDAMENTALS COMPLEM; Smith RC, 1996, PATIENTS STORY INTEG; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125	23	55	57	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				1029	1034		10.7326/0003-4819-128-12_Part_1-199806150-00014	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00014			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625666				2022-12-24	WOS:000074201300010
J	Moser, M				Moser, M			Why are physicians not prescribing diuretics more frequently in the management of hypertension?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; ANTIHYPERTENSIVE DRUG-THERAPY; LEFT-VENTRICULAR HYPERTROPHY; FACTOR INTERVENTION TRIAL; DIABETIC-PATIENTS; CARDIAC-ARREST; BETA-BLOCKERS; RISK; LIPOPROTEINS; LIPIDS	Diuretics have again been recommended by the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) as one of the first-choice medications in the management of hypertension. This recommendation is based on the results of numerous randomized, diuretic-based, long-term controlled clinical trials that have demonstrated a reduction in both cerebrovascular and cardiovascular morbidity. Despite this and other national recommendations, the use of diuretics has steadily decreased over the past 15 years. Reasons include heavy promotion of other medications and the perception that diuretics produce adverse metabolic effects and do not reduce coronary heart disease events. Data, however, indicate that (1) changes in glucose and cholesterol metabolism are minor, especially with the smaller doses now being used; (2) cardiovascular morbidity and mortality have been reduced in hypertensive patients, even in those with hyperlipidemia or diabetes, when diuretics are used; and (3) concerns about hypokalemia-induced arrhythmias have been overstated. While special indications exist for other medications in the treatment of hypertension, for example, use of an angiotensin-converting enzyme inhibitor (usually in addition to a diuretic) for a patient with heart failure or diabetic nephropathy, most patients, including those with hyperlipidemia or glucose intolerance, can be effectively treated with a diuretic as initial therapy or as part of a combination regimen, Diuretics should be used more not less frequently; use of diuretics would reduce the number of resistant hypertensive patients.	Yale Univ, Sch Med, New Haven, CT USA	Yale University	Moser, M (corresponding author), 13 Murray Hill Rd, Scarsdale, NY 10583 USA.							AMES RP, 1986, DRUGS, V32, P260, DOI 10.2165/00003495-198632030-00003; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; BLACK HR, 1993, HYPERTENSION, V21, P335; Borhani NO, 1996, JAMA-J AM MED ASSOC, V276, P785, DOI 10.1001/jama.276.10.785; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; EPSTEIN M, 1995, ARCH INTERN MED, V155, P2150, DOI 10.1001/archinte.155.20.2150; Gottdiener JS, 1997, CIRCULATION, V95, P2007, DOI 10.1161/01.CIR.95.8.2007; GREENBERG G, 1984, AM J MED, V76, P45, DOI 10.1016/0002-9343(84)90956-2; Grimm RH, 1997, ARCH INTERN MED, V157, P638, DOI 10.1001/archinte.157.6.638; GURWITZ JH, 1993, ANN INTERN MED, V118, P273, DOI 10.7326/0003-4819-118-4-199302150-00005; HEBERT PR, 1993, ARCH INTERN MED, V153, P578, DOI 10.1001/archinte.153.5.578; HOES AW, 1995, ANN INTERN MED, V123, P481, DOI 10.7326/0003-4819-123-7-199510010-00001; HOLLAND OB, 1981, AM J MED, V70, P762, DOI 10.1016/0002-9343(81)90530-1; HOLLIFIELD JW, 1981, ACTA MED SCAND, P67; HOUSTON MC, 1989, AM HEART J, V117, P911, DOI 10.1016/0002-8703(89)90631-5; *HYP DET FOLL UP P, 1988, JAMA-J AM MED ASSOC, V259, P2118; Kaplan NM, 1996, JAMA-J AM MED ASSOC, V275, P1577, DOI 10.1001/jama.275.20.1577; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; LANGFORD HG, 1986, PROG CARDIOVASC DIS, V29, P29, DOI 10.1016/0033-0620(86)90033-2; LASSER NL, 1984, AM J MED, V76, P52, DOI 10.1016/0002-9343(84)90957-4; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MANOLIO TA, 1995, ARCH INTERN MED, V155, P829, DOI 10.1001/archinte.155.8.829; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MCINNES GT, 1992, J HYPERTENS, V10, P317; MESSERLI FH, 1989, ARCH INTERN MED, V149, P1263, DOI 10.1001/archinte.149.6.1263; MIALL WE, 1983, BMJ-BRIT MED J, V287, P1249; MIDDEKE M, 1987, CLIN CARDIOL, V10, P94, DOI 10.1002/clc.4960100204; MOSER M, 1991, JAMA-J AM MED ASSOC, V265, P498, DOI 10.1001/jama.265.4.498; Moser M, 1996, J AM COLL CARDIOL, V27, P1214, DOI 10.1016/0735-1097(95)00606-0; MOSER M, 1993, CLEV CLIN J MED, V60, P27; MOSER M, 1984, AM HEART J, V107, P616, DOI 10.1016/0002-8703(84)90121-2; MOSER M, 1994, NEW ENGL J MED, V331, P1235; MOSER M, 1991, EUR HEART J, V12, P1034, DOI 10.1093/eurheartj/12.9.1034; MOSER M, 1989, AM HEART J, V118, P1362, DOI 10.1016/0002-8703(89)90059-8; MOSER M, 1992, EUR HEART J, V13, P72, DOI 10.1093/eurheartj/13.suppl_G.72; MOSER M, 1993, DIABETES CARE, V16, P542, DOI 10.2337/diacare.16.2.542; MOSER M, 1979, CHLORTHALIDONE 25 MG, P13; *MRFIT RES GROUP, 1990, JAMA-J AM MED ASSOC, V263, P1765; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; OGILVIE RI, 1993, CAN MED ASSOC J, V149, P575; PAPADEMETRIOU V, 1988, ARCH INTERN MED, V148, P1272, DOI 10.1001/archinte.148.6.1272; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; *ROYAL AUSTR COLL, 1991, HYP DIAGN TREATM MAI; Savage PJ, 1998, ARCH INTERN MED, V158, P741, DOI 10.1001/archinte.158.7.741; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SHAPIRO AP, 1961, NEW ENGL J MED, V265, P1028, DOI 10.1056/NEJM196111232652102; Siegel D, 1997, JAMA-J AM MED ASSOC, V278, P1745, DOI 10.1001/jama.278.21.1745; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; ZANCHETTI A, 1993, BMJ-BRIT MED J, V307, P1541, DOI 10.1136/bmj.307.6918.1541; ZUSMAN RM, 1986, HYPERTENSION, V8, P837, DOI 10.1161/01.HYP.8.10.837	55	74	75	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1813	1816		10.1001/jama.279.22.1813	http://dx.doi.org/10.1001/jama.279.22.1813			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR635	9628713				2022-12-24	WOS:000073998500034
J	Nightingale, SL				Nightingale, SL			Hypersensitivity to chlorhexidine-impregnated medical devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	10	11	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1684	1684		10.1001/jama.279.21.1684	http://dx.doi.org/10.1001/jama.279.21.1684			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624011				2022-12-24	WOS:000073878700005
J	Leeman, E				Leeman, E			Misuse of psychiatric epidemiology	LANCET			English	Editorial Material							NATIONAL-COMORBIDITY-SURVEY; UNITED-STATES; PREVALENCE; DISORDERS		Columbia Univ, Dept Psychiat, New York, NY 10032 USA	Columbia University	Leeman, E (corresponding author), Columbia Univ, Dept Psychiat, New York, NY 10032 USA.							BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; EATON WW, 1984, ARCH GEN PSYCHIAT, V41, P942; FREEDMAN DX, 1984, ARCH GEN PSYCHIAT, V41, P931; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; *PC MENT HLTH, 1978, REP PRES PRES COMM M, V1; Regier DA, 1998, ARCH GEN PSYCHIAT, V55, P109, DOI 10.1001/archpsyc.55.2.109; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; REGIER DA, 1984, ARCH GEN PSYCHIAT, V41, P934; ROBINS LN, 1982, PSYCHOL MED, V12, P855, DOI 10.1017/S0033291700049151; Spitzer RL, 1998, ARCH GEN PSYCHIAT, V55, P120, DOI 10.1001/archpsyc.55.2.120	10	5	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	1998	351	9116					1601	1602		10.1016/S0140-6736(05)77684-4	http://dx.doi.org/10.1016/S0140-6736(05)77684-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZR900	9620712				2022-12-24	WOS:000074026600005
J	Reidy, A; Minassian, DC; Vafidis, G; Joseph, J; Farrow, S; Wu, J; Desai, P; Connolly, A				Reidy, A; Minassian, DC; Vafidis, G; Joseph, J; Farrow, S; Wu, J; Desai, P; Connolly, A			Prevalence of serious eye disease and visual impairment in a north London population: population based, cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							URBAN-POPULATION	Objective: To estimate the magnitude of serious eye disorders and of visual impairment in a defined elderly population of a typical metropolitan area in England, and to assess the frequency they were in touch with, Or known to, the eye care services. Design: Cross sectional survey using two stage cluster random sampling. Setting: General practices in north London. Subjects: Random sample of people aged 65 and older, drawn from a defined population of elderly people registered with 17 general practice groups. Main outcome measures: Proportions and population prevalence estimates were determined for visual acuity, assessed with the person's own spectacles (if any), classified into four categories: prevalence of cataract, age related macular degeneration, and refractive error causing visual impairment and of definite primary open angle glaucoma; and status of contact with eye services. Results: 1547 of 1840 (84%) eligible people were examined. The population prevalence of bilateral Sampling visual impairment (visual acuity < 6/12) was 30%, of which 72% was potentially remediable. 92 of these 448 cases (21%) had visual acuity < 6/60 ("blindness") in one or both eyes. Prevalence of cataract causing visual impairment was 30%; 88% of these people were not in touch with the eye services. The prevalence of vision impairing, age related macular degeneration was 8% and of glaucoma (definite cases) was 3%. Three quarters of the people with definite glaucoma were not known to the eye services. Conclusions: Untreated visual impairment and eye disorders affect a substantial proportion of people aged 65 years and older. These findings should contribute to the setting up of future strategies for preservation of sight and eye health services in general.	UCL, Inst Ophthalmol, London EC1V 9EJ, England; Southampton Gen Hosp, Southampton SO16 6YD, Hants, England; Cent Middlesex Hosp, London NW10 7NS, England; Middlesex Univ, London N11 2NQ, England; Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England	University of London; University College London; University of Southampton; Imperial College London; Middlesex University; University of Southampton	Minassian, DC (corresponding author), UCL, Inst Ophthalmol, London EC1V 9EJ, England.							Attebo K, 1996, OPHTHALMOLOGY, V103, P357; CHYLACK LT, 1988, ARCH OPHTHALMOL-CHIC, V106, P330; Cochran W. G., 1977, SAMPLING TECHNIQUES; COFFEY M, 1993, BRIT J OPHTHALMOL, V77, P17, DOI 10.1136/bjo.77.1.17; GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; Leibowitz H M, 1980, Surv Ophthalmol, V24, P335; Livingston P M, 1995, Ophthalmic Epidemiol, V2, P151, DOI 10.3109/09286589509057097; Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1; Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; WORMALD RPL, 1992, BRIT MED J, V304, P1226, DOI 10.1136/bmj.304.6836.1226	12	165	168	0	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 30	1998	316	7145					1643	1646		10.1136/bmj.316.7145.1643	http://dx.doi.org/10.1136/bmj.316.7145.1643			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR867	9603746	Bronze, Green Published			2022-12-24	WOS:000074022700023
J	Khokhlatchev, AV; Canagarajah, B; Wilsbacher, J; Robinson, M; Atkinson, M; Goldsmith, E; Cobb, MH				Khokhlatchev, AV; Canagarajah, B; Wilsbacher, J; Robinson, M; Atkinson, M; Goldsmith, E; Cobb, MH			Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation	CELL			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; C-JUN; CRYSTAL-STRUCTURE; PC12 CELLS; MITOGEN; TRANSCRIPTION; RECEPTOR; SIGNAL; JNK	The MAP kinase ERK2 is widely involved in eukaryotic signal transduction. Upon activation it translocates to the nucleus of the stimulated cell, where it phosphorylates nuclear targets. We find that nuclear accumulation of microinjected ERK2 depends on its phosphorylation state rather than on its activity or on upstream components of its signaling pathway. Phosphorylated ERK2 forms dimers with phosphorylated and unphosphorylated ERK2 partners. Disruption of dimerization by mutagenesis of ERK2 reduces its ability to accumulate in the nucleus, suggesting that dimerization is essential for its normal ligand-dependent relocalization. The crystal structure of phosphorylated ERK2 reveals the basis for dimerization. Other MAP kinase family members also form dimers. The generality of this behavior suggests that dimerization is part of the mechanism of action of the MAP kinase family.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, Tyler, TX 75710 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.			Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK46993, DK34128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R01DK046993] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CASSEL D, 1982, P NATL ACAD SCI-BIOL, V79, P2231, DOI 10.1073/pnas.79.7.2231; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; CHIYING FH, 1996, P NATL ACAD SCI USA, V93, P10078; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DURSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4185; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Moriguchi T, 1996, Adv Pharmacol, V36, P121, DOI 10.1016/S1054-3589(08)60579-7; NGAI PK, 1991, BIOCHEM J, V280, P805, DOI 10.1042/bj2800805; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; SETH A, 1992, J BIOL CHEM, V267, P24796; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	64	565	603	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					605	615		10.1016/S0092-8674(00)81189-7	http://dx.doi.org/10.1016/S0092-8674(00)81189-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604935	Bronze			2022-12-24	WOS:000073722200013
J	Wang, DG; Fan, JB; Siao, CJ; Berno, A; Young, P; Sapolsky, R; Ghandour, G; Perkins, N; Winchester, E; Spencer, J; Kruglyak, L; Stein, L; Hsie, L; Topaloglou, T; Hubbell, E; Robinson, E; Mittmann, M; Morris, MS; Shen, NP; Kilburn, D; Rioux, J; Nusbaum, C; Rozen, S; Hudson, TJ; Lipshutz, R; Chee, M; Lander, ES				Wang, DG; Fan, JB; Siao, CJ; Berno, A; Young, P; Sapolsky, R; Ghandour, G; Perkins, N; Winchester, E; Spencer, J; Kruglyak, L; Stein, L; Hsie, L; Topaloglou, T; Hubbell, E; Robinson, E; Mittmann, M; Morris, MS; Shen, NP; Kilburn, D; Rioux, J; Nusbaum, C; Rozen, S; Hudson, TJ; Lipshutz, R; Chee, M; Lander, ES			Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome	SCIENCE			English	Article							ARRAYS; HYBRIDIZATION; MAP	Single-nucleotide polymorphisms (SNPs) are the most frequent type of variation in the human genome, and they provide powerful tools for a variety of medical genetic studies. In a large-scale survey for SNPs, 2.3 megabases of human genomic DNA was examined by a combination of gel-based sequencing and high-density variation-detection DNA chips. A total of 3241 candidate SNPs were identified. A genetic map was constructed showing the location of 2227 of these SNPs. Prototype genotyping chips were developed that allow simultaneous genotyping of 500 SNPs. The results provide a characterization of human diversity at the nucleotide level and demonstrate the feasibility of large-scale identification of human SNPs.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Affymetrix Inc, Santa Clara, CA 95051 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Affymetrix	Lipshutz, R (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Rioux, John D/A-9599-2015; Rozen, Steven G./J-5939-2013	Rioux, John D/0000-0001-7560-8326; Spencer, Jessica/0000-0001-8156-514X; Hubbell, Earl/0000-0001-7301-3759; Rozen, Steven G./0000-0002-4288-0056	NHGRI NIH HHS [HG01323, HG00098] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG001323] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AYALA FJ, 1995, SCIENCE, V270, P1930, DOI 10.1126/science.270.5244.1930; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; CONNER BJ, 1983, P NATL ACAD SCI-BIOL, V80, P278, DOI 10.1073/pnas.80.1.278; COOPER DN, 1990, HUM GENET, V85, P55; Cronin MT, 1996, HUM MUTAT, V7, P244, DOI 10.1002/(SICI)1098-1004(1996)7:3<244::AID-HUMU9>3.0.CO;2-A; DEANGELIS MM, 1995, NUCLEIC ACIDS RES, V23, P4742, DOI 10.1093/nar/23.22.4742; deJong D. H., UNPUB; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; KOONTZ WLG, 1972, IEEE T COMPUT, VC 21, P171, DOI 10.1109/TC.1972.5008922; Kruglyak L, 1997, NAT GENET, V17, P21, DOI 10.1038/ng0997-21; Lewontin RC, 1972, EVOLUTIONARY BIOL, V6, P381, DOI [10.1007/978-1-4684-9063-3_14, DOI 10.1007/978-1-4684-9063-3_14]; Li W-H, 1997, MOL EVOLUTION; NEI M, 1984, EVOL BIOL, V17, P73; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Takahata N, 1997, P NATL ACAD SCI USA, V94, P4811, DOI 10.1073/pnas.94.9.4811; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22	19	1576	1971	3	171	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1077	1082		10.1126/science.280.5366.1077	http://dx.doi.org/10.1126/science.280.5366.1077			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9582121				2022-12-24	WOS:000073663600047
J	Leakey, MG; Feibel, CS; McDougall, I; Ward, C; Walker, A				Leakey, MG; Feibel, CS; McDougall, I; Ward, C; Walker, A			New specimens and confirmation of an early ape for Australopithecus anamensis	NATURE			English	Article							1974-1977 COLLECTIONS; HADAR FORMATION; ETHIOPIA; HOMINID	The discovery of Australopithecus anamensis fossils(1) from strata lying between tephra dated at 4.17 and 4.12 million years ago, and from slightly higher strata not well constrained in age by overlying dated units, provoked the claim that more than one species might be represented: it was suggested that the stratigraphically higher fossils, which include the important tibia, humerus and a large, presumed male, mandible (KNM-KP 29287), might belong to a later, more derived hominid(2). We have recovered new fossils from Kanapoi and Allia Bay Kenya, during field work in 1995-1997 that confirm the primitive status of Austalopithecus anamensis, the earliest species of Australopithecus. Isotope dating confirms A. anamensis' intermediate age as being between those of Ardipithecus ramidus(3,4) and Australopithecus afarensis(5,6). New specimens of maxilla, mandible and capitate show that this species is demonstrably more primitive than A. afarensis. A lower first deciduous molar (dm1) is intermediate in morphology between that reported for Ardipithecus ramidus(4) and A. afarensis(7). Single-crystal 40Ar-39Ar age determinations on the Kanapoi Tuff show that, except for a large mandible, all of the hominid fossils from Kanapoi are from sediments deposited between 4.17 +/- 0.03 and 4.07 +/- 0.02 million years ago.	Natl Museums Kenya, Nairobi, Kenya; Rutgers State Univ, Dept Anthropol, New Brunswick, NJ 08901 USA; Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; Univ Missouri, Dept Antropol & Pathol, Columbia, MO 65211 USA; Univ Missouri, Dept Anat Sci, Columbia, MO 65211 USA; Penn State Univ, Dept Anthropol, University Pk, PA 16802 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA	Rutgers State University New Brunswick; Australian National University; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Leakey, MG (corresponding author), Natl Museums Kenya, POB 40658, Nairobi, Kenya.	mfgupa@iconnect.co.ke		Ward, Carol/0000-0001-6255-9668				ANDREWS P, 1995, NATURE, V376, P555, DOI 10.1038/376555a0; BUSH ME, 1982, AM J PHYS ANTHROPOL, V57, P651, DOI 10.1002/ajpa.1330570410; Cebula G. T., 1986, TERRA COGNITA, V6, P139; Gould SJ, 1997, NAT HIST, V106, P20; GOULD SJ, 1997, NAT HIST, V106, P69; HAFLEAB B, 1995, GEOCHEMISTRY GEOCHRO; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P545, DOI 10.1002/ajpa.1330570406; JOHANSON DC, 1979, SCIENCE, V203, P321, DOI 10.1126/science.104384; KIMBEL WH, 1994, NATURE, V368, P449, DOI 10.1038/368449a0; LEAKEY MG, 1995, NATURE, V376, P565, DOI 10.1038/376565a0; MCDOUGALL I, 1988, GEOCHRONOLOGY THERMO; POWERS DW, 1980, GEOLOGY MIOCENE SEDI; Robinson J.T., 1972, EARLY HOMINID POSTUR; WHITE TD, 1995, NATURE, V375, P88, DOI 10.1038/375088a0; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0	15	197	203	0	28	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 7	1998	393	6680					62	66		10.1038/29972	http://dx.doi.org/10.1038/29972			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590689				2022-12-24	WOS:000073497500046
J	Olson, TM; Michels, VV; Thibodeau, SN; Tai, YS; Keating, MT				Olson, TM; Michels, VV; Thibodeau, SN; Tai, YS; Keating, MT			Actin mutations in dilated cardiomyopathy, a heritable form of heart failure	SCIENCE			English	Article							HYPERTROPHIC CARDIOMYOPATHY; ALPHA-ACTININ; MUSCLE; GENE; EXPRESSION	To test the hypothesis that actin dysfunction leads to heart failure, patients with hereditary idiopathic dilated cardiomyopathy (IDC) were examined for mutations in the cardiac actin gene (ACTC). Missense mutations in ACTC that cosegregate with IDC were identified in two unrelated families. Both mutations affect universally conserved amino acids in domains of actin that attach to Z bands and intercalated discs. Coupled with previous data showing that dystrophin mutations also cause dilated cardiomyopathy, these results raise the possibility that defective transmission of force in cardiac myocytes is a mechanism underlying heart failure.	Univ Utah, Hlth Sci Ctr, Dept Pediat, Div Cardiol, Salt Lake City, UT 84112 USA; Mayo Clin & Mayo Fdn, Dept Med Genet, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Univ Utah, Hlth Sci Ctr, Dept Human Genet, Eccles Inst Human Genet,Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Mayo Clinic; Mayo Clinic; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Olson, TM (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Pediat, Div Cardiol, Salt Lake City, UT 84112 USA.				NCRR NIH HHS [M01-RR00064] Funding Source: Medline; NHLBI NIH HHS [5-P50-HL-53773] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL053773] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham WT, 1997, CIRCULATION, V96, P2755, DOI 10.1161/01.CIR.96.9.2755; Bowles KR, 1996, J CLIN INVEST, V98, P1355, DOI 10.1172/JCI118922; DEC GW, 1994, NEW ENGL J MED, V331, P1564, DOI 10.1056/NEJM199412083312307; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; GIMONA M, 1994, CELL MOTIL CYTOSKEL, V27, P108, DOI 10.1002/cm.970270203; Gregorio CC, 1997, CELL STRUCT FUNCT, V22, P191, DOI 10.1247/csf.22.191; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P5901, DOI 10.1073/pnas.79.19.5901; HENNESSEY ES, 1993, BIOCHEM J, V282, P657; HENRY WL, 1980, CIRCULATION, V62, P1054, DOI 10.1161/01.CIR.62.5.1054; Herman IM, 1993, CURR OPIN CELL BIOL, V5, P48, DOI 10.1016/S0955-0674(05)80007-9; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KASPER EK, 1994, J AM COLL CARDIOL, V23, P586, DOI 10.1016/0735-1097(94)90740-4; KUHLMAN PA, 1992, FEBS LETT, V304, P201, DOI 10.1016/0014-5793(92)80619-R; Kumar A, 1997, P NATL ACAD SCI USA, V94, P4406, DOI 10.1073/pnas.94.9.4406; LANKFORD EB, 1995, J CLIN INVEST, V95, P1409, DOI 10.1172/JCI117795; LEVINE BA, 1992, FEBS LETT, V298, P44, DOI 10.1016/0014-5793(92)80019-D; LU MH, 1992, J CELL BIOL, V117, P1007, DOI 10.1083/jcb.117.5.1007; MANOLIO TA, 1992, AM J CARDIOL, V69, P1458, DOI 10.1016/0002-9149(92)90901-A; MESTRONI L, 1994, BRIT HEART J, V72, pS35; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; MICHELS VV, 1985, AM J CARDIOL, V55, P1232, DOI 10.1016/0002-9149(85)90675-7; Olson TM, 1997, TRENDS CARDIOVAS MED, V7, P60, DOI 10.1016/S1050-1738(96)00139-9; Olson TM, 1996, J CLIN INVEST, V97, P528, DOI 10.1172/JCI118445; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITZLOPEZ R, 1997, CIRCULATION, V95, P2434; Reisler E, 1993, CURR OPIN CELL BIOL, V5, P41, DOI 10.1016/S0955-0674(05)80006-7; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; VANDEKERCKHOVE J, 1986, J BIOL CHEM, V261, P1838; Watkins H, 1996, J CLIN INVEST, V98, P2456, DOI 10.1172/JCI119063	30	530	553	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					750	752		10.1126/science.280.5364.750	http://dx.doi.org/10.1126/science.280.5364.750			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563954				2022-12-24	WOS:000073415600052
J	Quensen, JF; Mueller, SA; Jain, MK; Tiedje, JM				Quensen, JF; Mueller, SA; Jain, MK; Tiedje, JM			Reductive dechlorination of DDE to DDMU in marine sediment microcosms	SCIENCE			English	Article								DDT is reductively dechlorinated to DDD and dehydrochlorinated to DDE; it has been thought that DDE is not degraded further in the environment. Laboratory experiments with DDE-containing marine sediments showed that DDE is dechlorinated to DDMU in both methanogenic and sulfidogenic microcosms and that DDD is dehydrochlorinated to DDMU three orders of magnitude more slowly. Thus, DDD does not appear to be an important precursor of the DDMU found in these sediments. These results imply that remediation decisions and risk assessments based on the recalcitrance of DDE in marine and estuarine sediments should be reevaluated.	MBI Int, Lansing, MI 48909 USA; Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA	Michigan State University	Quensen, JF (corresponding author), MBI Int, 3900 Collins Rd,POB 27609, Lansing, MI 48909 USA.							LEE HJ, 1994, DISTRIBUTION CHARACT; LIST EJ, 1997, UNPUB EROSION PALOS; LIST EJ, 1997, BIODEGRADATION DDT D; Niedoroda AW, 1996, SCI TOTAL ENVIRON, V179, P109, DOI 10.1016/0048-9697(95)04875-8; QUENSEN JF, 1988, SCIENCE, V242, P752, DOI 10.1126/science.242.4879.752; QUENSEN JF, 1990, APPL ENV MIROBIOL, V56, P2368; ROCHKIND ML, 1986, MICROBIAL DECOMPOSIT, P138; Sayles GD, 1997, ENVIRON SCI TECHNOL, V31, P3448, DOI 10.1021/es9701669; VOGEL TM, 1987, ENVIRON SCI TECHNOL, V21, P722, DOI 10.1021/es00162a001; WEDEMEYER G, 1967, APPL MICROBIOL, V15, P569, DOI 10.1128/AEM.15.3.569-574.1967; World Health Organization (WHO), 1979, ENV HLTH CRIT, V9; [No title captured]	12	134	144	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					722	724		10.1126/science.280.5364.722	http://dx.doi.org/10.1126/science.280.5364.722			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563945				2022-12-24	WOS:000073415600043
J	Kubori, T; Matsushima, Y; Nakamura, D; Uralil, J; Lara-Tejero, M; Sukhan, A; Galan, JE; Aizawa, S				Kubori, T; Matsushima, Y; Nakamura, D; Uralil, J; Lara-Tejero, M; Sukhan, A; Galan, JE; Aizawa, S			Supramolecular structure of the Salmonella typhimurium type III protein secretion system	SCIENCE			English	Article							FUNCTIONAL CONSERVATION; INVASION GENES; HOST-CELLS; BASAL BODY; IDENTIFICATION; COMPLEX; FAMILY	The type III secretion system of Salmonella typhimurium directs the translocation of proteins into host cells. Evolutionarily related to the flagellar assembly machinery, this system is also present in other pathogenic bacteria, but its organization is unknown. Electron microscopy revealed supramolecular structures spanning the inner and outer membranes of flagellated and nonflagellated strains; such structures were not detected in strains carrying null mutations in components of the type III apparatus. Isolated structures were found to contain at least three proteins of this secretion system. Thus, the type III apparatus of S. typhimurium, and presumably other bacteria, exists as a supramolecular structure in the bacterial envelope.	Teikyo Univ, Dept Biosci, Utsunomiya, Tochigi 320, Japan; SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Teikyo University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Galan, JE (corresponding author), Teikyo Univ, Dept Biosci, 1-1 Toyosatodai, Utsunomiya, Tochigi 320, Japan.		Kubori, Tomoko/AAH-3609-2019	Kubori, Tomoko/0000-0003-1098-6021; Aizawa, Shin-Ichi/0000-0002-9068-0825				AIZAWA S, 1985, J BACTERIOL, V161, P836, DOI 10.1128/JB.161.3.836-849.1985; Aizawa SI, 1996, MOL MICROBIOL, V19, P1, DOI 10.1046/j.1365-2958.1996.344874.x; Collazo CM, 1996, INFECT IMMUN, V64, P3524, DOI 10.1128/IAI.64.9.3524-3531.1996; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; Fu YX, 1998, MOL MICROBIOL, V27, P359, DOI 10.1046/j.1365-2958.1998.00684.x; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GALAN JE, 1996, ANNU REV CELL DEV BI, V12, P219; GINOCCHIO CC, 1995, INFECT IMMUN, V63, P729, DOI 10.1128/IAI.63.2.729-732.1995; GINOCCHIO CC, 1994, CELL, V76, P717, DOI 10.1016/0092-8674(94)90510-X; Hardt WD, 1997, P NATL ACAD SCI USA, V94, P9887, DOI 10.1073/pnas.94.18.9887; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; KANIGA K, 1994, MOL MICROBIOL, V13, P555, DOI 10.1111/j.1365-2958.1994.tb00450.x; Koster M, 1997, MOL MICROBIOL, V26, P789, DOI 10.1046/j.1365-2958.1997.6141981.x; KUBORI T, 1992, J MOL BIOL, V226, P433, DOI 10.1016/0022-2836(92)90958-M; KUBORI T, UNPUB; Linderoth NA, 1997, SCIENCE, V278, P1635, DOI 10.1126/science.278.5343.1635; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; PEGUES DA, 1995, MOL MICROBIOL, V17, P169, DOI 10.1111/j.1365-2958.1995.mmi_17010169.x; Roine E, 1997, P NATL ACAD SCI USA, V94, P3459, DOI 10.1073/pnas.94.7.3459; ROSQVIST R, 1995, EMBO J, V14, P4187, DOI 10.1002/j.1460-2075.1995.tb00092.x; Shea JE, 1996, P NATL ACAD SCI USA, V93, P2593, DOI 10.1073/pnas.93.6.2593; UENO T, 1994, J MOL BIOL, V236, P546, DOI 10.1006/jmbi.1994.1164; YAMAGUCHI S, 1986, J BACTERIOL, V166, P187, DOI 10.1128/jb.166.1.187-193.1986	24	684	714	1	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					602	605		10.1126/science.280.5363.602	http://dx.doi.org/10.1126/science.280.5363.602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554854				2022-12-24	WOS:000073242100051
J	Molkentin, JD; Lu, JR; Antos, CL; Markham, B; Richardson, J; Robbins, J; Grant, SR; Olson, EN				Molkentin, JD; Lu, JR; Antos, CL; Markham, B; Richardson, J; Robbins, J; Grant, SR; Olson, EN			A calcineurin-dependent transcriptional pathway for cardiac hypertrophy	CELL			English	Article							NATRIURETIC-PEPTIDE GENE; T-CELL ACTIVATION; MYOCYTES IN-VITRO; HEAVY-CHAIN GENE; PROTEIN-KINASE-C; CYCLOSPORINE-A; FACTOR NFAT1; MECHANICAL-STRESS; NUCLEAR FACTOR; FAMILY MEMBER	In response to numerous pathologic stimuli, the myocardium undergoes a hypertrophic response characterized by increased myocardial cell size and activation of fetal cardiac genes. We show that cardiac hypertrophy is induced by the calcium-dependent phosphatase calcineurin, which dephosphorylates the transcription factor NF-AT3, enabling it to translocate to the nucleus. NF-AT3 interacts with the cardiac zinc finger transcription factor GATA4, resulting in synergistic activation of cardiac transcription. Transgenic mice that express activated forms of calcineurin or NF-AT3 in the heart develop cardiac hypertrophy and heart failure that mimic human heart disease. Pharmacologic inhibition of calcineurin activity blocks hypertrophy in vivo and in vitro. These results define a novel hypertrophic signaling pathway and suggest pharmacologic approaches to prevent cardiac hypertrophy and heart failure.	Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75225 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75225 USA; Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Univ N Texas, Hlth Sci Ctr, Lab Cardiac & Vasc Mol Genet, Inst Cardiovasc Res, Ft Worth, TX 76107 USA; Warner Lambert Parke Davis, Ann Arbor, MI 48105 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cincinnati Children's Hospital Medical Center; University of North Texas System; University of North Texas Health Science Center; Pfizer	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, 6000 Harry Hines Blvd, Dallas, TX 75225 USA.		Antos, Christopher L/E-8171-2010; Lu, Jianrong/F-5240-2013	Lu, Jianrong/0000-0002-4969-6040; Molkentin, Jeffery/0000-0002-3558-6529	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053351] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL053351] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOTINELLI R, 1997, CIRC RES, V82, P106; BUSTAMANTE JO, 1991, J CARDIOVASC PHARM, V17, pS110, DOI 10.1097/00005344-199117002-00024; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; Evans T, 1997, TRENDS CARDIOVAS MED, V7, P75, DOI 10.1016/S1050-1738(97)00010-8; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; Hasegawa K, 1997, CIRCULATION, V96, P3943; HAVERICH A, 1994, TRANSPLANT P, V26, P2713; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HONGO K, 1995, AM J PHYSIOL-CELL PH, V269, pC690, DOI 10.1152/ajpcell.1995.269.3.C690; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; JONES WK, 1994, DEV DYNAM, V200, P117, DOI 10.1002/aja.1002000204; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARLINER JS, 1990, EXPERIENTIA, V46, P81, DOI 10.1007/BF01955423; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KovacicMilivojevic B, 1996, ENDOCRINOLOGY, V137, P1108, DOI 10.1210/en.137.3.1108; Kudoh S, 1997, CIRC RES, V80, P139, DOI 10.1161/01.RES.80.1.139; LEGUENNEC JY, 1991, EXP PHYSIOL, V76, P975, DOI 10.1113/expphysiol.1991.sp003560; LEITE MF, 1994, AM J PHYSIOL-HEART C, V267, pH2193, DOI 10.1152/ajpheart.1994.267.6.H2193; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Loh C, 1996, MOL CELL BIOL, V16, P3945; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; MARBAN E, 1987, P NATL ACAD SCI USA, V84, P6005, DOI 10.1073/pnas.84.16.6005; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Molkentin JD, 1997, CIRCULATION, V96, P3833; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OGAWA Y, 1995, J MOL MED-JMM, V73, P457; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Palmiter KA, 1997, BASIC RES CARDIOL, V92, P63, DOI 10.1007/BF00794070; Park JC, 1996, J BIOL CHEM, V271, P20914, DOI 10.1074/jbc.271.34.20914; PERREAULT CL, 1994, AM J PHYSIOL, V266, pH2436, DOI 10.1152/ajpheart.1994.266.6.H2436; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; REID CJ, 1988, BRIT HEART J, V59, P397; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SAEKI Y, 1993, ADV EXP MED BIOL, V332, P639; SCHWINGER RHG, 1995, CIRCULATION, V92, P3220, DOI 10.1161/01.CIR.92.11.3220; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; SU QX, 1995, EUR J BIOCHEM, V230, P469, DOI 10.1111/j.1432-1033.1995.0469h.x; THORBURN A, 1993, J BIOL CHEM, V268, P2244; Vikstrom KL, 1996, CURR OPIN CELL BIOL, V8, P97, DOI 10.1016/S0955-0674(96)80053-6; WATKINS H, 1995, HUM MOL GENET, V4, P1721, DOI 10.1093/hmg/4.suppl_1.1721; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; Woods A, 1994, LAB HISTOPATHOLOGY C; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; Yamazaki T, 1997, CIRCULATION, V95, P1260; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	61	2088	2239	4	111	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					215	228		10.1016/S0092-8674(00)81573-1	http://dx.doi.org/10.1016/S0092-8674(00)81573-1			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568714	Green Accepted, Bronze			2022-12-24	WOS:000073174000008
J	Casares, F; Mann, RS				Casares, F; Mann, RS			Control of antennal versus leg development in Drosophila	NATURE			English	Article							ECTOPIC EXPRESSION; GENE-EXPRESSION; IMAGINAL DISKS; MELANOGASTER; PROTEIN; SPECIFICATION; EXTRADENTICLE; SEGMENTATION; ORGANIZATION; LOCALIZATION	During the evolution of insects from a millipede-like ancestor, the Hox genes are thought to have promoted the diversification of originally identical body structures(1,2). In Drosophila melanogaster ter, antennae and legs are homologous structures that differ from each other as a result of the Hox gene Antennapedia (Antp), which promotes leg identities by repressing unknown antennal-determining genes(3-7). Here we present four lines of evidence that identify extradenticle (exd) and homothorax (hth) as antennal-determining genes. First, removing the function of exd(8,9) or hth, which is required for the nuclear localization of Exd protein(10), transforms the antenna into leg; such transformations occur without activation of Antp. Second, hth is expressed and Exd is nuclear in most antennal cells, whereas both are restricted to proximal cells of the leg. Third, Antp is a repressor of hth. Fourth, ectopic expression of Meisl, a murine hth homologue(10), can trigger antennal development elsewhere in the fly. Taken together, these data indicate that hth is an antennal selector gene, and that Antp promotes leg development by repressing hth and consequently nuclear Exd.	Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University	Mann, RS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, Ctr Neurobiol & Behav, 701 W 168th St,HHSC 1108, New York, NY 10032 USA.		Casares, Fernando/M-5451-2019	Casares, Fernando/0000-0002-2181-3858	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054510, R01GM058575] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058575, R01 GM054510] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT MK, 1986, GENETICS, V114, P919; AKAM M, 1988, DEVELOPMENT S, P123; Azpiazu N, 1998, GENE DEV, V12, P261, DOI 10.1101/gad.12.2.261; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brower, 1991, DROSOPHILA INFORMATI, V70, P52; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; CARROLL SB, 1986, CELL, V47, P113, DOI 10.1016/0092-8674(86)90372-7; Casares F, 1997, DEV GENES EVOL, V207, P216, DOI 10.1007/s004270050110; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; Freeland DE, 1996, MECH DEVELOP, V56, P61, DOI 10.1016/0925-4773(96)00511-4; Gehring W., 1966, ARCH JULIUS KALAUSST, V41, P44; GIBSON G, 1988, DEVELOPMENT, V102, P657; GONZALEZCRESPO S, 1995, DEVELOPMENT, V121, P2117; GonzalezCrespo S, 1996, DEVELOPMENT, V122, P3921; KAUFMAN TC, 1980, GENETICS, V94, P115; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; PANGANIBAN G, 1995, SCIENCE, V270, P1363, DOI 10.1126/science.270.5240.1363; Pignoni F, 1997, DEVELOPMENT, V124, P271; RAUSKOLB C, 1995, DEVELOPMENT, V121, P3663; RAUSKOLB C, 1993, CELL, V74, P1; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; SCHNEUWLY S, 1987, EMBO J, V6, P201, DOI 10.1002/j.1460-2075.1987.tb04739.x; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; STEINER E, 1976, ROUX ARCH DEV BIOL, V180, P9, DOI 10.1007/BF00848882; STRUHL G, 1981, NATURE, V292, P635, DOI 10.1038/292635a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; WIRZ J, 1986, EMBO J, V5, P3327, DOI 10.1002/j.1460-2075.1986.tb04647.x	31	244	247	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1998	392	6677					723	726		10.1038/33706	http://dx.doi.org/10.1038/33706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565034				2022-12-24	WOS:000073129000061
J	Hall, RA; Premont, RT; Chow, CW; Blitzer, JT; Pitcher, JA; Claing, A; Stoffel, RH; Barak, LS; Shenolikar, S; Weinman, EJ; Grinstein, S; Lefkowitz, RJ				Hall, RA; Premont, RT; Chow, CW; Blitzer, JT; Pitcher, JA; Claing, A; Stoffel, RH; Barak, LS; Shenolikar, S; Weinman, EJ; Grinstein, S; Lefkowitz, RJ			The beta(2)-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange	NATURE			English	Article							NA-H EXCHANGE; BETA-ADRENERGIC-RECEPTOR; PARATHYROID-HORMONE; PROXIMAL TUBULE; CAMP; SEQUESTRATION; REABSORPTION; ACTIVATION; INHIBITION; COFACTOR	Stimulation of beta(2)-adrenergic receptors on the cell surface by adrenaline or noradrenaline leads to alterations in the metabolism, excitability, differentiation and growth of many cell types. These effects have traditionally been thought to be mediated exclusively by receptor activation of intracellular G proteins(1). However, certain physiological effects of beta(2)-adrenergic receptor stimulation, notably the regulation of cellular pH by modulation of Na+/H+ exchanger (NHE) function, do not seem to be entirely dependent on G-protein activation(2-7). We report here a direct agonist-promoted association of the beta(2)-adrenergic receptor with the Na+/H+ exchanger regulatory factor (NHERF), a protein that regulates the activity of the Na+/H+ exchanger type 3 (NHE3)(8). NHERF binds to the beta(2)-adrenergic receptor by means of a PDZ-domain-mediated interaction with the last few residues of the carboxy-terminal cytoplasmic domain of the receptor. Mutation of the final residue of the beta(2)-adrenergic receptor from leucine to alanine abolishes the receptor's interaction with NHERF and also markedly alters beta(2)-adrenergic receptor regulation of NHE3 in cells without altering receptor-mediated activation of adenylyl cyclase. Our findings indicate that agonist-defendent beta(2)-adrenergic receptor binding of NHERF plays a role in beta(2)-adrenergic receptor-mediated regulation of Na+/H+ exchange.	Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Hosp Sick Children, Res Inst, Div Cell Biol, Toronto, ON M5G 1X8, Canada; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; W Virginia Univ, Dept Med, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA; Dept Vet Affairs Med Ctr, Med Serv, Clarksburg, WV 26301 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Duke University; West Virginia University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021; Pitcher, Julie/ABH-2078-2020; Chow, Chung-Wai/AAP-5533-2020	Chow, Chung-Wai/0000-0001-9344-8522; Premont, Richard/0000-0002-8053-5026; Hall, Randy/0000-0002-8318-8728				AGUS ZS, 1971, J CLIN INVEST, V50, P617, DOI 10.1172/JCI106532; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARBER DL, 1992, J BIOL CHEM, V267, P20607; BARBER DL, 1992, MOL PHARMACOL, V41, P1056; BELLOREUSS E, 1980, AM J PHYSIOL, V238, pF347, DOI 10.1152/ajprenal.1980.238.5.F347; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; Cabado AG, 1996, J BIOL CHEM, V271, P3590; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOLSON GM, 1985, AM J PHYSIOL, V249, pF409, DOI 10.1152/ajprenal.1985.249.3.F409; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; GANZ MB, 1990, J BIOL CHEM, V265, P8989; KAHN AM, 1985, AM J PHYSIOL, V248, pF212, DOI 10.1152/ajprenal.1985.248.2.F212; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; WEINMAN EJ, 1987, AM J PHYSIOL, V252, pF19, DOI 10.1152/ajprenal.1987.252.1.F19; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; WEINMAN EJ, 1982, J MEMBRANE BIOL, V69, P107, DOI 10.1007/BF01872270; WEINMAN EJ, 1993, ANNU REV PHYSIOL, V55, P289, DOI 10.1146/annurev.ph.55.030193.001445; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	30	482	490	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					626	630		10.1038/33458	http://dx.doi.org/10.1038/33458			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560162				2022-12-24	WOS:000072987200066
J	Pagan-Westphal, SM; Tabin, CJ				Pagan-Westphal, SM; Tabin, CJ			The transfer of left-right positional information during chick embryogenesis	CELL			English	Article							LEFT-RIGHT ASYMMETRY; SONIC HEDGEHOG; NODAL EXPRESSION; INDUCTION; GENE; RECEPTOR; MICE; CONSERVATION; PATHWAY; EMBRYO	The earliest known left-right asymmetric genes are expressed at Hensen's node during chick gastrulation. Gene expression following reorientation of the node shows asymmetry is instructed by adjacent tissue, hence left-right information originates outside the node. Subsequently, the node signals back to the lateral tissue, initiating a cascade leading to left-sided expression of nodal in the lateral plate mesoderm. Loss of nodal expression in the presence of blocking antibodies confirms that Sonic hedgehog is the key signal conveying left-right information from the node; however, manipulation of explant cultures suggests that the induction of nodal requires secondary signals produced in the paraxial mesoderm. These experiments establish the time of action of these signals to and from Hensen's node in establishing left-right asymmetry.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Tabin, CJ (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.							ABERCROMBIE M, 1950, PHILOS T R SOC B, V234, P317, DOI 10.1098/rstb.1950.0004; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; EKKER SC, 1995, DEVELOPMENT, V121, P2337; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Heymer J, 1997, MECH DEVELOP, V66, P5, DOI 10.1016/S0925-4773(97)00084-1; HYATT BA, 1998, CELL, V93; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; KING T, 1997, CURR BIOL, V7, pF212; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; LEVIN M, 1996, THESIS HARVARD U CAM; LOHR JL, 1997, DEVELOPMENT, V124, P1467; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; Marigo V, 1996, DEVELOPMENT, V122, P1225; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; Nascone N, 1997, DEV BIOL, V189, P68, DOI 10.1006/dbio.1997.8635; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P326; Pannett C.A., 1924, LANCET, V206, P381; Psychoyos D, 1996, DEVELOPMENT, V122, P3263; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Sampath K, 1997, DEVELOPMENT, V124, P3293; Schultheiss TM, 1995, DEVELOPMENT, V121, P4203; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1	31	152	156	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					25	35		10.1016/S0092-8674(00)81143-5	http://dx.doi.org/10.1016/S0092-8674(00)81143-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546389	Bronze			2022-12-24	WOS:000072910800007
J	Schacter, DL				Schacter, DL			Memory and awareness	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; IMPLICIT MEMORY; HIPPOCAMPUS; ACTIVATION; HUMANS		Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA	Harvard University	Schacter, DL (corresponding author), Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA.			Schacter, Daniel/0000-0002-2460-6061	NATIONAL INSTITUTE ON AGING [R37AG008441, R01AG008441] Funding Source: NIH RePORTER; NIA NIH HHS [AG08441] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berns GS, 1997, SCIENCE, V276, P1272, DOI 10.1126/science.276.5316.1272; Blaxton TA, 1996, J NEUROSCI, V16, P4032; BOWERS JS, 1990, J EXP PSYCHOL LEARN, V16, P404, DOI 10.1037/0278-7393.16.3.404; Clark RE, 1998, SCIENCE, V280, P77, DOI 10.1126/science.280.5360.77; CURRAN T, 1997, HDB IMPLICIT LEARNIN, P365; GRAF P, 1984, J EXP PSYCHOL LEARN, V10, P164, DOI 10.1037/0278-7393.10.1.164; McKone E, 1997, MEM COGNITION, V25, P352, DOI 10.3758/BF03211291; MERIKLE PM, 1991, J EXP PSYCHOL LEARN, V17, P224, DOI 10.1037/0278-7393.17.2.224; Rugg MD, 1997, NEUROREPORT, V8, P1283, DOI 10.1097/00001756-199703240-00045; Schacter DL, 1998, NEURON, V20, P185, DOI 10.1016/S0896-6273(00)80448-1; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SHANKS DR, 1994, BEHAV BRAIN SCI, V17, P367, DOI 10.1017/S0140525X00035032; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; UNGERLEIDER LG, 1995, SCIENCE, V270, P769, DOI 10.1126/science.270.5237.769	16	45	46	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					59	60		10.1126/science.280.5360.59	http://dx.doi.org/10.1126/science.280.5360.59			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZF314	9556454				2022-12-24	WOS:000072885100033
J	Jones, TW; Porter, P; Sherwin, RS; Davis, EA; O'Leary, P; Frazer, F; Byrne, G; Stick, S; Tamborlane, WV				Jones, TW; Porter, P; Sherwin, RS; Davis, EA; O'Leary, P; Frazer, F; Byrne, G; Stick, S; Tamborlane, WV			Decreased epinephrine responses to hypoglycemia during sleep	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; NOCTURNAL HYPOGLYCEMIA; HORMONAL COUNTERREGULATION; GLUCOSE COUNTERREGULATION; SUBSEQUENT HYPOGLYCEMIA; INSULIN THERAPY; NERVE ACTIVITY; HUMANS	Background In patients with type I diabetes mellitus, hypoglycemia occurs commonly during sleep and is frequently asymptomatic. This raises the question of whether sleep is associated with reduced counterregulatory-hormone responses to hypoglycemia. Methods We studied the counterregulatory-hormone responses to insulin-induced hypoglycemia in eight adolescent patients with type I diabetes and six age-matched normal subjects when they were awake during the day, asleep at night, and awake at night. In each study, the plasma glucose concentration was stabilized for 60 minutes at approximately 100 mg per deciliter (5.6 mmol per liter) and then reduced to 50 mg per deciliter (2.8 mmol per liter) and maintained at that concentration for 40 minutes. Plasma free insulin, epinephrine, norepinephrine, cortisol, and growth hormone were measured frequently during each study. Sleep was monitored by polysomnography. Results The plasma glucose and free insulin concentrations were similar in both groups during all studies. During the studies when the subjects were asleep, no one was awakened during the hypoglycemic phase, but during the final 30 minutes of the studies when the subjects were awake both the patients with diabetes and the normal subjects had symptoms of hypoglycemia. In the patients with diabetes, plasma epinephrine responses to hypoglycemia were blunted when they were asleep (mean [+/-SE] peak plasma epinephrine concentration, 70+/-14 pg per milliliter [382+/-76 pmol per liter]; P=0.3 for the comparison with base line), as compared with when they were awake during the day or night (238+/-39 pg per milliliter [1299+/-213 pmol per liter], P=0.004 for the comparison with base line, and 296+/-60 pg per milliliter [1616+/-327 pmol per liter], P=0.004, respectively). The patients' plasma norepinephrine responses were also reduced during sleep, whereas their plasma cortisol concentrations did not increase and their plasma growth hormone concentrations increased, slightly. The patterns of counterregulatory-hormone responses in the normal subjects were similar. Conclusions Sleep impairs counterregulatory-hormone responses to hypoglycemia in patients with diabetes and normal subject. (C) 1998, Massachusetts Medical Society.	Princess Margaret Hosp Children, Dept Endocrinol & Diabet, Perth, WA 6001, Australia; Princess Margaret Hosp Children, Dept Resp Med, Perth, WA 6001, Australia; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA	University of Western Australia; University of Western Australia; Yale University; Yale University	Jones, TW (corresponding author), Princess Margaret Hosp Children, Dept Endocrinol & Diabet, Box D184, Perth, WA 6001, Australia.		Porter, Paul/R-2362-2018; Stick, Stephen/AAA-5945-2021; Stick, Stephen/GZG-7584-2022; Stick, Stephen/O-5683-2014	Porter, Paul/0000-0001-9051-589X; Stick, Stephen/0000-0002-5386-8482; Davis, Elizabeth/0000-0003-4244-5473; Jones, Timothy/0000-0002-7989-1998; O'Leary, Peter/0000-0001-9375-0801	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00125, RR06020] Funding Source: Medline; PHS HHS [10495] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMIEL SA, 1987, NEW ENGL J MED, V316, P1376, DOI 10.1056/NEJM198705283162205; BENDTSON I, 1993, ACTA ENDOCRINOL-COP, V128, P109, DOI 10.1530/acta.0.1280109; BOLLI G, 1983, DIABETES, V32, P134, DOI 10.2337/diabetes.32.2.134; CADUFF F, 1989, SCHWEIZ MED WSCHR, V119, P9; CRYER PE, 1989, DIABETES, V38, P1193, DOI 10.2337/diabetes.38.9.1193; CRYER PE, 1994, DIABETES CARE, V17, P734, DOI 10.2337/diacare.17.7.734; DAGOGOJACK SE, 1993, J CLIN INVEST, V91, P819, DOI 10.1172/JCI116302; Davis EA, 1997, DIABETES CARE, V20, P22, DOI 10.2337/diacare.20.1.22; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; GALE EAM, 1979, LANCET, V1, P1049; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; HORNYAK M, 1991, BRAIN, V114, P1281, DOI 10.1093/brain/114.3.1281; Kryger M, 1994, PRINCIPLES PRACTICE; Maggs DG, 1997, DIABETES, V46, P70, DOI 10.2337/diabetes.46.1.70; OKADA H, 1991, NEUROLOGY, V41, P1961, DOI 10.1212/WNL.41.12.1961; Porter PA, 1996, ARCH DIS CHILD, V75, P120, DOI 10.1136/adc.75.2.120; SHALWITZ RA, 1990, J PEDIATR-US, V116, P685, DOI 10.1016/S0022-3476(05)82648-4; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIMONSON DC, 1985, ANN INTERN MED, V103, P184, DOI 10.7326/0003-4819-103-2-184; VENEMAN T, 1993, DIABETES, V42, P1233, DOI 10.2337/diabetes.42.9.1233	20	182	182	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1998	338	23					1657	1662		10.1056/NEJM199806043382303	http://dx.doi.org/10.1056/NEJM199806043382303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR451	9614256	Bronze			2022-12-24	WOS:000073978000003
J	Altare, F; Durandy, A; Lammas, D; Emile, JF; Lamhamedi, S; Le Deist, F; Drysdale, P; Jouanguy, E; Doffinger, R; Bernaudin, F; Jeppsson, O; Gollob, JA; Meinl, E; Segal, AW; Fischer, A; Kumararatne, D; Casanova, JL				Altare, F; Durandy, A; Lammas, D; Emile, JF; Lamhamedi, S; Le Deist, F; Drysdale, P; Jouanguy, E; Doffinger, R; Bernaudin, F; Jeppsson, O; Gollob, JA; Meinl, E; Segal, AW; Fischer, A; Kumararatne, D; Casanova, JL			Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency	SCIENCE			English	Article							IFN-GAMMA PRODUCTION; HUMAN T-CELLS; INFECTION; CYTOKINE; RESISTANCE; COMPLEX; PROTEIN; MICE	In humans, interferon gamma (IFN-gamma) receptor deficiency leads to a predisposition to mycobacterial infections and impairs the formation of mature granulomas. Interleukin-12 (IL-12) receptor deficiency was found in otherwise healthy individuals with mycobacterial infections. Mature granulomas were seen, surrounded by T cells and centered with epithelioid and multinucleated giant cells, yet reduced IFN-gamma concentrations were found to be secreted by activated natural killer and T cells. Thus, IL-12-dependent IFN-gamma secretion in humans seems essential in the control of mycobacterial infections, despite the formation of mature granulomas due to IL-12-independent IFN-gamma secretion.	Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, F-75015 Paris, France; Hop Necker Enfants Malad, INSERM, U429, F-75015 Paris, France; UCL, Dept Med, London WC1 E6JJ, England; Univ Erlangen Nurnberg, D-91054 Erlangen, Germany; Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Hosp, Dept Pediat, S-14501 Norsborg, Sweden; Ctr Hosp Intercommunal, Serv Pediat, F-94010 Creteil, France; Hop Paul Brousse, Serv Anatomopathol, F-94804 Villejuif, France; Univ Birmingham, Sch Med, Dept Immunol, Birmingham B15 2TT, W Midlands, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of London; University College London; University of Erlangen Nuremberg; Harvard University; Dana-Farber Cancer Institute; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; University of Birmingham	Casanova, JL (corresponding author), Hop Necker Enfants Malad, INSERM, U429, F-75015 Paris, France.	casanova@ceylan.necker.fr	Casanova, Jean-Laurent/I-3418-2017; Jouanguy, Emmanuelle/H-7901-2017; altare, frederic/K-8664-2015; Durandy, Anne/H-7475-2017	Jouanguy, Emmanuelle/0000-0002-7358-9157; altare, frederic/0000-0002-5077-4616; Meinl, Edgar/0000-0002-2570-6785; Segal, Anthony/0000-0001-7602-9043; Durandy, Anne/0000-0001-7706-8466; Casanova, Jean-Laurent/0000-0002-7782-4169				Altare F, 1998, AM J HUM GENET, V62, P723, DOI 10.1086/301750; ALTARE F, 1997, RES INFECT DIS B I P, V95, P143; ANDERSON P, 1990, J IMMUNOL, V144, P574; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; CASANOVA JL, 1995, LANCET, V346, P581, DOI 10.1016/S0140-6736(95)91421-8; Casanova JL, 1996, PEDIATRICS, V98, P774; CASANOVA JL, IN PRESS PRIMARY IMM; CHUA AO, 1994, J IMMUNOL, V153, P128; Cooper AM, 1997, J EXP MED, V186, P39, DOI 10.1084/jem.186.1.39; de Jong R, 1998, SCIENCE, V280, P1435; deJong R, 1997, J IMMUNOL, V159, P786; Emile JF, 1997, J PATHOL, V181, P25, DOI 10.1002/(SICI)1096-9896(199701)181:1<25::AID-PATH747>3.0.CO;2-Z; Frucht DM, 1996, J IMMUNOL, V157, P411; Gollob JA, 1997, EUR J IMMUNOL, V27, P647, DOI 10.1002/eji.1830270311; Jouanguy E, 1997, J CLIN INVEST, V100, P2658, DOI 10.1172/JCI119810; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; Jouanguy E, 1997, J INTERF CYTOK RES, V17, P583, DOI 10.1089/jir.1997.17.583; JOUANGUY E, UNPUB; Kohno K, 1997, J IMMUNOL, V158, P1541; Lamhamedi S, 1998, INT J MOL MED, V1, P415; LEDEIST F, 1987, J IMMUNOL, V138, P423; LEVIN M, 1995, LANCET, V345, P79, DOI 10.1016/S0140-6736(95)90059-4; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Mattner F, 1997, INFECT IMMUN, V65, P4378, DOI 10.1128/IAI.65.11.4378-4383.1997; Mattner F, 1996, EUR J IMMUNOL, V26, P1553, DOI 10.1002/eji.1830260722; Medley QG, 1996, P NATL ACAD SCI USA, V93, P685, DOI 10.1073/pnas.93.2.685; MEINL E, 1995, IMMUNOL TODAY, V16, P55, DOI 10.1016/0167-5699(95)80087-5; Micallef MJ, 1996, EUR J IMMUNOL, V26, P1647, DOI 10.1002/eji.1830260736; Modlin RL, 1995, RES IMMUNOL, V146, P526, DOI 10.1016/0923-2494(96)83027-6; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; PierreAudigier C, 1997, CLIN INFECT DIS, V24, P982, DOI 10.1093/clinids/24.5.982; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; Romani L, 1997, CLIN MICROBIOL REV, V10, P611, DOI 10.1128/CMR.10.4.611; STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Wu CY, 1997, J IMMUNOL, V159, P1658	39	650	667	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 29	1998	280	5368					1432	1435		10.1126/science.280.5368.1432	http://dx.doi.org/10.1126/science.280.5368.1432			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9603732				2022-12-24	WOS:000073883400055
J	Astin, JA				Astin, JA			Why patients use alternative medicine - Results of a national study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPLEMENTARY MEDICINE; UNITED-STATES; CARE; PRACTITIONERS; SOMATIZATION; PREVALENCE; THERAPIES; ATTITUDES; BEHAVIORS; DOCTORS	Context.-Research both in the United States and abroad suggests that significant numbers of people are involved with various forms of alternative medicine. However, the reasons for such use are, at present, poorly understood. Objective.-To investigate possible predictors of alternative health care use. Methods.-Three primary hypotheses were tested. People seek out these alternatives because (1) they are dissatisfied in some way with conventional treatment; (2) they see alternative treatments as offering more personal autonomy and control over health care decisions; and (3) the alternatives are seen as more compatible with the patients' values, worldview, or beliefs regarding the nature and meaning of health and illness. Additional predictor variables explored included demographics and health status. Design.-A written survey examining use of alternative health care, health status, values, and attitudes toward conventional medicine. Multiple logistic regression analyses were used in an effort to identify predictors of alternative health care use. Setting and Participants.-A total of 1035 individuals randomly selected from a panel who had agreed to participate in mail surveys and who live throughout the United States. Main Outcome Measure.-Use of alternative medicine within the previous year. Results.-The response rate was 69%. The following variables emerged as predictors of alternative health care use: more education (odds ratio [OR], 1.2; 95% confidence interval [CI], 1.1-1.3); poorer health status (OR, 1.3, 95% CI, 1.1-1.5); a holistic orientation to health (OR, 1.4; 95% CI, 1.1-1.9); having had a transformational experience that changed the person's worldview (OR, 1.8; 95% CI, 1.3-2.5); any of the following health problems: anxiety (OR, 3.1; 95% CI, 1.6-6.0); back problems (OR, 2.3; 95% CI, 1.7-3.2); chronic pain (OR, 2.0; 95% CI, 1.1-3.5); urinary tract problems (OR, 2.2; 95% CI, 1.3-3.5); and classification in a cultural group identifiable by their commitment to environmentalism, commitment to feminism, and interest in spirituality and personal growth psychology (OR, 2.0; 95% CI, 1.4-2.7). Dissatisfaction with conventional medicine did not predict use of alternative medicine. Only 4.4% of those surveyed reported relying primarily on alternative therapies. Conclusion.-Along with being more educated and reporting poorer health status, the majority of alternative medicine users appear to be doing so not so much as a result of being dissatisfied with conventional medicine but largely because they find these health care alternatives to be more congruent with their own values, beliefs, and philosophical orientations toward health and life.	Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, Palo Alto, CA 94304 USA	Stanford University	Astin, JA (corresponding author), Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, 730 Welch Rd, Palo Alto, CA 94304 USA.							AVINA RL, 1978, WESTERN J MED, V128, P366; BARSKY AJ, 1995, JAMA-J AM MED ASSOC, V274, P1931, DOI 10.1001/jama.274.24.1931; Bernstein JH, 1997, SOC SCI MED, V44, P1341, DOI 10.1016/S0277-9536(97)84076-2; BORKAN J, 1994, J FAM PRACTICE, V39, P545; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; CHARLTON BG, 1993, J ROY SOC MED, V86, P125; DEAN K, 1981, SOC SCI MED-MED SOC, V15, P673, DOI 10.1016/0271-7123(81)90091-2; Dimmock S, 1996, CLIN RHEUMATOL, V15, P478, DOI 10.1007/BF02229645; Duggan R M, 1995, Altern Ther Health Med, V1, P28; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Fuller R., 1989, ALTERNATIVE MED AM R; FURNHAM A, 1988, SOC SCI MED, V26, P685, DOI 10.1016/0277-9536(88)90060-3; FURNHAM A, 1993, BRIT J CLIN PSYCHOL, V32, P237, DOI 10.1111/j.2044-8260.1993.tb01051.x; FURNHAM A, 1994, J CLIN PSYCHOL, V50, P458, DOI 10.1002/1097-4679(199405)50:3<458::AID-JCLP2270500318>3.0.CO;2-V; JENSEN P, 1990, ACTA DERM-VENEREOL, V70, P425; KLEINMAN A, 1984, ALTERNATIVE MED POPU; Kraemer HC, 1997, ARCH GEN PSYCHIAT, V54, P337; Kuhn T.S., 2012, STRUCTURE SCI REVOLU, V4th Edn, DOI [10.7208/chicago/9780226458144.001.0001, DOI 10.7208/CHICAGO/9780226458144.001.0001]; LEVIN JS, 1986, SOC SCI MED, V23, P889, DOI 10.1016/0277-9536(86)90217-0; LIPOWSKI ZJ, 1988, AM J PSYCHIAT, V145, P1358; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; MARQUIS MS, 1983, MED CARE, V21, P821, DOI 10.1097/00005650-198308000-00006; McGuire Meredith, 1988, RITUAL HEALING SUBUR; Millar WJ, 1997, CAN J PUBLIC HEALTH, V88, P154, DOI 10.1007/BF03403879; MURRAY RH, 1992, NEW ENGL J MED, V326, P61, DOI 10.1056/NEJM199201023260113; Ostrow MJ, 1997, J ACQ IMMUN DEF SYND, V15, P115, DOI 10.1097/00042560-199706010-00003; OTHS K, 1994, CULT MED PSYCHIAT, V18, P83, DOI 10.1007/BF01384878; PERKIN MR, 1994, J ROY SOC MED, V87, P523; RAY PH, 1997, AM DEMOGRAPHICS  FEB; RAY PH, IN PRESS CULTURAL CR; RIESMANN F, 1994, SOC POLICY       SPR, P53; SALMON JW, 1984, ALTERNATIVE MED POPU; SUTHERLAND LR, 1994, J CLIN GASTROENTEROL, V19, P194, DOI 10.1097/00004836-199410000-00004; Vincent C, 1996, BRIT J CLIN PSYCHOL, V35, P37, DOI 10.1111/j.2044-8260.1996.tb01160.x	34	1903	1947	9	230	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1548	1553		10.1001/jama.279.19.1548	http://dx.doi.org/10.1001/jama.279.19.1548			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZN087	9605899	Bronze			2022-12-24	WOS:000073608100033
J	Lees, KR				Lees, KR			Does neuroprotection improve stroke outcome?	LANCET			English	Editorial Material							DOUBLE-BLIND; TRIAL		Univ Glasgow, Western Infirm, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Lees, KR (corresponding author), Univ Glasgow, Western Infirm, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland.							Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Bath P, 1997, BRIT MED J, V315, P1167; CANDELISE L, 1995, LANCET, V346, P1509; Davis SM, 1997, LANCET, V349, P32, DOI 10.1016/S0140-6736(05)62166-6; Diener HC, 1998, CEREBROVASC DIS, V8, P172, DOI 10.1159/000015847; Diener HC, 1996, STROKE, V27, P76, DOI 10.1161/01.STR.27.1.76; DONNAN GA, 1995, LANCET, V345, P578; Dyker Alexander G., 1997, Stroke, V28, P233; Grotta J, 1997, STROKE, V28, P2338, DOI 10.1161/01.STR.28.12.2338; Hommel M, 1996, NEW ENGL J MED, V335, P145; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MUIR KW, 1995, STROKE, V26, P1183, DOI 10.1161/01.STR.26.7.1183; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; MUIR KW, 1996, CEREBROVASC DIS, V6; Ronning OM, 1998, STROKE, V29, P58, DOI 10.1161/01.STR.29.1.58; Sandercock P, 1997, LANCET, V349, P1569; Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5; Weir CJ, 1997, BMJ-BRIT MED J, V314, P1303, DOI 10.1136/bmj.314.7090.1303	18	47	47	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 16	1998	351	9114					1447	1448		10.1016/S0140-6736(05)78865-6	http://dx.doi.org/10.1016/S0140-6736(05)78865-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605797				2022-12-24	WOS:000073707300003
J	Saunders, RC; Kolachana, BS; Bachevalier, J; Weinberger, DR				Saunders, RC; Kolachana, BS; Bachevalier, J; Weinberger, DR			Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine	NATURE			English	Article							VENTRAL TEGMENTAL AREA; CAUDATE-NUCLEUS; SUBCORTICAL DOPAMINE; RHESUS-MONKEY; RELEASE; CORTEX; RATS; SCHIZOPHRENIA; PROJECTIONS; DAMAGE	The effects of early brain damage are often, but not always, milder than the effects of comparable damage in adults, depending on the age at which injury occurred, the region of the brain damaged, and the brain functions involved(1-7). Studies of the impact of early brain damage have generally focused on functions primarily associated with the neural structures injured, even though the development and function of distant but interconnected neural systems might also show effects. Here we examine the regulation of striatal dopamine by the dorsolateral prefrontal cortex, in adult monkeys that had had either neonatal or adult lesions of the medial-temporal lobe and in normal animals. We use microdialysis to measure the dopamine response in the caudate nucleus after the infusion of amphetamine into the dorsolateral prefrontal cortex. Normal animals and those with adult lesions showed a reduction in dopamine overflow; in contrast, monkeys with neonatal lesions showed increased dopamine release. Thus, early injury to the primate medial-temporal lobe disrupts the normal regulation of striatal dopamine activity by the dorsolateral prefrontal cortex during adulthood. Early focal lesions may have substantial and long-lasting impacts on the function of a distant neural system.	Univ Texas, Dept Neurobiol & Anat, Houston, TX 77030 USA; St Elizabeths Hosp, NIMH, Ctr Neurosci, Clin Brain Disorders Branch, Washington, DC 20032 USA	University of Texas System; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Saunders, RC (corresponding author), NIMH, Clin Brain Disorders Branch, Bldg 49,Room 1B80,49 Convent Dr, Bethesda, MD 20892 USA.	rcs@ln.nimh.nih.gov						Bebbington P. E., 1995, P587; Bertolino A, 1997, CEREB CORTEX, V7, P740, DOI 10.1093/cercor/7.8.740; Breier A, 1997, P NATL ACAD SCI USA, V94, P2569, DOI 10.1073/pnas.94.6.2569; Carlsson A, 1997, LIFE SCI, V61, P75, DOI 10.1016/S0024-3205(97)00228-2; Fuster J.M., 1989, PREFRONTAL CORTEX; GOLDMAN PS, 1974, PLASTICITY RECOVERY, P147; GOLDMANRAKIC PS, 1984, NEUROSCIENCE, V12, P719, DOI 10.1016/0306-4522(84)90166-0; HIKOSAKA O, 1993, EXP BRAIN RES, V95, P457; JAKOB H, 1986, J NEURAL TRANSM, V65, P303, DOI 10.1007/BF01249090; Karreman M, 1996, J NEUROCHEM, V66, P589; KOLACHANA BS, 1995, NEUROSCIENCE, V69, P859, DOI 10.1016/0306-4522(95)00246-F; Kolachana BS, 1997, SYNAPSE, V25, P285; KOLB B, 1987, BEHAV BRAIN RES, V25, P205, DOI 10.1016/0166-4328(87)90069-6; KOLB B, 1994, BRAIN RES, V645, P85, DOI 10.1016/0006-8993(94)91641-1; Laruelle M, 1996, P NATL ACAD SCI USA, V93, P9235, DOI 10.1073/pnas.93.17.9235; LIPSKA BK, 1995, P NATL ACAD SCI USA, V92, P8906, DOI 10.1073/pnas.92.19.8906; MAHUT H, 1986, HIPPOCAMPUS, V4, P241; Malkova L, 1997, ANN NY ACAD SCI, V807, P538, DOI 10.1111/j.1749-6632.1997.tb51961.x; MALKOVA L, 1995, BEHAV NEUROSCI, V109, P212, DOI 10.1037/0735-7044.109.2.212; MOGHADDAM B, 1993, SYNAPSE, V13, P215, DOI 10.1002/syn.890130304; ROBERTS AC, 1994, J NEUROSCI, V14, P2531; RUSSCHEN FT, 1985, BRAIN RES, V329, P241, DOI 10.1016/0006-8993(85)90530-X; SESACK SR, 1992, J COMP NEUROL, V320, P145, DOI 10.1002/cne.903200202; SMITH Y, 1986, NEUROSCIENCE, V18, P347, DOI 10.1016/0306-4522(86)90159-4; TABER MT, 1995, J NEUROCHEM, V65, P1407; WEBSTER MJ, 1991, NEUROREPORT, V2, P769, DOI 10.1097/00001756-199112000-00010; Weinberger DR, 1996, PHILOS T R SOC B, V351, P1495, DOI 10.1098/rstb.1996.0135; WEINBERGER DR, 1995, SCHIZOPHR RES, V16, P87, DOI 10.1016/0920-9964(95)00013-C; [No title captured]	29	125	125	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1998	393	6681					169	171		10.1038/30245	http://dx.doi.org/10.1038/30245			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN200	9603519				2022-12-24	WOS:000073619900048
J	Sankila, R; Olsen, JH; Anderson, H; Garwicz, S; Glattre, E; Hertz, H; Langmark, F; Lanning, M; Moller, T; Tulinius, H				Sankila, R; Olsen, JH; Anderson, H; Garwicz, S; Glattre, E; Hertz, H; Langmark, F; Lanning, M; Moller, T; Tulinius, H		Assoc Nordic Canc Registries; Nordic Soc Paediatric Haematology Oncology	Risk of cancer among offspring of childhood-cancer survivors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Increasing numbers of children with cancer survive and reach reproductive age. However, the risk of cancer (other than retinoblastoma) in the offspring of survivors of childhood and adolescent cancer is uncertain. Methods Using data from national cancer and birth registries, we assessed the risk of cancer among 5847 offspring of 14,652 survivors of cancer in childhood or adolescence diagnosed since the 1940s and 1950s in Denmark, Finland, Iceland, Norway, and Sweden. The offspring were followed up for a diagnosis of cancer for 86,780 person-years, and standardized incidence ratios were calculated. Results Among the 5847 offspring, 44 malignant neoplasms were diagnosed (standardized incidence ratio, 2.6; 95 percent confidence interval, 1.9 to 3.5). There were 17 retinoblastomas, yielding a standardized incidence ratio of 37. There were 27 neoplasms other than retinoblastoma (standardized incidence ratio, 1.6; 95 percent confidence interval, 1.1 to 2.4). The second most common primary site of cancer among the offspring was the brain and nervous system, in which eight tumors were observed (standardized incidence ratio, 2.0; 95 percent confidence interval, 0.9 to 3.9). There were between zero and four apparently sporadic cases of cancer in other primary sites among the offspring. Excluding 4 likely cases of hereditary cancer and 2 subsequent cancers among the offspring with hereditary retinoblastoma, there were 22 sporadic cancers, for a standardized incidence ratio of 1.3 (95 percent confidence interval, 0.8 to 2.0). Conclusions There is no evidence of a significantly increased risk of nonhereditary cancer among the offspring of survivors of cancer in childhood. (C)1998, Massachusetts Medical Society.	Finnish Canc Registry, FIN-00170 Helsinki, Finland; Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark; So Swedish Reg Canc Registry, Lund, Sweden; Univ Lund Hosp, Dept Pediat, S-22185 Lund, Sweden; Canc Registry Norway, Oslo, Norway; Copenhagen Univ Hosp, Dept Pediat, Copenhagen, Denmark; Univ Hosp Oulu, Dept Pediat, Oulu, Finland; Iceland Canc Registry, Reykjavik, Iceland	Finnish Cancer Registry; Danish Cancer Society; Lund University; Skane University Hospital; University of Oslo; University of Copenhagen	Sankila, R (corresponding author), Finnish Canc Registry, Liisankatu 21 B, FIN-00170 Helsinki, Finland.			Olsen, Jorgen Helge/0000-0001-9633-5662				BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; BROWN PD, 1995, ACTA PAEDIATR, V84, P316, DOI 10.1111/j.1651-2227.1995.tb13636.x; *CAN SOC FINL, 1996, CANC SOC FINL PUBL, V57; HAWKINS MM, 1995, BRIT J CANCER, V71, P1335, DOI 10.1038/bjc.1995.259; HAWKINS MM, 1989, INT J CANCER, V43, P975, DOI 10.1002/ijc.2910430604; MULVIHILL JJ, 1987, LANCET, V2, P813; OLSEN JH, 1993, BRIT MED J, V307, P1030, DOI 10.1136/bmj.307.6911.1030; *WHO, 1957, MAN INT STAT CLASS D, V1	8	120	122	1	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1998	338	19					1339	1344		10.1056/NEJM199805073381902	http://dx.doi.org/10.1056/NEJM199805073381902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL720	9571253	Bronze			2022-12-24	WOS:000073463700002
J	Schrenzel, J; Serrander, L; Banfi, B; Nusse, O; Fouyouzi, R; Lew, DP; Demaurex, N; Krause, KH				Schrenzel, J; Serrander, L; Banfi, B; Nusse, O; Fouyouzi, R; Lew, DP; Demaurex, N; Krause, KH			Electron currents generated by the human phagocyte NADPH oxidase	NATURE			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; HUMAN-NEUTROPHILS; CONDUCTANCE; METABOLISM; CHANNELS; CELLS	Electron transport across biological membranes is a well-known feature of bacteria, mitochondria and chloroplasts, where it provides motive forces for vectorial transport processes(1). In contrast, electron transport is generally not found in the plasma membrane of eukaryotic cells, possibly because it would interfere with electric processes at the plasma membrane. An exception is provided by the phagocyte NADPH oxidase, which generates superoxide (O-2(.-)) through electron transfer from cytosolic NADPH to extracellular oxygen(2-5). The enzyme is essential for host defence, and patients with chronic granulomatous disease, who lack the functional enzyme, suffer from severe infections(6,7). It has been suggested that electron transfer by the NADPH oxidase might be electrogenic(8). Here we demonstrate, using the whole-cell patch-clamp technique, the generation of electron currents by the NADPH oxidase in human eosinophil granulocytes. The currents were absent in granulocytes of sufferers of chronic granulomatous disease and under conditions of low oxygen. Generation of electron currents across the plasma membrane of eukaryotic cells has not been observed previously and might be - independently of the generation of superoxide - a physiologically relevant function of the phagocyte NADPH oxidase.	Univ Hosp Geneva, Dept Med, Div Infect Dis, CH-1211 Geneva 4, Switzerland; Univ Geneva, Med Ctr, Dept Physiol, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Krause, KH (corresponding author), Univ Hosp Geneva, Dept Med, Div Infect Dis, CH-1211 Geneva 4, Switzerland.		Nüsse, Oliver/J-8645-2013; Schrenzel, Jacques/P-8525-2017; Krause, Karl-Heinz/E-8030-2011; Serrander, Lena/W-4117-2017	Nüsse, Oliver/0000-0003-0068-8346; Schrenzel, Jacques/0000-0001-5464-7764; Krause, Karl-Heinz/0000-0002-9033-6768; Serrander, Lena/0000-0002-9058-3582; Demaurex, Nicolas/0000-0002-9933-6772; Banfi, Botond/0000-0001-9273-1318				BENESCH RE, 1953, SCIENCE, V118, P447, DOI 10.1126/science.118.3068.447; Boxer L A, 1996, Pediatr Rev, V17, P19, DOI 10.1542/pir.17-1-19; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHERNY VV, 1995, J GEN PHYSIOL, V105, P861, DOI 10.1085/jgp.105.6.861; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, HOSP PRACT, V25, P51; CORRONS JLV, 1982, BLOOD, V59, P428; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DEMAUREX N, 1993, EUR J HAEMATOL, V51, P309; DEMAUREX N, 1992, J CLIN INVEST, V90, P830, DOI 10.1172/JCI115958; GALLIN EK, 1990, CURR TOP MEMBR TRANS, V35, P127; GORDIENKO DV, 1996, J PHYSL, V496, P229; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; Hille B., 1992, IONIC CHANNELS EXCIT; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; MITCHELL P, 1991, BIOSCIENCE REP, V11, P297, DOI 10.1007/BF01130212; NANDA A, 1991, Cellular Physiology and Biochemistry, V1, P65, DOI 10.1159/000154595; NEWBURGER PE, 1979, NEW ENGL J MED, V300, P178, DOI 10.1056/NEJM197901253000406; Saier MH, 1997, ASM NEWS, V63, P13; Schrenzel J, 1996, AM J PHYSIOL-CELL PH, V271, pC1861, DOI 10.1152/ajpcell.1996.271.6.C1861; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SHULT PA, 1985, J LAB CLIN MED, V106, P638; VARNAI P, 1993, J PHYSIOL-LONDON, V472, P373, DOI 10.1113/jphysiol.1993.sp019952; ZIMMERLI W, 1983, HELV PAEDIATR ACTA, V38, P51	24	165	168	2	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1998	392	6677					734	737		10.1038/33725	http://dx.doi.org/10.1038/33725			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565037				2022-12-24	WOS:000073129000064
J	Kanegae, Y; Tavares, AT; Belmonte, JCI; Verma, IM				Kanegae, Y; Tavares, AT; Belmonte, JCI; Verma, IM			Role of Rel/NF-kappa B transcription factors during the outgrowth of the vertebrate limb	NATURE			English	Article							APICAL ECTODERMAL RIDGE; SONIC-HEDGEHOG; FEEDBACK LOOP; CHICK; INITIATION; GROWTH; BUD; EXPRESSION; DROSOPHILA; INDUCTION	The development of the vertebrate limb serves as an amenable system for studying signaling pathways that lead to tissue patterning and proliferation(1). Limbs originate as a consequence of a differential growth of cells from the lateral plate mesoderm at specific axial levels(2). At the tip of the limb primordia the progress zone, a proliferating group of mesenchymal cells, induces the overlying ectoderm to differentiate into a specialized structure termed the apical ectodermal ridge. Subsequent limb outgrowth requires reciprocal signalling between the ridge and the progress zone(3-6). The Rel/NF-kappa B family of transcription factors is induced in response to several signals that lead to cell growth, differentiation, inflammatory responses, apoptosis and neoplastic transformation(7), In unstimulated cells, NF-kappa B is associated in the cytoplasm with an inhibitory protein, I-kappa B. In response to an external signal, I-kappa B is phosphorylated, ubiquitinated and degraded, releasing NF-kappa B to enter the nucleus and activate transcription(7). Here we show that Rel/NF-kappa B genes are expressed in the progress zone of the developing chick limb bud. When the activity of Rel/NF-kappa B proteins is blocked by infection with viral vectors that produce transdominant-negative I-kappa B alpha proteins, limb outgrowth is arrested, Our results indicate that Rel/NF-kappa B transcription factors play a role in vertebrate limb development.	Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Verma, IM (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Tavares, Ana Teresa/I-3086-2013	Tavares, Ana Teresa/0000-0002-3495-5513				BELMONTE JCI, 1993, CELL, V74, P645; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; DAVIDSON DR, 1991, NATURE, V352, P429, DOI 10.1038/352429a0; Deng CX, 1997, DEV BIOL, V185, P42, DOI 10.1006/dbio.1997.8553; ElGhouzzi V, 1997, NAT GENET, V15, P42; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; KIENY M, 1960, J EMBRYOL EXP MORPH, V8, P457; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; Ogura T, 1996, DEVELOPMENT, V122, P537; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROBERT B, 1991, GENE DEV, V5, P2363, DOI 10.1101/gad.5.12b.2363; ROWE DA, 1982, J EMBRYOL EXP MORPH, V68, P1; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SEARLS RL, 1971, DEV BIOL, V24, P198, DOI 10.1016/0012-1606(71)90095-9; SHEN RQ, 1994, CELL MOL BIOL RES, V40, P297; SHISHIDO E, 1993, DEVELOPMENT, V117, P751; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Vogel A, 1996, DEVELOPMENT, V122, P1737	30	182	187	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					611	614		10.1038/33429	http://dx.doi.org/10.1038/33429			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560158				2022-12-24	WOS:000072987200062
J	Carvalho, JS; Moscoso, G; Ville, Y				Carvalho, JS; Moscoso, G; Ville, Y			First-trimester transabdominal fetal echocardiography	LANCET			English	Article							NUCHAL TRANSLUCENCY THICKNESS; CONGENITAL HEART-DISEASE; MATERNAL AGE; HIGH-RISK; DIAGNOSIS; GESTATION; PREGNANCIES; FETUSES; DEFECTS	Background Fetal echocardiography is usually done during the second trimester of pregnancy, but waiting until that time can lead to anxiety for the parents if the fetus is at high risk of having cardiac abnormalities. We report the feasibility of transabdominal first-trimester fetal echocardiography for early reassurance of normality or a prenatal diagnosis of a cardiac malformation. Methods We did first-trimester fetal echocardiography and colour-flow mapping with a 5 MHz curvilinear transducer at 13 weeks' gestation (range 12-13+6 days) in 15 fetuses at risk of cardiac defects. The fetus was judged to be normal if the investigation showed normal visceral situs, four-chamber view, and two normally related great arteries of similar size. We did second-trimester scans and neonatal follow-up for the women who continued with their pregnancies; necropsy was done in two cases of pregnancy termination. Findings Ten fetuses had normal hearts at the time of the first scan, which was confirmed during second-trimester assessment, In one fetus, the four-chamber view was asymmetrical and a moderate-sized apical muscular ventricular septal defect (VSD) was diagnosed after birth. In another two fetuses we diagnosed small muscular VSD on the second-trimester scans. A complex cardiac malformation was correctly diagnosed in one fetus at 12 weeks of gestation. Thus, in 11 fetuses, the imaging was of sufficient quality to reassure the family or to diagnose an abnormality. In the other four fetuses, the investigation was judged to be incomplete, but no definite cardiac abnormality was identified. Interpretation Transabdominal fetal echocardiography in the first trimester of pregnancy is feasible. In most patients the resolution of images is sufficient to allow assessment of basic cardiac anatomy, when normal, or detection of complex malformations, when present.	Royal Brompton Hosp NHS Trust, London SW3 6NP, England; St Georges Hosp NHS Trust, Fetal Med Unit, London, England	Royal Brompton Hospital; St Georges University London	Carvalho, JS (corresponding author), Royal Brompton Hosp NHS Trust, London SW3 6NP, England.	carvalho@eas-jsc.demon.co.uk	Carvalho, Julene/E-8842-2015	Carvalho, Julene/0000-0002-5698-5828				ACHIRON R, 1994, J ULTRAS MED, V13, P783; Allan LD, 1997, HEART, V77, P68, DOI 10.1136/hrt.77.1.68; ALLAN LD, 1994, J AM COLL CARDIOL, V23, P1452, DOI 10.1016/0735-1097(94)90391-3; ALLAN LD, 1986, AM J CARDIOL, V58, P334, DOI 10.1016/0002-9149(86)90072-X; Bjorkhem G, 1997, J Matern Fetal Med, V6, P87; BRONSHTEIN M, 1993, OBSTET GYNECOL, V82, P225; Buskens E, 1996, OBSTET GYNECOL, V87, P423, DOI 10.1016/0029-7844(95)00439-4; DAMELIO R, 1991, PRENATAL DIAG, V11, P69, DOI 10.1002/pd.1970110202; DOLKART LA, 1991, AM J OBSTET GYNECOL, V165, P688, DOI 10.1016/0002-9378(91)90310-N; DONNAI P, 1981, BRIT MED J, V282, P621, DOI 10.1136/bmj.282.6264.621; GEMBRUCH U, 1993, ULTRASOUND OBST GYN, V3, P310, DOI 10.1046/j.1469-0705.1993.03050310.x; GEMBRUCH U, 1990, OBSTET GYNECOL, V75, P496; GITTENBERGERDEG.AC, 1996, ULTRASOUND FETAL HEA, P1; Hyett J, 1996, ULTRASOUND OBST GYN, V7, P245, DOI 10.1046/j.1469-0705.1996.07040245.x; Hyett JA, 1997, ULTRASOUND OBST GYN, V10, P242, DOI 10.1046/j.1469-0705.1997.10040242.x; HYETT JA, 1995, AM J MED GENET, V58, P374, DOI 10.1002/ajmg.1320580415; OTT WJ, 1995, AM J OBSTET GYNECOL, V172, P1741, DOI 10.1016/0002-9378(95)91406-4; Pandya PP, 1995, BRIT J OBSTET GYNAEC, V102, P957, DOI 10.1111/j.1471-0528.1995.tb10902.x; PANDYA PP, 1995, ULTRASOUND OBST GYN, V5, P15, DOI 10.1046/j.1469-0705.1995.05010015.x; Sebire NJ, 1996, BRIT J OBSTET GYNAEC, V103, P999, DOI 10.1111/j.1471-0528.1996.tb09550.x	20	83	86	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1023	1027		10.1016/S0140-6736(97)08406-7	http://dx.doi.org/10.1016/S0140-6736(97)08406-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546509				2022-12-24	WOS:000072927200013
J	Whittle, IR; Pringle, AM; Taylor, R				Whittle, IR; Pringle, AM; Taylor, R			Effects of resective surgery for left-sided intracranial tumours on language function: a prospective study	LANCET			English	Article							DOMINANT HEMISPHERE; LOCALIZATION; GLIOMAS; APHASIA; TUMORS; AGE	Background Although language disorders occur in about 50% of patients with a left hemispheric tumour and are a significant cause of morbidity, the effects of resective neurosurgery and their relation to tumour pathology are unclear. We report the immediate effects of resective surgery on language functions in a heterogeneous group of patients with left-sided intracranial tumours. Methods 40 patients were studied. The Western Aphasia Battery (WAB) and Boston Naming Test (BNT) were administered preoperatively and before discharge following resective neurosurgery. Dexamethasone dose at time of testing was recorded, as was time taken to complete the tests, and tumour neuropathology. Findings 15 patients with normal aphasia quotients and language quotients before resective surgery all had normal quotients postoperatively. 25 who were dysphasic tie, aphasia quotient <93.8) preoperatively showed significant postoperative improvements in both their mean aphasia quotient (from 81.8 to 89.1, p=0.004) and their mean language quotient (from 73.4 to 85.4, p=0.001), though 13 remained dysphasic. Two of the 25 dysphasic patients had their WAB scores lowered by tumour resection. The findings and postoperative changes in BNT scores were almost identical to the pattern of those in WAB scores. At second assessment, dexamethasone therapy was significantly (p<0.01) lower than preoperative dose (reduction from mean 10.3 mg/day to 0.7 mg/day in the dysphasic group). Patients with glioblastoma were more likely to have lower aphasia quotients, language quotients, and BNT scores than patients with anaplastic glioma, metastasis, or meningioma, Although the glioblastoma group had the greatest improvements in WAB operative scores, 57% remained dysphasic after resective surgery. Two additional patients declined postoperative assessment. Interpretation Resective surgery for left-sided intracranial tumours significantly improves language function in dysphasic patients, and is unlikely to impair language functions in non-dysphasic patients. Dysphasia and its response to resective surgery are related to the tumour neuropathology.	Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Whittle, IR (corresponding author), Western Gen Hosp, Dept Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	irw@skull.dcn.ac.ed.uk	whittle, ian/AAX-7309-2021					BRIGGS G G, 1975, Cortex, V11, P230; BURGER PC, 1988, J NEUROSURG, V68, P698, DOI 10.3171/jns.1988.68.5.0698; CABANTOG AM, 1994, CAN J NEUROL SCI, V21, P213, DOI 10.1017/S0317167100041184; CIRIC I, 1987, NEUROSURGERY, V21, P21, DOI 10.1227/00006123-198707000-00005; COHADON F, 1990, ADV TECHNICAL STANDA, V17, P190; Dorward NL, 1997, BRIT J NEUROSURG, V11, P101, DOI 10.1080/02688699746429; FADUL C, 1988, NEUROLOGY, V38, P1374, DOI 10.1212/WNL.38.9.1374; HAGLUND MM, 1994, NEUROSURGERY, V34, P567, DOI 10.1227/00006123-199404000-00001; HERMANN BP, 1994, NEUROSURGERY, V35, P52, DOI 10.1227/00006123-199407000-00008; Kaplan E., 1983, BOSTON DIAGNOSTIC AP; Kertesz A., 2007, W APHASIA BATTERY RE; KETESZ A, 1979, APHASIA ASS DISORDER; LATIF AZB, 1998, IN PRESS J NEUROL NE; LATIF AZB, 1998, IN PRESS BR J NEUROS; MICELI G, 1981, ACTA NEUROL SCAND, V64, P370; OJEMANN G, 1989, J NEUROSURG, V71, P316, DOI 10.3171/jns.1989.71.3.0316; RECHT LD, 1989, NEUROLOGY, V39, P48, DOI 10.1212/WNL.39.1.48; ROSTOMILY RC, 1991, J NEUROSURG, V75, P62, DOI 10.3171/jns.1991.75.1.0062; Russell D, 1989, PATHOLOGY TUMOURS NE; SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22; Skirboll SS, 1996, NEUROSURGERY, V38, P678, DOI 10.1227/00006123-199604000-00008; TANDON P, 1993, ACT NEUR S, V56, P67; THOMSON AM, 1997, J NEUROSURG, V89, P923; VECHT CJ, 1990, J NEUROL NEUROSUR PS, V53, P466, DOI 10.1136/jnnp.53.6.466; WEISSMAN DE, 1987, J NEURO-ONCOL, V5, P125, DOI 10.1007/BF02571300; WHITTLE IR, 1991, AUST NZ J SURG, V61, P919, DOI 10.1111/j.1445-2197.1991.tb00010.x; WHITTLE IR, 1992, NEUROSURG QUART, V2, P174	27	31	33	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1014	1018		10.1016/S0140-6736(97)08295-0	http://dx.doi.org/10.1016/S0140-6736(97)08295-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546507				2022-12-24	WOS:000072927200011
J	Gulmezoglu, AM; Duley, L				Gulmezoglu, AM; Duley, L			Use of anticonvulsants in eclampsia and pre-eclampsia: survey of obstetricians in the United Kingdom and Republic of Ireland	BRITISH MEDICAL JOURNAL			English	Article									Radcliffe Infirm, Natl Perinatal Epidemiol Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Gulmezoglu, AM (corresponding author), United Kingdom Cochrane Ctr, NHS Res & Dev Programme, Summertown Pavil, Oxford OX2 7LG, England.	mgulmezoglu@cochrane.co.uk	Duley, Lelia/E-8107-2015	Duley, Lelia/0000-0001-6721-5178				CHAMBERLAIN GVP, 1978, BRIT MED J, V276, P626; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; DULEY L, 1995, LANCET, V345, P1455; DULEY L, 1997, COCHRANE LIB COCHRAN; HUTTON JD, 1992, BRIT J OBSTET GYNAEC, V99, P554, DOI 10.1111/j.1471-0528.1992.tb13819.x	5	36	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					975	976		10.1136/bmj.316.7136.975	http://dx.doi.org/10.1136/bmj.316.7136.975			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550956	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000072856100020
J	Savulescu, J				Savulescu, J			Commentary: Safety of participants in non-therapeutic research must be ensured	BRITISH MEDICAL JOURNAL			English	Editorial Material							HYPOXIA		Monash Univ, Ctr Human Bioeth, Clayton, Vic 3168, Australia	Monash University	Savulescu, J (corresponding author), Monash Univ, Ctr Human Bioeth, Gallery Bldg,Wellington Rd, Clayton, Vic 3168, Australia.							*COUNC INT ORG MED, 1993, INT ETH GUID BIOM RE; FOSTER L, 1996, MANUAL RES ETHICS CO; *ROYAL COLL PHYS, 1986, RES HLTH VOL WORK PA; SEVERINGHAUS JW, 1989, J CLIN MONITOR, V5, P72, DOI 10.1007/BF01617877; Waters KA, 1996, RESP PHYSIOL, V105, P135, DOI 10.1016/0034-5687(96)00046-1	5	13	13	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					891	892						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9569393				2022-12-24	WOS:000072713300023
